anti-tuberculous O
drugs O
had O
been O
stopped O
on O
the O
2nd O
day O
of O
therapy O
due O
to O
development O
of O
optic B-ADR
neuritis I-ADR
secondary O
to O
ethambutol B-DRUG
administration O
at O
another O
hospital O

phantom O
limb O
pain O
as O
a O
manifestation O
of O
paclitaxel B-DRUG
neurotoxicity B-ADR

lithium B-DRUG
treatment O
was O
terminated O
in O
1975 O
because O
of O
lithium O
intoxication O
with O
a O
diabetes B-ADR
insipidus-like I-ADR
syndrome I-ADR

hypernatraemia B-ADR
induced O
by O
sodium B-DRUG
polystyrene I-DRUG
sulphonate I-DRUG
( O
kayexalate O
) O
in O
two O
extremely O
low O
birth O
weight O
newborns O

penicillin-induced O
jarisch-herxheimer B-ADR
reaction I-ADR

aim O
: O
to O
report O
a O
patient O
with O
diabetic O
rubeosis O
who O
suffered O
from O
acute O
retinal O
ischemic O
change O
and O
stroke B-ADR
after O
intravitreal O
injection O
of O
bevacizumab B-DRUG

conclusions O
: O
the O
value O
of O
multihormonal O
therapy O
in O
breast O
carcinoma O
is O
not O
established O
, O
and O
the O
addition O
of O
progestogens O
to O
tamoxifen B-DRUG
may O
not O
reduce O
of O
developing O
endometrial B-ADR
lesions I-ADR
, O
including O
carcinoma O

conclusions O
: O
this O
case O
describes O
the O
clinically O
significant O
increase B-ADR
of I-ADR
inr I-ADR
in O
an O
elderly O
patient O
after O
adding O
a O
chemotherapy O
regimen O
of O
levamisole O
and O
5-fu B-DRUG
to O
a O
previous O
regimen O
of O
warfarin O
alone O

patients O
with O
vitamin O
b12 O
deficiency O
are O
exceedingly O
sensitive O
to O
neurologic B-ADR
deterioration I-ADR
following O
nitrous B-DRUG
oxide I-DRUG
anesthesia O

type O
i O
second-degree O
av O
block O
( O
mobitz O
type O
i O
, O
wenckebach B-ADR
av I-ADR
block I-ADR
) O
during O
ritodrine B-DRUG
therapy O
for O
preterm O
labor O

we O
report O
a O
patient O
with O
pulmonary O
adenocarcinoma O
complicated O
by O
the O
syndrome O
of O
inappropriate O
secretion O
of O
antidiuretic O
hormone O
( O
siadh B-ADR
) O
following O
systemic O
chemotherapy O
with O
cisplatin B-DRUG
( O
cddp O
) O
and O
vindesine O
( O
vds O

we O
report O
a O
case O
of O
a O
patient O
with O
pulmonary O
hypertension O
and O
undifferentiated O
connective O
tissue O
disease O
who O
, O
after O
2 O
months O
of O
treatment O
with O
epoprostenol B-DRUG
, O
presented O
with O
rapidly O
progressive O
erythema O
, O
scaling O
, O
nausea O
and O
vomiting O
, O
and O
fever B-ADR

carbamazepine B-DRUG
induced O
right B-ADR
bundle I-ADR
branch I-ADR
block I-ADR
in O
a O
greenlandic O
patient O

diagnosis O
: O
severe O
temozolomide-induced O
immunosuppression O
, O
exacerbated O
by O
corticosteroids O
, O
with O
profound O
t-cell O
lymphocytopenia O
and O
simultaneous O
opportunistic O
infections O
with O
pneumocystis O
jiroveci O
pneumonia O
, O
brain B-ADR
abscess I-ADR
with I-ADR
listeria I-ADR
monocytogenes I-ADR
, O
and O
cutaneous O
kaposi O
's O
sarcoma O

graves' B-ADR
hyperthyroidism I-ADR
following O
transient O
thyrotoxicosis O
during O
interferon B-DRUG
therapy O
for O
chronic O
hepatitis O
type O
c O

the O
administration O
of O
" O
sweet O
spirits O
of O
nitre O
" O
( O
4 B-DRUG
% I-DRUG
ethyl I-DRUG
nitrite I-DRUG
ch3ch2ono I-DRUG
in I-DRUG
70 I-DRUG
% I-DRUG
ethyl I-DRUG
alcohol I-DRUG
) O
was O
followed O
by O
acute O
methemoglobinemia O
and O
severe O
anoxic O
metabolic O
acidosis O
in O
infant O
twins O
, O
methylene O
blue O
administration O
reversed O
methemoglobinemia O
in O
both O
, O
but O
one O
twin O
died B-ADR
from O
the O
consequences O
of O
hypoxemia O

the O
patient O
was O
given O
methimazole B-DRUG
instead O
of O
propylthiouracil O
but O
, O
10 O
weeks O
later O
, O
agranulocytosis B-ADR
again O
occurred O

after O
an O
extensive O
review O
of O
the O
literature O
, O
we O
believe O
that O
this O
is O
the O
first O
communication O
of O
the O
successful O
use O
of O
amiodarone O
to O
control O
hyperthyroidism O
in O
a O
patient O
with O
ptu-induced O
fulminant B-ADR
hepatitis I-ADR

the O
fetal B-ADR
valproate I-ADR
syndrome I-ADR
( O
fvs O
) O
is O
characterized O
by O
distinctive O
facial O
appearance O
, O
major O
and O
minor O
malformations O
, O
and O
developmental O
delay O

acute B-ADR
intravascular I-ADR
hemolysis I-ADR
developed O
when O
a O
diabetic O
patient O
, O
previously O
treated O
with O
glyburide O
, O
was O
started O
on O
another O
oral O
sulfonylurea O
drug O
, O
chlorpropamide B-DRUG

we O
describe O
2 O
male O
patients O
, O
a O
49-year-old O
with O
psoriatic O
arthritis O
and O
impaired O
renal O
function O
and O
a O
43-year-old O
renal O
transplant O
recipient O
, O
who O
both O
sustained O
a O
marked O
decline B-ADR
in I-ADR
glomerular I-ADR
filtration I-ADR
rate I-ADR
in O
conjunction O
with O
a O
selective O
inhibitor O
of O
cyclooxygenase-2 O
( O
cox-2 O
) O
, O
rofecoxib B-DRUG

to O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
significant O
hypotension B-ADR
associated O
with O
intravenous O
valproate B-DRUG
in O
the O
treatment O
of O
status O
epilepticus O
in O
the O
pediatric O
population O

massive B-ADR
subfascial I-ADR
hematoma I-ADR
after O
alteplase B-DRUG
therapy O
for O
acute O
myocardial O
infarction O

severe O
rash O
, O
including O
the O
stevens-johnson B-ADR
syndrome I-ADR
( O
sjs O
) O
, O
is O
the O
major O
toxicity O
of O
nevirapine B-DRUG
and O
is O
described O
in O
the O
package O
labeling O
with O
a O
prominent O
, O
boxed O
warning O

conclusions O
: O
these O
results O
suggest O
that O
clozapine B-DRUG
may O
cause O
td B-ADR
; O
however O
, O
the O
prevalence O
is O
low O
and O
the O
severity O
is O
relatively O
mild O
, O
with O
no O
or O
mild O
self-reported O
discomfort O

troglitazone-induced O
fulminant B-ADR
hepatic I-ADR
failure I-ADR

behavioral O
side O
effects O
associated O
with O
clonazepam B-DRUG
may O
include O
agitation O
, O
aggression O
, O
hyperactivity O
, O
irritability O
, O
property B-ADR
destruction I-ADR
, O
and O
temper O
tantrums O

marked B-ADR
hyperkalemia I-ADR
was O
observed O
during O
and O
immediately O
after O
an O
infusion O
of O
arginine B-DRUG
monohydrochloride I-DRUG
in O
two O
patients O
with O
severe O
hepatic O
disease O
and O
moderate O
renal O
insufficiency O

the O
hiv O
protease O
inhibitor O
indinavir B-DRUG
may O
cause O
nephrolithiasis B-ADR
and O
interstitial O
nephritis O

the O
patient O
suffered O
a O
life-threatening B-ADR
anaphylactoid I-ADR
reaction I-ADR
to O
amifostine B-DRUG

to O
our O
knowledge O
this O
is O
the O
first O
report O
that O
demonstrates O
histological B-ADR
abnormalities I-ADR
of I-ADR
the I-ADR
glomerulus I-ADR
associated O
with O
postoperative O
ifn-beta B-DRUG
therapy O
for O
the O
malignant O
melanoma O

conclusions O
: O
sustained-release O
verapamil B-DRUG
is O
thought O
to O
be O
the O
cause O
of O
the O
asthma B-ADR
attack I-ADR
in O
this O
patient O
because O
she O
was O
not O
taking O
any O
other O
preparations O
; O
the O
symptoms O
started O
with O
the O
administration O
of O
sustained-release O
verapamil B-DRUG
and O
were O
relieved O
after O
its O
discontinuation O

objective O
: O
to O
report O
a O
case O
of O
serotonin B-ADR
syndrome I-ADR
associated O
with O
interaction O
between O
fentanyl O
and O
citalopram B-DRUG
, O
as O
evidenced O
by O
medication O
history O
, O
clinical O
features O
and O
reversal O
following O
discontinuation O
of O
fentanyl O

in O
case O
1 O
, O
a O
total O
daily O
dose O
of O
25 O
mg O
sertraline O
, O
with O
nondetectable O
sertraline O
and O
desmethylsertraline O
blood O
levels O
, O
resulted O
in O
a O
doubling B-ADR
of I-ADR
the I-ADR
lamotrigine I-ADR
blood I-ADR
level I-ADR
with O
symptoms O
of O
toxicity O

objective O
: O
to O
report O
a O
case O
of O
possible O
foscarnet-induced O
severe O
hypomagnesemia O
and O
other O
electrolyte B-ADR
disorders I-ADR

the O
case O
of O
a O
29-year-old O
man O
suffering O
from O
falciparum O
malaria O
disease O
who O
got O
a O
reversible B-ADR
hearing I-ADR
loss I-ADR
from O
quinine B-DRUG
therapy O
is O
presented O

a O
complex O
pattern O
of O
melanonychia B-ADR
and O
onycholysis O
after O
treatment O
with O
pemetrexed B-DRUG
for O
lung O
cancer O

the O
incidence O
of O
5-fluorouracil O
( O
5-fu B-DRUG
)- O
related O
cardiotoxicity B-ADR
seems O
to O
be O
dosage O
and O
schedule O
dependent O

prolongation B-ADR
of I-ADR
the I-ADR
qt I-ADR
interval I-ADR
and O
ventricular O
tachyarrhymias O
have O
been O
described O
in O
patients O
on O
amiodarone B-DRUG
therapy O

we O
describe O
two O
cases O
that O
illustrate O
the O
use O
of O
lithium B-DRUG
in O
the O
treatment O
of O
veterans O
with O
ptsd O
who O
complained O
of O
serious O
problems O
with O
irritability B-ADR
or O
angry O
outbursts O

this O
case O
presentation O
is O
of O
a O
patient O
who O
had O
the O
clinical O
appearance O
of O
epiglottitis O
, O
but O
actually O
had O
an O
oro-pharyngeal B-ADR
dystonic I-ADR
reaction I-ADR
to O
prochlorperazine B-DRUG

we O
report O
marked O
qt O
prolongation O
and O
torsades O
de O
pointes O
in O
a O
setting O
of O
flash B-ADR
pulmonary I-ADR
edema I-ADR
resulting O
from O
acute O
myocardial O
ischemia O
in O
a O
patient O
who O
was O
being O
treated O
with O
dofetilide B-DRUG
for O
atrial O
fibrillation O

tegaserod-associated O
ischemic B-ADR
colitis I-ADR

a O
retrospective O
study O
was O
conducted O
of O
40 O
loperamide B-ADR
poisoning I-ADR
cases O
recorded O
at O
the O
centre O
national O
d'informations O
toxicologiques O
veterinaires O

in O
this O
report O
, O
a O
patient O
who O
had O
undergone O
a O
renal O
transplantation O
as O
a O
result O
of O
malignant O
hypertension O
, O
and O
who O
was O
on O
immunosuppressive O
therapy O
consisting O
of O
cyclosporin O
, O
prednisone O
and O
azathioprine B-DRUG
, O
developed O
thrombosis B-ADR
of O
the O
central O
retinal O
vein O
5 O
years O
following O
the O
transplantation O

severe O
autoimmune B-ADR
hemolytic I-ADR
anemia I-ADR
following O
rituximab B-DRUG
therapy O
in O
a O
patient O
with O
a O
lymphoproliferative O
disorder O

the O
use O
of O
cyclosporin B-DRUG
has O
been O
associated O
with O
the O
development O
of O
cholelithiasis B-ADR
in O
transplant O
recipients O

we O
report O
a O
case O
of O
ibuprofen-induced O
meningitis B-ADR
in O
an O
otherwise O
healthy O
individual O

ciprofloxacin-induced O
hemorrhagic B-ADR
vasculitis I-ADR

a O
72-year-old O
woman O
with O
a O
history O
of O
thyrotoxicosis O
presented O
with O
sore O
throat O
and O
fever B-ADR
two O
weeks O
after O
starting O
carbimazole B-DRUG

the O
latter O
form O
( O
macrodantin B-DRUG
) O
is O
reported O
to O
engender O
less O
gastrointestinal O
intolerance O
but O
it O
can O
produce O
the O
same O
adverse O
effects O
as O
the O
conventional O
form O
-- O
liver O
damage O
, O
acute B-ADR
and I-ADR
chronic I-ADR
pulmonary I-ADR
reactions I-ADR
, O
peripheral O
neuropathy O
, O
blood O
dyscrasias O
and O
allergic O
reactions O
-- O
and O
does O
so O
just O
as O
rapidly O
and O
floridly O
; O
one O
such O
case O
is O
reported O
here O

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin O
, O
grepafloxacin B-DRUG
, O
trovafloxacin O
, O
gatifloxacin O
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache B-ADR
, O
dizziness O
and O
insomnia O

rifampin O
( O
rfp B-DRUG
) O
increases O
hepatic O
microsomal O
enzyme O
activity O
, O
and O
there O
are O
case O
reports O
of O
rfp-induced O
hypothyroidism O
, O
all O
associated O
with O
hashimoto B-ADR
's I-ADR
thyroiditis I-ADR

we O
report O
the O
successful O
treatment O
of O
heparin-induced O
thrombocytopenia B-ADR
and O
subsequent O
hemorrhagic O
complications O
postoperatively O
in O
a O
2-year-old O
child O
with O
danaparoid O
( O
orgaran O

there O
are O
major O
side O
effects O
of O
anastrozole B-DRUG
including O
decrease O
in O
both O
lumbar O
spine O
and O
total O
hip O
bone O
mineral O
density O
, O
increase B-ADR
in I-ADR
the I-ADR
incidence I-ADR
of I-ADR
all I-ADR
bone I-ADR
fractures I-ADR
( O
especially O
fractures O
of O
spine O
, O
hip O
and O
wrist O
) O
, O
joint O
disorders O
and O
increase O
in O
the O
cholesterol O
level O

cessation O
of O
d-pen B-DRUG
and O
the O
start O
of O
corticosteroid O
therapy O
were O
followed O
by O
recovery O
from O
bicytopenia B-ADR

one O
of O
these O
was O
clofazimine B-DRUG
, O
an O
aniline O
aposafranine O
derivative O
known O
to O
produce O
a O
ceroid-like B-ADR
pigment I-ADR
in O
the O
tissues O
of O
patients O
treated O
with O
this O
drug O
or O
lepromatous O
leprosy O

one O
explanation O
for O
the O
noted O
increase B-ADR
in I-ADR
the I-ADR
theophylline I-ADR
level I-ADR
is O
that O
metabolism O
occurs O
mainly O
by O
cytochrome O
p450 O
( O
cyp O
1a2 O
) O
, O
an O
enzyme O
that O
is O
known O
to O
be O
inhibited O
with O
high O
concentrations O
of O
zafirlukast O

ten O
days O
after O
itraconazole B-DRUG
was O
started O
, O
he O
developed O
paralytic O
ileus O
, O
neurogenic O
bladder O
, O
mild O
left O
ptosis O
, O
and O
absence O
of O
deep O
reflexes O
, O
with O
severe O
paralysis O
of O
the O
lower O
extremities O
and O
mild B-ADR
weakness I-ADR
of I-ADR
the I-ADR
upper I-ADR
extremities I-ADR

muscle O
biopsy O
revealed O
variation B-ADR
in I-ADR
muscle I-ADR
fiber I-ADR
size I-ADR
and O
few O
vacuolated O
fibers O
which O
were O
features O
of O
colchicine-induced O
myopathy O

an O
association O
of O
granulocytopenia B-ADR
, O
eosinophilia O
, O
skin O
reaction O
and O
hepatitis O
during O
propylthiouracil B-DRUG
( O
ptu O
) O
therapy O
for O
thyrotoxicosis O
in O
a O
47 O
year O
old O
black O
female O
is O
reported O

fluoxetine-induced O
akathisia B-ADR
: O
clinical O
and O
theoretical O
implications O

conclusions O
: O
this O
report O
indicates O
clindamycin B-DRUG
phosphate I-DRUG
vaginal O
cream O
as O
the O
most O
probable O
cause O
of O
cdic O
due O
to O
the O
temporal O
relationship O
between O
the O
occurrence O
of O
diarrhea B-ADR
and O
clindamycin O
administration O
, O
lack O
of O
concomitant O
medications O
, O
and O
documentation O
of O
c. O
difficile O
toxin O

a O
high O
dose O
of O
cotrimoxazole B-DRUG
induced O
hyperkalaemia O
with O
the O
elevation B-ADR
of I-ADR
serum I-ADR
creatinine I-ADR
and I-ADR
blood I-ADR
urea I-ADR
, O
and O
increased O
urinary O
n-acetyl O
glucosaminase O
after O
several O
days O
of O
the O
drug O
administration O
in O
these O
patients O
; O
one O
patient O
became O
unconscious O

hypernatraemia B-ADR
induced O
by O
sodium O
polystyrene O
sulphonate O
( O
kayexalate B-DRUG
) O
in O
two O
extremely O
low O
birth O
weight O
newborns O

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate O
with O
folinic B-DRUG
acid I-DRUG
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia O
, O
hyperkalaemia O
and O
hyperphosphataemia B-ADR
with O
hypocalcaemia O
and O
tetany O
, O
with O
metabolic O
acidosis O
and O
acute O
renal O
impairment O
) O
are O
described O

spindle B-ADR
coma I-ADR
in O
benzodiazepine B-DRUG
toxicity O
: O
case O
report O

patient O
a O
reported O
right O
leg O
weakness O
( O
foot B-ADR
drop I-ADR
) O
during O
week O
4 O
of O
cap-xrt B-DRUG
( O
1600 O
mg O
/ O
m2 O

however O
, O
peripheral O
neuropathy O
and O
bone B-ADR
marrow I-ADR
depression I-ADR
led O
to O
linezolid B-DRUG
withdrawal O
in O
seven O
patients O
, O
and O
neuropathy O
may O
not O
be O
fully O
reversible O
in O
all O
patients O

to O
our O
knowledge O
, O
four O
cases O
of O
interstitial B-ADR
pneumonitis I-ADR
associated O
with O
fludarabine B-DRUG
have O
been O
reported O
in O
medical O
literature O

when O
tuberculosis O
patients O
on O
isoniazid B-DRUG
eat O
certain O
varieties O
of O
fish O
they O
may O
develop O
a O
histamine B-ADR
reaction I-ADR

vancomycin B-DRUG
is O
widely O
used O
against O
methicillin-resistant O
staphylococcus O
aureus O
infections O
, O
but O
it O
is O
associated O
with O
many O
adverse O
effects O
such O
as O
nephrotoxicity O
, O
ototoxicity B-ADR
, O
gastrointestinal O
disturbances O
, O
blood O
disorders O
, O
and O
two O
types O
of O
hypersensitivity O
reactions O
- O
an O
anaphylactoid O
reaction O
known O
as O
" O
red O
man O
syndrome O
" O
and O
anaphylaxis O

a O
case O
of O
acute B-ADR
subdural I-ADR
haematoma I-ADR
originating O
spontaneously O
from O
an O
angiomatous O
meningioma O
in O
a O
patient O
receiving O
prophylactic O
aspirin B-DRUG
therapy O
is O
presented O

one O
patient O
developed O
severe B-ADR
hyponatremia I-ADR
with O
serum O
na O
+ O
of O
108 O
meq O
/ O
l O
when O
hydrochlorothiazide B-DRUG
was O
given O
to O
control O
hypertension O

cholestatic O
liver O
disease O
with O
ductopenia O
( O
vanishing B-ADR
bile I-ADR
duct I-ADR
syndrome I-ADR
) O
after O
administration O
of O
clindamycin O
and O
trimethoprim-sulfamethoxazole B-DRUG

we O
report O
a O
case O
of O
senna-induced O
cholestatic B-ADR
hepatitis I-ADR
which O
was O
not O
diagnosed O
at O
presentation O

acute B-ADR
renal I-ADR
failure I-ADR
during O
lisinopril B-DRUG
and O
losartan O
therapy O
for O
proteinuria O

nonconvulsive B-ADR
status I-ADR
epilepticus I-ADR
: O
the O
role O
of O
morphine B-DRUG
and O
its O
antagonist O

autopsy O
evidence O
of O
herpesvirus B-ADR
infection I-ADR
was O
found O
in O
visceral O
organs O
of O
four O
leukemic O
patients O
who O
had O
received O
large O
doses O
of O
cytarabine B-DRUG
( O
cytosine O
arabinoside O
; O
ara-c O
) O
shortly O
before O
their O
death O

withdrawal B-ADR
emergent I-ADR
syndrome I-ADR
in O
an O
infant O
associated O
with O
maternal O
haloperidol B-DRUG
therapy O

our O
cases O
constitute O
the O
most O
severe O
cases O
of O
benzarone B-DRUG
hepatotoxicity O
reported O
so O
far O
, O
and O
comprise O
the O
first O
cases O
of O
( O
sub O
) O
fulminant O
hepatitis O
and O
cirrhosis O
related O
to O
benzarone B-DRUG

we O
report O
on O
a O
patient O
who O
developed O
hypersensitivity B-ADR
pneumonitis I-ADR
during O
treatment O
with O
the O
beta-blocker O
, O
celiprolol B-DRUG

hypoglycemia B-ADR
can O
be O
a O
serious O
side O
effect O
of O
etanercept B-DRUG
in O
patients O
already O
on O
antidiabetic O
medications O
known O
to O
cause O
hypoglycemia O
, O
such O
as O
sulfonylureas O
, O
meglitinides O
, O
and O
insulin O

a O
dapsone B-DRUG
hypersensitivity O
syndrome O
, O
consisting O
of O
fever O
, O
headache O
, O
nausea O
, O
vomiting O
, O
lymphadenopathy O
, O
hepatitis O
, O
hemolysis O
, O
leukopenia B-ADR
, O
and O
mononucleosis O
, O
has O
been O
described O
in O
patients O
treated O
with O
the O
drug O
for O
leprosy O

visual B-ADR
hallucinations I-ADR
after O
intravitreal O
injection O
of O
bevacizumab B-DRUG
in O
vascular O
age-related O
macular O
degeneration O

we O
report O
a O
5-year-old O
boy O
with O
cf O
who O
had O
a O
stricture O
of O
the O
hepatic O
flexure O
region O
with O
associated O
narrowing O
due O
to O
submucosal B-ADR
fibrosis I-ADR
of I-ADR
the I-ADR
transverse I-ADR
colon I-ADR
, O
secondary O
to O
high-lipase B-DRUG
pancreatin I-DRUG
therapy O

we O
report O
a O
case O
of O
generalized B-ADR
cutaneous I-ADR
sclerosis I-ADR
associated O
with O
muscle O
and O
oesophageal O
involvement O
in O
a O
patient O
exposed O
to O
herbicides O
containing O
bromocil B-DRUG
, O
diuron O
and O
aminotriazole O

autoimmune B-ADR
thyroid I-ADR
disease I-ADR
is O
a O
common O
side-effect O
of O
interferon-alpha B-DRUG
( O
ifn-alpha O
) O
treatment O
of O
viral O
hepatitis O
c O

colchicine-induced O
rhabdomyolysis B-ADR
is O
a O
rare O
complication O
, O
and O
the O
postulated O
mechanisms O
and O
risk O
factors O
for O
this O
severe O
complication O
are O
discussed O

we O
report O
the O
occurrence O
of O
renal O
failure O
due O
to O
cholesterol B-ADR
crystal I-ADR
embolization I-ADR
following O
thrombolytic O
therapy O
with O
intravenous O
recombinant O
tissue-type O
plasminogen O
activator O
( O
t-pa B-DRUG

an O
adolescent O
male O
developed O
acute B-ADR
pancreatitis I-ADR
and O
pseudocyst O
of O
the O
pancreas O
16 O
weeks O
after O
cessation O
of O
intramuscular O
l-asparaginase B-DRUG

in O
addition O
to O
its O
known O
effect O
on O
gallbladder O
stasis O
, O
octreotide B-DRUG
alters O
bile O
acid O
composition O
and O
may O
thus O
hasten O
intrahepatic O
sludge O
and O
stone B-ADR
formation I-ADR

when O
sasp O
was O
changed O
to O
5-aminosalicylic B-DRUG
acid I-DRUG
( O
5-asa O
) O
, O
his O
skin O
eruptions O
were O
resolved O
, O
however O
, O
he O
developed O
weakness B-ADR
and O
atrophy O
in O
his O
right O
arm O
as O
well O
as O
progressive O
worsening O
of O
the O
dysesthesia O
in O
his O
legs O
and O
gait O
disturbance O

isotretinoin B-DRUG
teratogenicity B-ADR

although O
gabapentin B-DRUG
withdrawal O
has O
been O
previously O
reported O
and O
usually O
consists O
of O
anxiety O
, O
diaphoresis O
, O
and O
palpitations O
, O
this O
is O
the O
first O
reported O
patient O
with O
generalized B-ADR
seizures I-ADR
and O
status O
epilepticus O
secondary O
to O
gabapentin B-DRUG
withdrawal O

the O
more O
common O
grade O
3 O
or O
4 O
adverse O
effects O
of O
sunitinib B-DRUG
include O
hypertension O
, O
fatigue B-ADR
, O
hand-foot O
syndrome O
, O
elevated O
lipase O
and O
lymphopenia O

haemolytic-uraemic B-ADR
syndrome I-ADR
complicating O
long-term O
mitomycin O
c O
and O
5-fluorouracil B-DRUG
therapy O
for O
gastric O
carcinoma O

the O
medical O
examiner O
's O
report O
indicated O
death B-ADR
caused O
by O
fluoxetine B-DRUG
toxicity O

indinavir-associated O
nephrolithiasis B-ADR
and O
chronic O
interstitial O
nephritis O
were O
the O
only O
possible O
causes O
identified O
in O
this O
patient O

reye-like B-ADR
syndrome I-ADR
following O
treatment O
with O
the O
pantothenic O
acid O
antagonist O
, O
calcium B-DRUG
hopantenate I-DRUG

hypersensitivity O
to O
aspirin B-DRUG
can O
be O
manifested O
as O
acute O
asthma O
, O
urticaria B-ADR
and O
/ O
or O
angioedema O
, O
or O
a O
systemic O
anaphylactoid O
reaction O

we O
present O
a O
46-year-old O
african-american O
man O
with O
aids O
who O
was O
admitted O
on O
two O
different O
occasions O
within O
three O
weeks O
for O
signs O
and O
symptoms O
of O
meningitis B-ADR
after O
using O
trimethoprim O
/ O
sulfamethoxazole O
( O
tmp O
/ O
smx B-DRUG

prenatal O
cytomegalovirus O
( O
cmv O
) O
infection O
associated O
with O
severe O
brain B-ADR
damage I-ADR
was O
detected O
in O
an O
infant O
whose O
mother O
had O
been O
treated O
with O
prednisolone O
and O
azathioprine B-DRUG
for O
systemic O
lupus O
erythematosus O
( O
sle O

acute O
interstitial B-ADR
pneumonia I-ADR
induced O
by O
ono-1078 B-DRUG
( O
pranlukast O
) O
, O
a O
leukotriene O
receptor O
antagonist O

a O
64 O
year O
old O
man O
with O
recurrent O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
developed O
severe B-ADR
skin I-ADR
rash I-ADR
and O
bone O
marrow O
aplasia O
4 O
and O
7 O
days O
, O
respectively O
, O
following O
a O
single O
dose O
of O
40 O
mg O
/ O
m2 O
methotrexate O
( O
mtx B-DRUG

three O
of O
these O
patients O
had O
convulsions O
attributed O
to O
imipenem O
/ O
cilastatin B-DRUG
; O
3.6 O
% O
of O
the O
patients O
had O
seizure B-ADR
, O
or O
2 O
% O
of O
imipenem O
/ O
cilastatin B-DRUG
administrations O
was O
followed O
by O
a O
seizure B-ADR
attack O

a O
teenage O
girl O
with O
crescentic O
glomerulonephritis O
had O
antineutrophil B-ADR
cytoplasmic I-ADR
antibody I-ADR
( O
anca O
) O
detected O
after O
she O
had O
received O
propylthiouracil O
( O
ptu B-DRUG
) O
for O
hyperthyroidism O
without O
cutaneous O
vasculitis O

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin O
, O
grepafloxacin B-DRUG
, O
trovafloxacin O
, O
gatifloxacin O
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache O
, O
dizziness O
and O
insomnia B-ADR

cardiomyopathy B-ADR
after O
widely O
separated O
courses O
of O
adriamycin O
exacerbated O
by O
actinomycin-d O
and O
mithramycin B-DRUG

prior O
to O
surgery O
, O
levodopa B-DRUG
induced O
dyskinesia B-ADR
had O
improved O
(< O
or O
= O
50 O
%) O
under O
treatment O
with O
amantadine O
( O
400 O
mg O
/ O
day O
, O
po O
) O
in O
all O
three O
patients O

hyponatraemia B-ADR
developed O
after O
rechallenge O
with O
controlled O
release O
carbamazepine B-DRUG

a O
patient O
receiving O
vancomycin B-DRUG
for O
a O
serious O
staphylococcal O
infection O
had O
a O
lupus-like O
syndrome O
characterized O
by O
a O
malar O
rash O
, O
pain O
and O
erythema O
of O
the O
cartilage O
of O
both O
ears O
, O
and O
tender B-ADR
erythematous I-ADR
and O
hemorrhagic O
lesions O
of O
the O
finger O
tips O

a O
36-year-old O
man O
being O
treated O
with O
cisplatinum O
, O
vinblastine B-DRUG
, O
and O
bleomycin O
for O
testicular O
carcinoma O
developed O
a O
dense O
left B-ADR
homonymous I-ADR
hemianopsia I-ADR
, O
encephalopathy O
, O
and O
a O
partial O
nondominant O
parietal O
lobe O
syndrome O

clozapine B-DRUG
induced O
polyserositis B-ADR

we O
have O
reported O
six O
cases O
of O
metoclopramide-induced O
parkinsonism B-ADR
seen O
in O
consultation O
over O
a O
two-year O
period O

fatal B-ADR
pulmonary I-ADR
fibrosis I-ADR
following O
1,3-bis O
( O
2-chloroethyl O
)- O
1-nitrosourea O
( O
bcnu O
) O
therapy O

the O
mechanism O
of O
anaphylactoid B-ADR
reaction I-ADR
to O
zomepirac B-DRUG
in O
this O
case O
, O
therefore O
, O
remains O
unclear O

toxicity B-ADR
, O
pharmacokinetics O
, O
and O
in O
vitro O
hemodialysis O
clearance O
of O
ifosfamide B-DRUG
and O
metabolites O
in O
an O
anephric O
pediatric O
patient O
with O
wilms' O
tumor O

in O
addition O
, O
there O
is O
a O
report O
on O
prolonged B-ADR
ect I-ADR
seizure I-ADR
related O
to O
ciprofloxacin B-DRUG
, O
which O
has O
an O
epileptogenic O
property O
with O
a O
similar O
action O
to O
beta-lactam O
antibiotics O

to O
treat O
hepatitis O
b O
, O
interferon B-DRUG
alpha I-DRUG
was O
administered O
until O
the O
proximal O
muscle B-ADR
weakness I-ADR
developed O

it O
was O
highly O
suspected O
that O
finasteride B-DRUG
was O
associated O
with O
the O
anterior B-ADR
subcapsular I-ADR
opacity I-ADR
on I-ADR
the I-ADR
lens I-ADR
, O
and O
the O
patient O
therefore O
discontinued O
use O
of O
finasteride B-DRUG

thalidomide B-DRUG
neuropathy B-ADR
in O
childhood O

the O
patient O
completed O
a O
10-month O
follow-up O
, O
maintaining O
a O
complete O
resolution O
of O
the O
treated O
skin O
lesions O
; O
however O
, O
the O
development O
of O
a O
painful O
hand O
ulcer O
, O
possibly O
associated O
with O
the O
hydroxyurea B-DRUG
, O
and O
new O
skin B-ADR
cancers I-ADR
were O
observed O
at O
the O
last O
follow-up O
visit O

we O
report O
a O
53-year-old-man O
who O
developed O
rippling O
muscle O
disease O
( O
rmd B-ADR
) O
2 O
months O
after O
starting O
simvastatin B-DRUG
therapy O
for O
hypercholesterolemia O

objective O
: O
to O
report O
the O
occurrence O
of O
anterior B-ADR
ischemic I-ADR
optic I-ADR
neuropathy I-ADR
as O
a O
complication O
of O
treatment O
with O
interferon B-DRUG
alfa I-DRUG
and O
to O
consider O
the O
possible O
underlying O
mechanisms O
for O
this O
association O

during O
clarithromycin B-DRUG
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate-to-severe O
toxic O
symptoms O
of O
carbamazepine O
, O
such O
as O
drowsiness O
, O
dizziness O
, O
and O
ataxia B-ADR
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin B-DRUG
discontinuation O

after O
the O
dose O
of O
methylprednisolone B-DRUG
was O
reduced O
from O
40 O
mg O
to O
20 O
mg O
i.v. O
q6h O
and O
shifted O
to O
other O
anti-asthma O
treatment O
by O
procaterol O
metered O
dose O
inhaler O
via O
spacer O
, O
the O
psychotic B-ADR
reaction I-ADR
disappeared O
a O
few O
hours O
later O

a O
patient O
is O
presented O
with O
typical O
hyperthyroidism B-ADR
, O
who O
developed O
a O
severe O
proximal O
muscle O
weakness O
and O
a O
raised O
creatine O
phosphokinase O
after O
treatment O
for O
hyperthyroidism B-ADR
with O
propylthiouracil B-DRUG
( O
100 O
mg O
orally O
, O
three O
times O
a O
day O

early O
recognition O
of O
hereditary O
motor O
and O
sensory O
neuropathy O
type O
1 O
can O
avoid O
life-threatening B-ADR
vincristine I-ADR
neurotoxicity I-ADR

we O
present O
three O
patients O
with O
paradoxical O
seizures B-ADR
; O
their O
serum O
phenytoin B-DRUG
levels O
were O
43.5 O
mcg O
/ O
ml O
, O
46.5 O
mcg O
/ O
ml O
and O
38.3 O
mcg O
/ O
ml O

objective O
: O
to O
report O
the O
case O
of O
a O
young O
woman O
with O
graves' O
disease O
in O
whom O
ototoxicity O
developed O
because O
of O
propylthiouracil B-DRUG
( O
ptu O
)- O
induced O
antineutrophil O
cytoplasmic O
antibody O
( O
anca O
)- O
associated O
vasculitis O

fever O
, O
lymphadenopathy O
, O
eosinophilia O
, O
lymphocytosis O
, O
hepatitis B-ADR
, O
and O
dermatitis O
: O
a O
severe O
adverse O
reaction O
to O
minocycline B-DRUG

aims O
: O
to O
present O
a O
case O
of O
piloerection B-ADR
after O
replacing O
fluvoxamine B-DRUG
maleate I-DRUG
with O
milnacipran O
hydrochloride O
, O
and O
to O
analyse O
this O
effect O
based O
on O
receptor O
occupancy O
theory O

in O
this O
article O
, O
we O
describe O
another O
case O
of O
subcutaneous O
changes O
following O
repeated O
glatiramer B-DRUG
acetate I-DRUG
injection O
, O
presented O
as O
localized B-ADR
panniculitis I-ADR
in O
the O
area O
around O
the O
injection O
sites O
, O
in O
a O
46-year-old O
female O
patient O
who O
was O
treated O
with O
glatiramer B-DRUG
acetate I-DRUG
for O
18 O
months O

conclusions O
: O
sd-oct O
and O
ao O
detected O
abnormalities O
that O
correlate O
topographically O
with O
visual O
field O
loss O
from O
hydroxychloroquine B-DRUG
toxicity O
as O
demonstrated O
by O
hvf O
10-2 O
and O
may O
be O
useful O
in O
the O
detection O
of O
subclinical O
abnormalities O
that O
precede O
symptoms O
or O
objective B-ADR
visual I-ADR
field I-ADR
loss I-ADR

conclusions O
: O
clinicians O
should O
be O
aware O
of O
a O
risk O
of O
serotonin B-ADR
syndrome I-ADR
with O
serious O
extrapyramidal O
reactions O
in O
patients O
receiving O
sertraline O
or O
venlafaxine B-DRUG
when O
metoclopramide O
is O
coadministered O
even O
in O
a O
single O
, O
conventional O
dose O

we O
report O
the O
case O
of O
an O
adult O
patient O
with O
acute O
lymphoblastic O
leukemia O
who O
presented O
with O
repeated O
transient O
ischemic O
attacks O
followed O
by O
a O
seizure B-ADR
during O
consolidation O
treatment O
with O
l-asparaginase B-DRUG

one O
patient O
who O
received O
clindamycin B-DRUG
had O
liver O
biopsy O
findings O
of O
marked O
cholestasis O
, O
portal O
inflammation O
, O
bile B-ADR
duct I-ADR
injury I-ADR
and O
bile O
duct O
paucity O
( O
ductopenia O

putaminal B-ADR
infarct I-ADR
in O
methanol B-DRUG
intoxication O
: O
case O
report O
and O
role O
of O
brain O
imaging O
studies O

purpose O
: O
to O
report O
a O
case O
of O
bilateral B-ADR
anterior I-ADR
uveitis I-ADR
associated O
with O
ovulation O
induction O
therapy O
using O
clomiphene B-DRUG
citrate I-DRUG

our O
case O
is O
the O
second O
one O
in O
which O
hemorrhage B-ADR
from O
a O
meningioma O
may O
have O
been O
induced O
by O
aspirin B-DRUG
prophylaxis O

reversible B-ADR
mr I-ADR
imaging I-ADR
and I-ADR
mr I-ADR
spectroscopy I-ADR
abnormalities I-ADR
in O
association O
with O
metronidazole B-DRUG
therapy O

graft O
versus O
host-like O
illness O
in O
a O
child O
with O
phenobarbital B-DRUG
hypersensitivity B-ADR

one O
week O
after O
the O
initial-dose O
of O
adalimumab B-DRUG
( O
160 O
mg O
) O
, O
which O
was O
initiated O
due O
to O
an O
acute O
exacerbation O
of O
crohn O
's O
disease O
, O
the O
patient O
developed O
a O
fulminant B-ADR
cardiomyopathy I-ADR

seven O
patients O
with O
hematologic O
malignancies O
who O
were O
treated O
with O
miconazole B-DRUG
for O
either O
suspected O
or O
proven O
fungal O
infections O
developed O
eight O
episodes O
of O
major O
adverse O
cardiorespiratory B-ADR
and I-ADR
anaphylactic I-ADR
reactions I-ADR

three O
months O
after O
starting O
citalopram B-DRUG
, O
she O
experienced O
episodes O
of O
chest O
tightness O
and O
dizziness B-ADR

cisplatin-induced O
syndrome O
of O
inappropriate O
antidiuretic O
hormone O
( O
siadh B-ADR
) O
in O
a O
patient O
with O
neuroendocrine O
tumor O
of O
the O
cervix O
: O
a O
case O
report O
and O
review O
of O
the O
literature O

infliximab O
and O
its O
serious O
adverse O
effects O
are O
discussed O
, O
and O
other O
cases O
of O
osteomyelitis B-ADR
with O
infliximab B-DRUG
use O
are O
also O
reviewed O

in O
this O
report O
, O
one O
patient O
who O
developed O
gangrene O
after O
bleomycin O
and O
vincristine B-DRUG
/ O
vinblastine O
chemotherapy O
for O
aids-related O
kaposi O
's O
sarcoma O
and O
another O
hiv-infected O
patient O
who O
exhibited O
symptoms O
of O
severe B-ADR
raynaud I-ADR
's I-ADR
phenomenon I-ADR
related O
to O
the O
same O
regimen O
are O
presented O

the O
renal B-ADR
insufficiency I-ADR
of O
three O
patients O
and O
the O
timing O
of O
the O
seizures O
implicate O
accumulation O
of O
ofloxacin B-DRUG
as O
a O
contributing O
factor O

we O
report O
a O
case O
of O
a O
60-year-old O
woman O
affected O
by O
squamous O
lung O
carcinoma O
, O
who O
developed O
paroxysmal B-ADR
supraventricular I-ADR
tachycardia I-ADR
during O
cisplatin O
and O
etoposide B-DRUG
combination O
chemotherapy O

conclusions O
: O
cefazolin B-DRUG
was O
a O
probable O
cause O
of O
this O
patient O
's O
leukopenia B-ADR

two O
patients O
with O
bipolar O
affective O
disorder O
and O
a O
history O
of O
bronchospastic O
phenomena O
experienced O
tremor B-ADR
during O
lithium B-DRUG
carbonate I-DRUG
therapy O

a O
7-year-old O
with O
congenital O
toxoplasmosis O
who O
took O
pyrimethamine B-DRUG
and O
sulfadiazine O
for O
reactivated O
chorioretinitis O
developed O
fever O
, O
severe O
cutaneous O
involvement O
, O
swelling B-ADR
, O
abdominal O
pain O
and O
transaminitis O
, O
persisting O
weeks O
after O
withholding O
medicines O

it O
is O
suggested O
that O
the O
fatal B-ADR
stroke I-ADR
may O
have O
resulted O
from O
arterial O
spasm O
caused O
by O
ergotamine B-DRUG
overdosage O
and O
possibly O
complicated O
by O
thrombosis O

many O
clinicians O
appear O
to O
be O
concerned O
about O
the O
potential O
hepatotoxicity B-ADR
of O
the O
opiate O
antagonist O
naltrexone O
( O
ntx B-DRUG
) O
and O
this O
may O
be O
one O
reason O
why O
it O
is O
not O
used O
more O
widely O
in O
treating O
both O
heroin O
and O
alcohol O
abusers O

the O
pro-arrhythmic B-ADR
effects I-ADR
of O
procainamide B-DRUG
may O
be O
explained O
on O
the O
basis O
of O
both O
its O
vagolytic O
action O
on O
the O
atrioventricular O
node O
as O
well O
as O
by O
prolongation O
of O
refractoriness O
in O
the O
accessory O
pathway O

seventy-four O
per O
cent O
of O
patients O
with O
epileptogenic O
disorders O
seen O
at O
the O
emergency O
unit O
at O
groote O
schuur O
hospital O
were O
on O
phenytoin B-DRUG
and O
11.6 O
% O
of O
these O
had O
blood B-ADR
levels I-ADR
in I-ADR
the I-ADR
toxic I-ADR
range I-ADR

to O
develop O
information O
on O
the O
relative O
rarity O
or O
frequency O
of O
neurologic O
worsening O
with O
the O
initiation O
of O
penicillamine B-DRUG
therapy O
, O
we O
conducted O
a O
retrospective O
survey O
of O
25 O
additional O
patients O
with O
wilson O
's O
disease O
who O
met O
the O
criteria O
of O
presenting O
with O
neurologic B-ADR
disease I-ADR
and O
having O
been O
treated O
with O
penicillamine B-DRUG

three O
of O
these O
patients O
had O
convulsions O
attributed O
to O
imipenem O
/ O
cilastatin B-DRUG
; O
3.6 O
% O
of O
the O
patients O
had O
seizure B-ADR
, O
or O
2 O
% O
of O
imipenem O
/ O
cilastatin B-DRUG
administrations O
was O
followed O
by O
a O
seizure B-ADR
attack O

we O
describe O
a O
case O
of O
advanced O
ovarian O
carcinoma O
who O
developed O
difficulty O
walking O
because O
of O
marked B-ADR
pain I-ADR
in O
the O
lower O
extremities O
and O
loss O
of O
proprioception O
25 O
days O
after O
treatment O
with O
weekly O
taxol B-DRUG
( O
80 O
mg O
/ O
m O
( O
2 O
) O
x3 O

however O
, O
as O
the O
use O
of O
hepatitis B-DRUG
b I-DRUG
vaccination I-DRUG
is O
growing O
, O
adverse O
side O
effects O
, O
including O
mental B-ADR
nerve I-ADR
neuropathy I-ADR
, O
should O
be O
observed O
with O
an O
increased O
frequency O

in O
all O
cases O
, O
seizures B-ADR
were O
controlled O
by O
withdrawal O
of O
phenytoin B-DRUG
and O
reduction O
of O
drug O
levels O

due O
to O
discomfort O
, O
diplopia O
and O
lagophthalmos O
, O
the O
haematoma B-ADR
necessitated O
suspension O
of O
warfarin B-DRUG
therapy O
and O
a O
surgical O
evacuation O

a O
21-year-old O
man O
with O
tourette O
's O
syndrome O
, O
pedophilia O
, O
asperger O
's O
syndrome O
, O
and O
multiple O
sclerosis O
experienced O
seizures B-ADR
after O
receiving O
therapy O
with O
interferon B-DRUG
beta-1a I-DRUG

nodular B-ADR
scleritis I-ADR
following O
alendronate B-DRUG
therapy O

a O
patient O
with O
a O
large O
hydatid O
cyst O
of O
the O
left O
lobe O
of O
the O
liver O
developed O
metabolic B-ADR
acidosis I-ADR
following O
rather O
liberal O
use O
of O
cetrimide-chlorhexidine O
solution O
as O
a O
scolicidal O
agent O

we O
observed O
2 O
cases O
of O
hepatotoxicity B-ADR
after O
a O
high-dose O
methylprednisolone B-DRUG
treatment O
of O
a O
demyelinating O
disease O
and O
evaluated O
the O
potential O
relationship O
in O
the O
light O
of O
available O
evidence O

one O
should O
therefore O
be O
aware O
of O
possible O
extrapyramidal B-ADR
side I-ADR
effects I-ADR
with O
olanzapine B-DRUG
that O
are O
reduced O
compared O
to O
classical O
neuroleptic O
drugs O
but O
not O
completely O
eliminated O

diphenylhydantoin B-DRUG
apparently O
adversely O
affected O
both O
the O
clinical O
and O
biochemical O
parameters O
of O
the O
acute B-ADR
intermittent I-ADR
porphyria I-ADR

psoriasis-like B-ADR
skin I-ADR
reaction I-ADR
in O
a O
patient O
with O
rheumatoid O
arthritis O
after O
sulphasalazine B-DRUG
therapy O

a O
16-year-old O
boy O
developed O
fever O
, O
generalized O
rigidity O
, O
leukocytosis B-ADR
, O
and O
increased O
serum O
transaminase O
and O
creatine O
kinase O
levels O
while O
receiving O
treatment O
with O
olanzapine B-DRUG
and O
lithium O

we O
report O
the O
case O
of O
a O
child O
with O
metastatic O
osteosarcoma O
, O
who O
experienced O
an O
anaphylactic B-ADR
/ I-ADR
anaphylactoid I-ADR
reaction I-ADR
to O
methotrexate B-DRUG

a O
review O
of O
the O
literature O
found O
11 O
children O
and O
2 O
adults O
in O
whom O
intranasal O
desmopressin B-DRUG
was O
associated O
with O
hyponatremia B-ADR
, O
all O
of O
whom O
experienced O
seizures O
or O
altered O
mental O
status O

carbamazepine-induced O
diabetes B-ADR
mellitus I-ADR

the O
second O
had O
acute O
cystitis O
and O
was O
treated O
by O
sulphonamide B-DRUG
and O
the O
third O
developed O
myopia B-ADR
coincident O
with O
metronidazole O
treatment O
for O
trichomonas O
vaginalis O

ocular B-ADR
ethambutol I-ADR
toxicity I-ADR

five O
patients O
receiving O
fluoxetine B-DRUG
for O
the O
treatment O
of O
obsessive O
compulsive O
disorder O
or O
major O
depression O
developed O
akathisia B-ADR

we O
report O
a O
case O
of O
vitiligo B-ADR
that O
occurred O
during O
the O
second O
month O
of O
interferon B-DRUG
alpha I-DRUG
2a I-DRUG
therapy O
for O
chronic O
active O
hepatitis O
c O

septic B-ADR
knee I-ADR
arthritis I-ADR
after O
intra-articular O
hyaluronate B-DRUG
injection O

an O
11-year-old O
boy O
developed O
a O
severe B-ADR
enteropathy I-ADR
2 O
years O
after O
initiation O
of O
clofazimine B-DRUG
treatment O
for O
graft-versus-host O
disease O

we O
present O
two O
children O
with O
acute O
lymphocytic O
leukemia O
who O
developed O
leukoencephalopathy B-ADR
following O
administration O
of O
a O
combination O
of O
intravenous O
ara B-DRUG
= I-DRUG
c I-DRUG
and O
methotrexate O
during O
the O
consolidation O
phase O
of O
chemotherapy O

massive O
prolapse B-ADR
of I-ADR
the I-ADR
urethral I-ADR
mucosa I-ADR
following O
periurethral O
injection O
of O
calcium B-DRUG
hydroxylapatite I-DRUG
for O
stress O
urinary O
incontinence O

localized B-ADR
panniculitis I-ADR
and O
subsequent O
lipoatrophy O
with O
subcutaneous O
glatiramer B-DRUG
acetate I-DRUG
( O
copaxone O
) O
injection O
for O
the O
treatment O
of O
multiple O
sclerosis O

we O
believe O
this O
is O
the O
first O
report O
of O
myocardial O
infarction O
due O
to O
coronary B-ADR
spasm I-ADR
, O
demonstrated O
by O
angiography O
associated O
with O
l-thyroxine B-DRUG
therapy O

conclusion O
: O
this O
rare O
case O
of O
ptu-induced O
anca-associated O
vasculitis O
manifested O
with O
ototoxicity B-ADR
in O
combination O
with O
systemic O
involvement O

disseminated O
muscular O
cysticercosis O
with O
myositis B-ADR
induced O
by O
praziquantel B-DRUG
therapy O

bone B-ADR
formation I-ADR
induced O
in O
an O
infant O
by O
systemic O
prostaglandin-e2 B-DRUG
administration O

acute O
myopathy O
with O
selective O
degeneration B-ADR
of I-ADR
myosin I-ADR
filaments I-ADR
following O
status O
asthmaticus O
treated O
with O
methylprednisolone O
and O
vecuronium B-DRUG

a O
macrophage B-ADR
activation I-ADR
syndrome I-ADR
, O
possibly O
related O
to O
methotrexate B-DRUG
toxicity O
, O
developed O
in O
a O
boy O
with O
systemic O
juvenile O
rheumatoid O
arthritis O

hepato-biliary B-ADR
abnormalities I-ADR
secondary O
to O
ceftriaxone B-DRUG
use O
: O
a O
case O
report O

the O
authors O
describe O
a O
case O
of O
combined O
lithium B-DRUG
and O
haloperidol O
toxicity O
characterized O
by O
hyperpyrexia B-ADR
, O
severe O
rigidity O
, O
mutism O
, O
and O
development O
of O
irreversible O
tardive O
dyskinesia O

this O
report O
describes O
a O
13-year-old O
female O
with O
a O
right O
frontal O
high-grade O
glioma O
and O
complex O
partial O
seizures O
who O
developed O
localized B-ADR
purpura I-ADR
after O
23 O
months O
of O
lamotrigine B-DRUG
monotherapy O

a O
56-year-old O
woman O
with O
scleroderma O
developed O
rapidly B-ADR
progressive I-ADR
glomerulonephritis I-ADR
with O
epithelial O
crescents O
associated O
with O
hemoptysis O
after O
27 O
months O
of O
d-penicillamine B-DRUG
therapy O
and O
a O
cumulative O
dose O
of O
1,200 O
g O

this O
is O
the O
second O
report O
of O
lactic B-ADR
acidosis I-ADR
in O
a O
patient O
on O
stavudine O
and O
lamivudine B-DRUG

the O
possibility O
of O
phenytoin B-DRUG
hypersensitivity B-ADR
reactions I-ADR
should O
be O
considered O
when O
patients O
receiving O
phenytoin B-DRUG
have O
unusual O
symptoms O
, O
particularly O
fever O
, O
rash O
, O
and O
lymphadenopathy O

extrapyramidal B-ADR
side I-ADR
effects I-ADR
induced O
by O
some O
selective O
serotonin O
reuptake O
inhibitors O
( O
ssris O
) O
, O
i.e. O
fluoxetine B-DRUG
and O
sertraline O
, O
have O
been O
previously O
reported O
in O
patients O
with O
depression O
and O
obsessive-compulsive O
disorder O
( O
ocd O

progressive B-ADR
pulmonary I-ADR
fibrosis I-ADR
complicating O
cyclophosphamide B-DRUG
therapy O

this O
selective O
closure O
of O
the O
ductus O
arteriosus O
suggests O
that O
the O
affected O
twin O
was O
predisposed O
to O
hypoxia O
and O
thus O
was O
more O
susceptible O
to O
ductal B-ADR
closure I-ADR
in O
response O
to O
indomethacin B-DRUG
exposure O

enalapril-induced O
anemia B-ADR
in O
two O
kidney O
transplant O
recipients O

a O
70-year-old O
man O
was O
admitted O
to O
our O
hospital O
because O
of O
dyspnea B-ADR
after O
taking O
an O
antihistaminic O
agent O
( O
homochlorcyclizine B-DRUG
hydrochloride I-DRUG
) O
for O
itching O

a O
case O
of O
recall B-ADR
pneumonitis I-ADR
induced O
by O
gemcitabine B-DRUG
is O
reported O

argatroban B-DRUG
is O
hepatically O
cleared O
and O
may O
be O
the O
preferred O
direct O
thrombin O
inhibitor O
in O
the O
presence O
of O
significant O
renal O
impairment O
, O
but O
conversely O
has O
prolonged O
effects O
in O
hepatic B-ADR
failure I-ADR

the O
increasing O
prevalence O
of O
methamphetamine B-DRUG
abuse O
and O
the O
severity O
of O
the O
associated O
ulcers B-ADR
should O
alert O
ophthalmologists O
to O
the O
problem O
of O
methamphetamine-related O
keratitis O

here O
we O
describe O
a O
patient O
with O
crohn O
's O
disease O
who O
developed O
a O
severe O
infliximab B-DRUG
infusion O
reaction O
( O
iir O
) O
, O
complicated O
1 O
day O
later O
by O
severe B-ADR
swelling I-ADR
of I-ADR
the I-ADR
forearm I-ADR
and I-ADR
hand I-ADR
ipsilateral I-ADR
to O
the O
site O
of O
infliximab B-DRUG
infusion O

abnormal B-ADR
retinal I-ADR
function I-ADR
associated O
with O
isotretinoin B-DRUG
therapy O
for O
acne O

after O
rechallenge O
with O
monotherapy O
pegvisomant B-DRUG
, O
however O
, O
the O
hepatic O
enzyme O
disturbances O
reappeared O
within O
a O
few O
weeks O
, O
indicating O
that O
most O
likely O
pegvisomant B-DRUG
alone O
and O
not O
the O
long-acting O
somatostatin O
analog O
or O
the O
combination O
of O
these O
two O
drugs O
was O
responsible O
for O
this O
case O
of O
drug-induced O
hepatitis B-ADR

a O
53 O
year O
old O
greenlandic O
male O
was O
admitted O
twice O
over O
a O
period O
of O
4 O
years O
with O
a O
new O
complete O
right B-ADR
bundle I-ADR
branch I-ADR
block I-ADR
after O
ingestion O
of O
10 O
g O
and O
4 O
g O
of O
carbamazepine B-DRUG
respectively O

atenolol-induced O
pseudolymphoma B-ADR

a O
case O
history O
of O
a O
15-year-old O
boy O
who O
developed O
incapacitating O
tardive B-ADR
dyskinesia I-ADR
that O
resolved O
during O
treatment O
with O
deanol B-DRUG
is O
presented O

a O
case O
of O
barbiturate-induced O
submassive B-ADR
hepatic I-ADR
necrosis I-ADR
is O
presented O
and O
the O
literature O
is O
reviewed O

we O
conclude O
that O
neurosurgeons O
and O
neurologists O
should O
be O
aware O
of O
calcium O
antagonist O
-- O
related O
ileus B-ADR
in O
patients O
treated O
with O
nimodipine B-DRUG

to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
griseofulvin-exacerbated O
lupus O
in O
which O
nephrotic B-ADR
syndrome I-ADR
has O
been O
observed O

isoniazid B-DRUG
causing O
breast B-ADR
tissue I-ADR
enlargement I-ADR
has O
been O
very O
rarely O
reported O

interpretation O
: O
when O
high O
doses O
of O
fluticasone B-DRUG
propionate I-DRUG
are O
used O
, O
growth O
may O
be O
retarded O
and O
adrenal B-ADR
suppression I-ADR
may O
occur O

background O
: O
colchicine B-DRUG
has O
a O
known O
adverse O
effect O
on O
wound O
healing O
through O
its O
inhibitory O
effect O
on O
tubulin-dependent O
cell O
functions O
and O
through O
collagenase B-ADR
activation I-ADR

pneumocystis O
pneumonia O
should O
be O
considered O
in O
asthmatic O
patients O
taking O
methotrexate B-DRUG
who O
present O
with O
fever O
, O
pulmonary O
infiltrates O
, O
and O
hypoxia B-ADR

background O
: O
fluoxetine B-DRUG
, O
a O
highly O
specific O
serotonin O
reuptake O
inhibitor O
, O
has O
been O
reported O
to O
cause O
sexual B-ADR
dysfunction I-ADR
in O
a O
minority O
of O
patients O

we O
conclude O
that O
myocardial B-ADR
infarction I-ADR
may O
develop O
in O
patients O
treated O
with O
high-dose O
glucocorticoids B-DRUG
for O
graves' O
ophthalmopathy O
, O
and O
increased O
blood O
pressure O
may O
herald O
this O
complication O

we O
present O
a O
case O
of O
the O
syndrome B-ADR
of I-ADR
inappropriate I-ADR
antidiuretic I-ADR
hormone I-ADR
( O
siadh O
) O
secondary O
to O
cisplatin B-DRUG
therapy O
in O
a O
patient O
with O
advanced-stage O
large O
cell O
neuroendocrine O
carcinoma O
of O
the O
cervix O

an O
episode O
of O
subacute O
encephalopathy B-ADR
after O
the O
infusion O
of O
a O
moderate O
dose O
of O
methotrexate B-DRUG
( O
1500 O
mg O
/ O
m2 O
) O
( O
mtx O
) O
is O
reported O
in O
a O
young O
adult O
with O
metastastic O
gastric O
cancer O

flutamide B-ADR
withdrawal I-ADR
syndrome I-ADR
is O
characterized O
by O
a O
decrease O
in O
prostate-specific O
antigen O
( O
psa O
) O
after O
flutamide O
withdrawal O
in O
a O
subset O
of O
patients O
with O
progressing O
metastatic O
carcinoma O
of O
the O
prostate O

renal B-ADR
failure I-ADR
associated O
with O
acetazolamide B-DRUG
therapy O
for O
glaucoma O

a O
small O
initial O
dose O
of O
prazosin B-DRUG
ranging O
from O
0.5 O
to O
1 O
mg O
has O
been O
recommended O
to O
avoid O
the O
first-dose O
phenomenon O
characterized O
by O
a O
sudden O
and O
severe B-ADR
drop I-ADR
in I-ADR
blood I-ADR
pressure I-ADR
after O
the O
administration O
of O
the O
first O
dose O
of O
prazosin B-DRUG

tacrolimus O
( O
fk506 B-DRUG
) O
, O
an O
immunosuppressant O
, O
has O
been O
associated O
with O
mutism B-ADR
in O
adults O
after O
liver O
transplant O

tacrolimus O
( O
fk506 B-DRUG
)- O
induced O
mutism B-ADR
after O
liver O
transplant O

clinicians O
have O
been O
aware O
of O
lithium B-DRUG
toxicity O
for O
many O
years O
and O
traditionally O
have O
administered O
thiazide O
diuretics O
for O
lithium-induced O
polyuria O
and O
nephrogenic B-ADR
diabetes I-ADR
insipidus I-ADR

the O
most O
common O
side O
effects O
associated O
with O
amifostine B-DRUG
are O
nausea O
, O
vomiting B-ADR
, O
hypotension O
, O
hypocalcemia O
and O
allergic O
reactions O

thirty O
patients O
with O
hepatic B-ADR
reactions I-ADR
to O
cyclofenil B-DRUG
, O
a O
non-steroidal O
drug O
with O
a O
stimulating O
effect O
on O
ovulation O
, O
are O
reviewed O

sulfasalazine-induced O
lung O
disorder O
is O
an O
extremely O
rare O
entity O
which O
must O
be O
considered O
in O
all O
ulcerative B-ADR
colitis I-ADR
patients O
while O
on O
sulfasalazine O
therapy O
, O
despite O
the O
absence O
of O
pulmonary O
symptomatology O

conclusions O
: O
for O
all O
patients O
with O
vancomycin-induced O
neutropenia B-ADR
, O
possible O
cross-reactivity O
of O
teicoplanin O
should O
be O
monitored O

eosinophilic B-ADR
cystitis I-ADR
after O
bladder O
instillation O
with O
dimethyl B-DRUG
sulfoxide I-DRUG

propranolol-induced O
hypertension B-ADR
in O
treatment O
of O
cocaine O
intoxication O

we O
report O
a O
case O
of O
acute O
generalized O
exanthematous O
pustulosis O
( O
agep B-ADR
) O
in O
a O
50-year-old O
woman O
that O
was O
attributed O
to O
the O
ingestion O
of O
nimesulide B-DRUG

we O
report O
a O
43-year-old O
woman O
who O
developed O
sore O
throat O
, O
swelling O
of O
the O
lips O
and O
oral O
cavity O
and O
dysphagia B-ADR
, O
2 O
weeks O
after O
the O
use O
of O
budesonide B-DRUG
spray O
( O
budefat O
) O
for O
treatment O
of O
bronchial O
asthma O

on O
the O
3rd O
day O
, O
an O
inferior O
vena O
cava O
( O
ivc O
) O
filter O
was O
placed O
with O
a O
heparin B-DRUG
flush O
, O
after O
which O
massive O
ivc B-ADR
thrombosis I-ADR
developed O

visual O
system O
side O
effects O
caused O
by O
parasympathetic B-ADR
dysfunction I-ADR
after O
botulinum B-DRUG
toxin I-DRUG
type I-DRUG
b I-DRUG
injections O

nitrofurantoin-induced O
pulmonary B-ADR
toxicity I-ADR
during O
pregnancy O
: O
a O
report O
of O
a O
case O
and O
review O
of O
the O
literature O

captopril-induced O
pulmonary B-ADR
infiltrates I-ADR
with I-ADR
eosinophilia I-ADR
in O
an O
infant O
with O
congenital O
heart O
disease O

levofloxacin-induced O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
in O
an O
elderly O
patient O

a O
case O
of O
colchicine-induced O
rhabdomyolysis B-ADR
is O
reported O

an O
unusual O
presentation O
of O
spontaneous O
sub-conjunctival B-ADR
haematoma I-ADR
in O
a O
patient O
receiving O
warfarin B-DRUG

chlorpropamide-induced O
hemolytic B-ADR
anemia I-ADR

we O
report O
a O
patient O
with O
pulmonary O
adenocarcinoma O
complicated O
by O
the O
syndrome O
of O
inappropriate O
secretion O
of O
antidiuretic O
hormone O
( O
siadh B-ADR
) O
following O
systemic O
chemotherapy O
with O
cisplatin O
( O
cddp O
) O
and O
vindesine O
( O
vds B-DRUG

heparin-associated O
thrombocytopenia O
and O
thrombosis B-ADR
is O
a O
severe O
complication O
of O
systemic O
heparin O
therapy O

case O
report O
: O
a O
six-year-old O
boy O
with O
transfusion-dependent O
beta-thalassaemia O
developed O
a O
unilateral B-ADR
hearing I-ADR
loss I-ADR
shortly O
after O
commencing O
desferrioxamine B-DRUG
therapy O

beneficial O
effect O
of O
low-dose O
mianserin O
on O
fluvoxamine-induced O
akathisia B-ADR
in O
an O
obsessive-compulsive O
patient O

fatal B-ADR
digoxin I-ADR
poisoning I-ADR
: O
an O
unsuccessful O
resuscitation O
with O
use O
of O
digoxin-immune O
fab O

bleomycin B-DRUG
induced O
hyperpigmentation B-ADR
with O
yolk O
sac O
tumor O

trimethoprim-sulfamethoxazole-induced O
hypersensitivity B-ADR
syndrome I-ADR
associated O
with O
reactivation O
of O
human O
herpesvirus-6 O

we O
report O
the O
case O
of O
a O
patient O
who O
developed O
polyserositis O
( O
pericardial B-ADR
effusion I-ADR
, O
pleural O
effusion O
, O
and O
pericarditis O
) O
after O
being O
started O
on O
clozapine B-DRUG
, O
and O
whose O
symptoms O
remitted O
upon O
discontinuation O
of O
clozapine B-DRUG

physicians O
should O
be O
aware O
that O
indinavir B-DRUG
nephrolithiasis B-ADR
may O
cause O
papillary O
necrosis O

objective O
: O
to O
describe O
a O
case O
of O
severe O
skin B-ADR
necrosis I-ADR
resulting O
from O
peripheral O
intravenous O
administration O
of O
low-dose O
vasopressin B-DRUG
in O
a O
patient O
with O
catecholamine-resistant O
septic O
shock O

the O
induction O
of O
hypoglycaemia B-ADR
with O
pas B-DRUG
in O
this O
patient O
suggests O
a O
potential O
role O
for O
pas B-DRUG
in O
the O
treatment O
of O
diabetes O
mellitus O

we O
report O
five O
cases O
of O
carboplatin O
( O
cbdca O
) O
hypersensitivity B-ADR
after O
weekly O
low-dose O
paclitaxel B-DRUG
( O
60 O
mg O
/ O
m2 O
)/ O
cbdca O
( O
area O
under O
the O
concentration O
curve O
= O
2 O
) O
therapy O
in O
patients O
with O
recurrent O
ovarian O
cancer O
receiving O
multiple O
platinum-based O
chemotherapy O

the O
pharmaceutical O
company O
producing O
halfan B-DRUG
has O
reported O
8 O
cardiac O
arrests O
, O
leading O
to O
6 O
deaths B-ADR
, O
when O
a O
higher O
dose O
than O
recommended O
was O
used O
, O
there O
was O
recent O
or O
concomitant O
treatment O
with O
mefloquine O
, O
there O
was O
pre-existing O
prolongation O
of O
the O
qt O
interval O
or O
the O
patient O
had O
a O
thiamine O
deficiency O

vancomycin B-DRUG
is O
widely O
used O
against O
methicillin-resistant O
staphylococcus O
aureus O
infections O
, O
but O
it O
is O
associated O
with O
many O
adverse O
effects O
such O
as O
nephrotoxicity O
, O
ototoxicity O
, O
gastrointestinal O
disturbances O
, O
blood O
disorders O
, O
and O
two O
types O
of O
hypersensitivity O
reactions O
- O
an O
anaphylactoid O
reaction O
known O
as O
" O
red B-ADR
man I-ADR
syndrome I-ADR
" O
and O
anaphylaxis O

conclusions O
: O
itraconazole-induced O
liver B-ADR
injury I-ADR
presents O
with O
a O
cholestatic O
pattern O
of O
injury O
with O
damage O
to O
the O
interlobular O
bile O
ducts O
, O
possibly O
leading O
to O
ductopenia O

other O
thiazolidinediones O
currently O
in O
clinical O
trials O
may O
be O
able O
to O
provide O
the O
therapeutic O
benefits O
of O
troglitazone B-DRUG
without O
significant O
hepatotoxicity B-ADR

d-penicillamine B-DRUG
induced O
crescentic B-ADR
glomerulonephritis I-ADR
: O
report O
and O
review O
of O
the O
literature O

objective O
: O
the O
purpose O
of O
this O
study O
was O
to O
report O
the O
concomitant O
occurrence O
of O
multiple B-ADR
squamous I-ADR
cell I-ADR
carcinomas I-ADR
and O
diffuse O
nail O
hyperpigmentation O
associated O
with O
hydroxyurea B-DRUG
treatment O
, O
and O
to O
describe O
a O
successful O
therapeutic O
approach O
using O
imiquimod O
5 O

physicians O
should O
keep O
in O
mind O
that O
taxanes O
such O
as O
paclitaxel B-DRUG
have O
the O
potential O
to O
cause O
pneumonitis O
and O
lung B-ADR
fibrosis I-ADR

the O
authors O
present O
a O
case O
of O
t-aml B-ADR
that O
developed O
in O
a O
child O
with O
metastatic O
neuroblastoma O
18 O
months O
after O
he O
received O
oral O
etoposide B-DRUG
, O
given O
for O
palliation O
purpose O

the O
possibility O
of O
phenytoin B-DRUG
hypersensitivity B-ADR
reactions I-ADR
should O
be O
considered O
when O
patients O
receiving O
phenytoin B-DRUG
have O
unusual O
symptoms O
, O
particularly O
fever O
, O
rash O
, O
and O
lymphadenopathy O

amifostine-induced O
fever B-ADR
: O
case O
report O
and O
review O
of O
the O
literature O

after O
administration O
of O
oxybutynin O
concomitantly O
with O
an O
increase O
in O
the O
dose O
of O
dantrolene B-DRUG
, O
she O
presented O
the O
clinical O
symptoms O
and O
laboratory O
finding O
of O
carbamazepine B-ADR
intoxication I-ADR

a O
variety O
of O
movement O
disorders O
are O
known O
to O
occur O
in O
association O
with O
carbamazepine O
( O
cbz B-DRUG
) O
therapy O
in O
adults O
and O
children O
, O
but O
development O
of O
tics B-ADR
has O
been O
described O
infrequently O
and O
only O
in O
patients O
with O
underlying O
tourette O
's O
syndrome O
or O
other O
movement O
disorders O

the O
temporal O
sequence O
of O
the O
respiratory O
insufficiency O
and O
the O
histopathology O
, O
when O
compared O
to O
the O
previous O
examples O
in O
the O
literature O
, O
suggest O
that O
cyclophosphamide B-DRUG
was O
aetiologically O
responsible O
for O
the O
lung B-ADR
disease I-ADR

we O
describe O
a O
detailed O
case O
of O
fulminant B-ADR
hepatitis I-ADR
induced O
by O
nevirapine B-DRUG
( O
viramune O
) O
and O
treated O
by O
liver O
transplantation O

we O
believe O
that O
this O
is O
the O
first O
description O
of O
acute B-ADR
hepatitis I-ADR
caused O
by O
an O
idiosyncratic O
adverse O
reaction O
to O
gliclazide B-DRUG
or O
to O
one O
of O
its O
metabolites O

conclusions O
: O
infectious B-ADR
endophthalmitis I-ADR
is O
a O
potential O
complication O
of O
intravitreal O
bevacizumab B-DRUG
injection O

purpose O
: O
to O
report O
that O
acute O
lamotrigine B-DRUG
poisoning O
may O
result O
in O
severe O
encephalopathy B-ADR

the O
authors O
present O
a O
case O
report O
of O
a O
granulomatous B-ADR
reaction I-ADR
leading O
to O
urethral O
prolapse O
, O
3 O
months O
after O
the O
transurethral O
injection O
of O
calcium B-DRUG
hydroxylapatite I-DRUG

conclusion O
: O
a O
37-year-old O
african O
- O
american O
man O
with O
g6pd O
deficiency O
developed O
hemolytic O
anemia O
, O
hepatitis B-ADR
, O
orthostatic O
hypotension O
, O
and O
aseptic O
meningitis O
simultaneously O
after O
using O
trimethoprim-sulfamethoxazole O

a O
toxic O
encephalopathy O
characterized O
by O
depressed O
level O
of O
consciousness O
, O
marked B-ADR
irritability I-ADR
, O
and O
ataxia O
developed O
in O
seven O
children O
, O
5 O
years O
of O
age O
and O
younger O
, O
following O
administration O
of O
an O
antiemetic O
combination O
of O
pentobarbital O
and O
pyrilamine B-DRUG
maleate I-DRUG

since O
the O
thrombocyte B-ADR
count I-ADR
started I-ADR
to I-ADR
increase I-ADR
immediately O
after O
initiation O
and O
dropped O
immediately O
after O
discontinuation O
of O
ciprofloxacin O
and O
tazobactam B-DRUG
/ O
piperacillin O
and O
all O
other O
drugs O
were O
discontinued O
already O
before O
or O
were O
started O
after O
the O
nadir O
of O
the O
thrombocyte O
count O
, O
these O
two O
antibiotics O
were O
regarded O
causative O

a O
74-year-old O
hypercholestrerolaemic O
woman O
taking O
cerivastatin B-DRUG
( O
0.15 O
mg O
/ O
day O
) O
for O
22 O
days O
complained O
of O
general O
muscle B-ADR
weakness I-ADR
and O
muscle O
pain O

the O
introduction O
of O
para-aminosalicylic O
acid O
( O
pas B-DRUG
) O
led O
to O
hypoglycaemic B-ADR
coma I-ADR

an O
association O
of O
granulocytopenia O
, O
eosinophilia B-ADR
, O
skin O
reaction O
and O
hepatitis O
during O
propylthiouracil B-DRUG
( O
ptu O
) O
therapy O
for O
thyrotoxicosis O
in O
a O
47 O
year O
old O
black O
female O
is O
reported O

this O
treatment O
has O
the O
potential O
to O
cause O
severe O
vision O
loss O
as O
a O
result O
of O
intractable O
corticosteroid-induced O
glaucoma B-ADR

a O
toxic B-ADR
encephalopathy I-ADR
characterized O
by O
depressed O
level O
of O
consciousness O
, O
marked O
irritability O
, O
and O
ataxia O
developed O
in O
seven O
children O
, O
5 O
years O
of O
age O
and O
younger O
, O
following O
administration O
of O
an O
antiemetic O
combination O
of O
pentobarbital O
and O
pyrilamine B-DRUG
maleate I-DRUG

we O
report O
a O
50-year-old O
male O
patient O
with O
a O
15-year O
history O
of O
psoriasis O
including O
mutilating O
psoriatic O
arthritis O
, O
in O
whom O
the O
withdrawal O
of O
cyclosporin B-DRUG
a I-DRUG
induced O
a O
generalised O
pustular O
exacerbation O
and O
a O
aggravation B-ADR
of I-ADR
the I-ADR
joint I-ADR
condition I-ADR

complications O
of O
chemotherapy O
for O
a O
synovial O
sarcoma O
in O
an O
eight-year O
old O
boy O
included O
cisplatinum O
nephrotoxicity O
and O
adriamycin B-DRUG
cardiotoxicity B-ADR

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin O
, O
grepafloxacin B-DRUG
, O
trovafloxacin O
, O
gatifloxacin O
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache O
, O
dizziness B-ADR
and O
insomnia O

ciprofloxacin B-DRUG
is O
one O
drug O
that O
has O
been O
reported O
to O
cause O
interstitial B-ADR
nephritis I-ADR

the O
more O
common O
grade O
3 O
or O
4 O
adverse O
effects O
of O
sunitinib B-DRUG
include O
hypertension B-ADR
, O
fatigue O
, O
hand-foot O
syndrome O
, O
elevated O
lipase O
and O
lymphopenia O

we O
present O
a O
case O
of O
a O
58-year-old O
female O
patient O
with O
graves' O
disease O
who O
developed O
aa B-ADR
in O
the O
third O
exposure O
to O
methimazole B-DRUG
( O
mmi O

liver B-ADR
disease I-ADR
induced O
by O
perhexiline B-DRUG
maleate I-DRUG

nine O
azotemic O
patients O
who O
developed O
a O
coagulopathy B-ADR
associated O
with O
the O
use O
of O
either O
cephalosporin B-DRUG
or O
moxalactam O
antibiotics O
are O
reported O

purpose O
: O
to O
report O
a O
case O
of O
traumatic B-ADR
flap I-ADR
dehiscence I-ADR
and O
enterobacter O
keratitis O
34 O
months O
after O
lasik B-DRUG

physicians O
should O
be O
aware O
of O
the O
risk O
of O
severe O
aiha B-ADR
in O
cll O
patients O
with O
a O
history O
of O
aiha B-ADR
or O
positivation O
of O
the O
dat O
during O
previous O
fludarabine B-DRUG
administration O
, O
or O
in O
case O
of O
secondary O
fixation O
of O
complement O
to O
the O
red O
cell O
membrane O
occurring O
during O
fludarabine B-DRUG
treatment O

fulminant B-ADR
hepatitis I-ADR
and O
lymphocyte O
sensitization O
due O
to O
propylthiouracil B-DRUG

retrospectively O
, O
bucillamine O
was O
believed O
to O
be O
the O
cause O
of O
the O
giant O
hypertrophy O
because O
of O
its O
structural O
similarity O
to O
d-penicillamine B-DRUG
, O
which O
was O
the O
subject O
of O
an O
abundance O
of O
reports O
of O
mammary B-ADR
hyperplasia I-ADR

a O
case O
of O
toxic B-ADR
hepatitis I-ADR
caused O
by O
combination O
therapy O
with O
methotrexate B-DRUG
and O
etretinate O
in O
the O
treatment O
of O
severe O
psoriasis O
is O
presented O
in O
a O
47-year-old O
woman O

lithium B-DRUG
therapy O
was O
discontinued O
because O
of O
poor O
compliance O
to O
the O
medication O
and O
intolerable O
polyuria B-ADR

the O
exophthalmos B-ADR
improved O
dramatically O
within O
72 O
hours O
of O
the O
withdrawal O
of O
lithium B-DRUG

cyclosporine-induced O
pain B-ADR
syndrome I-ADR
in O
a O
child O
undergoing O
hematopoietic O
stem O
cell O
transplant O

we O
report O
a O
case O
of O
a O
patient O
with O
mild O
chronic O
renal O
insufficiency O
who O
had O
been O
taking O
simvastatin O
for O
over O
a O
year O
and O
developed O
acute B-ADR
weakness I-ADR
within O
3 O
weeks O
after O
the O
start O
of O
treatment O
with O
colchicine B-DRUG
for O
acute O
gouty O
bursitis O

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash O
, O
fever O
, O
leukopenia B-ADR
and O
positive O
anti-nuclear O
antibody O
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine O
( O
cbz B-DRUG
; O
tegretol O
) O
used O
against O
benign O
rolandic O
epilepsy O

intra-neural B-ADR
ceroid-like I-ADR
pigment I-ADR
following O
the O
treatment O
of O
lepromatous O
leprosy O
with O
clofazimine O
( O
b663 O
; O
lamprene B-DRUG

less O
common O
adverse O
events O
to O
dapsone B-DRUG
include O
the O
idiosyncratic O
reactions O
of O
leukopenia O
and O
agranulocytosis O
, O
cutaneous O
eruptions O
, O
peripheral O
neuropathy O
, O
psychosis O
, O
toxic B-ADR
hepatitis I-ADR
, O
cholestatic O
jaundice O
, O
nephrotic O
syndrome O
, O
renal O
papillary O
necrosis O
, O
severe O
hypoalbuminemia O
without O
proteinuria O
, O
an O
infectious O
mononucleosis-like O
syndrome O
, O
and O
minor O
neurological O
and O
gastrointestinal O
complaints O

conclusions O
: O
clinicians O
should O
be O
aware O
of O
the O
possible O
association O
of O
thrombocytopenia B-ADR
with O
lansoprazole B-DRUG
and O
discontinue O
the O
drug O
if O
thrombocytopenia B-ADR
becomes O
apparent O

conclusion O
: O
healthcare O
professionals O
should O
be O
aware O
of O
the O
possible O
development O
of O
serotonin B-ADR
syndrome I-ADR
as O
a O
complication O
of O
initiation O
of O
fentanyl B-DRUG
and O
other O
phenylpiperidine O
opioids O
in O
patients O
treated O
with O
ssris O

to O
date O
, O
eight O
cases O
of O
ten O
and O
one O
of O
sjs B-ADR
related O
to O
lamotrigine B-DRUG
administration O
have O
been O
reported O
in O
the O
literature O

a O
retrospective O
epidemiological O
study O
of O
deaths O
from O
hepatic B-ADR
angiosarcoma I-ADR
( O
has O
) O
in O
the O
u.s. O
showed O
that O
during O
1964 O
-- O
74 O
there O
were O
168 O
such O
cases O
, O
of O
which O
37 O
( O
22 O
%) O
were O
associated O
with O
previously O
known O
causes O
( O
vinyl B-DRUG
chloride I-DRUG
, O
' O
thorotrast O
' O
, O
and O
inorganic O
arsenic O
) O
and O
4 O
( O
3.1 O
%) O
of O
the O
remaining O
131 O
cases O
with O
the O
use O
of O
androgenic-anabolic O
steroids O

gold B-ADR
nephropathy I-ADR
due O
to O
auranofin O
obscured O
by O
tolmetin O
pseudoproteinuria O

immunosuppression O
elicited O
by O
the O
extensive O
administration O
of O
prednisolone B-DRUG
was O
suspected O
for O
the O
initiation O
of O
the O
generalized O
mite B-ADR
infestation I-ADR

case O
presentation O
: O
three O
cases O
of O
leishmania O
infantum O
leishmaniasis O
in O
corticosteroid O
( O
cs B-DRUG
)- O
treated O
patients O
are O
reported O
: O
an O
isolated O
lingual O
leishmaniasis O
in O
a O
farmer O
treated O
with O
cs B-DRUG
for O
asthma O
, O
a O
severe O
visceral O
leishmaniasis O
associated O
with O
cutaneous O
lesions O
in O
a O
woman O
with O
myasthenia O
gravis O
, O
and O
a O
visceral O
involvement O
after O
cutaneous B-ADR
leishmaniasis I-ADR
in O
a O
man O
receiving O
cs B-DRUG

the O
day O
after O
clozapine B-DRUG
was O
stopped O
, O
while O
he O
was O
still O
receiving O
clomipramine O
150 O
mg O
/ O
d O
, O
he O
began O
behaving O
oddly O
, O
started O
sweating O
profusely O
, O
shivering O
, O
and O
became O
tremulous O
, O
agitated O
, O
and O
confused B-ADR

we O
report O
four O
cases O
of O
sensorimotor B-ADR
axonal I-ADR
neuropathy I-ADR
in O
children O
aged O
10-15 O
years O
, O
treated O
with O
thalidomide B-DRUG
for O
myxopapillary O
ependymoma O
, O
crohn O
's O
disease O
and O
recurrent O
giant O
aphthous O
ulceration O

we O
report O
a O
case O
of O
a O
bullous B-ADR
lichenoid I-ADR
eruption I-ADR
due O
to O
the O
intake O
of O
captopril B-DRUG

we O
present O
the O
case O
of O
a O
postictal O
patient O
with O
lethargy B-ADR
, O
hyperammonemia O
, O
otherwise O
normal O
liver O
function O
tests O
, O
and O
a O
therapeutic O
valproic B-DRUG
acid I-DRUG
level O

severe O
abdominal B-ADR
pain I-ADR
in O
low O
dosage O
clofazimine B-DRUG

although O
dyspnea O
associated O
with O
verapamil B-DRUG
administration O
has O
been O
reported O
, O
this O
is O
the O
first O
report O
of O
an O
elderly O
asymptomatic O
asthmatic O
patient O
with O
hypertension O
who O
developed O
an O
acute B-ADR
asthma I-ADR
attack O
following O
sustained-release O
verapamil B-DRUG
administration O

total B-ADR
blindness I-ADR
with I-ADR
a I-ADR
transient I-ADR
tonic I-ADR
pupillary I-ADR
response I-ADR
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual-evoked O
potentials O
developed O
in O
a O
54-year-old O
man O
after O
the O
use O
of O
quinine B-DRUG
sulfate I-DRUG
for O
leg O
cramps O

significant O
clinical O
improvement O
of O
the O
porphyria B-ADR
followed O
withdrawal O
of O
the O
diphenylhydantoin B-DRUG

after O
three O
weeks O
of O
carbamazepine B-DRUG
therapy O
, O
the O
patient O
arrived O
at O
the O
emergency O
department O
( O
ed O
) O
with O
severe B-ADR
agitation I-ADR
and O
aggressive O
behavior O

increased B-ADR
libido I-ADR
in O
a O
woman O
treated O
with O
fluvoxamine B-DRUG
: O
a O
case O
report O

symptoms O
and O
signs O
of O
augmentation B-ADR
were O
related O
to O
low O
plasma O
levodopa B-DRUG
levels O
, O
abating O
75 O
minutes O
after O
oral O
levodopa B-DRUG
administration O
and O
reappearing O
after O
3 O
hours O
, O
closely O
mirroring O
the O
rapid O
rise O
and O
fall O
of O
plasma O
levodopa B-DRUG
concentration O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly B-ADR
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp O
)- O
sulfamethoxazole B-DRUG
( O
smx O
) O
treatment O

alprazolam B-DRUG
withdrawal O
delirium B-ADR
unresponsive O
to O
diazepam O
: O
case O
report O

diagnosis O
: O
sustained B-ADR
ventricular I-ADR
tachycardia I-ADR
possibly O
owing O
to O
thalidomide B-DRUG
treatment O

we O
report O
a O
case O
of O
severe O
hypotension B-ADR
associated O
with O
intravenous O
valproate B-DRUG
used O
to O
treat O
status O
epilepticus O
in O
an O
11-year-old O
girl O

background O
: O
headaches B-ADR
have O
been O
reported O
as O
a O
potential O
side O
effect O
of O
capecitabine B-DRUG
therapy O

the O
possibility O
can O
be O
raised O
that O
m-csf B-DRUG
accelerated O
the O
underlying O
renal O
disease O
in O
this O
case O
through O
enhancing O
macrophage O
accumulation O
into O
the O
glomerulus O
, O
leading O
to O
the O
development O
of O
nephrotic B-ADR
syndrome I-ADR

aim O
: O
report O
of O
a O
case O
of O
a O
woman O
patient O
who O
developed O
celiac B-ADR
disease I-ADR
after O
pegylated B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
and O
ribavirin O
use O
for O
chronic O
hepatitis O
c O

central O
pontine O
myelinolysis O
manifested O
by O
temporary B-ADR
blindness I-ADR
: O
a O
possible O
complication O
of O
lithium B-DRUG
toxicity O

a O
generalized B-ADR
tonic-clonic I-ADR
seizure I-ADR
occurred O
a O
few O
minutes O
after O
injection O
of O
the O
morphine O
antagonist O
naloxone B-DRUG

the O
incidence O
of O
oral-verapamil-induced O
hypotension B-ADR
in O
the O
presence O
of O
concomitant O
beta-adrenergic O
blockade O
by O
the O
oral O
route O
is O
quite O
rare O

we O
report O
a O
case O
of O
stevens-johnson O
syndrome O
/ O
toxic O
epidermal O
necrolysis O
( O
sjs O
/ O
ten B-ADR
) O
secondary O
to O
trimethoprim-sulfamethoxazole O
( O
tmp-sx B-DRUG
) O
therapy O
for O
presumed O
community-associated O
methicillin-resistant O
staphylococcus O
aureus O
( O
ca-mrsa O
) O
infection O

here O
we O
report O
ramipril-induced O
cutaneous B-ADR
vasculitis I-ADR
in O
a O
patient O
who O
required O
steroid O
therapy O
to O
control O
it O

allergic O
and O
irritant B-ADR
contact I-ADR
dermatitis I-ADR
to O
calcipotriol B-DRUG

in O
four O
patients O
, O
spasm B-ADR
occurred O
spontaneous O
and O
in O
one O
patient O
after O
0.05 O
mg O
of O
ergonovine B-DRUG

the O
abnormal B-ADR
rhythm I-ADR
disappeared O
with O
the O
withdrawal O
of O
propranolol B-DRUG
and O
when O
the O
drug O
was O
restarted O
a O
2 O
/ O
1 O
s-a O
block O
was O
seen O

neuroleptic B-ADR
malignant I-ADR
syndrome I-ADR
due O
to O
risperidone B-DRUG
treatment O
in O
a O
child O
with O
joubert O
syndrome O

we O
describe O
rupture B-ADR
of I-ADR
a I-ADR
cerebral I-ADR
arterial I-ADR
aneurysm I-ADR
in O
a O
32 O
year O
old O
hypertensive O
woman O
following O
the O
introduction O
of O
nifedipine B-DRUG
treatment O

a O
patient O
that O
received O
methadone B-DRUG
for O
cancer-associated O
pain O
developed O
myoclonus B-ADR
as O
a O
side O
effect O

phenytoin O
was O
discontinued O
after O
admission O
; O
however O
, O
phenytoin B-DRUG
1 O
g O
i.v. O
was O
given O
for O
a O
tonic-clonic O
seizure O
two O
days O
after O
admission O
, O
after O
which O
swelling B-ADR
of I-ADR
the I-ADR
face I-ADR
and I-ADR
legs I-ADR
and O
pruritus O
developed O

in O
four O
patients O
, O
thrombosis O
occurred O
2-45 O
days O
after O
severe O
hepatic O
veno-occlusive O
disease O
( O
hvod B-ADR
) O
secondary O
to O
intensive O
chemotherapy O
containing O
busulfan B-DRUG

neutrophilic B-ADR
dermatoses I-ADR
in O
two O
children O
with O
idiopathic O
neutropenia O
: O
association O
with O
granulocyte B-DRUG
colony-stimulating I-DRUG
factor I-DRUG
( O
g-csf O
) O
therapy O

a O
female O
patient O
with O
her2 O
positive O
, O
metastatic O
breast O
cancer O
presented O
with O
pulmonary B-ADR
infiltrates I-ADR
, O
and O
a O
plural O
effusion O
dyspnoea O
after O
several O
months O
of O
trastuzumab B-DRUG
treatment O

during O
clarithromycin B-DRUG
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate-to-severe O
toxic O
symptoms O
of O
carbamazepine O
, O
such O
as O
drowsiness B-ADR
, O
dizziness O
, O
and O
ataxia O
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin B-DRUG
discontinuation O

the O
principle O
treatment O
for O
dpd-deficient O
patients O
with O
severe O
acute O
5-fu B-DRUG
reactions O
is O
supportive O
care O
; O
however O
, O
the O
administration O
of O
thymidine O
potentially O
may O
reverse O
severe O
5-fu-induced O
neurologic O
symptoms O
such O
as O
encephalopathy O
and O
coma B-ADR

neurotoxicity B-ADR
of O
intrathecal O
methotrexate B-DRUG
: O
mr O
imaging O
findings O

an O
infant O
who O
developed O
pancreatitis B-ADR
during O
meglumine B-DRUG
antimoniate I-DRUG
treatment O
for O
visceral O
leishmaniasis O
and O
who O
was O
successfully O
treated O
with O
a O
combination O
of O
allopurinol O
and O
ketoconazole O
is O
reported O

managing O
cardiovascular B-ADR
collapse I-ADR
in O
severe O
flecainide B-DRUG
overdose O
without O
recourse O
to O
extracorporeal O
therapy O

purpose O
/ O
objectives O
: O
to O
describe O
the O
pharmacogenetic O
syndrome O
of O
dihydropyrimidine O
dehydrogenase O
( O
dpd O
) O
deficiency O
, O
which O
predisposes O
patients O
with O
cancer O
to O
potentially O
lethal B-ADR
adverse I-ADR
reactions I-ADR
following O
5-fluorouracil O
( O
5-fu B-DRUG
)- O
based O
chemotherapy O

potential O
causes O
of O
methamphetamine-related O
keratitis B-ADR
can O
be O
divided O
into O
four O
categories O
resulting O
from O
( O
a O
) O
direct O
pharmacologic O
and O
physical O
effects O
of O
methamphetamine O
; O
( O
b O
) O
the O
toxic O
effects O
of O
diluting O
or O
" O
cutting O
" O
agents O
such O
as O
lidocaine O
and O
quinine B-DRUG
; O
( O
c O
) O
effects O
related O
to O
the O
route O
of O
drug O
administration O
( O
intravenous O
, O
inhalation O
, O
smoking O
) O
; O
and O
( O
d O
) O
manufacture-related O
effects O
of O
exposure O
to O
unintentional O
caustic O
contaminants O
in O
the O
final O
product O

rapamycin O
/ O
sirolimus O
( O
sr B-DRUG
) O
, O
trade O
named O
rapammune O
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression O
, O
hypertension O
, O
hyperlipidemia O
, O
and O
infection B-ADR

cholestatic O
liver O
disease O
with O
ductopenia B-ADR
( O
vanishing O
bile O
duct O
syndrome O
) O
after O
administration O
of O
clindamycin O
and O
trimethoprim-sulfamethoxazole B-DRUG

exacerbation O
of O
schizophrenia B-ADR
associated O
with O
amantadine B-DRUG

pirmenol B-DRUG
hydrochloride-induced O
qt B-ADR
prolongation I-ADR
and O
t O
wave O
inversion O
on O
electrocardiogram O
during O
treatment O
for O
symptomatic O
atrial O
fibrillation O

conclusion O
: O
there O
are O
only O
a O
few O
confirmed O
cases O
of O
gemcitabine-associated O
hus B-ADR
despite O
the O
widespread O
use O
of O
the O
drug O

we O
describe O
a O
74-year-old O
man O
with O
rheumatoid O
arthritis O
( O
ra O
) O
who O
developed O
syndrome O
of O
inappropriate O
secretion O
of O
antidiuretic O
hormone O
( O
siadh B-ADR
) O
1.5 O
months O
after O
commencement O
of O
mizoribin B-DRUG
prescription O
when O
his O
arthritis O
was O
improved O

we O
present O
a O
depressive O
patient O
who O
developed O
mild O
parkinsonian O
signs O
and O
camptocormia B-ADR
after O
the O
introduction O
of O
olanzapine B-DRUG

cardiopulmonary B-ADR
arrest I-ADR
following O
intravenous O
phenytoin B-DRUG
loading O

objective O
: O
to O
report O
a O
case O
of O
ciprofloxacin-induced O
psychosis B-ADR
and O
to O
discuss O
occurrence O
rates O
, O
risk O
factors O
, O
possible O
etiologies O
, O
preventive O
measures O
, O
and O
treatment O
courses O
for O
this O
adverse O
reaction O

methods O
: O
two O
patients O
with O
exudative O
age-related O
macular O
degeneration O
were O
treated O
sequentially O
with O
an O
intravitreal O
injection O
of O
bevacizumab B-DRUG
and O
developed O
signs O
of O
severe O
but O
painless B-ADR
infectious I-ADR
endophthalmitis I-ADR
2 O
days O
later O

the O
two O
middle O
aged O
women O
presented O
with O
respiratory B-ADR
symptoms I-ADR
after O
prolonged O
treatment O
with O
nitrofurantoin B-DRUG

peripheral O
neuropathy O
and O
cerebellar B-ADR
syndrome I-ADR
associated O
with O
amiodarone B-DRUG
therapy O

methotrexate-induced O
diffuse B-ADR
interstitial I-ADR
pulmonary I-ADR
fibrosis I-ADR

vancomycin B-DRUG
is O
widely O
used O
against O
methicillin-resistant O
staphylococcus O
aureus O
infections O
, O
but O
it O
is O
associated O
with O
many O
adverse O
effects O
such O
as O
nephrotoxicity O
, O
ototoxicity O
, O
gastrointestinal O
disturbances O
, O
blood B-ADR
disorders I-ADR
, O
and O
two O
types O
of O
hypersensitivity O
reactions O
- O
an O
anaphylactoid O
reaction O
known O
as O
" O
red O
man O
syndrome O
" O
and O
anaphylaxis O

this O
confirmed O
the O
history O
of O
captopril-related O
asthma B-ADR

probable O
enoxaparin-induced O
hepatotoxicity B-ADR

renal B-ADR
failure I-ADR
appeared O
8 O
to O
17 O
days O
after O
beginning O
gentamicin B-DRUG
therapy O
and O
was O
characterized O
by O
creatinine O
clearances O
4 O
to O
10 O
ml O
/ O
min O
, O
urine O
to O
plasma O
creatinine O
ratios O
less O
than O
20 O
, O
urinary O
sodium O
concentrations O
16 O
to O
60 O
meq O
/ O
liter O
, O
proteinuria O
, O
and O
cylindruria O

in O
all O
three O
cases O
, O
autopsy O
revealed O
gross O
and O
microscopic O
features O
indistinguishable O
from O
those O
seen O
in O
the O
hamman-rich O
syndrome O
, O
and O
methotrexate B-DRUG
hepatotoxicity B-ADR
was O
present O
in O
one O

gynecomastia B-ADR
developed O
in O
two O
epileptic O
patients O
some O
months O
after O
the O
addition O
of O
oral O
fluoresone B-DRUG
750 O
mg O
daily O
to O
the O
phenobarbital O
and O
phenytoin O
already O
being O
administered O

four O
days O
after O
the O
initial O
injection O
of O
3.6 O
mg O
of O
goserelin B-DRUG
acetate I-DRUG
, O
severe O
dyspnea O
developed O
due O
to O
worsening B-ADR
pleuritis I-ADR
carcinomatosa I-ADR
, O
which O
was O
considered O
as O
a O
flare-up O

treatment O
of O
elp O
in O
children O
is O
generally O
supportive O
, O
with O
the O
symptoms O
and O
roentgenographic B-ADR
abnormalities I-ADR
resolving O
within O
months O
after O
stopping O
the O
use O
of O
mineral B-DRUG
oil I-DRUG

four O
years O
after O
the O
beginning O
of O
ifn B-DRUG
therapy O
, O
he O
acutely O
developed O
moderate B-ADR
hyperglycemia I-ADR
and O
severe O
ketonuria O
with O
positive O
islet O
cell O
antibody O
, O
and O
then O
28 O
units O
/ O
day O
of O
insulin O
injection O
was O
started O

we O
report O
the O
use O
of O
pamidronate O
for O
acute O
, O
severe B-ADR
hypercalcemia I-ADR
secondary O
to O
iatrogenic O
vitamin B-DRUG
d I-DRUG
poisoning O

this O
is O
the O
first O
report O
of O
acute O
kidney O
injury O
due O
to O
zonisamide-induced O
dress B-ADR
/ O
dihs O

we O
report O
two O
patients O
with O
anhedonic O
ejaculation O
( O
ejaculation B-ADR
without I-ADR
orgasm I-ADR
) O
associated O
with O
initiation O
of O
treatment O
with O
desipramine B-DRUG

in O
the O
present O
paper O
the O
authors O
describe O
2 O
female O
patients O
who O
developed O
incontinence B-ADR
secondary O
to O
the O
selective O
serotonin O
reuptake O
inhibitors O
paroxetine O
and O
sertraline B-DRUG
, O
as O
well O
as O
a O
third O
who O
developed O
this O
side O
effect O
on O
venlafaxine O

first O
, O
a O
review O
of O
the O
literature O
produced O
41 O
anecdotic O
cases O
of O
neutropenia O
or O
agranulocytosis B-ADR
during O
treatment O
with O
olanzapine O
( O
zyprexa B-DRUG
) O
reported O
in O
a O
total O
of O
24 O
publications O

this O
case O
describes O
a O
52-year-old O
white O
woman O
who O
developed O
a O
spontaneous B-ADR
nasal I-ADR
septal I-ADR
perforation I-ADR
after O
given O
the O
antiangiogenic O
drug O
, O
bevacizumab B-DRUG
, O
for O
metastatic O
ovarian O
cancer O
treatment O

captopril-related O
( O
and O
- O
induced O
?) O
asthma B-ADR

pediatric O
heparin-induced O
thrombocytopenia B-ADR
: O
management O
with O
danaparoid O
( O
orgaran O

case O
report O
: O
we O
report O
a O
patient O
who O
developed O
a O
dat-positive B-ADR
hemolytic I-ADR
episode I-ADR
after O
a O
red O
cell O
( O
rbc O
) O
transfusion O
was O
delivered O
during O
the O
infusion O
of O
her O
17th O
cycle O
of O
oxaliplatin B-DRUG

conclusions O
: O
itraconazole-induced O
liver O
injury O
presents O
with O
a O
cholestatic O
pattern O
of O
injury O
with O
damage B-ADR
to I-ADR
the I-ADR
interlobular I-ADR
bile I-ADR
ducts I-ADR
, O
possibly O
leading O
to O
ductopenia O

purpose O
: O
to O
report O
a O
case O
of O
severe O
corticosteroid-induced O
glaucoma B-ADR
after O
intravitreal O
injection O
of O
triamcinolone B-DRUG
acetate I-DRUG
in O
a O
34-year-old O
man O
without O
a O
history O
of O
glaucoma B-ADR

a O
36-year-old O
man O
being O
treated O
with O
cisplatinum O
, O
vinblastine B-DRUG
, O
and O
bleomycin O
for O
testicular O
carcinoma O
developed O
a O
dense O
left O
homonymous O
hemianopsia O
, O
encephalopathy B-ADR
, O
and O
a O
partial O
nondominant O
parietal O
lobe O
syndrome O

when O
the O
acute O
manic O
state O
is O
characterized O
by O
marked O
psychotic O
symptoms O
and O
intense O
anxiety O
, O
it O
may O
be O
associated O
with O
increased O
vulnerability O
to O
the O
development O
of O
severe O
lithium B-DRUG
neurotoxicity B-ADR

one O
patient O
required O
nursing O
home O
placement O
and O
a O
feeding O
gastrostomy O
as O
a O
result O
of O
the O
worsening B-ADR
parkinsonism I-ADR
during O
risperidone B-DRUG
treatment O
, O
but O
was O
able O
to O
return O
home O
and O
have O
the O
gastrostomy O
removed O
after O
switching O
from O
risperidone B-DRUG
to O
clozapine O

atypical O
ventricular O
tachycardia O
( O
torsade O
de O
pointes O
) O
induced O
by O
amiodarone O
: O
arrhythmia B-ADR
previously O
induced O
by O
quinidine B-DRUG
and O
disopyramide O

spontaneous B-ADR
nasal I-ADR
septal I-ADR
perforation I-ADR
with O
antiangiogenic O
bevacizumab B-DRUG
therapy O

conclusions O
: O
this O
patient O
's O
rhabdomyolysis B-ADR
was O
probably O
induced O
by O
sertraline B-DRUG
therapy O

we O
present O
a O
20-year-old O
woman O
with O
basedow-graves' O
disease O
who O
developed O
ptu-induced O
fulminant B-ADR
hepatitis I-ADR
, O
which O
progressed O
to O
acute O
hepatic O
failure O
with O
grade O
iii O
hepatic O
encephalopathy O

thirty-six O
patients O
with O
al O
received O
, O
in O
a O
three-month O
period O
, O
51 O
cycles O
of O
combined O
chemotherapy O
which O
included O
, O
in O
all O
of O
them O
, O
cytosine B-DRUG
arabinoside I-DRUG
( O
ara-c O
) O
; O
among O
them O
, O
along O
with O
myelosuppression O
, O
five O
experienced O
fever O
, O
infectious O
complications O
, O
gastrointestinal B-ADR
tract I-ADR
symptoms I-ADR
and O
severe O
myalgias O

background O
: O
methotrexate O
( O
mtx B-DRUG
) O
may O
induce O
liver O
damage O
, O
which O
in O
some O
psoriatics O
will O
lead O
to O
fibrosis B-ADR
or O
cirrhosis O

hepatotoxicity O
associated O
with O
choline O
magnesium O
trisalicylate O
: O
case O
report O
and O
review O
of O
salicylate-induced O
hepatotoxicity B-ADR

a O
medline O
search O
identified O
all O
the O
reported O
cases O
of O
hypersensitivity B-ADR
reactions I-ADR
to O
cyclosporine B-DRUG

conclusions O
: O
sustained-release O
verapamil B-DRUG
is O
thought O
to O
be O
the O
cause O
of O
the O
asthma B-ADR
attack I-ADR
in O
this O
patient O
because O
she O
was O
not O
taking O
any O
other O
preparations O
; O
the O
symptoms O
started O
with O
the O
administration O
of O
sustained-release O
verapamil B-DRUG
and O
were O
relieved O
after O
its O
discontinuation O

we O
evaluated O
a O
patient O
who O
developed O
a O
psychotic B-ADR
disorder I-ADR
after O
4 O
months O
of O
isoniazid B-DRUG
prophylaxis O
for O
a O
positive O
tuberculosis O
tine O
test O

acute B-ADR
renal I-ADR
insufficiency I-ADR
is O
known O
to O
occur O
in O
patients O
who O
are O
taking O
ciprofloxacin B-DRUG
, O
particularly O
the O
elderly O

we O
report O
a O
case O
of O
stevens-johnson O
syndrome O
/ O
toxic O
epidermal O
necrolysis O
( O
sjs B-ADR
/ O
ten O
) O
secondary O
to O
trimethoprim-sulfamethoxazole O
( O
tmp-sx B-DRUG
) O
therapy O
for O
presumed O
community-associated O
methicillin-resistant O
staphylococcus O
aureus O
( O
ca-mrsa O
) O
infection O

this O
is O
the O
first O
report O
on O
the O
histopathological O
findings O
of O
thyroid O
tissue O
from O
a O
patient O
with O
amiodarone-induced O
hypothyroidism B-ADR

we O
present O
the O
first O
case O
of O
wes B-ADR
in O
an O
infant O
born O
to O
a O
mother O
taking O
haloperidol B-DRUG
during O
her O
pregnancy O

psoriasis B-ADR
triggered O
by O
toll-like O
receptor O
7 O
agonist O
imiquimod B-DRUG
in O
the O
presence O
of O
dermal O
plasmacytoid O
dendritic O
cell O
precursors O

glaucoma B-ADR
secondary O
to O
epithelial O
downgrowth O
and O
5-fluorouracil B-DRUG

the O
present O
report O
illustrates O
a O
rare O
case O
of O
refractory O
akathisia B-ADR
after O
interferon-alpha B-DRUG
treatment O
and O
also O
that O
levodopa O
treatment O
would O
be O
theoretically O
and O
practically O
useful O
in O
reducing O
the O
neurotoxicity O
associated O
with O
interferon-alpha B-DRUG

ceftriaxone-induced O
fixed B-ADR
drug I-ADR
eruption I-ADR
: O
first O
report O

while O
undergoing O
treatment O
with O
albendazole B-DRUG
, O
he O
developed O
worsening O
diarrhea O
with O
abdominal B-ADR
pain I-ADR
and O
fever O

gabapentin B-DRUG
toxicity O
in O
renal B-ADR
failure I-ADR
: O
the O
importance O
of O
dose O
adjustment O

he O
had O
been O
taking O
trimethoprim-sulfamethoxazole O
for O
approximately O
eight O
days O
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches O
, O
dizziness O
, O
difficulty B-ADR
with I-ADR
speech I-ADR
, O
weakness O
, O
and O
itching O
on O
the O
trunk O
of O
his O
body O
and O
legs O
, O
where O
a O
maculopapular O
rash O
was O
noted O

ziprasidone B-DRUG
is O
an O
atypical O
antipsychotic O
drug O
that O
is O
believed O
to O
have O
a O
low O
propensity O
for O
inducing O
extrapyramidal O
symptoms O
, O
including O
tardive O
dyskinesia O
( O
td B-ADR

fever B-ADR
caused O
by O
the O
use O
of O
furosemide B-DRUG
was O
proved O
; O
the O
fever O
resolved O
after O
discontinuation O
of O
this O
medication O
and O
recurred O
after O
its O
reintroduction O

thrombocytosis B-ADR
associated O
with O
enoxaparin B-DRUG
: O
a O
very O
rare O
cause O
in O
newborns O

clinicians O
should O
be O
aware O
of O
the O
signs O
and O
symptoms O
of O
neurotoxicity B-ADR
during O
treatment O
, O
as O
well O
as O
predisposing O
factors O
that O
put O
patients O
receiving O
methotrexate B-DRUG
at O
risk O
for O
neurotoxic O
effects O

drug-induced O
fever B-ADR
should O
be O
considered O
in O
patients O
who O
have O
unexplained O
high O
temperatures O
during O
diltiazem B-DRUG
therapy O

paroxysmal B-ADR
supraventricular I-ADR
tachycardia I-ADR
during O
treatment O
with O
cisplatin B-DRUG
and O
etoposide O
combination O

we O
diagnosed O
this O
case O
as O
danazol B-DRUG
induced O
thrombocytopenia B-ADR

concomitant O
administration O
of O
lithium O
with O
olanzapine B-DRUG
may O
place O
patients O
at O
risk O
for O
nms B-ADR

intranasal O
desmopressin-induced O
hyponatremia B-ADR

we O
describe O
a O
case O
of O
pres B-ADR
in O
a O
patient O
with O
collapsing O
focal O
glomeruloesclerosis O
( O
collapsing O
fgs O
) O
with O
complete O
recovery O
after O
withdrawal O
of O
cyclosporine B-DRUG
( O
csa O

rifampin B-DRUG
can O
be O
associated O
with O
severe O
adverse O
effects O
such O
as O
hepatitis O
, O
acute O
renal O
failure O
, O
hemolytic B-ADR
anemia I-ADR
, O
and O
thrombocytopenia O

conclusions O
: O
hypersensitivity B-ADR
reactions I-ADR
to O
cyclosporine B-DRUG
are O
due O
to O
cremophor O
el O

renal B-ADR
damage I-ADR
associated O
with O
long O
term O
use O
of O
lithium B-DRUG
carbonate I-DRUG

a O
case O
of O
aseptic B-ADR
pleuropericarditis I-ADR
in O
a O
patient O
with O
chronic O
plaque O
psoriasis O
under O
methotrexate B-DRUG
therapy O

objective O
: O
the O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
desensitization O
to O
nph O
insulin B-DRUG
, O
as O
well O
as O
standard O
insulin B-DRUG
desensitization O
, O
could O
control O
allergic B-ADR
symptoms I-ADR
in O
a O
patient O
allergic O
to O
both O
nph O
and O
regular O
insulin B-DRUG

progressive B-ADR
anemia I-ADR
following O
combination O
therapy O
with O
interferon-alpha O
and O
interleukin-2 B-DRUG
in O
a O
patient O
with O
metastatic O
renal O
cell O
carcinoma O

dipyrone B-DRUG
, O
also O
known O
as O
metamizole O
, O
is O
an O
analgesic O
and O
antipyretic O
drug O
that O
was O
banned O
by O
the O
united O
states O
food O
and O
drug O
administration O
because O
of O
its O
association O
with O
agranulocytosis B-ADR

on O
the O
fifth O
day O
after O
administration O
of O
a O
high O
dose O
of O
ara-c B-DRUG
( O
2 O
g O
/ O
m2 O
intravenously O
every O
12 O
hours O
) O
, O
she O
developed O
bullous O
lesions O
on O
the O
hands O
and O
soles O
that O
disseminated O
, O
evolving O
to O
necrosis O
, O
sepsis O
, O
and O
death B-ADR
on O
the O
22nd O
day O

acyclovir B-DRUG
produces O
neurologic B-ADR
symptoms I-ADR
that O
resemble O
extension O
of O
viral O
infection O
into O
the O
central O
nervous O
system O

this O
is O
the O
first O
report O
of O
a O
disulfiram-like B-ADR
reaction I-ADR
with O
cefmenoxime B-DRUG

pemphigus B-ADR
foliaceus I-ADR
induced O
by O
rifampicin B-DRUG

recognition O
of O
a O
potential O
drug-induced O
fanconi B-ADR
syndrome I-ADR
is O
important O
when O
managing O
pediatric O
oncology O
patients O
previously O
treated O
with O
ifosfamide B-DRUG

after O
a O
second O
dose O
of O
metoclopramide B-DRUG
, O
these O
symptoms O
recurred O
and O
were O
associated O
with O
confusion O
, O
agitation O
, O
fever O
, O
diaphoresis O
, O
tachypnea B-ADR
, O
tachycardia O
, O
and O
hypertension O

in O
addition O
, O
an O
immediate B-ADR
erythematous O
macule O
was O
observed O
on O
the O
photopatch O
test O
site O
of O
mequitazine B-DRUG
directly O
after O
uv O
exposure O
which O
was O
similar O
to O
the O
immediate B-ADR
erythema I-ADR
noted O
in O
chlorpromazine O
photoallergy O

a O
case O
of O
noncardiogenic B-ADR
pulmonary I-ADR
edema I-ADR
by O
ethanolamine B-DRUG
oleate I-DRUG

although O
they O
had O
only O
a O
few O
nodules B-ADR
at O
diagnosis O
, O
the O
nodules B-ADR
increased O
in O
number O
and O
size O
3 O
to O
4 O
months O
after O
the O
start O
of O
methotrexate B-DRUG
therapy O
in O
both O
patients O

we O
describe O
two O
cases O
of O
sulfadiazine-induced O
crystalluria B-ADR
and O
renal O
failure O
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
, O
review O
the O
pertinent O
literature O
, O
and O
discuss O
the O
pathogenesis O

these O
data O
indicated O
that O
infliximab B-DRUG
possibly O
triggered O
production O
of O
granulocyte O
and O
neutrophil O
autoantibodies O
with O
resultant O
autoimmune B-ADR
agranulocytosis I-ADR

potential O
mechanisms O
involved O
in O
the O
occurrence O
of O
ischemic B-ADR
colitis I-ADR
in O
patients O
receiving O
tegaserod B-DRUG
are O
also O
discussed O

masculinization B-ADR
of I-ADR
a I-ADR
female I-ADR
fetus I-ADR
occurred O
in O
5 O
of O
39 O
( O
12.8 O
%) O
exposed O
to O
norethisterone B-DRUG
; O
all O
were O
cases O
of O
clitoral O
hypertrophy O
not O
requiring O
surgical O
treatment O

the O
case O
concerns O
the O
sudden B-ADR
death I-ADR
of O
a O
29-year-old O
male O
during O
clozapine B-DRUG
therapy O
started O
2 O
weeks O
before O

cystoid B-ADR
macular I-ADR
edema I-ADR
in O
a O
low-risk O
patient O
after O
switching O
from O
latanoprost B-DRUG
to O
bimatoprost O

six O
days O
after O
starting O
acyclovir B-DRUG
she O
exhibited O
signs O
of O
lithium B-ADR
toxicity I-ADR

to O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
bromide B-ADR
intoxication I-ADR
due O
to O
pyridostigmine B-DRUG
bromide I-DRUG
administration O

we O
present O
a O
patient O
with O
human O
immunodeficiency O
virus O
infection O
under O
treatment O
with O
foscarnet B-DRUG
for O
cmv O
retinitis O
who O
complained O
of O
thirst B-ADR
and O
polyuria O

this O
review O
presents O
the O
first O
case O
series O
of O
dic O
associated O
with O
acute B-ADR
hemoglobinemia I-ADR
or O
hemoglobinuria O
following O
anti-d B-DRUG
igiv I-DRUG
administration O
for O
itp O

use O
of O
the O
naranjo O
probability O
scale O
determined O
the O
association O
between O
cephalosporin B-DRUG
use O
and O
leukopenia B-ADR
to O
be O
probable O

during O
the O
first O
treatment O
, O
dysarthria B-ADR
and O
ataxia O
were O
seen O
after O
completion O
of O
the O
patient O
's O
eighth O
and O
final O
dose O
of O
hdarac B-DRUG

after O
the O
first O
oral O
dose O
of O
propranolol B-DRUG
, O
syncope B-ADR
developed O
together O
with O
atrioventricular O
block O

purple B-ADR
glove I-ADR
syndrome I-ADR
, O
named O
for O
its O
distinctive O
purple O
discoloration O
and O
swelling O
of O
the O
hands O
in O
the O
distribution O
of O
a O
glove O
, O
is O
an O
uncommon O
complication O
of O
intravenous O
phenytoin B-DRUG
administration O
through O
small O
dorsal O
veins O
of O
the O
hands O

rapamycin O
/ O
sirolimus O
( O
sr B-DRUG
) O
, O
trade O
named O
rapammune O
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression O
, O
hypertension O
, O
hyperlipidemia B-ADR
, O
and O
infection O

although O
neurotoxicity O
is O
a O
frequent O
complication O
of O
methotrexate B-DRUG
therapy O
, O
fatal B-ADR
acute I-ADR
neurotoxicity I-ADR
is O
extremely O
uncommon O
, O
especially O
in O
adults O

amphotericin B-DRUG
b I-DRUG
( O
amb O
) O
is O
effective O
, O
but O
its O
use O
is O
limited O
by O
toxicity O
: O
renal O
impairment O
, O
anaemia O
, O
fever O
, O
malaise B-ADR
, O
and O
hypokalaemia O
are O
common O

in O
this O
case O
senna B-DRUG
was O
likely O
the O
cause O
of O
a O
subacute O
cholestatic O
hepatitis O
exemplifying O
again O
the O
potential O
role O
of O
herbal O
related O
liver B-ADR
injury I-ADR

given O
that O
discontinuation O
of O
nitrofurantoin B-DRUG
and O
introduction O
of O
methylprednisolon O
therapy O
significantly O
lowered O
liver O
enzyme O
levels O
, O
restoring O
most O
of O
them O
to O
normal O
, O
we O
concluded O
that O
this O
was O
probably O
the O
case O
of O
toxic B-ADR
liver I-ADR
damage I-ADR
caused O
by O
nitrofurantoin B-DRUG

paralytic B-ADR
ileus I-ADR
in O
patients O
undergoing O
bortezomib B-DRUG
treatment O
has O
been O
reported O
, O
although O
a O
definite O
attribution O
to O
bortezomib B-DRUG
administration O
has O
not O
been O
established O

we O
concluded O
that O
the O
colonic B-ADR
ulcer I-ADR
and O
the O
sigmoidovesical O
fistula O
had O
been O
caused O
by O
the O
administration O
of O
calcium O
polystyrene O
sulfonate O
and O
sorbitol B-DRUG

we O
report O
two O
cases O
of O
fulminant B-ADR
hepatic I-ADR
failure I-ADR
in O
hiv-1-infected O
patients O
treated O
with O
didanosine B-DRUG
( O
ddi O

this O
article O
describes O
a O
patient O
with O
suspected O
ciprofloxacin-induced O
interstitial B-ADR
nephritis I-ADR

we O
describe O
2 O
patients O
with O
prior O
amputation O
who O
experienced O
phantom O
limb O
pain O
( O
plp B-ADR
) O
after O
receiving O
paclitaxel B-DRUG
therapy O

herein O
, O
we O
describe O
a O
patient O
with O
aids O
who O
presented O
to O
medical O
attention O
with O
pancytopenia B-ADR
48 O
months O
postchemotherapy O
with O
etoposide O
, O
prednisone O
, O
vincristine O
, O
cyclophosphamide B-DRUG
, O
doxorubicin O
, O
and O
rituximab O
( O
r-epoch O
) O
for O
diffuse O
large O
b-cell O
lymphoma O

fatal B-ADR
interstitial I-ADR
lung I-ADR
disease I-ADR
after O
erlotinib B-DRUG
administration O
in O
a O
patient O
with O
radiation O
fibrosis O

can O
roxithromycin B-DRUG
and O
betamethasone O
induce O
acute B-ADR
pancreatitis I-ADR
? O
a O
case O
report O

dystonia B-ADR
associated O
with O
carbamazepine B-DRUG
administration O
: O
experience O
in O
brain-damaged O
children O

methods O
: O
we O
report O
two O
cases O
of O
pseudoporphyria B-ADR
caused O
by O
naproxen B-DRUG
and O
oxaprozin O

severe B-ADR
hypo-alpha-lipoproteinemia I-ADR
during O
treatment O
with O
rosiglitazone B-DRUG

conclusions O
: O
this O
case O
suggests O
that O
losartan B-DRUG
can O
induce O
late-onset O
angioedema B-ADR
in O
patients O
with O
normal O
renal O
function O
and O
that O
the O
reaction O
can O
recur O
after O
initial O
resolution O
of O
the O
symptoms O

ccbs O
should O
be O
considered O
in O
the O
treatment O
of O
5-fu O
or O
capecitabine-induced O
headaches B-ADR

moreover O
, O
treatment O
with O
immunosuppressive O
drugs O
such O
as O
cyclosporine O
, O
cisplatin O
, O
tacrolimus O
, O
and O
interferon-alpha B-DRUG
can O
induce O
a O
condition O
resembling O
rpls B-ADR

recurrent O
hypotension O
immediately O
after O
seizures B-ADR
in O
nortriptyline B-DRUG
overdose O

background O
: O
accutane B-DRUG
a O
teratogenic B-ADR
prescription O
drug O
licensed O
to O
treat O
severe O
, O
recalcitrant O
nodular O
acne O

less O
common O
adverse O
events O
to O
dapsone B-DRUG
include O
the O
idiosyncratic O
reactions O
of O
leukopenia O
and O
agranulocytosis O
, O
cutaneous O
eruptions O
, O
peripheral O
neuropathy O
, O
psychosis O
, O
toxic O
hepatitis O
, O
cholestatic B-ADR
jaundice I-ADR
, O
nephrotic O
syndrome O
, O
renal O
papillary O
necrosis O
, O
severe O
hypoalbuminemia O
without O
proteinuria O
, O
an O
infectious O
mononucleosis-like O
syndrome O
, O
and O
minor O
neurological O
and O
gastrointestinal O
complaints O

a O
26-year-old O
japanese O
man O
, O
who O
had O
been O
receiving O
medical O
attention O
for O
ulcerative O
colitis O
for O
one O
year O
, O
presented O
with O
diffuse O
erythema O
and O
pustules B-ADR
on O
his O
face O
and O
trunk O
, O
malaise O
, O
and O
fever O
up O
to O
39 O
degrees O
c O
one O
day O
after O
the O
administration O
of O
salazosulfapyridine B-DRUG

interstitial B-ADR
pneumonia I-ADR
probably O
associated O
with O
sorafenib B-DRUG
treatment O
: O
an O
alert O
of O
an O
adverse O
event O

videopolysomnographic O
and O
pharmacokinetic O
studies O
with O
monitoring O
of O
plasma O
levodopa B-DRUG
levels O
demonstrated O
marked O
motor O
hyperactivity O
during O
augmentation O
, O
with O
anarchic O
discharges O
of O
motor O
unit O
potentials O
, O
tonic B-ADR
grouped I-ADR
discharges I-ADR
and O
flexor O
spasms O
, O
associated O
with O
painful O
dysesthesia O

the O
biochemistry O
of O
paracetamol B-DRUG
hepatotoxicity O
is O
outlined O
and O
the O
increased O
susceptibility O
of O
alcoholic O
patients O
to O
the O
hepatotoxic B-ADR
effects I-ADR
of O
paracetamol B-DRUG
is O
remarked O
upon O

the O
presence O
of O
a O
lymphocyte O
alveolitis O
with O
a O
predominance O
of O
cd4 O
+ O
t O
cells O
in O
3 O
ra O
patients O
and O
cd8 O
+ O
t O
cells O
with O
a O
concomitant O
increase O
in O
neutrophils O
in O
another O
case O
suggests O
that O
immunologically O
mediated O
reactions O
may O
be O
one O
damage O
mechanism O
in O
mtx-induced O
pneumonitis B-ADR

case O
summary O
: O
a O
57-year-old O
female O
with O
cardiomyopathy O
and O
" O
sulfa O
" O
( O
trimethoprim O
/ O
sulfamethoxazole O
) O
allergy O
documented O
as O
pancreatitis B-ADR
presented O
with O
symptoms O
consistent O
with O
pancreatitis B-ADR
after O
use O
of O
furosemide B-DRUG

simvastatin-induced O
rhabdomyolysis B-ADR
following O
cyclosporine O
treatment O
for O
uveitis O

diarrhoea O
, O
t-cd4 O
+ O
lymphopenia O
and O
bilateral O
patchy O
pulmonary O
infiltrates O
developed O
in O
a O
male O
60 O
yrs O
of O
age O
, O
who O
was O
treated O
with O
oxaliplatinum B-DRUG
and O
5-fluorouracil O
for O
unresectable O
rectum O
carcinoma O

does O
acyclovir B-DRUG
increase B-ADR
serum I-ADR
lithium I-ADR
levels I-ADR

of O
the O
four O
patients O
who O
responded O
to O
hu B-DRUG
with O
an O
increase B-ADR
in I-ADR
total I-ADR
hb I-ADR
, O
all O
reported O
symptomatic O
improvement O
and O
three O
have O
not O
required O
further O
transfusions O

the O
use O
of O
pamidronate O
for O
hypercalcemia O
secondary O
to O
acute O
vitamin B-ADR
d I-ADR
intoxication I-ADR

carbamyl O
phosphate O
synthetase-1 O
deficiency O
discovered O
after O
valproic B-DRUG
acid-induced O
coma B-ADR

intra-neural B-ADR
ceroid-like I-ADR
pigment I-ADR
following O
the O
treatment O
of O
lepromatous O
leprosy O
with O
clofazimine O
( O
b663 B-DRUG
; O
lamprene O

she O
was O
diagnosed O
with O
epstein-barr B-ADR
virus-associated I-ADR
polymorphic I-ADR
lymphoproliferative I-ADR
disorder I-ADR
( O
lpd O
) O
due O
to O
immunodeficiency O
caused O
by O
mtx B-DRUG
administration O

five O
personal O
observations O
of O
an O
acute B-ADR
amnestic I-ADR
episode I-ADR
in O
younger O
individuals O
after O
intake O
of O
clioquinol B-DRUG
are O
described O
together O
with O
three O
observations O
from O
the O
medical O
literature O

a O
high O
dose O
of O
cotrimoxazole B-DRUG
induced O
hyperkalaemia O
with O
the O
elevation O
of O
serum O
creatinine O
and O
blood O
urea O
, O
and O
increased B-ADR
urinary I-ADR
n-acetyl I-ADR
glucosaminase I-ADR
after O
several O
days O
of O
the O
drug O
administration O
in O
these O
patients O
; O
one O
patient O
became O
unconscious O

on O
the O
fifth O
day O
of O
tocolysis O
with O
magnesium B-DRUG
sulfate I-DRUG
, O
nifedipine O
, O
terbutaline O
and O
betamethasone O
, O
edema B-ADR
developed O
in O
both O
labia O

thrombocytosis B-ADR
under O
ciprofloxacin O
and O
tazobactam O
/ O
piperacillin B-DRUG

the O
authors O
report O
five O
cases O
of O
tremor B-ADR
related O
to O
itraconazole B-DRUG
therapy O
, O
which O
occurred O
within O
1-12 O
months O
of O
initiating O
treatment O
and O
resolved O
gradually O
following O
itraconazole B-DRUG
withdrawal O

discussion O
: O
central O
nervous O
system O
( O
cns O
) O
toxicity O
has O
been O
described O
with O
ifosfamide B-DRUG
, O
with O
most O
cases O
reported O
in O
the O
pediatric O
population O

only O
two O
case O
reports O
of O
adults O
with O
allergic B-ADR
contact I-ADR
dermatitis I-ADR
to O
this O
chemical O
exist O
in O
the O
literature O
, O
and O
we O
describe O
three O
more O
cases O
of O
children O
with O
recalcitrant O
atopic O
dermatitis O
found O
to O
have O
potential O
allergic B-ADR
contact I-ADR
dermatitis I-ADR
to O
bisabolol B-DRUG
- O
a O
component O
of O
the O
aquaphor O
emollient O
they O
were O
using O
to O
treat O
their O
atopic O
dermatitis O

a O
case O
of O
phenytoin-induced O
hepatitis O
with O
mononucleosis O
is O
reported O
, O
and O
syndromes O
associated O
with O
phenytoin B-DRUG
hypersensitivity B-ADR
reactions I-ADR
are O
discussed O

this O
report O
describes O
an O
unexpected O
drug-induced O
hepatitis B-ADR
in O
a O
previously O
healthy O
young O
woman O
exposed O
to O
2 O
doses O
of O
amodiaquine O
and O
artesunate B-DRUG

clinical O
signs O
of O
hypermagnesemia B-ADR
are O
an O
uncommon O
complication O
following O
oral O
administration O
of O
magnesium B-DRUG
sulfate I-DRUG

when O
the O
patient O
was O
treated O
again O
with O
fludarabine B-DRUG
nine O
months O
later O
, O
the O
dat B-ADR
became I-ADR
positive I-ADR
with I-ADR
anti-igg I-ADR
and I-ADR
anti-c3d I-ADR
antiglobulins I-ADR
after O
the O
second O
course O
of O
treatment O

acyclovir B-DRUG
neurotoxicity B-ADR
: O
clinical O
experience O
and O
review O
of O
the O
literature O

choanal B-ADR
atresia I-ADR
and O
athelia O
: O
methimazole B-DRUG
teratogenicity O
or O
a O
new O
syndrome O

atenolol B-DRUG
induced O
memory B-ADR
impairment I-ADR
: O
a O
case O
report O

we O
propose O
a O
mechanism O
of O
vancomycin-induced O
mast O
cell O
degranulation O
and O
subsequent O
release O
of O
eosinophil O
chemotactic O
factor O
as O
a O
cause O
of O
csfe B-ADR

a O
61-year-old O
man O
with O
early O
diffuse O
cutaneous O
scleroderma O
with O
myositis O
and O
progressive O
interstitial O
pneumonia O
developed O
generalized B-ADR
erythema I-ADR
with O
high O
fever O
3 O
weeks O
after O
taking O
sulfamethoxazole O
/ O
trimethoprim B-DRUG

infants O
are O
particularly O
susceptible O
to O
chronic O
nitrate-induced O
methemoglobinemia B-ADR
because O
of O
their O
low O
stomach O
acid O
production O
, O
large O
numbers O
of O
nitrite-reducing O
bacteria O
, O
and O
the O
relatively O
easy O
oxidation O
of O
fetal O
hemoglobin O

there O
have O
been O
more O
than O
20 O
observations O
of O
the O
appearance O
or O
aggravation O
of O
this O
granulomatosis B-ADR
with O
interferon B-DRUG
alfa I-DRUG
and O
more O
recently O
with O
the O
combination O
of O
interferon B-DRUG
alfa I-DRUG
plus O
ribavirin O

sulindac O
( O
clinoril B-DRUG
) O
, O
a O
nonsteroidal O
anti-inflammatory O
agent O
, O
has O
few O
reported O
neurologic B-ADR
toxic I-ADR
effects I-ADR
, O
all O
of O
which O
have O
been O
associated O
with O
systemic O
disease O

method O
: O
case O
analysis O
of O
a O
poly-drug O
overdose O
( O
venlafaxine O
, O
topiramate O
, O
divalproex B-DRUG
sodium I-DRUG
, O
risperidone O
, O
and O
carbamazepine O
) O
presenting O
with O
mixed O
ss O
/ O
nms B-ADR
features O
and O
whose O
clinical O
management O
suggests O
a O
practical O
algorithm O
for O
treatment O
of O
undifferentiated O
ss O
/ O
nms B-ADR
in O
critical O
care O
settings O

pravastatin B-DRUG
is O
associated O
with O
myotonia B-ADR
in O
animals O

in O
three O
of O
these O
patients O
the O
infection O
was O
clinically O
unsuspected O
; O
in O
the O
fourth O
, O
cutaneous B-ADR
herpes I-ADR
zoster I-ADR
developed O
after O
administration O
of O
300 O
mg O
of O
cytarabine B-DRUG
daily O
for O
the O
preceding O
five O
days O

conclusion O
: O
tamoxifen B-DRUG
may O
cause O
malignant B-ADR
transformation I-ADR
of I-ADR
endometriosis I-ADR
through O
atypical O
endometriosis O
even O
in O
the O
postmenopausal O
state O

sodium B-DRUG
valproate I-DRUG
and O
carbamazepine O
, O
antiepileptic O
drugs O
that O
are O
associated O
with O
a O
relatively O
low O
rate O
of O
adverse O
cutaneous O
reactions O
, O
should O
be O
added O
to O
the O
growing O
list O
of O
drugs O
that O
produce O
psoriasiform B-ADR
eruptions I-ADR

methods O
: O
growth B-ADR
retardation I-ADR
was O
observed O
in O
six O
severely O
asthmatic O
children O
after O
introduction O
of O
high-dose O
fluticasone B-DRUG
propionate I-DRUG
treatment O
( O
dry O
powder O

objectives O
: O
to O
describe O
the O
presentation O
and O
treatment O
of O
acute O
isoniazid B-DRUG
( O
inh O
) O
neurotoxicity B-ADR
appearing O
at O
an O
inner-city O
municipal O
hospital O

a O
twelve O
year-old-girl O
with O
idiopathic O
partial O
epilepsy O
with O
secondary O
generalization O
, O
developed O
acute B-ADR
psychosis I-ADR
10 O
days O
after O
the O
administration O
of O
levetiracetam B-DRUG

it O
may O
cause O
a O
severe O
adverse O
drug O
reaction O
with O
multiorgan O
involvement O
known O
as O
dapsone B-DRUG
hypersensitivity B-ADR
syndrome I-ADR

the O
incidence O
of O
5-fluorouracil B-DRUG
( O
5-fu O
)- O
related O
cardiotoxicity B-ADR
seems O
to O
be O
dosage O
and O
schedule O
dependent O

a O
26-year-old O
japanese O
man O
, O
who O
had O
been O
receiving O
medical O
attention O
for O
ulcerative O
colitis O
for O
one O
year O
, O
presented O
with O
diffuse B-ADR
erythema I-ADR
and O
pustules O
on O
his O
face O
and O
trunk O
, O
malaise O
, O
and O
fever O
up O
to O
39 O
degrees O
c O
one O
day O
after O
the O
administration O
of O
salazosulfapyridine B-DRUG

we O
describe O
a O
case O
of O
subcutaneous B-ADR
metastasis I-ADR
along O
the O
needle O
track O
after O
percutaneous O
ethanol B-DRUG
injection O
( O
pei O
) O
for O
treatment O
of O
hepatocellular O
carcinoma O

we O
present O
a O
neonate O
with O
a O
seizure O
disorder O
who O
acutely O
developed O
pupillary B-ADR
mydriasis I-ADR
secondary O
to O
lidocaine B-DRUG
overdose O

we O
describe O
the O
side O
effects O
of O
5-fu B-DRUG
in O
a O
colon O
cancer O
patient O
who O
suffered O
severe O
mucositis O
, O
desquamating O
dermatitis O
, O
prolonged O
myelosuppression O
, O
and O
neurologic B-ADR
toxicity I-ADR
that O
required O
admission O
to O
the O
intensive O
care O
unit O

propecia-associated O
bilateral B-ADR
cataract I-ADR

administration O
of O
lamotrigine O
, O
especially O
in O
combination O
with O
valproic B-DRUG
acid I-DRUG
, O
may O
lead O
to O
the O
development O
of O
ten B-ADR

although O
dyspnea B-ADR
associated O
with O
verapamil B-DRUG
administration O
has O
been O
reported O
, O
this O
is O
the O
first O
report O
of O
an O
elderly O
asymptomatic O
asthmatic O
patient O
with O
hypertension O
who O
developed O
an O
acute O
asthma O
attack O
following O
sustained-release O
verapamil B-DRUG
administration O

a O
possible O
case O
of O
carbamazepine B-DRUG
induced O
pancreatitis B-ADR

a O
52-year-old O
woman O
developed O
symmetric B-ADR
sensorimotor I-ADR
polyneuropathy I-ADR
and O
cerebellar O
syndrome O
after O
24 O
months O
of O
amiodarone B-DRUG
treatment O

while O
the O
introduction O
of O
carmustine B-DRUG
wafers O
( O
gliadel O
wafers O
) O
into O
the O
tumor O
resection O
cavity O
has O
been O
shown O
to O
be O
a O
beneficial O
therapy O
for O
malignant O
glioma O
, O
it O
is O
recognized O
that O
clinically O
significant O
cerebral B-ADR
edema I-ADR
is O
a O
potential O
adverse O
effect O

conclusion O
: O
a O
patient O
with O
chf O
and O
esrd O
developed O
myoclonic B-ADR
muscle I-ADR
spasms I-ADR
after O
receiving O
dobutamine B-DRUG
by O
continuous O
i.v. O
infusion O

methods O
: O
a O
55-year-old O
woman O
became O
stuporous B-ADR
after O
overdose O
with O
lamotrigine O
( O
ltg O
) O
and O
valproic O
acid O
( O
vpa B-DRUG
) O
tablets O

bowel B-ADR
perforation I-ADR
associated O
with O
intraperitoneal O
chromic B-DRUG
phosphate I-DRUG
instillation O

lupus-like B-ADR
syndrome I-ADR
caused O
by O
5-aminosalicylic B-DRUG
acid I-DRUG
in O
patients O
with O
inflammatory O
bowel O
disease O

it O
is O
presumed O
that O
her O
hyperchloremic B-ADR
metabolic I-ADR
acidosis I-ADR
was O
secondary O
to O
cholestyramine B-DRUG
because O
of O
the O
similarity O
to O
pediatric O
reports O
; O
the O
rapid O
and O
lasting O
response O
to O
intravenous O
sodium O
bicarbonate O
; O
the O
absence O
of O
another O
etiology O
; O
normal O
serum O
potassium O
, O
chloride O
and O
bicarbonate O
despite O
continued O
spironolactone O
therapy O
after O
recovery O

to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
ivermectin-induced O
severe B-ADR
liver I-ADR
disease I-ADR
published O
in O
the O
literature O

rhabdomyolysis B-ADR
associated O
with O
clozapine B-DRUG
treatment O
in O
a O
patient O
with O
decreased O
calcium-dependent O
potassium O
permeability O
of O
cell O
membranes O

the O
patient O
's O
arthritis B-ADR
flared O
after O
the O
second O
infusion O
of O
infliximab B-DRUG
, O
which O
was O
discontinued O

lithium B-DRUG
is O
known O
to O
cause O
acute O
renal O
failure O
and O
tubulo-interstitial O
disease O
, O
but O
the O
recently O
described O
association O
with O
proteinuria B-ADR
or O
nephrotic O
syndrome O
is O
little O
recognized O

we O
report O
a O
45-year-old O
chinese O
man O
with O
cml O
and O
chronic O
hepatitis O
b O
virus O
infection O
, O
on O
imatinib B-DRUG
treatment O
, O
presenting O
with O
herpetic O
rash O
and O
acute B-ADR
liver I-ADR
failure I-ADR

this O
report O
describes O
an O
individual O
with O
mental O
retardation O
who O
experienced O
behavioral B-ADR
exacerbation I-ADR
associated O
with O
clonazepam B-DRUG
prescribed O
at O
2 O
mg O
/ O
day O
( O
0.02 O
mg O
/ O
kg O
/ O
day O
) O
to O
treat O
aggression O
, O
self-injurious O
behavior O
, O
property O
destruction O
, O
and O
screaming O
, O
which O
was O
measured O
with O
a O
15-minute O
partial O
interval O
recording O
measurement O
method O

we O
herein O
described O
an O
additional O
patient O
with O
bcr-abl O
( O
ela2 O
) O
positive O
acute O
lymphoblastic O
leukemia O
who O
developed O
tumor B-ADR
lysis I-ADR
syndrome I-ADR
after O
10-day O
treatment O
with O
imatinib B-DRUG

however O
, O
to O
our O
knowledge O
, O
in O
newborns O
there O
have O
been O
no O
reported O
cases O
to O
date O
of O
thrombocytosis B-ADR
induced O
by O
enoxaparin B-DRUG

the O
purpose O
of O
this O
review O
is O
to O
increase O
awareness O
among O
physicians O
and O
other O
health O
care O
professionals O
that O
dic B-ADR
may O
be O
a O
rare O
but O
potentially O
severe O
complication O
of O
anti-d B-DRUG
igiv I-DRUG
treatment O

on O
the O
second O
day O
of O
hospitalization O
, O
it O
was O
noted O
that O
the O
patient O
's O
dyspnea B-ADR
and O
sinus O
bradycardia O
could O
be O
related O
to O
a O
recent O
increase O
in O
his O
timolol B-DRUG
dosage O

the O
fetal O
valproate B-DRUG
syndrome O
( O
fvs O
) O
is O
characterized O
by O
distinctive O
facial O
appearance O
, O
major B-ADR
and I-ADR
minor I-ADR
malformations I-ADR
, O
and O
developmental O
delay O

a O
17-year-old O
boy O
with O
refractory O
psoriatic O
arthritis O
and O
alpha-1 O
antitrypsin O
deficiency O
who O
developed O
a O
syringotropic B-ADR
hypersensitivity I-ADR
reaction I-ADR
after O
9 O
months O
of O
therapy O
with O
infliximab B-DRUG
and O
leflunomide O
is O
described O

itch O
and O
skin B-ADR
rash I-ADR
from O
chocolate O
during O
fluoxetine O
and O
sertraline B-DRUG
treatment O
: O
case O
report O

a O
7-year-old O
with O
congenital O
toxoplasmosis O
who O
took O
pyrimethamine B-DRUG
and O
sulfadiazine O
for O
reactivated O
chorioretinitis O
developed O
fever B-ADR
, O
severe O
cutaneous O
involvement O
, O
swelling O
, O
abdominal O
pain O
and O
transaminitis O
, O
persisting O
weeks O
after O
withholding O
medicines O

milk-alkali B-ADR
syndrome I-ADR
induced O
by O
1,25 O
( O
oh O
) O
2d O
in O
a O
patient O
with O
hypoparathyroidism O

we O
report O
a O
patient O
with O
chronic O
renal O
failure O
and O
ischemic O
heart O
disease O
who O
developed O
clinically O
significant O
methemoglobinemia B-ADR
after O
an O
axillary O
block O
with O
bupivacaine O
and O
additional O
injection O
of O
lidocaine B-DRUG
in O
the O
operative O
field O

lipoid B-ADR
pneumonia I-ADR
: O
a O
silent O
complication O
of O
mineral B-DRUG
oil I-DRUG
aspiration O

treatment O
with O
infliximab B-DRUG
is O
known O
to O
produce O
an O
increase O
of O
autoantibodies O
( O
antinuclear O
antibodies O
, O
anti-double-stranded B-ADR
dna I-ADR
) O
, O
but O
not O
clinical O
disease O

this O
case O
study O
describes O
an O
atypical O
case O
of O
refractory O
, O
sodium B-DRUG
warfarin-induced O
necrotizing O
fasciitis O
and O
myonecrosis B-ADR

pregabalin-induced O
cortical B-ADR
negative I-ADR
myoclonus I-ADR
in O
a O
patient O
with O
neuropathic O
pain O

clinicians O
have O
been O
aware O
of O
lithium B-DRUG
toxicity O
for O
many O
years O
and O
traditionally O
have O
administered O
thiazide O
diuretics O
for O
lithium-induced O
polyuria B-ADR
and O
nephrogenic O
diabetes O
insipidus O

three O
distinct O
types O
of O
minocycline-induced O
cutaneous B-ADR
pigmentation I-ADR
have O
been O
described O

hepatopathy B-ADR
subsided O
after O
the O
cessation O
of O
carbamazepine O
and O
lynestrenol B-DRUG

after O
5 O
weeks O
of O
therapy O
, O
she O
stopped O
taking O
pantoprazole B-DRUG
due O
to O
general B-ADR
malaise I-ADR

administration O
of O
intravenous O
nitroglycerin B-DRUG
in O
a O
patient O
with O
idiopathic O
pulmonary O
hypertension O
resulted O
in O
an O
increase O
in O
pulmonary O
artery O
pressure O
associated O
with O
a O
decrease O
in O
blood O
flow O
that O
is O
best O
explained O
by O
an O
increase B-ADR
in I-ADR
pulmonary I-ADR
vascular I-ADR
resistance I-ADR

carbamazepine-induced O
tics B-ADR

toxic B-ADR
hepatitis I-ADR
due O
to O
combination O
therapy O
with O
methotrexate B-DRUG
and O
etretinate O
in O
psoriasis O

previous O
studies O
have O
demonstrated O
the O
interaction O
of O
mtx B-DRUG
and O
a O
variety O
of O
non-steroidal O
, O
anti-inflammatory O
drugs O
( O
nsaids O
) O
with O
various O
clinical O
manifestations O
including O
acute O
renal O
failure O
, O
pancytopenia O
, O
vomiting B-ADR
, O
diarrhea O
, O
elevated O
liver O
transaminases O
, O
jaundice O
, O
mucosal O
ulcerations O
, O
and O
pyrexia O

erythromycin B-DRUG
is O
a O
macrolide O
antibiotic O
that O
may O
increase O
the O
risk O
of O
lovastatin-induced O
rhabdomyolysis B-ADR

acute B-ADR
myocardial I-ADR
infarction I-ADR
due O
to O
coronary O
spasm O
associated O
with O
l-thyroxine B-DRUG
therapy O

in O
this O
report O
, O
one O
patient O
who O
developed O
gangrene B-ADR
after O
bleomycin B-DRUG
and O
vincristine O
/ O
vinblastine O
chemotherapy O
for O
aids-related O
kaposi O
's O
sarcoma O
and O
another O
hiv-infected O
patient O
who O
exhibited O
symptoms O
of O
severe O
raynaud O
's O
phenomenon O
related O
to O
the O
same O
regimen O
are O
presented O

conclusions O
: O
there O
is O
very O
little O
published O
information O
regarding O
ofloxacin-induced O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR

palpable B-ADR
purpuric I-ADR
skin I-ADR
lesions I-ADR
on O
the O
anterior O
surface O
of O
both O
legs O
appeared O
on O
the O
55th O
day O
of O
amphotericin B-DRUG
b I-DRUG
treatment O

case O
presentation O
: O
three O
cases O
of O
leishmania B-ADR
infantum I-ADR
leishmaniasis I-ADR
in O
corticosteroid B-DRUG
( O
cs O
)- O
treated O
patients O
are O
reported O
: O
an O
isolated O
lingual O
leishmaniasis O
in O
a O
farmer O
treated O
with O
cs O
for O
asthma O
, O
a O
severe O
visceral O
leishmaniasis O
associated O
with O
cutaneous O
lesions O
in O
a O
woman O
with O
myasthenia O
gravis O
, O
and O
a O
visceral O
involvement O
after O
cutaneous O
leishmaniasis O
in O
a O
man O
receiving O
cs O

choanal O
atresia O
and O
athelia O
: O
methimazole B-DRUG
teratogenicity B-ADR
or O
a O
new O
syndrome O

acute O
kidney O
injury O
caused O
by O
zonisamide-induced O
hypersensitivity B-ADR
syndrome I-ADR

drug-induced O
psychosis B-ADR
resulted O
from O
the O
administration O
of O
quinacrine B-DRUG
hydrochloride I-DRUG
at O
a O
dosage O
of O
100 O
mg O
twice O
daily O
for O
the O
treatment O
of O
discoid O
lupus O

conclusions O
: O
because O
of O
its O
structural O
similarity O
to O
the O
other O
vinca O
alkaloids O
, O
vinorelbine B-DRUG
is O
believed O
to O
be O
responsible O
for O
siadh B-ADR
in O
our O
patient O

we O
report O
the O
case O
of O
an O
11-year-old O
female O
treated O
for O
mediastinal O
t-cell O
lymphoma O
who O
presented O
renal B-ADR
failure I-ADR
following O
the O
second O
cycle O
of O
high-dose O
methotrexate O
( O
hdmtx B-DRUG

conclusions O
: O
there O
was O
a O
temporal O
relationship O
between O
the O
onset O
of O
nonconvulsive B-ADR
status I-ADR
epilepticus I-ADR
and O
initiation O
of O
ifosfamide B-DRUG
infusion O

we O
present O
a O
case O
of O
ethylenediamine-induced O
delayed B-ADR
hypersensitivity I-ADR
reaction I-ADR
in O
a O
46-year-old O
woman O
who O
received O
parenteral O
aminophylline B-DRUG
for O
an O
acute O
asthma O
exacerbation O

this O
severe O
illness O
was O
likely O
caused O
by O
minocycline B-DRUG
, O
and O
we O
speculate O
that O
minocycline B-DRUG
may O
have O
acted O
as O
a O
superantigen O
, O
causing O
lymphocyte B-ADR
over-activation I-ADR
and O
massive O
cytokine O
release O

worsening B-ADR
of I-ADR
neurologic I-ADR
syndrome I-ADR
in O
patients O
with O
wilson O
's O
disease O
with O
initial O
penicillamine B-DRUG
therapy O

administration O
of O
excessive O
insulin B-DRUG
induced O
hypoglycemia B-ADR
within O
4 O
to O
8 O
hours O
, O
followed O
by O
rebound O
hyperglycemia O

we O
report O
a O
patient O
in O
whom O
the O
anti-depressant O
trazodone B-DRUG
hydrochloride I-DRUG
( O
molipaxin O
, O
roussel O
) O
, O
a O
serotonin O
antagonist O
, O
provoked O
generalized O
pustular O
psoriasis O
( O
gpp B-ADR

hyperkalaemia B-ADR
with O
renal O
tubular O
dysfunction O
by O
oral O
therapy O
of O
sulfamethoxazole-trimethoprim O
( O
co-trimoxazole B-DRUG
) O
is O
described O
in O
2 O
elderly O
japanese O
patients O
with O
lymphoid O
malignancy O
, O
who O
developed O
pneumocystis O
carinii O
pneumonia O
and O
improved O

we O
recommend O
the O
cautious O
use O
of O
ketorolac B-DRUG
in O
patients O
with O
underlying O
illnesses O
where O
nsaid-induced O
ototoxicity B-ADR
could O
result O
in O
adverse O
otologic O
consequences O

he O
had O
been O
taking O
trimethoprim-sulfamethoxazole O
for O
approximately O
eight O
days O
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches O
, O
dizziness O
, O
difficulty B-ADR
with I-ADR
speech I-ADR
, O
weakness O
, O
and O
itching O
on O
the O
trunk O
of O
his O
body O
and O
legs O
, O
where O
a O
maculopapular O
rash O
was O
noted O

results O
: O
five O
of O
70 O
patients O
who O
had O
begun O
leflunomide B-DRUG
therapy O
had O
significant O
weight B-ADR
loss I-ADR
that O
could O
not O
be O
linked O
to O
other O
identifiable O
etiologies O

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate O
with O
folinic B-DRUG
acid I-DRUG
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia O
, O
hyperkalaemia O
and O
hyperphosphataemia O
with O
hypocalcaemia B-ADR
and O
tetany O
, O
with O
metabolic O
acidosis O
and O
acute O
renal O
impairment O
) O
are O
described O

we O
report O
a O
59-year-old O
patient O
with O
chronic O
myeloid O
leukemia O
, O
who O
developed O
severe B-ADR
interstitial I-ADR
lung I-ADR
fibrosis I-ADR
after O
short O
term O
and O
sequential O
treatment O
with O
melphalan O
and O
busulfan B-DRUG

therefore O
, O
clinicians O
should O
pay O
close O
attention O
to O
possible O
onset O
of O
rd B-ADR
in O
patients O
with O
multiple O
risk O
factors O
for O
td O
, O
even O
when O
sda B-DRUG
therapy O
is O
used O

sixteen O
of O
33 O
patients O
developed O
significant O
hyponatremia O
and O
hypoosmolality B-ADR
during O
oral O
treatment O
with O
lorcainide B-DRUG

results O
: O
a O
52-year-old O
woman O
with O
parkinson O
disease O
who O
had O
taken O
amantadine B-DRUG
for O
6 O
years O
had O
bilateral B-ADR
corneal I-ADR
edema I-ADR
for O
2 O
months O
at O
baseline O

in O
this O
article O
, O
we O
describe O
another O
case O
of O
subcutaneous B-ADR
changes I-ADR
following O
repeated O
glatiramer B-DRUG
acetate I-DRUG
injection O
, O
presented O
as O
localized O
panniculitis O
in O
the O
area O
around O
the O
injection O
sites O
, O
in O
a O
46-year-old O
female O
patient O
who O
was O
treated O
with O
glatiramer B-DRUG
acetate I-DRUG
for O
18 O
months O

we O
present O
a O
case O
of O
the O
syndrome O
of O
inappropriate O
antidiuretic O
hormone O
( O
siadh B-ADR
) O
secondary O
to O
cisplatin B-DRUG
therapy O
in O
a O
patient O
with O
advanced-stage O
large O
cell O
neuroendocrine O
carcinoma O
of O
the O
cervix O

treatment O
of O
carbimazole-induced O
agranulocytosis B-ADR
and O
sepsis O
with O
granulocyte O
colony O
stimulating O
factor O

linezolid-associated O
acute O
interstitial O
nephritis O
and O
drug B-ADR
rash I-ADR
with I-ADR
eosinophilia I-ADR
and I-ADR
systemic I-ADR
symptoms I-ADR
( O
dress O
) O
syndrome O

we O
report O
a O
case O
of O
a O
64-year-old O
man O
with O
secondary O
adrenocortical B-ADR
insufficiency I-ADR
who O
has O
been O
on O
a O
chronic O
transdermal O
fentanyl B-DRUG
treatment O
because O
of O
sciatic O
pain O
syndrome O

high-dose O
phosphate B-DRUG
treatment O
leads O
to O
hypokalemia B-ADR
in O
hypophosphatemic O
osteomalacia O

anaphylaxis B-ADR
to O
cisplatin B-DRUG
following O
nine O
previous O
uncomplicated O
cycles O

we O
describe O
the O
development O
of O
ischemic B-ADR
colitis I-ADR
in O
a O
woman O
who O
was O
treated O
with O
tegaserod B-DRUG
and O
review O
the O
relationship O
among O
ischemic B-ADR
colitis I-ADR
, O
tegaserod B-DRUG
use O
, O
and O
irritable O
bowel O
syndrome O

we O
believe O
that O
mucositis O
was O
a O
contributing O
factor O
to O
this O
case O
of O
fatal B-ADR
hyperkalemia I-ADR
after O
administration O
of O
succinylcholine B-DRUG
, O
with O
a O
mechanism O
similar O
to O
that O
reported O
with O
thermal O
injury O

a O
case O
is O
reported O
of O
a O
40 O
year O
old O
woman O
treated O
with O
intraventricular O
il-2 B-DRUG
for O
leptomeningeal O
disease O
who O
developed O
progressive O
cognitive B-ADR
dysfunction I-ADR

well-known O
signs O
of O
methotrexate B-DRUG
toxicity O
include O
bone B-ADR
marrow I-ADR
suppression I-ADR
and O
oral O
and O
gastrointestinal O
ulceration O

there O
have O
been O
several O
reported O
cases O
of O
omeprazole-induced O
ain B-ADR

these O
two O
cases O
highlight O
the O
importance O
of O
considering O
lopinavir O
/ O
ritonavir B-DRUG
induced O
arrhythmias B-ADR
when O
dealing O
with O
hiv-positive O
individuals O

although O
gabapentin B-DRUG
withdrawal O
has O
been O
previously O
reported O
and O
usually O
consists O
of O
anxiety B-ADR
, O
diaphoresis O
, O
and O
palpitations O
, O
this O
is O
the O
first O
reported O
patient O
with O
generalized O
seizures O
and O
status O
epilepticus O
secondary O
to O
gabapentin B-DRUG
withdrawal O

we O
report O
the O
first O
case O
of O
rhabdomyolysis B-ADR
related O
to O
the O
administration O
of O
clarithromycin B-DRUG
without O
concurrent O
use O
of O
other O
medications O

a O
58-year-old O
woman O
with O
rheumatoid O
arthritis O
( O
ra O
) O
developed O
fever O
, O
skin B-ADR
eruptions I-ADR
, O
leukocytopenia O
, O
and O
thrombocytopenia O
, O
3 O
weeks O
after O
treatment O
with O
sulfasalazine B-DRUG

pulmonary B-ADR
lymphohistiocytic I-ADR
reactions I-ADR
temporally O
related O
to O
etanercept B-DRUG
therapy O

results O
: O
our O
patient O
developed O
crohn B-ADR
's I-ADR
disease I-ADR
while O
on O
copaxone B-DRUG
treatment O
as O
a O
consequence O
of O
long-term O
immunosuppression O

conclusion O
: O
the O
chronic O
use O
of O
hcq B-DRUG
for O
rheumatic O
diseases O
, O
or O
as O
an O
anti-malarial O
drug O
, O
should O
be O
balanced O
against O
the O
risk O
of O
developing O
potentially O
lethal O
cardiac B-ADR
arrhythmias I-ADR

she O
was O
admitted O
following O
a O
fall O
and O
, O
after O
being O
given O
metoclopramide B-DRUG
, O
developed O
movement O
disorder O
and O
a O
period O
of O
unresponsiveness B-ADR

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate O
with O
folinic B-DRUG
acid I-DRUG
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia B-ADR
, O
hyperkalaemia O
and O
hyperphosphataemia O
with O
hypocalcaemia O
and O
tetany O
, O
with O
metabolic O
acidosis O
and O
acute O
renal O
impairment O
) O
are O
described O

sirolimus-eluting B-ADR
stent I-ADR
thrombosis I-ADR
several O
years O
after O
clopidogrel B-DRUG
discontinuation O

we O
describe O
a O
patient O
with O
a O
liver O
abscess O
due O
to O
entamoeba O
histolytica O
, O
in O
whom O
metronidazole B-DRUG
therapy O
( O
total O
dose O
, O
21 O
g O
over O
14 O
days O
) O
was O
complicated O
by O
reversible O
deafness O
, O
tinnitus O
, O
and O
ataxia B-ADR
and O
who O
relapsed O
5 O
months O
later O
with O
a O
splenic O
abscess O

total O
blindness O
with O
a O
transient O
tonic O
pupillary O
response O
, O
denervation B-ADR
supersensitivity I-ADR
, O
and O
abnormal O
visual-evoked O
potentials O
developed O
in O
a O
54-year-old O
man O
after O
the O
use O
of O
quinine B-DRUG
sulfate I-DRUG
for O
leg O
cramps O

herein O
, O
we O
describe O
2 O
patients O
who O
developed O
unusual O
cd8 O
+ O
cutaneous O
lymphoproliferative O
disorders O
after O
treatment O
with O
efalizumab O
and O
infliximab B-DRUG

we O
report O
a O
case O
of O
a O
patient O
with O
ciprofloxacin-induced O
sjs O
and O
acute O
onset O
of O
vbds B-ADR
, O
and O
reviewed O
the O
related O
literature O

the O
first O
case O
concerns O
a O
70-year-old O
man O
who O
developed O
severe O
aplastic B-ADR
anemia I-ADR
7 O
weeks O
after O
treatment O
with O
500 O
mg O
of O
ticlopidine B-DRUG
daily O

the O
authors O
present O
an O
elderly O
patient O
with O
mixed O
dementia O
who O
developed O
td O
at O
multiple O
sites O
, O
( O
including O
respiratory O
dyskinesia O
[ O
rd O
] O
, O
limb B-ADR
dyskinesia I-ADR
, O
and O
orofacial O
dyskinesia O
) O
following O
abrupt O
withdrawal O
of O
risperidone B-DRUG
therapy O

the O
pharmaceutical O
company O
producing O
halfan O
has O
reported O
8 O
cardiac B-ADR
arrests I-ADR
, O
leading O
to O
6 O
deaths O
, O
when O
a O
higher O
dose O
than O
recommended O
was O
used O
, O
there O
was O
recent O
or O
concomitant O
treatment O
with O
mefloquine B-DRUG
, O
there O
was O
pre-existing O
prolongation O
of O
the O
qt O
interval O
or O
the O
patient O
had O
a O
thiamine O
deficiency O

paradoxical B-ADR
precipitation I-ADR
of I-ADR
tonic I-ADR
seizures I-ADR
by O
lorazepam B-DRUG
in O
a O
child O
with O
atypical O
absence O
seizures O

a O
patient O
with O
psoriasis O
is O
described O
who O
had O
an O
abnormal O
response O
to O
the O
glucose O
tolerance O
test O
without O
other O
evidence O
of O
diabetes O
and O
then O
developed O
postprandial O
hyperglycemia O
and O
glycosuria B-ADR
during O
a O
period O
of O
topical O
administration O
of O
a O
corticosteroid O
cream O
, O
halcinonide B-DRUG
cream O
0.1 O
% O
, O
under O
occlusion O

development O
of O
peyronie B-ADR
's I-ADR
disease I-ADR
during O
long-term O
colchicine B-DRUG
treatment O

allergic O
side O
effects O
of O
aza B-DRUG
are O
rare O
, O
and O
reported O
allergic B-ADR
skin I-ADR
eruptions I-ADR
from O
aza B-DRUG
are O
very O
limited O
in O
japan O

conclusions O
: O
topiramate B-DRUG
may O
be O
associated O
with O
ciliochoroidal O
effusion O
with O
forward O
displacement O
of O
the O
lens-iris O
diaphragm O
and O
anterior O
chamber O
shallowing O
, O
resulting O
in O
acute B-ADR
myopia I-ADR
and O
angle-closure O
glaucoma O

discussion O
: O
amphotericin B-DRUG
b I-DRUG
deoxycholate I-DRUG
has O
been O
reported O
to O
produce O
significant O
cardiac B-ADR
toxicity I-ADR
, O
with O
ventricular O
arrhythmias O
and O
bradycardia O
reported O
in O
overdoses O
in O
children O
and O
in O
adults O
with O
preexisting O
cardiac O
disease O
, O
even O
when O
administered O
in O
conventional O
dosages O
and O
infusion O
rates O

ifosfamide-associated O
neurotoxicity B-ADR
was O
noted O
within O
hours O
of O
drug O
administration O
and O
improved O
rapidly O
following O
hemodialysis O

we O
report O
a O
case O
of O
fatal B-ADR
pulmonary I-ADR
toxicity I-ADR
in O
a O
patient O
with O
advanced O
non-small O
cell O
lung O
cancer O
who O
received O
erlotinib B-DRUG

a O
case O
of O
phenobarbital B-DRUG
exacerbation B-ADR
of I-ADR
a I-ADR
preexisting I-ADR
maladaptive I-ADR
behavior I-ADR
partially O
suppressed O
by O
chlorpromazine O
and O
misinterpreted O
as O
chlorpromazine O
efficacy O

a O
case O
of O
prolonged O
suxamethonium B-DRUG
apnoea B-ADR
successfully O
terminated O
by O
the O
infusion O
of O
a O
commercial O
preparation O
of O
serumcholinesterase O
is O
reported O

the O
principle O
treatment O
for O
dpd-deficient O
patients O
with O
severe O
acute O
5-fu B-DRUG
reactions O
is O
supportive O
care O
; O
however O
, O
the O
administration O
of O
thymidine O
potentially O
may O
reverse O
severe O
5-fu-induced O
neurologic B-ADR
symptoms I-ADR
such O
as O
encephalopathy O
and O
coma O

we O
present O
a O
case O
of O
ethylenediamine-induced O
delayed B-ADR
hypersensitivity I-ADR
reaction I-ADR
in O
a O
46-year-old O
woman O
who O
received O
parenteral O
aminophylline O
for O
an O
acute O
asthma O
exacerbation O

the O
induced O
hyperglycaemia O
could O
not O
be O
controlled O
sufficiently O
, O
despite O
a O
high O
dose O
of O
insulin B-DRUG
(> O
110 O
units O
/ O
day O
) O
, O
suggesting O
the O
existence O
of O
insulin B-ADR
insensitivity I-ADR
and O
hyperinsulinaemia O

early-onset O
acute B-ADR
transverse I-ADR
myelitis I-ADR
following O
hepatitis B-DRUG
b I-DRUG
vaccination I-DRUG
and O
respiratory O
infection O
: O
case O
report O

pulmonary B-ADR
fibrosis I-ADR
is O
a O
complication O
of O
paclitaxel B-DRUG
therapy O
that O
may O
occur O
despite O
treatments O
with O
corticosteroids O

three O
cases O
of O
pseudocyst B-ADR
of I-ADR
the I-ADR
pancreas I-ADR
in O
two O
women O
and O
one O
man O
have O
previously O
been O
reported O
with O
the O
use O
of O
intravenous O
l-asparaginase B-DRUG

first O
, O
a O
review O
of O
the O
literature O
produced O
41 O
anecdotic O
cases O
of O
neutropenia B-ADR
or O
agranulocytosis O
during O
treatment O
with O
olanzapine B-DRUG
( O
zyprexa O
) O
reported O
in O
a O
total O
of O
24 O
publications O

myoclonus O
was O
induced O
and O
enhanced O
by O
l-dopa B-DRUG
, O
developing O
into O
generalized B-ADR
seizures I-ADR

a O
case O
of O
polymyositis O
with O
dilated B-ADR
cardiomyopathy I-ADR
associated O
with O
interferon B-DRUG
alpha I-DRUG
treatment O
for O
hepatitis O
b O

caution O
with O
use O
of O
cimetidine B-DRUG
in O
tolazoline O
induced O
upper B-ADR
gastrointestinal I-ADR
bleeding I-ADR

we O
report O
a O
case O
of O
intrathecal O
methotrexate B-DRUG
neurotoxicity O
manifesting O
as O
left O
arm O
weakness O
and O
aphasia B-ADR

disopyramide O
( O
norpace B-DRUG
)- O
induced O
hypoglycemia B-ADR

toxic B-ADR
hepatitis I-ADR
due O
to O
combination O
therapy O
with O
methotrexate O
and O
etretinate B-DRUG
in O
psoriasis O

it O
is O
concluded O
that O
' O
cerebral B-ADR
atrophy I-ADR
' O
on O
ct O
scans O
may O
represent O
an O
accumulative O
effect O
of O
acth B-DRUG
and O
that O
acth B-DRUG
should O
be O
given O
with O
the O
utmost O
discretion O
, O
and O
in O
as O
low O
a O
dose O
as O
possible O

syringotropic B-ADR
hypersensitivity I-ADR
reaction I-ADR
associated O
with O
infliximab O
and O
leflunomide B-DRUG
combination O
therapy O
in O
a O
child O
with O
psoriatic O
arthritis O

we O
report O
the O
specifics O
of O
12 O
cases O
of O
severe B-ADR
hypertension I-ADR
after O
the O
intraoperative O
use O
of O
topical O
phenylephrine O
, O
submucosal O
epinephrine B-DRUG
, O
or O
both O

however O
, O
the O
amount O
of O
prednisone B-DRUG
required O
to O
maintain O
normotension O
resulted O
in O
cushingoid B-ADR
features I-ADR
and O
has O
been O
discontinued O

a O
severe O
form O
of O
exophthalmos B-ADR
resulting O
from O
lithium B-DRUG
therapy O
has O
not O
been O
described O
in O
the O
literature O

further O
studies O
are O
necessary O
to O
evaluate O
whether O
the O
study O
of O
hla O
antigens O
may O
be O
a O
very O
useful O
tool O
to O
detect O
the O
patients O
with O
a O
predisposition O
to O
develop O
autoimmune B-ADR
thyroiditis I-ADR
, O
in O
order O
to O
make O
a O
early O
diagnosis O
of O
thyroid O
disorders O
during O
the O
ifn-alpha B-DRUG
treatment O

a O
49-year-old O
man O
with O
crohn O
's O
disease O
treated O
with O
prednisone O
and O
mesalamine B-DRUG
( O
5-asa O
) O
developed O
worsening B-ADR
respiratory I-ADR
distress I-ADR
and O
fever O

cutaneous B-ADR
reactions I-ADR
to O
propylthiouracil O
and O
methimazole B-DRUG
occur O
in O
3 O
%- O
5 O
% O
of O
adults O

in O
this O
case O
report O
, O
we O
present O
clinical O
and O
laboratory O
findings O
of O
a O
case O
with O
chronic O
hepatitis O
b O
that O
developed O
acute B-ADR
dystonia I-ADR
soon O
after O
the O
first O
dose O
of O
pegylated B-DRUG
interferon I-DRUG
alpha I-DRUG

uncontrolled O
headache B-ADR
induced O
by O
oxcarbazepine B-DRUG

ibuprofen B-DRUG
overdose O
is O
usually O
characterized O
by O
gi B-ADR
upset I-ADR
, O
dizziness O
, O
and O
mild O
sedation O

thrombocytosis B-ADR
under O
ciprofloxacin B-DRUG
and O
tazobactam O
/ O
piperacillin O

these O
evolutional O
changes O
in O
both O
proteinuria O
and O
glomerular O
histology O
suggest O
a O
close O
linkage O
between O
the O
m-csf B-DRUG
treatment O
and O
macrophage-related B-ADR
glomerular I-ADR
injury I-ADR

we O
describe O
a O
patient O
who O
developed O
neh B-ADR
on O
three O
separate O
occasions O
provoked O
by O
two O
different O
chemotherapeutic O
agents O
-- O
cytarabine B-DRUG
and O
mitoxantrone O

fracture B-ADR
of I-ADR
the I-ADR
femoral I-ADR
neck I-ADR
occurred O
in O
one O
patient O
during O
psl B-DRUG
therapy O
, O
although O
the O
relationship O
between O
the O
fracture O
and O
psl B-DRUG
therapy O
was O
uncertain O

acute B-ADR
dystonia I-ADR
during O
pegylated B-DRUG
interferon I-DRUG
alpha I-DRUG
therapy O
in O
a O
case O
with O
chronic O
hepatitis O
b O
infection O

the O
possible O
effects O
of O
tamoxifen B-DRUG
upon O
the O
uterus O
are O
discussed O
in O
this O
article O
, O
in O
view O
of O
reports O
of O
tamoxifen B-DRUG
associated O
with O
endometrial O
carcinoma O
and O
endometriosis B-ADR

posterior B-ADR
leukoencephalopathy I-ADR
following O
cisplatin B-DRUG
, O
bleomycin O
and O
vinblastine O
therapy O
for O
germ O
cell O
tumor O
of O
the O
ovary O

generalized B-ADR
argyria I-ADR
after O
habitual O
use O
of O
agno3 B-DRUG

the O
reported O
case O
represents O
an O
unusual O
association O
between O
medication O
with O
the O
proton O
pump O
inhibitor O
lansoprazole B-DRUG
and O
the O
development O
of O
collagenous B-ADR
colitis I-ADR
suggesting O
the O
importance O
of O
evaluation O
of O
drug O
use O
in O
patients O
with O
microscopic O
colitis O

administration O
of O
intrathecal O
ara-c B-DRUG
in O
the O
same O
dose O
over O
longer O
intervals O
within O
3-5 O
days O
between O
consecutive O
doses O
resulted O
in O
mild O
, O
transient O
neurological O
symptoms O
( O
paresthesias B-ADR
) O
in O
only O
one O
of O
30 O
patients O
so O
treated O

severe B-ADR
visual I-ADR
loss I-ADR
after O
a O
single O
dose O
of O
vincristine B-DRUG
in O
a O
patient O
with O
spinal O
cord O
astrocytoma O

a O
75-year-old O
man O
developed O
bilateral B-ADR
lower I-ADR
leg I-ADR
edema I-ADR
6 O
months O
after O
switching O
from O
troglitazone O
to O
pioglitazone B-DRUG

subsequently O
, O
he O
developed O
hyperglycemia B-ADR
( O
fasting O
blood O
glucose O
138 O
mg O
/ O
dl O
) O
that O
resolved O
when O
olanzapine B-DRUG
was O
stopped O
and O
recurred O
( O
fasting O
blood O
glucose O
150 O
mg O
/ O
dl O
) O
after O
2 O
days O
of O
rechallenge O
with O
olanzapine B-DRUG
2.5 O
mg O
twice O
daily O

ototoxicity B-ADR
as O
a O
result O
of O
cis-platinum B-DRUG
administration O
is O
well O
documented O

case O
summary O
: O
a O
45-year-old O
hiv-positive O
man O
( O
cd4 O
+ O
count O
450 O
cells O
/ O
mm O
( O
3 O
) O
and O
history O
of O
aids-defining O
illness O
) O
presented O
with O
jhr B-ADR
after O
an O
initial O
intravenous O
dose O
of O
penicillin B-DRUG
g I-DRUG
for O
presumed O
neurosyphilis O

a O
64-year-old O
man O
with O
schizophrenia O
developed O
myoclonic B-ADR
jerks I-ADR
when O
given O
higher O
doses O
of O
quetiapine B-DRUG

the O
known O
side O
effects O
of O
sibutramine B-DRUG
, O
ie O
, O
hypertension B-ADR
and O
tachycardia O
, O
depend O
on O
its O
adrenergic O
and O
serotoninergic O
effects O

we O
present O
a O
case O
report O
of O
a O
patient O
with O
alveolar O
hydatid O
disease O
, O
whose O
treatment O
with O
mebendazole B-DRUG
was O
brief O
due O
to O
side O
effects O
of O
alopecia O
and O
granulocytopenia B-ADR
; O
and O
review O
the O
features O
of O
this O
disease O
which O
, O
with O
increasing O
international O
migration O
, O
may O
be O
encountered O
more O
frequently O
in O
australia O

severe B-ADR
osteomalacia I-ADR
was O
present O
in O
two O
epileptic O
patients O
who O
were O
under O
long-term O
treatment O
with O
congeners O
of O
phenytoin O
, O
phenobarbital O
, O
and O
acetazolamide B-DRUG

aggressive O
management O
of O
doxorubicin-induced O
cardiomyopathy B-ADR
associated O
with O
' O
low O
' O
doses O
of O
doxorubicin B-DRUG

we O
report O
3 O
cases O
of O
children O
with O
acute O
lymphoblastic O
leukemia O
who O
developed O
seizures B-ADR
and O
altered O
sensorium O
after O
l-asparaginase B-DRUG
therapy O

however O
, O
in O
order O
to O
avoid O
neuropathic B-ADR
side I-ADR
effects I-ADR
, O
patients O
under O
thalidomide B-DRUG
therapy O
should O
be O
monitored O
every O
6 O
months O
with O
nerve O
conduction O
studies O
while O
taking O
the O
drug O

the O
following O
is O
a O
report O
of O
2 O
cases O
of O
rifampicin-induced O
renal B-ADR
insufficiency I-ADR

a O
45-year-old O
woman O
with O
thyrotoxicosis O
developed O
agranulocytosis B-ADR
after O
treatment O
with O
propylthiouracil B-DRUG

a O
21-year-old O
woman O
suffering O
from O
bipolar O
affective O
disorder O
developed O
systemic O
lupus O
erythematosus O
( O
sle B-ADR
) O
with O
characteristic O
laboratory O
findings O
, O
18 O
months O
after O
starting O
carbamazepine B-DRUG
maintenance O
treatment O

methods O
: O
the O
patient O
required O
insulin B-DRUG
desensitization O
for O
severe O
urticaria O
, O
angioedema O
, O
and O
occasional O
wheezing B-ADR
resulting O
from O
her O
insulin B-DRUG
dose O

a O
59-year-old O
woman O
with O
myasthenia O
gravis O
who O
received O
a O
large O
dose O
of O
pyridostigmine B-DRUG
bromide I-DRUG
developed O
postoperative B-ADR
psychosis I-ADR
and O
was O
diagnosed O
as O
having O
bromide O
intoxication O

scleroderma-like B-ADR
reaction I-ADR
induced O
by O
uracil-tegafur B-DRUG
( O
uft O
) O
, O
a O
second-generation O
anticancer O
agent O

we O
report O
five O
cases O
of O
restless O
legs O
syndrome O
( O
rls O
) O
and O
periodic O
limb O
movements O
during O
sleep O
( O
plms B-ADR
) O
that O
were O
probably O
associated O
with O
olanzapine B-DRUG

the O
former O
patient O
had O
complained O
once O
that O
his O
visual B-ADR
acuity I-ADR
had I-ADR
decreased I-ADR
after O
the O
termination O
of O
ifn B-DRUG
therapy O
, O
and O
the O
latter O
patient O
complained O
twice O
during O
ifn B-DRUG
therapy O
that O
his O
visual B-ADR
acuity I-ADR
had I-ADR
decreased I-ADR

conclusions O
: O
this O
report O
indicates O
clindamycin B-DRUG
phosphate O
vaginal O
cream O
as O
the O
most O
probable O
cause O
of O
cdic B-ADR
due O
to O
the O
temporal O
relationship O
between O
the O
occurrence O
of O
diarrhea O
and O
clindamycin B-DRUG
administration O
, O
lack O
of O
concomitant O
medications O
, O
and O
documentation O
of O
c. O
difficile O
toxin O

we O
report O
a O
43-year-old O
woman O
who O
developed O
sore B-ADR
throat I-ADR
, O
swelling O
of O
the O
lips O
and O
oral O
cavity O
and O
dysphagia O
, O
2 O
weeks O
after O
the O
use O
of O
budesonide B-DRUG
spray O
( O
budefat O
) O
for O
treatment O
of O
bronchial O
asthma O

papilloedema O
and O
hepatic B-ADR
dysfunction I-ADR
apparently O
induced O
by O
perhexiline B-DRUG
maleate I-DRUG
( O
pexid O

a O
7-year-old O
with O
congenital O
toxoplasmosis O
who O
took O
pyrimethamine O
and O
sulfadiazine B-DRUG
for O
reactivated O
chorioretinitis O
developed O
fever O
, O
severe O
cutaneous O
involvement O
, O
swelling O
, O
abdominal B-ADR
pain I-ADR
and O
transaminitis O
, O
persisting O
weeks O
after O
withholding O
medicines O

ovarian B-ADR
endometrioid I-ADR
adenocarcinoma I-ADR
arising O
from O
an O
endometriotic O
cyst O
in O
a O
postmenopausal O
woman O
under O
tamoxifen B-DRUG
therapy O
for O
breast O
cancer O
: O
a O
case O
report O

clinicians O
have O
been O
aware O
of O
lithium B-DRUG
toxicity O
for O
many O
years O
and O
traditionally O
have O
administered O
thiazide O
diuretics O
for O
lithium-induced O
polyuria B-ADR
and O
nephrogenic O
diabetes O
insipidus O

we O
describe O
a O
case O
of O
infection O
with O
mycobacterium B-ADR
abscessus I-ADR
in O
a O
67-year-old O
woman O
receiving O
infliximab B-DRUG
as O
a O
component O
of O
her O
therapy O
for O
ra O

pseudoephedrine-induced O
hemorrhage B-ADR
associated O
with O
a O
cerebral O
vascular O
malformation O

successful O
challenge O
with O
clozapine B-DRUG
in O
a O
history O
of O
eosinophilia B-ADR

we O
cared O
for O
a O
patient O
with O
progressive O
renal O
impairment O
who O
presented O
with O
blurred O
vision O
, O
qrs B-ADR
broadening I-ADR
and O
cardiac O
failure O
due O
to O
chronic O
cibenzoline B-DRUG
intoxication O

she O
had O
been O
taking O
nabumetone B-DRUG
for O
6 O
months O
, O
but O
had O
discontinued O
the O
agent O
2 O
weeks O
before O
admission O
due O
to O
progressive O
edema B-ADR

sustained B-ADR
ventricular I-ADR
tachycardia I-ADR
in O
a O
thalidomide-treated O
patient O
with O
primary O
plasma-cell O
leukemia O

symptoms O
and O
signs O
of O
augmentation B-ADR
were O
related O
to O
low O
plasma O
levodopa B-DRUG
levels O
, O
abating O
75 O
minutes O
after O
oral O
levodopa B-DRUG
administration O
and O
reappearing O
after O
3 O
hours O
, O
closely O
mirroring O
the O
rapid O
rise O
and O
fall O
of O
plasma O
levodopa B-DRUG
concentration O

from O
these O
data O
, O
acute O
generalized O
dystonia O
with O
brainstem B-ADR
and I-ADR
thalamic I-ADR
lesions I-ADR
may O
occur O
in O
wd O
patients O
after O
an O
initial O
d-penicillamine B-DRUG
therapy O

reduction O
of O
methylprednisolone B-DRUG
dosage O
rather O
than O
insulin O
therapy O
resulted O
in O
better O
control O
of O
glycemia B-ADR

a O
12 O
year O
old O
patient O
with O
atrial O
flutter O
is O
presented O
, O
in O
whom O
intravenous O
adenosine B-DRUG
was O
followed O
by O
acceleration O
of O
the O
heart O
rate O
to O
a O
potentially O
dangerous O
arrhythmia B-ADR

we O
report O
a O
case O
admitted O
with O
a O
first-detected O
, O
symptomatic B-ADR
paroxysmal I-ADR
atrial I-ADR
fibrillation I-ADR
in O
a O
healthy O
patient O
after O
self-medication O
with O
vardenafil B-DRUG

cataracts B-ADR
induced O
by O
intermittent O
decadron B-DRUG
used O
as O
an O
antiemetic O

results O
: O
at O
our O
institution O
, O
no O
children O
appeared O
with O
acute O
inh B-DRUG
neurotoxicity B-ADR
in O
the O
period O
1985 O
through O
1990 O
, O
whereas O
seven O
patients O
were O
treated O
from O
1991 O
through O
1993 O

these O
in O
vitro O
findings O
and O
clinical O
course O
suggest O
that O
trab O
/ O
tbii O
without O
thyroid-stimulating O
activity O
may O
develop O
in O
patients O
with O
amiodarone-induced O
destructive O
thyroiditis B-ADR
, O
as O
reported O
in O
patients O
with O
destructive O
thyroiditis B-ADR
, O
such O
as O
subacute O
and O
silent O
thyroiditis B-ADR

histological O
examination O
of O
the O
dacryolith B-ADR
suggested O
its O
derivation O
from O
breakdown O
products O
of O
adrenaline B-DRUG

a O
few O
recent O
individual O
case O
reports O
have O
suggested O
that O
a O
myasthenic B-ADR
syndrome I-ADR
may O
be O
associated O
with O
statin B-DRUG
treatment O
, O
but O
this O
association O
is O
not O
well O
described O

atrial B-ADR
fibrillation I-ADR
after O
vardenafil B-DRUG
therapy O

doxycycline-induced O
photo-onycholysis B-ADR

the O
risk O
of O
developing O
saml B-ADR
is O
estimated O
to O
be O
between O
1 O
% O
and O
5 O
% O
, O
2-20 O
years O
after O
exposure O
to O
etoposide B-DRUG
but O
may O
also O
be O
related O
to O
cumulative O
drug O
doses O
, O
treatment O
schedules O
, O
host O
factors O
and O
co-administration O
of O
other O
antineoplastic O
agents O

here O
we O
describe O
a O
patient O
with O
crohn O
's O
disease O
who O
developed O
a O
severe O
infliximab B-DRUG
infusion O
reaction O
( O
iir O
) O
, O
complicated O
1 O
day O
later O
by O
severe B-ADR
swelling I-ADR
of I-ADR
the I-ADR
forearm I-ADR
and I-ADR
hand I-ADR
ipsilateral I-ADR
to O
the O
site O
of O
infliximab B-DRUG
infusion O

several O
case O
reports O
of O
aplastic B-ADR
anemia I-ADR
with O
use O
of O
acetazolamide B-DRUG
, O
and O
two O
cases O
with O
use O
of O
methazolamide O
, O
have O
appeared O
in O
the O
literature O

children O
with O
acute O
lymphoblastic O
leukemia O
( O
all O
) O
, O
treated O
with O
l-asparaginase B-DRUG
are O
at O
risk O
for O
cerebral O
thrombosis O
or O
hemorrhage O
because O
of O
coagulation B-ADR
protein I-ADR
deficiencies I-ADR

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity O
reactions O
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general O
erythema O
, O
dyspnea B-ADR
, O
and O
hypotension O
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal O
pain O
, O
general O
erythema O
, O
and O
fever O

a O
young O
woman O
with O
epilepsy O
had O
tonic-clonic B-ADR
seizures I-ADR
during O
antineoplastic O
therapy O
with O
adriamycin B-DRUG
and O
cisplatin O

intrahepatic O
cholestasis O
and O
cutaneous B-ADR
bullae I-ADR
associated O
with O
glibenclamide B-DRUG
therapy O
are O
described O
in O
a O
61-year-old O
diabetic O
patient O
who O
presented O
wit O
hypoglycaemic O
coma O

conclusions O
: O
the O
3 O
cases O
presented O
here O
illustrate O
the O
development O
of O
reproductive B-ADR
endocrine I-ADR
disorders I-ADR
after O
the O
initiation O
of O
valproate B-DRUG
therapy O
in O
women O
with O
epilepsy O

verapamil B-DRUG
in O
effort-induced O
angina B-ADR
pectoris I-ADR
in O
patients O
with O
normal O
coronary O
arteries O

the O
clinical O
aspect O
closely O
resembled O
classical O
transient B-ADR
global I-ADR
amnesia I-ADR
but O
the O
episode O
after O
clioquinol B-DRUG
lasted O
longer O
( O
24 O
hours O
to O
three O
days O
) O
and O
a O
more O
or O
less O
extensive O
retrograde O
amnesia O
persisted O
permanently O

comparable O
adverse O
effects O
, O
such O
as O
disorientation B-ADR
and O
temporary O
amnesia O
, O
have O
been O
reported O
in O
patients O
in O
the O
analogous O
agent O
, O
propranolol B-DRUG

objectives O
: O
a O
delayed O
stroke-like B-ADR
leukoencephalopathy I-ADR
has O
been O
observed O
in O
patients O
receiving O
methotrexate O
( O
mtx B-DRUG
) O
for O
childhood O
leukemia O

intravenous O
verapamil O
therapy O
in O
babies O
may O
cause O
apnea B-ADR
, O
hypotension O
, O
and O
bradycardia O
; O
continued O
episodes O
of O
atrial O
flutter O
in O
a O
child O
may O
cause O
sudden O
death O
; O
quinidine B-DRUG
may O
be O
related O
to O
the O
death O
; O
children O
with O
" O
familial O
seizure O
disorders O
" O
may O
in O
fact O
have O
the O
long O
qt O
interval O
syndrome O

the O
hearing B-ADR
impairment I-ADR
and O
tinnitus O
were O
gradually O
reduced O
after O
ptu B-DRUG
withdrawal O
and O
corticosteroid O
and O
azathioprine O
treatment O

cefuroxime-induced O
immune B-ADR
hemolysis I-ADR

in O
this O
report O
we O
present O
four O
patients O
treated O
with O
a O
combination O
of O
different O
psychotropic O
drugs O
, O
in O
whom O
asterixis B-ADR
was O
triggered O
either O
by O
adding O
carbamazepine B-DRUG
( O
cbz O
) O
to O
a O
treatment O
regimen O
, O
or O
by O
increasing O
its O
dosage O

conclusion O
: O
although O
a O
definite O
association O
has O
not O
been O
proven O
, O
clinicians O
should O
be O
aware O
of O
the O
possibility O
of O
agranulocytosis B-ADR
while O
using O
quetiapine B-DRUG

ten O
years O
of O
behavioral O
data O
are O
presented O
to O
support O
the O
hypothesis O
that O
phenobarbital B-DRUG
was O
exacerbating O
maladaptive B-ADR
behaviors I-ADR

we O
believe O
this O
is O
the O
first O
report O
of O
intrathecal O
diamorphine B-DRUG
causing O
anaphylaxis B-ADR

case O
2 O
, O
a O
29-year-old O
woman O
, O
developed O
bilateral O
optic O
neuritis O
combined O
with O
numbness O
of O
the O
lower O
extremities O
as O
well O
as O
bowel B-ADR
and I-ADR
bladder I-ADR
dysfunction I-ADR
after O
a O
22-month O
use O
of O
recombinant B-DRUG
interferon I-DRUG
alpha-2b I-DRUG
for O
chronic O
myelogenous O
leukemia O

a O
patient O
with O
disseminated O
herpes O
zoster O
developed O
a O
syndrome B-ADR
of I-ADR
inappropriate I-ADR
antidiuretic I-ADR
hormone I-ADR
and O
profound O
hyponatremia O
secondary O
to O
the O
administration O
of O
adenine B-DRUG
arabinoside I-DRUG

discussion O
: O
to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
report O
illustrating O
neuralgic B-ADR
amyotrophy I-ADR
triggered O
by O
exposure O
to O
the O
antibiotics O
vancomycin O
, O
tobramycin O
, O
and O
piperacillin O
/ O
tazobactam B-DRUG

following O
7 O
days O
of O
tigecycline B-DRUG
she O
developed O
severe O
abdominal O
pain O
and O
elevated B-ADR
pancreatic I-ADR
enzymes I-ADR
suggesting O
acute O
pancreatitis O

a O
60-year-old O
white O
man O
with O
chronic O
bronchitis O
was O
noted O
to O
develop O
acute B-ADR
respiratory I-ADR
failure I-ADR
and O
metabolic O
acidosis O
four O
days O
after O
being O
started O
on O
methazolamide B-DRUG
( O
neptazane O
) O
for O
an O
ophthalmologic O
problem O

diarrhoea O
, O
t-cd4 O
+ O
lymphopenia O
and O
bilateral B-ADR
patchy I-ADR
pulmonary I-ADR
infiltrates I-ADR
developed O
in O
a O
male O
60 O
yrs O
of O
age O
, O
who O
was O
treated O
with O
oxaliplatinum O
and O
5-fluorouracil B-DRUG
for O
unresectable O
rectum O
carcinoma O

the O
renal O
insufficiency O
of O
three O
patients O
and O
the O
timing O
of O
the O
seizures B-ADR
implicate O
accumulation O
of O
ofloxacin B-DRUG
as O
a O
contributing O
factor O

in O
this O
case O
, O
discontinuing O
piroxicam B-DRUG
, O
a O
nonsteroidal O
anti-inflammatory O
drug O
, O
and O
starting O
a O
palliative O
treatment O
plan O
helped O
resolve O
a O
patient O
's O
ulcers B-ADR

we O
describe O
a O
case O
of O
intraoperative O
gelatine-induced O
anaphylaxis B-ADR
whose O
diagnosis O
was O
delayed O
as O
the O
use O
of O
gelatine B-DRUG
during O
surgical O
procedures O
was O
omitted O
for O
two O
times O
in O
patient O
's O
medical O
records O

he O
became O
hyperkalemic B-ADR
on O
rechallenge O
with O
timolol B-DRUG
and O
normokalemic O
following O
its O
withdrawal O

while O
undergoing O
treatment O
with O
albendazole B-DRUG
, O
he O
developed O
worsening O
diarrhea O
with O
abdominal O
pain O
and O
fever B-ADR

the O
most O
likely O
cause O
of O
such O
hyponatremic B-ADR
episode I-ADR
is O
vinblastine B-DRUG

methemoglobinemia B-ADR
associated O
with O
dermal O
application O
of O
benzocaine B-DRUG
cream O
in O
a O
cat O

the O
authors O
describe O
valproate-induced O
hyperammonemia O
and O
mental B-ADR
status I-ADR
changes I-ADR
in O
an O
88-year-old O
man O
, O
the O
first O
known O
reported O
case O
in O
an O
elderly O
patient O

acute O
dystonia O
with O
thalamic B-ADR
and I-ADR
brainstem I-ADR
lesions I-ADR
after O
initial O
penicillamine B-DRUG
treatment O
in O
wilson O
's O
disease O

a O
53-year-old O
male O
, O
without O
any O
prior O
history O
of O
psychosis O
, O
developed O
schizophrenia B-ADR
4 O
days O
after O
starting O
low-dose O
bromocriptine B-DRUG
therapy O
for O
a O
macroprolactinoma O

first O
, O
a O
review O
of O
the O
literature O
produced O
41 O
anecdotic O
cases O
of O
neutropenia B-ADR
or O
agranulocytosis O
during O
treatment O
with O
olanzapine O
( O
zyprexa B-DRUG
) O
reported O
in O
a O
total O
of O
24 O
publications O

a O
case O
of O
congestive B-ADR
heart I-ADR
failure I-ADR
in O
a O
child O
with O
wilms' O
tumor O
treated O
adriamycin B-DRUG
is O
presented O
and O
discussed O

fever B-ADR
, O
pulmonary O
infiltrates O
, O
and O
pleural O
effusion O
following O
acyclovir B-DRUG
therapy O
for O
herpes O
zoster O
ophthalmicus O

aminophylline B-ADR
hypersensitivity I-ADR
apparently O
due O
to O
ethylenediamine O

three O
years O
later O
, O
treatment O
with O
ampicillin B-DRUG
caused O
another O
episode O
of O
cholestatic O
hepatitis O
with O
cholestasis B-ADR
and O
duct O
paucity O
on O
rebiopsy O

the O
patient O
experienced O
hallucinations O
, O
agitation O
, O
vomiting O
, O
tachycardia B-ADR
and O
seizures O
after O
ingestion O
of O
1050 O
( O
48 O
mg O
/ O
kg O
) O
of O
extended-release O
bupropion B-DRUG

papilloedema B-ADR
and O
hepatic O
dysfunction O
apparently O
induced O
by O
perhexiline O
maleate O
( O
pexid B-DRUG

the O
clinical O
course O
suggested O
that O
recombinant O
alpha-2b O
peginterferon O
plus O
ribavirin B-DRUG
provoked O
type B-ADR
1 I-ADR
diabetes I-ADR
mellitus I-ADR
, O
therefore O
, O
in O
patients O
who O
are O
candidates O
for O
interferon O
therapy O
the O
presence O
of O
pancreatic O
autoantibodies O
and O
the O
fasting O
plasma O
glucose O
level O
should O
be O
investigated O
before O
and O
during O
treatment O

we O
report O
an O
allogeneic O
bone O
marrow O
transplant O
recipient O
who O
developed O
cmv B-ADR
infection I-ADR
refractory O
to O
sequential O
therapy O
with O
ganciclovir O
, O
foscarnet O
, O
and O
cidofovir B-DRUG

these O
findings O
suggest O
that O
clozapine-induced O
seizures B-ADR
can O
be O
successfully O
treated O
, O
that O
gradual O
dose O
titration O
can O
reduce O
the O
likelihood O
of O
further O
episodes O
of O
seizures B-ADR
and O
that O
concomitant O
use O
of O
a O
suitable O
mood O
stabilizer O
/ O
anti-epileptic O
medication O
can O
improve O
the O
outcome O
of O
treatment-resistant O
schizophrenia O

hydroxyurea B-DRUG
associated O
with O
concomitant O
occurrence O
of O
diffuse O
longitudinal O
melanonychia O
and O
multiple B-ADR
squamous I-ADR
cell I-ADR
carcinomas I-ADR
in O
an O
elderly O
subject O

this O
case O
of O
linezolid-associated O
acute O
interstitial O
nephritis O
within O
the O
context O
of O
a O
drug B-ADR
rash I-ADR
with I-ADR
eosinophilia I-ADR
and I-ADR
systemic I-ADR
symptoms I-ADR
( O
dress O
) O
syndrome O
in O
a O
patient O
treated O
with O
linezolid B-DRUG
raises O
concerns O
about O
the O
presumed O
renal O
safety O
of O
this O
drug O

discussion O
: O
to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
report O
illustrating O
neuralgic B-ADR
amyotrophy I-ADR
triggered O
by O
exposure O
to O
the O
antibiotics O
vancomycin B-DRUG
, O
tobramycin O
, O
and O
piperacillin O
/ O
tazobactam O

cholelithiasis O
and O
thrombosis B-ADR
of I-ADR
the I-ADR
central I-ADR
retinal I-ADR
vein I-ADR
in O
a O
renal O
transplant O
recipient O
treated O
with O
cyclosporin B-DRUG

we O
describe O
a O
life O
threatening O
side O
effect O
of O
acute O
epoprostenol B-DRUG
infusion O
( O
pulmonary B-ADR
edema I-ADR
) O
in O
a O
patient O
with O
pulmonary O
hypertension O
associated O
with O
limited O
scleroderma O
and O
discuss O
its O
management O
and O
potential O
etiology O

the O
toxic O
effects O
of O
methotrexate B-DRUG
included O
elevated O
liver O
transaminases O
( O
3 O
/ O
4 O
) O
, O
nausea O
( O
2 O
/ O
4 O
) O
, O
abdominal O
pain O
( O
2 O
/ O
4 O
) O
, O
bone B-ADR
pain I-ADR
( O
2 O
/ O
4 O
) O
, O
mild O
neutropenia O
( O
1 O
/ O
4 O
) O
, O
and O
mild O
pruritus O
( O
1 O
/ O
4 O

fatal O
gemcitabine-induced O
pulmonary B-ADR
toxicity I-ADR
in O
metastatic O
gallbladder O
adenocarcinoma O

myoclonus B-ADR
and O
seizures O
in O
a O
patient O
with O
parkinsonism O
: O
induction O
by O
levodopa B-DRUG
and O
its O
confirmation O
on O
seps O

drug-induced O
hepatitis B-ADR
in O
an O
acromegalic O
patient O
during O
combined O
treatment O
with O
pegvisomant B-DRUG
and O
octreotide O
long-acting O
repeatable O
attributed O
to O
the O
use O
of O
pegvisomant B-DRUG

a O
mentally O
retarded O
23-year-old O
woman O
with O
myoclonic O
astatic O
epilepsy O
developed O
an O
abnormal O
posture O
of O
extreme O
forward O
flexion O
, O
called O
camptocormia B-ADR
, O
during O
valproate B-DRUG
monotherapy O

papilloedema O
and O
hepatic B-ADR
dysfunction I-ADR
apparently O
induced O
by O
perhexiline O
maleate O
( O
pexid B-DRUG

one O
patient O
who O
received O
clindamycin B-DRUG
had O
liver O
biopsy O
findings O
of O
marked O
cholestasis O
, O
portal B-ADR
inflammation I-ADR
, O
bile O
duct O
injury O
and O
bile O
duct O
paucity O
( O
ductopenia O

surprisingly O
, O
we O
found O
that O
three O
patients O
appeared O
to O
develop O
tardive B-ADR
ogc I-ADR
while O
taking O
clozapine B-DRUG

objective O
: O
to O
describe O
a O
case O
of O
exacerbated O
mania B-ADR
potentially O
related O
to O
an O
interaction O
between O
lopinavir B-DRUG
/ O
ritonavir O
and O
valproic O
acid O
( O
vpa O
) O
and O
propose O
a O
mechanism O
of O
action O
for O
this O
interaction O

we O
report O
a O
case O
of O
baclofen B-DRUG
withdrawal B-ADR
syndrome I-ADR
resulting O
from O
oral O
baclofen B-DRUG
underdosing O

pseudoephedrine-induced O
hemorrhage O
associated O
with O
a O
cerebral B-ADR
vascular I-ADR
malformation I-ADR

despite O
the O
low O
dosage O
of O
warfarin B-DRUG
, O
international O
normalized O
ratio O
( O
inr O
) O
was O
markedly O
elevated O
from O
1.15 O
to O
11.28 O
for O
only O
4 O
days O
, O
and O
bleeding B-ADR
symptoms I-ADR
concurrently O
developed O

we O
conclude O
that O
vincristine O
and O
actinomycin B-DRUG
d I-DRUG
were O
the O
cause O
of O
this O
rare O
from O
of O
hepatotoxicity B-ADR
and O
that O
chemotherapy O
for O
the O
underlying O
malignant O
disease O
could O
be O
given O
safely O
after O
clinical O
recovery O

less O
common O
adverse O
events O
to O
dapsone B-DRUG
include O
the O
idiosyncratic O
reactions O
of O
leukopenia O
and O
agranulocytosis O
, O
cutaneous O
eruptions O
, O
peripheral O
neuropathy O
, O
psychosis O
, O
toxic O
hepatitis O
, O
cholestatic O
jaundice O
, O
nephrotic O
syndrome O
, O
renal O
papillary O
necrosis O
, O
severe B-ADR
hypoalbuminemia I-ADR
without I-ADR
proteinuria I-ADR
, O
an O
infectious O
mononucleosis-like O
syndrome O
, O
and O
minor O
neurological O
and O
gastrointestinal O
complaints O

antibiotic-associated O
colitis O
( O
pseudomembranous B-ADR
colitis I-ADR
) O
developed O
in O
four O
patients O
with O
spinal O
cord O
injury O
and O
taking O
oral O
trimethoprim-sulfamethoxazole O

although O
an O
association O
between O
exposure O
to O
bleomycin B-DRUG
and O
the O
development O
of O
scleroderma B-ADR
has O
been O
suspected O
, O
few O
cases O
are O
reported O

we O
describe O
the O
exceptional O
development O
of O
aml B-ADR
and O
lung O
cancer O
in O
a O
patient O
with O
previously O
diagnosed O
cll O
in O
minimal O
residual O
disease O
status O
after O
fludarabine B-DRUG
treatment O
followed O
by O
autologous O
peripheral O
blood O
stem-cell O
transplantation O

surgeons O
and O
physicians O
should O
therefore O
be O
aware O
of O
the O
potential O
for O
rta B-ADR
to O
occur O
with O
fk506 B-DRUG
after O
any O
organ O
transplantation O

a O
case O
of O
a O
21-year-old O
woman O
who O
had O
developed O
mild O
hepatotoxicity B-ADR
while O
receiving O
choline B-DRUG
magnesium I-DRUG
trisalicylate I-DRUG
therapy O
is O
described O

objectives O
: O
to O
describe O
clinical O
and O
pathologic O
findings O
in O
patients O
noted O
to O
develop O
lower B-ADR
gastrointestinal I-ADR
symptoms I-ADR
when O
exposed O
to O
rofecoxib B-DRUG

the O
day O
after O
clozapine O
was O
stopped O
, O
while O
he O
was O
still O
receiving O
clomipramine B-DRUG
150 O
mg O
/ O
d O
, O
he O
began O
behaving O
oddly O
, O
started O
sweating O
profusely O
, O
shivering O
, O
and O
became O
tremulous O
, O
agitated B-ADR
, O
and O
confused O

itch B-ADR
and O
skin O
rash O
from O
chocolate O
during O
fluoxetine B-DRUG
and O
sertraline O
treatment O
: O
case O
report O

osteonecrosis B-ADR
is O
a O
serious O
side O
effect O
of O
antiemetic O
treatment O
with O
dexamethasone B-DRUG
and O
this O
serious O
complication O
should O
be O
incorporated O
in O
the O
current O
guidelines O

during O
clarithromycin B-DRUG
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate-to-severe O
toxic B-ADR
symptoms I-ADR
of O
carbamazepine O
, O
such O
as O
drowsiness O
, O
dizziness O
, O
and O
ataxia O
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin B-DRUG
discontinuation O

this O
severe O
illness O
was O
likely O
caused O
by O
minocycline B-DRUG
, O
and O
we O
speculate O
that O
minocycline B-DRUG
may O
have O
acted O
as O
a O
superantigen O
, O
causing O
lymphocyte O
over-activation O
and O
massive B-ADR
cytokine I-ADR
release I-ADR

although O
retinoic B-DRUG
acid I-DRUG
is O
well O
tolerated O
by O
the O
majority O
of O
patients O
with O
this O
disease O
, O
a O
potentially O
fatal O
complication O
of O
this O
kind O
of O
treatment O
has O
been O
reported O
: O
" O
the O
retinoic B-ADR
acid I-ADR
syndrome I-ADR

the O
principle O
treatment O
for O
dpd-deficient O
patients O
with O
severe O
acute O
5-fu B-DRUG
reactions O
is O
supportive O
care O
; O
however O
, O
the O
administration O
of O
thymidine O
potentially O
may O
reverse O
severe O
5-fu-induced O
neurologic O
symptoms O
such O
as O
encephalopathy O
and O
coma B-ADR

after O
excluding O
other O
causes O
of O
long O
qt O
syndrome O
, O
the O
hcq B-DRUG
was O
suspected O
as O
the O
cause O
of O
her O
ventricular B-ADR
tachycardia I-ADR

acute O
interstitial B-ADR
pneumonia I-ADR
induced O
by O
ono-1078 O
( O
pranlukast B-DRUG
) O
, O
a O
leukotriene O
receptor O
antagonist O

we O
describe O
a O
heroin O
abuser O
in O
whom O
clinical O
and O
laboratory O
manifestations O
of O
acute B-ADR
hepatitis I-ADR
b I-ADR
and I-ADR
c I-ADR
appeared O
a O
few O
days O
after O
the O
insertion O
of O
a O
subcutaneous O
naltrexone B-DRUG
implant O

use O
of O
the O
naranjo O
probability O
scale O
indicated O
a O
highly O
probable O
relationship O
between O
the O
observed O
cardiac B-ADR
toxicity I-ADR
and O
amphotericin B-DRUG
b I-DRUG
deoxycholate I-DRUG
therapy O
in O
this O
patient O

prolonged O
used O
of O
hydroxyurea B-DRUG
in O
patients O
with O
et O
may O
lead O
to O
therapy-associated O
acute B-ADR
leukemia I-ADR

a O
33-year-old O
man O
with O
a O
history O
of O
recreational O
benztropine B-DRUG
abuse O
presented O
to O
the O
emergency O
department O
with O
confusion O
, O
abdominal B-ADR
pain I-ADR
, O
and O
distention O

pulmonary B-ADR
edema I-ADR
as O
a O
delayed O
complication O
of O
ritodrine B-DRUG
therapy O

we O
report O
4 O
patients O
, O
2 O
on O
methylphenidate O
and O
2 O
on O
dextroamphetamine B-DRUG
who O
presented O
with O
acral O
cyanosis O
, O
livedo O
reticularis O
, O
or O
raynaud B-ADR
phenomenon I-ADR

anaphylaxis B-ADR
to O
cisplatin B-DRUG
is O
an O
infrequent O
life-threatening O
complication O
which O
may O
occur O
even O
in O
patients O
who O
have O
received O
prior O
treatment O
with O
cisplatin B-DRUG

ten O
days O
after O
itraconazole B-DRUG
was O
started O
, O
he O
developed O
paralytic O
ileus O
, O
neurogenic O
bladder O
, O
mild O
left O
ptosis O
, O
and O
absence O
of O
deep O
reflexes O
, O
with O
severe B-ADR
paralysis I-ADR
of I-ADR
the I-ADR
lower I-ADR
extremities I-ADR
and O
mild O
weakness O
of O
the O
upper O
extremities O

however O
, O
we O
have O
recently O
had O
four O
cases O
of O
clofibrate-induced O
myopathy B-ADR
in O
patients O
with O
diabetes O
insipidus O
due O
to O
hypothalamic O
lesions O

the O
second O
had O
acute O
cystitis O
and O
was O
treated O
by O
sulphonamide O
and O
the O
third O
developed O
myopia B-ADR
coincident O
with O
metronidazole B-DRUG
treatment O
for O
trichomonas O
vaginalis O

an O
apparent O
link O
is O
described O
between O
the O
use O
of O
mmf O
with O
prednisone B-DRUG
to O
treat O
pemphigus O
vulgaris O
and O
the O
development O
of O
red B-ADR
blood I-ADR
cell I-ADR
anemia I-ADR

we O
report O
a O
fatal B-ADR
case I-ADR
of I-ADR
acute I-ADR
interstitial I-ADR
pneumonitis I-ADR
in O
a O
patient O
treated O
with O
carmustine O
( O
bcnu B-DRUG
) O
for O
a O
brain O
tumor O

discussion O
: O
colchicine B-DRUG
, O
the O
most O
important O
drug O
in O
treatment O
of O
fmf O
, O
can O
cause O
myopathy B-ADR
in O
patients O
with O
impaired O
renal O
and O
hepatic O
function O

we O
explored O
ophthalmic B-ADR
and I-ADR
neurologic I-ADR
findings I-ADR
in O
two O
children O
who O
have O
been O
exposed O
prenatally O
to O
vgb B-DRUG

in O
one O
patient O
the O
vasculitis B-ADR
resolved O
after O
termination O
of O
the O
ciprofloxacin B-DRUG
therapy O
; O
in O
the O
other O
patient O
the O
ciprofloxacin-induced O
hemorrhagic O
vasculitis B-ADR
was O
superimposed O
on O
a O
severe O
forefoot O
infection O
, O
leading O
to O
progressive O
gangrene O
and O
a O
below-knee O
amputation O

sixteen O
hours O
after O
the O
first O
administration O
of O
ifn B-DRUG
, O
ifn B-DRUG
was O
suspended O
by O
the O
symptoms O
of O
congestive O
heart O
failure O
( O
chf B-ADR

there O
have O
been O
numerous O
case O
reports O
of O
hyperglycemia B-ADR
with O
olanzapine B-DRUG
in O
the O
literature O
, O
but O
none O
reported O
hyperglycemia B-ADR
within O
days O
of O
initiation O
of O
the O
medication O

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash O
, O
fever O
, O
leukopenia B-ADR
and O
positive O
anti-nuclear O
antibody O
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine B-DRUG
( O
cbz O
; O
tegretol O
) O
used O
against O
benign O
rolandic O
epilepsy O

after O
infliximab B-DRUG
treatment O
, O
additional O
sleep O
studies O
revealed O
an O
increase O
in O
the O
number O
of O
apneic O
events O
and O
sao2 B-ADR
dips I-ADR
suggesting O
that O
tnfalpha O
plays O
an O
important O
role O
in O
the O
pathophysiology O
of O
sleep O
apnea O

anaphylactoid O
shock O
, O
disseminated B-ADR
intravascular I-ADR
coagulation I-ADR
, O
and O
anuric O
renal O
failure O
requiring O
dialysis O
occurred O
in O
a O
patient O
receiving O
zomepirac B-DRUG
sodium O
for O
toothache O

we O
report O
the O
case O
of O
a O
young O
man O
, O
affected O
by O
rheumatoid O
arthritis O
who O
developed O
a O
rapid-onset O
short-of-breath O
, O
hemoptysis O
, O
and O
severe B-ADR
weakness I-ADR
, O
about O
2 O
weeks O
after O
the O
administration O
of O
leflunomide B-DRUG

here O
, O
we O
describe O
a O
case O
of O
vogt-koyanagi-harada B-ADR
disease I-ADR
occurring O
4 O
months O
after O
the O
start O
of O
interferon B-DRUG
alpha I-DRUG
treatment O
, O
probably O
induced O
by O
the O
immunomodulatory O
effects O
of O
interferon O

the O
photosensitivity B-ADR
is O
still O
present O
3 O
years O
after O
the O
withdrawal O
of O
quinine B-DRUG

progression O
of O
chronic O
myeloid O
leukemia O
to O
blast B-ADR
crisis I-ADR
during O
treatment O
with O
imatinib B-DRUG
mesylate I-DRUG

hypersensitivity B-ADR
to O
carboplatin B-DRUG
is O
a O
rare O
but O
real O
complication O
of O
therapy O
and O
should O
be O
considered O
in O
patients O
presenting O
with O
hyperacute O
changes O
on O
ecg O
whilst O
receiving O
carboplatin B-DRUG
therapy O

after O
seven O
months' O
continuous O
treatment O
for O
suspected O
tuberculosis O
with O
rifampicin O
and O
ethambutol B-DRUG
a O
nine-year-old O
boy O
developed O
polyarthritis O
, O
rash B-ADR
and O
hepatitis O
in O
association O
with O
anti-native O
dna O
antibodies O
and O
positive O
antinuclear O
factor O

physicians O
should O
be O
aware O
that O
plp B-ADR
can O
occur O
after O
initiation O
of O
paclitaxel B-DRUG

a O
dapsone B-DRUG
hypersensitivity O
syndrome O
, O
consisting O
of O
fever O
, O
headache O
, O
nausea O
, O
vomiting O
, O
lymphadenopathy B-ADR
, O
hepatitis O
, O
hemolysis O
, O
leukopenia O
, O
and O
mononucleosis O
, O
has O
been O
described O
in O
patients O
treated O
with O
the O
drug O
for O
leprosy O

while O
for O
ribavirin O
antidepressant O
effects O
are O
not O
known O
, O
we O
suppose O
that O
antidepressants O
may O
prevent O
changes B-ADR
in I-ADR
serotonergic I-ADR
or I-ADR
noradrenergic I-ADR
neurotransmission I-ADR
caused O
by O
ifn-alpha B-DRUG

two O
patients O
who O
were O
receiving O
tolazoline B-DRUG
by O
infusion O
developed O
duodenal O
ulceration O
and O
subsequent O
intestinal B-ADR
perforation I-ADR

acute B-ADR
dystonia I-ADR
induced O
by O
lamivudine B-DRUG

after O
stopping O
indapamide B-DRUG
, O
glucose B-ADR
tolerance I-ADR
impairing I-ADR
may O
be O
reversed O

although O
both O
the O
spontaneous O
occurrence O
of O
sle B-ADR
and O
the O
psychosis O
as O
a O
sign O
of O
cns O
involvement O
of O
sle B-ADR
cannot O
be O
excluded O
, O
sle B-ADR
could O
be O
considered O
as O
an O
adverse O
effect O
of O
carbamazepine B-DRUG

we O
present O
two O
children O
with O
acute O
lymphocytic O
leukemia O
who O
developed O
leukoencephalopathy B-ADR
following O
administration O
of O
a O
combination O
of O
intravenous O
ara O
= O
c O
and O
methotrexate B-DRUG
during O
the O
consolidation O
phase O
of O
chemotherapy O

ampicillin-associated O
seizures B-ADR

a O
second O
episode O
of O
jaundice B-ADR
followed O
the O
intravaginal O
administration O
of O
a O
mixture O
of O
furazolidone B-DRUG
and O
nifuroxime O

objective O
: O
to O
report O
a O
case O
of O
phenolphthalein-induced O
toxic O
epidermal O
necrolysis O
( O
ten B-ADR
) O
in O
a O
patient O
maintained O
on O
several O
other O
medications O
more O
commonly O
known O
to O
be O
associated O
with O
ten B-ADR

cerebral B-ADR
infarcts I-ADR
in O
a O
pediatric O
patient O
secondary O
to O
phenylpropanolamine B-DRUG
, O
a O
recalled O
medication O

pneumonitis O
with O
pleural B-ADR
and I-ADR
pericardial I-ADR
effusion I-ADR
and O
neuropathy O
during O
amiodarone B-DRUG
therapy O

late O
development O
of O
diabetes B-ADR
mellitus I-ADR
after O
interferon-alfa B-DRUG
and O
ribavirin O
therapy O
for O
chronic O
hepatitis O
c O
: O
a O
case O
report O

we O
report O
a O
patient O
in O
whom O
the O
anti-depressant O
trazodone O
hydrochloride O
( O
molipaxin B-DRUG
, O
roussel O
) O
, O
a O
serotonin O
antagonist O
, O
provoked O
generalized O
pustular O
psoriasis O
( O
gpp B-ADR

a O
49-year-old O
man O
with O
crohn O
's O
disease O
treated O
with O
prednisone O
and O
mesalamine B-DRUG
( O
5-asa O
) O
developed O
worsening O
respiratory O
distress O
and O
fever B-ADR

conclusions O
: O
this O
is O
the O
first O
report O
of O
a O
possible O
interaction O
between O
propafenone O
and O
citalopram B-DRUG
, O
which O
caused O
propafenone O
adverse O
effects O
( O
eg O
, O
dizziness O
, O
falls O
) O
and O
mimicked O
coronary B-ADR
artery I-ADR
disease I-ADR

psychotic B-ADR
disorder I-ADR
associated O
with O
isoniazid B-DRUG

results O
: O
the O
patient O
, O
a O
27-year-old O
married O
japanese O
woman O
with O
borderline O
personality O
disorder O
, O
developed O
an O
increased B-ADR
libido I-ADR
with O
the O
administration O
of O
fluvoxamine B-DRUG

background O
: O
aphthous B-ADR
stomatitis I-ADR
, O
a O
common O
mucocutaneous O
disorder O
, O
is O
a O
well O
accepted O
complication O
of O
sirolimus B-DRUG
therapy O

gliclazide-induced O
acute B-ADR
hepatitis I-ADR

in O
this O
paper O
, O
we O
report O
a O
patient O
with O
primary O
anti-phospholipid O
syndrome O
treated O
by O
corticosteroid B-DRUG
, O
who O
developed O
disseminated B-ADR
nocardiosis I-ADR

however O
, O
a O
large O
case-control O
study O
included O
three O
cases O
of O
either O
stevens-johnson B-ADR
syndrome I-ADR
or O
toxic O
epidermal O
necrolysis O
associated O
with O
ofloxacin B-DRUG
use O
, O
but O
no O
details O
of O
the O
cases O
were O
given O

recurrent B-ADR
hypotension I-ADR
immediately O
after O
seizures O
in O
nortriptyline B-DRUG
overdose O

objective O
: O
to O
our O
knowledge O
, O
this O
is O
the O
first O
published O
case O
report O
of O
an O
adolescent O
girl O
with O
a O
mitochondrial O
disorder O
and O
depression O
who O
displayed O
both O
new-onset O
psychotic O
and O
increased B-ADR
mood I-ADR
symptoms I-ADR
during O
treatment O
with O
risperidone B-DRUG

polymyositis B-ADR
is O
a O
rare O
complication O
of O
interferon B-DRUG
alpha I-DRUG
treatment O
as O
a O
result O
of O
immune-modulating O
role O
of O
the O
drug O
itself O

severe B-ADR
leukopenia I-ADR
associated O
with O
mild O
hepatotoxicity O
in O
an O
hiv O
carrier O
treated O
with O
nevirapine B-DRUG

prolongation O
of O
the O
qt O
interval O
and O
ventricular B-ADR
tachyarrhymias I-ADR
have O
been O
described O
in O
patients O
on O
amiodarone B-DRUG
therapy O

pvt O
during O
chemotherapy O
in O
children O
is O
a O
rare O
event O
and O
appears O
to O
be O
closely O
related O
to O
intensive O
chemotherapy O
containing O
busulfan B-DRUG
and O
to O
be O
associated O
with O
hvod B-ADR

to O
our O
knowledge O
, O
our O
report O
is O
one O
of O
the O
first O
on O
shock O
and O
angio-oedema B-ADR
from O
irbesartan B-DRUG

a O
patient O
is O
described O
with O
the O
characteristic O
features O
of O
phenytoin B-DRUG
hypersensitivity O
syndrome O
( O
phs O
) O
including O
fever O
, O
erythroderma B-ADR
, O
tibial O
and O
facial O
oedema O
, O
pinhead-sized O
facial O
pustules O
and O
abnormal O
liver O
function O
tests O

hyperkalaemia O
with O
renal B-ADR
tubular I-ADR
dysfunction I-ADR
by O
oral O
therapy O
of O
sulfamethoxazole-trimethoprim B-DRUG
( O
co-trimoxazole O
) O
is O
described O
in O
2 O
elderly O
japanese O
patients O
with O
lymphoid O
malignancy O
, O
who O
developed O
pneumocystis O
carinii O
pneumonia O
and O
improved O

visceral O
leishmaniasis O
and O
macrophagic B-ADR
activation I-ADR
syndrome I-ADR
in O
a O
patient O
with O
rheumatoid O
arthritis O
under O
treatment O
with O
adalimumab B-DRUG

we O
report O
three O
cases O
of O
patients O
who O
developed O
leukopenia B-ADR
during O
olanzapine B-DRUG
treatment O

conclusions O
: O
acute B-ADR
severe I-ADR
hepatitis I-ADR
though O
rare O
is O
occasionally O
observed O
with O
egfr O
inhibitors O
gefitinib B-DRUG
or O
erlotinib O

since O
amiodarone B-DRUG
was O
first O
marketed O
in O
1992 O
in O
japan O
, O
the O
incidence O
of O
amiodarone-induced O
thyrotoxicosis O
( O
ait B-ADR
) O
has O
been O
increasing O

she O
continued O
to O
receive O
regular O
insulin B-DRUG
4 O
times O
per O
day O
over O
the O
following O
3 O
years O
with O
only O
occasional O
hives B-ADR

1. O
changes B-ADR
in I-ADR
the I-ADR
plasma I-ADR
cortisol I-ADR
level I-ADR
were O
reported O
in O
a O
male O
patient O
with O
panic O
disorder O
during O
the O
period O
of O
low-dose O
alprazolam B-DRUG
treatment O
( O
mean O
0.62 O
+/- O
0.15 O
mg O
/ O
day O
) O
compared O
with O
during O
the O
period O
of O
high-dose O
period O
( O
mean O
1.08 O
+/- O
0.28 O
mg O
/ O
day O

relief O
by O
naloxone O
of O
morphine-induced O
spasm B-ADR
of O
the O
sphincter O
of O
oddi O
in O
a O
post-cholecystectomy O
patient O

quetiapine B-DRUG
and O
obsessive-compulsive O
symptoms O
( O
ocs B-ADR
) O
: O
case O
report O
and O
review O
of O
atypical O
antipsychotic-induced O
ocs B-ADR

persistent B-ADR
hypoglycemia I-ADR
in O
a O
patient O
with O
diabetes O
taking O
etanercept B-DRUG
for O
the O
treatment O
of O
psoriasis O

the O
literature O
is O
also O
reviewed O
for O
arf O
associated O
with O
mannitol B-DRUG
infusion O
in O
patients O
who O
received O
dialysis O
and O
those O
who O
did O
not O
receive O
dialysis O
; O
and O
the O
possible O
mechanism O
( O
s O
) O
of O
mannitol B-DRUG
nephrotoxicity B-ADR
are O
discussed O

warfarin-induced O
skin B-ADR
necrosis I-ADR
and O
heparin-induced O
thrombocytopenia O
following O
mitral O
valve O
replacement O
for O
marantic O
endocarditis O

gold B-DRUG
nephropathy B-ADR

oxygen O
potentiation O
of O
bleomycin-induced O
pulmonary B-ADR
toxicity I-ADR
is O
discussed O

unintended O
exposure O
to O
acyclovir B-DRUG
early O
in O
pregnancy O
, O
which O
is O
not O
uncommon O
, O
may O
cause O
excessive B-ADR
maternal I-ADR
and I-ADR
physician I-ADR
anxiety I-ADR

the O
pharmaceutical O
company O
producing O
halfan B-DRUG
has O
reported O
8 O
cardiac B-ADR
arrests I-ADR
, O
leading O
to O
6 O
deaths O
, O
when O
a O
higher O
dose O
than O
recommended O
was O
used O
, O
there O
was O
recent O
or O
concomitant O
treatment O
with O
mefloquine O
, O
there O
was O
pre-existing O
prolongation O
of O
the O
qt O
interval O
or O
the O
patient O
had O
a O
thiamine O
deficiency O

he O
was O
later O
skin O
tested O
to O
confirm O
allergy B-ADR
to O
mtx B-DRUG

the O
ototoxicity B-ADR
of O
quinine B-DRUG
can O
accurately O
be O
studied O
with O
ultrahigh O
frequency O
audiometry O
( O
up O
to O
20 O
khz O

however O
, O
several O
case O
reports O
have O
suggested O
that O
clozapine B-DRUG
could O
also O
cause O
td B-ADR

in O
two O
of O
these O
cases O
akathisia B-ADR
resolved O
after O
withdrawal O
of O
olanzapine B-DRUG
and O
substitution O
by O
a O
classical O
or O
an O
atypical O
neuroleptic O
agent O
, O
respectively O

this O
is O
a O
report O
of O
a O
case O
of O
anuric B-ADR
arf I-ADR
after O
high-dose O
mannitol B-DRUG
infusion O
for O
treatment O
of O
narrow-angle O
glaucoma O
that O
readily O
responded O
to O
acute O
hemodialysis O

we O
report O
two O
cases O
that O
developed O
acute O
myeloid O
leukaemia O
( O
aml B-ADR
) O
during O
tamoxifen B-DRUG
therapy O
for O
breast O
cancer O

capecitabine B-DRUG
was O
discontinued O
and O
the O
allergic B-ADR
reactions I-ADR
resolved O
after O
the O
woman O
took O
diphenhydramine O
for O
1 O
week O

a O
32-year-old O
man O
with O
a O
family O
history O
of O
type O
2 O
diabetes O
mellitus O
presented O
with O
circulatory O
collapse O
and O
deep B-ADR
coma I-ADR
after O
9 O
days O
of O
treatment O
with O
perospirone B-DRUG
hydrochloride I-DRUG
, O
a O
recently O
developed O
atypical O
antipsychotic O
agent O
available O
only O
in O
japan O

adrenaline B-DRUG
dacryolith B-ADR
: O
detection O
by O
ultrasound O
examination O
of O
the O
nasolacrimal O
duct O

celiac B-ADR
disease I-ADR
onset O
after O
pegylated B-DRUG
interferon I-DRUG
and O
ribavirin O
treatment O
of O
chronic O
hepatitis O
c O

we O
present O
a O
case O
of O
acute O
epinephrine B-DRUG
toxicity O
resulting O
in O
acute O
myocardial O
ischemia O
in O
a O
young O
boy O
with O
combined O
variable O
immunodeficiency O
syndrome O
who O
developed O
severe B-ADR
allergic I-ADR
reaction I-ADR
to O
intravenous O
immunoglobulin O
, O
and O
was O
subsequently O
given O
epinephrine B-DRUG
by O
mistake O
intravenously O
rather O
than O
subcutaneously O

neutropenia B-ADR
and O
agranulocytosis O
are O
risks O
known O
to O
occur O
with O
phenothiazines B-DRUG
and O
clozapine O

methyldopa-induced O
liver B-ADR
injury I-ADR

since O
recent O
studies O
have O
reported O
no O
negative O
interactions O
with O
concurrent O
use O
, O
we O
here O
report O
three O
cases O
( O
one O
case O
of O
a O
prolonged B-ADR
seizure I-ADR
, O
a O
serotonin O
syndrome O
and O
a O
focal O
seizure O
) O
of O
severe O
lithium-induced O
side O
effects O
while O
patients O
underwent O
ect O
without O
complications O
and O
lithium B-DRUG
serum O
levels O
were O
still O
subtherapeutic O

a O
16-year-old O
white O
male O
with O
acute O
biphenotypic O
leukemia O
developed O
evidence O
of O
the O
eosinophilia B-ADR
myalgia I-ADR
syndrome I-ADR
associated O
with O
total O
parenteral O
nutritional O
support O
with O
solutions O
containing O
tryptophan B-DRUG
, O
which O
were O
given O
during O
his O
initial O
induction O
chemotherapy O
and O
also O
after O
autologous O
marrow O
transplantation O

by O
means O
of O
the O
in O
vitro O
heparin-induced O
platelet B-ADR
activation I-ADR
( O
hipa O
) O
assay O
it O
was O
shown O
that O
standard O
heparin O
and O
the O
lmw O
heparins O
fragmin B-DRUG
and O
fraxiparin O
( O
sanofi O
labaz O
, O
munich O
, O
frg O
) O
, O
as O
well O
as O
the O
enoxaparine O
clexane O
( O
nattermann O
, O
cologne O
, O
frg O
) O
, O
all O
induced O
platelet B-ADR
activation I-ADR
with O
the O
patient O
's O
serum O

all-trans B-DRUG
retinoic I-DRUG
acid-induced O
focal O
myositis O
, O
synovitis O
, O
and O
mononeuritis B-ADR

additionally O
, O
danazol B-DRUG
produces O
hepatocellular B-ADR
damage I-ADR
in O
approximately O
10 O
% O
of O
women O

atypical O
ventricular O
tachycardia O
( O
torsade B-ADR
de I-ADR
pointes I-ADR
) O
induced O
by O
amiodarone B-DRUG
: O
arrhythmia O
previously O
induced O
by O
quinidine O
and O
disopyramide O

isoniazid B-DRUG
inhibits O
the O
conversion O
of O
tryptophan O
to O
niacin O
and O
may O
induce O
pellagra B-ADR
, O
particularly O
in O
poorly O
nourished O
patients O

a O
26-year-old O
japanese O
man O
, O
who O
had O
been O
receiving O
medical O
attention O
for O
ulcerative O
colitis O
for O
one O
year O
, O
presented O
with O
diffuse O
erythema O
and O
pustules O
on O
his O
face O
and O
trunk O
, O
malaise B-ADR
, O
and O
fever O
up O
to O
39 O
degrees O
c O
one O
day O
after O
the O
administration O
of O
salazosulfapyridine B-DRUG

management O
and O
successful O
desensitization O
in O
methotrexate-induced O
anaphylaxis B-ADR

patient O
1 O
presented O
bilateral B-ADR
ballism I-ADR
1 O
week O
after O
intravenous O
heroin B-DRUG
injection O

conclusion O
: O
the O
findings O
in O
these O
two O
patients O
suggest O
that O
colchicine B-DRUG
may O
delay B-ADR
corneal I-ADR
wound I-ADR
healing I-ADR

aluminum B-DRUG
intoxication O
, O
along O
with O
other O
factors O
, O
was O
considered O
to O
be O
the O
cause O
of O
tc B-ADR
development O

dyspnea O
, O
hypoxemia B-ADR
, O
and O
pleuritic O
chest O
pain O
occurred O
within O
24 O
hours O
of O
rituximab B-DRUG
administration O
, O
and O
there O
was O
no O
other O
apparent O
explanation O

posthypoglycemic O
hyperglycemia O
( O
rebound B-ADR
hyperglycemia I-ADR
) O
after O
overdosing O
of O
insulin B-DRUG
was O
diagnosed O
in O
6 O
cats O
with O
diabetes O
mellitus O

when O
the O
disease O
recurred O
conventional O
amphotericin B-DRUG
b I-DRUG
was O
used O
again O
, O
but O
had O
to O
be O
stopped O
because O
of O
severe B-ADR
side I-ADR
effects I-ADR

aripiprazole-induced O
hiccups B-ADR
: O
a O
case O
report O

background O
: O
we O
describe O
the O
ophthalmic O
features O
and O
clinical O
course O
of O
two O
cases O
of O
acute O
syphilitic O
posterior O
placoid O
chorioretinitis O
( O
asppc B-ADR
) O
that O
developed O
after O
intravitreal O
triamcinolone B-DRUG
acetonide I-DRUG
( O
ivta O
) O
injection O

rituximab-chop B-DRUG
induced O
interstitial B-ADR
pneumonitis I-ADR
in O
patients O
with O
disseminated O
extranodal O
marginal O
zone O
b O
cell O
lymphoma O

rapid O
onset O
of O
muscle O
weakness O
( O
rhabdomyolysis B-ADR
) O
associated O
with O
the O
combined O
use O
of O
simvastatin B-DRUG
and O
colchicine O

two O
patients O
with O
imminent O
gangrene O
of O
the O
extremities O
caused O
by O
ergot-induced O
arteriospasm B-ADR
underwent O
mechanical O
dilatation O
of O
the O
arteries O
when O
conventional O
measures O
such O
as O
anticoagulation O
, O
vasodilation O
, O
and O
sympathetic O
blockade O
produced O
no O
improvement O

attempts O
were O
made O
to O
stop O
and O
then O
restart O
the O
theophylline B-DRUG
therapy O
at O
progressively O
lower O
doses O
; O
however O
, O
with O
each O
attempt O
, O
the O
patient O
's O
reaction B-ADR
to I-ADR
the I-ADR
drug I-ADR
became I-ADR
more I-ADR
toxic I-ADR
, O
with O
serum O
theophylline B-DRUG
levels O
ranging O
between O
99.9 O
and O
149.9 O
micromol O
/ O
l O
( O
18 O
and O
27 O
microg O
/ O
ml O

although O
this O
g-csf-driven O
leucocytosis B-ADR
was O
alarming O
it O
did O
not O
appear O
to O
have O
adversely O
affected O
the O
patient O
's O
prognosis O

baclofen B-DRUG
withdrawal B-ADR
syndrome I-ADR
resulting O
from O
underdosing O
of O
oral O
baclofen O
should O
be O
considered O
as O
a O
potential O
source O
of O
prolonged O
fever O
in O
the O
intensive O
care O
unit O

multiple B-ADR
pulmonary I-ADR
nodules I-ADR
: O
an O
unusual O
presentation O
of O
fludarabine B-DRUG
pulmonary O
toxicity O
: O
case O
report O
and O
review O
of O
literature O

an O
adolescent O
male O
developed O
acute O
pancreatitis O
and O
pseudocyst B-ADR
of I-ADR
the I-ADR
pancreas I-ADR
16 O
weeks O
after O
cessation O
of O
intramuscular O
l-asparaginase B-DRUG

this O
is O
the O
first O
case O
of O
tmp-smx-induced O
hypersensitivity B-ADR
syndrome I-ADR
associated O
with O
the O
reactivation O
of O
a O
latent O
viral O
infection O

however O
, O
he O
developed O
acute O
renal O
failure O
, O
hyperkalemia O
, O
and O
hyperuricemia B-ADR
30 O
d O
after O
receiving O
the O
sorafenib B-DRUG
treatment O

here O
, O
we O
describe O
a O
case O
of O
vogt-koyanagi-harada B-ADR
disease I-ADR
occurring O
4 O
months O
after O
the O
start O
of O
interferon B-DRUG
alpha O
treatment O
, O
probably O
induced O
by O
the O
immunomodulatory O
effects O
of O
interferon B-DRUG

lithium-induced O
creutzfeldt-jakob B-ADR
syndrome I-ADR

fulminant B-ADR
hepatic I-ADR
failure I-ADR
is O
a O
rare O
complication O
of O
disulfiram B-DRUG
treatment O
for O
alcoholism O

a O
62-year-old O
woman O
who O
was O
being O
treated O
for O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
developed O
a O
chemotherapy-related O
hemolytic-uremic B-ADR
syndrome I-ADR
during O
the O
second O
cycle O
of O
neoadjuvant O
chemotherapy O
consisting O
of O
cisplatin O
, O
bleomycin O
, O
and O
methotrexate B-DRUG

based O
on O
the O
naranjo O
probability O
scale O
, O
serotonin B-ADR
syndrome I-ADR
was O
a O
probable O
adverse O
reaction O
associated O
with O
co-administration O
of O
citalopram O
and O
fentanyl B-DRUG

acute B-ADR
dystonia I-ADR
with O
thalamic O
and O
brainstem O
lesions O
after O
initial O
penicillamine B-DRUG
treatment O
in O
wilson O
's O
disease O

these O
observations O
indicate O
that O
submassive B-ADR
hepatic I-ADR
necrosis I-ADR
may O
result O
from O
treatment O
with O
propylthiouracil B-DRUG
and O
are O
consistent O
with O
the O
notion O
that O
sensitization O
mechanisms O
may O
be O
responsible O
for O
the O
hepatic O
injury O
induced O
by O
this O
drug O

similar O
to O
reports O
in O
patients O
receiving O
gefitinib O
, O
those O
with O
pathologic O
findings O
of O
uip O
on O
resected O
lung O
specimens O
or O
known O
pulmonary B-ADR
fibrosis I-ADR
may O
be O
at O
particular O
risk O
for O
erlotinib B-DRUG
pulmonary O
toxicity O

clinicians O
should O
be O
aware O
of O
the O
possibility O
that O
vinorelbine B-DRUG
may O
cause O
siadh B-ADR
and O
possibly O
hypokalemia O

hypersensitivity B-ADR
reactions I-ADR
due O
to O
chloramphenicol B-DRUG
are O
rarely O
reported O
in O
the O
literature O

vincristine B-DRUG
induced O
cranial B-ADR
polyneuropathy I-ADR

interstitial O
lung O
disease O
( O
ild B-ADR
) O
related O
to O
therapy O
with O
the O
drug O
gefitinib B-DRUG
has O
been O
well O
reported O

a O
dapsone B-DRUG
hypersensitivity O
syndrome O
, O
consisting O
of O
fever O
, O
headache O
, O
nausea O
, O
vomiting O
, O
lymphadenopathy O
, O
hepatitis O
, O
hemolysis B-ADR
, O
leukopenia O
, O
and O
mononucleosis O
, O
has O
been O
described O
in O
patients O
treated O
with O
the O
drug O
for O
leprosy O

we O
have O
seen O
a O
case O
of O
terminal O
malignant O
melanoma O
in O
which O
clinical O
manifestations O
, O
indicative O
of O
anterior B-ADR
spinal I-ADR
artery I-ADR
syndrome I-ADR
, O
developed O
following O
the O
injection O
of O
0.3 O
ml O
of O
10 O
% O
phenol-glycerine B-DRUG
into O
the O
cervical O
subarachnoid O
space O
at O
the O
c4 O
-- O
c5 O
level O
for O
the O
control O
of O
severe O
right O
arm O
pain O

we O
present O
the O
first O
case O
( O
to O
our O
knowledge O
) O
of O
a O
potentially O
serious O
drug-drug B-ADR
interaction I-ADR
between O
zafirlukast B-DRUG
and O
theophylline O

a O
23-year-old O
woman O
with O
systemic O
lupus O
erythematosus O
had O
a O
severe B-ADR
hypersensitivity I-ADR
reaction I-ADR
to O
the O
drug O
ibuprofen B-DRUG

findings O
: O
six O
children O
with O
growth O
retardation O
noted O
after O
treatment O
with O
high-dose O
fluticasone B-DRUG
propionate I-DRUG
were O
found O
to O
have O
adrenal B-ADR
suppression I-ADR

we O
stress O
the O
potential O
of O
benzarone B-DRUG
to O
cause O
hepatotoxicity O
, O
which O
usually O
resembles O
severe B-ADR
chronic I-ADR
active I-ADR
hepatitis I-ADR

ethambutol B-DRUG
is O
frequently O
used O
in O
the O
treatment O
of O
tuberculosis O
, O
and O
, O
although O
optic B-ADR
neuropathies I-ADR
have O
been O
reported O
with O
the O
use O
of O
ethambutol O
, O
this O
adverse O
side O
effect O
has O
been O
considered O
to O
be O
rare O
and O
generally O
reversible O
with O
discontinuation O
of O
the O
medication O

anaphylactoid O
shock O
, O
disseminated O
intravascular O
coagulation O
, O
and O
anuric B-ADR
renal I-ADR
failure I-ADR
requiring O
dialysis O
occurred O
in O
a O
patient O
receiving O
zomepirac B-DRUG
sodium O
for O
toothache O

possible O
serotonin B-ADR
syndrome I-ADR
associated O
with O
clomipramine B-DRUG
after O
withdrawal O
of O
clozapine O

clonidine-induced O
bradycardia B-ADR
in O
patients O
with O
spinal O
cord O
injury O

we O
experienced O
2 O
cases O
of O
mequitazine-induced O
photosensitivity B-ADR
reaction I-ADR
in O
patients O
who O
took O
mequitazine B-DRUG
for O
their O
dermatologic O
problems O

the O
wide O
use O
of O
phenytoin B-DRUG
during O
the O
recent O
tuberculosis O
epidemic O
makes O
it O
imperative O
to O
suspect O
this O
drug O
interaction O
in O
patients O
exhibiting O
clinical O
features O
that O
might O
be O
related O
to O
phenytoin B-ADR
toxicity I-ADR

results O
: O
a O
44-year-old O
man O
taking O
naproxen O
for O
chronic O
low O
back O
pain O
and O
a O
20-year-old O
woman O
on O
oxaprozin B-DRUG
for O
rheumatoid O
arthritis O
presented O
with O
tense O
bullae O
and O
cutaneous B-ADR
fragility I-ADR
on O
the O
face O
and O
the O
back O
of O
the O
hands O

the O
occurrence O
of O
neuromuscular O
blockade O
and O
the O
resulting O
potentiation B-ADR
of I-ADR
muscle I-ADR
relaxants I-ADR
during O
magnesium B-DRUG
sulfate I-DRUG
( O
mgso4 O
) O
administration O
is O
well O
known O

malignant B-ADR
mixed I-ADR
mullerian I-ADR
tumor I-ADR
of I-ADR
the I-ADR
uterus I-ADR
in O
a O
patient O
taking O
raloxifene B-DRUG

skin O
manifestations O
of O
a O
case O
of O
phenylbutazone-induced O
serum B-ADR
sickness-like I-ADR
reactions I-ADR

there O
have O
been O
only O
two O
reports O
of O
cimetidine-induced O
hepatitis B-ADR

this O
report O
describes O
two O
patients O
who O
developed O
acute B-ADR
myelocytic I-ADR
leukemia I-ADR
only O
after O
exposure O
to O
cyclophosphamide O
, O
methotrexate B-DRUG
, O
and O
5-fluorouracil O
adjuvant O
therapy O

treatment O
of O
apl O
in O
pregnancy O
is O
controversial O
as O
the O
use O
of O
atra B-DRUG
has O
been O
questioned O
due O
to O
the O
teratogenic B-ADR
effect I-ADR
of O
retinoids O

a O
case O
of O
phenytoin-induced O
hepatitis O
with O
mononucleosis B-ADR
is O
reported O
, O
and O
syndromes O
associated O
with O
phenytoin B-DRUG
hypersensitivity O
reactions O
are O
discussed O

we O
report O
marked O
qt O
prolongation O
and O
torsades O
de O
pointes O
in O
a O
setting O
of O
flash O
pulmonary O
edema O
resulting O
from O
acute B-ADR
myocardial I-ADR
ischemia I-ADR
in O
a O
patient O
who O
was O
being O
treated O
with O
dofetilide B-DRUG
for O
atrial O
fibrillation O

a O
paradoxical B-ADR
ocular I-ADR
effect I-ADR
of O
brimonidine B-DRUG

dural B-ADR
sinus I-ADR
thrombosis I-ADR
developed O
in O
two O
children O
with O
acute O
lymphoblastic O
leukemia O
during O
induction O
treatment O
with O
vincristine B-DRUG
sulfate I-DRUG
, O
prednisone O
, O
and O
asparaginase O

we O
suggest O
adding O
this O
side O
effect O
to O
the O
list O
of O
untoward O
effects O
of O
lidocaine B-DRUG
and O
to O
the O
differential O
diagnosis O
of O
fixed O
dilated B-ADR
pupils I-ADR
in O
neonates O
treated O
with O
lidocaine B-DRUG

a O
21-year-old O
woman O
suffering O
from O
bipolar O
affective O
disorder O
developed O
systemic B-ADR
lupus I-ADR
erythematosus I-ADR
( O
sle O
) O
with O
characteristic O
laboratory O
findings O
, O
18 O
months O
after O
starting O
carbamazepine B-DRUG
maintenance O
treatment O

on O
the O
next O
day O
, O
after O
a O
total O
dose O
of O
only O
600 O
mg O
of O
danazol B-DRUG
, O
gingival B-ADR
bleeding I-ADR
and O
purpura O
occurred O

results O
: O
three O
patients O
who O
developed O
symptoms O
of O
inflammatory O
bowel O
disease O
( O
ibd B-ADR
) O
during O
rofecoxib B-DRUG
exposure O
are O
described O
along O
with O
pathology O
findings O

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin B-DRUG
, O
sparfloxacin O
, O
grepafloxacin O
, O
trovafloxacin O
, O
gatifloxacin O
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache O
, O
dizziness O
and O
insomnia B-ADR

after O
the O
addition O
of O
citalopram B-DRUG
, O
a O
desmethylclomipramine B-ADR
plasma I-ADR
level I-ADR
increase I-ADR
and O
an O
8-hydroacy-desmethylclomipramine O
plasma O
level O
decrease O
were O
observed O

we O
report O
a O
case O
of O
cough B-ADR
following O
the O
administration O
of O
quinapril B-DRUG
, O
with O
complete O
resolution O
after O
changing O
to O
the O
alternative O
ace O
inhibitor O
fosinopril O
in O
a O
patient O
with O
essential O
hypertension O

both O
pan O
and O
methotrexate B-DRUG
have O
been O
independently O
demonstrated O
to O
cause O
sensorineural B-ADR
hearing I-ADR
loss I-ADR

on O
day O
7 O
of O
linezolid B-DRUG
treatment O
, O
the O
patient O
developed O
severe O
pruritus O
, O
macular O
rash O
, O
facial O
edema O
, O
eosinophilia O
, O
marked B-ADR
increase I-ADR
in I-ADR
serum I-ADR
creatinine I-ADR
level I-ADR
, O
and O
mild O
hepatitis O

evidence O
obtained O
indicated O
that O
the O
reye-like B-ADR
syndrome I-ADR
might O
be O
caused O
by O
calcium B-DRUG
hopantenate I-DRUG
possibly O
due O
to O
the O
induction O
of O
pantothenic O
acid O
deficiency O

thrombocytopenia B-ADR
with O
or O
without O
microangiopathy O
following O
quinine B-DRUG
is O
often O
referred O
to O
as O
quinine B-DRUG
" O
hypersensitivity. O
" O
when O
schistocytes O
are O
present O
it O
is O
frequently O
termed O
" O
quinine-associated O
ttp O
/ O
hus. O
" O
a O
severe O
deficiency O
of O
the O
vwf-cleaving O
protease O
, O
adamts13 O
, O
is O
associated O
with O
idiopathic O
ttp O

psoriasis B-ADR
induced O
by O
interferon-alpha B-DRUG

in O
patients O
with O
swallowing B-ADR
dysfunction I-ADR
and O
pneumonia O
, O
a O
history O
of O
mineral B-DRUG
oil I-DRUG
use O
should O
be O
obtained O
and O
a O
diagnosis O
of O
elp O
should O
be O
considered O
in O
the O
differential O
diagnoses O
if O
mineral B-DRUG
oil I-DRUG
use O
has O
occurred O

a O
chronic O
reaction O
associated O
with O
long-term O
treatment O
with O
nitrofurantoin B-DRUG
has O
also O
been O
reported O
and O
causes O
irreversible O
pulmonary B-ADR
fibrosis I-ADR

in O
this O
paper O
we O
report O
a O
case O
of O
nimodipine B-DRUG
overdosage O
resulting O
in O
prolonged B-ADR
hypotension I-ADR
and O
hypoxemia O
, O
which O
was O
successfully O
treated O
with O
calcium O
gluconate O

this O
is O
an O
image O
and O
brief O
case O
report O
of O
a O
13-year-old O
boy O
who O
presented O
with O
severe B-ADR
rash I-ADR
and O
systemic O
symptoms O
after O
starting O
oxcarbazepine B-DRUG

we O
conjectured O
that O
the O
side O
effects O
of O
insulin B-DRUG
, O
such O
as O
anti-natriuresis O
and O
increased B-ADR
vascular I-ADR
permeability I-ADR
, O
might O
be O
pronounced O
in O
the O
presence O
of O
the O
hepatic O
dysfunction O
that O
accompanies O
insulin B-DRUG
insensitivity O
, O
hyperinsulinaemia O
and O
hypoalbuminaemia O

this O
pattern O
is O
suggestive O
of O
renal B-ADR
toxicity I-ADR
due O
to O
tobramycin B-DRUG

this O
case O
demonstrates O
the O
association O
of O
selective O
iga B-ADR
deficiency I-ADR
with O
remission O
in O
rheumatoid O
arthritis O
induced O
by O
fenclofenac O
as O
well O
as O
aurothiomalate O
and O
sulphasalazine B-DRUG

it O
is O
concluded O
that O
the O
aforementioned O
pathological O
manifestations O
were O
due O
to O
chemotherapy O
and O
included O
a O
pulmonary B-ADR
adverse I-ADR
reaction I-ADR
, O
a O
feature O
never O
previously O
associated O
with O
oxaliplatinum O
and O
5-fluorouracil B-DRUG
regimens O

protamine-induced O
fatal B-ADR
anaphylaxis I-ADR

quinine O
and O
its O
isomer O
quinidine B-DRUG
are O
well-known O
causes O
of O
iatrogenic B-ADR
hypoglycaemia I-ADR
, O
due O
to O
excessive O
insulin O
secretion O

only O
3 O
cases O
of O
imatinib-induced O
tumor B-ADR
lysis I-ADR
syndrome I-ADR
have O
been O
reported O

presented O
is O
a O
case O
story O
of O
a O
woman O
with O
classical O
rheumatoid O
arthritis O
, O
who O
during O
introduction O
of O
sulphasalazine O
( O
sasp B-DRUG
) O
therapy O
developed O
a O
severe O
and O
lasting O
psoriasis-like B-ADR
skin I-ADR
reaction I-ADR

gynecomastia B-ADR
in O
epileptics O
treated O
with O
phenobarbital O
, O
phenytoin B-DRUG
and O
fluoresone O
: O
two O
case O
reports O

we O
report O
the O
first O
histopathologically O
documented O
case O
of O
oral B-ADR
mucosa I-ADR
pigmentation I-ADR
after O
olp O
treatment O
with O
topical O
tacrolimus B-DRUG

previous O
studies O
have O
demonstrated O
the O
interaction O
of O
mtx B-DRUG
and O
a O
variety O
of O
non-steroidal O
, O
anti-inflammatory O
drugs O
( O
nsaids O
) O
with O
various O
clinical O
manifestations O
including O
acute B-ADR
renal I-ADR
failure I-ADR
, O
pancytopenia O
, O
vomiting O
, O
diarrhea O
, O
elevated O
liver O
transaminases O
, O
jaundice O
, O
mucosal O
ulcerations O
, O
and O
pyrexia O

following O
the O
institution O
of O
intravenous O
therapy O
with O
acyclovir B-DRUG
, O
the O
patient O
developed O
fever O
, O
hemoptysis O
, O
and O
a O
pleural B-ADR
friction I-ADR
rub I-ADR

objective O
: O
to O
report O
a O
case O
of O
angioedema B-ADR
associated O
with O
losartan B-DRUG
administration O

in O
the O
first O
patient O
, O
two O
episodes O
of O
ventricular B-ADR
tachycardia I-ADR
requiring O
cardioversion O
occurred O
in O
close O
temporal O
sequence O
with O
administering O
bretylium B-DRUG

when O
pilsicainide B-DRUG
is O
prescribed O
in O
patients O
with O
coronary O
artery O
disease O
or O
renal O
dysfunction O
, O
close O
attention O
must O
be O
paid O
to O
avoid O
life-threatening B-ADR
arrhythmias I-ADR
due O
to O
high O
plasma O
concentrations O
of O
the O
drug O

trichiasis B-ADR
associated O
with O
prostaglandin B-DRUG
analog O
use O

objective O
: O
we O
report O
a O
case O
of O
cutaneous B-ADR
ks I-ADR
lesions I-ADR
in O
a O
patient O
affected O
by O
cml O
treated O
with O
imatinib B-DRUG

after O
seven O
months' O
continuous O
treatment O
for O
suspected O
tuberculosis O
with O
rifampicin O
and O
ethambutol B-DRUG
a O
nine-year-old O
boy O
developed O
polyarthritis B-ADR
, O
rash O
and O
hepatitis O
in O
association O
with O
anti-native O
dna O
antibodies O
and O
positive O
antinuclear O
factor O

we O
describe O
the O
side O
effects O
of O
5-fu B-DRUG
in O
a O
colon O
cancer O
patient O
who O
suffered O
severe O
mucositis O
, O
desquamating O
dermatitis O
, O
prolonged B-ADR
myelosuppression I-ADR
, O
and O
neurologic O
toxicity O
that O
required O
admission O
to O
the O
intensive O
care O
unit O

background O
: O
the O
risk O
/ O
benefit O
ratio O
of O
warfarin B-DRUG
therapy O
changes O
in O
the O
over O
75s O
, O
when O
haemorrhagic B-ADR
side-effects I-ADR
become O
more O
common O

we O
report O
two O
new O
cases O
of O
sarcoidosis B-ADR
in O
two O
patients O
with O
hepatitis O
c O
virus O
infection O
treated O
with O
interferon O
alfa O
and O
ribavirin B-DRUG

we O
report O
for O
the O
first O
time O
the O
development O
of O
symptomatic B-ADR
methemoglobinemia I-ADR
after O
an O
acute O
ingestion O
of O
divalproex B-DRUG
sodium I-DRUG
( O
depakote O
) O
, O
resulting O
in O
serum O
concentrations O
10 O
times O
greater O
than O
the O
therapeutic O
range O

gastric O
tumor O
, O
endometrial B-ADR
carcinoma I-ADR
and O
cervical O
adenocarcinoma O
in O
situ O
were O
detected O
after O
treatment O
with O
tamoxifen B-DRUG
for O
breast O
cancer O

in O
contrast O
to O
chronic O
or O
subacute O
thyroiditis O
, O
graves' B-ADR
disease I-ADR
rarely O
complicates O
ifn-alpha B-DRUG
therapy O
for O
chronic O
viral O
c O
hepatitis O

the O
authors O
describe O
a O
case O
of O
oral-facial B-ADR
dyskinesia I-ADR
that O
occurred O
after O
discontinuation O
of O
amoxapine B-DRUG
, O
and O
antidepressant O
which O
may O
also O
have O
neuroleptic O
effects O

presented O
is O
a O
case O
story O
of O
a O
woman O
with O
classical O
rheumatoid O
arthritis O
, O
who O
during O
introduction O
of O
sulphasalazine B-DRUG
( O
sasp O
) O
therapy O
developed O
a O
severe O
and O
lasting O
psoriasis-like B-ADR
skin I-ADR
reaction I-ADR

acne B-ADR
provoked O
by O
gold B-DRUG
seems O
not O
to O
have O
been O
described O
elsewhere O

myotonia B-ADR
associated O
with O
sarcoidosis O
: O
marked O
exacerbation O
with O
pravastatin B-DRUG

further O
studies O
are O
necessary O
to O
evaluate O
whether O
the O
study O
of O
hla O
antigens O
may O
be O
a O
very O
useful O
tool O
to O
detect O
the O
patients O
with O
a O
predisposition O
to O
develop O
autoimmune O
thyroiditis O
, O
in O
order O
to O
make O
a O
early O
diagnosis O
of O
thyroid B-ADR
disorders I-ADR
during O
the O
ifn-alpha B-DRUG
treatment O

we O
report O
the O
syndrome O
of O
inappropriate O
antidiuresis B-ADR
as O
a O
much O
earlier O
side-effect O
of O
carbamazepine B-DRUG
administration O
in O
a O
29-year O
nigerian O
female O
patient O
with O
generalized O
tonic-elonic O
seizures O

idiosyncratic O
pulmonary O
reactions O
to O
nitrofurantoin B-DRUG
are O
not O
unusual O
, O
often O
presenting O
as O
eosinophilic B-ADR
pneumonia I-ADR

the O
authors O
postulate O
that O
two O
types O
of O
combined O
lithium-neuroleptic O
toxicity O
occur O
: O
a O
neuroleptic B-ADR
malignant I-ADR
extrapyramidal I-ADR
syndrome I-ADR
and O
a O
lithium B-DRUG
toxicity O
that O
occurs O
in O
combination O
with O
phenothiazines O
, O
primarily O
thioridazine O

introduction O
: O
we O
describe O
the O
neurointensive O
care O
( O
nic O
) O
management O
of O
a O
patient O
with O
severe B-ADR
cerebral I-ADR
swelling I-ADR
and O
raised O
intracranial O
pressure O
( O
icp O
) O
after O
severe O
sodium B-DRUG
valproic I-DRUG
acid I-DRUG
( O
vpa O
) O
intoxication O

fulminant B-ADR
hepatitis I-ADR
with O
severe O
lactate O
acidosis O
in O
hiv-infected O
patients O
on O
didanosine B-DRUG
therapy O

this O
case O
demonstrates O
the O
association O
of O
selective O
iga B-ADR
deficiency I-ADR
with O
remission O
in O
rheumatoid O
arthritis O
induced O
by O
fenclofenac B-DRUG
as O
well O
as O
aurothiomalate O
and O
sulphasalazine O

the O
authors O
report O
a O
case O
of O
focal B-ADR
myocardial I-ADR
necrosis I-ADR
, O
presenting O
clinically O
as O
an O
acute O
myocardial O
infarction O
during O
the O
administration O
of O
the O
antineoplastic O
drug O
, O
amsacrine B-DRUG
, O
in O
a O
patient O
without O
coronary O
artery O
disease O

telescoped B-ADR
digits I-ADR
of I-ADR
the I-ADR
hands I-ADR
and I-ADR
feet I-ADR
developed O
in O
a O
69-year-old O
male O
with O
severe O
chronic O
tophaceous O
gout O
during O
allopurinol B-DRUG
treatment O

protamine B-ADR
allergy I-ADR
as O
a O
complication O
of O
insulin B-DRUG
hypersensitivity O
: O
a O
case O
report O

captopril-induced O
acute B-ADR
reversible I-ADR
renal I-ADR
failure I-ADR

acute B-ADR
renal I-ADR
failure I-ADR
following O
intravenous O
immunoglobulin B-DRUG
therapy O
in O
a O
hiv-infected O
patient O

nifedipine B-DRUG
may O
induce O
, O
or O
aggravate O
, O
pre-existing O
, O
gastro-oesophageal B-ADR
reflux I-ADR

zolpidem O
tissue O
concentrations O
in O
a O
multiple O
drug O
related O
death B-ADR
involving O
ambien B-DRUG

a O
patient O
with O
psoriasis O
is O
described O
who O
had O
an O
abnormal O
response O
to O
the O
glucose O
tolerance O
test O
without O
other O
evidence O
of O
diabetes O
and O
then O
developed O
postprandial B-ADR
hyperglycemia I-ADR
and O
glycosuria O
during O
a O
period O
of O
topical O
administration O
of O
a O
corticosteroid O
cream O
, O
halcinonide B-DRUG
cream O
0.1 O
% O
, O
under O
occlusion O

retinal O
dysfunction O
and O
anterior B-ADR
segment I-ADR
deposits I-ADR
in O
a O
patient O
treated O
with O
rifabutin B-DRUG

a O
patient O
, O
while O
on O
intravenous O
ritodrine B-DRUG
therapy O
for O
preterm O
labor O
, O
experienced O
an O
episode O
of O
acute B-ADR
chest I-ADR
pain I-ADR

triazolam-induced O
nocturnal B-ADR
bingeing I-ADR
with O
amnesia O

reversible B-ADR
corneal I-ADR
keratinization I-ADR
following O
trabeculectomy O
and O
treatment O
with O
5-fluorouracil B-DRUG

the O
chemotherapeutics O
, O
including O
vincristine O
, O
actinomycin O
d O
, O
and O
epirubicin B-DRUG
in O
case O
1 O
and O
vincristine O
and O
actinomycin O
d O
in O
case O
2 O
, O
were O
given O
before O
the O
hepatotoxicity B-ADR
developed O

we O
present O
a O
fatal B-ADR
case O
of O
subacute O
methanol B-DRUG
toxicity O
with O
associated O
diffuse O
brain O
involvement O
, O
including O
bilateral O
putaminal O
necrosis O
and O
cerebral O
edema O
with O
ventricular O
compression O

sulfasalazine-induced O
hypersensitivity O
syndrome O
and O
hemophagocytic B-ADR
syndrome I-ADR
associated O
with O
reactivation O
of O
epstein-barr O
virus O

purpose O
: O
to O
describe O
bilateral B-ADR
optic I-ADR
neuritis I-ADR
that O
occurred O
as O
an O
adverse O
effect O
of O
recombinant O
and O
natural O
interferon B-DRUG
alpha I-DRUG
administration O

conclusion O
: O
this O
report O
describes O
a O
case O
of O
a O
probable O
interaction O
between O
topical O
econazole O
lotion O
1 O
% O
and O
acenocoumarol B-DRUG
that O
resulted O
in O
overanticoagulation O
and O
a O
life-threatening O
laryngeal B-ADR
hematoma I-ADR
in O
this O
elderly O
patient O

systemic O
corticosteroids O
in O
the O
phenytoin B-ADR
hypersensitivity I-ADR
syndrome I-ADR

the O
main O
clinical O
features O
of O
this O
58-year-old O
female O
patient O
were O
laboratory O
evidence O
of O
leucopenia B-ADR
and O
cholestasis O
, O
and O
biopsy O
features O
of O
fatty O
liver O
parenchyma O
degeneration O
with O
granulocytic O
portal O
infiltration O
and O
bile O
stasis O
, O
demonstrated O
20 O
days O
after O
the O
initiation O
of O
antithyroid O
therapy O
with O
20 O
mg O
methimazole B-DRUG
daily O

we O
present O
the O
cases O
of O
two O
female O
patients O
diagnosed O
with O
relapsing-remitting O
multiple O
sclerosis O
( O
rrms O
) O
who O
developed O
inflammatory B-ADR
musculoskeletal I-ADR
manifestations I-ADR
, O
following O
ifn-beta B-DRUG
therapy O

three O
days O
after O
receiving O
intravitreal O
injection O
of O
bevacizumab B-DRUG
( O
1.25 O
mg O
in O
0.1 O
ml O
) O
, O
he O
developed O
acute O
vision O
loss O
and O
change B-ADR
of I-ADR
consciousness I-ADR

gemcitabine B-DRUG
is O
a O
known O
risk O
factor O
for O
hemolytic B-ADR
uremic I-ADR
syndrome I-ADR
( O
hus O
) O
, O
which O
can O
often O
have O
a O
rapidly O
fatal O
clinical O
course O
despite O
intervention O
with O
steroids O
, O
plasmapheresis O
and O
hemodialysis O

a O
43-year-old O
white O
man O
developed O
a O
shallow O
erosion B-ADR
of I-ADR
a I-ADR
psoriatic I-ADR
plaque I-ADR
after O
chronic O
administration O
of O
methotrexate B-DRUG

however O
, O
repeated O
intracameral O
tpa B-DRUG
injections O
may O
cause O
unwanted O
complications O
such O
as O
vitreous B-ADR
hemorrhage I-ADR

objective O
: O
to O
report O
the O
first O
five O
cases O
of O
amphotericin B-DRUG
b I-DRUG
overdose O
with O
secondary O
cardiac B-ADR
complications I-ADR
in O
a O
pediatric O
population O

she O
was O
receiving O
phenytoin B-DRUG
sodium I-DRUG
300 O
mg O
/ O
day O
; O
carbamazepine O
200 O
mg O
four O
times O
daily O
had O
been O
discontinued O
four O
days O
before O
admission O
because O
of O
leukopenia B-ADR

a O
77-year-old O
woman O
with O
no O
history O
of O
epilepsy O
presented O
a O
probable O
nonconvulsive B-ADR
status I-ADR
epilepticus I-ADR
while O
receiving O
continuous O
intravenous O
morphine B-DRUG
for O
back O
pain O
relating O
to O
vertebral O
metastasis O
of O
a O
malignant O
lymphoma O

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate O
with O
folinic B-DRUG
acid I-DRUG
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia O
, O
hyperkalaemia B-ADR
and O
hyperphosphataemia O
with O
hypocalcaemia O
and O
tetany O
, O
with O
metabolic O
acidosis O
and O
acute O
renal O
impairment O
) O
are O
described O

a O
high O
dose O
of O
cotrimoxazole B-DRUG
induced O
hyperkalaemia B-ADR
with O
the O
elevation O
of O
serum O
creatinine O
and O
blood O
urea O
, O
and O
increased O
urinary O
n-acetyl O
glucosaminase O
after O
several O
days O
of O
the O
drug O
administration O
in O
these O
patients O
; O
one O
patient O
became O
unconscious O

we O
described O
the O
occurrence O
of O
l-dopa-induced O
myoclonus O
and O
seizures B-ADR
in O
a O
case O
of O
parkinsonism O
with O
its O
seps O
findings O

baclofen O
withdrawal B-ADR
syndrome I-ADR
resulting O
from O
underdosing O
of O
oral O
baclofen B-DRUG
should O
be O
considered O
as O
a O
potential O
source O
of O
prolonged O
fever O
in O
the O
intensive O
care O
unit O

reinstitution O
of O
penicillamine B-DRUG
treatment O
caused O
a O
recurrence O
thus O
proving O
a O
causal O
relationship O
between O
penicillamine B-DRUG
and O
the O
described O
nail-changes B-ADR

we O
report O
the O
case O
of O
a O
27-year-old O
indian O
woman O
who O
developed O
maculopapular B-ADR
rash I-ADR
and O
angioedema O
secondary O
to O
carbamazepine B-DRUG
administration O

the O
clinical O
course O
suggests O
that O
caffeine B-DRUG
, O
which O
is O
present O
in O
oolong O
tea O
, O
was O
mainly O
responsible O
for O
the O
rhabdomyolysis B-ADR
as O
well O
as O
the O
delirium O
, O
although O
severe O
hyponatremia O
has O
been O
reported O
to O
cause O
rhabdomyolysis B-ADR
on O
rare O
occasions O

the O
vomiting B-ADR
occurred O
on O
switching O
to O
different O
pancreatic O
enzymes O
preparations O
, O
ie O
, O
creon O
10 O
, O
viokase O
, O
and O
pancrease B-DRUG
mt I-DRUG
16 I-DRUG

niacin B-DRUG
maculopathy B-ADR

serotonin B-ADR
syndrome I-ADR
caused O
by O
selective O
serotonin O
reuptake-inhibitors-metoclopramide O
interaction O

the O
cause O
is O
presumed O
to O
be O
secondary O
to O
hypercoagulability O
due O
to O
asparaginase-induced O
antithrombin B-ADR
iii I-ADR
deficiency I-ADR

severe B-ADR
osteomalacia I-ADR
was O
present O
in O
two O
epileptic O
patients O
who O
were O
under O
long-term O
treatment O
with O
congeners O
of O
phenytoin O
, O
phenobarbital B-DRUG
, O
and O
acetazolamide O

methotrexate B-DRUG
may O
rarely O
provoke O
serositis B-ADR
, O
even O
with O
low O
doses O
and O
after O
just O
a O
few O
weeks O
of O
therapy O

in O
addition O
to O
the O
recognized O
arrhythmic O
complications O
, O
the O
authors O
emphasize O
myocardial O
necrosis O
as O
a O
possible O
further O
manifestation O
of O
amsacrine-related O
cardiotoxicity B-ADR

asthma O
and O
urticaria B-ADR
during O
disodium B-DRUG
cromoglycate I-DRUG
treatment O

acute O
asymptomatic B-ADR
hepatitis I-ADR
in O
a O
healthy O
normal O
volunteer O
exposed O
to O
2 O
oral O
doses O
of O
amodiaquine O
and O
artesunate B-DRUG

introduction O
: O
we O
describe O
the O
neurointensive O
care O
( O
nic O
) O
management O
of O
a O
patient O
with O
severe B-ADR
cerebral I-ADR
swelling I-ADR
and O
raised O
intracranial O
pressure O
( O
icp O
) O
after O
severe O
sodium O
valproic O
acid O
( O
vpa B-DRUG
) O
intoxication O

minimal B-ADR
change I-ADR
nephrotic I-ADR
syndrome I-ADR
developing O
during O
postoperative O
interferon-beta B-DRUG
therapy O
for O
malignant O
melanoma O

allopurinol-associated O
hand B-ADR
and I-ADR
foot I-ADR
deformities I-ADR
in O
chronic O
tophaceous O
gout O

we O
describe O
a O
renal O
transplant O
recipient O
maintained O
on O
cyclosporine B-DRUG
and O
prednisone O
developing O
nocardia B-ADR
asteroides I-ADR
brain I-ADR
abscess I-ADR

this O
case O
report O
describes O
the O
development O
of O
asymptomatic O
visual B-ADR
field I-ADR
defects I-ADR
( O
vfds O
) O
in O
a O
psychiatric O
patient O
with O
bipolar O
disorder O
receiving O
adjunctive O
tiagabine B-DRUG
treatment O

phenylpropanolamine B-DRUG
( O
ppa O
) O
recently O
has O
been O
publicly O
implicated O
as O
a O
cause O
of O
stroke O
and O
other O
neurologic B-ADR
events I-ADR

methods O
: O
a O
79-year-old O
woman O
being O
treated O
with O
imiquimod B-DRUG
5 O
days O
per O
week O
for O
a O
nodular O
basal O
cell O
developed O
a O
verrucous B-ADR
plaque I-ADR
over O
the O
treatment O
area O
after O
7 O
weeks O
of O
therapy O

gentamicin-associated O
acute B-ADR
renal I-ADR
failure I-ADR

postoperatively O
, O
the O
first O
two O
patients O
treated O
with O
1 O
to O
2 O
cc O
of O
thrombin B-DRUG
were O
slow O
to O
awaken O
; O
one O
had O
evidence O
of O
vasospasm B-ADR
by O
transcranial O
doppler O
ultrasound O
studies O
and O
multiple O
infarcts O
on O
cranial O
computerized O
tomography O
, O
while O
the O
other O
had O
a O
moderate-sized O
frontal O
hematoma O
with O
intracranial O
hypertension O

we O
report O
the O
case O
of O
a O
patient O
with O
chronic O
lymphocytic O
leukemia O
( O
cll O
) O
who O
developed O
fatal B-ADR
intravascular I-ADR
autoimmune I-ADR
hemolytic I-ADR
anemia I-ADR
( O
aiha O
) O
after O
fludarabine B-DRUG
treatment O

a O
10-year-old O
boy O
with O
osteosarcoma O
and O
normal O
renal O
function O
manifested O
laboratory O
evidence O
of O
impending O
renal B-ADR
toxicity I-ADR
and O
extreme O
elevation O
of O
aspartate O
aminotrasferase O
and O
alanine O
aminotransferase O
within O
2 O
hours O
after O
the O
completion O
of O
a O
4-hour O
infusion O
of O
high-dose O
methotrexate B-DRUG
( O
mtx O
) O
( O
12 O
g O
/ O
m2 O
) O
, O
and O
went O
on O
to O
develop O
acute O
renal O
failure O
with O
life-threatening O
hyperkalemia O
29 O
hours O
later O

we O
report O
a O
case O
of O
hepatolithiasis B-ADR
( O
intrahepatic O
stone O
) O
complicated O
by O
gram-negative O
sepsis O
in O
a O
37 O
year O
old O
male O
with O
acromegaly O
being O
treated O
with O
octreotide B-DRUG

ibuprofen-induced O
meningitis B-ADR
: O
detection O
of O
intrathecal O
igg O
synthesis O
and O
immune O
complexes O

patients O
treated O
with O
captopril B-DRUG
who O
develop O
" O
atypical O
cholangitis O
" O
should O
be O
suspected O
of O
having O
captopril-associated O
liver B-ADR
damage I-ADR

ccbs O
should O
be O
considered O
in O
the O
treatment O
of O
5-fu B-DRUG
or O
capecitabine-induced O
headaches B-ADR

after O
therapy O
with O
parenteral O
amiodarone B-DRUG
( O
2300 O
mg O
in O
3 O
days O
) O
and O
other O
measures O
, O
signs O
of O
congestive O
heart O
failure O
disappeared O
; O
subsequently O
the O
patient O
developed O
jaundice O
, O
marked O
increase O
in O
serum O
transaminase O
levels O
and O
fall O
in O
prothrombin O
time O
, O
and O
histologic O
changes O
of O
severe B-ADR
centrilobular I-ADR
necrosis I-ADR
were O
observed O
in O
hepatic O
biopsy O

this O
report O
suggests O
that O
anemia B-ADR
can O
occur O
due O
to O
mmf O
, O
in O
particular O
when O
it O
is O
given O
with O
prednisone B-DRUG
, O
a O
side O
effect O
well O
documented O
in O
the O
transplantation O
literature O
when O
the O
triple O
combination O
of O
mmf O
, O
cyclosporine O
and O
prednisone B-DRUG
is O
used O

alveolar-interstitial B-ADR
pneumopathy I-ADR
after O
gold-salts O
compounds O
administration O
, O
requiring O
mechanical O
ventilation O

the O
patient O
's O
previous O
rash O
and O
the O
temporal O
relation O
of O
this O
event O
and O
the O
ingestion O
of O
phenolphthalein B-DRUG
, O
as O
well O
as O
the O
similarity O
of O
this O
case O
to O
other O
reports O
, O
point O
to O
phenolphthalein B-DRUG
as O
the O
cause O
of O
ten B-ADR
in O
this O
patient O

diagnosis O
of O
sclerosing B-ADR
glomerulonephritis I-ADR
occurred O
in O
this O
patient O
during O
anastrozole B-DRUG
use O
, O
suggesting O
a O
newly O
defined O
side O
effect O
of O
anastrozole B-DRUG

the O
association O
of O
phenothiazine B-DRUG
overdose O
and O
respiratory B-ADR
distress I-ADR
syndrome I-ADR
merits O
consideration O

case O
study O
: O
a O
modified O
topical O
treatment O
regimen O
for O
sodium O
warfarin-induced O
necrotizing B-ADR
fasciitis I-ADR

we O
recommend O
that O
clinicians O
monitor O
patients O
for O
signs O
and O
symptoms O
of O
pancreatitis B-ADR
, O
including O
abdominal O
pain O
, O
during O
treatment O
with O
tigecycline B-DRUG

slow O
acetylators O
, O
who O
comprise O
roughly O
50 O
% O
of O
the O
south O
african O
population O
, O
are O
likely O
to O
develop O
clinical O
and O
biochemical O
features O
of O
phenytoin B-ADR
toxicity I-ADR
when O
this O
drug O
is O
given O
together O
with O
antituberculosis O
therapy O

the O
authors O
describe O
a O
woman O
with O
chronic O
schizophrenia O
who O
experienced O
delirium B-ADR
, O
grand O
mal O
seizure O
, O
and O
photosensitivity O
after O
the O
addition O
of O
propranolol B-DRUG
to O
her O
neuroleptic O
regimen O

a O
61-year-old O
man O
developed O
clinical B-ADR
lupus I-ADR
syndrome I-ADR
with O
positive O
antinuclear O
antibody O
, O
positive O
lupus O
erythematosus O
( O
le O
) O
cell O
preparation O
, O
and O
diffuse O
proliferative O
glomerulonephritis O
following O
26 O
months O
of O
procainamide B-DRUG
therapy O

after O
the O
patient O
discontinued O
rifampicin B-DRUG
, O
the O
skin B-ADR
lesions I-ADR
cleared O
completely O
within O
5 O
weeks O
without O
any O
systemic O
medication O

colonic B-ADR
mucosal I-ADR
necrosis I-ADR
following O
administration O
of O
calcium O
polystryrene O
sulfonate O
( O
kalimate B-DRUG
) O
in O
a O
uremic O
patient O

the O
epivodes O
of O
nms B-ADR
occured O
under O
treatment O
with O
clozapine O
, O
risperidone O
, O
and O
amisulpride B-DRUG

physicians O
should O
be O
aware O
of O
the O
risk O
of O
severe O
aiha B-ADR
in O
cll O
patients O
with O
a O
history O
of O
aiha B-ADR
or O
positivation O
of O
the O
dat O
during O
previous O
fludarabine B-DRUG
administration O
, O
or O
in O
case O
of O
secondary O
fixation O
of O
complement O
to O
the O
red O
cell O
membrane O
occurring O
during O
fludarabine B-DRUG
treatment O

this O
case O
report O
describes O
an O
adolescent O
with O
severe B-ADR
lupus I-ADR
erythematosus I-ADR
who O
received O
cyclophosphamide O
( O
cy B-DRUG
) O
paired O
with O
taste O
( O
cod O
liver O
oil O
) O
and O
smell O
( O
rose O
perfume O
) O
as O
conditioned O
stimuli O

a O
child O
in O
whom O
a O
phenobarbital B-DRUG
hypersensitivity O
drug O
reaction O
developed O
which O
consisted O
of O
fever O
, O
a B-ADR
pruritic I-ADR
desquamating I-ADR
erythrodermic I-ADR
rash I-ADR
, O
alopecia O
, O
icterus O
, O
protein-losing O
enteropathy O
, O
myositis O
, O
and O
nephritis O
, O
is O
described O

a O
36-year-old O
man O
being O
treated O
with O
cisplatinum O
, O
vinblastine O
, O
and O
bleomycin B-DRUG
for O
testicular O
carcinoma O
developed O
a O
dense O
left O
homonymous O
hemianopsia O
, O
encephalopathy O
, O
and O
a O
partial B-ADR
nondominant I-ADR
parietal I-ADR
lobe I-ADR
syndrome I-ADR

an O
obese O
patient O
, O
not O
diabetic O
, O
treated O
with O
metformin B-DRUG
for O
some O
weeks O
, O
was O
referred O
to O
us O
with O
severe B-ADR
inferior I-ADR
digestive I-ADR
hemorrhage I-ADR
, O
diagnosed O
with O
meckel O
's O
diverticulum O

transient O
left O
homonymous O
hemianopsia O
and O
encephalopathy B-ADR
following O
treatment O
of O
testicular O
carcinoma O
with O
cisplatinum O
, O
vinblastine O
, O
and O
bleomycin B-DRUG

four O
days O
after O
the O
initial O
injection O
of O
3.6 O
mg O
of O
goserelin B-DRUG
acetate I-DRUG
, O
severe B-ADR
dyspnea I-ADR
developed O
due O
to O
worsening O
pleuritis O
carcinomatosa O
, O
which O
was O
considered O
as O
a O
flare-up O

the O
clinical O
course O
suggests O
that O
the O
interstitial B-ADR
pneumonitis I-ADR
was O
induced O
by O
hydroxyurea B-DRUG

in O
patients O
with O
chronic O
heart O
failure O
, O
spironolactone B-DRUG
added O
to O
conventional O
treatment O
may O
lead O
to O
serious B-ADR
and I-ADR
, I-ADR
occasionally I-ADR
, I-ADR
fatal I-ADR
hyperkalaemia I-ADR

hydroxyurea B-DRUG
associated O
with O
concomitant O
occurrence O
of O
diffuse B-ADR
longitudinal I-ADR
melanonychia I-ADR
and O
multiple O
squamous O
cell O
carcinomas O
in O
an O
elderly O
subject O

a O
44-year-old O
woman O
is O
described O
in O
whom O
amiodarone O
, O
disopyramide O
, O
and O
quinidine B-DRUG
, O
administered O
alone O
separately O
, O
induced O
atypical B-ADR
ventricular I-ADR
tachycardia I-ADR
( O
avt O
, O
torsade O
de O
pointes O

systemic O
disease O
, O
most O
commonly O
renal O
dysfunction O
, O
preceded O
all O
30 O
reported O
cases O
of O
acyclovir B-DRUG
neurotoxicity B-ADR

recovery O
of O
the O
tubular B-ADR
dysfunction I-ADR
took O
15 O
days O
following O
cessation O
of O
the O
offending O
drug O
, O
amikacin B-DRUG

polyarthritis O
, O
hepatitis O
and O
anti-native B-ADR
dna I-ADR
antibodies I-ADR
after O
treatment O
with O
ethambutol B-DRUG
and O
rifampicin O

conclusion O
: O
we O
report O
a O
case O
of O
the O
use O
of O
pamidronate O
for O
significant O
hypercalcemia O
secondary O
to O
acute B-ADR
vitamin I-ADR
d I-ADR
poisoning I-ADR

we O
report O
a O
case O
of O
acute O
hyperphosphatemia B-ADR
secondary O
to O
rectal O
administration O
of O
sodium O
phosphate O
and O
sodium B-DRUG
biphosphate I-DRUG
( O
fleet O
enema O

we O
present O
two O
cases O
of O
nitrofurantoin-induced O
pulmonary B-ADR
toxicity I-ADR
in O
which O
the O
initial O
hrct O
showed O
a O
widespread O
reticular O
pattern O
and O
associated O
distortion O
of O
the O
lung O
parenchyma O
, O
thought O
to O
represent O
established O
fibrosis O

our O
report O
suggested O
that O
cbdca B-DRUG
hypersensitivity B-ADR
was O
correlated O
with O
the O
total O
dose O
of O
previously O
administered O
platinum O
agents O
and O
that O
cbdca B-DRUG
should O
be O
excluded O
in O
patients O
who O
have O
received O
multiple O
platinum-based O
chemotherapy O
, O
even O
in O
platinum-sensitive O
cases O
, O
because O
cbdca B-DRUG
hypersensitivity B-ADR
can O
occur O
even O
with O
low-dose O
cbdca B-DRUG
administration O

during O
her O
third O
cycle O
, O
she O
again O
received O
cisplatin B-DRUG
100 B-ADR
mg I-ADR
/ I-ADR
m2 I-ADR
over O
30 O
minutes O
and O
developed O
palmar O
pruritus O
, O
urticaria O
, O
and O
edema O

case O
summary O
: O
a O
61-year-old O
woman O
with O
no O
apparent O
risk O
factors O
for O
liver O
injury O
developed O
acute B-ADR
hepatitis I-ADR
one O
week O
after O
the O
final O
dose O
of O
a O
long-term O
course O
of O
pulse O
itraconazole B-DRUG
therapy O
( O
200 O
mg O
orally O
twice O
daily O
, O
1 O
wk O
on O
, O
3 O
wk O
off O
, O
for O
24 O
wk O
) O
for O
onychomycosis O

it O
is O
thought O
that O
the O
clinico-pathological O
features O
and O
chronology O
of O
this O
case O
bore O
the O
hallmarks O
of O
the O
so-called O
" O
3-week O
sulphasalazine B-DRUG
syndrome O
" O
, O
a O
rare O
, O
but O
often O
fatal O
, O
immunoallergic B-ADR
reaction I-ADR
to O
sulphasalazine B-DRUG

nabumetone-associated O
interstitial B-ADR
nephritis I-ADR

however O
, O
the O
use O
of O
lithium B-DRUG
should O
be O
avoided O
with O
any O
patient O
who O
is O
purging O
, O
since O
it O
may O
exacerbate O
the O
loss O
of O
intracellular O
potassium O
, O
thereby O
increasing O
the O
risk O
of O
cardiac B-ADR
toxicity I-ADR

in O
addition O
to O
disease O
refractoriness O
, O
rare O
instances O
of O
disease O
progression O
from O
chronic O
phase O
to O
blast B-ADR
crisis I-ADR
during O
imatinib B-DRUG
therapy O
have O
recently O
been O
anecdotally O
reported O

parenteral O
pyridoxine O
, O
the O
specific O
antidote O
for O
inh-induced O
refractory B-ADR
seizures I-ADR
, O
should O
be O
readily O
available O
in O
every O
emergency O
department O
in O
the O
areas O
similarly O
experiencing O
increasing O
trends O
of O
tb O

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash O
, O
fever B-ADR
, O
leukopenia O
and O
positive O
anti-nuclear O
antibody O
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine O
( O
cbz B-DRUG
; O
tegretol O
) O
used O
against O
benign O
rolandic O
epilepsy O

the O
patient O
whose O
case O
is O
reviewed O
had O
migraine B-ADR
headaches I-ADR
and O
received O
methysergide B-DRUG
maleate O
for O
13 O
years O

serious O
phenytoin B-DRUG
hypersensitivity O
reactions O
may O
appear O
as O
dermatologic B-ADR
, I-ADR
lymphoid I-ADR
, I-ADR
or I-ADR
hepatic I-ADR
syndromes I-ADR

methods O
: O
a O
patient O
who O
developed O
dramatic O
, O
permanent O
vision B-ADR
loss I-ADR
after O
a O
9-month O
course O
of O
treatment O
with O
ethambutol O
and O
isoniazid B-DRUG
for O
pulmonary O
tuberculosis O
is O
presented O

infliximab B-DRUG
and O
its O
serious O
adverse O
effects O
are O
discussed O
, O
and O
other O
cases O
of O
osteomyelitis B-ADR
with O
infliximab O
use O
are O
also O
reviewed O

optic B-ADR
neuropathy I-ADR
in O
ethambutol-treated O
renal O
tuberculosis O

metoclopramide-induced O
parkinsonism B-ADR

the O
evidence O
of O
high O
plasmatic O
levels O
of O
cbz B-DRUG
and O
the O
absence O
of O
other O
aetiologic O
factors O
lead O
the O
authors O
to O
conclude O
that O
the O
overdose O
of O
cbz B-DRUG
could O
have O
represented O
the O
precipitating O
of O
the O
episode O
of O
acute B-ADR
pancreatitis I-ADR

the O
principle O
treatment O
for O
dpd-deficient O
patients O
with O
severe O
acute O
5-fu B-DRUG
reactions O
is O
supportive O
care O
; O
however O
, O
the O
administration O
of O
thymidine O
potentially O
may O
reverse O
severe O
5-fu-induced O
neurologic O
symptoms O
such O
as O
encephalopathy B-ADR
and O
coma O

the O
risk O
of O
new-onset O
diabetic B-ADR
ketoacidosis I-ADR
in O
patients O
with O
diabetic O
risk O
factors O
who O
are O
taking O
perospirone B-DRUG
hydrochloride I-DRUG
or O
other O
atypical O
antipsychotics O
should O
be O
kept O
in O
mind O

we O
describe O
a O
patient O
with O
a O
liver B-ADR
abscess I-ADR
due O
to O
entamoeba O
histolytica O
, O
in O
whom O
metronidazole B-DRUG
therapy O
( O
total O
dose O
, O
21 O
g O
over O
14 O
days O
) O
was O
complicated O
by O
reversible O
deafness O
, O
tinnitus O
, O
and O
ataxia O
and O
who O
relapsed O
5 O
months O
later O
with O
a O
splenic O
abscess O

a O
young O
diamond O
dealer O
developed O
visual O
impairment O
attributed O
to O
bilateral B-ADR
posterior I-ADR
subcapsular I-ADR
cataracts I-ADR
following O
only O
four O
courses O
of O
intermittent O
decadron B-DRUG
used O
as O
part O
of O
a O
five-drug O
antiemetic O
regimen O
for O
cisplatin-associated O
nausea O

thus O
, O
tardive B-ADR
seizures I-ADR
in O
our O
cases O
are O
thought O
to O
be O
related O
to O
piperacillin O
and O
cefotiam B-DRUG

common O
adverse O
events O
( O
frequency O
10 O
%) O
of O
lacosamide B-DRUG
doses O
up O
to O
600 O
mg O
/ O
day O
include O
nonspecific O
central O
nervous O
system O
effects O
( O
e.g. O
, O
dizziness O
, O
ataxia O
, O
diplopia B-ADR
, O
and O
somnolence O

systemic B-ADR
allergic I-ADR
contact I-ADR
dermatitis I-ADR
to O
8-methoxypsoralen B-DRUG
( O
8-mop O

tardive B-ADR
dyskinesia I-ADR
induced O
by O
sulpiride B-DRUG

acute B-ADR
pancreatitis I-ADR
is O
a O
known O
, O
although O
rare O
, O
complication O
of O
mesalamine B-DRUG
treatment O

pulmonary B-ADR
eosinophilia I-ADR
or O
granulomas O
, O
classically O
seen O
in O
previously O
reported O
cases O
of O
methotrexate B-DRUG
pneumonitis O
, O
were O
not O
observed O

risperidone-induced O
psychosis B-ADR
and O
depression O
in O
a O
child O
with O
a O
mitochondrial O
disorder O

we O
recommended O
periodic O
examination O
of O
the O
serum O
proteins O
in O
patients O
receiving O
diphenylhydantoin B-DRUG
in O
order O
to O
detect O
development O
of O
monoclonal B-ADR
gammopathy I-ADR

this O
paper O
reports O
an O
autopsy O
case O
of O
a O
78-year-old O
male O
with O
multiple B-ADR
nodules I-ADR
in I-ADR
the I-ADR
liver I-ADR
developed O
after O
long-termed O
administration O
of O
phosphate O
diethylstilbestrol O
( O
pdes B-DRUG
) O
for O
prostatic O
cancer O

effect O
of O
beta-blockade O
on O
symptomatic O
dexamethasone-induced O
hypertrophic B-ADR
obstructive I-ADR
cardiomyopathy I-ADR
in O
premature O
infants O
: O
three O
case O
reports O
and O
literature O
review O

one O
of O
the O
side-effects O
of O
intravitreal O
triamcinolone B-DRUG
is O
the O
development O
of O
cataract B-ADR
, O
and O
it O
is O
known O
that O
cataract B-ADR
extraction O
can O
exacerbate O
macular O
degeneration O

lansoprazole-induced O
thrombocytopenia B-ADR

hypoglycemia O
can O
be O
a O
serious O
side O
effect O
of O
etanercept B-DRUG
in O
patients O
already O
on O
antidiabetic O
medications O
known O
to O
cause O
hypoglycemia B-ADR
, O
such O
as O
sulfonylureas O
, O
meglitinides O
, O
and O
insulin O

the O
main O
clinical O
features O
of O
this O
58-year-old O
female O
patient O
were O
laboratory O
evidence O
of O
leucopenia O
and O
cholestasis B-ADR
, O
and O
biopsy O
features O
of O
fatty O
liver O
parenchyma O
degeneration O
with O
granulocytic O
portal O
infiltration O
and O
bile O
stasis O
, O
demonstrated O
20 O
days O
after O
the O
initiation O
of O
antithyroid O
therapy O
with O
20 O
mg O
methimazole B-DRUG
daily O

in O
deciding O
if O
tamoxifen B-DRUG
therapy O
is O
warranted O
, O
all O
potentially O
life-threatening O
adverse O
events O
associated O
with O
tamoxifen B-DRUG
should O
be O
considered O
, O
including O
endometrial O
adenocarcinoma O
or O
uterine B-ADR
sarcoma I-ADR

a O
patient O
with O
monocular O
open-angle O
glaucoma O
had O
trichiasis B-ADR
, O
a O
condition O
associated O
with O
the O
use O
of O
a O
prostaglandin B-DRUG
analog O

minocycline-induced O
autoimmune B-ADR
hepatitis I-ADR
is O
usually O
identical O
to O
sporadic O
autoimmune B-ADR
hepatitis I-ADR

encephalopathy B-ADR
and O
seizures O
induced O
by O
intravesical O
alum B-DRUG
irrigations O

pseudomembranous B-ADR
colitis I-ADR
readily O
occurs O
in O
at O
least O
certain O
population O
groups O
receiving O
trimethoprim-sulfamethoxazole O

children O
with O
acute O
lymphoblastic O
leukemia O
( O
all O
) O
, O
treated O
with O
l-asparaginase B-DRUG
are O
at O
risk O
for O
cerebral O
thrombosis O
or O
hemorrhage B-ADR
because O
of O
coagulation O
protein O
deficiencies O

asthma B-ADR
and O
urticaria O
during O
disodium B-DRUG
cromoglycate I-DRUG
treatment O

rebound B-ADR
hyperglycemia I-ADR
was O
observed O
with O
both O
intermediate O
( O
neutral O
protamine B-DRUG
hagedorn I-DRUG
) O
and O
long-acting O
( O
protamine O
zinc O
iletin O
) O
insulins O
, O
and O
the O
range O
of O
insulin O
doses O
at O
which O
the O
disorder O
developed O
overlapped O
previously O
determined O
therapeutic O
doses O
for O
these O
insulins O
in O
the O
cat O

conclusion O
: O
hypersensitivity O
reaction O
should O
be O
considered O
in O
patients O
who O
develop O
recurrent O
eosinophilia O
and O
deterioration B-ADR
of I-ADR
pulmonary I-ADR
function I-ADR
following O
the O
use O
of O
tobramycin B-DRUG
by O
inhalation O
or O
by O
intravenous O
administration O

after O
therapy O
for O
diabetic O
coma O
with O
insulin B-DRUG
( O
containing O
the O
preservative O
cresol O
) O
and O
electrolyte O
solutions O
was O
started O
, O
the O
patient O
complained O
of O
increasing B-ADR
myalgia I-ADR
, O
developed O
a O
high O
fever O
and O
respiratory O
and O
metabolic O
acidosis O
and O
lost O
consciousness O

we O
present O
a O
fatal O
case O
of O
subacute O
methanol B-DRUG
toxicity O
with O
associated O
diffuse O
brain O
involvement O
, O
including O
bilateral B-ADR
putaminal I-ADR
necrosis I-ADR
and O
cerebral O
edema O
with O
ventricular O
compression O

postoperative O
hypocalcemic B-ADR
tetany I-ADR
caused O
by O
fleet B-DRUG
phospho-soda I-DRUG
preparation O
in O
a O
patient O
taking O
alendronate O
sodium O
: O
report O
of O
a O
case O

rapamycin O
/ O
sirolimus O
( O
sr B-DRUG
) O
, O
trade O
named O
rapammune O
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression B-ADR
, O
hypertension O
, O
hyperlipidemia O
, O
and O
infection O

the O
electrocardiogram O
( O
ecg O
) O
, O
which O
was O
read O
as O
normal O
prior O
to O
ritodrine B-DRUG
infusion O
, O
demonstrated O
a O
type B-ADR
i I-ADR
second-degree I-ADR
av I-ADR
block I-ADR
which O
disappeared O
upon O
discontinuation O
of O
ritodrine B-DRUG
therapy O

fever O
, O
pulmonary O
infiltrates O
, O
and O
pleural B-ADR
effusion I-ADR
following O
acyclovir B-DRUG
therapy O
for O
herpes O
zoster O
ophthalmicus O

uveitis B-ADR
associated O
with O
rifabutin B-DRUG
therapy O
: O
a O
clinical O
alert O

of O
371 O
patients O
treated O
with O
8mop B-DRUG
, O
three O
( O
0.8 O
%) O
developed O
an O
acute B-ADR
dermatitis I-ADR
in O
the O
puva-treated O
areas O

though O
proteinuria B-ADR
and O
nephrotic O
syndrome O
is O
a O
rare O
adverse O
effect O
of O
ifn-beta-1b B-DRUG
therapy O
, O
physicians O
treating O
ms O
patients O
with O
this O
agent O
should O
pay O
careful O
attention O
to O
new O
clinical O
symptoms O
and O
laboratory O
findings O

vortex B-ADR
keratopathy I-ADR
associated O
with O
atovaquone B-DRUG

a O
17-year-old O
boy O
with O
refractory O
psoriatic O
arthritis O
and O
alpha-1 O
antitrypsin O
deficiency O
who O
developed O
a O
syringotropic B-ADR
hypersensitivity I-ADR
reaction I-ADR
after O
9 O
months O
of O
therapy O
with O
infliximab O
and O
leflunomide B-DRUG
is O
described O

inappropriate B-ADR
antidiuretic I-ADR
hormone I-ADR
secretion I-ADR
after O
high O
dose O
vinblastine B-DRUG

we O
conclude O
that O
while O
thrombocytopenia O
and O
schistocytosis O
can O
be O
seen O
in O
quinine-associated O
ttp B-ADR
/ I-ADR
hus I-ADR
, O
the O
pathophysiology O
seems O
to O
be O
distinct O
from O
that O
seen O
in O
most O
cases O
of O
idiopathic O
ttp O
( O
i.e. O
, O
severely O
decreased O
adamts13 O
with O
an O
inhibitor O

2-cda B-DRUG
typically O
causes O
a O
long-lasting O
state O
of O
immunodeficiency B-ADR
and O
the O
profound O
influence O
of O
this O
drug O
on O
the O
immune O
system O
has O
raised O
questions O
concerning O
the O
emergence O
of O
secondary O
neoplasms O
after O
its O
use O

cis-retinoic O
acid O
( O
ra B-DRUG
) O
may O
further O
increase O
the O
risk O
of O
developing O
bmtn B-ADR

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly B-ADR
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim B-DRUG
( O
tmp O
)- O
sulfamethoxazole O
( O
smx O
) O
treatment O

study O
design O
: O
case O
reports O
are O
presented O
of O
three O
premature O
infants O
( O
mean O
gestational O
age O
27 O
weeks O
) O
cared O
for O
in O
the O
intensive O
care O
nursery O
in O
whom O
clinically O
significant O
septal O
hypertrophy O
and O
left B-ADR
ventricular I-ADR
outflow I-ADR
tract I-ADR
obstruction I-ADR
developed O
during O
dexamethasone B-DRUG
treatment O
for O
bronchopulmonary O
dysplasia O

chronic O
hydroxychloroquine B-DRUG
use O
associated O
with O
qt O
prolongation O
and O
refractory B-ADR
ventricular I-ADR
arrhythmia I-ADR

atypical O
ventricular O
tachycardia O
( O
torsade O
de O
pointes O
) O
induced O
by O
amiodarone O
: O
arrhythmia B-ADR
previously O
induced O
by O
quinidine O
and O
disopyramide B-DRUG

recurrent B-ADR
hyponatremia I-ADR
associated O
with O
citalopram O
and O
mirtazapine B-DRUG

this O
case O
highlights O
the O
possible O
development O
of O
acute B-ADR
coronary I-ADR
syndrome I-ADR
as O
a O
side O
effect O
of O
capecitabine B-DRUG
therapy O

leflunomide-associated O
infections B-ADR
in O
rheumatoid O
arthritis O

with O
the O
use O
of O
optical O
coherence O
tomography O
( O
oct O
) O
, O
two O
patients O
with O
ifn-associated O
retinopathy O
who O
had O
developed O
macular B-ADR
edema I-ADR
and O
reduced O
visual O
acuity O
during O
the O
clinical O
course O
of O
ifn B-DRUG
therapy O
were O
observed O

method O
: O
we O
describe O
two O
patients O
who O
presented O
with O
diabetic B-ADR
ketoacidosis I-ADR
after O
treatment O
with O
quetiapine O
and O
risperidone B-DRUG
, O
respectively O

insulin-dependent B-ADR
diabetes I-ADR
mellitus I-ADR
associated O
with O
danazol B-DRUG

a O
lupus-like B-ADR
syndrome I-ADR
associated O
with O
infliximab B-DRUG
therapy O

diabetes B-ADR
mellitus I-ADR
was O
observed O
in O
a O
patient O
given O
carbamazepine B-DRUG

both O
6-mp O
and O
aza B-DRUG
are O
widely O
used O
and O
are O
known O
to O
cause O
hepatotoxicity B-ADR
in O
a O
proportion O
of O
patients O

the O
9 O
other O
reported O
cases O
of O
d-penicillamine B-DRUG
induced O
rapidly B-ADR
progressive I-ADR
glomerulonephritis I-ADR
have O
been O
reviewed O

we O
report O
an O
additional O
case O
of O
isotretinoin B-DRUG
teratogenicity O
in O
which O
the O
patient O
had O
agenesis O
of O
the O
cerebellar O
vermis O
, O
multiple O
leptomeningeal O
neuroglial O
heterotopias O
, O
hydrocephalus O
, O
and O
abnormalities B-ADR
of I-ADR
the I-ADR
corticospinal I-ADR
tracts I-ADR

peripheral B-ADR
neuropathy I-ADR
associated O
with O
capecitabine B-DRUG

one O
patient O
on O
ouabain B-DRUG
also O
developed O
cardiomyopathy B-ADR

clinicians O
should O
be O
cognizant O
of O
this O
possibility O
and O
consider O
a O
diagnosis O
of O
hdas O
in O
patients O
with O
ongoing O
thrombosis B-ADR
who O
are O
receiving O
heparin B-DRUG
therapy O

there O
have O
been O
more O
than O
20 O
observations O
of O
the O
appearance O
or O
aggravation O
of O
this O
granulomatosis B-ADR
with O
interferon B-DRUG
alfa I-DRUG
and O
more O
recently O
with O
the O
combination O
of O
interferon B-DRUG
alfa I-DRUG
plus O
ribavirin O

although O
a O
few O
case O
reports O
link O
metronidazole B-DRUG
with O
the O
development O
of O
pseudomembranous B-ADR
colitis I-ADR
, O
albendazole O
has O
not O
been O
associated O
with O
the O
development O
of O
this O
condition O

fever O
, O
lymphadenopathy B-ADR
, O
eosinophilia O
, O
lymphocytosis O
, O
hepatitis O
, O
and O
dermatitis O
: O
a O
severe O
adverse O
reaction O
to O
minocycline B-DRUG

erythema B-ADR
multiforme I-ADR
associated O
with O
phenytoin B-DRUG
and O
cranial O
radiation O
therapy O
: O
a O
report O
of O
three O
patients O
and O
review O
of O
the O
literature O

in O
each O
of O
the O
three O
reported O
patients O
, O
alteration B-ADR
of I-ADR
eyelid I-ADR
appearance I-ADR
with O
deepening O
of O
the O
lid O
sulcus O
was O
evident O
as O
the O
result O
of O
topical O
bimatoprost B-DRUG
therapy O

we O
report O
an O
unusual O
pattern O
of O
supravenous B-ADR
hyperpigmentation I-ADR
occurring O
after O
chop B-DRUG
chemotherapy O

we O
report O
a O
case O
of O
unintentional O
overdose O
of O
oral O
pilocarpine B-DRUG
tablets O
that O
resulted O
in O
bradycardia O
, O
mild O
hypotension O
, O
and O
muscarinic B-ADR
symptoms I-ADR
in O
a O
patient O
with O
sjogren O
's O
syndrome O

it O
carries O
a O
well-known O
risk O
of O
neutropenia B-ADR
and O
agranulocytosis O
, O
which O
necessitates O
the O
immediate O
discontinuation O
of O
clozapine B-DRUG

according O
to O
the O
naranjo O
adverse O
drug O
reaction O
probability O
scale O
, O
tigecycline B-DRUG
was O
the O
probable O
cause O
of O
her O
acute B-ADR
pancreatitis I-ADR

naproxen-associated O
sudden B-ADR
sensorineural I-ADR
hearing I-ADR
loss I-ADR

asterixis B-ADR
induced O
by O
carbamazepine B-DRUG
therapy O

sustained B-ADR
hypothyroidism I-ADR
induced O
by O
recombinant B-DRUG
alpha I-DRUG
interferon I-DRUG
in O
patients O
with O
chronic O
hepatitis O
c O

she O
received O
an O
accidental O
450-mg O
bolus O
injection O
of O
morphine B-DRUG
intrathecally O
and O
developed O
hypertension O
, O
status B-ADR
epilepticus I-ADR
, O
intracerebral O
hemorrhage O
, O
and O
respiratory O
failure O

methods O
: O
the O
patient O
required O
insulin B-DRUG
desensitization O
for O
severe O
urticaria O
, O
angioedema B-ADR
, O
and O
occasional O
wheezing O
resulting O
from O
her O
insulin B-DRUG
dose O

two O
of O
these O
patients O
, O
who O
also O
received O
the O
anti-emetic O
prochlorperazine B-DRUG
, O
lost B-ADR
consciousness I-ADR
for O
48-72 O
h O
and O
then O
fully O
recovered O

the O
day O
after O
clozapine O
was O
stopped O
, O
while O
he O
was O
still O
receiving O
clomipramine B-DRUG
150 O
mg O
/ O
d O
, O
he O
began O
behaving O
oddly O
, O
started O
sweating B-ADR
profusely I-ADR
, O
shivering O
, O
and O
became O
tremulous O
, O
agitated O
, O
and O
confused O

erythropoietin O
is O
beneficial O
in O
mitomycin-induced O
hemolytic-uremic B-ADR
syndrome I-ADR

severe B-ADR
hepatotoxicity I-ADR
related O
to O
benzarone B-DRUG
: O
a O
report O
of O
three O
cases O
with O
two O
fatalities O

the O
aim O
of O
this O
paper O
is O
to O
report O
the O
case O
of O
rosaceiform B-ADR
eruption I-ADR
induced O
by O
erlotinib B-DRUG
in O
an O
81-year-old-man O
and O
to O
discuss O
the O
pathogenetic O
role O
of O
demodex O
folliculorum O
mites O
, O
found O
in O
the O
present O
patient O
, O
using O
skin O
scraping O

a O
7-year-old O
boy O
developed O
a O
severe B-ADR
unilateral I-ADR
grand I-ADR
mal I-ADR
seizure I-ADR
at O
the O
age O
of O
5 O
years O
( O
phenobarbitone B-DRUG
therapy O
) O
; O
1.5 O
years O
later O
valproate O
( O
2-propylpentanoic O
acid O
, O
vpa O
) O
was O
added O
to O
the O
therapy O

bone O
marrow O
aplasia O
and O
severe B-ADR
skin I-ADR
rash I-ADR
after O
a O
single O
low O
dose O
of O
methotrexate B-DRUG

a O
25-year-old O
man O
with O
a O
history O
of O
mid-borderline O
( O
bb O
) O
hansen O
's O
disease O
developing O
a O
reversal B-ADR
reaction I-ADR
after O
starting O
dapsone O
and O
rifampin B-DRUG
therapy O
is O
presented O

corneal B-ADR
edema I-ADR
recurred O
when O
the O
administration O
of O
amantadine B-DRUG
was O
resumed O

we O
report O
a O
case O
of O
48-year-old O
woman O
with O
seizure O
disorder O
on O
divalproex B-DRUG
sodium I-DRUG
( O
depakote O
) O
who O
presented O
with O
dyspnea B-ADR

acute O
abdomen O
due O
to O
endometriosis B-ADR
in O
a O
premenopausal O
woman O
taking O
tamoxifen B-DRUG

we O
report O
three O
cases O
of O
ifn B-DRUG
beta I-DRUG
induced O
hepatitis O
in O
ms O
and O
discuss O
the O
pathology O
findings O
and O
possible O
mechanisms O
of O
drug-induced O
liver B-ADR
injury I-ADR

we O
describe O
a O
43-year-old O
man O
who O
developed O
signs O
and O
symptoms O
of O
bilateral B-ADR
optic I-ADR
neuropathy I-ADR
during O
treatment O
with O
ethambutol B-DRUG

we O
have O
safely O
used O
recombinant O
factor O
viia O
to O
treat O
bleeding O
in O
the O
immediate O
and O
long-term O
period O
following O
pcc-related O
mi B-ADR

six O
patients O
developed O
peripheral O
neuropathy O
and O
five O
patients O
bone B-ADR
marrow I-ADR
depression I-ADR
, O
blood O
transfusions O
were O
given O
to O
three O
patients O
and O
in O
all O
five O
patients O
bone O
marrow O
function O
normalized O
after O
cessation O
of O
linezolid B-DRUG

it O
has O
been O
suggested O
that O
ppe B-ADR
caused O
by O
cytarabine B-DRUG
does O
not O
recur O
with O
subsequent O
cytarabine B-DRUG
re-challenge O

we O
report O
the O
first O
case O
of O
a O
patient O
in O
a O
promethazine-induced O
coma B-ADR
responding O
to O
treatment O
with O
flumazenil O

in O
2 O
of O
the O
3 O
cases O
the O
patients O
were O
also O
taking O
lithium B-DRUG
carbonate I-DRUG
and O
beta-blockers O
, O
both O
of O
which O
could O
have O
contributed O
to O
the O
incontinence B-ADR

a O
patient O
developed O
cholestatic B-ADR
hepatitis I-ADR
while O
being O
treated O
with O
nitrofurantoin B-DRUG

a O
cause-effect O
relationship O
to O
capecitabine B-DRUG
was O
suggested O
due O
to O
resolution O
of O
headache B-ADR
with O
capecitabine B-DRUG
withdrawal O
and O
reappearance O
with O
capecitabine B-DRUG
rechallenge O

this O
report O
rules O
out O
other O
causes O
of O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
and O
implicates O
ofloxacin B-DRUG
in O
what O
appears O
to O
be O
an O
atypical O
presentation O
of O
drug-induced O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR

atrial B-ADR
fibrillation I-ADR
was O
induced O
by O
diltiazem B-DRUG
in O
two O
patients O
and O
verapamil O
induced O
syncope O
in O
one O
patient O

this O
entity O
is O
probably O
related O
to O
a O
combination O
of O
high O
doses O
of O
corticosteroids O
, O
vecuronium B-DRUG
administration O
and O
metabolic O
abnormalities O
associated O
with O
respiratory B-ADR
failure I-ADR

we O
report O
a O
patient O
with O
recurrent O
, O
increasingly O
severe O
episodes O
of O
ppe B-ADR
, O
ultimately O
complicated O
by O
a O
severe O
bullous O
eruption O
, O
following O
successive O
cycles O
of O
high-dose O
cytarabine B-DRUG
for O
the O
treatment O
of O
acute O
lymphoblastic O
leukaemia O

l-asparaginase-provoked O
seizures O
as O
singular O
expression O
of O
central B-ADR
nervous I-ADR
toxicity I-ADR

a O
brief O
review O
of O
reported O
cases O
of O
chloramphenicol B-DRUG
hypersensitivity B-ADR
in O
the O
english-language O
literature O
, O
as O
well O
as O
possible O
alternative O
explanations O
in O
this O
case O
, O
are O
provided O

depressive B-ADR
symptoms I-ADR
disappeared O
after O
interferon B-DRUG
therapy O
was O
stopped O

this O
report O
suggests O
that O
anemia B-ADR
can O
occur O
due O
to O
mmf B-DRUG
, O
in O
particular O
when O
it O
is O
given O
with O
prednisone O
, O
a O
side O
effect O
well O
documented O
in O
the O
transplantation O
literature O
when O
the O
triple O
combination O
of O
mmf B-DRUG
, O
cyclosporine O
and O
prednisone O
is O
used O

a O
57-year-old O
man O
developed O
chronic B-ADR
, I-ADR
watery I-ADR
diarrhea I-ADR
four O
weeks O
after O
helicobacter O
pylori O
eradication O
therapy O
including O
lansoprazole B-DRUG
followed O
by O
lansoprazole B-DRUG
monotherapy O
for O
gastroesophageal O
reflux O
disease O

a O
55-yr-old O
man O
developed O
prolonged B-ADR
jaundice I-ADR
and O
sicca O
complex O
after O
a O
course O
of O
thiabendazole B-DRUG
therapy O

four O
weeks O
earlier O
she O
had O
developed O
hepatopathy B-ADR
during O
a O
regimen O
of O
carbamazepine O
, O
lynestrenol O
and O
sodium B-DRUG
valproate I-DRUG

it O
is O
suggested O
therefore O
that O
methotrexate B-DRUG
be O
added O
to O
the O
list O
of O
agents O
capable O
of O
inducing O
diffuse B-ADR
interstitial I-ADR
pulmonary I-ADR
fibrosis I-ADR

conclusions O
: O
clinicians O
should O
be O
aware O
that O
crohn B-ADR
's I-ADR
disease I-ADR
is O
a O
potential O
novel O
adverse O
drug O
effect O
of O
copaxone B-DRUG

such O
anagen B-ADR
effluvium I-ADR
with O
lichenoid O
eruption O
following O
inh B-DRUG
therapy O
has O
not O
been O
observed O
previously O

pneumocystis O
pneumonia O
should O
be O
considered O
in O
asthmatic O
patients O
taking O
methotrexate B-DRUG
who O
present O
with O
fever O
, O
pulmonary B-ADR
infiltrates I-ADR
, O
and O
hypoxia O

behavioral O
side O
effects O
associated O
with O
clonazepam B-DRUG
may O
include O
agitation O
, O
aggression O
, O
hyperactivity B-ADR
, O
irritability O
, O
property O
destruction O
, O
and O
temper O
tantrums O

we O
describe O
two O
patients O
in O
whom O
painful O
erosions O
of O
their O
psoriasis O
developed O
as O
the O
presenting O
sign O
of O
methotrexate B-ADR
toxicity I-ADR
and O
review O
the O
literature O
, O
emphasizing O
the O
risk O
factors O
associated O
with O
this O
manifestation O

these O
cases O
demonstrate O
that O
cbz B-DRUG
can O
induce O
simple O
motor B-ADR
tics I-ADR
in O
children O

we O
report O
an O
82-year-old O
man O
who O
developed O
ventricular B-ADR
tachycardia I-ADR
and O
torsades O
de O
pointes O
( O
tdp O
) O
after O
oral O
administration O
of O
garenoxacin B-DRUG
, O
a O
novel O
quinolone O
antibiotic O
agent O
that O
differs O
from O
the O
third-generation O
quinolones O
, O
for O
pneumonia O

purpose O
: O
to O
report O
a O
case O
of O
traumatic O
flap O
dehiscence O
and O
enterobacter B-ADR
keratitis I-ADR
34 O
months O
after O
lasik B-DRUG

large B-ADR
cerebral I-ADR
infarction I-ADR
during O
praziquantel B-DRUG
therapy O
in O
neurocysticercosis O

nephrogenic B-ADR
diabetes I-ADR
insipidus I-ADR
and O
renal O
tubular O
acidosis O
secondary O
to O
foscarnet B-DRUG
therapy O

antineutrophil B-ADR
cytoplasmic I-ADR
antibody-positive I-ADR
crescentic I-ADR
glomerulonephritis I-ADR
associated O
with O
propylthiouracil B-DRUG
therapy O

the O
second O
was O
an O
82-year-old O
man O
receiving O
ticlopidine B-DRUG
for O
2 O
years O
when O
, O
during O
a O
febrile O
episode O
, O
he O
was O
found O
neutropenic O
with O
marrow B-ADR
aplasia I-ADR

the O
patient O
's O
clinical O
presentation O
, O
histologic O
features O
on O
liver O
biopsy O
and O
favorable O
course O
after O
stopping O
the O
drug O
suggest O
that O
barbiturates B-DRUG
can O
be O
added O
to O
the O
list O
of O
agents O
which O
can O
cause O
submassive B-ADR
hepatic I-ADR
necrosis I-ADR

due O
to O
discomfort B-ADR
, O
diplopia O
and O
lagophthalmos O
, O
the O
haematoma O
necessitated O
suspension O
of O
warfarin B-DRUG
therapy O
and O
a O
surgical O
evacuation O

case O
report O
: O
we O
describe O
here O
a O
case O
of O
a O
60 O
year O
old O
female O
that O
experienced O
a O
relapse O
of O
symptomatic B-ADR
hyperlactatemia I-ADR
after O
being O
switched O
from O
stavudine O
to O
zidovudine B-DRUG
and O
how O
the O
case O
was O
managed O
at O
the O
infectious O
diseases O
institute O
, O
kampala O
, O
uganda O

atypical O
endometriosis O
may O
act O
as O
a O
precancerous O
lesion O
in O
the O
process O
of O
tamoxifen-induced O
malignant B-ADR
transformation I-ADR
of I-ADR
endometriosis I-ADR

the O
medical O
examiner O
's O
report O
indicated O
death O
caused O
by O
fluoxetine B-ADR
toxicity I-ADR

a O
young O
diamond O
dealer O
developed O
visual B-ADR
impairment I-ADR
attributed O
to O
bilateral O
posterior O
subcapsular O
cataracts O
following O
only O
four O
courses O
of O
intermittent O
decadron B-DRUG
used O
as O
part O
of O
a O
five-drug O
antiemetic O
regimen O
for O
cisplatin-associated O
nausea O

the O
ocular O
toxicity O
of O
dcf B-DRUG
, O
previously O
described O
as O
conjunctivitis B-ADR
, O
appears O
to O
be O
a O
keratitis O
of O
moderate O
severity O
which O
requires O
further O
study O

a O
34-year-old O
lady O
developed O
a O
constellation B-ADR
of I-ADR
dermatitis I-ADR
, O
fever O
, O
lymphadenopathy O
and O
hepatitis O
, O
beginning O
on O
the O
17th O
day O
of O
a O
course O
of O
oral O
sulphasalazine B-DRUG
for O
sero-negative O
rheumatoid O
arthritis O

the O
patient O
presented O
with O
fulminant B-ADR
microangiopathic I-ADR
hemolytic I-ADR
anemia I-ADR
and O
thrombocytopenia O
within O
48 O
hr O
of O
initiating O
therapy O
with O
trimethoprim-sulfamethoxazole O

currently O
the O
use O
of O
zidovudine B-DRUG
is O
one O
of O
the O
few O
specific O
measures O
available O
, O
and O
as O
a O
potentially O
teratogenic B-ADR
and O
fetotoxic O
agent O
, O
any O
decision O
for O
its O
use O
requires O
evaluation O
of O
the O
potential O
for O
fetal O
damage O

results O
: O
one O
case O
of O
recurrent O
primary O
peritoneal O
carcinoma O
previously O
treated O
with O
a O
carboplatin-based O
regimen O
, O
developed O
a O
platinum B-ADR
hypersensitivity I-ADR

gold B-ADR
nephropathy I-ADR
due O
to O
auranofin B-DRUG
obscured O
by O
tolmetin O
pseudoproteinuria O

awareness O
of O
this O
route O
of O
intoxication O
might O
be O
important O
in O
patients O
in O
whom O
neurologic O
or O
psychiatric B-ADR
symptoms I-ADR
develop O
while O
large O
amounts O
of O
lidocaine B-DRUG
cream O
are O
being O
used O

a O
patient O
suffering O
from O
heparin-associated O
thrombocytopenia O
( O
hat O
) O
, O
recurrent O
arteriothromboses O
, O
and O
acute B-ADR
renal I-ADR
failure I-ADR
after O
treatment O
with O
standard O
heparin B-DRUG
is O
described O

severe O
rash O
, O
including O
the O
stevens-johnson O
syndrome O
( O
sjs B-ADR
) O
, O
is O
the O
major O
toxicity O
of O
nevirapine B-DRUG
and O
is O
described O
in O
the O
package O
labeling O
with O
a O
prominent O
, O
boxed O
warning O

this O
is O
, O
to O
the O
best O
of O
our O
knowledge O
, O
the O
first O
report O
of O
a O
case O
in O
which O
agranulocytosis B-ADR
followed O
treatment O
with O
both O
propylthiouracil O
and O
methimazole B-DRUG
in O
the O
same O
patient O

use O
of O
the O
naranjo O
adverse O
drug O
reaction O
probability O
scale O
indicated O
a O
probable O
relationship O
( O
score O
of O
5 O
) O
between O
the O
patient O
's O
development O
of O
hepatotoxicity B-ADR
and O
the O
tmp-smx B-DRUG
therapy O

this O
is O
the O
first O
histologically O
confirmed O
case O
of O
nash B-ADR
that O
was O
aggravated O
by O
raloxifene B-DRUG

since O
elevated O
cortisol O
levels O
in O
cushing O
's O
disease O
poses O
a O
threat O
for O
pancreatitis O
, O
there O
is O
a O
possibility O
that O
patients O
with O
cushing O
's O
disease O
might O
be O
more O
prone O
to O
acute B-ADR
pancreatitis I-ADR
following O
propofol B-DRUG
administration O

prolonged O
severe O
5-fluorouracil-associated O
neurotoxicity B-ADR
in O
a O
patient O
with O
dihydropyrimidine O
dehydrogenase O
deficiency O

to O
the O
best O
of O
our O
knowledge O
, O
corneoscleral B-ADR
melting I-ADR
in O
the O
first O
postoperative O
week O
after O
a O
single O
intraoperative O
application O
of O
mitomycin B-DRUG
c I-DRUG
has O
not O
been O
reported O

transient B-ADR
neurological I-ADR
disturbances I-ADR
induced O
by O
the O
chemotherapy O
of O
high-dose O
methotrexate B-DRUG
for O
osteogenic O
sarcoma O

in O
one O
patient O
the O
vasculitis O
resolved O
after O
termination O
of O
the O
ciprofloxacin B-DRUG
therapy O
; O
in O
the O
other O
patient O
the O
ciprofloxacin-induced O
hemorrhagic B-ADR
vasculitis I-ADR
was O
superimposed O
on O
a O
severe O
forefoot O
infection O
, O
leading O
to O
progressive O
gangrene O
and O
a O
below-knee O
amputation O

we O
reviewed O
the O
literature O
in O
an O
attempt O
to O
characterize O
the O
pattern O
and O
predictors O
of O
tmp O
/ O
smx-induced O
aseptic B-ADR
meningitis I-ADR

the O
administration O
of O
" O
sweet O
spirits O
of O
nitre O
" O
( O
4 B-DRUG
% I-DRUG
ethyl I-DRUG
nitrite I-DRUG
ch3ch2ono I-DRUG
in I-DRUG
70 I-DRUG
% I-DRUG
ethyl I-DRUG
alcohol I-DRUG
) O
was O
followed O
by O
acute B-ADR
methemoglobinemia I-ADR
and O
severe O
anoxic O
metabolic O
acidosis O
in O
infant O
twins O
, O
methylene O
blue O
administration O
reversed O
methemoglobinemia O
in O
both O
, O
but O
one O
twin O
died O
from O
the O
consequences O
of O
hypoxemia O

multiple B-ADR
sclerosis-like I-ADR
disease I-ADR
secondary O
to O
alpha B-DRUG
interferon I-DRUG

prolonged O
responses O
were O
achieved O
with O
low O
doses O
of O
hu B-DRUG
( O
3-10 O
mg O
/ O
kg O
/ O
day O
) O
and O
higher O
doses O
were O
associated O
with O
mild B-ADR
reversible I-ADR
hematologic I-ADR
or O
hepatic O
toxicity O
and O
no O
further O
increases O
in O
hb O

temsirolimus-induced O
glomerulopathy B-ADR

a O
52 O
year-old O
male O
patient O
diagnosed O
of O
ankylosing O
spondylitis O
presented O
with O
an O
iron B-ADR
deficiency I-ADR
anemia I-ADR
after O
a O
ten-month O
treatment O
of O
methotrexate B-DRUG

objective O
: O
to O
report O
a O
case O
of O
serotonin B-ADR
syndrome I-ADR
associated O
with O
interaction O
between O
fentanyl B-DRUG
and O
citalopram O
, O
as O
evidenced O
by O
medication O
history O
, O
clinical O
features O
and O
reversal O
following O
discontinuation O
of O
fentanyl B-DRUG

graft B-ADR
versus I-ADR
host-like I-ADR
illness I-ADR
in O
a O
child O
with O
phenobarbital B-DRUG
hypersensitivity O

fixed B-ADR
drug I-ADR
eruption I-ADR
of I-ADR
the I-ADR
scrotum I-ADR
due O
to O
methylphenidate B-DRUG

we O
present O
a O
case O
report O
of O
a O
patient O
with O
alveolar O
hydatid O
disease O
, O
whose O
treatment O
with O
mebendazole B-DRUG
was O
brief O
due O
to O
side O
effects O
of O
alopecia B-ADR
and O
granulocytopenia O
; O
and O
review O
the O
features O
of O
this O
disease O
which O
, O
with O
increasing O
international O
migration O
, O
may O
be O
encountered O
more O
frequently O
in O
australia O

in O
two O
patients O
, O
apomorphine B-DRUG
remained O
effective O
in O
the O
morning O
, O
but O
increased O
the O
intensity O
of O
the O
dyskinesias B-ADR
in O
the O
afternoon O

epsilon-aminocaproic B-DRUG
acid I-DRUG
and O
renal B-ADR
complications I-ADR
: O
case O
report O
and O
review O
of O
the O
literature O

we O
recommend O
that O
a O
tma O
in O
association O
with O
quinine B-DRUG
be O
consistently O
referred O
to O
as O
quinine-associated O
thrombotic B-ADR
microangiopathy I-ADR
( O
quinine-tma O
) O
to O
better O
distinguish O
this O
entity O
from O
idiopathic O
ttp O

intravenous O
azithromycin-induced O
ototoxicity B-ADR

cimetidine B-DRUG
is O
a O
rare O
cause O
of O
drug-induced O
fever B-ADR

we O
report O
a O
case O
of O
noncardiogenic B-ADR
pulmonary I-ADR
edema I-ADR
developed O
after O
therapeutic O
trial O
of O
eo B-DRUG
as O
sclerosing O
agent O
for O
esophageal O
varix O

the O
authors O
suggest O
that O
fluoxetine-induced O
akathisia B-ADR
may O
be O
caused O
by O
serotonergically O
mediated O
inhibition O
of O
dopaminergic O
neurotransmission O
and O
that O
the O
pathophysiology O
of O
fluoxetine-induced O
akathisia B-ADR
and O
tricyclic O
antidepressant-induced O
" O
jitteriness O
" O
may O
be O
identical O

we O
report O
the O
occurrence O
of O
renal O
failure O
due O
to O
cholesterol B-ADR
crystal I-ADR
embolization I-ADR
following O
thrombolytic O
therapy O
with O
intravenous O
recombinant B-DRUG
tissue-type I-DRUG
plasminogen I-DRUG
activator I-DRUG
( O
t-pa O

extrapyramidal B-ADR
symptoms I-ADR
are O
well-documented O
complications O
of O
therapy O
with O
haloperidol B-DRUG
, O
even O
when O
small O
doses O
are O
used O

a O
12 O
year O
old O
patient O
with O
atrial O
flutter O
is O
presented O
, O
in O
whom O
intravenous O
adenosine B-DRUG
was O
followed O
by O
acceleration B-ADR
of I-ADR
the I-ADR
heart I-ADR
rate I-ADR
to O
a O
potentially O
dangerous O
arrhythmia O

following O
are O
two O
clinical O
case O
reports O
demonstrating O
profound O
cerebral B-ADR
edema I-ADR
associated O
with O
implantation O
of O
gliadel B-DRUG
wafers O

generalized B-ADR
lichen I-ADR
nitidus I-ADR
with O
involvement O
of O
the O
palms O
following O
interferon B-DRUG
alpha I-DRUG
treatment O

prominent O
positive B-ADR
u I-ADR
waves I-ADR
appearing O
with O
high-dose O
intravenous O
phenylephrine B-DRUG

we O
report O
two O
cases O
of O
cerebrospinal O
fluid O
eosinophilia O
( O
csfe B-ADR
) O
secondary O
to O
the O
intraventricular O
administration O
of O
vancomycin B-DRUG

angioedema B-ADR
, O
a O
rare O
side O
effect O
of O
carbamazepine B-DRUG
, O
involves O
vascular O
leakage O
in O
dermis O
and O
subcutis O
mediated O
by O
immunoglobulin O
e O
and O
/ O
or O
bradykinins O

a O
33-year-old O
male O
presented O
with O
brown B-ADR
discolouration I-ADR
of I-ADR
the I-ADR
fingernails I-ADR
following O
the O
application O
of O
4 O
% O
hydroquinone O
in O
sorbolene O
cream O
and O
0.1 B-DRUG
% I-DRUG
tretinoin I-DRUG
cream I-DRUG
to O
the O
face O
intermittently O
for O
9 O
months O

this O
treatment O
has O
the O
potential O
to O
cause O
severe B-ADR
vision I-ADR
loss I-ADR
as O
a O
result O
of O
intractable O
corticosteroid-induced O
glaucoma O

a O
42 O
year O
old O
man O
, O
treated O
for O
testicular O
carcinoma O
with O
combination O
chemotherapy O
that O
included O
bleomycin B-DRUG
, O
developed O
life O
threatening O
interstitial B-ADR
pneumonitis I-ADR

from O
these O
data O
, O
acute B-ADR
generalized I-ADR
dystonia I-ADR
with O
brainstem O
and O
thalamic O
lesions O
may O
occur O
in O
wd O
patients O
after O
an O
initial O
d-penicillamine B-DRUG
therapy O

we O
suggest O
that O
sarcoidosis B-ADR
may O
develop O
in O
chronic O
hepatitis O
c O
patients O
during O
interferon B-DRUG
alpha I-DRUG
and O
/ O
or O
ribavirin O
treatment O
, O
and O
diagnostic O
tests O
for O
this O
adverse O
effect O
should O
be O
performed O
during O
the O
follow-ups O

erosion O
of O
psoriatic O
plaques O
: O
an O
early O
sign O
of O
methotrexate B-ADR
toxicity I-ADR

rapamycin O
/ O
sirolimus O
( O
sr O
) O
, O
trade O
named O
rapammune B-DRUG
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression B-ADR
, O
hypertension O
, O
hyperlipidemia O
, O
and O
infection O

background O
: O
gemcitabine B-DRUG
has O
mild O
renal B-ADR
toxicity I-ADR
, O
but O
cases O
of O
gemcitabine-associated O
hemolytic-uremic O
syndrome O
( O
hus O
) O
have O
been O
reported O

based O
upon O
the O
observed O
fall B-ADR
of I-ADR
the I-ADR
filtration I-ADR
fraction I-ADR
, O
the O
rise O
in O
the O
relative O
clearance O
of O
99tc-dimercaptosuccinic O
acid O
and O
the O
increase O
in O
proteinuria O
, O
we O
suggest O
that O
in O
this O
case O
the O
tubules O
and O
/ O
or O
interstitium O
are O
the O
main O
targets O
for O
cyclosporine B-DRUG
a I-DRUG
nephrotoxicity O

fludarabine B-DRUG
induced O
lung O
toxicity O
must O
be O
considered O
in O
all O
patients O
who O
develop O
unexplained O
lung B-ADR
disease I-ADR
while O
receiving O
fludarabine O

methods O
: O
repeated O
blood O
samples O
were O
drawn O
in O
a O
patient O
with O
severe O
acyclovir B-DRUG
overdose O
who O
developed O
coma O
and O
nonoliguric B-ADR
renal I-ADR
failure I-ADR

an O
apparent O
link O
is O
described O
between O
the O
use O
of O
mmf B-DRUG
with O
prednisone O
to O
treat O
pemphigus O
vulgaris O
and O
the O
development O
of O
red B-ADR
blood I-ADR
cell I-ADR
anemia I-ADR

the O
increased B-ADR
libido I-ADR
disappeared O
after O
fluvoxamine B-DRUG
was O
discontinued O

the O
current O
report O
describes O
a O
man O
who O
was O
prescribed O
zonisamide B-DRUG
for O
epilepsy O
and O
subsequently O
developed O
widespread O
skin O
rash O
, O
acute O
kidney O
injury O
, O
high-grade B-ADR
fever I-ADR
, O
eosinophilia O
, O
liver O
dysfunction O
, O
lymphadenopathy O
and O
an O
increase O
in O
antihuman O
herpesvirus-6 O
immunoglobulin O
g O
titer O

aseptic O
meningitis O
, O
hemolytic B-ADR
anemia I-ADR
, O
hepatitis O
, O
and O
orthostatic O
hypotension O
in O
a O
patient O
treated O
with O
trimethoprim-sulfamethoxazole O

transient B-ADR
central I-ADR
diabetes I-ADR
insipidus I-ADR
in O
the O
setting O
of O
underlying O
chronic O
nephrogenic O
diabetes O
insipidus O
associated O
with O
lithium B-DRUG
use O

we O
describe O
a O
case O
of O
intraoperative O
gelatine-induced O
anaphylaxis B-ADR
whose O
diagnosis O
was O
delayed O
as O
the O
use O
of O
gelatine B-DRUG
during O
surgical O
procedures O
was O
omitted O
for O
two O
times O
in O
patient O
's O
medical O
records O

acute B-ADR
coronary I-ADR
syndromes I-ADR
complicating O
the O
first O
infusion O
of O
rituximab B-DRUG

purpose O
: O
to O
report O
a O
case O
of O
nodular B-ADR
scleritis I-ADR
following O
alendronate B-DRUG
sodium I-DRUG

severe B-ADR
neurotoxicity I-ADR
with O
methyl B-DRUG
g I-DRUG
: I-DRUG
calgb I-DRUG
experience O

we O
consider O
asterixis B-ADR
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity O
, O
which O
may O
occur O
even O
at O
low O
or O
moderate O
dosage O
levels O
, O
if O
certain O
drugs O
as O
lithium O
or O
clozapine O
are O
used O
in O
combination O
with O
cbz B-DRUG

to O
the O
best O
of O
the O
authors' O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
propecia-associated O
cataract B-ADR

furosemide-associated O
fever B-ADR

arrhythmias B-ADR
and O
cardiac O
arrest O
have O
been O
reported O
during O
amphotericin B-DRUG
b I-DRUG
administration O
but O
no O
effective O
technique O
has O
been O
described O
to O
prevent O
them O

during O
the O
first O
treatment O
, O
dysarthria O
and O
ataxia B-ADR
were O
seen O
after O
completion O
of O
the O
patient O
's O
eighth O
and O
final O
dose O
of O
hdarac B-DRUG

because O
nephrotic B-ADR
syndrome I-ADR
may O
be O
induced O
by O
ifn B-DRUG
therapy O
, O
the O
ifn B-DRUG
was O
stopped O

we O
present O
a O
46-year-old O
african-american O
man O
with O
aids O
who O
was O
admitted O
on O
two O
different O
occasions O
within O
three O
weeks O
for O
signs O
and O
symptoms O
of O
meningitis B-ADR
after O
using O
trimethoprim O
/ O
sulfamethoxazole O
( O
tmp B-DRUG
/ O
smx O

gynecomastia B-ADR
in O
epileptics O
treated O
with O
phenobarbital B-DRUG
, O
phenytoin O
and O
fluoresone O
: O
two O
case O
reports O

evidence O
is O
shown O
in O
this O
report O
that O
adenosine B-DRUG
was O
associated O
with O
dangerous O
worsening O
of O
arrhythmia B-ADR
in O
patients O
with O
atrial O
flutter O

less O
common O
adverse O
events O
to O
dapsone B-DRUG
include O
the O
idiosyncratic O
reactions O
of O
leukopenia O
and O
agranulocytosis O
, O
cutaneous O
eruptions O
, O
peripheral O
neuropathy O
, O
psychosis O
, O
toxic O
hepatitis O
, O
cholestatic O
jaundice O
, O
nephrotic O
syndrome O
, O
renal O
papillary O
necrosis O
, O
severe O
hypoalbuminemia O
without O
proteinuria O
, O
an O
infectious O
mononucleosis-like O
syndrome O
, O
and O
minor B-ADR
neurological I-ADR
and I-ADR
gastrointestinal I-ADR
complaints I-ADR

an O
association O
of O
granulocytopenia O
, O
eosinophilia B-ADR
, O
skin O
reaction O
and O
hepatitis O
during O
propylthiouracil O
( O
ptu B-DRUG
) O
therapy O
for O
thyrotoxicosis O
in O
a O
47 O
year O
old O
black O
female O
is O
reported O

tacrolimus-induced O
hus B-ADR
: O
an O
unusual O
cause O
of O
acute O
renal O
failure O
in O
nephrotic O
syndrome O

sagittal B-ADR
sinus I-ADR
thrombosis I-ADR
associated O
with O
transient O
free O
protein O
s O
deficiency O
after O
l-asparaginase B-DRUG
treatment O
: O
case O
report O
and O
review O
of O
the O
literature O

2-cda B-DRUG
induces O
lymphocytopenia B-ADR
, O
which O
may O
explain O
the O
improvement O
in O
this O
patient O
's O
psoriasis O

seizures B-ADR
occurred O
in O
two O
patients O
with O
probable O
alzheimer O
's O
disease O
who O
were O
receiving O
long-term O
treatment O
with O
metrifonate B-DRUG
, O
an O
irreversible O
acetylcholinesterase O
inhibitor O

flurbiprofen-associated O
acute B-ADR
tubulointerstitial I-ADR
nephritis I-ADR

without O
other O
causes O
for O
the O
hyponatremia O
, O
she O
was O
diagnosed O
with O
the O
syndrome B-ADR
of I-ADR
inappropriate I-ADR
antidiuretic I-ADR
hormone I-ADR
, O
presumably O
caused O
by O
desmopressin B-DRUG

in O
addition O
to O
its O
known O
effect O
on O
gallbladder B-ADR
stasis I-ADR
, O
octreotide B-DRUG
alters O
bile O
acid O
composition O
and O
may O
thus O
hasten O
intrahepatic O
sludge O
and O
stone O
formation O

a O
17-year-old O
female O
patient O
who O
had O
been O
taking O
oral O
minocycline B-DRUG
( O
50 O
mg O
twice O
daily O
) O
for O
3 O
weeks O
for O
acne O
developed O
an O
eruption B-ADR
that O
progressed O
to O
an O
exfoliative O
dermatitis O

we O
report O
a O
patient O
with O
type O
2 O
diabetes O
mellitus O
who O
, O
while O
treated O
with O
the O
antitumor O
necrosis O
factor-alpha O
blocking O
agent O
etanercept B-DRUG
for O
severe O
plaque O
psoriasis O
, O
experienced O
persistent B-ADR
hypoglycemia I-ADR
requiring O
the O
lowering O
and O
eventual O
elimination O
of O
his O
previous O
insulin O
regimen O

despite O
a O
response O
of O
the O
meningeal O
tumor O
the O
patient O
developed O
in O
the O
third O
week O
of O
mtx O
treatment O
a O
progressive B-ADR
visual I-ADR
loss I-ADR
and O
loss O
of O
consciousness O
which O
worsened O
during O
subsequent O
ara-c B-DRUG
treatment O
and O
led O
to O
death O
within O
3 O
weeks O

observations O
: O
a O
48-year-old O
woman O
presented O
with O
disfiguring B-ADR
facial I-ADR
edema I-ADR
10 O
weeks O
after O
she O
began O
antiviral O
therapy O
with O
peginterferon O
alfa-2a O
and O
ribavirin B-DRUG
for O
chronic O
hepatitis O
c O
infection O

fatal B-ADR
pulmonary I-ADR
fibrosis I-ADR
induced O
by O
paclitaxel B-DRUG
: O
a O
case O
report O
and O
review O
of O
the O
literature O

disseminated B-ADR
salmonellosis I-ADR
in O
a O
patient O
treated O
with O
temozolomide B-DRUG

the O
5 O
patients O
had O
severe O
renovascular O
disease O
which O
might O
thus O
represent O
a O
significant O
risk O
factor O
in O
the O
development O
of O
captopril-induced O
acute B-ADR
renal I-ADR
failure I-ADR

a O
2-year-old O
mentally O
retarded O
boy O
with O
frontal O
lobe O
epilepsy O
presented O
with O
an O
episode O
that O
resembled O
heat B-ADR
stroke I-ADR
during O
the O
administration O
of O
zonisamide B-DRUG

retinal B-ADR
abnormalities I-ADR
, O
including O
retinal O
hemorrhage O
and O
" O
cotton-wool O
" O
spots O
, O
often O
occur O
within O
the O
first O
8 O
weeks O
in O
the O
course O
of O
interferon B-DRUG
therapy O
in O
patients O
with O
chronic O
hepatitis O
c O

a O
53-year-old O
man O
developed O
lower B-ADR
leg I-ADR
edema I-ADR
4 O
weeks O
after O
rosiglitazone B-DRUG
was O
increased O
from O
4 O
mg O
once O
/ O
day O
to O
4 O
mg O
twice O
/ O
day O

we O
report O
the O
case O
of O
a O
patient O
who O
developed O
polyserositis O
( O
pericardial O
effusion O
, O
pleural O
effusion O
, O
and O
pericarditis B-ADR
) O
after O
being O
started O
on O
clozapine B-DRUG
, O
and O
whose O
symptoms O
remitted O
upon O
discontinuation O
of O
clozapine B-DRUG

a O
depressed O
woman O
with O
no O
history O
of O
bipolar O
illness O
developed O
a O
manic B-ADR
episode I-ADR
during O
treatment O
with O
fluoxetine B-DRUG

during O
her O
third O
cycle O
, O
she O
again O
received O
cisplatin B-DRUG
100 O
mg O
/ O
m2 O
over O
30 O
minutes O
and O
developed O
palmar O
pruritus O
, O
urticaria B-ADR
, O
and O
edema O

after O
discontinuing O
captopril B-DRUG
and O
starting O
systemic O
steroids O
, O
her O
symptomatology O
rapidly O
improved O
, O
and O
her O
eosinophilia B-ADR
and O
radiographic O
abnormalities O
both O
resolved O

we O
report O
a O
case O
of O
severe B-ADR
anemia I-ADR
, O
which O
responded O
well O
to O
steroid O
therapy O
, O
in O
a O
patient O
receiving O
il-2 B-DRUG
plus O
ifn-alpha O
for O
metastatic O
renal O
cell O
carcinoma O

heat B-ADR
stroke-like I-ADR
episode I-ADR
in O
a O
child O
caused O
by O
zonisamide B-DRUG

a O
58-yr-old O
male O
patient O
with O
essential O
thrombocythaemia O
( O
et O
) O
developed O
chronic B-ADR
myeloid I-ADR
leukaemia I-ADR
( O
cml O
) O
after O
continuous O
uneventful O
treatment O
with O
hydroxyurea B-DRUG
for O
18 O
yr O

two O
years O
later O
, O
24 O
hours O
following O
an O
increase O
in O
the O
dose O
of O
disopyramide B-DRUG
from O
300 O
to O
600 O
mg O
/ O
day O
, O
avt O
with O
syncope B-ADR
occurred O
; O
isoproterenol O
abolished O
the O
arrhythmia O
instantly O

an O
amiodarone B-DRUG
optic B-ADR
neuropathy I-ADR
has O
been O
described O

a O
case O
of O
acute B-ADR
respiratory I-ADR
failure I-ADR
due O
to O
diaphragmatic O
weakness O
following O
adalimumab B-DRUG
therapy O
for O
psoriasis O
is O
described O

the O
clinical O
aspect O
closely O
resembled O
classical O
transient O
global O
amnesia O
but O
the O
episode O
after O
clioquinol B-DRUG
lasted O
longer O
( O
24 O
hours O
to O
three O
days O
) O
and O
a O
more O
or O
less O
extensive O
retrograde B-ADR
amnesia I-ADR
persisted O
permanently O

three O
male O
patients O
aged O
78-83 O
years O
are O
presented O
, O
in O
whom O
severe B-ADR
hepatotoxic I-ADR
reactions I-ADR
emerged O
after O
cpa B-DRUG
administration O

hepatotoxicity B-ADR
associated O
with O
6-thioguanine B-DRUG
therapy O
for O
crohn O
's O
disease O

serotonin B-ADR
syndrome I-ADR
induced O
by O
transitioning O
from O
phenelzine O
to O
venlafaxine B-DRUG
: O
four O
patient O
reports O

a O
third O
patient O
experienced O
disabling B-ADR
neurotoxicity I-ADR
in O
the O
extremity O
of O
a O
prior O
ulnar O
nerve O
and O
tendon O
transposition O
after O
receiving O
paclitaxel B-DRUG

rapamycin B-DRUG
/ O
sirolimus O
( O
sr O
) O
, O
trade O
named O
rapammune O
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression O
, O
hypertension B-ADR
, O
hyperlipidemia O
, O
and O
infection O

we O
report O
an O
unusual O
case O
of O
massive O
fluoxetine B-DRUG
ingestion O
resulting O
in O
neurological O
and O
cardiovascular O
toxicity O
resulting O
in O
death B-ADR

however O
, O
adenosine B-DRUG
shortens O
the O
antegrade O
refractoriness O
of O
accessory O
atrioventricular O
connections O
and O
may O
cause O
acceleration B-ADR
of I-ADR
the I-ADR
ventricular I-ADR
rate I-ADR
during O
atrial O
fibrillation O

acute O
severe O
intoxication O
with O
carbamazepine B-DRUG
is O
associated O
with O
seizures B-ADR
, O
coma O
and O
respiratory O
depression O

discussion O
: O
the O
main O
adverse O
effects O
of O
leflunomide B-DRUG
consist O
of O
diarrhea O
, O
nausea O
, O
liver O
enzyme O
elevation O
, O
hypertension O
, O
alopecia O
, O
and O
allergic B-ADR
skin I-ADR
reactions I-ADR

we O
experienced O
a O
male O
patient O
with O
psoriasis O
and O
hypertension O
whose O
conditions O
were O
treated O
with O
tacalcitol B-DRUG
ointment O
and O
thiazide O
, O
respectively O
, O
resulting O
in O
hypercalciuria B-ADR
and O
hypercalcemia O

all O
patients O
had O
taken O
phenytoin B-DRUG
for O
variable O
time O
periods O
( O
range O
16-80 O
days O
; O
mean O
: O
40 O
) O
and O
were O
on O
the O
medication O
when O
the O
skin B-ADR
lesions I-ADR
first O
appeared O

two O
cases O
of O
sirolimus-associated O
pneumonitis B-ADR
have O
been O
reported O
after O
cardiac O
transplantation O

four O
weeks O
earlier O
she O
had O
developed O
hepatopathy B-ADR
during O
a O
regimen O
of O
carbamazepine O
, O
lynestrenol B-DRUG
and O
sodium O
valproate O

methods O
: O
the O
patient O
required O
insulin B-DRUG
desensitization O
for O
severe O
urticaria O
, O
angioedema O
, O
and O
occasional O
wheezing B-ADR
resulting O
from O
her O
insulin B-DRUG
dose O

rhabdomyolysis B-ADR
following O
clarithromycin B-DRUG
monotherapy O

the O
toxicity B-ADR
and O
plasma O
concentrations O
of O
ifosfamide O
, O
chloroacetaldehyde B-DRUG
, O
and O
4-hydroxyifosfamide O
were O
then O
determined O
over O
24 O
h O
after O
a O
single O
1.6 O
g O
/ O
m2 O
dose O
of O
ifosfamide O

clozapine-induced O
akathisia B-ADR
in O
children O
with O
schizophrenia O

acute B-ADR
hemorrhagic I-ADR
gastritis I-ADR
associated O
with O
acetazolamide B-DRUG
intoxication O
in O
a O
patient O
with O
chronic O
renal O
failure O

traumatic O
late O
flap O
dehiscence O
and O
enterobacter B-ADR
keratitis I-ADR
following O
lasik B-DRUG

this O
paper O
reports O
an O
autopsy O
case O
of O
a O
78-year-old O
male O
with O
multiple B-ADR
nodules I-ADR
in I-ADR
the I-ADR
liver I-ADR
developed O
after O
long-termed O
administration O
of O
phosphate B-DRUG
diethylstilbestrol I-DRUG
( O
pdes O
) O
for O
prostatic O
cancer O

we O
describe O
a O
patient O
who O
, O
after O
receiving O
his O
first O
dose O
of O
pregabalin B-DRUG
to O
relieve O
neuropathic O
pain O
, O
presented O
with O
a O
negative B-ADR
myoclonus I-ADR

we O
report O
a O
53-year-old-man O
who O
developed O
rippling B-ADR
muscle I-ADR
disease I-ADR
( O
rmd O
) O
2 O
months O
after O
starting O
simvastatin B-DRUG
therapy O
for O
hypercholesterolemia O

the O
association O
between O
heparin B-DRUG
and O
priapism O
is O
often O
recognized O
; O
abnormal B-ADR
platelet I-ADR
aggregation I-ADR
could O
play O
a O
role O
in O
the O
pathogenesis O
of O
this O
side O
effect O

we O
report O
two O
cases O
of O
tenofovir O
( O
tdf B-DRUG
)- O
associated O
nephrotoxicity B-ADR
in O
perinatally O
hiv-infected O
adolescents O

the O
cause O
of O
these O
previously O
unreported O
side O
effects O
of O
niacin B-DRUG
therapy O
is O
uncertain O
but O
may O
be O
related O
to O
prostaglandin-mediated O
vasodilatation O
, O
hyperalgesia O
of O
sensory O
nerve O
receptors O
, O
and O
potentiation O
of O
inflammation O
in O
the O
gingiva O
with O
referral O
of O
pain B-ADR
to I-ADR
the I-ADR
teeth I-ADR

the O
occurrence O
of O
symptoms O
that O
could O
be O
ascribed O
to O
an O
acute B-ADR
coronary I-ADR
syndrome I-ADR
should O
always O
be O
taken O
seriously O
during O
the O
first O
rituximab B-DRUG
infusion O
and O
investigated O
aggressively O

after O
administration O
of O
oxybutynin B-DRUG
concomitantly O
with O
an O
increase O
in O
the O
dose O
of O
dantrolene O
, O
she O
presented O
the O
clinical O
symptoms O
and O
laboratory O
finding O
of O
carbamazepine B-ADR
intoxication I-ADR

sulfasalazine B-DRUG
has O
been O
associated O
with O
bronchopulmonary B-ADR
complications I-ADR
of I-ADR
inflammatory I-ADR
bowel I-ADR
disease I-ADR
( O
ibd O
) O
in O
adults O

the O
day O
after O
clozapine B-DRUG
was O
stopped O
, O
while O
he O
was O
still O
receiving O
clomipramine O
150 O
mg O
/ O
d O
, O
he O
began O
behaving O
oddly O
, O
started O
sweating O
profusely O
, O
shivering B-ADR
, O
and O
became O
tremulous O
, O
agitated O
, O
and O
confused O

however O
, O
in O
the O
mid-to-late O
1980s O
, O
a O
series O
of O
letters O
to O
the O
editor O
and O
case O
reports O
announced O
an O
association O
between O
tamoxifen B-DRUG
therapy O
in O
women O
with O
breast O
cancer O
and O
the O
development O
of O
endometrial B-ADR
carcinoma I-ADR

the O
knowledge O
concerning O
vgb-associated O
visual B-ADR
dysfunction I-ADR
in O
pediatric O
patients O
, O
particularly O
in O
those O
who O
have O
been O
exposed O
to O
vgb B-DRUG
in O
utero O
is O
limited O

case O
report O
: O
mannitol B-DRUG
nephrotoxicity B-ADR
syndrome I-ADR
: O
role O
of O
hemodialysis O
and O
postulate O
of O
mechanisms O

we O
have O
described O
three O
patients O
with O
hepatitis O
c O
for O
whom O
ifn-alpha O
and O
ribavirin B-DRUG
were O
prescribed O
and O
who O
developed O
two O
successive O
phases O
of O
silent O
thyroiditis B-ADR
followed O
by O
hyperthryroidism O
relapse O
due O
to O
graves' O
disease O

azathioprine B-DRUG
can O
cause O
severe O
myelosuppression B-ADR

autoimmune B-ADR
thyroid I-ADR
disease I-ADR
is O
a O
common O
side-effect O
of O
interferon-alpha O
( O
ifn-alpha B-DRUG
) O
treatment O
of O
viral O
hepatitis O
c O

objective O
: O
the O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
desensitization O
to O
nph B-DRUG
insulin I-DRUG
, O
as O
well O
as O
standard O
insulin O
desensitization O
, O
could O
control O
allergic B-ADR
symptoms I-ADR
in O
a O
patient O
allergic O
to O
both O
nph O
and O
regular O
insulin O

dihydropyrimidine O
dehydrogenase O
deficiency O
: O
a O
pharmacogenetic O
defect O
causing O
severe B-ADR
adverse I-ADR
reactions I-ADR
to O
5-fluorouracil-based O
chemotherapy O

colonic B-ADR
mucosal I-ADR
necrosis I-ADR
following O
administration O
of O
calcium B-DRUG
polystryrene I-DRUG
sulfonate I-DRUG
( O
kalimate O
) O
in O
a O
uremic O
patient O

an O
association O
of O
granulocytopenia O
, O
eosinophilia O
, O
skin O
reaction O
and O
hepatitis B-ADR
during O
propylthiouracil O
( O
ptu B-DRUG
) O
therapy O
for O
thyrotoxicosis O
in O
a O
47 O
year O
old O
black O
female O
is O
reported O

mean O
time O
between O
initiation O
of O
gemcitabine B-DRUG
therapy O
and O
onset O
of O
hus B-ADR
was O
7.4 O
+/- O
3.5 O
months O
, O
or O
21.9 O
+/- O
10.9 O
doses O
of O
gemcitabine B-DRUG

ards B-ADR
has O
been O
associated O
with O
the O
administration O
of O
other O
monoclonal O
antibodies O
, O
such O
as O
infliximab O
, O
gemtuzumab O
ozogamicin O
, O
and O
okt3 B-DRUG
and O
is O
believed O
to O
be O
directly O
mediated O
by O
release O
of O
proinflammatory O
cytokines O

clofazimine B-DRUG
enteropathy B-ADR
in O
a O
pediatric O
bone O
marrow O
transplant O
recipient O

the O
pharmaceutical O
company O
producing O
halfan O
has O
reported O
8 O
cardiac O
arrests O
, O
leading O
to O
6 O
deaths B-ADR
, O
when O
a O
higher O
dose O
than O
recommended O
was O
used O
, O
there O
was O
recent O
or O
concomitant O
treatment O
with O
mefloquine B-DRUG
, O
there O
was O
pre-existing O
prolongation O
of O
the O
qt O
interval O
or O
the O
patient O
had O
a O
thiamine O
deficiency O

severe O
loss O
of O
vision O
after O
removal O
of O
cataract B-ADR
caused O
by O
intravitreal O
triamcinolone B-DRUG
in O
combination O
with O
photodynamic O
therapy O
for O
exudative O
age-related O
macular O
degeneration O

this O
is O
a O
unique O
autopsy O
case O
of O
hepatocellular B-ADR
carcinoma I-ADR
closely O
related O
to O
diethylstilbestrol O
( O
des B-DRUG
) O
therapy O
for O
prostatic O
cancer O

the O
interval O
between O
initiating O
treatment O
with O
interferon B-DRUG
alfa I-DRUG
and O
onset O
of O
anterior B-ADR
ischemic I-ADR
optic I-ADR
neuropathy I-ADR
was O
similar O
to O
that O
of O
interferon-associated O
vascular O
retinopathy O

listeria B-ADR
brain I-ADR
abscess I-ADR
, O
pneumocystis O
pneumonia O
and O
kaposi O
's O
sarcoma O
after O
temozolomide B-DRUG

the O
possible O
effects O
of O
tamoxifen B-DRUG
upon O
the O
uterus O
are O
discussed O
in O
this O
article O
, O
in O
view O
of O
reports O
of O
tamoxifen B-DRUG
associated O
with O
endometrial B-ADR
carcinoma I-ADR
and O
endometriosis O

aminophylline B-ADR
hypersensitivity I-ADR
apparently O
due O
to O
ethylenediamine B-DRUG

a O
44-year-old O
woman O
is O
described O
in O
whom O
amiodarone B-DRUG
, O
disopyramide O
, O
and O
quinidine O
, O
administered O
alone O
separately O
, O
induced O
atypical O
ventricular O
tachycardia O
( O
avt B-ADR
, O
torsade O
de O
pointes O

we O
report O
the O
case O
of O
a O
51-year-old O
man O
in O
whom O
ifn-alpha B-DRUG
treatment O
was O
followed O
by O
recurrence O
of O
graves' B-ADR
disease I-ADR
10 O
years O
after O
thyroidectomy O
was O
performed O
and O
the O
patient O
was O
declared O
cured O

thrombotic B-ADR
thrombocytopenic I-ADR
purpura I-ADR
induced O
by O
trimethoprim-sulfamethoxazole O
in O
a O
jehovah O
's O
witness O

discussion O
: O
amphotericin B-DRUG
b I-DRUG
deoxycholate I-DRUG
has O
been O
reported O
to O
produce O
significant O
cardiac O
toxicity O
, O
with O
ventricular O
arrhythmias O
and O
bradycardia B-ADR
reported O
in O
overdoses O
in O
children O
and O
in O
adults O
with O
preexisting O
cardiac O
disease O
, O
even O
when O
administered O
in O
conventional O
dosages O
and O
infusion O
rates O

acute B-ADR
sensorineural I-ADR
hearing I-ADR
loss I-ADR
following O
intravenous O
ketoralac B-DRUG
administration O

after O
rechallenge O
with O
monotherapy O
pegvisomant B-DRUG
, O
however O
, O
the O
hepatic B-ADR
enzyme I-ADR
disturbances I-ADR
reappeared O
within O
a O
few O
weeks O
, O
indicating O
that O
most O
likely O
pegvisomant B-DRUG
alone O
and O
not O
the O
long-acting O
somatostatin O
analog O
or O
the O
combination O
of O
these O
two O
drugs O
was O
responsible O
for O
this O
case O
of O
drug-induced O
hepatitis O

the O
case O
of O
an O
adult O
who O
developed O
both O
hepatic B-ADR
dysfunction I-ADR
and O
an O
impaired O
macrophage O
migration O
after O
exposure O
to O
cimetidine B-DRUG
is O
discussed O

heparin-induced O
thrombocytopenia O
complicated O
with O
massive B-ADR
thrombosis I-ADR
of I-ADR
the I-ADR
inferior I-ADR
vena I-ADR
cava I-ADR
after O
filter O
placement O

acute B-ADR
pancreatitis I-ADR
associated O
with O
danazol B-DRUG
treatment O
for O
endometriosis O

posterior B-ADR
reversible I-ADR
encephalopathy I-ADR
syndrome I-ADR
( O
pres B-DRUG
) O
induced O
by O
cyclosporine O
use O
in O
a O
patient O
with O
collapsing O
focal O
glomeruloesclerosis O

this O
case O
highlights O
the O
need O
to O
monitor O
liver O
enzymes O
in O
patients O
treated O
with O
6-tg O
and O
identifies O
the O
need O
for O
additional O
research O
focused O
on O
the O
mechanism O
of O
thiopurine-induced O
hepatic B-ADR
injury I-ADR

mannitol-induced O
arf B-ADR
responds O
promptly O
to O
hemodialysis O
with O
rapid O
resolution O
of O
anuria O
and O
recovery O
of O
renal O
failure O

the O
authors O
also O
determined O
that O
their O
case O
of O
myositis O
developing O
in O
the O
rectus O
abdominus O
muscle O
of O
a O
patient O
with O
pancreatic O
adenocarcinoma O
was O
the O
manifestation O
of O
radiation B-ADR
recall I-ADR
, O
thereby O
bringing O
the O
number O
of O
patients O
who O
developed O
radiation B-ADR
recall I-ADR
to O
gemcitabine B-DRUG
and O
were O
discussed O
in O
the O
current O
study O
to O
13 O

after O
the O
addition O
of O
citalopram B-DRUG
, O
a O
desmethylclomipramine O
plasma O
level O
increase O
and O
an O
8-hydroacy-desmethylclomipramine B-ADR
plasma I-ADR
level I-ADR
decrease I-ADR
were O
observed O

the O
authors O
present O
an O
elderly O
patient O
with O
mixed O
dementia O
who O
developed O
td B-ADR
at O
multiple O
sites O
, O
( O
including O
respiratory O
dyskinesia O
[ O
rd O
] O
, O
limb O
dyskinesia O
, O
and O
orofacial O
dyskinesia O
) O
following O
abrupt O
withdrawal O
of O
risperidone B-DRUG
therapy O

mr O
findings O
in O
methotrexate-induced O
cns B-ADR
abnormalities I-ADR

transient O
left O
homonymous O
hemianopsia O
and O
encephalopathy B-ADR
following O
treatment O
of O
testicular O
carcinoma O
with O
cisplatinum B-DRUG
, O
vinblastine O
, O
and O
bleomycin O

three O
patients O
developed O
proteinuria B-ADR
following O
gold B-DRUG
therapy O
for O
rheumatoid O
arthritis O

the O
mechanism O
of O
the O
decrease B-ADR
in I-ADR
plasma I-ADR
potassium I-ADR
induced O
by O
phosphate B-DRUG
treatment O
was O
investigated O
in O
a O
24-year-old O
hypertensive O
patient O
with O
hypophosphatemic O
osteomalacia O
, O
who O
was O
the O
youngest O
of O
four O
patients O
, O
belonging O
to O
a O
23 O
number O
kindred O
of O
five O
generations O

background O
: O
we O
describe O
the O
ophthalmic O
features O
and O
clinical O
course O
of O
two O
cases O
of O
acute B-ADR
syphilitic I-ADR
posterior I-ADR
placoid I-ADR
chorioretinitis I-ADR
( O
asppc O
) O
that O
developed O
after O
intravitreal O
triamcinolone B-DRUG
acetonide I-DRUG
( O
ivta O
) O
injection O

diffuse B-ADR
alveolar I-ADR
hemorrhage I-ADR
after O
leflunomide B-DRUG
therapy O
in O
a O
patient O
with O
rheumatoid O
arthritis O

case O
4 O
: O
a O
61-year-old O
male O
alcoholic O
who O
remained O
completely O
abstinent O
while O
taking O
cyanamide B-DRUG
for O
3 O
years O
showed O
slight O
elevation B-ADR
of I-ADR
serum I-ADR
transaminases I-ADR

our O
case O
points O
to O
the O
need O
for O
increased O
awareness O
by O
the O
general O
pediatricians O
of O
the O
potential B-ADR
hazards I-ADR
of O
mineral B-DRUG
oil I-DRUG
use O
for O
chronic O
constipation O

prenatal O
cytomegalovirus O
( O
cmv O
) O
infection O
associated O
with O
severe O
brain O
damage O
was O
detected O
in O
an O
infant O
whose O
mother O
had O
been O
treated O
with O
prednisolone B-DRUG
and O
azathioprine O
for O
systemic O
lupus O
erythematosus O
( O
sle O

heparin-induced O
thrombocytopenia B-ADR
is O
a O
rare O
and O
serious O
complication O
of O
anticoagulation O
therapy O

l-dopa-induced O
excessive O
daytime B-ADR
sleepiness I-ADR
in O
pd O
: O
a O
placebo-controlled O
case O
with O
mslt O
assessment O

ards O
is O
rarely O
associated O
with O
rituximab B-DRUG
infusion O
for O
lympho-proliferative O
disorders O
, O
but O
it O
should O
be O
considered O
by O
those O
administering O
rituximab B-DRUG
, O
especially O
when O
a O
patient O
develops O
severe B-ADR
pulmonary I-ADR
symptoms I-ADR
soon O
after O
infusion O

we O
report O
here O
two O
cases O
of O
dyserythropoietic B-ADR
anaemia I-ADR
associated O
with O
long-term O
linezolid B-DRUG
use O
that O
share O
striking O
similarities O
to O
chloramphenicol-associated O
myelotoxicity O

clofazimine B-DRUG
enteropathy O
caused O
by O
crystal O
deposition O
can O
be O
life-threatening B-ADR

therapy O
with O
ifn-alpha B-DRUG
may O
be O
associated O
with O
a O
number O
of O
neuropsychiatric O
symptoms O
, O
such O
as O
parkinsonism O
, O
akathisia O
, O
seizure O
, O
and O
depressive B-ADR
disorders I-ADR

hepatitis O
with O
bridging O
fibrosis O
and O
reversible B-ADR
hepatic I-ADR
insufficiency I-ADR
in O
a O
woman O
with O
rheumatoid O
arthritis O
taking O
methotrexate B-DRUG

after O
three O
weeks O
of O
carbamazepine B-DRUG
therapy O
, O
the O
patient O
arrived O
at O
the O
emergency O
department O
( O
ed O
) O
with O
severe O
agitation O
and O
aggressive B-ADR
behavior I-ADR

drug-induced O
hepatitis B-ADR
in O
an O
acromegalic O
patient O
during O
combined O
treatment O
with O
pegvisomant O
and O
octreotide B-DRUG
long-acting O
repeatable O
attributed O
to O
the O
use O
of O
pegvisomant O

to O
the O
best O
of O
our O
knowledge O
only O
two O
previous O
cases O
of O
aml B-ADR
have O
been O
linked O
to O
treatment O
of O
hcl O
with O
purine O
analogs O
, O
both O
with O
2-chlorodeoxyadenosine B-DRUG

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate B-DRUG
with O
folinic O
acid O
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia B-ADR
, O
hyperkalaemia O
and O
hyperphosphataemia O
with O
hypocalcaemia O
and O
tetany O
, O
with O
metabolic O
acidosis O
and O
acute O
renal O
impairment O
) O
are O
described O

gemcitabine-associated O
hemolytic-uremic B-ADR
syndrome I-ADR

the O
third O
patient O
had O
been O
suffering O
from O
serious O
akathisia B-ADR
while O
on O
risperidone B-DRUG
, O
and O
was O
cured O
after O
switching O
to O
olanzapine O
, O
but O
thereafter O
the O
patient O
suffered O
from O
rls O
at O
nighttime O

in O
case O
no O
. O
2 O
, O
the O
pathogenic O
mechanism O
seemed O
to O
be O
persistent O
light O
reaction O
preceded O
by O
systemic O
photoallergy O
, O
as O
he O
had O
taken O
mequitazine B-DRUG
for O
6 O
months O
, O
and O
there O
were O
strong O
positive O
photopatch O
test O
results O
with O
immediate O
erythema B-ADR
reaction O
, O
cross-reaction O
to O
promethazine O
, O
decreased O
med O
to O
both O
uva O
and O
uvb O
, O
and O
persistence O
of O
the O
photosensitivity O
over O
a O
3-year O
follow-up O
period O
after O
discontinuation O
of O
the O
mequitazine B-DRUG

a O
patient O
with O
acute O
changes O
suggesting O
acute B-ADR
hepatitis I-ADR
after O
parenteral O
amiodarone B-DRUG
administration O
is O
described O

nonoliguric B-ADR
acute I-ADR
renal I-ADR
failure I-ADR
after O
captopril B-DRUG
therapy O

we O
postulate O
that O
cyclosporin O
, O
possibly O
together O
with O
ganciclovir B-DRUG
, O
can O
produce O
transient O
brain O
stem O
or O
neuromuscular O
dysfunction O
with O
eye B-ADR
movement I-ADR
abnormality I-ADR
in O
occasional O
patients O

osteomyelitis B-ADR
occurring O
during O
infliximab B-DRUG
treatment O
of O
severe O
psoriasis O

intravenous O
administration O
of O
levodopa O
ameliorated O
a O
refractory O
akathisia B-ADR
case O
induced O
by O
interferon-alpha B-DRUG

acute O
severe O
intoxication O
with O
carbamazepine B-DRUG
is O
associated O
with O
seizures O
, O
coma O
and O
respiratory B-ADR
depression I-ADR

accordingly O
, O
camptocormia B-ADR
is O
a O
dose-dependent O
side O
effect O
of O
valproate B-DRUG

hypersensitivity B-ADR
to O
carboplatin B-DRUG
has O
been O
reported O
in O
up O
to O
44 O
% O
of O
patients O
receiving O
this O
antineoplastic O
agent O
, O
usually O
occurring O
after O
several O
courses O
of O
treatment O

gemcitabine-related O
radiation B-ADR
recall I-ADR
preferentially O
involves O
internal O
tissue O
and O
organs O

we O
report O
a O
case O
of O
a O
previously O
healthy O
, O
postmenopausal O
woman O
who O
developed O
anticonvulsant B-ADR
hypersensitivity I-ADR
syndrome I-ADR
while O
taking O
bellamine B-DRUG
s I-DRUG
( O
belladonna O
alkaloids O
; O
ergotamine O
; O
phenobarbital O
) O
for O
hot O
flashes O

nephrotic B-ADR
syndrome I-ADR
associated O
with O
interferon-beta-1b B-DRUG
therapy O
for O
multiple O
sclerosis O

although O
this O
combination O
agent O
has O
been O
associated O
with O
a O
hypersensitivity O
syndrome O
involving O
cutaneous O
skin O
eruptions O
, O
pediatric O
cases O
of O
tmp-smx-induced O
hepatotoxicity B-ADR
are O
rare O

background O
: O
to O
assess O
the O
nature O
, O
incidence O
, O
and O
risk O
factors O
of O
retinopathy B-ADR
associated O
with O
pegylated B-DRUG
interferon I-DRUG
and O
ribavirin O
combination O
therapy O
in O
chronic O
hepatitis O
c O
patients O

objective O
: O
to O
describe O
two O
cases O
of O
rhabdomyolysis B-ADR
in O
patients O
taking O
lovastatin O
that O
were O
precipitated O
by O
the O
use O
of O
the O
newer O
macrolide O
antibiotics O
clarithromycin B-DRUG
and O
azithromycin O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever B-ADR
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp O
)- O
sulfamethoxazole O
( O
smx B-DRUG
) O
treatment O

results O
: O
a O
44-year-old O
man O
taking O
naproxen O
for O
chronic O
low O
back O
pain O
and O
a O
20-year-old O
woman O
on O
oxaprozin B-DRUG
for O
rheumatoid O
arthritis O
presented O
with O
tense B-ADR
bullae I-ADR
and O
cutaneous O
fragility O
on O
the O
face O
and O
the O
back O
of O
the O
hands O

the O
cases O
of O
cbz-induced O
sle B-ADR
reported O
in O
the O
literature O
were O
reviewed O

prenatal O
cytomegalovirus O
( O
cmv O
) O
infection O
associated O
with O
severe O
brain B-ADR
damage I-ADR
was O
detected O
in O
an O
infant O
whose O
mother O
had O
been O
treated O
with O
prednisolone B-DRUG
and O
azathioprine O
for O
systemic O
lupus O
erythematosus O
( O
sle O

paradoxical O
seizures B-ADR
in O
phenytoin B-DRUG
toxicity O

delay B-ADR
of I-ADR
corneal I-ADR
wound I-ADR
healing I-ADR
in O
patients O
treated O
with O
colchicine B-DRUG

the O
relation O
between O
tacrolimus B-DRUG
treatment O
and O
staining O
was O
suggested O
by O
the O
appearance O
of O
pigmentation B-ADR
during O
topical O
tacrolimus B-DRUG
treatment O
and O
its O
clinical O
disappearance O
when O
treatment O
was O
stopped O

however O
, O
there O
remain O
questions O
concerning O
whether O
these O
drugs O
, O
especially O
methimazole O
( O
mmi B-DRUG
) O
, O
may O
be O
associated O
with O
aplasia O
cutis O
congenita O
( O
acc B-ADR
) O
and O
how O
best O
to O
avoid O
impairment O
of O
fetal O
thyroid O
function O
during O
their O
use O

while O
on O
a O
maximal O
dose O
of O
phenylephrine B-DRUG
she O
developed O
prominent O
positive B-ADR
u I-ADR
waves I-ADR
, O
which O
disappeared O
with O
the O
cessation O
of O
the O
drug O

the O
case O
histories O
are O
presented O
of O
two O
patients O
who O
developed O
lung O
disease O
associated O
with O
the O
use O
of O
nitrofurantoin B-DRUG
with O
histological O
features O
of O
bronchiolitis O
obliterans O
organising O
pneumonia O
( O
boop B-ADR
) O
, O
a O
rare O
but O
recognised O
form O
of O
drug O
induced O
injury O

generalized B-ADR
maculopapular I-ADR
and I-ADR
papular I-ADR
purpuric I-ADR
eruptions I-ADR
are O
perhaps O
the O
most O
common O
thionamide-induced O
reactions O

although O
the O
two O
local O
anesthetics O
usually O
do O
not O
cause O
methemoglobinemia B-ADR
, O
we O
suspect O
that O
the O
displacement O
of O
lidocaine B-DRUG
from O
protein O
binding O
by O
bupivacaine O
, O
in O
combination O
with O
metabolic O
acidosis O
and O
treatment O
with O
other O
oxidants O
, O
was O
the O
reason O
for O
the O
development O
of O
methemoglobinemia B-ADR

we O
report O
a O
case O
of O
a O
young O
woman O
with O
sle O
and O
thrombocytopenia O
, O
who O
developed O
severe B-ADR
perspiration I-ADR
, O
headache O
, O
and O
seizure O
after O
receiving O
cyclosporine B-DRUG

we O
report O
the O
first O
case O
of O
fulminant O
adult B-ADR
respiratory I-ADR
distress I-ADR
syndrome I-ADR
( O
ards O
) O
associated O
with O
pegylated O
interferon O
alpha-2a O
( O
pegifnalpha-2a O
) O
and O
ribavirin B-DRUG
use O
for O
hepatitis O
c O
, O
complicated O
by O
subsequent O
and O
ultimately O
fatal O
sepsis O
and O
multiorgan O
failure O

background O
: O
methotrexate O
( O
mtx B-DRUG
) O
may O
induce O
liver O
damage O
, O
which O
in O
some O
psoriatics O
will O
lead O
to O
fibrosis O
or O
cirrhosis B-ADR

ten O
days O
after O
itraconazole B-DRUG
was O
started O
, O
he O
developed O
paralytic O
ileus O
, O
neurogenic O
bladder O
, O
mild O
left O
ptosis O
, O
and O
absence B-ADR
of I-ADR
deep I-ADR
reflexes I-ADR
, O
with O
severe O
paralysis O
of O
the O
lower O
extremities O
and O
mild O
weakness O
of O
the O
upper O
extremities O

skin B-ADR
necrosis I-ADR
after O
extravasation O
of O
low-dose O
vasopressin B-DRUG
administered O
for O
septic O
shock O

subglottic B-ADR
stenosis I-ADR
in O
wegener O
's O
granulomatosis O
: O
development O
during O
cyclophosphamide B-DRUG
treatment O
with O
response O
to O
carbon O
dioxide O
laser O
therapy O

possible O
mechanisms O
by O
which O
clonidine B-DRUG
decreases O
spasticity O
are O
described O
, O
probable O
mechanisms O
of O
induced O
bradycardia B-ADR
are O
reviewed O
, O
and O
specific O
treatment O
recommendations O
for O
the O
use O
of O
clonidine B-DRUG
in O
spinal O
cord O
injured O
patients O
are O
presented O

eleven O
patients O
developed O
infection O
requiring O
hospitalization O
while O
taking O
leflunomide B-DRUG
including O
: O
lower O
respiratory O
tract O
infections O
( O
3 O
) O
, O
cellulitis O
( O
2 O
) O
, O
disseminated O
herpes O
zoster O
( O
2 O
) O
, O
probable O
tb O
liver O
( O
1 O
) O
, O
abdominal B-ADR
sepsis I-ADR
( O
1 O
) O
, O
mycotic O
aneurysm O
( O
1 O
) O
and O
gastroenteritis O
( O
1 O

administration O
of O
intravenous O
nitroglycerin B-DRUG
in O
a O
patient O
with O
idiopathic O
pulmonary O
hypertension O
resulted O
in O
an O
increase B-ADR
in I-ADR
pulmonary I-ADR
artery I-ADR
pressure I-ADR
associated O
with O
a O
decrease O
in O
blood O
flow O
that O
is O
best O
explained O
by O
an O
increase O
in O
pulmonary O
vascular O
resistance O

we O
describe O
a O
case O
of O
fibrosing B-ADR
alveolitis I-ADR
, O
diagnosed O
by O
lung O
biopsy O
, O
in O
a O
patient O
receiving O
amiodarone B-DRUG
which O
responded O
to O
corticosteroid O
therapy O

conclusions O
: O
topiramate B-DRUG
may O
be O
associated O
with O
ciliochoroidal O
effusion O
with O
forward O
displacement O
of O
the O
lens-iris O
diaphragm O
and O
anterior O
chamber O
shallowing O
, O
resulting O
in O
acute O
myopia O
and O
angle-closure B-ADR
glaucoma I-ADR

a O
44-year-old O
woman O
is O
described O
in O
whom O
amiodarone O
, O
disopyramide B-DRUG
, O
and O
quinidine O
, O
administered O
alone O
separately O
, O
induced O
atypical B-ADR
ventricular I-ADR
tachycardia I-ADR
( O
avt O
, O
torsade O
de O
pointes O

we O
report O
a O
case O
of O
acute B-ADR
generalized I-ADR
exanthematous I-ADR
pustulosis I-ADR
( O
agep O
) O
induced O
by O
salazosulfapyridine B-DRUG
in O
a O
patient O
with O
ulcerative O
colitis O

the O
patient O
experienced O
muscle O
twitches O
, O
tremulousness B-ADR
, O
and O
anxiety O
on O
day O
17 O
of O
foscarnet B-DRUG
therapy O

we O
describe O
a O
patient O
with O
a O
liver O
abscess O
due O
to O
entamoeba O
histolytica O
, O
in O
whom O
metronidazole B-DRUG
therapy O
( O
total O
dose O
, O
21 O
g O
over O
14 O
days O
) O
was O
complicated O
by O
reversible O
deafness O
, O
tinnitus B-ADR
, O
and O
ataxia O
and O
who O
relapsed O
5 O
months O
later O
with O
a O
splenic O
abscess O

this O
case O
report O
describes O
a O
patient O
who O
was O
previously O
prescribed O
alendronate B-DRUG
( O
fosamax O
) O
and O
presented O
with O
postoperative O
hypophosphatemia O
and O
hypocalcemic B-ADR
tetany I-ADR
after O
bowel O
preparation O
with O
fleet O
phospho-soda O

hypoglycemia O
can O
be O
a O
serious O
side O
effect O
of O
etanercept O
in O
patients O
already O
on O
antidiabetic O
medications O
known O
to O
cause O
hypoglycemia B-ADR
, O
such O
as O
sulfonylureas B-DRUG
, O
meglitinides O
, O
and O
insulin O

quinapril B-DRUG
is O
an O
angiotensin-converting O
enzyme O
inhibitor O
( O
ace-inhibitor O
) O
and O
overdose O
can O
lead O
to O
prolonged O
hypotension O
and O
, O
less O
frequently O
, O
transient B-ADR
renal I-ADR
impairment I-ADR

a O
62-year-old O
woman O
who O
was O
being O
treated O
for O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
developed O
a O
chemotherapy-related O
hemolytic-uremic B-ADR
syndrome I-ADR
during O
the O
second O
cycle O
of O
neoadjuvant O
chemotherapy O
consisting O
of O
cisplatin O
, O
bleomycin B-DRUG
, O
and O
methotrexate O

thirty-six O
patients O
with O
al O
received O
, O
in O
a O
three-month O
period O
, O
51 O
cycles O
of O
combined O
chemotherapy O
which O
included O
, O
in O
all O
of O
them O
, O
cytosine B-DRUG
arabinoside I-DRUG
( O
ara-c O
) O
; O
among O
them O
, O
along O
with O
myelosuppression O
, O
five O
experienced O
fever O
, O
infectious B-ADR
complications I-ADR
, O
gastrointestinal O
tract O
symptoms O
and O
severe O
myalgias O

interstitial B-ADR
pneumopathy I-ADR
and O
low-dosage O
amiodarone B-DRUG

cd4 B-ADR
t-lymphocyte I-ADR
depletion I-ADR
, O
myelosuppression O
, O
and O
subsequent O
severe O
infections O
are O
the O
major O
side O
effects O
of O
fludarabine B-DRUG
phosphate I-DRUG
therapy O

objective O
: O
to O
describe O
two O
cases O
of O
rhabdomyolysis B-ADR
in O
patients O
taking O
lovastatin O
that O
were O
precipitated O
by O
the O
use O
of O
the O
newer O
macrolide O
antibiotics O
clarithromycin O
and O
azithromycin B-DRUG

ticlopidine B-DRUG
is O
an O
oral O
antiplatelet O
agent O
frequently O
utilized O
in O
the O
treatment O
of O
cerebrovascular O
disease O
and O
is O
rarely O
associated O
with O
severe O
bone O
marrow O
suppression O
, O
typically O
aplastic B-ADR
anemia I-ADR

this O
report O
describes O
a O
case O
of O
flucytosine-associated O
ulcerating B-ADR
enteritis I-ADR
in O
which O
the O
small O
bowel O
x-ray O
demonstrated O
severe O
luminal O
narrowing O
, O
ulceration O
, O
and O
marked O
separation O
of O
loops O
of O
bowel O

fever O
, O
pulmonary B-ADR
infiltrates I-ADR
, O
and O
pleural O
effusion O
following O
acyclovir B-DRUG
therapy O
for O
herpes O
zoster O
ophthalmicus O

bronchiolitis B-ADR
obliterans I-ADR
organising I-ADR
pneumonia I-ADR
associated O
with O
the O
use O
of O
nitrofurantoin B-DRUG

therefore O
, O
we O
diagnosed O
her O
eruption B-ADR
as O
contact O
dermatitis O
due O
to O
sodium B-DRUG
bisulfite I-DRUG

thrombotic B-ADR
thrombocytopenic I-ADR
purpura I-ADR
( O
ttp O
) O
developed O
in O
a O
patient O
with O
seropositive O
rheumatoid O
arthritis O
( O
ra O
) O
after O
2 O
1 O
/ O
2 O
months O
of O
treatment O
with O
penicillamine B-DRUG

the O
day O
after O
clozapine O
was O
stopped O
, O
while O
he O
was O
still O
receiving O
clomipramine B-DRUG
150 O
mg O
/ O
d O
, O
he O
began O
behaving O
oddly O
, O
started O
sweating O
profusely O
, O
shivering O
, O
and O
became O
tremulous B-ADR
, O
agitated O
, O
and O
confused O

parenteral-verapamil-induced O
sustained B-ADR
hypotension I-ADR

patients O
: O
three O
patients O
developed O
a O
reproductive B-ADR
endocrine I-ADR
disorder I-ADR
during O
treatment O
with O
valproate B-DRUG

we O
report O
a O
case O
of O
thrombotic B-ADR
thrombocytopenic I-ADR
purpura I-ADR
occurring O
as O
an O
allergic O
response O
to O
trimethoprim-sulfamethoxazole O
therapy O
( O
bactrim O
, O
septra O
) O
in O
a O
jehovah O
's O
witness O
patient O

a O
58-year-old O
man O
with O
rheumatoid O
arthritis O
developed O
lichen B-ADR
planus I-ADR
during O
treatment O
with O
gold B-DRUG

two O
children O
, O
1 O
with O
idiopathic O
nephrotic O
syndrome O
and O
1 O
with O
endo-extracapillary O
glomerulonephritis O
, O
presented O
an O
episode O
of O
seizures O
and O
transient B-ADR
blindness I-ADR
at O
different O
times O
after O
i.v. O
pulse O
methylprednisolone B-DRUG
( O
ivpmp O
) O
treatment O

a O
68-year-old O
female O
patient O
with O
advanced O
ovarian O
carcinoma O
collapsed B-ADR
whilst O
receiving O
a O
carboplatin B-DRUG
and O
cyclophosphamide O
infusion O

progressive B-ADR
interstitial I-ADR
lung I-ADR
disease I-ADR
from O
prolonged O
methotrexate B-DRUG
therapy O

however O
, O
one O
patient O
exhibited O
severe O
hypersensitivity O
reactions O
including O
cardiac O
arrest O
and O
apnea B-ADR
, O
and O
another O
four O
patients O
developed O
eruptions O
, O
hypotension O
, O
and O
tachycardia O
soon O
after O
administration O
of O
cbdca B-DRUG

i O
report O
a O
35-year-old O
woman O
with O
occult O
coronary O
artery O
disease O
who O
experienced O
cardiac B-ADR
arrest I-ADR
within O
minutes O
after O
receiving O
a O
first-time O
dose O
of O
subcutaneous O
sumatriptan B-DRUG
for O
migraine O

following O
the O
institution O
of O
intravenous O
therapy O
with O
acyclovir B-DRUG
, O
the O
patient O
developed O
fever B-ADR
, O
hemoptysis O
, O
and O
a O
pleural O
friction O
rub O

our O
patient O
was O
a O
72-year-old O
man O
with O
advanced O
parkinson O
's O
disease O
( O
pd O
) O
who O
received O
levodopa B-DRUG
and O
anti-cholinergic O
drugs O
and O
whose O
head O
had O
become O
almost O
completely B-ADR
bald I-ADR

to O
develop O
information O
on O
the O
relative O
rarity O
or O
frequency O
of O
neurologic B-ADR
worsening I-ADR
with O
the O
initiation O
of O
penicillamine B-DRUG
therapy O
, O
we O
conducted O
a O
retrospective O
survey O
of O
25 O
additional O
patients O
with O
wilson O
's O
disease O
who O
met O
the O
criteria O
of O
presenting O
with O
neurologic O
disease O
and O
having O
been O
treated O
with O
penicillamine B-DRUG

a O
patient O
developed O
restless B-ADR
legs I-ADR
symptoms I-ADR
paralleling O
the O
course O
of O
interferon-alpha O
( O
ifn B-DRUG
alpha I-DRUG
) O
therapy O
for O
chronic O
hepatitis O
c O

four O
days O
after O
intravenous O
zoledronic B-DRUG
acid I-DRUG
, O
the O
patient O
presented O
to O
emergency O
room O
with O
complaints O
of O
carpopedal O
spasm O
and O
bronchospasm B-ADR

we O
report O
the O
case O
of O
an O
87-year-old O
white O
woman O
with O
myasthenia O
gravis O
who O
presented O
with O
nausea O
, O
shortness O
of O
breath O
, O
azotemia B-ADR
, O
and O
hyperkalemia O
shortly O
after O
completing O
a O
course O
of O
intravenous O
immunoglobulin O
( O
ivig B-DRUG

a O
noninvasive O
method O
in O
the O
differential O
diagnosis O
of O
vecuronium-induced O
and O
magnesium-induced O
protracted B-ADR
neuromuscular I-ADR
block I-ADR
in O
a O
severely O
preeclamptic O
patient O

it O
is O
increasingly O
recognized O
that O
dose O
adjustment O
of O
oral O
valacyclovir B-DRUG
in O
renal O
failure O
is O
necessary O
to O
avoid O
neurotoxicity B-ADR

we O
report O
a O
case O
of O
a O
patient O
with O
mild B-ADR
chronic I-ADR
renal I-ADR
insufficiency I-ADR
who O
had O
been O
taking O
simvastatin B-DRUG
for O
over O
a O
year O
and O
developed O
acute O
weakness O
within O
3 O
weeks O
after O
the O
start O
of O
treatment O
with O
colchicine O
for O
acute O
gouty O
bursitis O

progressive B-ADR
hypoxemia I-ADR
mandated O
endotracheal O
intubation O
1 O
week O
after O
rituximab B-DRUG
administration O
and O
led O
to O
death O
4 O
weeks O
after O
admission O

although O
gabapentin B-DRUG
withdrawal O
has O
been O
previously O
reported O
and O
usually O
consists O
of O
anxiety O
, O
diaphoresis O
, O
and O
palpitations O
, O
this O
is O
the O
first O
reported O
patient O
with O
generalized O
seizures O
and O
status B-ADR
epilepticus I-ADR
secondary O
to O
gabapentin B-DRUG
withdrawal O

hepatotoxicity B-ADR
of O
paracetamol B-DRUG
enhanced O
by O
ingestion O
of O
alcohol O
: O
report O
of O
two O
cases O

type O
ii O
heparin-induced O
thrombocytopenia B-ADR
( O
hit O
) O
is O
an O
immunological O
disorder O
characterized O
by O
antibodies O
to O
heparin-platelet O
factor O
4 O
complexes O
and O
a O
high O
risk O
of O
thrombotic O
complications O

indolent O
aspergillus B-ADR
arthritis I-ADR
complicating O
fludarabine-based O
non-myeloablative O
stem O
cell O
transplantation O

methods O
: O
the O
patient O
required O
insulin B-DRUG
desensitization O
for O
severe O
urticaria O
, O
angioedema B-ADR
, O
and O
occasional O
wheezing O
resulting O
from O
her O
insulin B-DRUG
dose O

localized B-ADR
purpura I-ADR
associated O
with O
lamotrigine B-DRUG

thrombin B-DRUG
is O
highly O
effective O
for O
stopping O
intractable O
arterial O
hemorrhage O
during O
stereotactic O
brain O
biopsy O
; O
however O
, O
it O
is O
a O
vasospastic O
agent O
and O
may O
have O
been O
responsible O
for O
the O
cerebral B-ADR
infarctions I-ADR
in O
one O
patient O

however O
, O
in O
1993 O
, O
a O
clinical O
study O
involving O
400 O
patients O
on O
the O
thai-burmese O
border O
revealed O
cardiac O
effects O
of O
antimalarial O
treatment O
with O
halofantrine B-DRUG
, O
including O
one O
sudden B-ADR
death I-ADR
after O
the O
treatment O

discussion O
: O
this O
case O
shows O
that O
switching O
to O
zidovudine B-DRUG
potentially O
can O
lead O
to O
a O
hyperlactatemia B-ADR
relapse I-ADR

since O
tamoxifen B-DRUG
therapy O
can O
induce O
endometrial B-ADR
disorders I-ADR
, O
surveillance O
schemes O
of O
women O
taking O
tamoxifen B-DRUG
have O
been O
recommended O

listeria O
brain O
abscess O
, O
pneumocystis B-ADR
pneumonia I-ADR
and O
kaposi O
's O
sarcoma O
after O
temozolomide B-DRUG

conclusion O
: O
therapy O
with O
indapamide B-DRUG
may O
induce O
diabetes B-ADR
in O
essential O
hypertension O
patients O

only O
one O
case O
of O
a O
generalized B-ADR
maculopapular I-ADR
rash I-ADR
with O
enoxaparin B-DRUG
has O
been O
reported O
in O
europe O

the O
patient O
presented O
with O
fulminant B-ADR
microangiopathic I-ADR
hemolytic I-ADR
anemia I-ADR
and O
thrombocytopenia O
within O
48 O
hr O
of O
initiating O
therapy O
with O
trimethoprim-sulfamethoxazole O

ischaemic B-ADR
colitis I-ADR
in O
a O
patient O
taking O
meloxicam B-DRUG

lamotrigine B-ADR
toxicity I-ADR
secondary O
to O
sertraline B-DRUG

one O
type O
of O
smon O
is O
associated O
with O
acrodermatitis B-ADR
enteropathica I-ADR
which O
has O
a O
very O
high O
frequency O
of O
occurrence O
in O
association O
with O
administration O
of O
clioquinol B-DRUG

exacerbations B-ADR
of I-ADR
the I-ADR
heart I-ADR
failure I-ADR
were O
temporally O
related O
to O
the O
administration O
of O
the O
antitumor O
antibiotics O
actinomycin-d O
( O
nsc-3053 B-DRUG
) O
and O
mithramycin O
( O
nsc-24559 O

although O
tardive B-ADR
dyskinesia I-ADR
is O
a O
known O
adverse O
reaction O
of O
sustained O
treatment O
with O
traditional O
neuroleptic O
agents O
, O
it O
was O
only O
rarely O
reported O
in O
association O
with O
sulpiride B-DRUG
, O
a O
selective O
d2-receptor O
antagonist O

we O
report O
on O
a O
37-year-old O
female O
who O
complained O
of O
moderate O
hair B-ADR
loss I-ADR
during O
paroxetine B-DRUG
treatment O

to O
our O
knowledge O
, O
these O
cases O
represent O
the O
first O
reports O
of O
tdf-associated O
irreversible O
renal O
failure O
and O
rickets B-ADR
in O
pediatric O
patients O

metabolic O
balance O
studies O
and O
rechallenge O
with O
hydrochlorothiazide B-DRUG
were O
undertaken O
to O
investigate O
the O
mechanism O
of O
the O
thiazide-induced O
hyponatremia B-ADR

sulfasalazine-induced O
hypersensitivity B-ADR
syndrome I-ADR
and O
hemophagocytic O
syndrome O
associated O
with O
reactivation O
of O
epstein-barr O
virus O

after O
therapy O
with O
parenteral O
amiodarone B-DRUG
( O
2300 O
mg O
in O
3 O
days O
) O
and O
other O
measures O
, O
signs O
of O
congestive O
heart O
failure O
disappeared O
; O
subsequently O
the O
patient O
developed O
jaundice O
, O
marked O
increase O
in O
serum O
transaminase O
levels O
and O
fall B-ADR
in I-ADR
prothrombin I-ADR
time I-ADR
, O
and O
histologic O
changes O
of O
severe O
centrilobular O
necrosis O
were O
observed O
in O
hepatic O
biopsy O

a O
45-year-old O
woman O
with O
steroid-dependent O
crohn O
's O
colitis O
, O
successfully O
managed O
with O
maintenance O
infliximab O
infusions O
and O
methotrexate B-DRUG
, O
developed O
a O
lupus-like B-ADR
syndrome I-ADR
eight O
months O
after O
her O
initial O
infusion O

three O
months O
after O
starting O
citalopram B-DRUG
, O
she O
experienced O
episodes O
of O
chest B-ADR
tightness I-ADR
and O
dizziness O

linear B-ADR
iga I-ADR
bullous I-ADR
dermatosis I-ADR
occurring O
after O
carbamazepine B-DRUG

ezetimibe-induced O
acute B-ADR
pancreatitis I-ADR

a O
review O
of O
the O
literature O
showed O
no O
previous O
description O
of O
this O
pattern O
in O
benzodiazepine B-DRUG
coma B-ADR

imidazoline B-ADR
intoxication I-ADR
in O
children O

the O
main O
clinical O
features O
of O
this O
58-year-old O
female O
patient O
were O
laboratory O
evidence O
of O
leucopenia O
and O
cholestasis O
, O
and O
biopsy O
features O
of O
fatty O
liver O
parenchyma O
degeneration O
with O
granulocytic B-ADR
portal I-ADR
infiltration I-ADR
and O
bile O
stasis O
, O
demonstrated O
20 O
days O
after O
the O
initiation O
of O
antithyroid O
therapy O
with O
20 O
mg O
methimazole B-DRUG
daily O

we O
report O
a O
case O
of O
stevens-johnson O
syndrome O
/ O
toxic O
epidermal O
necrolysis O
( O
sjs B-ADR
/ O
ten O
) O
secondary O
to O
trimethoprim-sulfamethoxazole B-DRUG
( O
tmp-sx O
) O
therapy O
for O
presumed O
community-associated O
methicillin-resistant O
staphylococcus O
aureus O
( O
ca-mrsa O
) O
infection O

multicentric B-ADR
hepatocellular I-ADR
carcinoma I-ADR
following O
phosphate B-DRUG
diethylstilbestrol I-DRUG
therapy O
for O
prostatic O
cancer O

embolia B-ADR
cutis I-ADR
medicamentosa I-ADR
following O
subcutaneous O
injection O
of O
glatiramer B-DRUG
acetate I-DRUG

he O
had O
been O
taking O
trimethoprim-sulfamethoxazole O
for O
approximately O
eight O
days O
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches O
, O
dizziness O
, O
difficulty O
with O
speech O
, O
weakness O
, O
and O
itching O
on O
the O
trunk O
of O
his O
body O
and O
legs O
, O
where O
a O
maculopapular B-ADR
rash I-ADR
was O
noted O

acute B-ADR
coronary I-ADR
syndromes I-ADR
can O
be O
associated O
with O
the O
infusion O
of O
rituximab B-DRUG

we O
report O
the O
first O
case O
of O
tuberculous B-ADR
uveitis I-ADR
due O
to O
etanercept B-DRUG

ampicillin B-DRUG
increased O
the O
preexisting O
electrical B-ADR
decrement I-ADR
in O
three O
rabbits O
with O
experimental O
autoimmune O
myasthenia O
gravis O
while O
the O
drug O
had O
no O
deleterious O
effects O
in O
less O
affected O
or O
normal O
animals O

hypersensitivity B-ADR
pneumonitis-like I-ADR
syndrome I-ADR
associated O
with O
the O
use O
of O
lenalidomide B-DRUG

with O
the O
use O
of O
optical O
coherence O
tomography O
( O
oct O
) O
, O
two O
patients O
with O
ifn-associated O
retinopathy B-ADR
who O
had O
developed O
macular O
edema O
and O
reduced O
visual O
acuity O
during O
the O
clinical O
course O
of O
ifn B-DRUG
therapy O
were O
observed O

a O
7-year-old O
boy O
developed O
a O
severe B-ADR
unilateral I-ADR
grand I-ADR
mal I-ADR
seizure I-ADR
at O
the O
age O
of O
5 O
years O
( O
phenobarbitone O
therapy O
) O
; O
1.5 O
years O
later O
valproate B-DRUG
( O
2-propylpentanoic O
acid O
, O
vpa O
) O
was O
added O
to O
the O
therapy O

we O
report O
a O
case O
of O
drug-induced O
pemphigus B-ADR
caused O
by O
an O
angiotensin-converting O
enzyme O
inhibitor O
, O
captopril B-DRUG

native O
arterial B-ADR
thrombosis I-ADR
, O
though O
recognized O
as O
a O
severe O
complication O
of O
thrombin B-DRUG
injection O
, O
has O
not O
been O
well O
described O
in O
the O
literature O

can O
roxithromycin O
and O
betamethasone B-DRUG
induce O
acute B-ADR
pancreatitis I-ADR
? O
a O
case O
report O

results O
: O
quetiapine B-DRUG
was O
associated O
with O
leucopenia O
in O
two O
patients O
and O
clinically O
apparent O
agranulocytosis B-ADR
in O
one O
patient O

we O
report O
two O
patients O
who O
developed O
intense O
livedo B-ADR
reticularis I-ADR
clearly O
related O
to O
the O
administration O
of O
interferon B-DRUG
alpha I-DRUG
2b I-DRUG
as O
an O
adjuvant O
therapy O
for O
melanoma O

risperidone-induced O
psychosis O
and O
depression B-ADR
in O
a O
child O
with O
a O
mitochondrial O
disorder O

amoxapine-induced O
cognitive B-ADR
impairment I-ADR
in O
two O
patients O

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin B-DRUG
, O
grepafloxacin O
, O
trovafloxacin O
, O
gatifloxacin O
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache O
, O
dizziness B-ADR
and O
insomnia O

cardiac O
hypersensitivity O
and O
myopericarditis B-ADR
have O
been O
reported O
during O
long-term O
treatment O
with O
mesalazine B-DRUG

although O
heparin-dependent O
antibodies O
( O
hdas O
) O
typically O
manifest O
with O
thrombocytopenia B-ADR
as O
in O
heparin-induced O
thrombocytopenia B-ADR
( O
hit O
) O
, O
they O
may O
also O
manifest O
with O
preserved O
platelet O
counts O

background O
: O
hypersensitivity B-ADR
reactions I-ADR
to O
cyclosporine B-DRUG
are O
rare O

methemoglobinemia B-ADR
: O
an O
occupational O
hazard O
of O
phenylpropanolamine B-DRUG
production O

we O
report O
a O
case O
of O
a O
child O
with O
neurodevelopmental O
delay O
with O
chronic O
constipation O
and O
a O
history O
of O
chronic O
mineral B-DRUG
oil I-DRUG
ingestion O
presenting O
as O
asymptomatic O
exogenous B-ADR
lipoid I-ADR
pneumonia I-ADR
( O
elp O

clinicians O
who O
manage O
cachectic O
patients O
, O
particularly O
those O
with O
protracted O
diarrhoea O
and O
/ O
or O
receiving O
anti-malarial O
drugs O
including O
mefloquine B-DRUG
, O
should O
be O
aware O
of O
the O
risk O
of O
severe B-ADR
hypoglycaemia I-ADR

this O
is O
the O
second O
report O
of O
acute O
lung O
injury O
and O
diffuse B-ADR
alveolar I-ADR
damage I-ADR
caused O
by O
mefloquine B-DRUG

nonsustained B-ADR
polymorphous I-ADR
ventricular I-ADR
tachycardia I-ADR
during O
amiodarone B-DRUG
therapy O
for O
atrial O
fibrillation O
complicating O
cardiomyopathy O

we O
describe O
a O
patient O
who O
had O
a O
systemic B-ADR
allergic I-ADR
contact I-ADR
dermatitis I-ADR
to O
8-mop B-DRUG
develop O
during O
her O
second O
course O
of O
puva O
treatment O
for O
psoriasis O

the O
patient O
described O
in O
this O
paper O
was O
a O
78-year-old O
diabetic O
man O
who O
developed O
oral B-ADR
lesions I-ADR
of I-ADR
pv I-ADR
following O
institution O
of O
glibenclamide B-DRUG
therapy O

posterior B-ADR
reversible I-ADR
encephalopathy I-ADR
syndrome I-ADR
associated O
with O
methotrexate B-DRUG
neurotoxicity O
: O
conventional O
magnetic O
resonance O
and O
diffusion-weighted O
imaging O
findings O

methanol B-DRUG
toxicity O
can O
cause O
severe O
central O
nervous O
system O
insult O
in O
which O
a O
characteristic O
pattern O
of O
bilateral B-ADR
putaminal I-ADR
injury I-ADR
is O
noted O
on O
brain O
imaging O
studies O

rapid O
onset O
of O
muscle O
weakness O
( O
rhabdomyolysis B-ADR
) O
associated O
with O
the O
combined O
use O
of O
simvastatin O
and O
colchicine B-DRUG

cimetidine-induced O
fever B-ADR

conclusions O
: O
low O
dosages O
of O
quinacrine B-DRUG
used O
for O
malaria O
prophylaxis O
can O
be O
associated O
with O
a O
delayed O
, O
severe B-ADR
maculopathy I-ADR
indistinguishable O
from O
chloroquine O
maculopathy O
in O
certain O
patients O

we O
report O
a O
5-year-old O
boy O
with O
cf O
who O
had O
a O
stricture B-ADR
of I-ADR
the I-ADR
hepatic I-ADR
flexure I-ADR
region I-ADR
with I-ADR
associated I-ADR
narrowing I-ADR
due O
to O
submucosal O
fibrosis O
of O
the O
transverse O
colon O
, O
secondary O
to O
high-lipase B-DRUG
pancreatin I-DRUG
therapy O

objective O
: O
to O
investigate O
the O
mechanisms O
involved O
in O
hypersensitivity B-ADR
reactions I-ADR
to O
cyclosporine B-DRUG
and O
determine O
the O
feasibility O
of O
future O
cyclosporine B-DRUG
use O

an O
infertile O
patient O
with O
amenorrhea-galactorrhea O
syndrome O
lost B-ADR
vision I-ADR
during O
a O
pregnancy O
occurring O
after O
bromocryptine B-DRUG
treatment O

transtentorial B-ADR
herniation I-ADR
caused O
by O
an O
intracranial O
mass O
lesion O
following O
high-dose O
methotrexate B-DRUG

interference B-ADR
with I-ADR
the I-ADR
cortisol I-ADR
axis I-ADR
by O
the O
microtubule O
antagonist O
, O
cph82 B-DRUG

a O
patient O
with O
parkinson O
's O
disease O
, O
initially O
treated O
with O
bromocriptine O
and O
subsequently O
with O
cabergoline B-DRUG
, O
developed O
progressive O
pleuropulmonary B-ADR
abnormalities I-ADR
during O
the O
latter O
therapy O

case O
1 O
, O
a O
62-year-old O
woman O
, O
developed O
bilateral O
optic O
neuritis O
with O
decreased O
sensation O
of O
vibration O
and O
increased B-ADR
deep I-ADR
tendon I-ADR
reflex I-ADR
in O
the O
lower O
extremities O
after O
a O
seven-month O
use O
of O
recombinant B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
for O
chronic O
active O
hepatitis O
c O

moreover O
, O
treatment O
with O
immunosuppressive O
drugs O
such O
as O
cyclosporine O
, O
cisplatin O
, O
tacrolimus B-DRUG
, O
and O
interferon-alpha O
can O
induce O
a O
condition O
resembling O
rpls B-ADR

loperamide B-ADR
poisoning I-ADR
in O
the O
dog O

we O
report O
a O
case O
of O
48-year-old O
woman O
with O
seizure O
disorder O
on O
divalproex O
sodium O
( O
depakote B-DRUG
) O
who O
presented O
with O
dyspnea B-ADR

intrathecal O
methotrexate-induced O
acute B-ADR
cerebellar I-ADR
syndrome I-ADR

gemcitabine-induced O
pericardial O
effusion O
and O
tamponade B-ADR
after O
unblocked O
cardiac O
irradiation O

a O
7-year-old O
with O
congenital O
toxoplasmosis O
who O
took O
pyrimethamine B-DRUG
and O
sulfadiazine O
for O
reactivated O
chorioretinitis O
developed O
fever O
, O
severe B-ADR
cutaneous I-ADR
involvement I-ADR
, O
swelling O
, O
abdominal O
pain O
and O
transaminitis O
, O
persisting O
weeks O
after O
withholding O
medicines O

conclusions O
: O
the O
administration O
of O
prostaglandin B-DRUG
e1 I-DRUG
to O
neonates O
can O
cause O
gastric-outlet O
obstruction O
due O
to O
antral B-ADR
hyperplasia I-ADR

prazosin-induced O
first-dose O
phenomenon O
possibly O
associated O
with O
hemorrhagic B-ADR
stroke I-ADR
: O
a O
report O
of O
three O
cases O

we O
present O
a O
pediatric O
patient O
with O
leukemia O
and O
a O
severe O
, O
l-asparaginase-induced O
necrotizing B-ADR
pancreatitis I-ADR
, O
treated O
successfully O
with O
percutaneous O
drainage O
used O
to O
flush O
the O
infected O
necrotic O
parts O

neutropenia B-ADR
and O
agranulocytosis O
are O
risks O
known O
to O
occur O
with O
phenothiazines O
and O
clozapine B-DRUG

the O
authors O
report O
two O
cases O
of O
acute O
dystonic O
reactions O
( O
adrs B-ADR
) O
as O
a O
side O
effect O
of O
lamivudine B-DRUG

to O
date O
, O
eight O
cases O
of O
ten B-ADR
and O
one O
of O
sjs O
related O
to O
lamotrigine B-DRUG
administration O
have O
been O
reported O
in O
the O
literature O

the O
following O
is O
a O
case O
report O
analysis O
intended O
to O
draw O
attention O
to O
the O
need O
for O
better O
care O
coordination O
by O
describing O
the O
observed O
relationship O
of O
olanzapine B-DRUG
to O
metabolic O
changes O
manifested O
as O
uncontrolled O
diabetes O
mellitus O
and O
weight B-ADR
gain I-ADR

soon O
after O
introduction O
of O
insulin B-DRUG
therapy O
, O
she O
developed O
severe O
anasarca O
, O
including O
marked O
peripheral B-ADR
oedema I-ADR
, O
ascites O
and O
pleural O
effusion O

gemcitabine-induced O
pulmonary B-ADR
toxicity I-ADR
is O
usually O
a O
dramatic O
condition O

in O
this O
report O
, O
we O
describe O
a O
patient O
receiving O
lenalidomide B-DRUG
in O
whom O
dyspnea B-ADR
, O
fever O
, O
hypoxia O
, O
and O
diffuse O
pulmonary O
infiltrates O
developed O

a O
57-year-old O
woman O
with O
right O
bundle O
branch O
block O
+ O
lph O
and O
ventricular O
premature O
contractions O
developed O
complete B-ADR
heart I-ADR
block I-ADR
( O
chb O
) O
following O
administration O
of O
disopyramide B-DRUG
phosphate I-DRUG
( O
norpace O

our O
findings O
suggest O
that O
hyperkalemia B-ADR
can O
develop O
with O
the O
use O
of O
low-dose O
heparin B-DRUG
, O
within O
seven O
days O
of O
initiating O
heparin B-DRUG
therapy O
, O
and O
that O
patients O
with O
diabetes O
mellitus O
or O
chronic O
renal O
insufficiency O
are O
especially O
predisposed O
to O
this O
complication O

iv O
propranolol B-DRUG
was O
used O
as O
the O
initial O
treatment O
for O
his O
hyperadrenergic O
state O
, O
resulting O
in O
a O
decrease B-ADR
in I-ADR
heart I-ADR
rate I-ADR
but O
a O
paroxsymal O
increase O
in O
blood O
pressure O

the O
typical O
fluoxetine-induced O
symptoms O
of O
restlessness O
, O
constant O
pacing O
, O
purposeless B-ADR
movements I-ADR
of I-ADR
the I-ADR
feet I-ADR
and I-ADR
legs I-ADR
, O
and O
marked O
anxiety O
were O
indistinguishable O
from O
those O
of O
neuroleptic-induced O
akathisia O

this O
case O
report O
illustrates O
the O
neurotoxicity B-ADR
unique O
to O
hdarac B-DRUG

an O
infant O
girl O
with O
choanal B-ADR
atresia I-ADR
, O
athelia O
, O
minor O
anomalies O
, O
and O
mild O
to O
moderate O
mental O
retardation O
was O
born O
to O
a O
woman O
treated O
for O
hyperthyroidism O
throughout O
pregnancy O
with O
methimazole O
and O
propranolol B-DRUG

hypotension O
and O
sinus B-ADR
arrest I-ADR
with O
nifedipine B-DRUG
in O
pulmonary O
hypertension O

here O
we O
describe O
a O
patient O
with O
crohn O
's O
disease O
who O
developed O
a O
severe B-ADR
infliximab I-ADR
infusion I-ADR
reaction I-ADR
( O
iir O
) O
, O
complicated O
1 O
day O
later O
by O
severe O
swelling O
of O
the O
forearm O
and O
hand O
ipsilateral O
to O
the O
site O
of O
infliximab B-DRUG
infusion O

following O
several O
of O
these O
courses O
of O
therapy O
, O
respiratory B-ADR
distress I-ADR
occurred O
9 O
to O
12 O
days O
after O
the O
chlorambucil B-DRUG
was O
given O

pneumocystis B-ADR
carinii I-ADR
pneumonia I-ADR
as O
a O
complication O
of O
methotrexate B-DRUG
treatment O
of O
asthma O

in O
a O
female O
with O
acute O
lymphoblastic O
leukemia O
, O
inadvertent O
doxorubicin B-DRUG
administration O
intrathecally O
caused O
severe O
, O
life-threatening O
, O
acute B-ADR
encephalopathy I-ADR
with O
high-pressure O
hydrocephalus O

spectral-domain O
optical O
coherence O
tomography O
and O
adaptive O
optics O
may O
detect O
hydroxychloroquine B-DRUG
retinal B-ADR
toxicity I-ADR
before O
symptomatic O
vision O
loss O

conventional O
and O
diffusion-weighted O
mri O
findings O
of O
methotrexate B-DRUG
related O
sub-acute B-ADR
neurotoxicity I-ADR

we O
assume O
that O
rifn-gamma B-DRUG
induced O
the O
de O
novo O
development O
of O
sle B-ADR
in O
our O
patient O

acute B-ADR
renal I-ADR
failure I-ADR
is O
a O
rare O
complication O
following O
the O
administration O
of O
intravenous O
immunoglobulin B-DRUG
( O
ivig O

we O
report O
the O
case O
of O
an O
11-year-old O
female O
treated O
for O
mediastinal O
t-cell O
lymphoma O
who O
presented O
renal B-ADR
failure I-ADR
following O
the O
second O
cycle O
of O
high-dose O
methotrexate B-DRUG
( O
hdmtx O

prenatal O
cytomegalovirus O
( O
cmv O
) O
infection O
associated O
with O
severe O
brain O
damage O
was O
detected O
in O
an O
infant O
whose O
mother O
had O
been O
treated O
with O
prednisolone O
and O
azathioprine B-DRUG
for O
systemic O
lupus O
erythematosus O
( O
sle O

this O
panic B-ADR
anxiety I-ADR
was O
not O
relieved O
by O
taking O
etizolam O
and O
flunitrazepam O
again O
, O
but O
subsided O
rapidly O
by O
the O
re-administration O
of O
mianserin B-DRUG
30 O
mg O
/ O
day O
, O
and O
because O
of O
that O
the O
depressive O
symptom O
also O
disappeared O

however O
, O
the O
use O
of O
lithium B-DRUG
should O
be O
avoided O
with O
any O
patient O
who O
is O
purging O
, O
since O
it O
may O
exacerbate O
the O
loss B-ADR
of I-ADR
intracellular I-ADR
potassium I-ADR
, O
thereby O
increasing O
the O
risk O
of O
cardiac O
toxicity O

objective O
: O
to O
report O
the O
occurrence O
of O
anaphylactoid B-ADR
reactions I-ADR
to O
intraperitoneal O
cisplatin B-DRUG
in O
3 O
patients O

we O
hypothesize O
that O
caffeine B-ADR
toxicity I-ADR
injured O
the O
muscle O
cells O
, O
which O
were O
fragile O
due O
to O
the O
potassium O
depletion O
induced O
by O
the O
coexisting O
hyponatremia O
, O
to O
result O
in O
unusually O
severe O
rhabdomyolysis O

conclusions O
: O
this O
is O
the O
first O
report O
of O
a O
possible O
interaction O
between O
propafenone B-DRUG
and O
citalopram O
, O
which O
caused O
propafenone B-DRUG
adverse O
effects O
( O
eg O
, O
dizziness O
, O
falls O
) O
and O
mimicked O
coronary B-ADR
artery I-ADR
disease I-ADR

celiprolol B-DRUG
pneumonitis B-ADR

we O
describe O
the O
first O
case O
of O
disseminated B-ADR
salmonellosis I-ADR
in O
a O
patient O
treated O
with O
temozolomide B-DRUG

a O
10-year-old O
boy O
with O
osteosarcoma O
and O
normal O
renal O
function O
manifested O
laboratory O
evidence O
of O
impending O
renal O
toxicity O
and O
extreme O
elevation O
of O
aspartate O
aminotrasferase O
and O
alanine O
aminotransferase O
within O
2 O
hours O
after O
the O
completion O
of O
a O
4-hour O
infusion O
of O
high-dose O
methotrexate O
( O
mtx B-DRUG
) O
( O
12 O
g O
/ O
m2 O
) O
, O
and O
went O
on O
to O
develop O
acute B-ADR
renal I-ADR
failure I-ADR
with O
life-threatening O
hyperkalemia O
29 O
hours O
later O

we O
report O
a O
fatal O
case O
of O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
( O
ten O
) O
resulting O
from O
a O
high O
dose O
of O
cytosine B-DRUG
arabinoside I-DRUG
( O
ara-c O

mtx-induced O
hepatic B-ADR
injury I-ADR
and O
liver O
enzyme O
elevations O
have O
been O
demonstrated O
after O
treatment O
of O
leukemia O
, O
gestational O
disease O
and O
during O
treatment O
of O
psoriasis O
and O
rheumatoid O
arthritis O

we O
describe O
a O
renal O
transplant O
recipient O
maintained O
on O
cyclosporine O
and O
prednisone B-DRUG
developing O
nocardia B-ADR
asteroides I-ADR
brain I-ADR
abscess I-ADR

this O
unusual O
pattern O
of O
low-grade B-ADR
endometrial I-ADR
carcinoma I-ADR
adds O
to O
the O
spectrum O
of O
uterine O
neoplasia O
associated O
with O
tamoxifen B-DRUG
therapy O

within O
3 O
weeks O
of O
beginning O
continuous O
daily O
isoniazid B-DRUG
and O
rifampin O
therapy O
for O
pulmonary O
tuberculosis O
, O
a O
patient O
developed O
acute B-ADR
renal I-ADR
failure I-ADR

results O
: O
both O
patients O
experienced O
a O
previously O
unreported O
side O
effect O
-- O
falling B-ADR
backward I-ADR
-- O
associated O
with O
bupropion B-DRUG
use O

however O
, O
re-initiation O
of O
sunitinib B-DRUG
treatment O
was O
followed O
by O
bilateral B-ADR
breast I-ADR
enlargement I-ADR
again O

massive B-ADR
pulmonary I-ADR
embolism I-ADR
due O
to O
late-onset O
heparin-induced O
thrombocytopenia O
following O
coronary O
artery O
bypass O
graft O
surgery O
: O
successful O
treatment O
with O
lepirudin O

the O
literature O
is O
also O
reviewed O
for O
arf B-ADR
associated O
with O
mannitol B-DRUG
infusion O
in O
patients O
who O
received O
dialysis O
and O
those O
who O
did O
not O
receive O
dialysis O
; O
and O
the O
possible O
mechanism O
( O
s O
) O
of O
mannitol B-DRUG
nephrotoxicity O
are O
discussed O

amiodarone B-DRUG
hydrochloride I-DRUG
, O
a O
new O
antiarrhythmic O
agent O
, O
has O
been O
associated O
with O
pulmonary O
toxicity O
characterized O
by O
cough O
, O
dyspnea B-ADR
and O
diffuse O
pulmonary O
infiltrates O

cutaneous B-ADR
eruptions I-ADR
occur O
in O
3 O
% O
of O
individuals O
administered O
carbamazepine B-DRUG

however O
, O
in O
1993 O
, O
a O
clinical O
study O
involving O
400 O
patients O
on O
the O
thai-burmese O
border O
revealed O
cardiac B-ADR
effects I-ADR
of O
antimalarial O
treatment O
with O
halofantrine B-DRUG
, O
including O
one O
sudden O
death O
after O
the O
treatment O

we O
report O
a O
case O
of O
fatal B-ADR
fulminant I-ADR
hepatitis I-ADR
caused O
by O
the O
use O
of O
disulfiram B-DRUG
in O
a O
man O
with O
previously O
normal O
hepatocellular O
function O

increased B-ADR
lash I-ADR
length I-ADR
, O
thickness O
, O
and O
pigmentation O
are O
well-documented O
side O
effects O
of O
prostaglandin B-DRUG
analog O
glaucoma O
drops O

in O
patients O
with O
methotrexate-induced O
anaphylaxis B-ADR
, O
discontinuation O
of O
treatment O
may O
increase O
the O
risk O
of O
death O
due O
to O
cancer O
progression O

skin B-ADR
manifestations I-ADR
of O
a O
case O
of O
phenylbutazone-induced O
serum O
sickness-like O
reactions O

clofibrate-induced O
myopathy B-ADR
in O
patients O
with O
diabetes O
insipidus O

to O
our O
knowledge O
, O
no O
prior O
cases O
of O
penicillamine-induced O
ttp B-ADR
in O
ra O
have O
been O
reported O

we O
report O
the O
first O
case O
of O
acute O
renal O
failure O
with O
hyperkalemia B-ADR
associated O
with O
the O
recently O
marketed O
direct O
renin O
inhibitor O
aliskiren B-DRUG

methods O
: O
we O
queried O
35 O
rheumatologists O
at O
the O
robert O
breck O
brigham O
arthritis O
center O
to O
determine O
if O
weight B-ADR
loss I-ADR
had O
occurred O
as O
an O
adverse O
event O
in O
patients O
treated O
with O
leflunomide B-DRUG
between O
november O
1998 O
and O
january O
2000 O

purpose O
: O
to O
determine O
the O
cause O
of O
spontaneous B-ADR
choroidal I-ADR
hemorrhage I-ADR
in O
a O
67-year-old O
man O
after O
a O
myocardial O
infarction O
and O
administration O
of O
tissue B-DRUG
plasminogen I-DRUG
activator I-DRUG

the O
authors O
describe O
a O
case O
of O
combined O
lithium B-DRUG
and O
haloperidol O
toxicity O
characterized O
by O
hyperpyrexia O
, O
severe O
rigidity O
, O
mutism O
, O
and O
development O
of O
irreversible B-ADR
tardive I-ADR
dyskinesia I-ADR

we O
report O
a O
rare O
case O
of O
colonic B-ADR
mucosal I-ADR
necrosis I-ADR
following O
kalimate B-DRUG
( O
calcium O
polystryrene O
sulfonate O
) O
, O
an O
analogue O
of O
kayexalate O
without O
sorbitol O
in O
a O
34-yr-old O
man O

on O
day O
7 O
of O
linezolid B-DRUG
treatment O
, O
the O
patient O
developed O
severe O
pruritus O
, O
macular O
rash O
, O
facial O
edema O
, O
eosinophilia B-ADR
, O
marked O
increase O
in O
serum O
creatinine O
level O
, O
and O
mild O
hepatitis O

exacerbations B-ADR
of I-ADR
the I-ADR
heart I-ADR
failure I-ADR
were O
temporally O
related O
to O
the O
administration O
of O
the O
antitumor O
antibiotics O
actinomycin-d B-DRUG
( O
nsc-3053 O
) O
and O
mithramycin O
( O
nsc-24559 O

the O
development O
of O
systemic O
lupus O
erythematosus O
( O
sle B-ADR
) O
after O
38 O
months O
of O
therapy O
with O
recombinant O
human O
interferon O
gamma O
( O
rifn-gamma B-DRUG
) O
was O
observed O
in O
a O
patient O
with O
rheumatoid O
arthritis O

phenylpropanolamine O
( O
ppa B-DRUG
) O
recently O
has O
been O
publicly O
implicated O
as O
a O
cause O
of O
stroke O
and O
other O
neurologic B-ADR
events I-ADR

hepatotoxicity B-ADR
after O
high-dose O
methylprednisolone B-DRUG
for O
demyelinating O
disease O

he O
developed O
fever B-ADR
, O
nausea O
, O
diarrhea O
, O
and O
malaise O
and O
stopped O
taking O
on O
the O
third O
day O
after O
commencing O
pentasa B-DRUG

two O
patients O
treated O
with O
5-fluorouracil O
( O
5-fu B-DRUG
) O
for O
disseminated O
adenocarcinoma O
of O
the O
colon O
developed O
cerebellar B-ADR
dysfunction I-ADR
typical O
of O
5-fu B-DRUG
neurotoxicity O

the O
possibility O
of O
severe O
rhabdomyolysis O
should O
be O
considered O
in O
a O
patient O
with O
water B-ADR
intoxication I-ADR
due O
to O
massive O
ingestion O
of O
caffeine-containing O
beverages O

we O
report O
three O
cases O
of O
ifn B-DRUG
beta I-DRUG
induced O
hepatitis B-ADR
in O
ms O
and O
discuss O
the O
pathology O
findings O
and O
possible O
mechanisms O
of O
drug-induced O
liver O
injury O

a O
34-year-old O
lady O
developed O
a O
constellation O
of O
dermatitis O
, O
fever O
, O
lymphadenopathy B-ADR
and O
hepatitis O
, O
beginning O
on O
the O
17th O
day O
of O
a O
course O
of O
oral O
sulphasalazine B-DRUG
for O
sero-negative O
rheumatoid O
arthritis O

factors O
that O
suggested O
an O
association O
between O
the O
severe B-ADR
angioedematous I-ADR
reaction I-ADR
and O
bp B-DRUG
topical O
application O
include O
the O
strong O
reaction O
to O
bp B-DRUG
in O
the O
patch-test O
, O
the O
temporal O
relationship O
, O
the O
complete O
resolution O
of O
symptoms O
after O
the O
drug O
was O
withdrawn O
and O
the O
absence O
of O
other O
identified O
explanations O

the O
nodules B-ADR
regressed O
after O
withdrawal O
of O
methotrexate B-DRUG
therapy O
in O
one O
patient O
and O
were O
arrested O
with O
the O
addition O
of O
hydroxychloroquine O
in O
the O
other O

there O
is O
a O
dose-effect O
relationship O
between O
doxorubicin B-DRUG
and O
the O
incidence O
of O
symptomatic B-ADR
cardiac I-ADR
failure I-ADR

purpose O
: O
to O
describe O
the O
clinical O
and O
electrophysiological O
findings O
in O
a O
young O
boy O
with O
decreased B-ADR
vision I-ADR
possibly O
due O
to O
retinal O
damage O
by O
rifabutin B-DRUG

acute B-ADR
renal I-ADR
failure I-ADR
in O
a O
patient O
receiving O
treatment O
with O
suramin B-DRUG

the O
patient O
had O
recurrence O
of O
urticaria O
and O
angioedema B-ADR
a O
year O
and O
a O
half O
later O
, O
at O
which O
point O
the O
nph B-DRUG
was O
stopped O
and O
she O
was O
desensitized O
to O
regular O
insulin O

we O
discuss O
a O
patient O
who O
developed O
severe O
renal O
tubular O
dysfunction O
secondary O
to O
short-term O
therapy O
with O
amikacin B-DRUG
, O
resulting O
in O
refractory O
hypokalemia O
, O
hypocalcemia O
, O
hypomagnesemia B-ADR
, O
metabolic O
alkalosis O
, O
and O
polyuria O

conclusion O
: O
we O
report O
a O
case O
of O
the O
use O
of O
pamidronate O
for O
significant O
hypercalcemia B-ADR
secondary O
to O
acute O
vitamin B-DRUG
d I-DRUG
poisoning O

we O
report O
a O
46-yr-old O
woman O
with O
ovarian O
carcinoma O
who O
developed O
porphyria B-ADR
cutanea I-ADR
tarda I-ADR
while O
undergoing O
treatment O
with O
cisplatin B-DRUG
and O
cyclophosphamide O

the O
possibility O
of O
phenytoin B-DRUG
hypersensitivity O
reactions O
should O
be O
considered O
when O
patients O
receiving O
phenytoin B-DRUG
have O
unusual O
symptoms O
, O
particularly O
fever B-ADR
, O
rash O
, O
and O
lymphadenopathy O

in O
this O
report O
we O
described O
a O
case O
of O
juvenile O
idiopathic O
arthritis O
patient O
who O
developed O
thymic O
enlargement O
( O
true O
thymic B-ADR
hyperplasia I-ADR
) O
, O
mediastinal O
lymphadenopathy O
and O
pleurisy O
associated O
with O
systemic O
symptoms O
under O
etanercept B-DRUG
treatment O

a O
62-year-old O
caucasian O
man O
with O
atrial O
fibrillation O
who O
was O
taking O
warfarin B-DRUG
reported O
an O
episode O
of O
hematochezia B-ADR
; O
his O
international O
normalized O
ratio O
( O
inr O
) O
was O
1.74 O

we O
report O
such O
a O
series O
of O
patients O
who O
had O
transient B-ADR
asymptomatic I-ADR
bradycardia I-ADR
after O
being O
treated O
with O
continuous O
infusion O
5-fu B-DRUG

four O
cases O
of O
adverse B-ADR
experiences I-ADR
with O
clonidine B-DRUG
are O
described O

objective O
: O
to O
describe O
a O
case O
of O
exacerbated O
mania B-ADR
potentially O
related O
to O
an O
interaction O
between O
lopinavir O
/ O
ritonavir B-DRUG
and O
valproic O
acid O
( O
vpa O
) O
and O
propose O
a O
mechanism O
of O
action O
for O
this O
interaction O

this O
is O
the O
first O
reported O
case O
of O
hepatolithiasis B-ADR
during O
octreotide B-DRUG
therapy O

esophageal B-ADR
spasm I-ADR
following O
propranolol B-DRUG
overdose O
relieved O
by O
glucagon O

ara-c B-DRUG
is O
frequently O
associated O
with O
dermatologic B-ADR
toxicity I-ADR
, O
but O
this O
is O
only O
the O
second O
case O
of O
toxic O
epidermal O
necrolysis O
described O
in O
connection O
with O
this O
drug O

the O
3-week O
sulphasalazine B-ADR
syndrome I-ADR
strikes O
again O

we O
describe O
the O
clinical O
response O
, O
as O
determined O
by O
increases B-ADR
in I-ADR
total I-ADR
hb I-ADR
and O
decreased O
transfusion O
needs O
, O
in O
five O
patients O
with O
thalassemia O
intermedia O
treated O
with O
hu O
alone O
or O
in O
combination O
with O
spb B-DRUG

this O
sulfonamide O
like O
nephropathy O
should O
be O
differentiated O
from O
acetazolamide-related O
calcium B-ADR
phosphate I-ADR
nephrolithiasis I-ADR

purpose O
: O
the O
case O
of O
a O
patient O
who O
developed O
aseptic B-ADR
meningitis I-ADR
, O
hemolytic O
anemia O
, O
hepatitis O
, O
and O
orthostatic O
hypotension O
simultaneously O
during O
treatment O
with O
trimethoprim-sulfamethoxazole O
is O
described O

young O
children O
undergoing O
cisplatin B-DRUG
chemotherapy O
are O
known O
to O
be O
at O
risk O
for O
progressive B-ADR
sensorineural I-ADR
hearing I-ADR
loss I-ADR

we O
report O
four O
cases O
of O
hemodynamically O
significant O
pericardial B-ADR
effusion I-ADR
in O
patients O
with O
refractory O
lymphoma O
who O
were O
receiving O
gemcitabine B-DRUG
, O
all O
of O
whom O
had O
a O
history O
of O
mediastinal O
radiation O
without O
subcarinal O
blocking O

a O
patient O
developed O
papilloedema B-ADR
and O
hepatic O
dysfunction O
while O
being O
treated O
with O
perhexiline B-DRUG
maleate I-DRUG

conclusions O
: O
sd-oct O
and O
ao O
detected O
abnormalities O
that O
correlate O
topographically O
with O
visual B-ADR
field I-ADR
loss I-ADR
from O
hydroxychloroquine B-DRUG
toxicity O
as O
demonstrated O
by O
hvf O
10-2 O
and O
may O
be O
useful O
in O
the O
detection O
of O
subclinical O
abnormalities O
that O
precede O
symptoms O
or O
objective O
visual B-ADR
field I-ADR
loss I-ADR

acute O
myocardial O
infarction O
due O
to O
coronary B-ADR
spasm I-ADR
associated O
with O
l-thyroxine B-DRUG
therapy O

this O
report O
suggests O
that O
anemia B-ADR
can O
occur O
due O
to O
mmf O
, O
in O
particular O
when O
it O
is O
given O
with O
prednisone B-DRUG
, O
a O
side O
effect O
well O
documented O
in O
the O
transplantation O
literature O
when O
the O
triple O
combination O
of O
mmf O
, O
cyclosporine O
and O
prednisone B-DRUG
is O
used O

gastric O
tumor O
, O
endometrial O
carcinoma O
and O
cervical B-ADR
adenocarcinoma I-ADR
in O
situ O
were O
detected O
after O
treatment O
with O
tamoxifen B-DRUG
for O
breast O
cancer O

restless O
legs O
syndrome O
and O
periodic B-ADR
limb I-ADR
movements I-ADR
during I-ADR
sleep I-ADR
probably O
associated O
with O
olanzapine B-DRUG

hypersensitivity O
to O
aspirin B-DRUG
can O
be O
manifested O
as O
acute O
asthma O
, O
urticaria O
and O
/ O
or O
angioedema B-ADR
, O
or O
a O
systemic O
anaphylactoid O
reaction O

we O
report O
a O
case O
of O
sweet B-ADR
's I-ADR
syndrome I-ADR
in O
association O
with O
sargramostim B-DRUG
treatment O
following O
chemotherapy O
for O
acute O
myelogenous O
leukemia O

in O
patients O
with O
swallowing O
dysfunction O
and O
pneumonia B-ADR
, O
a O
history O
of O
mineral B-DRUG
oil I-DRUG
use O
should O
be O
obtained O
and O
a O
diagnosis O
of O
elp O
should O
be O
considered O
in O
the O
differential O
diagnoses O
if O
mineral B-DRUG
oil I-DRUG
use O
has O
occurred O

a O
62-year-old O
indian O
with O
diabetic O
nephropathy O
controlled O
with O
metformin B-DRUG
, O
developed O
miliary B-ADR
tuberculosis I-ADR
for O
which O
he O
was O
treated O
with O
rifampicin O
, O
isoniazid O
and O
ethambutol O

three O
of O
50 O
patients O
treated O
with O
isotretinoin B-DRUG
( O
1 O
mg O
/ O
kg O
/ O
day O
) O
for O
cystic O
acne O
complained O
of O
poor B-ADR
night I-ADR
vision I-ADR
and O
/ O
or O
excessive O
glare O
sensitivity O

conclusion O
: O
this O
report O
describes O
a O
case O
of O
a O
probable O
interaction O
between O
topical O
econazole B-DRUG
lotion O
1 O
% O
and O
acenocoumarol O
that O
resulted O
in O
overanticoagulation O
and O
a O
life-threatening O
laryngeal B-ADR
hematoma I-ADR
in O
this O
elderly O
patient O

the O
development O
of O
an O
igg O
lambda-type O
monoclonal O
gammopathy O
and O
subsequent O
multiple B-ADR
myeloma I-ADR
in O
an O
epilepsy O
patient O
on O
diphenylhydantoin B-DRUG
( O
dilantin O
) O
therapy O
for O
20 O
years O
is O
reported O

aseptic O
meningitis O
, O
hemolytic B-ADR
anemia I-ADR
, O
hepatitis O
, O
and O
orthostatic O
hypotension O
in O
a O
patient O
treated O
with O
trimethoprim-sulfamethoxazole O

this O
case O
is O
remarkable O
since O
1 O
) O
ecm O
developed O
after O
subcutaneous O
and O
not O
after O
intramuscular O
injection O
, O
2 O
) O
the O
injection O
was O
given O
by O
the O
patient O
himself O
, O
and O
3 O
) O
glatiramer B-DRUG
acetate I-DRUG
can O
induce O
skin B-ADR
necrosis I-ADR
as O
a O
side O
effect O

multiple O
complications O
of O
propylthiouracil B-DRUG
treatment O
: O
granulocytopenia O
, O
eosinophilia O
, O
skin O
reaction O
and O
hepatitis B-ADR
with O
lymphocyte O
sensitization O

pilocarpine B-ADR
toxicity I-ADR
and O
the O
treatment O
of O
xerostomia O

moxalactam B-DRUG
is O
more O
likely O
to O
be O
associated O
with O
platelet B-ADR
dysfunction I-ADR

this O
article O
describes O
the O
case O
of O
a O
25-year-old O
man O
found O
dead B-ADR
at O
home O
who O
had O
been O
prescribed O
olanzapine B-DRUG
for O
schizophrenia O

hepatic B-ADR
angiosarcoma I-ADR
occurring O
after O
cyclophosphamide B-DRUG
therapy O
: O
case O
report O
and O
review O
of O
the O
literature O

conclusions O
: O
the O
risk O
of O
drug-induced O
rhabdomyolysis B-ADR
due O
to O
the O
potential O
interaction O
between O
lovastatin B-DRUG
and O
azithromycin O
or O
clarithromycin O
should O
be O
considered O
before O
the O
concomitant O
use O
of O
these O
agents O

except O
hypothyroidism B-ADR
after O
radioiodine B-DRUG
treatment O
( O
euthyroid O
under O
substitutional O
therapy O
) O
, O
she O
suffered O
from O
no O
other O
diseases O

we O
recommend O
that O
clinicians O
monitor O
patients O
for O
signs O
and O
symptoms O
of O
pancreatitis O
, O
including O
abdominal B-ADR
pain I-ADR
, O
during O
treatment O
with O
tigecycline B-DRUG

co-trimoxazole B-DRUG
red B-ADR
cell I-ADR
aplasia I-ADR
in O
leukaemia O

while O
most O
physicians O
are O
aware O
of O
heparin-induced O
thrombocytopenia B-ADR
and O
skin O
necrosis O
, O
the O
association O
of O
heparin B-DRUG
and O
hyperkalemia O
is O
less O
well O
recognized O

possible O
interaction O
between O
lopinavir O
/ O
ritonavir B-DRUG
and O
valproic O
acid O
exacerbates O
bipolar B-ADR
disorder I-ADR

a O
case O
of O
a O
53-year-old O
man O
who O
developed O
acute B-ADR
pneumonitis I-ADR
after O
bleomycin B-DRUG
and O
moderate O
oxygen O
administration O
is O
presented O

such O
anagen O
effluvium O
with O
lichenoid B-ADR
eruption I-ADR
following O
inh B-DRUG
therapy O
has O
not O
been O
observed O
previously O

we O
report O
a O
case O
of O
mmc-related O
hemolytic B-ADR
uremic I-ADR
syndrome I-ADR
, O
and O
discuss O
the O
etiologic O
parameters O
, O
clinical O
aspects O
, O
prognosis O
and O
treatment O
modalities O
of O
this O
severe O
syndrome O

according O
to O
the O
naranjo O
probability O
scale O
, O
the O
relationship O
of O
gemcitabine B-DRUG
treatment O
with O
cutaneous B-ADR
eruption I-ADR
in O
our O
patient O
is O
possible O

multiple O
complications O
of O
propylthiouracil B-DRUG
treatment O
: O
granulocytopenia O
, O
eosinophilia O
, O
skin B-ADR
reaction I-ADR
and O
hepatitis O
with O
lymphocyte O
sensitization O

careful O
follow-up O
of O
so-called O
" O
self-limited O
" O
insulin B-DRUG
edema B-ADR
is O
encouraged O
, O
and O
the O
early O
institution O
of O
diuretic O
therapy O
is O
advocated O
in O
elderly O
patients O
to O
prevent O
the O
development O
of O
overt O
cardiac O
failure O

while O
the O
mechanism O
of O
dextran-associated O
renal B-ADR
failure I-ADR
remains O
unsolved O
, O
plasma O
exchange O
seems O
to O
be O
effective O
therapy O

incidence O
of O
seizures B-ADR
in O
pediatric O
cancer O
patients O
treated O
with O
imipenem B-DRUG
/ O
cilastatin O

we O
report O
a O
case O
of O
a O
child O
with O
neurodevelopmental O
delay O
with O
chronic O
constipation O
and O
a O
history O
of O
chronic O
mineral B-DRUG
oil I-DRUG
ingestion O
presenting O
as O
asymptomatic O
exogenous O
lipoid O
pneumonia O
( O
elp B-ADR

diarrhoea O
, O
t-cd4 O
+ O
lymphopenia O
and O
bilateral O
patchy O
pulmonary O
infiltrates O
developed O
in O
a O
male O
60 O
yrs O
of O
age O
, O
who O
was O
treated O
with O
oxaliplatinum O
and O
5-fluorouracil B-DRUG
for O
unresectable O
rectum O
carcinoma O

we O
present O
the O
management O
of O
agranulocytosis B-ADR
and O
neutropenic O
sepsis O
secondary O
to O
carbimazole B-DRUG
with O
recombinant O
human O
granulocyte O
colony O
stimulating O
factor O
( O
g-csf O

recent O
studies O
have O
shown O
that O
under O
experimental O
conditions O
ferrous B-DRUG
sulfate I-DRUG
may O
reduce B-ADR
the I-ADR
gastrointestinal I-ADR
absorption I-ADR
of I-ADR
orally I-ADR
administered I-ADR
levothyroxine I-ADR
sodium I-ADR
in O
patients O
with O
primary O
hypothyroidism O

we O
report O
a O
case O
of O
unintentional O
overdose O
of O
oral O
pilocarpine B-DRUG
tablets O
that O
resulted O
in O
bradycardia B-ADR
, O
mild O
hypotension O
, O
and O
muscarinic O
symptoms O
in O
a O
patient O
with O
sjogren O
's O
syndrome O

conclusion O
: O
the O
administration O
of O
tissue B-DRUG
plasminogen I-DRUG
activator I-DRUG
was O
responsible O
for O
the O
large O
extent O
of O
hemorrhage B-ADR
and O
should O
be O
considered O
in O
the O
differential O
diagnosis O
of O
hemorrhagic O
choroidal O
detachment O

rupture B-ADR
of I-ADR
a I-ADR
cerebral I-ADR
aneurysm I-ADR
associated O
with O
nifedipine B-DRUG
treatment O

the O
mean O
time O
from O
starting O
mmf B-DRUG
to O
the O
development O
of O
neutropenia B-ADR
was O
4 O
months O

many O
clinicians O
appear O
to O
be O
concerned O
about O
the O
potential O
hepatotoxicity B-ADR
of O
the O
opiate O
antagonist O
naltrexone B-DRUG
( O
ntx O
) O
and O
this O
may O
be O
one O
reason O
why O
it O
is O
not O
used O
more O
widely O
in O
treating O
both O
heroin O
and O
alcohol O
abusers O

bilateral O
acoustic O
( O
viii O
) O
nerve O
palsy O
in O
this O
patient O
was O
most O
likely O
a O
manifestation O
of O
vincristine B-DRUG
neurotoxicity O

the O
most O
likely O
cause O
of O
liver O
failure O
in O
this O
patient O
was O
, O
therefore O
, O
clarithromycin B-DRUG
, O
which O
undergoes O
hepatic O
metabolism O
and O
has O
been O
reported O
to O
cause O
fulminant B-ADR
hepatic I-ADR
failure I-ADR

renal B-ADR
failure I-ADR
is O
a O
rare O
complication O
associated O
with O
the O
use O
of O
rifampicin B-DRUG
for O
the O
treatment O
of O
tuberculosis O
, O
usually O
occurring O
well O
into O
the O
course O
of O
therapy O

three O
nephrotic O
patients O
who O
had O
reduced O
renal O
function O
and O
active O
renal O
disease O
with O
progressive O
deterioration O
of O
renal O
function O
prior O
to O
the O
use O
of O
mp B-DRUG
developed O
transient B-ADR
renal I-ADR
failure I-ADR
following O
an O
mp B-DRUG
pulse O
therapy O

conclusions O
: O
clinicians O
should O
be O
aware O
of O
a O
risk O
of O
serotonin O
syndrome O
with O
serious O
extrapyramidal B-ADR
reactions I-ADR
in O
patients O
receiving O
sertraline O
or O
venlafaxine B-DRUG
when O
metoclopramide O
is O
coadministered O
even O
in O
a O
single O
, O
conventional O
dose O

neuroleptic B-ADR
malignant I-ADR
syndrome I-ADR
in O
an O
adolescent O
receiving O
olanzapine-lithium O
combination O
therapy O

reversible O
sirolimus-associated O
pneumonitis B-ADR
after O
heart O
transplantation O

serotonin B-ADR
syndrome I-ADR
caused O
by O
interaction O
between O
citalopram B-DRUG
and O
fentanyl O

after O
nine O
previous O
uncomplicated O
cycles O
she O
developed O
severe O
anaphylaxis B-ADR
to O
cisplatin B-DRUG

conclusions O
: O
these O
results O
suggest O
that O
clozapine B-DRUG
may O
cause O
td O
; O
however O
, O
the O
prevalence O
is O
low O
and O
the O
severity O
is O
relatively O
mild O
, O
with O
no O
or O
mild O
self-reported O
discomfort B-ADR

we O
report O
the O
specifics O
of O
12 O
cases O
of O
severe B-ADR
hypertension I-ADR
after O
the O
intraoperative O
use O
of O
topical O
phenylephrine B-DRUG
, O
submucosal O
epinephrine O
, O
or O
both O

diphenhydramine-induced O
wide O
complex O
dysrhythmia B-ADR
responds O
to O
treatment O
with O
sodium O
bicarbonate O

thrombotic O
thrombocytopenic O
purpura O
( O
ttp B-ADR
) O
developed O
in O
a O
patient O
with O
seropositive O
rheumatoid O
arthritis O
( O
ra O
) O
after O
2 O
1 O
/ O
2 O
months O
of O
treatment O
with O
penicillamine B-DRUG

thirty-six O
patients O
with O
al O
received O
, O
in O
a O
three-month O
period O
, O
51 O
cycles O
of O
combined O
chemotherapy O
which O
included O
, O
in O
all O
of O
them O
, O
cytosine O
arabinoside O
( O
ara-c B-DRUG
) O
; O
among O
them O
, O
along O
with O
myelosuppression O
, O
five O
experienced O
fever O
, O
infectious B-ADR
complications I-ADR
, O
gastrointestinal O
tract O
symptoms O
and O
severe O
myalgias O

we O
report O
a O
case O
of O
iddm B-ADR
which O
occurred O
during O
interferon B-DRUG
therapy O
for O
chronic O
hepatitis O

a O
9-year-old O
boy O
developed O
acute B-ADR
renal I-ADR
failure I-ADR
following O
intravenous O
acyclovir B-DRUG
( O
30 O
mg O
/ O
kg O
per O
day O
) O
administered O
for O
6 O
days O
to O
treat O
herpetic O
encephalitis O

we O
observed O
3 O
diabetic O
patients O
with O
intolerable O
dizziness O
followed O
by O
nausea B-ADR
and O
vomiting O
immediately O
after O
an O
initial O
administration O
of O
the O
alpha-glucosidase O
inhibitor O
, O
voglibose B-DRUG

at O
the O
end O
of O
his O
fifth O
cycle O
of O
sunitinib B-DRUG
therapy O
, O
the O
patient O
complained O
of O
the O
development O
of O
abnormally O
large O
mammary O
glands O
associated O
with O
pain O
and O
peri-areolar B-ADR
erythema I-ADR

markedly O
increased B-ADR
pigmementation I-ADR
of I-ADR
skin I-ADR
immediately O
overlying O
veins O
used O
for O
multiple O
5-fluorouracil B-DRUG
infusions O
was O
noted O

methods O
: O
a O
76-year-old O
woman O
with O
primary O
open-angle O
glaucoma O
and O
no O
history O
of O
ocular O
surgery O
developed O
a O
choroidal B-ADR
detachment I-ADR
12 O
hours O
after O
initiation O
of O
therapy O
with O
dorzolamide B-DRUG
eye O
drops O

in O
case O
no O
. O
2 O
, O
the O
pathogenic O
mechanism O
seemed O
to O
be O
persistent O
light O
reaction O
preceded O
by O
systemic O
photoallergy O
, O
as O
he O
had O
taken O
mequitazine O
for O
6 O
months O
, O
and O
there O
were O
strong O
positive O
photopatch O
test O
results O
with O
immediate O
erythema O
reaction O
, O
cross-reaction B-ADR
to I-ADR
promethazine I-ADR
, O
decreased O
med O
to O
both O
uva O
and O
uvb O
, O
and O
persistence O
of O
the O
photosensitivity O
over O
a O
3-year O
follow-up O
period O
after O
discontinuation O
of O
the O
mequitazine O

though O
hypotension O
, O
dry B-ADR
mouth I-ADR
, O
and O
constipation O
are O
well-documented O
possible O
adverse O
effects O
, O
the O
possibility O
of O
clonidine-induced O
bradycardia O
is O
less O
well O
recognized O
and O
is O
rare O

motor B-ADR
fluctuations I-ADR
appear O
after O
2-3 O
years O
of O
levodopa B-DRUG
treatment O
, O
and O
affect O
at O
least O
50 O
% O
of O
patients O
after O
five O
years O

we O
describe O
a O
73-year-old O
woman O
who O
developed O
serious O
systemic B-ADR
vasculitis I-ADR
with O
associated O
thrombocytopenia O
in O
the O
course O
of O
treatment O
with O
cladribine B-DRUG

in O
this O
report O
, O
we O
present O
a O
case O
of O
hypoglycaemic B-ADR
coma I-ADR
associated O
with O
sp B-DRUG
, O
an O
adverse O
reaction O
that O
is O
likely O
to O
be O
underreported O
and O
expected O
to O
occur O
with O
greater O
frequency O
as O
the O
use O
of O
sp B-DRUG
increases O

only O
one O
case O
of O
severe B-ADR
symptomatic I-ADR
hepatitis I-ADR
occurring O
after O
pulse O
therapy O
with O
itraconazole B-DRUG
for O
onychomycosis O
and O
requiring O
transplantation O
has O
been O
reported O
previously O

a O
review O
of O
the O
literature O
revealed O
two O
other O
cases O
of O
hepatic B-ADR
angiosarcoma I-ADR
in O
patients O
after O
long-term O
cyclophosphamide B-DRUG
treatment O

carboplatin O
hypersensitivity B-ADR
induced O
by O
low-dose O
paclitaxel O
/ O
carboplatin B-DRUG
in O
multiple O
platinum-treated O
patients O
with O
recurrent O
ovarian O
cancer O

we O
highlight O
two O
instances O
of O
systemic B-ADR
allergic I-ADR
reaction I-ADR
, O
and O
discuss O
the O
potential O
side O
effects O
of O
local O
aprotinin B-DRUG
injections O
in O
the O
orthopaedic O
setting O
as O
well O
as O
the O
evidence O
base O
for O
its O
use O

pharmacokinetic O
determinants O
of O
6-mercaptopurine B-DRUG
myelotoxicity B-ADR
and O
therapeutic O
failure O
in O
children O
with O
acute O
lymphoblastic O
leukemia O

prior O
neurologic O
illness O
or O
cns O
insult O
of O
any O
kind O
is O
known O
to O
increase O
the O
vulnerability O
to O
neurotoxicity B-ADR
of O
lithium B-DRUG

l-asparaginase-induced O
pancreatitis B-ADR
is O
an O
uncommon O
but O
potential O
lethal O
complication O
of O
the O
treatment O
of O
leukemia O

we O
report O
a O
rare O
case O
of O
colonic B-ADR
mucosal I-ADR
necrosis I-ADR
following O
kalimate O
( O
calcium B-DRUG
polystryrene I-DRUG
sulfonate I-DRUG
) O
, O
an O
analogue O
of O
kayexalate O
without O
sorbitol O
in O
a O
34-yr-old O
man O

the O
second O
is O
a O
29-year-old O
man O
with O
cd O
in O
whom O
nodular B-ADR
sclerosing I-ADR
hodgkin I-ADR
's I-ADR
lymphoma I-ADR
was O
diagnosed O
3 O
weeks O
after O
infusion O
with O
infliximab B-DRUG

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia B-ADR
two O
weeks O
after O
receiving O
trimethoprim B-DRUG
( O
tmp O
)- O
sulfamethoxazole O
( O
smx O
) O
treatment O

phenylpropanolamine B-DRUG
( O
ppa O
) O
recently O
has O
been O
publicly O
implicated O
as O
a O
cause O
of O
stroke B-ADR
and O
other O
neurologic O
events O

we O
report O
a O
case O
of O
myoclonus B-ADR
induced O
by O
quetiapine B-DRUG

the O
reversal O
of O
heparin O
by O
protamine B-DRUG
may O
cause O
severe O
hemodynamic O
deterioration O
, O
characterized O
by O
systemic O
hypotension O
, O
pulmonary O
hypertension O
, O
and O
bronchoconstriction B-ADR

methemoglobinemia B-ADR
after O
axillary O
block O
with O
bupivacaine O
and O
additional O
injection O
of O
lidocaine B-DRUG
in O
the O
operative O
field O

videopolysomnographic O
and O
pharmacokinetic O
studies O
with O
monitoring O
of O
plasma O
levodopa B-DRUG
levels O
demonstrated O
marked O
motor O
hyperactivity O
during O
augmentation O
, O
with O
anarchic B-ADR
discharges I-ADR
of I-ADR
motor I-ADR
unit I-ADR
potentials I-ADR
, O
tonic O
grouped O
discharges O
and O
flexor O
spasms O
, O
associated O
with O
painful O
dysesthesia O

a O
case O
is O
reported O
in O
which O
severe B-ADR
hypocalcemia I-ADR
, O
with O
a O
low O
plasma O
parathyroid O
hormone O
( O
pth O
) O
concentration O
, O
resulted O
from O
the O
therapeutic O
use O
of O
magnesium B-DRUG
sulfate I-DRUG
for O
toxemia O
of O
pregnancy O

although O
adverse O
effects O
are O
usually O
mild O
, O
the O
author O
reports O
here O
a O
case O
of O
leucocytopenia B-ADR
and O
thrombocytopenia O
with O
quetiapine B-DRUG
treatment O
that O
required O
its O
discontinuation O

a O
previous O
review O
described O
data O
on O
15 O
patients O
who O
experienced O
acute B-ADR
hemoglobinemia I-ADR
or O
hemoglobinuria O
following O
anti-d B-DRUG
igiv I-DRUG
administration O
for O
itp O
or O
secondary O
thrombocytopenia O

however O
, O
peripheral B-ADR
neuropathy I-ADR
and O
bone O
marrow O
depression O
led O
to O
linezolid B-DRUG
withdrawal O
in O
seven O
patients O
, O
and O
neuropathy O
may O
not O
be O
fully O
reversible O
in O
all O
patients O

symptomatic B-ADR
hypocalcaemia I-ADR
and O
renal O
impairment O
associated O
with O
bisphosphonate B-DRUG
treatment O
in O
patients O
with O
multiple O
myeloma O

prolonged O
prostate-specific O
antigen O
response O
in O
flutamide B-ADR
withdrawal I-ADR
syndrome I-ADR
despite O
disease O
progression O

after O
39 O
hours O
on O
argatroban B-DRUG
, O
the O
infusion O
was O
stopped O
when O
minor O
bleeding B-ADR
was O
observed O
with O
a O
concurrent O
activated O
partial O
thromboplastin O
time O
( O
aptt O
) O
of O
100 O
seconds O

stroke-like O
syndrome O
after O
gold B-DRUG
sodium I-DRUG
thiomalate I-DRUG
induced O
vasomotor B-ADR
reaction I-ADR

after O
5 O
days O
of O
treatment O
with O
il-2 B-DRUG
, O
the O
patient O
developed O
a O
hemorrhagic O
lesion O
that O
progressed O
to O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
, O
as O
well O
as O
grade O
4 O
pancytopenia O

akathisia B-ADR
appeared O
to O
be O
a O
common O
side O
effect O
of O
fluoxetine B-DRUG
and O
generally O
responded O
well O
to O
treatment O
with O
the O
beta-adrenergic O
antagonist O
propranolol O
, O
dose O
reduction O
, O
or O
both O

during O
clarithromycin O
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate-to-severe O
toxic O
symptoms O
of O
carbamazepine B-DRUG
, O
such O
as O
drowsiness O
, O
dizziness O
, O
and O
ataxia B-ADR
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin O
discontinuation O

goiter B-ADR
and O
hypothyroidism O
during O
re-treatment O
with O
amiodarone B-DRUG
in O
a O
patient O
who O
previously O
experienced O
amiodarone-induced O
thyrotoxicosis O

possible O
pathophysiological O
mechanisms O
which O
may O
have O
been O
operative O
in O
this O
case O
include O
: O
a O
direct O
central O
nervous O
system O
( O
cns O
) O
toxic O
effect O
of O
valproic B-DRUG
acid I-DRUG
; O
a O
paradoxical O
epileptogenic O
effect O
secondary O
to O
the O
drug O
; O
and O
an O
indirect O
cns O
toxic O
effect O
mediated O
through O
valproic B-DRUG
acid-induced O
hyperammonemia B-ADR

objective O
: O
to O
report O
a O
case O
of O
neuroleptic O
malignant O
syndrome O
( O
nms B-ADR
) O
associated O
with O
fluphenazine B-DRUG
in O
a O
schizophrenic O
patient O
and O
review O
the O
literature O
related O
to O
this O
condition O

hepatotoxicity B-ADR
associated O
with O
use O
of O
d-penicillamine B-DRUG
in O
rheumatoid O
arthritis O

we O
report O
the O
case O
of O
a O
14-year-old O
female O
with O
acute O
promyelocytic O
leukemia O
who O
developed O
symptomatic B-ADR
cardiomyopathy I-ADR
only O
4 O
months O
into O
treatment O
with O
a O
combination O
of O
daunomycin B-DRUG
and O
all-trans O
retinoic O
acid O
( O
atra O

these O
cases O
were O
considered O
unusual O
in O
light O
of O
the O
short O
delay O
of O
their O
onset O
after O
initiation O
of O
immunosuppressive O
therapy O
and O
their O
fulminant O
course O
: O
3 O
of O
these O
patients O
died B-ADR
of O
pcp O
occurring O
during O
the O
first O
month O
of O
treatment O
with O
prednisone B-DRUG

the O
goal O
of O
this O
study O
is O
to O
describe O
three O
patients O
diagnosed O
with O
migraine O
and O
epilepsy O
( O
both O
under O
control O
) O
who O
evolved O
into O
status B-ADR
migrainosus I-ADR
after O
the O
introduction O
of O
oxcarbazepine B-DRUG
( O
oxc O
) O
, O
as O
part O
of O
a O
switch O
off O
from O
carbamazepine O
( O
cbz O

we O
report O
5 O
patients O
( O
3 O
patients O
with O
chronic O
hepatitis O
c O
treated O
with O
pegylated O
interferon O
alfa-2b O
in O
association O
with O
oral O
ribavirin B-DRUG
and O
two O
patients O
with O
chronic O
myelocytic O
leukemia O
) O
who O
developed O
local B-ADR
cutaneous I-ADR
reactions I-ADR
at O
sites O
of O
injection O
after O
the O
administration O
of O
weekly O
subcutaneous O
injections O
of O
pegylated O
interferon O
alfa-2b O
at O
different O
doses O

cyanamide-induced O
liver B-ADR
dysfunction I-ADR
after O
abstinence O
in O
alcoholics O
: O
a O
long-term O
follow-up O
study O
on O
four O
cases O

metastatic B-ADR
osteomyelitis I-ADR
following O
bcg B-DRUG
vaccination O

hyperglycemia B-ADR
and O
diabetic O
coma O
: O
possible O
relationship O
to O
diuretic-propranolol O
therapy O

nonconvulsive B-ADR
status I-ADR
epilepticus I-ADR
due O
to O
ifosfamide B-DRUG

we O
report O
the O
case O
of O
an O
87-year-old O
white O
woman O
with O
myasthenia O
gravis O
who O
presented O
with O
nausea O
, O
shortness B-ADR
of I-ADR
breath I-ADR
, O
azotemia O
, O
and O
hyperkalemia O
shortly O
after O
completing O
a O
course O
of O
intravenous O
immunoglobulin O
( O
ivig B-DRUG

objective O
: O
to O
report O
the O
case O
of O
a O
young O
woman O
with O
graves' O
disease O
in O
whom O
ototoxicity B-ADR
developed O
because O
of O
propylthiouracil B-DRUG
( O
ptu O
)- O
induced O
antineutrophil O
cytoplasmic O
antibody O
( O
anca O
)- O
associated O
vasculitis O

we O
report O
4 O
patients O
who O
developed O
symptoms O
of O
myasthenia B-ADR
gravis I-ADR
within O
2 O
weeks O
of O
starting O
treatment O
with O
a O
statin B-DRUG
drug O

massive O
pulmonary O
embolism O
due O
to O
late-onset O
heparin-induced O
thrombocytopenia B-ADR
following O
coronary O
artery O
bypass O
graft O
surgery O
: O
successful O
treatment O
with O
lepirudin O

conclusion O
: O
a O
woman O
receiving O
enoxaparin B-DRUG
every O
12 O
hours O
developed O
signs O
and O
symptoms O
of O
hepatotoxicity B-ADR
after O
the O
second O
dose O

rapamycin O
/ O
sirolimus-induced O
pneumonitis O
has O
been O
described O
previously O
in O
renal O
transplant O
recipients O
, O
and O
this O
report O
describes O
a O
stable O
heart-lung O
transplant O
recipient O
who O
developed O
a O
pulmonary B-ADR
infiltrate I-ADR
that O
reversed O
after O
ceasing O
sr O
therapy O

heparin-associated O
thrombocytopenia B-ADR
and O
thrombosis O
is O
a O
severe O
complication O
of O
systemic O
heparin O
therapy O

it O
carries O
a O
well-known O
risk O
of O
neutropenia O
and O
agranulocytosis B-ADR
, O
which O
necessitates O
the O
immediate O
discontinuation O
of O
clozapine B-DRUG

we O
report O
a O
45-year-old O
chinese O
man O
with O
cml O
and O
chronic O
hepatitis O
b O
virus O
infection O
, O
on O
imatinib B-DRUG
treatment O
, O
presenting O
with O
herpetic B-ADR
rash I-ADR
and O
acute O
liver O
failure O

two O
cases O
are O
reported O
of O
patients O
who O
developed O
a O
hematologic B-ADR
malignancy I-ADR
several O
years O
after O
intravesical O
chemotherapy O
of O
superficial O
bladder O
cancer O
with O
etoglucid O
, O
doxorubicin O
, O
and O
mitomycin B-DRUG
c I-DRUG

we O
report O
a O
case O
of O
intrathecal O
methotrexate B-DRUG
neurotoxicity O
manifesting O
as O
left B-ADR
arm I-ADR
weakness I-ADR
and O
aphasia O

inhaled O
tobramycin B-DRUG
solution-associated O
recurrent B-ADR
eosinophilia I-ADR
and O
severe O
persistent O
bronchospasm O
in O
a O
patient O
with O
cystic O
fibrosis O
: O
a O
case O
report O

severe O
rhabdomyolysis B-ADR
following O
massive O
ingestion O
of O
oolong O
tea O
: O
caffeine B-DRUG
intoxication O
with O
coexisting O
hyponatremia O

acute B-ADR
psychosis I-ADR
associated O
with O
levetiracetam B-DRUG

marked O
qt O
prolongation O
and O
torsades O
de O
pointes O
secondary O
to O
acute B-ADR
ischemia I-ADR
in O
an O
elderly O
man O
taking O
dofetilide B-DRUG
for O
atrial O
fibrillation O
: O
a O
cautionary O
tale O

two O
cases O
of O
hypothyroidism B-ADR
in O
patients O
with O
chronic O
hepatitis O
c O
treated O
with O
recombinant B-DRUG
alpha I-DRUG
interferon I-DRUG
are O
reported O

these O
nail B-ADR
changes I-ADR
gradually O
disappeared O
when O
the O
dose O
of O
clofazimine B-DRUG
was O
reduced O

we O
describe O
2 O
patients O
with O
cutaneous O
lupus O
erythematosus O
who O
developed O
severe O
dapsone B-ADR
reaction I-ADR
after O
low O
dose O
therapy O
, O
with O
a O
fatal O
outcome O
in O
one O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical B-ADR
lymphadenopathy I-ADR
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp O
)- O
sulfamethoxazole B-DRUG
( O
smx O
) O
treatment O

heparin-associated O
thrombocytopenia O
and O
thrombosis B-ADR
is O
a O
severe O
complication O
of O
systemic O
heparin B-DRUG
therapy O

acute O
severe O
intoxication O
with O
carbamazepine B-DRUG
is O
associated O
with O
seizures O
, O
coma B-ADR
and O
respiratory O
depression O

objective O
: O
the O
aim O
of O
this O
paper O
is O
to O
describe O
a O
case O
of O
increased B-ADR
libido I-ADR
during O
fluvoxamine B-DRUG
therapy O

a O
60-year-old O
white O
man O
with O
chronic O
bronchitis O
was O
noted O
to O
develop O
acute B-ADR
respiratory I-ADR
failure I-ADR
and O
metabolic O
acidosis O
four O
days O
after O
being O
started O
on O
methazolamide O
( O
neptazane B-DRUG
) O
for O
an O
ophthalmologic O
problem O

a O
patient O
suffering O
from O
heparin-associated O
thrombocytopenia O
( O
hat B-ADR
) O
, O
recurrent O
arteriothromboses O
, O
and O
acute O
renal O
failure O
after O
treatment O
with O
standard O
heparin B-DRUG
is O
described O

a O
57-year-old O
man O
developed O
morphea B-ADR
while O
taking O
bromocriptine B-DRUG

objective O
: O
to O
report O
a O
case O
of O
reversible O
nonthrombocytopenic B-ADR
palpable I-ADR
purpura I-ADR
associated O
with O
metoclopramide B-DRUG

myoclonic B-ADR
spasms I-ADR
following O
intrathecal O
morphine B-DRUG

in O
this O
article O
, O
we O
present O
the O
case O
of O
a O
vitiligo O
patient O
who O
was O
admitted O
to O
our O
facility O
with O
an O
intense B-ADR
burn I-ADR
after O
the O
topical O
use O
of O
8-methoxypsoralen B-DRUG
solution O
as O
a O
suntanning O
agent O

a O
mentally O
retarded O
23-year-old O
woman O
with O
myoclonic O
astatic O
epilepsy O
developed O
an O
abnormal B-ADR
posture I-ADR
of I-ADR
extreme I-ADR
forward I-ADR
flexion I-ADR
, O
called O
camptocormia O
, O
during O
valproate B-DRUG
monotherapy O

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity B-ADR
reactions I-ADR
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general O
erythema O
, O
dyspnea O
, O
and O
hypotension O
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal O
pain O
, O
general O
erythema O
, O
and O
fever O

we O
report O
2 O
patients O
who O
developed O
polyarteritis B-ADR
nodosa I-ADR
following O
vaccination B-DRUG
against I-DRUG
hepatitis I-DRUG
b I-DRUG

a O
36-year-old O
man O
being O
treated O
with O
cisplatinum B-DRUG
, O
vinblastine O
, O
and O
bleomycin O
for O
testicular O
carcinoma O
developed O
a O
dense O
left B-ADR
homonymous I-ADR
hemianopsia I-ADR
, O
encephalopathy O
, O
and O
a O
partial O
nondominant O
parietal O
lobe O
syndrome O

we O
report O
the O
case O
of O
an O
87-year-old O
white O
woman O
with O
myasthenia O
gravis O
who O
presented O
with O
nausea O
, O
shortness O
of O
breath O
, O
azotemia O
, O
and O
hyperkalemia B-ADR
shortly O
after O
completing O
a O
course O
of O
intravenous O
immunoglobulin B-DRUG
( O
ivig O

additive B-ADR
pulmonary I-ADR
toxicity I-ADR
with O
melphalan B-DRUG
and O
busulfan O
therapy O

the O
principle O
treatment O
for O
dpd-deficient O
patients O
with O
severe O
acute O
5-fu B-DRUG
reactions O
is O
supportive O
care O
; O
however O
, O
the O
administration O
of O
thymidine O
potentially O
may O
reverse O
severe O
5-fu-induced O
neurologic B-ADR
symptoms I-ADR
such O
as O
encephalopathy O
and O
coma O

two O
patients O
on O
long-term O
lithium B-DRUG
therapy O
developed O
the O
nephrotic B-ADR
syndrome I-ADR

the O
major O
side O
effect O
of O
infliximab B-DRUG
is O
infection B-ADR

eleven O
patients O
developed O
infection B-ADR
requiring O
hospitalization O
while O
taking O
leflunomide B-DRUG
including O
: O
lower O
respiratory O
tract O
infections O
( O
3 O
) O
, O
cellulitis O
( O
2 O
) O
, O
disseminated O
herpes O
zoster O
( O
2 O
) O
, O
probable O
tb O
liver O
( O
1 O
) O
, O
abdominal O
sepsis O
( O
1 O
) O
, O
mycotic O
aneurysm O
( O
1 O
) O
and O
gastroenteritis O
( O
1 O

although O
interferon O
gamma O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
sarcoidosis B-ADR
, O
only O
a O
few O
cases O
of O
sarcoidosis B-ADR
associated O
with O
interferon B-DRUG
alpha I-DRUG
therapy O
have O
been O
reported O

hypertension B-ADR
develops O
in O
most O
patients O
after O
transplantation O
when O
immunosuppression O
is O
based O
on O
cyclosporine B-DRUG
and O
prednisone O

occult O
quinine-induced O
thrombocytopenia B-ADR

captopril-induced O
bone B-ADR
marrow I-ADR
suppression I-ADR
in O
two O
cardiac O
patients O
with O
trisomy O
21 O

interferon-based O
treatments O
have O
the O
potential O
to O
decrease O
the O
burden O
of O
disease O
, O
but O
are O
complicated O
by O
side O
effects O
, O
including O
neuropsychiatric B-ADR
symptoms I-ADR

we O
postulate O
that O
cyclosporin B-DRUG
, O
possibly O
together O
with O
ganciclovir O
, O
can O
produce O
transient B-ADR
brain I-ADR
stem I-ADR
or I-ADR
neuromuscular I-ADR
dysfunction I-ADR
with O
eye O
movement O
abnormality O
in O
occasional O
patients O

several O
hypersensitivity O
reactions O
to O
cloxacillin B-DRUG
have O
been O
reported O
, O
although O
ige-mediated B-ADR
allergic I-ADR
reactions I-ADR
to O
the O
drug O
are O
rare O
and O
there O
is O
little O
information O
about O
possible O
tolerance O
to O
other O
semisynthetic O
penicillins O
or O
cephalosporins O
in O
patients O
with O
cloxacillin B-DRUG
allergy O

clinical O
and O
morphological O
features O
of O
gold B-DRUG
neuropathy B-ADR

the O
latter O
form O
( O
macrodantin B-DRUG
) O
is O
reported O
to O
engender O
less O
gastrointestinal O
intolerance O
but O
it O
can O
produce O
the O
same O
adverse O
effects O
as O
the O
conventional O
form O
-- O
liver O
damage O
, O
acute O
and O
chronic O
pulmonary O
reactions O
, O
peripheral O
neuropathy O
, O
blood B-ADR
dyscrasias I-ADR
and O
allergic O
reactions O
-- O
and O
does O
so O
just O
as O
rapidly O
and O
floridly O
; O
one O
such O
case O
is O
reported O
here O

we O
report O
a O
case O
with O
chronic O
hepatitis O
c O
( O
chc O
) O
who O
developed O
sarcoidosis B-ADR
after O
the O
treatment O
by O
interferon B-DRUG
alpha I-DRUG
and O
ribavirin O

carbamazepine B-DRUG
hypersensitivity B-ADR
syndrome I-ADR
is O
a O
rare O
, O
life-threatening O
condition O

diclofenac-associated O
hepatitis B-ADR

after O
1 O
week O
of O
nefazodone B-DRUG
therapy O
the O
patient O
experienced O
headache B-ADR
, O
confusion O
, O
and O
" O
gray O
areas O
" O
in O
her O
vision O
, O
without O
abnormal O
ophthalmologic O
findings O

methotrexate-induced O
liver B-ADR
cirrhosis I-ADR

ten O
hours O
after O
the O
second O
methotrexate B-DRUG
injection O
, O
the O
patient O
experienced O
a O
diffuse B-ADR
pruritic I-ADR
papular I-ADR
eruption I-ADR
located O
mainly O
on O
the O
limbs O

we O
report O
the O
case O
of O
an O
87-year-old O
white O
woman O
with O
myasthenia O
gravis O
who O
presented O
with O
nausea B-ADR
, O
shortness O
of O
breath O
, O
azotemia O
, O
and O
hyperkalemia O
shortly O
after O
completing O
a O
course O
of O
intravenous O
immunoglobulin O
( O
ivig B-DRUG

a O
66-year-old O
mand O
suffering O
from O
severe O
coronary O
heart O
disease O
took O
digoxin B-DRUG
with O
suicidal O
intent O
an O
was O
treated O
for O
the O
ensuing O
complete B-ADR
atrioventricular I-ADR
block I-ADR
with O
digoxin-specific O
antibody O
fragments O

the O
possibility O
of O
severe O
rhabdomyolysis B-ADR
should O
be O
considered O
in O
a O
patient O
with O
water O
intoxication O
due O
to O
massive O
ingestion O
of O
caffeine-containing O
beverages O

that O
review O
suggested O
that O
patients O
receiving O
anti-d B-DRUG
igiv I-DRUG
be O
monitored O
for O
those O
and O
other O
potential O
complications O
of O
hemoglobinemia O
, O
particularly O
disseminated B-ADR
intravascular I-ADR
coagulation I-ADR
( O
dic O

it O
is O
the O
first O
case O
of O
ciprofloxacin-induced O
vbds B-ADR
successfully O
treated O
with O
tacrolimus O

there O
is O
evidence O
that O
the O
angiotensin O
ii O
receptor O
antagonist O
, O
losartan B-DRUG
, O
increases B-ADR
urate I-ADR
excretion I-ADR
by O
reducing O
reabsorption O
of O
urate O
in O
the O
renal O
proximal O
tubule O

cardiac B-ADR
arrest I-ADR
following O
use O
of O
sumatriptan B-DRUG

up O
to O
four O
percent O
of O
patients O
treated O
with O
imatinib B-DRUG
may O
develop O
hepatotoxicity B-ADR
, O
which O
usually O
resolves O
with O
discontinuation O
of O
the O
drug O

the O
naranjo O
probability O
scale O
indicated O
a O
probable O
relationship O
between O
apnea B-ADR
and O
exposure O
to O
lamotrigine B-DRUG
through O
breast-feeding O
in O
this O
infant O

background O
: O
interferon O
( O
ifn B-DRUG
)- O
associated O
retinopathy O
is O
typically O
characterized O
by O
retinal O
hemorrhages O
and O
cotton B-ADR
wool I-ADR
spots I-ADR
at O
the O
posterior O
fundus O
, O
but O
visual O
function O
is O
usually O
maintained O

we O
describe O
a O
patient O
who O
developed O
neh B-ADR
on O
three O
separate O
occasions O
provoked O
by O
two O
different O
chemotherapeutic O
agents O
-- O
cytarabine O
and O
mitoxantrone B-DRUG

lichenoid B-ADR
drug I-ADR
eruption I-ADR
to O
salsalate B-DRUG

a O
fatal B-ADR
case I-ADR
of I-ADR
pancytopenia I-ADR
due O
to O
levomepromazine B-DRUG

the O
occurrence O
of O
a O
myocardial B-ADR
infarction I-ADR
is O
reported O
after O
chemotherapy O
containing O
etoposide B-DRUG
, O
in O
a O
man O
with O
no O
risk O
factors O
for O
coronary O
heart O
disease O

we O
report O
an O
additional O
case O
of O
isotretinoin B-DRUG
teratogenicity O
in O
which O
the O
patient O
had O
agenesis O
of O
the O
cerebellar O
vermis O
, O
multiple O
leptomeningeal O
neuroglial O
heterotopias O
, O
hydrocephalus B-ADR
, O
and O
abnormalities O
of O
the O
corticospinal O
tracts O

pulmonary B-ADR
infiltrates I-ADR
and O
skin O
pigmentation O
associated O
with O
sulfasalazine B-DRUG

rhabdomyolysis B-ADR
associated O
with O
the O
use O
of O
intravenous O
vasopressin B-DRUG

in O
case O
no O
. O
2 O
, O
the O
pathogenic O
mechanism O
seemed O
to O
be O
persistent O
light O
reaction O
preceded O
by O
systemic O
photoallergy O
, O
as O
he O
had O
taken O
mequitazine O
for O
6 O
months O
, O
and O
there O
were O
strong O
positive O
photopatch O
test O
results O
with O
immediate O
erythema O
reaction O
, O
cross-reaction O
to O
promethazine B-DRUG
, O
decreased B-ADR
med I-ADR
to I-ADR
both I-ADR
uva I-ADR
and I-ADR
uvb I-ADR
, O
and O
persistence O
of O
the O
photosensitivity O
over O
a O
3-year O
follow-up O
period O
after O
discontinuation O
of O
the O
mequitazine O

terbinafine-induced O
cholestatic B-ADR
liver I-ADR
disease I-ADR

recurrent O
septicemia O
with O
lethal B-ADR
outcome O
during O
and O
after O
cyclosporine B-DRUG
therapy O
in O
severe O
ulcerative O
colitis O

eighty-two O
patients O
with O
various O
malignancies O
who O
received O
imipenem B-DRUG
/ O
cilastatin O
143 O
times O
for O
neutropenic B-ADR
fever I-ADR
between O
march O
1994 O
and O
october O
1999 O
in O
department O
of O
pediatric O
oncology O
, O
gazi O
university O
, O
were O
identified O

we O
describe O
a O
case O
of O
a O
man O
treated O
with O
an O
egfr-inhibitor O
( O
erlotinib B-DRUG
) O
for O
a O
cell O
lung O
cancer O
who O
developed O
skin B-ADR
manifestations I-ADR
localized O
in O
an O
uncommon O
area O
and O
with O
an O
atypical O
evolution O

objective O
: O
to O
describe O
two O
cases O
of O
rhabdomyolysis B-ADR
in O
patients O
taking O
lovastatin B-DRUG
that O
were O
precipitated O
by O
the O
use O
of O
the O
newer O
macrolide O
antibiotics O
clarithromycin O
and O
azithromycin O

disseminated O
intravascular O
coagulation O
associated O
with O
acute B-ADR
hemoglobinemia I-ADR
or O
hemoglobinuria O
following O
rh O
( O
0 O
)( O
d O
) O
immune O
globulin O
intravenous O
administration O
for O
immune O
thrombocytopenic O
purpura O

in O
the O
present O
paper O
, O
we O
discuss O
the O
first O
japanese O
vivax O
malaria O
patient O
whose O
qt B-ADR
interval I-ADR
was I-ADR
prolonged I-ADR
after O
treatment O
with O
halofantrine B-DRUG

fixed O
drug O
eruption B-ADR
in O
hands O
caused O
by O
omeprazole B-DRUG

the O
pulmonary B-ADR
toxicity I-ADR
of O
gold B-DRUG
salts O
is O
an O
uncommon O
cause O
of O
life-threatening O
respiratory O
failure O

ciprofloxacin-induced O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
in O
a O
patient O
with O
systemic O
lupus O
erythematosus O

after O
therapy O
for O
diabetic O
coma O
with O
insulin O
( O
containing O
the O
preservative O
cresol B-DRUG
) O
and O
electrolyte O
solutions O
was O
started O
, O
the O
patient O
complained O
of O
increasing O
myalgia O
, O
developed O
a O
high O
fever O
and O
respiratory B-ADR
and I-ADR
metabolic I-ADR
acidosis I-ADR
and O
lost O
consciousness O

objective O
: O
to O
study O
therapy O
with O
indapamide B-DRUG
impairing O
carbohydrate O
metabolism O
in O
essential O
hypertension O
patients O
and O
achieve O
earlier O
prevention O
, O
diagnoses O
and O
treatment O
of O
diabetes B-ADR
induced O
by O
indapamide B-DRUG

the O
third O
patient O
had O
been O
suffering O
from O
serious O
akathisia B-ADR
while O
on O
risperidone O
, O
and O
was O
cured O
after O
switching O
to O
olanzapine B-DRUG
, O
but O
thereafter O
the O
patient O
suffered O
from O
rls O
at O
nighttime O

the O
authors O
presented O
a O
case O
of O
pulmonary B-ADR
hypertension I-ADR
during O
lithium B-DRUG
therapy O
, O
while O
she O
has O
been O
on O
lithium B-DRUG
for O
6 O
years O

with O
the O
use O
of O
optical O
coherence O
tomography O
( O
oct O
) O
, O
two O
patients O
with O
ifn-associated O
retinopathy O
who O
had O
developed O
macular B-ADR
edema I-ADR
and O
reduced O
visual O
acuity O
during O
the O
clinical O
course O
of O
ifn B-DRUG
therapy O
were O
observed O

purpose O
: O
to O
report O
two O
cases O
in O
which O
topical O
brimonidine B-DRUG
resulted O
in O
apparent O
central B-ADR
nervous I-ADR
system I-ADR
depression I-ADR
and O
unresponsiveness O
in O
an O
infant O

in O
case O
1 O
, O
a O
total O
daily O
dose O
of O
25 O
mg O
sertraline O
, O
with O
nondetectable O
sertraline O
and O
desmethylsertraline O
blood O
levels O
, O
resulted O
in O
a O
doubling O
of O
the O
lamotrigine B-DRUG
blood O
level O
with O
symptoms B-ADR
of I-ADR
toxicity I-ADR

severe O
rhabdomyolysis O
following O
massive O
ingestion O
of O
oolong O
tea O
: O
caffeine B-ADR
intoxication I-ADR
with O
coexisting O
hyponatremia O

the O
current O
report O
describes O
a O
man O
who O
was O
prescribed O
zonisamide B-DRUG
for O
epilepsy O
and O
subsequently O
developed O
widespread O
skin B-ADR
rash I-ADR
, O
acute O
kidney O
injury O
, O
high-grade O
fever O
, O
eosinophilia O
, O
liver O
dysfunction O
, O
lymphadenopathy O
and O
an O
increase O
in O
antihuman O
herpesvirus-6 O
immunoglobulin O
g O
titer O

we O
describe O
the O
case O
of O
a O
nonatopic O
17-year-old O
girl O
with O
bronchial O
asthma O
and O
aspirin O
intolerance O
who O
developed O
a O
dramatic O
anaphylactic B-ADR
reaction I-ADR
to O
oral O
prednisone B-DRUG

cholestatic O
liver O
disease O
with O
ductopenia B-ADR
( O
vanishing O
bile O
duct O
syndrome O
) O
after O
administration O
of O
clindamycin B-DRUG
and O
trimethoprim-sulfamethoxazole O

this O
is O
the O
first O
report O
of O
non-convulsive B-ADR
status I-ADR
epilepticus I-ADR
provoked O
by O
tiagabine B-DRUG
in O
adolescent O
patients O

three O
cases O
of O
acute B-ADR
renal I-ADR
toxicity I-ADR
in O
patients O
receiving O
long-term O
therapy O
with O
mitomycin B-DRUG
c I-DRUG
and O
5-fluorouracil O
are O
reported O

caution O
in O
longterm O
usage O
and O
early O
recognition O
of O
pentazocine B-ADR
toxicity I-ADR
as O
a O
neuromuscular O
complication O
are O
important O
in O
order O
to O
prevent O
irreversible O
drug-induced O
fibrous O
myopathy O
and O
localized O
neuropathy O

ampicillin-induced O
interstitial B-ADR
nephritis I-ADR
with O
generalised O
exfoliative O
dermatitis O

an O
evaluation O
of O
ovarian O
structure O
and O
function O
should O
be O
considered O
in O
women O
of O
reproductive O
age O
being O
treated O
with O
valproate B-DRUG
for O
epilepsy O
, O
especially O
if O
they O
develop O
menstrual B-ADR
cycle I-ADR
disturbances I-ADR
during O
treatment O

heparin-associated O
thrombocytopenia B-ADR
and O
thrombosis O
is O
a O
severe O
complication O
of O
systemic O
heparin B-DRUG
therapy O

a O
toxic B-ADR
encephalopathy I-ADR
characterized O
by O
depressed O
level O
of O
consciousness O
, O
marked O
irritability O
, O
and O
ataxia O
developed O
in O
seven O
children O
, O
5 O
years O
of O
age O
and O
younger O
, O
following O
administration O
of O
an O
antiemetic O
combination O
of O
pentobarbital B-DRUG
and O
pyrilamine O
maleate O

imidazoline B-ADR
intoxication I-ADR
due O
to O
overdose O
or O
accidental O
ingestion O
but O
also O
after O
normal O
therapeutic O
usage O
is O
frequent O
in O
children O

nephrogenic B-ADR
diabetes I-ADR
insipidus I-ADR
( O
ndi O
) O
is O
a O
well-documented O
complication O
of O
lithium B-DRUG
use O

amiodarone B-DRUG
hydrochloride I-DRUG
, O
a O
new O
antiarrhythmic O
agent O
, O
has O
been O
associated O
with O
pulmonary O
toxicity O
characterized O
by O
cough O
, O
dyspnea O
and O
diffuse B-ADR
pulmonary I-ADR
infiltrates I-ADR

after O
therapy O
for O
diabetic O
coma O
with O
insulin B-DRUG
( O
containing O
the O
preservative O
cresol O
) O
and O
electrolyte O
solutions O
was O
started O
, O
the O
patient O
complained O
of O
increasing O
myalgia O
, O
developed O
a O
high B-ADR
fever I-ADR
and O
respiratory O
and O
metabolic O
acidosis O
and O
lost O
consciousness O

the O
present O
report O
suggests O
that O
clarithromycin B-DRUG
coadministration O
induces O
increased B-ADR
plasma I-ADR
carbamazepine I-ADR
concentrations O
, O
which O
may O
result O
in O
carbamazepine O
toxicity O

objectives O
: O
to O
describe O
the O
clinicopathologic O
features O
of O
3 O
patients O
with O
cml O
who O
rapidly O
progressed O
from O
chronic O
phase O
to O
blast B-ADR
crisis I-ADR
while O
taking O
imatinib B-DRUG
and O
to O
perform O
a O
review O
of O
the O
literature O

this O
is O
a O
unique O
autopsy O
case O
of O
hepatocellular B-ADR
carcinoma I-ADR
closely O
related O
to O
diethylstilbestrol B-DRUG
( O
des O
) O
therapy O
for O
prostatic O
cancer O

this O
clinical O
course O
suggests O
that O
the O
sensorimotor B-ADR
polyneuropathy I-ADR
may O
have O
been O
caused O
by O
5-asa B-DRUG

reversible O
sclerotic B-ADR
changes I-ADR
of I-ADR
lumbar I-ADR
spine I-ADR
and I-ADR
femur I-ADR
due O
to O
long-term O
oral O
isotretinoin B-DRUG
therapy O

we O
describe O
a O
patient O
who O
developed O
acute B-ADR
cerebellar I-ADR
syndrome I-ADR
after O
prophylactic O
intrathecal O
methotrexate B-DRUG
administration O
and O
recovered O
spontaneously O

piritrexim-induced O
pulmonary B-ADR
toxicity I-ADR

we O
report O
a O
case O
of O
stevens-johnson B-ADR
syndrome I-ADR
/ O
toxic O
epidermal O
necrolysis O
( O
sjs O
/ O
ten O
) O
secondary O
to O
trimethoprim-sulfamethoxazole O
( O
tmp-sx B-DRUG
) O
therapy O
for O
presumed O
community-associated O
methicillin-resistant O
staphylococcus O
aureus O
( O
ca-mrsa O
) O
infection O

recently O
, O
some O
studies O
have O
also O
reported O
association O
between O
patients O
with O
juvenile O
rheumatoid O
arthritis O
( O
jra O
) O
treated O
with O
methotrexate O
( O
mtx B-DRUG
) O
and O
malignant B-ADR
lymphoma I-ADR
developing O

leukopenia B-ADR
due O
to O
parvovirus O
b19 O
in O
a O
crohn O
's O
disease O
patient O
using O
azathioprine B-DRUG

a O
diagnosis O
of O
infliximab-induced O
lupus B-ADR
was O
made O
and O
the O
drug O
treatment O
was O
withdrawn O

the O
goal O
of O
this O
study O
is O
to O
describe O
three O
patients O
diagnosed O
with O
migraine O
and O
epilepsy O
( O
both O
under O
control O
) O
who O
evolved O
into O
status B-ADR
migrainosus I-ADR
after O
the O
introduction O
of O
oxcarbazepine O
( O
oxc B-DRUG
) O
, O
as O
part O
of O
a O
switch O
off O
from O
carbamazepine O
( O
cbz O

in O
case O
no O
. O
2 O
, O
the O
pathogenic O
mechanism O
seemed O
to O
be O
persistent O
light O
reaction O
preceded O
by O
systemic O
photoallergy O
, O
as O
he O
had O
taken O
mequitazine B-DRUG
for O
6 O
months O
, O
and O
there O
were O
strong O
positive O
photopatch O
test O
results O
with O
immediate O
erythema O
reaction O
, O
cross-reaction O
to O
promethazine O
, O
decreased O
med O
to O
both O
uva O
and O
uvb O
, O
and O
persistence B-ADR
of I-ADR
the I-ADR
photosensitivity I-ADR
over O
a O
3-year O
follow-up O
period O
after O
discontinuation O
of O
the O
mequitazine B-DRUG

rifampin B-DRUG
can O
be O
associated O
with O
severe O
adverse O
effects O
such O
as O
hepatitis O
, O
acute O
renal O
failure O
, O
hemolytic O
anemia O
, O
and O
thrombocytopenia B-ADR

the O
patient O
experienced O
muscle O
twitches O
, O
tremulousness O
, O
and O
anxiety B-ADR
on O
day O
17 O
of O
foscarnet B-DRUG
therapy O

acute O
drug O
induced O
hepatitis B-ADR
due O
to O
erlotinib B-DRUG

although O
it O
is O
difficult O
to O
solely O
attribute O
intratumoral B-ADR
hemorrhage I-ADR
to O
aspirin B-DRUG
, O
we O
have O
to O
be O
careful O
when O
prescribing O
aspirin B-DRUG
for O
patients O
who O
have O
asymptomatic O
meningioma O

however O
, O
peripheral O
neuropathy B-ADR
and O
bone O
marrow O
depression O
led O
to O
linezolid B-DRUG
withdrawal O
in O
seven O
patients O
, O
and O
neuropathy B-ADR
may O
not O
be O
fully O
reversible O
in O
all O
patients O

reversible O
cholestasis B-ADR
with O
bile O
duct O
injury O
following O
azathioprine B-DRUG
therapy O

objective O
: O
to O
report O
a O
case O
of O
carbamazepine B-ADR
toxicity I-ADR
following O
the O
administration O
of O
oxybutynin B-DRUG
and O
dantrolene O

fibrosis B-ADR
of I-ADR
corpus I-ADR
cavernosum I-ADR
after O
intracavernous O
injection O
of O
phentolamine B-DRUG
/ O
papaverine O

conclusions O
: O
patients O
receiving O
intravitreal O
injections O
of O
bevacizumab B-DRUG
should O
be O
evaluated O
for O
potential O
systemic O
risk O
factors O
such O
as O
carotid O
insufficiency O
, O
coagulopathy O
and O
poorly B-ADR
controlled I-ADR
diabetes I-ADR
mellitus I-ADR

a O
study O
of O
in O
vitro O
reactivity O
to O
l-t4 B-DRUG
, O
as O
assessed O
by O
peripheral O
blood O
lymphocyte O
transformation O
, O
was O
carried O
out O
in O
a O
patient O
with O
hashimoto O
's O
disease O
who O
developed O
leukopenia B-ADR
during O
treatment O
with O
l-t4 B-DRUG

lovastatin-induced O
rhabdomyolysis B-ADR
possibly O
associated O
with O
clarithromycin O
and O
azithromycin B-DRUG

objective O
: O
to O
report O
a O
case O
of O
carbamazepine B-ADR
toxicity I-ADR
following O
the O
administration O
of O
oxybutynin O
and O
dantrolene O

the O
most O
likely O
cause O
of O
liver B-ADR
failure I-ADR
in O
this O
patient O
was O
, O
therefore O
, O
clarithromycin B-DRUG
, O
which O
undergoes O
hepatic O
metabolism O
and O
has O
been O
reported O
to O
cause O
fulminant O
hepatic O
failure O

we O
discuss O
a O
patient O
who O
developed O
severe O
renal O
tubular O
dysfunction O
secondary O
to O
short-term O
therapy O
with O
amikacin B-DRUG
, O
resulting O
in O
refractory O
hypokalemia O
, O
hypocalcemia B-ADR
, O
hypomagnesemia O
, O
metabolic O
alkalosis O
, O
and O
polyuria O

the O
main O
side-effects O
of O
lp-tae B-DRUG
combined O
with O
ht O
were O
low-grade B-ADR
fever I-ADR
, O
localized O
pain O
, O
myelo-suppression O
and O
liver O
dysfunction O
, O
but O
these O
were O
transient O
and O
eventually O
disappeared O

photo-onycholysis B-ADR
caused O
by O
olanzapine B-DRUG
and O
aripiprazole O

pirmenol B-DRUG
hydrochloride-induced O
qt O
prolongation O
and O
t B-ADR
wave I-ADR
inversion I-ADR
on O
electrocardiogram O
during O
treatment O
for O
symptomatic O
atrial O
fibrillation O

conclusion O
: O
a O
37-year-old O
african O
- O
american O
man O
with O
g6pd O
deficiency O
developed O
hemolytic B-ADR
anemia I-ADR
, O
hepatitis O
, O
orthostatic O
hypotension O
, O
and O
aseptic O
meningitis O
simultaneously O
after O
using O
trimethoprim-sulfamethoxazole O

the O
typical O
fluoxetine-induced O
symptoms O
of O
restlessness O
, O
constant B-ADR
pacing I-ADR
, O
purposeless O
movements O
of O
the O
feet O
and O
legs O
, O
and O
marked O
anxiety O
were O
indistinguishable O
from O
those O
of O
neuroleptic-induced O
akathisia O

she O
developed O
a O
generalized O
rash O
and O
itching O
, O
sore O
throat O
, O
and O
dizziness B-ADR
approximately O
4 O
hours O
after O
the O
first O
dose O
of O
capecitabine B-DRUG

objective O
: O
to O
report O
on O
the O
possible O
development O
of O
serotonin B-ADR
syndrome I-ADR
in O
a O
patient O
receiving O
clomipramine O
after O
clozapine B-DRUG
was O
withdrawn O
from O
the O
treatment O
regimen O

we O
present O
two O
cases O
in O
which O
both O
patients O
suffered O
with O
cls B-ADR
, O
which O
we O
believe O
was O
caused O
following O
administration O
of O
granulocyte B-DRUG
colony-stimulating I-DRUG
factor I-DRUG
, O
to O
our O
knowledge O
not O
described O
in O
the O
intensive O
care O
patient O
previously O

reversal O
of O
ergotamine-induced O
arteriospasm B-ADR
by O
mechanical O
intra-arterial O
dilatation O

both O
the O
longitudinal B-ADR
melanonychia I-ADR
and O
the O
multiple O
skin O
cancers O
first O
appeared O
after O
approximately O
6 O
months O
of O
hydroxyurea B-DRUG
treatment O

during O
her O
third O
cycle O
, O
she O
again O
received O
cisplatin B-DRUG
100 O
mg O
/ O
m2 O
over O
30 O
minutes O
and O
developed O
palmar B-ADR
pruritus I-ADR
, O
urticaria O
, O
and O
edema O

objective O
: O
1 O
) O
to O
describe O
a O
patient O
with O
rheumatoid O
arthritis O
receiving O
adalimumab B-DRUG
who O
developed O
fever O
, O
pancytopenia B-ADR
, O
splenomegaly O
, O
and O
extreme O
hyperferritinemia O

the O
pathophysiological O
mechanisms O
remain O
unknown O
, O
although O
the O
drug O
could O
act O
through O
massive O
cytokines O
liberation O
after O
destruction B-ADR
of I-ADR
cd20 I-ADR
positive I-ADR
cells I-ADR
by O
rituximab B-DRUG

physicians O
should O
be O
aware O
of O
the O
potential O
for O
the O
development O
of O
rs B-ADR
among O
children O
who O
are O
receiving O
long-term O
aspirin B-DRUG
therapy O
for O
the O
treatment O
of O
systemic O
inflammatory O
illnesses O

assessment O
of O
cortisol O
response O
was O
by O
insulin-induced O
hypoglycaemia B-ADR
in O
three O
cases O
, O
by O
short O
tetracosactrin O
test O
in O
two O
, O
and O
by O
low-dose O
tetracosactrin O
and O
24-hour O
urinary O
cortisol O
/ O
creatinine O
ratio O
in O
one O

the O
condition O
should O
be O
suspected O
in O
patients O
who O
develop O
unexplained O
abdominal B-ADR
pain I-ADR
or O
collapse O
following O
vasopressin B-DRUG
treatment O

we O
consider O
asterixis B-ADR
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity O
, O
which O
may O
occur O
even O
at O
low O
or O
moderate O
dosage O
levels O
, O
if O
certain O
drugs O
as O
lithium B-DRUG
or O
clozapine O
are O
used O
in O
combination O
with O
cbz O

we O
discuss O
a O
patient O
who O
developed O
severe O
renal O
tubular O
dysfunction O
secondary O
to O
short-term O
therapy O
with O
amikacin B-DRUG
, O
resulting O
in O
refractory B-ADR
hypokalemia I-ADR
, O
hypocalcemia O
, O
hypomagnesemia O
, O
metabolic O
alkalosis O
, O
and O
polyuria O

adult B-ADR
respiratory I-ADR
distress I-ADR
syndrome I-ADR
after O
treatment O
with O
pegylated B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
and O
ribavirin O

stroke B-ADR
is O
an O
infrequent O
but O
recognized O
complication O
of O
heroin B-DRUG
addiction O

conclusions O
: O
itraconazole-induced O
liver O
injury O
presents O
with O
a O
cholestatic O
pattern O
of O
injury O
with O
damage O
to O
the O
interlobular O
bile O
ducts O
, O
possibly O
leading O
to O
ductopenia B-ADR

a O
44-year-old O
woman O
is O
described O
in O
whom O
amiodarone O
, O
disopyramide O
, O
and O
quinidine B-DRUG
, O
administered O
alone O
separately O
, O
induced O
atypical O
ventricular O
tachycardia O
( O
avt B-ADR
, O
torsade O
de O
pointes O

a O
patient O
developed O
transient O
, O
acute B-ADR
myopia I-ADR
while O
on O
isotretinoin B-DRUG
( O
accutane O
) O
therapy O
for O
acne O

results O
: O
replacing O
valproate B-DRUG
with O
lamotrigine O
resulted O
in O
a O
decrease O
in O
serum B-ADR
testosterone I-ADR
concentrations O
in O
all O
3 O
women O

clinicians O
should O
be O
vigilant O
when O
monitoring O
for O
cardiotoxicity B-ADR
in O
patients O
receiving O
pentamidine B-DRUG
throughout O
the O
duration O
of O
therapy O

lithium O
treatment O
was O
terminated O
in O
1975 O
because O
of O
lithium B-DRUG
intoxication O
with O
a O
diabetes B-ADR
insipidus-like I-ADR
syndrome I-ADR

l-asparaginase-induced O
pancreatitis B-ADR
has O
been O
reported O
during O
or O
closely O
following O
administration O
of O
the O
drug O

though O
they O
are O
generally O
considered O
safe O
, O
there O
have O
been O
a O
few O
reports O
of O
myocardial O
infarction O
and O
stroke B-ADR
associated O
with O
triptan B-DRUG
use O

to O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
lithium-associated O
cdi B-ADR
and O
ndi O
presenting O
concurrently O

in O
both O
cases O
, O
high O
fever O
, O
skin O
rash O
, O
liver B-ADR
dysfunction I-ADR
and O
atypical O
lymphocytosis O
developed O
3 O
weeks O
after O
initiating O
treatment O
with O
sasp B-DRUG

discussion O
: O
the O
main O
adverse O
effects O
of O
leflunomide B-DRUG
consist O
of O
diarrhea O
, O
nausea O
, O
liver O
enzyme O
elevation O
, O
hypertension B-ADR
, O
alopecia O
, O
and O
allergic O
skin O
reactions O

antibiotic-associated O
colitis O
( O
pseudomembranous B-ADR
colitis I-ADR
) O
developed O
in O
four O
patients O
with O
spinal O
cord O
injury O
and O
taking O
oral O
trimethoprim-sulfamethoxazole O

immobilization O
, O
while O
paget O
's O
bone O
disease O
was O
present O
, O
and O
perhaps O
enhanced O
activation O
of O
dihydrotachysterol B-DRUG
by O
rifampicin O
, O
could O
have O
led O
to O
increased B-ADR
calcium-release I-ADR
into O
the O
circulation O

an O
infant O
girl O
with O
choanal O
atresia O
, O
athelia O
, O
minor O
anomalies O
, O
and O
mild O
to O
moderate O
mental B-ADR
retardation I-ADR
was O
born O
to O
a O
woman O
treated O
for O
hyperthyroidism O
throughout O
pregnancy O
with O
methimazole O
and O
propranolol B-DRUG

triazolam-induced O
nocturnal O
bingeing O
with O
amnesia B-ADR

a O
patient O
receiving O
vancomycin B-DRUG
for O
a O
serious O
staphylococcal O
infection O
had O
a O
lupus-like O
syndrome O
characterized O
by O
a O
malar O
rash O
, O
pain O
and O
erythema O
of O
the O
cartilage O
of O
both O
ears O
, O
and O
tender O
erythematous O
and O
hemorrhagic B-ADR
lesions I-ADR
of I-ADR
the I-ADR
finger I-ADR
tips I-ADR

we O
document O
the O
abrupt O
development O
of O
an O
extensive O
choroidal B-ADR
detachment I-ADR
after O
initiation O
of O
dorzolamide B-DRUG
therapy O
in O
a O
surgically O
untreated O
eye O
with O
primary O
open-angle O
glaucoma O

refractory B-ADR
hypoglycemia I-ADR
from O
ciprofloxacin B-DRUG
and O
glyburide O
interaction O

occasionally O
, O
despite O
good O
therapeutic O
response O
, O
clozapine B-DRUG
must O
be O
stopped O
due O
to O
dangerous O
side O
effects O
such O
as O
agranulocytosis B-ADR

a O
40-year-old O
man O
with O
relapsing-remitting O
multiple O
sclerosis O
( O
ms O
) O
developed O
primary B-ADR
central I-ADR
nervous I-ADR
system I-ADR
lymphoma I-ADR
( O
pcnsl O
) O
after O
having O
received O
21 O
doses O
of O
natalizumab B-DRUG
monotherapy O

to O
our O
knowledge O
, O
the O
syndrome O
of O
fever O
, O
pulmonary O
infiltrates O
, O
and O
pleural B-ADR
effusion I-ADR
following O
use O
of O
acyclovir B-DRUG
has O
not O
been O
previously O
reported O

we O
consider O
asterixis O
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity B-ADR
, O
which O
may O
occur O
even O
at O
low O
or O
moderate O
dosage O
levels O
, O
if O
certain O
drugs O
as O
lithium O
or O
clozapine O
are O
used O
in O
combination O
with O
cbz B-DRUG

abrupt O
, O
accidental O
withdrawal O
of O
trihexyphenidyl B-DRUG
triggered O
severe O
exacerbation O
of O
the O
cranial O
dystonia O
associated O
with O
inspiratory B-ADR
stridor I-ADR
and O
acute O
respiratory O
difficulties O
, O
prompting O
emergency O
admission O

indinavir-associated O
nephrolithiasis O
and O
chronic O
interstitial B-ADR
nephritis I-ADR
were O
the O
only O
possible O
causes O
identified O
in O
this O
patient O

barbiturate-induced O
submassive B-ADR
hepatic I-ADR
necrosis I-ADR

in O
this O
paper O
, O
we O
report O
a O
case O
of O
severe B-ADR
hypercalcemia I-ADR
of O
immobilization O
in O
a O
40-year-old O
hemodialyzed O
woman O
treated O
by O
cinacalcet B-DRUG
hcl I-DRUG
for O
a O
severe O
hpth-ii O
( O
pth O
> O
1,000 O
pg O
/ O
ml O

pathogenesis O
of O
methotrexate-induced O
papular B-ADR
eruption I-ADR
in O
psoriasis O
may O
involve O
immune O
mechanisms O
other O
than O
those O
of O
methotrexate-induced O
cutaneous O
vasculitis O
in O
collagen O
vascular O
disease O

the O
authors O
report O
a O
longitudinal O
case O
study O
of O
a O
woman O
with O
a O
history O
of O
bipolar O
affective O
disorder O
in O
which O
l-dopa B-DRUG
shortened B-ADR
the I-ADR
manic-depressive I-ADR
cycle I-ADR
length O
when O
administered O
in O
a O
double-blind O
trial O

the O
development O
of O
cutaneous O
ecchymosis O
associated O
with O
a O
sudden B-ADR
fall I-ADR
in I-ADR
hemoglobin I-ADR
after O
the O
administration O
of O
alteplase B-DRUG
should O
strongly O
suggest O
the O
possibility O
of O
diffuse O
subfascial O
hematoma O

the O
toxicity B-ADR
and O
plasma O
concentrations O
of O
ifosfamide O
, O
chloroacetaldehyde O
, O
and O
4-hydroxyifosfamide B-DRUG
were O
then O
determined O
over O
24 O
h O
after O
a O
single O
1.6 O
g O
/ O
m2 O
dose O
of O
ifosfamide O

a O
32-year-old O
man O
with O
a O
family O
history O
of O
type O
2 O
diabetes O
mellitus O
presented O
with O
circulatory B-ADR
collapse I-ADR
and O
deep O
coma O
after O
9 O
days O
of O
treatment O
with O
perospirone B-DRUG
hydrochloride I-DRUG
, O
a O
recently O
developed O
atypical O
antipsychotic O
agent O
available O
only O
in O
japan O

quinapril B-DRUG
is O
an O
angiotensin-converting O
enzyme O
inhibitor O
( O
ace-inhibitor O
) O
and O
overdose O
can O
lead O
to O
prolonged B-ADR
hypotension I-ADR
and O
, O
less O
frequently O
, O
transient O
renal O
impairment O

we O
report O
a O
case O
of O
a O
patient O
with O
pulmonary O
hypertension O
and O
undifferentiated O
connective O
tissue O
disease O
who O
, O
after O
2 O
months O
of O
treatment O
with O
epoprostenol B-DRUG
, O
presented O
with O
rapidly B-ADR
progressive I-ADR
erythema I-ADR
, O
scaling O
, O
nausea O
and O
vomiting O
, O
and O
fever O

vancomycin B-DRUG
is O
widely O
used O
against O
methicillin-resistant O
staphylococcus O
aureus O
infections O
, O
but O
it O
is O
associated O
with O
many O
adverse O
effects O
such O
as O
nephrotoxicity O
, O
ototoxicity O
, O
gastrointestinal O
disturbances O
, O
blood O
disorders O
, O
and O
two O
types O
of O
hypersensitivity O
reactions O
- O
an O
anaphylactoid O
reaction O
known O
as O
" O
red O
man O
syndrome O
" O
and O
anaphylaxis B-ADR

massive B-ADR
plasmocytosis I-ADR
due O
to O
methimazole-induced O
bone O
marrow O
toxicity O

when O
measured O
, O
the O
serum B-ADR
lithium I-ADR
level I-ADR
had I-ADR
increased I-ADR
4-fold O
during O
acyclovir B-DRUG
therapy O

vocal B-ADR
cord I-ADR
paralysis I-ADR
as O
a O
consequence O
of O
peritonsillar O
infiltration O
with O
bupivacaine B-DRUG

we O
conclude O
peripheral B-ADR
neuropathy I-ADR
with O
5-fu B-DRUG
is O
rare O

this O
latest O
( O
third O
) O
report O
suggests O
that O
the O
safety O
profile O
should O
be O
reexamined O
and O
at O
least O
raises O
the O
question O
of O
potential O
renal B-ADR
toxicity I-ADR
of O
interferons B-DRUG
in O
ms O

conclusions O
: O
symptoms O
and O
pathologic O
changes O
of O
colitis B-ADR
are O
associated O
with O
exposure O
to O
rofecoxib B-DRUG

a O
case O
of O
severe B-ADR
visual I-ADR
loss I-ADR
following O
a O
single O
dose O
of O
vincristine B-DRUG
is O
described O

we O
report O
a O
case O
of O
interstitial B-ADR
pneumonitis I-ADR
induced O
by O
bicalutamide B-DRUG
and O
/ O
or O
leuprorelin O
acetate O
given O
as O
therapy O
for O
prostate O
cancer O
, O
in O
which O
the O
pneumonitis O
was O
successfully O
managed O
by O
steroid O
treatment O

an O
infant O
girl O
with O
choanal O
atresia O
, O
athelia B-ADR
, O
minor O
anomalies O
, O
and O
mild O
to O
moderate O
mental O
retardation O
was O
born O
to O
a O
woman O
treated O
for O
hyperthyroidism O
throughout O
pregnancy O
with O
methimazole B-DRUG
and O
propranolol O

after O
a O
two-month O
interruption O
of O
interferon O
administration O
, O
natural O
interferon B-DRUG
alpha I-DRUG
was O
given O
but O
followed O
by O
another O
episode O
of O
the O
same O
neurological B-ADR
manifestations I-ADR

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical B-ADR
lymphadenopathy I-ADR
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp B-DRUG
)- O
sulfamethoxazole O
( O
smx O
) O
treatment O

protease O
inhibitors O
( O
ritonavir O
and O
saquinavir B-DRUG
) O
were O
added O
to O
the O
treatment O
and O
the O
patient O
developed O
progressive B-ADR
ataxia I-ADR
related O
to O
carbamazepine O
toxicity O

we O
report O
the O
case O
of O
a O
lung O
cancer O
patient O
with O
bronquiloalveolar O
carcinoma O
( O
bac O
) O
presenting O
with O
boop O
after O
chemotherapy O
with O
docetaxel B-DRUG
and O
gemcitabine O
producing O
severe O
respiratory O
insufficiency O
, O
and O
simulating O
a O
progression B-ADR
of I-ADR
the I-ADR
tumor I-ADR

purpose O
: O
the O
case O
of O
a O
patient O
who O
developed O
aseptic B-ADR
meningitis I-ADR
, O
hemolytic O
anemia O
, O
hepatitis O
, O
and O
orthostatic O
hypotension O
simultaneously O
during O
treatment O
with O
trimethoprim-sulfamethoxazole O
is O
described O

muzolimine-induced O
severe B-ADR
neuromyeloencephalopathy I-ADR
: O
report O
of O
seven O
cases O

gallstones B-ADR
and O
bile O
sludge O
are O
common O
side O
effects O
of O
octreotide B-DRUG
therapy O
but O
rarely O
become O
symptomatic O
or O
require O
treatment O

skin B-ADR
necrosis I-ADR
is O
a O
rare O
complication O
of O
subcutaneous O
heparin B-DRUG
therapy O
that O
usually O
occurs O
at O
injection O
sites O

attempts O
were O
made O
to O
stop O
and O
then O
restart O
the O
theophylline B-DRUG
therapy O
at O
progressively O
lower O
doses O
; O
however O
, O
with O
each O
attempt O
, O
the O
patient O
's O
reaction B-ADR
to I-ADR
the I-ADR
drug I-ADR
became I-ADR
more I-ADR
toxic I-ADR
, O
with O
serum O
theophylline B-DRUG
levels O
ranging O
between O
99.9 O
and O
149.9 O
micromol O
/ O
l O
( O
18 O
and O
27 O
microg O
/ O
ml O

hypo-oestrogenic B-ADR
and I-ADR
anabolic I-ADR
/ I-ADR
androgenic I-ADR
side-effects I-ADR
of O
danazol B-DRUG
are O
well O
known O
by O
the O
gynaecologist O
and O
some O
of O
them O
are O
present O
in O
> O
50 O
% O
of O
patients O
being O
treated O
for O
endometriosis O

we O
report O
the O
case O
of O
a O
patient O
with O
multiple O
myeloma O
who O
developed O
acute O
life-threatening B-ADR
water I-ADR
intoxication I-ADR
following O
treatment O
with O
oral O
indomethacin O
and O
low O
dose O
intravenous O
cyclophosphamide B-DRUG

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash O
, O
fever O
, O
leukopenia B-ADR
and O
positive O
anti-nuclear O
antibody O
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine O
( O
cbz O
; O
tegretol B-DRUG
) O
used O
against O
benign O
rolandic O
epilepsy O

we O
describe O
two O
cases O
of O
psvt O
that O
changed O
to O
non-sustained B-ADR
polymorphic I-ADR
ventricular I-ADR
tachycardia I-ADR
after O
administration O
of O
verapamil B-DRUG

the O
day O
after O
clozapine B-DRUG
was O
stopped O
, O
while O
he O
was O
still O
receiving O
clomipramine O
150 O
mg O
/ O
d O
, O
he O
began O
behaving O
oddly O
, O
started O
sweating O
profusely O
, O
shivering O
, O
and O
became O
tremulous B-ADR
, O
agitated O
, O
and O
confused O

intracranial O
hemorrhage O
and O
focal B-ADR
seizures I-ADR
secondary O
to O
use O
of O
l-asparaginase B-DRUG
during O
induction O
therapy O
of O
acute O
lymphocytic O
leukemia O

he O
developed O
fever O
, O
nausea B-ADR
, O
diarrhea O
, O
and O
malaise O
and O
stopped O
taking O
on O
the O
third O
day O
after O
commencing O
pentasa B-DRUG

toxic B-ADR
hepatitis I-ADR
induced O
by O
disulfiram B-DRUG
in O
a O
non-alcoholic O

this O
case O
describes O
fulminant B-ADR
hepatic I-ADR
failure I-ADR
in O
a O
patient O
taking O
disulfiram B-DRUG
with O
no O
previous O
liver O
disease O
and O
report O
of O
being O
compliant O
with O
alcohol O
abstinence O

hyperkalemia B-ADR
as O
a O
late O
side O
effect O
of O
prolonged O
adrenocorticotropic B-DRUG
hormone I-DRUG
therapy O
for O
infantile O
spasms O

a O
61-year-old O
man O
with O
early O
diffuse O
cutaneous O
scleroderma O
with O
myositis O
and O
progressive O
interstitial O
pneumonia O
developed O
generalized B-ADR
erythema I-ADR
with O
high O
fever O
3 O
weeks O
after O
taking O
sulfamethoxazole B-DRUG
/ O
trimethoprim O

allergic O
reaction O
to O
gemfibrozil B-DRUG
manifesting O
as O
eosinophilic B-ADR
gastroenteritis I-ADR

she O
was O
administered O
metoclopramide B-DRUG
because O
of O
nausea O
and O
, O
within O
2 O
hours O
, O
developed O
agitation O
, O
dysarthria B-ADR
, O
diaphoresis O
, O
and O
a O
movement O
disorder O

thus O
, O
the O
patient O
's O
clinical O
course O
and O
workup O
strongly O
support O
a O
diagnosis O
of O
lenalidomide-induced O
hypersensitivity B-ADR
pneumonitis-like I-ADR
syndrome I-ADR

mtx-induced O
hepatic O
injury O
and O
liver B-ADR
enzyme I-ADR
elevations I-ADR
have O
been O
demonstrated O
after O
treatment O
of O
leukemia O
, O
gestational O
disease O
and O
during O
treatment O
of O
psoriasis O
and O
rheumatoid O
arthritis O

by O
means O
of O
the O
in O
vitro O
heparin-induced O
platelet B-ADR
activation I-ADR
( O
hipa O
) O
assay O
it O
was O
shown O
that O
standard O
heparin O
and O
the O
lmw O
heparins O
fragmin O
and O
fraxiparin B-DRUG
( O
sanofi O
labaz O
, O
munich O
, O
frg O
) O
, O
as O
well O
as O
the O
enoxaparine O
clexane O
( O
nattermann O
, O
cologne O
, O
frg O
) O
, O
all O
induced O
platelet B-ADR
activation I-ADR
with O
the O
patient O
's O
serum O

hepatic B-ADR
damage I-ADR
after O
danazol B-DRUG
treatment O

drug-induced O
mammary B-ADR
hyperplasias I-ADR
have O
been O
reported O
as O
rare O
complications O
of O
d-penicillamine O
and O
neothetazone B-DRUG

the O
current O
report O
describes O
a O
man O
who O
was O
prescribed O
zonisamide B-DRUG
for O
epilepsy O
and O
subsequently O
developed O
widespread O
skin O
rash O
, O
acute O
kidney O
injury O
, O
high-grade O
fever O
, O
eosinophilia B-ADR
, O
liver O
dysfunction O
, O
lymphadenopathy O
and O
an O
increase O
in O
antihuman O
herpesvirus-6 O
immunoglobulin O
g O
titer O

pulmonary O
hemorrhage O
as O
a O
clinical O
manifestation O
of O
hemolytic-uremic B-ADR
syndrome I-ADR
associated O
with O
mitomycin B-DRUG
c I-DRUG
therapy O

objective O
: O
to O
report O
2 O
cases O
of O
serotonin O
syndrome O
with O
serious O
extrapyramidal B-ADR
movement I-ADR
disorders I-ADR
occurring O
when O
metoclopramide O
was O
coadministered O
with O
sertraline B-DRUG
or O
venlafaxine O

shortly O
after O
chemotherapy O
and O
an O
injection O
of O
pegfilgrastim B-DRUG
, O
the O
patient O
developed O
poorly O
defined O
, O
rapidly O
progressive O
erythema O
, O
edema O
, O
and O
pain B-ADR
in I-ADR
his I-ADR
right I-ADR
forearm I-ADR

we O
describe O
the O
case O
of O
a O
50-year-old O
woman O
with O
advanced O
non-small O
cell O
lung O
cancer O
who O
developed O
status B-ADR
epilepticus I-ADR
shortly O
after O
receiving O
cisplatin B-DRUG
and O
gemcitabine O
chemotherapy O

a O
55-year-old O
woman O
presented O
an O
episode O
of O
acute B-ADR
urticaria I-ADR
and O
labial O
angioedema O
60 O
minutes O
after O
ingesting O
500 O
mg O
of O
cloxacillin B-DRUG
for O
a O
skin O
abscess O

we O
report O
the O
occurrence O
of O
spontaneous O
intracranial B-ADR
bleeding I-ADR
in O
an O
human O
immunodeficiency O
virus O
( O
hiv O
)- O
infected O
adolescent O
with O
hemophilia O
a O
who O
was O
receiving O
amprenavir B-DRUG
( O
apv O

observations O
in O
our O
patient O
suggest O
that O
the O
leukoencephalopathy B-ADR
that O
developed O
in O
previously O
reported O
patients O
who O
received O
5-fluorouracil O
and O
levamisole B-DRUG
may O
have O
been O
caused O
at O
least O
partly O
by O
levamisole B-DRUG

a O
58-year O
old O
patient O
is O
reported O
who O
developed O
an O
ischaemic B-ADR
cerebrovascular I-ADR
accident I-ADR
22 O
hours O
after O
successful O
thrombolysis O
with O
streptokinase B-DRUG
for O
life-threatening O
pulmonary O
emboli O

to O
our O
knowledge O
, O
this O
is O
the O
first O
granulomatous B-ADR
reaction I-ADR
described O
after O
calcium B-DRUG
hydroxylapatite I-DRUG
injection O

although O
it O
would O
be O
expected O
that O
, O
like O
other O
type O
ia O
toxicities O
, O
diphenhydramine-induced O
cardiotoxicity B-ADR
could O
be O
responsive O
to O
hypertonic O
sodium O
bicarbonate O
, O
this O
finding O
is O
largely O
unappreciated O

acute B-ADR
endophthalmitis I-ADR
following O
intravitreal O
bevacizumab B-DRUG
( O
avastin O
) O
injection O

paraplegia B-ADR
following O
prophylactic O
intrathecal O
cytosine O
arabinoside O
( O
ara-c B-DRUG
) O
is O
described O
in O
a O
patient O
with O
acute O
myelogenous O
leukemia O
in O
remission O
who O
received O
doses O
of O
100 O
mg O
/ O
m2 O
/ O
d O
for O
5 O
consecutive O
days O

ketanserin O
in O
the O
treatment O
of O
protamine-induced O
pulmonary B-ADR
hypertension I-ADR

we O
describe O
the O
development O
of O
ischemic B-ADR
colitis I-ADR
in O
a O
woman O
who O
was O
treated O
with O
tegaserod B-DRUG
and O
review O
the O
relationship O
among O
ischemic B-ADR
colitis I-ADR
, O
tegaserod B-DRUG
use O
, O
and O
irritable O
bowel O
syndrome O

case O
study O
: O
adverse B-ADR
response I-ADR
to O
clonidine B-DRUG

we O
report O
a O
patient O
with O
pulmonary O
adenocarcinoma O
complicated O
by O
the O
syndrome O
of O
inappropriate O
secretion O
of O
antidiuretic O
hormone O
( O
siadh B-ADR
) O
following O
systemic O
chemotherapy O
with O
cisplatin O
( O
cddp B-DRUG
) O
and O
vindesine O
( O
vds O

the O
toxicity B-ADR
and O
plasma O
concentrations O
of O
ifosfamide B-DRUG
, O
chloroacetaldehyde O
, O
and O
4-hydroxyifosfamide O
were O
then O
determined O
over O
24 O
h O
after O
a O
single O
1.6 O
g O
/ O
m2 O
dose O
of O
ifosfamide B-DRUG

choroidal B-ADR
hemorrhage I-ADR
associated O
with O
systemic O
tissue B-DRUG
plasminogen I-DRUG
activator I-DRUG

mucosal B-ADR
pigmentation I-ADR
after O
oral O
lichen O
planus O
treatment O
with O
topical O
tacrolimus B-DRUG

we O
report O
a O
case O
of O
hyponatremia B-ADR
associated O
with O
a O
grand O
mal O
seizure O
in O
a O
28 O
month-old O
child O
after O
intra-nasal O
desmopressin B-DRUG
administration O
for O
high O
fluid O
intake O
with O
nocturnal O
enuresis O

this O
profile O
should O
trigger O
a O
" O
red O
flag O
" O
as O
to O
the O
possibility O
of O
phenobarbital B-DRUG
behavioral B-ADR
side I-ADR
effects I-ADR
or O
exacerbation O
of O
preexisting O
maladaptive O
behaviors O

ophthalmologists O
should O
be O
aware O
of O
the O
ocular B-ADR
side I-ADR
effects I-ADR
of O
ifn B-DRUG
therapy O
and O
carefully O
monitor O
patients O
for O
the O
possible O
occurrence O
of O
hypoalbuminemia O
and O
thrombocytopenia O

we O
report O
the O
first O
case O
of O
a O
54-year-old O
turkish O
woman O
who O
presented O
with O
ceftriaxone-induced O
fde B-ADR

aminoglutethimide B-DRUG
was O
discontinued O
until O
completion O
of O
radiotherapy O
, O
and O
the O
rash B-ADR
resolved O

on O
day O
4 O
, O
following O
3 O
doses O
of O
dalteparin B-DRUG
, O
the O
patient O
developed O
acute B-ADR
respiratory I-ADR
distress I-ADR
attributable O
to O
a O
massive O
right O
hemothorax O
confirmed O
by O
computed O
tomography O
pulmonary O
angiography O
( O
ctpa O
) O
and O
intercostal O
drainage O
of O
1500 O
ml O
of O
frank O
blood O

myoclonus O
and O
seizures B-ADR
disappeared O
after O
discontinuation O
of O
l-dopa B-DRUG
and O
the O
introduction O
of O
valproate O
sodium O
( O
vpa O

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram B-DRUG
developed O
confusion O
, O
agitation B-ADR
, O
tachycardia O
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl O
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl O

we O
present O
a O
case O
of O
cutaneous B-ADR
leucocytoclastic I-ADR
vasculitis I-ADR
in O
which O
amphotericin B-DRUG
b I-DRUG
might O
presumably O
be O
the O
aetiological O
factor O

rapid O
onset O
of O
muscle B-ADR
weakness I-ADR
( O
rhabdomyolysis O
) O
associated O
with O
the O
combined O
use O
of O
simvastatin O
and O
colchicine B-DRUG

we O
report O
the O
first O
case O
of O
fulminant O
adult O
respiratory O
distress O
syndrome O
( O
ards B-ADR
) O
associated O
with O
pegylated O
interferon O
alpha-2a O
( O
pegifnalpha-2a O
) O
and O
ribavirin B-DRUG
use O
for O
hepatitis O
c O
, O
complicated O
by O
subsequent O
and O
ultimately O
fatal O
sepsis O
and O
multiorgan O
failure O

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram B-DRUG
developed O
confusion O
, O
agitation O
, O
tachycardia O
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin B-ADR
syndrome I-ADR
, O
following O
initiation O
of O
fentanyl O
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl O

the O
day O
after O
clozapine B-DRUG
was O
stopped O
, O
while O
he O
was O
still O
receiving O
clomipramine O
150 O
mg O
/ O
d O
, O
he O
began O
behaving B-ADR
oddly I-ADR
, O
started O
sweating O
profusely O
, O
shivering O
, O
and O
became O
tremulous O
, O
agitated O
, O
and O
confused O

six O
patients O
with O
no O
previous O
signs O
or O
symptoms O
suggestive O
of O
coronary O
artery O
disease O
developed O
acute O
coronary O
ischemia O
/ O
infarction B-ADR
shortly O
after O
cis-diamine-dichloroplatinum B-DRUG
ii I-DRUG
( O
cisplatin O
) O
- O
based O
chemotherapy O

anaphylaxis B-ADR
after O
the O
injection O
of O
chymopapain B-DRUG
occurs O
in O
about O
1 O
% O
of O
such O
cases O

the O
pharmacology O
and O
toxicology O
of O
chloral B-DRUG
hydrate I-DRUG
are O
discussed O
with O
particular O
reference O
to O
the O
cardiac B-ADR
arrhythmias I-ADR
that O
are O
seen O
with O
overdosage O

a O
case O
of O
allopurinol B-DRUG
hypersensitivity B-ADR
, O
possibly O
the O
first O
in O
a O
black O
african O
, O
is O
reported O

she O
was O
treated O
with O
acyclovir B-DRUG
and O
subsequently O
developed O
vzv B-ADR
antigen-positive I-ADR
zoster I-ADR

biomicroscopy O
revealed O
amiodarone B-DRUG
corneal B-ADR
deposits I-ADR

its O
overall O
toxicity O
is O
considerably O
less O
compared O
to O
standard O
induction O
chemotherapy O
; O
however O
, O
it O
is O
associated O
with O
a O
high O
incidence O
of O
a O
potentially O
fatal O
symptom O
complex O
referred O
to O
as O
" O
retinoic B-ADR
acid I-ADR
syndrome. O
" O
this O
report O
describes O
a O
patient O
with O
apl O
who O
developed O
the O
syndrome O
a O
few O
weeks O
after O
initiating O
induction O
therapy O
with O
atra O
despite O
being O
treated O
for O
hyperleukocytosis O

lovastatin-induced O
rhabdomyolysis B-ADR
possibly O
associated O
with O
clarithromycin B-DRUG
and O
azithromycin O

a O
50-year-old O
diabetic O
and O
hypertensive O
male O
patient O
is O
reported O
who O
had O
ticlopidine-induced O
marrow B-ADR
aplasia I-ADR
partially O
responsive O
to O
colony-stimulating O
factors O
and O
corticosteroids O
, O
but O
experienced O
complete O
recovery O
with O
cyclosporine O

this O
case O
had O
radiation O
fibrosis O
, O
so O
we O
suggest O
that O
radiation O
fibrosis O
may O
be O
another O
contributor O
of O
the O
occurrence O
of O
ild B-ADR
in O
patients O
taking O
erlotinib B-DRUG

we O
hypothesize O
that O
caffeine B-DRUG
toxicity O
injured O
the O
muscle O
cells O
, O
which O
were O
fragile O
due O
to O
the O
potassium O
depletion O
induced O
by O
the O
coexisting B-ADR
hyponatremia I-ADR
, O
to O
result O
in O
unusually O
severe O
rhabdomyolysis O

we O
report O
two O
new O
cases O
of O
sarcoidosis B-ADR
in O
two O
patients O
with O
hepatitis O
c O
virus O
infection O
treated O
with O
interferon B-DRUG
alfa I-DRUG
and O
ribavirin O

conclusions O
: O
among O
the O
many O
presentations O
of O
ifosfamide B-DRUG
neurotoxicity B-ADR
, O
clinicians O
should O
consider O
ncse O
as O
a O
possible O
explanation O
for O
changes O
in O
consciousness O
in O
a O
patient O
receiving O
this O
agent O

we O
experienced O
2 O
cases O
of O
mequitazine-induced O
photosensitivity B-ADR
reaction I-ADR
in O
patients O
who O
took O
mequitazine B-DRUG
for O
their O
dermatologic O
problems O

the O
fetal O
valproate B-DRUG
syndrome O
( O
fvs B-ADR
) O
is O
characterized O
by O
distinctive O
facial O
appearance O
, O
major O
and O
minor O
malformations O
, O
and O
developmental O
delay O

we O
present O
a O
depressive O
patient O
who O
developed O
mild B-ADR
parkinsonian I-ADR
signs I-ADR
and O
camptocormia O
after O
the O
introduction O
of O
olanzapine B-DRUG

it O
is O
very O
likely O
that O
the O
dexamethasone B-DRUG
used O
in O
the O
antiemetic O
drug O
regimen O
contributed O
to O
the O
development O
of O
osteonecrosis B-ADR
in O
these O
patients O

the O
patient O
was O
diagnosed O
with O
carbamazepine B-ADR
toxicity I-ADR
related O
to O
the O
introduction O
of O
ritonavir O

mesalamine B-DRUG
may O
cause O
hypersensitivity B-ADR
pneumonitis I-ADR
in O
patients O
with O
crohn O
's O
disease O

a O
22-year-old O
black O
man O
developed O
fever O
, O
chills O
, O
fatigue B-ADR
, O
night O
sweats O
, O
tender O
lymphadenopathy O
, O
and O
a O
generalized O
, O
pruritic O
, O
macular O
eruption O
3 O
weeks O
after O
starting O
minocycline B-DRUG
therapy O
for O
acne O

methylphenidate O
( O
ritalin B-DRUG
)- O
associated O
cataract B-ADR
and O
glaucoma O

lovastatin-induced O
rhabdomyolysis B-ADR
possibly O
associated O
with O
clarithromycin O
and O
azithromycin O

here O
, O
we O
present O
a O
case O
of O
sirolimus-associated O
interstitial B-ADR
pneumonitis I-ADR
in O
a O
cardiac O
transplant O
recipient O
that O
resolved O
completely O
with O
withdrawal O
of O
the O
drug O
and O
treatment O
with O
corticosteroids O

on O
the O
fifth O
day O
of O
tocolysis O
with O
magnesium O
sulfate O
, O
nifedipine O
, O
terbutaline O
and O
betamethasone B-DRUG
, O
edema B-ADR
developed O
in O
both O
labia O

until O
additional O
data O
are O
available O
, O
if O
intravenous O
acyclovir O
is O
administered O
concurrently O
with O
lithium B-DRUG
, O
we O
recommend O
closely O
monitoring O
patients O
for O
signs O
of O
lithium B-ADR
toxicity I-ADR
and O
measuring O
serum O
lithium B-DRUG
levels O
every O
second O
or O
third O
day O

we O
report O
a O
case O
of O
st B-ADR
elevation I-ADR
in I-ADR
right I-ADR
precordial I-ADR
leads I-ADR
compatible O
with O
type O
1 O
brugada O
syndrome O
following O
administration O
of O
propafenone B-DRUG
in O
a O
patient O
with O
wolff-parkinson-white O
syndrome O
who O
was O
receiving O
lithium O
at O
concentrations O
within O
therapeutic O
levels O

papilledema B-ADR
without O
peripheral O
neuropathy O
in O
a O
patient O
taking O
perhexiline B-DRUG
maleate I-DRUG

a O
case O
is O
presented O
in O
which O
a O
68-year-old O
man O
became O
delirious B-ADR
after O
being O
withdrawn O
from O
a O
low O
dosage O
of O
alprazolam B-DRUG

macular B-ADR
infarction I-ADR
after O
endophthalmitis O
treated O
with O
vitrectomy O
and O
intravitreal O
gentamicin B-DRUG

we O
report O
four O
cases O
of O
encephalopathy B-ADR
coincident O
with O
elevated O
aluminum O
levels O
as O
well O
as O
one O
patient O
who O
developed O
seizures O
while O
receiving O
continuous O
bladder O
irrigations O
with O
alum B-DRUG

metabolic B-ADR
acidosis I-ADR
induced O
by O
cetrimide-chlorhexidine O
solution O
in O
hydatid O
cyst O
surgery O

in O
vitro O
inhibition B-ADR
of I-ADR
hematopoiesis I-ADR
in O
a O
patient O
with O
systemic O
sclerosis O
treated O
with O
d-penicillamine B-DRUG

development O
of O
an O
extensive B-ADR
skin I-ADR
rash I-ADR
following O
a O
single O
dose O
of O
mtx B-DRUG
may O
be O
an O
early O
warning O
sign O
for O
life-threatening O
bone O
marrow O
aplasia O

his O
symptoms O
of O
brain O
stem O
compression O
were O
alleviated O
and O
the O
role O
of O
phenytoin B-DRUG
in O
the O
production O
of O
his O
craniocervical B-ADR
abnormality I-ADR
is O
discussed O

hemolytic B-ADR
uremic I-ADR
syndrome I-ADR
in O
a O
patient O
on O
cis-platinum O
, O
vinblastine O
and O
bleomycin B-DRUG

a O
lethal B-ADR
complication I-ADR
of O
peripheral O
vein O
vasopressin B-DRUG
infusion O

acetazolamide-accelerated O
anticonvulsant O
osteomalacia B-ADR

a O
patient O
suffering O
from O
a O
rare O
enzyme O
deficiency O
developed O
a O
malignant B-ADR
neuroleptic I-ADR
syndrome I-ADR
after O
having O
been O
treated O
with O
one O
single O
dose O
of O
haloperidol B-DRUG

the O
disease O
predisposes O
to O
severe O
vincristine B-ADR
neurotoxicity I-ADR

prolonged B-ADR
prostate-specific I-ADR
antigen I-ADR
response I-ADR
in O
flutamide B-DRUG
withdrawal O
syndrome O
despite O
disease O
progression O

skin O
rash O
began O
after O
2 O
weeks O
of O
treatment O
, O
and O
signs O
of O
hepatocellular B-ADR
failure I-ADR
developed O
3 O
weeks O
after O
phenobarbital B-DRUG
had O
been O
started O

the O
literature O
of O
vincristine B-DRUG
optic B-ADR
nerve I-ADR
toxicity I-ADR
is O
reviewed O

to O
our O
knowledge O
, O
these O
cases O
represent O
the O
first O
reports O
of O
tdf-associated O
irreversible B-ADR
renal I-ADR
failure I-ADR
and O
rickets O
in O
pediatric O
patients O

we O
reported O
3 O
patients O
who O
developed O
acute O
generalized O
dystonia O
and O
akinetic B-ADR
rigid I-ADR
syndrome I-ADR
following O
an O
initial O
therapy O
with O
d-penicillamine B-DRUG
125-500 O
mg O
daily O

transient B-ADR
cardiac I-ADR
arrhythmias I-ADR
related O
to O
lopinavir B-DRUG
/ O
ritonavir O
in O
two O
patients O
with O
hiv O
infection O

used O
injudiciously O
, O
naloxone B-DRUG
can O
lead O
to O
withdrawal O
syndrome O
, O
return O
of O
severe B-ADR
pain I-ADR
, O
and O
other O
adverse O
effects O

a O
drug B-ADR
interaction I-ADR
between O
zafirlukast B-DRUG
and O
theophylline O

initiation O
of O
posaconazole B-DRUG
led O
to O
clinical O
improvement O
until O
the O
patient O
's O
demise O
from O
bacteremic O
vancomycin-resistant O
enterococcal B-ADR
peritonitis I-ADR

two O
patients O
with O
imminent O
gangrene B-ADR
of I-ADR
the I-ADR
extremities I-ADR
caused O
by O
ergot-induced O
arteriospasm O
underwent O
mechanical O
dilatation O
of O
the O
arteries O
when O
conventional O
measures O
such O
as O
anticoagulation O
, O
vasodilation O
, O
and O
sympathetic O
blockade O
produced O
no O
improvement O

we O
report O
four O
cases O
of O
encephalopathy O
coincident O
with O
elevated O
aluminum O
levels O
as O
well O
as O
one O
patient O
who O
developed O
seizures B-ADR
while O
receiving O
continuous O
bladder O
irrigations O
with O
alum B-DRUG

paraplegia B-ADR
following O
intrathecal O
cytosine B-DRUG
arabinoside I-DRUG

cyclosporin B-DRUG
side O
effects O
included O
hirsutism B-ADR
, O
hypertension O
, O
increased O
blood O
levels O
of O
urea O
and O
creatinine O
, O
and O
abnormalities O
in O
liver O
function O
tests O

gangrene B-ADR
of O
the O
fingertips O
after O
bleomycin B-DRUG
and O
methotrexate O

objective O
: O
to O
report O
teicoplanin-related O
neutropenia B-ADR
that O
developed O
after O
an O
episode O
of O
neutropenia B-ADR
induced O
by O
vancomycin O
therapy O

the O
multiple O
comedones O
and O
ruptured B-ADR
epidermoid I-ADR
cysts I-ADR
are O
newly O
reported O
adverse O
effects O
of O
imiquimod B-DRUG
therapy O

upper B-ADR
gastrointestinal I-ADR
haemorrhage I-ADR
is O
a O
serious O
complication O
of O
aspirin O
and O
clopidogrel B-DRUG
( O
dual O
) O
anti-platelet O
therapy O
with O
a O
high O
morbidity O
and O
mortality O

discussion O
: O
to O
our O
knowledge O
this O
is O
the O
first O
reported O
case O
of O
tuberculous B-ADR
uveitis I-ADR
following O
treatment O
with O
etanercept B-DRUG

three O
patients O
receiving O
gold B-DRUG
salt O
treatment O
for O
rheumatoid O
arthritis O
developed O
severe O
aplastic B-ADR
anemia I-ADR

results O
: O
a O
34-year-old O
man O
acquired O
visual O
field O
defects O
and O
severe B-ADR
vision I-ADR
loss I-ADR
in O
both O
eyes O
after O
intravitreal O
injection O
of O
triamcinolone B-DRUG
for O
diabetic O
macular O
edema O

hypersensitivity B-ADR
to O
zonisamide B-DRUG
was O
confirmed O
by O
the O
skin O
patch O
test O

it O
is O
concluded O
that O
siadh B-ADR
is O
an O
important O
side O
effect O
of O
lorcainide B-DRUG
therapy O

purpose O
: O
we O
studied O
a O
case O
of O
vortex B-ADR
keratopathy I-ADR
that O
was O
associated O
with O
the O
use O
of O
atovaquone B-DRUG

a O
transient O
tonic O
pupillary O
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal B-ADR
visual-evoked I-ADR
potentials I-ADR
in O
quinine B-DRUG
toxicity O
, O
to O
our O
knowledge O
, O
have O
not O
been O
previously O
reported O

an O
83-year-old O
man O
receiving O
glipizide O
10 O
mg O
bid O
developed O
symptomatic B-ADR
hypoglycemia I-ADR
within O
three O
days O
of O
adding O
trimethoprim B-DRUG
/ O
sulfamethoxazole O
( O
tmp O
/ O
smx O
) O
to O
his O
regimen O

diffusion-weighted O
mri O
correlates O
of O
subacute O
methotrexate-related O
neurotoxicity B-ADR

we O
describe O
2 O
cases O
of O
sjs B-ADR
related O
to O
nevirapine B-DRUG
use O
and O
review O
the O
literature O
on O
this O
newly O
recognized O
association O

nineteen O
cases O
of O
unusual O
enhanced O
vincristine B-DRUG
neurotoxicity B-ADR
related O
to O
itraconazole O
have O
been O
reported O
in O
children O

new O
onset O
of O
crohn B-ADR
's I-ADR
disease I-ADR
during O
treatment O
of O
active O
ankylosing O
spondylitis O
with O
etanercept B-DRUG

myoclonus B-ADR
was O
induced O
and O
enhanced O
by O
l-dopa B-DRUG
, O
developing O
into O
generalized O
seizures O

nephrotic B-ADR
syndrome I-ADR
associated O
with O
lithium B-DRUG
therapy O

the O
potential O
for O
progressive O
brain O
injury O
and O
subsequent O
disability B-ADR
related O
to O
intraventricular O
il-2 B-DRUG
therapy O
is O
discussed O

however O
, O
given O
the O
clinically O
significant O
result O
to O
the O
interaction O
between O
tolazoline O
and O
cimetidine B-DRUG
we O
report O
, O
the O
use O
of O
cimetidine B-DRUG
in O
tolazoline O
induced O
upper B-ADR
gastrointestinal I-ADR
hemorrhage I-ADR
should O
deserve O
more O
attention O

beginning O
ductopenia O
was O
present O
in O
two O
, O
suggesting O
that O
itraconazole B-DRUG
might O
be O
responsible O
for O
the O
occurrence O
of O
prolonged O
drug-induced O
cholangiopathy B-ADR

our O
cases O
constitute O
the O
most O
severe O
cases O
of O
benzarone B-DRUG
hepatotoxicity O
reported O
so O
far O
, O
and O
comprise O
the O
first O
cases O
of O
( O
sub O
) O
fulminant O
hepatitis O
and O
cirrhosis O
related O
to O
benzarone B-DRUG

methemoglobinemia B-ADR
is O
another O
common O
finding O
among O
patients O
receiving O
dapsone B-DRUG
therapy O
, O
but O
rarely O
does O
it O
result O
in O
prominent O
symptoms O
other O
than O
transient O
pallor O

localized B-ADR
dyskeratotic I-ADR
plaque I-ADR
with O
milia O
associated O
with O
sorafenib B-DRUG

treatment O
of O
lithium-induced O
diabetes B-ADR
insipidus I-ADR
with O
amiloride O

a O
7-year-old O
girl O
developed O
diabetes B-ADR
mellitus I-ADR
and O
exocrine O
pancreatic O
insufficiency O
after O
3.5 O
years O
of O
almost O
continuous O
treatment O
with O
azathioprine B-DRUG
and O
/ O
or O
prednisone O
for O
idiopathic O
auto-immune O
haemolytic O
anaemia O

it O
is O
suggested O
that O
the O
patient O
had O
sulfasalazine-induced O
lupus B-ADR
, O
which O
manifested O
with O
serositis O
and O
pulmonary O
parenchymal O
involvement O
in O
the O
absence O
of O
joint O
symptoms O

scleroderma B-ADR
in O
association O
with O
the O
use O
of O
bleomycin B-DRUG
: O
a O
report O
of O
3 O
cases O

a O
26-year-old O
japanese O
man O
, O
who O
had O
been O
receiving O
medical O
attention O
for O
ulcerative O
colitis O
for O
one O
year O
, O
presented O
with O
diffuse O
erythema O
and O
pustules O
on O
his O
face O
and O
trunk O
, O
malaise O
, O
and O
fever B-ADR
up I-ADR
to I-ADR
39 I-ADR
degrees I-ADR
c I-ADR
one O
day O
after O
the O
administration O
of O
salazosulfapyridine B-DRUG

six O
of O
13 O
outpatients O
with O
schizophrenia O
who O
participated O
in O
a O
ten-week O
open O
trial O
of O
risperidone B-DRUG
had O
an O
initial O
good O
response O
to O
the O
medication O
followed O
by O
development O
of O
intolerable O
affect O
, O
including O
feelings O
of O
agitation O
and O
depression O
and O
periods B-ADR
of I-ADR
crying I-ADR
and O
insomnia O

sideroblastic B-ADR
anemia I-ADR
due O
to O
linezolid B-DRUG
in O
a O
patient O
with O
a O
left O
ventricular O
assist O
device O

we O
describe O
a O
10-year-old O
boy O
with O
ulcerative O
colitis O
who O
developed O
acute B-ADR
pancreatitis I-ADR
while O
on O
long-term O
treatment O
with O
5-aminosalicylic B-DRUG
acid I-DRUG

this O
unusual O
pattern O
of O
low-grade O
endometrial O
carcinoma O
adds O
to O
the O
spectrum O
of O
uterine B-ADR
neoplasia I-ADR
associated O
with O
tamoxifen B-DRUG
therapy O

albuterol-induced O
hypokalemia O
and O
its O
potential O
cardiac B-ADR
toxicity I-ADR
are O
discussed O
briefly O

central B-ADR
nervous I-ADR
system I-ADR
toxicity I-ADR
associated O
with O
meperidine B-DRUG
use O
in O
hepatic O
disease O

interstitial B-ADR
granulomatous I-ADR
dermatitis I-ADR
associated O
with O
darifenacin B-DRUG

granulocytopenia O
and O
agranulocytosis B-ADR
are O
considered O
among O
the O
most O
dangerous O
adverse O
effects O
of O
clozapine B-DRUG

voriconazole B-DRUG
( O
vrc O
) O
has O
not O
previously O
been O
reported O
to O
cause O
angio-oedema B-ADR

although O
this O
type O
of O
hyperpigmentation B-ADR
has O
been O
previously O
seen O
in O
patients O
with O
cancer O
who O
are O
receiving O
bleomycin B-DRUG
, O
this O
is O
, O
to O
our O
knowledge O
, O
the O
first O
reported O
case O
of O
bleomycin-induced O
hyperpigmentation B-ADR
in O
an O
aids O
patient O
and O
should O
be O
added O
to O
the O
growing O
list O
of O
cutaneous O
eruptions O
seen O
in O
these O
patients O

thrombolytic O
therapy O
with O
tissue O
plasminogen O
activator O
( O
tpa B-DRUG
) O
for O
acute O
myocardial O
infarction O
may O
result O
in O
major O
bleeding O
complications O
such O
as O
gastrointestinal B-ADR
or I-ADR
intracranial I-ADR
bleeding I-ADR

ara-c B-DRUG
is O
frequently O
associated O
with O
dermatologic O
toxicity O
, O
but O
this O
is O
only O
the O
second O
case O
of O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
described O
in O
connection O
with O
this O
drug O

although O
isradipine B-DRUG
has O
been O
associated O
with O
hepatocellular B-ADR
injury I-ADR
, O
there O
are O
no O
reports O
of O
fulminant O
liver O
failure O
with O
this O
agent O
, O
and O
our O
patient O
had O
been O
treated O
for O
> O
2 O
years O
without O
signs O
of O
toxicity O

radiation B-ADR
recall I-ADR
related O
to O
gemcitabine B-DRUG
has O
been O
reported O
in O
lung O
and O
breast O
cancer O

amiodarone B-DRUG
is O
well O
recognized O
as O
an O
anti-arrhythmic O
drug O
containing O
a O
high O
dose O
of O
iodine O
with O
considerable O
potential O
to O
cause O
thyroid B-ADR
dysfunction I-ADR

allergy B-ADR
to O
cloxacillin B-DRUG
with O
normal O
tolerance O
to O
amoxicillin O
and O
cefuroxime O

a O
case O
of O
polymyositis B-ADR
with O
dilated O
cardiomyopathy O
associated O
with O
interferon B-DRUG
alpha I-DRUG
treatment O
for O
hepatitis O
b O

we O
report O
on O
a O
patient O
with O
an O
embryonal O
teratocarcinoma O
of O
the O
testicle O
who O
had O
the O
syndrome O
of O
inappropriate B-ADR
secretion I-ADR
of I-ADR
antidiuretic I-ADR
hormone I-ADR
after O
receiving O
a O
high O
dose O
of O
vinblastine B-DRUG

these O
in O
vitro O
findings O
and O
clinical O
course O
suggest O
that O
trab B-ADR
/ I-ADR
tbii I-ADR
without I-ADR
thyroid-stimulating I-ADR
activity I-ADR
may O
develop O
in O
patients O
with O
amiodarone-induced O
destructive O
thyroiditis O
, O
as O
reported O
in O
patients O
with O
destructive O
thyroiditis O
, O
such O
as O
subacute O
and O
silent O
thyroiditis O

the O
cases O
of O
two O
asthmatic O
patients O
who O
became O
hypokalemic B-ADR
after O
inhalation O
of O
normal O
doses O
of O
albuterol B-DRUG
are O
presented O

the O
first O
patient O
developed O
mild O
nitritoid O
symptoms O
and O
pain B-ADR
in O
a O
band-like O
distribution O
, O
corresponding O
to O
t10-t12 O
dermatomes O
, O
shortly O
after O
gold O
sodium O
thiomalate O
( O
gstm B-DRUG
) O
injection O

a O
62-year-old O
woman O
who O
was O
being O
treated O
for O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
developed O
a O
chemotherapy-related O
hemolytic-uremic B-ADR
syndrome I-ADR
during O
the O
second O
cycle O
of O
neoadjuvant O
chemotherapy O
consisting O
of O
cisplatin B-DRUG
, O
bleomycin O
, O
and O
methotrexate O

conclusions O
: O
jet-injection O
devices O
might O
constitute O
a O
helpful O
method O
to O
treat O
those O
patients O
affected O
by O
severe O
human B-DRUG
insulin-induced O
lipoatrophy B-ADR

hepatic B-ADR
reactions I-ADR
to O
cyclofenil B-DRUG

a O
54-year-old O
man O
developed O
ten B-ADR
4 O
weeks O
after O
beginning O
lamotrigine B-DRUG
for O
complex O
partial O
seizures O
related O
to O
a O
glioblastoma O
multiforme O
brain O
tumor O

after O
several O
unrevealing O
medical O
work-ups O
, O
he O
was O
found O
to O
have O
a O
high B-ADR
blood I-ADR
lead I-ADR
level I-ADR
( O
122 O
microg O
/ O
dl O
) O
; O
he O
has O
a O
history O
of O
scraping O
and O
sanding O
lead B-DRUG
paint O
without O
adequate O
protective O
measures O

a O
60-year-old O
white O
man O
with O
chronic O
bronchitis O
was O
noted O
to O
develop O
acute O
respiratory O
failure O
and O
metabolic B-ADR
acidosis I-ADR
four O
days O
after O
being O
started O
on O
methazolamide B-DRUG
( O
neptazane O
) O
for O
an O
ophthalmologic O
problem O

background O
: O
how O
to O
best O
treat O
psychotic O
patients O
who O
have O
had O
past O
clozapine-induced O
agranulocytosis O
or O
granulocytopenia B-ADR
remains O
a O
problem O

propylthiouracil-induced O
sensorineural B-ADR
hearing I-ADR
loss I-ADR
associated O
with O
antineutrophil O
cytoplasmic O
antibodies O

a O
17-year-old O
boy O
with O
acute O
lymphoblastic O
leukemia O
developed O
acute B-ADR
renal I-ADR
failure I-ADR
within O
48 O
h O
of O
an O
intravenous O
high-dose O
methotrexate B-DRUG
( O
5 O
g O
/ O
m2 O
) O
infusion O

amiodarone-induced O
thyrotoxicosis B-ADR
associated O
with O
thyrotropin O
receptor O
antibody O

we O
report O
the O
case O
of O
a O
woman O
who O
developed O
photo-onycholysis B-ADR
on O
multiple O
nails O
after O
uptake O
of O
olanzapine B-DRUG

we O
describe O
a O
case O
of O
disseminated O
muscular O
cysticercosis O
followed O
by O
myositis B-ADR
( O
fever O
, O
diffuse O
myalgia O
, O
weakness O
of O
the O
lower O
limbs O
, O
and O
inflammatory O
reaction O
around O
dying O
cysticerci O
) O
induced O
by O
praziquantel B-DRUG
therapy O
, O
an O
event O
not O
described O
previously O

it O
is O
thought O
that O
the O
clinico-pathological O
features O
and O
chronology O
of O
this O
case O
bore O
the O
hallmarks O
of O
the O
so-called O
" O
3-week O
sulphasalazine B-ADR
syndrome I-ADR
" O
, O
a O
rare O
, O
but O
often O
fatal O
, O
immunoallergic O
reaction O
to O
sulphasalazine B-DRUG

a O
49-year-old O
man O
with O
crohn O
's O
disease O
treated O
with O
prednisone B-DRUG
and O
mesalamine O
( O
5-asa O
) O
developed O
worsening B-ADR
respiratory I-ADR
distress I-ADR
and O
fever O

5-fluorouracil B-DRUG
( O
5-fu O
)- O
associated O
peripheral B-ADR
neuropathy I-ADR
is O
an O
uncommon O
event O

objective O
: O
to O
report O
a O
case O
of O
possible O
foscarnet-induced O
severe B-ADR
hypomagnesemia I-ADR
and O
other O
electrolyte O
disorders O

ibuprofen B-DRUG
rarely O
causes O
lower O
gastrointestinal B-ADR
adverse I-ADR
reactions I-ADR
but O
has O
been O
implicated O
in O
systemic O
and O
local O
side O
effects O
in O
patients O
with O
lupus O

four O
patients O
in O
whom O
pulmonary B-ADR
oedema I-ADR
developed O
during O
tocolysis O
with O
hexoprenaline B-DRUG
are O
described O
and O
the O
aetiological O
factors O
and O
pathogenesis O
of O
this O
potentially O
lethal O
complication O
discussed O

the O
present O
case O
is O
the O
first O
report O
of O
hypercalcemia B-ADR
induced O
by O
vitamin O
d3 O
ointment O
and O
thiazide B-DRUG
simultaneously O

bleomycin O
and O
cyclophosphamide B-DRUG
toxicity O
simulating O
metastatic B-ADR
nodules I-ADR
to O
the O
lungs O
in O
childhood O
cancer O

in O
all O
cases O
, O
drugs O
in O
addition O
to O
quetiapine B-DRUG
were O
detected O
, O
but O
in O
cases O
# O
1 O
and O
# O
2 O
, O
the O
cause O
of O
death B-ADR
was O
considered O
to O
be O
a O
quetiapine B-DRUG
overdose O
and O
the O
other O
drugs O
were O
not O
considered O
to O
be O
contributory O

chloroquine-induced O
bilateral B-ADR
ptosis I-ADR

this O
case O
suggests O
that O
sarcoidosis O
and O
pravastatin B-DRUG
, O
two O
entities O
not O
frequently O
associated O
with O
myotonia B-ADR
, O
may O
interact O
in O
a O
synergistic O
manner O
to O
produce O
severe O
clinical O
myotonia B-ADR
in O
humans O

in O
patients O
with O
swallowing O
dysfunction O
and O
pneumonia O
, O
a O
history O
of O
mineral B-DRUG
oil I-DRUG
use O
should O
be O
obtained O
and O
a O
diagnosis O
of O
elp B-ADR
should O
be O
considered O
in O
the O
differential O
diagnoses O
if O
mineral B-DRUG
oil I-DRUG
use O
has O
occurred O

squamous-cell B-ADR
carcinoma I-ADR
arising O
in O
a O
basal-cell O
epithelioma O
treated O
with O
5-fluorouracil B-DRUG

in O
rare O
cases O
mitomycin O
c O
( O
mmc B-DRUG
) O
may O
induce O
cancer-associated O
hemolytic O
uremic O
syndrome O
, O
which O
is O
characterized O
by O
hemolytic O
anemia O
, O
thrombocytopenia O
and O
progressive B-ADR
renal I-ADR
failure I-ADR

we O
describe O
a O
case O
of O
ulcerative B-ADR
proctitis I-ADR
after O
ibuprofen B-DRUG
treatment O
in O
a O
girl O
with O
juvenile O
systemic O
lupus O
erythematosus O

the O
first O
reported O
case O
, O
in O
an O
adult O
, O
of O
cholestyramine B-DRUG
induced O
hyperchloremic B-ADR
metabolic I-ADR
acidosis I-ADR
is O
a O
70 O
year O
old O
female O
with O
a O
two O
year O
history O
of O
primary O
biliary O
cirrhosis O
confirmed O
by O
histologic O
and O
immunologic O
criteria O

in O
four O
patients O
, O
thrombosis B-ADR
occurred O
2-45 O
days O
after O
severe O
hepatic O
veno-occlusive O
disease O
( O
hvod O
) O
secondary O
to O
intensive O
chemotherapy O
containing O
busulfan B-DRUG

results O
: O
ethambutol B-DRUG
, O
and O
to O
a O
lesser O
extent O
isoniazid O
, O
are O
both O
implicated O
in O
the O
development B-ADR
of I-ADR
visually I-ADR
related I-ADR
side I-ADR
effects I-ADR

the O
authors O
report O
a O
case O
of O
urinary O
incontinence O
( O
ui B-ADR
) O
that O
occurred O
in O
a O
woman O
after O
administration O
of O
venlafaxine B-DRUG

purpose O
: O
the O
case O
of O
a O
patient O
who O
developed O
aseptic O
meningitis O
, O
hemolytic O
anemia O
, O
hepatitis O
, O
and O
orthostatic B-ADR
hypotension I-ADR
simultaneously O
during O
treatment O
with O
trimethoprim-sulfamethoxazole O
is O
described O

disulfiram-induced O
fulminant B-ADR
hepatic I-ADR
failure I-ADR
in O
an O
active O
duty O
soldier O

the O
visual B-ADR
loss I-ADR
in O
this O
patient O
seems O
to O
result O
from O
phenol B-DRUG
neurotoxicity O
rather O
than O
mechanical O
compression O
of O
the O
intraorbital O
optic O
nerve O

severe O
histological O
osteomalacia B-ADR
developed O
in O
a O
woman O
with O
crohn O
's O
disease O
2 O
years O
after O
ileal O
resection O
and O
the O
start O
of O
cholestyramine B-DRUG
therapy O

the O
authors O
report O
a O
case O
of O
focal O
myocardial O
necrosis O
, O
presenting O
clinically O
as O
an O
acute B-ADR
myocardial I-ADR
infarction I-ADR
during O
the O
administration O
of O
the O
antineoplastic O
drug O
, O
amsacrine B-DRUG
, O
in O
a O
patient O
without O
coronary O
artery O
disease O

the O
fetal O
valproate B-DRUG
syndrome O
( O
fvs O
) O
is O
characterized O
by O
distinctive B-ADR
facial I-ADR
appearance I-ADR
, O
major O
and O
minor O
malformations O
, O
and O
developmental O
delay O

patients O
with O
lymphoblastic O
lymphoma O
who O
had O
treatment O
with O
l-asparaginase B-DRUG
and O
steroid O
are O
predisposed O
to O
the O
development O
of O
cortical B-ADR
venous I-ADR
thrombosis I-ADR
and O
may O
have O
this O
syndrome O
in O
addition O
to O
a O
dural O
puncture O
headache O

ten O
to O
15 O
% O
of O
patients O
treated O
with O
ifosfamide B-DRUG
develop O
an O
encephalopathy B-ADR

thus O
cabergoline B-DRUG
may O
cause O
similar O
pleuropulmonary B-ADR
abnormalities I-ADR
to O
bromocriptine O

adriamycin-induced O
cardiomyopathy B-ADR
aggravated O
by O
cis-platinum O
nephrotoxicity O
requiring O
dialysis O

the O
mechanism O
of O
rta B-ADR
induced O
by O
fk506 B-DRUG
has O
not O
yet O
been O
clearly O
elucidated O

the O
authors O
conclude O
that O
among O
patients O
taking O
high O
doses O
of O
oral O
niacin B-DRUG
only O
those O
who O
experience O
visual B-ADR
symptoms I-ADR
need O
to O
be O
ophthalmologically O
evaluated O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia B-ADR
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp O
)- O
sulfamethoxazole O
( O
smx B-DRUG
) O
treatment O

he O
had O
an O
immediate O
hypersensitivity O
reaction O
during O
the O
initiation O
of O
the O
mtx B-DRUG
infusion O
with O
diffuse B-ADR
urticaria I-ADR
, O
facial O
swelling O
, O
cough O
, O
and O
chest O
tightness O

transient B-ADR
acute I-ADR
myopia I-ADR
resulting O
from O
isotretinoin O
( O
accutane B-DRUG
) O
therapy O

conclusions O
: O
patients O
receiving O
intravitreal O
injections O
of O
bevacizumab B-DRUG
should O
be O
evaluated O
for O
potential O
systemic O
risk O
factors O
such O
as O
carotid B-ADR
insufficiency I-ADR
, O
coagulopathy O
and O
poorly O
controlled O
diabetes O
mellitus O

we O
review O
the O
literature O
on O
previously O
reported O
cases O
of O
cutaneous B-ADR
necrosis I-ADR
after O
injection O
of O
standard O
interferon O
alfa O
or O
pegylated B-DRUG
interferon I-DRUG
alfa-2b I-DRUG
and O
discuss O
the O
different O
pathophysiologic O
mechanisms O
that O
might O
be O
involved O

diarrhoea O
, O
t-cd4 O
+ O
lymphopenia O
and O
bilateral B-ADR
patchy I-ADR
pulmonary I-ADR
infiltrates I-ADR
developed O
in O
a O
male O
60 O
yrs O
of O
age O
, O
who O
was O
treated O
with O
oxaliplatinum B-DRUG
and O
5-fluorouracil O
for O
unresectable O
rectum O
carcinoma O

methylphenidate B-DRUG
( O
ritalin O
)- O
associated O
cataract O
and O
glaucoma B-ADR

polyarthritis O
, O
hepatitis B-ADR
and O
anti-native O
dna O
antibodies O
after O
treatment O
with O
ethambutol O
and O
rifampicin B-DRUG

the O
patient O
described O
feeling B-ADR
cold I-ADR
with O
worsening O
headache O
and O
chills O
approximately O
one O
hour O
after O
infusion O
of O
the O
first O
dose O
of O
penicillin B-DRUG

we O
report O
a O
4-year-old O
girl O
who O
presented O
with O
acute O
bilateral O
blindness O
, O
a O
focal B-ADR
seizure I-ADR
and O
hypertension O
10 O
days O
after O
commencing O
oxybutynin B-DRUG
to O
treat O
enuresis O

the O
clinical O
picture O
was O
identical O
to O
that O
of O
chloroquine O
and O
hydroxychloroquine B-DRUG
maculopathy B-ADR

our O
patient O
had O
headache O
, O
mild O
fever O
, O
nausea B-ADR
, O
vomiting O
, O
rash O
, O
and O
eosinophilia O
after O
3 O
weeks O
of O
disulfiram B-DRUG
therapy O

differential O
diagnoses O
included O
ocular O
rosacea O
with O
cicatrizing O
conjunctivitis O
and O
5-fu-induced O
ectropion B-ADR

although O
adverse O
reactions O
to O
protamine B-DRUG
are O
reported O
infrequently O
and O
are O
usually O
mild O
, O
we O
recently O
observed O
the O
first O
fatal O
case O
of O
type B-ADR
i I-ADR
anaphylaxis I-ADR
resulting O
from O
protamine B-DRUG

we O
describe O
3 O
elderly O
patients O
with O
moderate O
to O
severe O
ataxia B-ADR
that O
occurred O
while O
they O
were O
taking O
propafenone B-DRUG

the O
first O
patient O
developed O
mild B-ADR
nitritoid I-ADR
symptoms I-ADR
and O
pain O
in O
a O
band-like O
distribution O
, O
corresponding O
to O
t10-t12 O
dermatomes O
, O
shortly O
after O
gold O
sodium O
thiomalate O
( O
gstm B-DRUG
) O
injection O

the O
day O
after O
clozapine O
was O
stopped O
, O
while O
he O
was O
still O
receiving O
clomipramine B-DRUG
150 O
mg O
/ O
d O
, O
he O
began O
behaving B-ADR
oddly I-ADR
, O
started O
sweating O
profusely O
, O
shivering O
, O
and O
became O
tremulous O
, O
agitated O
, O
and O
confused O

the O
relation O
between O
tacrolimus B-DRUG
treatment O
and O
staining O
was O
suggested O
by O
the O
appearance O
of O
pigmentation B-ADR
during O
topical O
tacrolimus B-DRUG
treatment O
and O
its O
clinical O
disappearance O
when O
treatment O
was O
stopped O

severe O
erythroderma B-ADR
as O
a O
complication O
of O
continuous O
epoprostenol B-DRUG
therapy O

a O
boy O
with O
chronic O
neutropenia O
and O
recurrent O
inflammatory O
skin O
lesions O
developed O
multiple B-ADR
erythematous I-ADR
nodules I-ADR
following O
administration O
of O
g-csf B-DRUG

human B-DRUG
insulin-induced O
lipoatrophy B-ADR

cephalosporins B-DRUG
are O
most O
likely O
associated O
with O
vitamin B-ADR
k I-ADR
deficiency I-ADR

four O
cases O
of O
fat B-ADR
embolism I-ADR
are O
described O
in O
infants O
receiving O
prolonged O
intravenous O
infusion O
of O
fat O
( O
intralipid B-DRUG
20 O

a O
dapsone B-DRUG
hypersensitivity O
syndrome O
, O
consisting O
of O
fever O
, O
headache O
, O
nausea O
, O
vomiting O
, O
lymphadenopathy O
, O
hepatitis B-ADR
, O
hemolysis O
, O
leukopenia O
, O
and O
mononucleosis O
, O
has O
been O
described O
in O
patients O
treated O
with O
the O
drug O
for O
leprosy O

we O
describe O
a O
case O
of O
ege B-ADR
manifested O
as O
an O
allergy O
to O
gemfibrozil B-DRUG

we O
present O
an O
aids O
patient O
with O
severe O
and O
prolonged O
lactic B-ADR
acidosis I-ADR
on O
stavudine B-DRUG
and O
lamivudine O

systemic B-ADR
capillary I-ADR
leak I-ADR
syndrome I-ADR
after O
granulocyte B-DRUG
colony-stimulating I-DRUG
factor I-DRUG
( O
g-csf O

conclusions O
: O
the O
observation O
that O
neurotoxicity B-ADR
developed O
with O
a O
delay O
of O
24 O
to O
48 O
hours O
after O
acyclovir B-DRUG
peak O
serum O
concentrations O
could O
explain O
the O
wide O
range O
of O
acyclovir B-DRUG
levels O
reported O
in O
similar O
cases O

the O
case O
is O
presented O
of O
a O
72-year-old O
man O
with O
hormone-refractory O
prostate O
cancer O
and O
weekly O
administration O
of O
30 O
mg O
/ O
m2 O
docetaxel B-DRUG
who O
developed O
subacute B-ADR
interstitial I-ADR
pneumonitis-related I-ADR
pulmonary I-ADR
fibrosis I-ADR
after O
seven O
doses O
and O
died O
despite O
mechanical O
ventilation O
and O
high-dose O
corticosteroid O
treatment O

we O
describe O
two O
dark-skinned O
patients O
who O
developed O
hyperpigmented B-ADR
skin I-ADR
and O
tongue O
lesions O
during O
combination O
therapy O
with O
ifn O
and O
ribavirin B-DRUG

calcification B-ADR
and O
ossification O
of O
the O
spinal O
arachnoid O
after O
intrathecal O
administration O
of O
depo-medrol B-DRUG

severe B-ADR
systemic I-ADR
hypersensitivity I-ADR
reaction I-ADR
to O
ibuprofen B-DRUG
occurring O
after O
prolonged O
therapy O

hepatitis B-ADR
following O
cimetidine B-DRUG
administration O

cholesterol O
crystal O
embolization-associated O
renal B-ADR
failure I-ADR
after O
therapy O
with O
recombinant O
tissue-type B-DRUG
plasminogen I-DRUG
activator I-DRUG

k O
bipolar O
manic-depressive O
patient O
, O
developed O
while O
on O
lithium B-DRUG
prophylaxis O
, O
akathisia O
at O
therapeutic O
serum O
lithium B-DRUG
levels O
and O
subsequently O
bucco-linguo-masticatory B-ADR
dyskinesia I-ADR

high-dose O
intravenous O
mannitol B-DRUG
infusion O
in O
various O
clinical O
settings O
may O
result O
in O
acute B-ADR
renal I-ADR
failure I-ADR
( O
arf O

metabolic B-ADR
acidosis I-ADR
induced O
by O
cetrimide-chlorhexidine O
solution O
in O
hydatid O
cyst O
surgery O

sudden O
cardiac O
death O
due O
to O
hypersensitivity B-ADR
myocarditis I-ADR
during O
clozapine B-DRUG
treatment O

we O
report O
the O
first O
case O
of O
iha B-ADR
associated O
with O
cefuroxime B-DRUG
administration O

however O
, O
as O
illustrated O
by O
these O
and O
other O
cases O
reported O
to O
date O
, O
the O
onset O
of O
troglitazone-induced O
liver B-ADR
injury I-ADR
is O
insidious O
and O
temporally O
variable O

on O
day O
7 O
of O
linezolid B-DRUG
treatment O
, O
the O
patient O
developed O
severe O
pruritus O
, O
macular O
rash O
, O
facial B-ADR
edema I-ADR
, O
eosinophilia O
, O
marked O
increase O
in O
serum O
creatinine O
level O
, O
and O
mild O
hepatitis O

we O
describe O
two O
elbw O
infants O
affected O
by O
hyperkalaemia O
, O
treated O
with O
kayexalate B-DRUG
, O
who O
developed O
serious O
hypernatraemia B-ADR
, O
that O
has O
never O
been O
reported O
before O
in O
preterm O
infants O

a O
73 O
year-old O
patient O
with O
wolff-parkinson-white O
syndrome O
and O
paroxysmic O
supraventricular O
tachycardia O
developed O
an O
acute B-ADR
reversible I-ADR
encephalopathy I-ADR
within O
15 O
days O
of O
initiation O
of O
flecainide B-DRUG

multiple O
syncopal O
episodes O
started O
to O
occur O
during O
thalidomide B-DRUG
treatment O
, O
and O
a O
holter O
electrocardiogram O
showed O
multiple O
abnormalities O
, O
with O
an O
episode O
of O
sustained B-ADR
ventricular I-ADR
tachycardia I-ADR

a O
female O
patient O
with O
her2 O
positive O
, O
metastatic O
breast O
cancer O
presented O
with O
pulmonary O
infiltrates O
, O
and O
a O
plural B-ADR
effusion I-ADR
dyspnoea I-ADR
after O
several O
months O
of O
trastuzumab B-DRUG
treatment O

agranulocytosis B-ADR
associated O
with O
ticlopidine B-DRUG
: O
a O
possible O
benefit O
with O
filgastim O

the O
pathogenic O
mechanisms O
involved O
in O
the O
development O
of O
adriamycin B-DRUG
cardiomyopathy B-ADR
are O
reviewed O
, O
and O
the O
possible O
synergistic O
effect O
of O
other O
antitumor O
antibiotics O
is O
discussed O

we O
thus O
concluded O
that O
an O
excessive O
dose O
of O
az B-DRUG
had O
probably O
destroyed O
the O
gastric O
mucosal O
barrier O
or O
thrombocytopenia O
due O
to O
bone O
marrow O
disorder O
and O
thus O
eventually O
led O
to O
the O
development O
of O
hemorrhagic B-ADR
gastritis I-ADR

we O
report O
the O
case O
histories O
of O
identical O
twin O
brothers O
who O
developed O
concordant O
acute O
lymphoblastic O
leukemia O
at O
the O
age O
of O
4 O
years O
and O
who O
later O
developed O
leukoencephalopathy B-ADR
and O
hydrocephalus O
related O
to O
central O
nervous O
system O
prophylaxis O
by O
, O
in O
the O
first O
case O
intrathecally O
administered O
methotrexate B-DRUG
and O
, O
in O
the O
second O
by O
intrathecally O
administered O
methotrexate B-DRUG
and O
cranial O
irradiation O

propoxyphene-induced O
wide B-ADR
qrs I-ADR
complex I-ADR
dysrhythmia I-ADR
responsive O
to O
sodium O
bicarbonate O
-- O
a O
case O
report O

development O
of O
sarcoidosis B-ADR
during O
interferon O
alpha O
2b O
and O
ribavirin B-DRUG
combination O
therapy O
for O
chronic O
hepatitis O
c O
-- O
a O
case O
report O
and O
review O
of O
the O
literature O

conclusion O
: O
the O
present O
findings O
suggest O
that O
: O
( O
i O
) O
amantadine O
probably O
exerts O
its O
anti-dyskinetic O
effect O
by O
acting O
on O
the O
" O
indirect O
" O
pathway O
; O
( O
ii O
) O
the O
pathophysiological O
mechanisms O
of O
subthalamotomy O
induced O
dyskinesias B-ADR
may O
differ O
from O
those O
involved O
in O
l-dopa B-DRUG
induced O
dyskinesias B-ADR
; O
( O
iii O
) O
dyskinesias B-ADR
induced O
by O
stn O
surgery O
resolve O
spontaneously O
as O
compensatory O
mechanisms O
develop O

conclusions O
: O
we O
report O
this O
case O
of O
the O
concomitant O
appearance O
of O
multiple O
skin O
cancers O
and O
nail B-ADR
changes I-ADR
associated O
with O
hydroxyurea B-DRUG
use O

this O
report O
details O
the O
pulmonary O
pathologic O
findings O
in O
four O
patients O
with O
rheumatoid O
arthritis O
, O
who O
developed O
new O
onset O
of O
pulmonary B-ADR
signs I-ADR
and I-ADR
symptoms I-ADR
with I-ADR
alveolar I-ADR
infiltrates I-ADR
temporally O
related O
to O
the O
institution O
of O
etanercept B-DRUG
therapy O

results O
: O
three O
patients O
who O
developed O
symptoms O
of O
inflammatory B-ADR
bowel I-ADR
disease I-ADR
( O
ibd O
) O
during O
rofecoxib B-DRUG
exposure O
are O
described O
along O
with O
pathology O
findings O

a O
10-year-old O
boy O
with O
osteosarcoma O
and O
normal O
renal O
function O
manifested O
laboratory O
evidence O
of O
impending O
renal B-ADR
toxicity I-ADR
and O
extreme O
elevation O
of O
aspartate O
aminotrasferase O
and O
alanine O
aminotransferase O
within O
2 O
hours O
after O
the O
completion O
of O
a O
4-hour O
infusion O
of O
high-dose O
methotrexate O
( O
mtx B-DRUG
) O
( O
12 O
g O
/ O
m2 O
) O
, O
and O
went O
on O
to O
develop O
acute O
renal O
failure O
with O
life-threatening O
hyperkalemia O
29 O
hours O
later O

a O
patient O
with O
coccidioidal O
meningitis O
was O
treated O
with O
intrathecally O
administered O
amphotericin B-DRUG
b I-DRUG
, O
and O
an O
acute B-ADR
toxic I-ADR
delirium I-ADR
with O
eeg O
abnormalities O
developed O

multiple B-ADR
syncopal I-ADR
episodes I-ADR
started O
to O
occur O
during O
thalidomide B-DRUG
treatment O
, O
and O
a O
holter O
electrocardiogram O
showed O
multiple O
abnormalities O
, O
with O
an O
episode O
of O
sustained O
ventricular O
tachycardia O

quetiapine-induced O
leucopenia B-ADR
and O
thrombocytopenia O

we O
report O
for O
the O
first O
time O
the O
development O
of O
symptomatic B-ADR
methemoglobinemia I-ADR
after O
an O
acute O
ingestion O
of O
divalproex O
sodium O
( O
depakote B-DRUG
) O
, O
resulting O
in O
serum O
concentrations O
10 O
times O
greater O
than O
the O
therapeutic O
range O

myoclonus B-ADR
and O
seizures O
disappeared O
after O
discontinuation O
of O
l-dopa B-DRUG
and O
the O
introduction O
of O
valproate O
sodium O
( O
vpa O

case O
report O
: O
soon O
after O
initiation O
of O
amiodarone B-DRUG
hcl I-DRUG
( O
200 O
mg O
/ O
day O
) O
, O
a O
76-year-old O
man O
came O
to O
us O
with O
symptoms O
of O
visual O
" O
shining O
," O
glare O
, O
color O
vision O
anomalies O
, O
and O
gradually O
decreased B-ADR
vision I-ADR

children O
with O
acute O
lymphoblastic O
leukemia O
( O
all O
) O
, O
treated O
with O
l-asparaginase B-DRUG
are O
at O
risk O
for O
cerebral B-ADR
thrombosis I-ADR
or O
hemorrhage O
because O
of O
coagulation O
protein O
deficiencies O

on O
the O
other O
hand O
, O
aspirin B-DRUG
may O
have O
promoted O
the O
enlargement B-ADR
of I-ADR
spontaneous I-ADR
hemorrhage I-ADR
from O
meningioma O

tuberculous B-ADR
uveitis I-ADR
after O
treatment O
with O
etanercept B-DRUG

his O
impaired B-ADR
memory I-ADR
was O
found O
to O
be O
due O
to O
the O
atenolol B-DRUG
he O
was O
on O
and O
he O
made O
a O
complete O
recovery O
on O
withdrawing O
the O
beta-blocker O

we O
concluded O
that O
the O
colonic B-ADR
ulcer I-ADR
and O
the O
sigmoidovesical O
fistula O
had O
been O
caused O
by O
the O
administration O
of O
calcium B-DRUG
polystyrene I-DRUG
sulfonate I-DRUG
and O
sorbitol O

although O
moderate O
myelosuppression O
is O
not O
uncommonly O
seen O
in O
patients O
treated O
with O
lenalidomide B-DRUG
, O
aplastic B-ADR
anemia I-ADR
has O
not O
previously O
been O
reported O
to O
be O
associated O
with O
this O
agent O

method O
: O
case O
analysis O
of O
a O
poly-drug O
overdose O
( O
venlafaxine B-DRUG
, O
topiramate O
, O
divalproex O
sodium O
, O
risperidone O
, O
and O
carbamazepine O
) O
presenting O
with O
mixed O
ss B-ADR
/ O
nms O
features O
and O
whose O
clinical O
management O
suggests O
a O
practical O
algorithm O
for O
treatment O
of O
undifferentiated O
ss B-ADR
/ O
nms O
in O
critical O
care O
settings O

we O
report O
3 O
patients O
with O
severe O
hepatocellular O
damage O
due O
to O
cpa B-DRUG
therapy O
, O
2 O
with O
fatal B-ADR
fulminant I-ADR
hepatitis I-ADR

we O
report O
the O
first O
case O
of O
fulminant O
adult O
respiratory O
distress O
syndrome O
( O
ards B-ADR
) O
associated O
with O
pegylated O
interferon O
alpha-2a O
( O
pegifnalpha-2a B-DRUG
) O
and O
ribavirin O
use O
for O
hepatitis O
c O
, O
complicated O
by O
subsequent O
and O
ultimately O
fatal O
sepsis O
and O
multiorgan O
failure O

iv O
propranolol B-DRUG
was O
used O
as O
the O
initial O
treatment O
for O
his O
hyperadrenergic O
state O
, O
resulting O
in O
a O
decrease O
in O
heart O
rate O
but O
a O
paroxsymal B-ADR
increase I-ADR
in I-ADR
blood I-ADR
pressure I-ADR

a O
patient O
receiving O
vancomycin B-DRUG
for O
a O
serious O
staphylococcal O
infection O
had O
a O
lupus-like B-ADR
syndrome I-ADR
characterized O
by O
a O
malar O
rash O
, O
pain O
and O
erythema O
of O
the O
cartilage O
of O
both O
ears O
, O
and O
tender O
erythematous O
and O
hemorrhagic O
lesions O
of O
the O
finger O
tips O

bisphosphonate-related O
osteonecrosis B-ADR
of I-ADR
the I-ADR
jaw I-ADR
( O
bronj O
) O
is O
reported O
in O
up O
to O
18.6 O
% O
of O
patients O
treated O
with O
intravenous O
bisphosphonates O
and O
can O
result O
in O
significant O
morbidity O

though O
proteinuria O
and O
nephrotic B-ADR
syndrome I-ADR
is O
a O
rare O
adverse O
effect O
of O
ifn-beta-1b B-DRUG
therapy O
, O
physicians O
treating O
ms O
patients O
with O
this O
agent O
should O
pay O
careful O
attention O
to O
new O
clinical O
symptoms O
and O
laboratory O
findings O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly B-ADR
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp O
)- O
sulfamethoxazole O
( O
smx B-DRUG
) O
treatment O

background O
: O
methotrexate B-DRUG
( O
mtx O
) O
may O
induce O
liver O
damage O
, O
which O
in O
some O
psoriatics O
will O
lead O
to O
fibrosis O
or O
cirrhosis B-ADR

after O
taking O
cholestyramine B-DRUG
ii I-DRUG
sachets O
twice O
daily O
for O
two O
months O
she O
presented O
with O
lethargy O
, O
confusion B-ADR
and O
drowsiness O

gastro-oesophageal B-ADR
reflux I-ADR
associated O
with O
nifedipine B-DRUG

a O
fatal B-ADR
pancytopenia I-ADR
occurred O
in O
a O
patient O
with O
an O
history O
of O
depression O
with O
hypomanic O
rebounds O
, O
admitted O
for O
a O
manic O
episode O
and O
treated O
with O
levomepromazine B-DRUG
, O
diazepam O
and O
lithium O
carbonate O

we O
now O
present O
four O
cases O
of O
rsds B-ADR
in O
kidney O
transplant O
recipients O
treated O
with O
tacrolimus B-DRUG

fde B-ADR
from O
cephalosporins O
has O
been O
rarely O
reported O
, O
and O
to O
the O
best O
of O
our O
knowledge O
there O
is O
no O
published O
report O
of O
ceftriaxone-induced O
fde B-ADR
in O
the O
literature O

a O
7-year-old O
girl O
developed O
diabetes O
mellitus O
and O
exocrine B-ADR
pancreatic I-ADR
insufficiency I-ADR
after O
3.5 O
years O
of O
almost O
continuous O
treatment O
with O
azathioprine B-DRUG
and O
/ O
or O
prednisone O
for O
idiopathic O
auto-immune O
haemolytic O
anaemia O

tacrolimus-induced O
hus O
: O
an O
unusual O
cause O
of O
acute B-ADR
renal I-ADR
failure I-ADR
in O
nephrotic O
syndrome O

captopril B-DRUG
is O
an O
angiotensin-converting O
enzyme O
( O
ace O
) O
inhibitor O
and O
their O
cutaneous B-ADR
side-effects I-ADR
are O
documented O
, O
but O
little O
has O
been O
published O
concerning O
the O
usefulness O
of O
patch O
test O
when O
they O
occur O

that O
review O
suggested O
that O
patients O
receiving O
anti-d B-DRUG
igiv I-DRUG
be O
monitored O
for O
those O
and O
other O
potential O
complications O
of O
hemoglobinemia B-ADR
, O
particularly O
disseminated O
intravascular O
coagulation O
( O
dic O

posterior B-ADR
leukoencephalopathy I-ADR
following O
cisplatin O
, O
bleomycin B-DRUG
and O
vinblastine O
therapy O
for O
germ O
cell O
tumor O
of O
the O
ovary O

we O
report O
the O
case O
of O
a O
lung O
cancer O
patient O
with O
bronquiloalveolar O
carcinoma O
( O
bac O
) O
presenting O
with O
boop O
after O
chemotherapy O
with O
docetaxel O
and O
gemcitabine B-DRUG
producing O
severe O
respiratory O
insufficiency O
, O
and O
simulating O
a O
progression B-ADR
of I-ADR
the I-ADR
tumor I-ADR

conclusions O
: O
amphotericin B-DRUG
b I-DRUG
overdose O
can O
be O
fatal B-ADR
in O
children O
and O
infants O

fulminant B-ADR
liver I-ADR
failure I-ADR
associated O
with O
clarithromycin B-DRUG

case O
summaries O
: O
two O
patients O
who O
received O
ifosfamide-containing O
chemotherapy O
developed O
ncse B-ADR

recently O
, O
her O
serum O
theophylline B-ADR
levels I-ADR
had I-ADR
increased I-ADR
to I-ADR
the I-ADR
toxic I-ADR
range I-ADR
( O
133.2 O
micromol O
/ O
l O
[ O
24 O
microg O
/ O
ml O
]) O
shortly O
after O
the O
addition O
of O
zafirlukast B-DRUG
( O
accolate O
, O
zeneca O
pharmaceuticals O
, O
wilmington O
, O
del O
) O
to O
her O
regimen O

although O
there O
have O
been O
numerous O
reports O
of O
effusions O
, O
none O
have O
provided O
complete O
pleural O
fluid O
analysis O
; O
therefore O
, O
we O
report O
2 O
patients O
with O
dasatinib-induced O
pleural B-ADR
effusion I-ADR
with O
complete O
pleural O
fluid O
analysis O

a O
44-year-old O
woman O
is O
described O
in O
whom O
amiodarone O
, O
disopyramide B-DRUG
, O
and O
quinidine O
, O
administered O
alone O
separately O
, O
induced O
atypical O
ventricular O
tachycardia O
( O
avt B-ADR
, O
torsade O
de O
pointes O

patients O
with O
lymphoblastic O
lymphoma O
who O
had O
treatment O
with O
l-asparaginase B-DRUG
and O
steroid O
are O
predisposed O
to O
the O
development O
of O
cortical O
venous O
thrombosis O
and O
may O
have O
this O
syndrome O
in O
addition O
to O
a O
dural B-ADR
puncture I-ADR
headache I-ADR

incidence O
of O
seizures B-ADR
in O
pediatric O
cancer O
patients O
treated O
with O
imipenem O
/ O
cilastatin B-DRUG

acute B-ADR
hepatic I-ADR
failure I-ADR
is O
a O
rare O
and O
potentially O
lethal O
complication O
of O
propylthiouracil O
( O
ptu B-DRUG
) O
use O
for O
hyperthyroidism O

since O
recent O
studies O
have O
reported O
no O
negative O
interactions O
with O
concurrent O
use O
, O
we O
here O
report O
three O
cases O
( O
one O
case O
of O
a O
prolonged O
seizure O
, O
a O
serotonin B-ADR
syndrome I-ADR
and O
a O
focal O
seizure O
) O
of O
severe O
lithium-induced O
side O
effects O
while O
patients O
underwent O
ect O
without O
complications O
and O
lithium B-DRUG
serum O
levels O
were O
still O
subtherapeutic O

since O
its O
fda O
approval O
in O
2002 O
, O
there O
are O
no O
known O
citations O
of O
ezetimibe-induced O
pancreatitis B-ADR

we O
describe O
a O
patient O
with O
the O
antiphospholipid O
syndrome O
who O
had O
skin B-ADR
necrosis I-ADR
develop O
from O
low-molecular B-DRUG
weight I-DRUG
heparin I-DRUG
therapy O
at O
sites O
distant O
from O
injection O
sites O

cerebral B-ADR
demyelinating I-ADR
disease I-ADR
developed O
in O
a O
patient O
during O
adjuvant O
therapy O
with O
levamisole B-DRUG
for O
malignant O
melanoma O

the O
pulmonary B-ADR
toxicity I-ADR
is O
probably O
induced O
by O
piritrexim B-DRUG

two O
cases O
of O
polymorphic B-ADR
ventricular I-ADR
tachycardia I-ADR
induced O
by O
the O
administration O
of O
verapamil B-DRUG
against O
paroxysmal O
supraventricular O
tachycardia O

three O
months O
following O
splenectomy O
, O
multiple B-ADR
abscesses I-ADR
occurred O
in O
the O
muscles O
of O
both O
thighs O
while O
the O
patient O
was O
receiving O
the O
third O
course O
of O
the O
chop B-DRUG
regimen O

cyclosporine O
is O
a O
potent O
inhibitor O
of O
simvastatin B-DRUG
metabolism O
, O
and O
may O
therefore O
facilitate O
simvastatin-induced O
rhabdomyolysis B-ADR

l-thyroxine-induced O
leukopenia B-ADR
in O
a O
patient O
with O
hashimoto O
's O
disease O
: O
involvement O
of O
suppressor-cytotoxic O
t O
cells O

these O
data O
indicated O
that O
infliximab B-DRUG
possibly O
triggered O
production B-ADR
of I-ADR
granulocyte I-ADR
and I-ADR
neutrophil I-ADR
autoantibodies I-ADR
with O
resultant O
autoimmune O
agranulocytosis O

in O
this O
report O
, O
a O
patient O
who O
had O
undergone O
a O
renal O
transplantation O
as O
a O
result O
of O
malignant O
hypertension O
, O
and O
who O
was O
on O
immunosuppressive O
therapy O
consisting O
of O
cyclosporin O
, O
prednisone B-DRUG
and O
azathioprine O
, O
developed O
thrombosis B-ADR
of O
the O
central O
retinal O
vein O
5 O
years O
following O
the O
transplantation O

succinylcholine-induced O
hyperkalemia B-ADR
in O
a O
patient O
with O
mucositis O
secondary O
to O
chemotherapy O

a O
79-year-old O
man O
with O
ischemic O
heart O
disease O
, O
chronic O
atrial O
fibrillation O
, O
chronic O
renal O
failure O
, O
hypothyroidism O
, O
and O
gout O
arthritis O
was O
hospitalized O
because O
of O
fatigue O
, O
myalgia B-ADR
, O
and O
leg O
weakness O
, O
shortly O
after O
starting O
treatment O
with O
colchicine B-DRUG

this O
case O
extends O
the O
spectrum O
of O
fludarabine B-DRUG
pulmonary B-ADR
toxicity I-ADR
to O
include O
pulmonary O
nodules O

this O
article O
presents O
a O
patient O
with O
hypoparathyroidism O
who O
was O
treated O
with O
calcium O
carbonate O
and O
calcitriol B-DRUG
resulting O
in O
two O
admissions O
to O
the O
hospital O
for O
milk-alkali B-ADR
syndrome I-ADR

inappropriate B-ADR
antidiuretic I-ADR
hormone I-ADR
following O
adenine B-DRUG
arabinoside I-DRUG
administration O

captopril-associated O
" O
pseudocholangitis B-ADR

rapamycin O
/ O
sirolimus B-DRUG
( O
sr O
) O
, O
trade O
named O
rapammune O
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression O
, O
hypertension O
, O
hyperlipidemia O
, O
and O
infection B-ADR

secondary B-ADR
hyperparathyroidism I-ADR
in O
certain O
patients O
with O
lithium B-DRUG
nephrotoxicity O
is O
also O
possible O

in O
this O
report O
we O
described O
a O
case O
of O
juvenile O
idiopathic O
arthritis O
patient O
who O
developed O
thymic O
enlargement O
( O
true O
thymic O
hyperplasia O
) O
, O
mediastinal B-ADR
lymphadenopathy I-ADR
and O
pleurisy O
associated O
with O
systemic O
symptoms O
under O
etanercept B-DRUG
treatment O

diagnosis O
: O
severe O
temozolomide-induced O
immunosuppression O
, O
exacerbated O
by O
corticosteroids O
, O
with O
profound O
t-cell B-ADR
lymphocytopenia I-ADR
and O
simultaneous O
opportunistic O
infections O
with O
pneumocystis O
jiroveci O
pneumonia O
, O
brain O
abscess O
with O
listeria O
monocytogenes O
, O
and O
cutaneous O
kaposi O
's O
sarcoma O

in O
the O
absence O
of O
mucositis O
or O
diarrhea O
, O
severe B-ADR
dermatologic I-ADR
toxicity I-ADR
following O
a O
single O
low O
dose O
of O
the O
drug O
suggests O
an O
' O
allergic O
' O
or O
acute O
hypersensitivity O
reaction O
to O
mtx B-DRUG
in O
this O
patient O

hydrocortisone O
may O
decrease O
the O
incidence O
of O
mortality O
associated O
with O
cardiac B-ADR
arrhythmias I-ADR
in O
children O
receiving O
amphotericin B-DRUG
b I-DRUG
overdoses O

eleven O
patients O
developed O
infection O
requiring O
hospitalization O
while O
taking O
leflunomide B-DRUG
including O
: O
lower O
respiratory O
tract O
infections O
( O
3 O
) O
, O
cellulitis O
( O
2 O
) O
, O
disseminated O
herpes O
zoster O
( O
2 O
) O
, O
probable O
tb B-ADR
liver I-ADR
( O
1 O
) O
, O
abdominal O
sepsis O
( O
1 O
) O
, O
mycotic O
aneurysm O
( O
1 O
) O
and O
gastroenteritis O
( O
1 O

methotrexate O
( O
mtx B-DRUG
) O
is O
a O
commonly O
used O
second O
line O
agent O
for O
ra O
, O
and O
there O
have O
been O
several O
recent O
reports O
of O
epstein-barr O
virus O
( O
ebv O
)- O
associated O
polyclonal O
b O
cell O
lymphoproliferative O
disorder O
in O
mtx-treated O
ra O
patients O

the O
present O
report O
describes O
the O
first O
case O
of O
acute B-ADR
pancreatitis I-ADR
associated O
with O
danazol B-DRUG
treatment O
of O
endometriosis O

aseptic B-ADR
meningitis I-ADR
, O
hemolytic O
anemia O
, O
hepatitis O
, O
and O
orthostatic O
hypotension O
in O
a O
patient O
treated O
with O
trimethoprim-sulfamethoxazole O

meperidine-associated O
central O
nervous O
system O
( O
cns O
) O
excitatory O
toxicities O
are O
believed O
to O
be O
caused O
by O
accumulation B-ADR
of I-ADR
the I-ADR
active I-ADR
metabolite I-ADR
normeperidine I-ADR

the O
authors O
report O
five O
additional O
cases O
of O
capecitabine-induced O
multifocal B-ADR
leukoencephalopathy I-ADR

the O
patient O
experienced O
muscle B-ADR
twitches I-ADR
, O
tremulousness O
, O
and O
anxiety O
on O
day O
17 O
of O
foscarnet B-DRUG
therapy O

we O
conclude O
that O
mb O
is O
an O
effective O
treatment O
for O
ifosfamide-induced B-ADR
encephalopathy I-ADR

after O
a O
six-week O
course O
of O
low-dose O
cyclosporine B-DRUG
a I-DRUG
, O
she O
developed O
a O
severe O
but O
reversible O
loss B-ADR
of I-ADR
glomerular I-ADR
filtration I-ADR
rate I-ADR
and O
effective O
renal O
plasma O
flow O
despite O
of O
low O
cyclosporine B-DRUG
a I-DRUG
plasma O
levels O

in O
case O
1 O
, O
a O
total O
daily O
dose O
of O
25 O
mg O
sertraline B-DRUG
, O
with O
nondetectable O
sertraline B-DRUG
and O
desmethylsertraline O
blood O
levels O
, O
resulted O
in O
a O
doubling B-ADR
of I-ADR
the I-ADR
lamotrigine I-ADR
blood I-ADR
level I-ADR
with O
symptoms O
of O
toxicity O

painful B-ADR
neutrophilic O
skin O
lesions O
were O
observed O
in O
two O
children O
receiving O
granulocyte B-DRUG
colony-stimulating I-DRUG
factor I-DRUG
( O
g-csf O
) O
for O
treatment O
of O
idiopathic O
neutropenia O

ciprofloxacin-induced O
renal B-ADR
insufficiency I-ADR
in O
cystic O
fibrosis O

vanishing O
bile O
duct O
and O
stevens-johnson B-ADR
syndrome I-ADR
associated O
with O
ciprofloxacin B-DRUG
treated O
with O
tacrolimus O

diagnosis O
: O
practolol B-DRUG
induced O
sclerosing B-ADR
peritonitis I-ADR

transfusion B-ADR
haemosiderosis I-ADR
inspite O
of O
regular O
use O
of O
desferrioxamine B-DRUG
: O
case O
report O

the O
other O
patient O
developed O
transient B-ADR
intraoperative I-ADR
hypertension I-ADR
immediately O
after O
inadvertent O
submucosal O
injection O
of O
concentrated O
epinephrine B-DRUG

transient B-ADR
left I-ADR
homonymous I-ADR
hemianopsia I-ADR
and O
encephalopathy O
following O
treatment O
of O
testicular O
carcinoma O
with O
cisplatinum O
, O
vinblastine O
, O
and O
bleomycin B-DRUG

a O
30-year-old O
pharmacist O
suffered O
from O
acute B-ADR
allergic I-ADR
contact I-ADR
dermatitis I-ADR
due O
to O
4-chloro-7-nitrobenzofurazan B-DRUG
( O
nbd-cl O

hemodialysis O
was O
also O
shown O
to O
reverse O
ifosfamide-related O
neurotoxicity B-ADR

she O
was O
administered O
metoclopramide B-DRUG
because O
of O
nausea O
and O
, O
within O
2 O
hours O
, O
developed O
agitation O
, O
dysarthria O
, O
diaphoresis B-ADR
, O
and O
a O
movement O
disorder O

the O
delayed O
encephalopathy B-ADR
developed O
9 O
and O
22 O
months O
respectively O
after O
the O
first O
dose O
of O
intrathecal O
methotrexate B-DRUG

amebic O
abscess O
of O
the O
spleen O
complicated O
by O
metronidazole-induced O
neurotoxicity B-ADR
: O
case O
report O

within O
6 O
months O
of O
pranlukast B-DRUG
withdrawal O
, O
anemia B-ADR
resolved O
and O
urinary O
sediment O
and O
renal O
function O
normalized O

gallstones O
and O
bile B-ADR
sludge I-ADR
are O
common O
side O
effects O
of O
octreotide B-DRUG
therapy O
but O
rarely O
become O
symptomatic O
or O
require O
treatment O

traumatic B-ADR
late I-ADR
flap I-ADR
dehiscence I-ADR
and O
enterobacter O
keratitis O
following O
lasik B-DRUG

the O
results O
of O
the O
ultrasound O
examination O
combined O
with O
clinical O
anamnesis O
allowed O
diagnosis O
of O
gastric B-ADR
mucosa I-ADR
foveolar I-ADR
hyperplasia I-ADR
due O
to O
prolonged O
pge1 B-DRUG
therapy O

eruptive B-ADR
epidermoid I-ADR
cysts I-ADR
resulting O
from O
treatment O
with O
imiquimod B-DRUG

we O
report O
a O
patient O
with O
inoperable O
pancreatic O
cancer O
who O
developed O
gastrointestinal B-ADR
bleeding I-ADR
secondary O
to O
radiation-recall O
related O
to O
gemcitabine B-DRUG
and O
review O
literature O

we O
report O
a O
case O
of O
acute O
hyperphosphatemia B-ADR
secondary O
to O
rectal O
administration O
of O
sodium B-DRUG
phosphate I-DRUG
and O
sodium O
biphosphate O
( O
fleet O
enema O

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash O
, O
fever O
, O
leukopenia O
and O
positive O
anti-nuclear O
antibody O
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine O
( O
cbz B-DRUG
; O
tegretol O
) O
used O
against O
benign O
rolandic O
epilepsy O

a O
case O
is O
reported O
in O
which O
severe O
hypocalcemia O
, O
with O
a O
low O
plasma O
parathyroid O
hormone O
( O
pth B-ADR
) O
concentration O
, O
resulted O
from O
the O
therapeutic O
use O
of O
magnesium B-DRUG
sulfate I-DRUG
for O
toxemia O
of O
pregnancy O

acute B-ADR
erythroid I-ADR
leukemia I-ADR
after O
cyclophosphamide B-DRUG
therapy O
for O
multiple O
myeloma O
: O
report O
of O
two O
cases O

a O
unique O
case O
of O
a O
transient O
, O
nonpigmenting O
fixed B-ADR
drug I-ADR
eruption I-ADR
caused O
by O
the O
radiopaque O
contrast O
medium O
iothalamate B-DRUG
is O
reported O

the O
observations O
suggest O
that O
testicular O
swelling O
and O
pain B-ADR
are O
side O
effects O
of O
desipramine B-DRUG

celiac B-ADR
disease I-ADR
onset O
after O
pegylated O
interferon O
and O
ribavirin B-DRUG
treatment O
of O
chronic O
hepatitis O
c O

after O
cessation O
of O
amantadine B-DRUG
, O
the O
edema B-ADR
resolved O
, O
and O
the O
endothelial O
cell O
densities O
were O
< O
or O
= O
600 O
/ O
mm O

its O
overall O
toxicity O
is O
considerably O
less O
compared O
to O
standard O
induction O
chemotherapy O
; O
however O
, O
it O
is O
associated O
with O
a O
high O
incidence O
of O
a O
potentially B-ADR
fatal I-ADR
symptom I-ADR
complex O
referred O
to O
as O
" O
retinoic B-DRUG
acid I-DRUG
syndrome. O
" O
this O
report O
describes O
a O
patient O
with O
apl O
who O
developed O
the O
syndrome O
a O
few O
weeks O
after O
initiating O
induction O
therapy O
with O
atra O
despite O
being O
treated O
for O
hyperleukocytosis O

a O
57-year-old O
man O
developed O
chronic B-ADR
, I-ADR
watery I-ADR
diarrhea I-ADR
four O
weeks O
after O
helicobacter O
pylori O
eradication O
therapy O
including O
lansoprazole B-DRUG
followed O
by O
lansoprazole B-DRUG
monotherapy O
for O
gastroesophageal O
reflux O
disease O

occurrence O
of O
iddm B-ADR
during O
interferon B-DRUG
therapy O
for O
chronic O
viral O
hepatitis O

severe B-ADR
hemolytic I-ADR
uremic I-ADR
syndrome I-ADR
in O
an O
advanced O
ovarian O
cancer O
patient O
treated O
with O
carboplatin B-DRUG
and O
gemcitabine O

this O
selective O
closure O
of O
the O
ductus O
arteriosus O
suggests O
that O
the O
affected O
twin O
was O
predisposed O
to O
hypoxia B-ADR
and O
thus O
was O
more O
susceptible O
to O
ductal O
closure O
in O
response O
to O
indomethacin B-DRUG
exposure O

conclusions O
: O
amantadine B-DRUG
can O
cause O
reversible B-ADR
corneal I-ADR
edema I-ADR
but O
can O
irreversibly O
reduce O
the O
density O
of O
endothelial O
cells O

in O
this O
report O
, O
we O
describe O
a O
patient O
receiving O
lenalidomide B-DRUG
in O
whom O
dyspnea O
, O
fever B-ADR
, O
hypoxia O
, O
and O
diffuse O
pulmonary O
infiltrates O
developed O

background O
: O
gemcitabine B-DRUG
has O
mild O
renal O
toxicity O
, O
but O
cases O
of O
gemcitabine-associated O
hemolytic-uremic B-ADR
syndrome I-ADR
( O
hus O
) O
have O
been O
reported O

methemoglobinemia B-ADR
after O
axillary O
block O
with O
bupivacaine B-DRUG
and O
additional O
injection O
of O
lidocaine O
in O
the O
operative O
field O

colchicine-induced O
myopathy B-ADR
in O
a O
teenager O
with O
familial O
mediterranean O
fever O

the O
case O
resembles O
two O
previously O
reported O
cases O
of O
optic B-ADR
neuropathy I-ADR
which O
occurred O
in O
patients O
with O
wilson O
's O
disease O
who O
were O
receiving O
penicillamine B-DRUG

we O
report O
a O
case O
of O
papillary B-ADR
necrosis I-ADR
in O
a O
patient O
treated O
with O
indinavir B-DRUG

a O
17-year-old O
female O
patient O
who O
had O
been O
taking O
oral O
minocycline B-DRUG
( O
50 O
mg O
twice O
daily O
) O
for O
3 O
weeks O
for O
acne O
developed O
an O
eruption O
that O
progressed O
to O
an O
exfoliative B-ADR
dermatitis I-ADR

this O
regimen O
could O
prove O
useful O
for O
other O
patients O
who O
develop O
hypersensitivity B-ADR
reactions O
to O
carboplatin B-DRUG
and O
allow O
therapy O
to O
continue O

a O
34-year-old O
lady O
developed O
a O
constellation O
of O
dermatitis O
, O
fever B-ADR
, O
lymphadenopathy O
and O
hepatitis O
, O
beginning O
on O
the O
17th O
day O
of O
a O
course O
of O
oral O
sulphasalazine B-DRUG
for O
sero-negative O
rheumatoid O
arthritis O

mechanisms O
and O
triggering O
factors O
of O
hypoglycaemia B-ADR
induced O
by O
mefloquine B-DRUG
and O
some O
other O
anti-malarial O
quinine O
analogues O
are O
discussed O

a O
33-year-old O
male O
presented O
with O
brown B-ADR
discolouration I-ADR
of I-ADR
the I-ADR
fingernails I-ADR
following O
the O
application O
of O
4 B-DRUG
% I-DRUG
hydroquinone I-DRUG
in I-DRUG
sorbolene I-DRUG
cream I-DRUG
and O
0.1 O
% O
tretinoin O
cream O
to O
the O
face O
intermittently O
for O
9 O
months O

leflunomide-associated O
weight B-ADR
loss I-ADR
in O
rheumatoid O
arthritis O

the O
neurotoxicity B-ADR
seen O
with O
hdarac B-DRUG
is O
dose-related O
and O
has O
occurred O
in O
up O
to O
60 O
percent O
of O
treated O
patients O

we O
report O
the O
case O
of O
a O
patient O
who O
developed O
polyserositis O
( O
pericardial O
effusion O
, O
pleural B-ADR
effusion I-ADR
, O
and O
pericarditis O
) O
after O
being O
started O
on O
clozapine B-DRUG
, O
and O
whose O
symptoms O
remitted O
upon O
discontinuation O
of O
clozapine B-DRUG

we O
report O
a O
case O
of O
severe O
respiratory B-ADR
failure I-ADR
due O
to O
gold B-DRUG
salt O
toxicity O
in O
a O
patient O
suffering O
from O
rheumatoid O
arthritis O
requiring O
mechanical O
ventilation O

nineteen O
cases O
of O
allergic B-ADR
contact I-ADR
dermatitis I-ADR
to O
compound O
tincture O
of O
benzoin B-DRUG
are O
described O

two O
cases O
of O
widespread O
cutaneous B-ADR
vasculitis I-ADR
are O
described O
in O
association O
with O
diltiazem B-DRUG
, O
a O
recently O
introduced O
calcium O
antagonist O

one O
patient O
had O
mri O
t2 O
abnormalities O
compatible O
with O
cyclosporin B-DRUG
neurotoxicity B-ADR

cases O
: O
two O
postmenopausal O
women O
treated O
with O
tamoxifen B-DRUG
and O
progestational O
agents O
for O
breast O
carcinoma O
developed O
uterine B-ADR
enlargement I-ADR
and O
intermittent O
spotting O

with O
the O
use O
of O
optical O
coherence O
tomography O
( O
oct O
) O
, O
two O
patients O
with O
ifn-associated O
retinopathy B-ADR
who O
had O
developed O
macular O
edema O
and O
reduced O
visual O
acuity O
during O
the O
clinical O
course O
of O
ifn B-DRUG
therapy O
were O
observed O

acute O
inh B-DRUG
neurotoxicity B-ADR
was O
not O
suspected O
on O
the O
first O
admission O
; O
however O
, O
when O
readmitted O
4 O
weeks O
later O
with O
another O
seizure O
, O
the O
diagnosis O
of O
acute O
inh B-DRUG
neurotoxicity B-ADR
was O
made O

in O
this O
case O
, O
cips B-ADR
was O
considered O
to O
be O
probably O
associated O
with O
cyclosporine B-DRUG
according O
to O
the O
naranjo O
probability O
scale O

salicylate B-DRUG
hepato B-ADR
toxicity I-ADR
in O
rheumatic O
fever O

acute B-ADR
ocular I-ADR
ischemic I-ADR
change I-ADR
may O
be O
associated O
with O
intravitreal O
injection O
of O
bevacizumab B-DRUG
in O
patients O
with O
vascular O
compromised O
diabetic O
retinopathy O
and O
/ O
or O
underlying O
stenosis O
of O
the O
carotid O
artery O

one O
patient O
required O
nursing O
home O
placement O
and O
a O
feeding B-ADR
gastrostomy I-ADR
as O
a O
result O
of O
the O
worsening O
parkinsonism O
during O
risperidone B-DRUG
treatment O
, O
but O
was O
able O
to O
return O
home O
and O
have O
the O
gastrostomy O
removed O
after O
switching O
from O
risperidone B-DRUG
to O
clozapine O

in O
addition O
, O
ethambutol B-DRUG
rarely O
causes O
visual B-ADR
loss I-ADR
during O
the O
early O
period O
or O
when O
given O
at O
lower O
doses O

we O
suggest O
discontinuing O
gemcitabine B-DRUG
if O
radiation B-ADR
recall I-ADR
is O
observed O

we O
report O
a O
child O
with O
yolk O
sac O
tumor O
who O
developed O
localized B-ADR
pigmentation I-ADR
after O
the O
first O
course O
of O
chemotherapy O
regimen O
that O
included O
cisplatin O
, O
etoposide O
and O
bleomycin B-DRUG

a O
retrospective O
review O
of O
ttp O
patients O
with O
quinine-associated O
thrombotic O
microangiopathy O
( O
tma B-ADR
) O
for O
whom O
adamts13 O
was O
measured O
before O
plasma O
exchange O
was O
performed O

severe O
leukopenia O
associated O
with O
mild B-ADR
hepatotoxicity I-ADR
in O
an O
hiv O
carrier O
treated O
with O
nevirapine B-DRUG

seizures B-ADR
and O
extrapyramidal O
symptoms O
in O
a O
patient O
with O
tourette O
's O
syndrome O
, O
asperger O
's O
syndrome O
, O
and O
multiple O
sclerosis O
treated O
with O
interferon B-DRUG
beta-1a I-DRUG
and O
clomipramine O

the O
noted O
increase B-ADR
in I-ADR
the I-ADR
theophylline I-ADR
level I-ADR
after O
zafirlukast B-DRUG
administration O
is O
in O
contrast O
to O
the O
original O
reports O
by O
the O
manufacturer O

he O
had O
been O
taking O
trimethoprim-sulfamethoxazole O
for O
approximately O
eight O
days O
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches O
, O
dizziness O
, O
difficulty O
with O
speech O
, O
weakness O
, O
and O
itching B-ADR
on I-ADR
the I-ADR
trunk I-ADR
of O
his O
body O
and O
legs O
, O
where O
a O
maculopapular O
rash O
was O
noted O

the O
epivodes O
of O
nms B-ADR
occured O
under O
treatment O
with O
clozapine B-DRUG
, O
risperidone O
, O
and O
amisulpride O

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram B-DRUG
developed O
confusion B-ADR
, O
agitation O
, O
tachycardia O
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl O
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl O

a O
36-year-old O
man O
being O
treated O
with O
cisplatinum O
, O
vinblastine O
, O
and O
bleomycin B-DRUG
for O
testicular O
carcinoma O
developed O
a O
dense O
left O
homonymous O
hemianopsia O
, O
encephalopathy B-ADR
, O
and O
a O
partial O
nondominant O
parietal O
lobe O
syndrome O

a O
patient O
with O
parkinson O
's O
disease O
, O
initially O
treated O
with O
bromocriptine B-DRUG
and O
subsequently O
with O
cabergoline O
, O
developed O
progressive O
pleuropulmonary B-ADR
abnormalities I-ADR
during O
the O
latter O
therapy O

reported O
are O
three O
children O
who O
developed O
progressive B-ADR
paraparesis I-ADR
after O
intrathecal O
methotrexate B-DRUG
administration O
followed O
by O
complete O
or O
partial O
recovery O

we O
report O
a O
case O
of O
interstitial B-ADR
pneumonitis I-ADR
induced O
by O
bicalutamide O
and O
/ O
or O
leuprorelin B-DRUG
acetate I-DRUG
given O
as O
therapy O
for O
prostate O
cancer O
, O
in O
which O
the O
pneumonitis O
was O
successfully O
managed O
by O
steroid O
treatment O

red B-ADR
blood I-ADR
cell I-ADR
anemia I-ADR
in O
a O
patient O
with O
pemphigus O
vulgaris O
induced O
by O
the O
use O
of O
mycophenolate B-DRUG
mofetil I-DRUG
and O
prednisone O

this O
case O
study O
is O
the O
second O
report O
of O
localized B-ADR
purpura I-ADR
after O
prolonged O
lamotrigine B-DRUG
treatment O
suggesting O
this O
may O
be O
an O
atypical O
lamotrigine-induced O
drug O
reaction O

intravenous O
cytarabine B-DRUG
and O
methotrexate O
appear O
to O
act O
synergistically O
to O
enhance O
the O
potential O
for O
central B-ADR
nervous I-ADR
system I-ADR
toxicity I-ADR

she O
was O
diagnosed O
with O
epstein-barr O
virus-associated O
polymorphic O
lymphoproliferative O
disorder O
( O
lpd B-ADR
) O
due O
to O
immunodeficiency O
caused O
by O
mtx B-DRUG
administration O

sulfadiazine B-DRUG
crystalluria B-ADR
revisited O

objective O
: O
to O
report O
2 O
cases O
of O
serotonin B-ADR
syndrome I-ADR
with O
serious O
extrapyramidal O
movement O
disorders O
occurring O
when O
metoclopramide O
was O
coadministered O
with O
sertraline O
or O
venlafaxine B-DRUG

thrombotic B-ADR
stroke I-ADR
associated O
with O
the O
use O
of O
porcine B-DRUG
factor I-DRUG
viii I-DRUG
in O
a O
patient O
with O
acquired O
haemophilia O

in O
case O
1 O
, O
a O
total O
daily O
dose O
of O
25 O
mg O
sertraline B-DRUG
, O
with O
nondetectable O
sertraline B-DRUG
and O
desmethylsertraline O
blood O
levels O
, O
resulted O
in O
a O
doubling B-ADR
of I-ADR
the I-ADR
lamotrigine I-ADR
blood I-ADR
level I-ADR
with O
symptoms O
of O
toxicity O

flecainide B-DRUG
is O
a O
rare O
cause O
of O
hypersensitivity B-ADR
pneumonitis I-ADR
, O
and O
few O
cases O
have O
been O
reported O

this O
is O
a O
case O
report O
of O
subtle O
, O
mild O
hypothermia B-ADR
in O
a O
54-year O
old O
female O
patient O
receiving O
risperidone B-DRUG
for O
schizophrenia O

secondary B-ADR
leukemia I-ADR
in O
a O
child O
with O
neuroblastoma O
while O
on O
oral O
etoposide B-DRUG
: O
what O
is O
the O
cause O

observations O
: O
we O
observed O
aggravation B-ADR
and I-ADR
spreading I-ADR
of I-ADR
a I-ADR
psoriatic I-ADR
plaque I-ADR
when O
treated O
topically O
with O
the O
toll-like O
receptor O
( O
tlr O
) O
7 O
agonist O
imiquimod B-DRUG

perinatal O
vasoconstrictive O
renal B-ADR
insufficiency I-ADR
associated O
with O
maternal O
nimesulide B-DRUG
use O

multiple O
complications O
of O
propylthiouracil B-DRUG
treatment O
: O
granulocytopenia O
, O
eosinophilia B-ADR
, O
skin O
reaction O
and O
hepatitis O
with O
lymphocyte O
sensitization O

an O
episode O
of O
leukoencephalopathy B-ADR
is O
reported O
in O
a O
13-year-old O
girl O
who O
, O
after O
standard O
radiotherapy O
for O
a O
posterior O
fossa O
medulloblastoma O
, O
received O
8 O
treatments O
with O
a O
protocol O
containing O
a O
4-hour O
infusion O
of O
500 O
mg O
/ O
m2 O
methotrexate B-DRUG
and O
12 O
mg O
intrathecal O
methotrexate B-DRUG

syndrome B-ADR
of I-ADR
inappropriate I-ADR
antidiuretic I-ADR
hormone I-ADR
associated O
with O
vinorelbine B-DRUG
therapy O

levofloxacin-induced O
delirium B-ADR
with I-ADR
psychotic I-ADR
features I-ADR

adh B-ADR
hypersecretion I-ADR
in O
relation O
to O
plasma O
osmolality O
was O
reversed O
by O
mizoribin B-DRUG
withdrawal O
, O
suggesting O
that O
bredinin O
might O
adversely O
induce O
siadh O

conclusions O
: O
the O
value O
of O
multihormonal O
therapy O
in O
breast O
carcinoma B-ADR
is O
not O
established O
, O
and O
the O
addition O
of O
progestogens O
to O
tamoxifen B-DRUG
may O
not O
reduce O
of O
developing O
endometrial O
lesions O
, O
including O
carcinoma B-ADR

we O
report O
a O
case O
of O
interstitial O
pulmonary O
disease O
that O
occurred O
together O
with O
lymphocytic B-ADR
colitis I-ADR
during O
treatment O
with O
ticlopidine B-DRUG

clinicians O
have O
been O
aware O
of O
lithium B-ADR
toxicity I-ADR
for O
many O
years O
and O
traditionally O
have O
administered O
thiazide O
diuretics O
for O
lithium-induced O
polyuria O
and O
nephrogenic O
diabetes O
insipidus O

risperidone-induced O
obsessive-compulsive B-ADR
symptoms I-ADR
in O
two O
children O

a O
67-year-old O
man O
developed O
diarrhea B-ADR
shortly O
after O
a O
10-day O
course O
of O
oral O
ampicillin B-DRUG

it O
is O
thought O
that O
the O
clinico-pathological O
features O
and O
chronology O
of O
this O
case O
bore O
the O
hallmarks O
of O
the O
so-called O
" O
3-week O
sulphasalazine B-DRUG
syndrome O
" O
, O
a O
rare O
, O
but O
often O
fatal B-ADR
, O
immunoallergic O
reaction O
to O
sulphasalazine B-DRUG

a O
61-year-old O
man O
developed O
clinical O
lupus O
syndrome O
with O
positive O
antinuclear O
antibody O
, O
positive O
lupus B-ADR
erythematosus I-ADR
( O
le O
) O
cell O
preparation O
, O
and O
diffuse O
proliferative O
glomerulonephritis O
following O
26 O
months O
of O
procainamide B-DRUG
therapy O

case O
2 O
, O
a O
29-year-old O
woman O
, O
developed O
bilateral O
optic O
neuritis O
combined O
with O
numbness B-ADR
of I-ADR
the I-ADR
lower I-ADR
extremities I-ADR
as O
well O
as O
bowel O
and O
bladder O
dysfunction O
after O
a O
22-month O
use O
of O
recombinant B-DRUG
interferon I-DRUG
alpha-2b I-DRUG
for O
chronic O
myelogenous O
leukemia O

we O
present O
a O
case O
of O
acute O
epinephrine B-DRUG
toxicity O
resulting O
in O
acute O
myocardial O
ischemia O
in O
a O
young O
boy O
with O
combined O
variable O
immunodeficiency O
syndrome O
who O
developed O
severe B-ADR
allergic I-ADR
reaction I-ADR
to O
intravenous O
immunoglobulin O
, O
and O
was O
subsequently O
given O
epinephrine B-DRUG
by O
mistake O
intravenously O
rather O
than O
subcutaneously O

we O
also O
describe O
a O
new O
, O
noninvasive O
method O
to O
assess O
magnesium-induced O
neuromuscular B-ADR
block I-ADR
when O
curariform O
muscle O
relaxant O
was O
given O
simultaneously O

transtentorial O
herniation O
caused O
by O
an O
intracranial B-ADR
mass I-ADR
lesion I-ADR
following O
high-dose O
methotrexate B-DRUG

eleven O
patients O
developed O
infection O
requiring O
hospitalization O
while O
taking O
leflunomide B-DRUG
including O
: O
lower O
respiratory O
tract O
infections O
( O
3 O
) O
, O
cellulitis O
( O
2 O
) O
, O
disseminated O
herpes O
zoster O
( O
2 O
) O
, O
probable O
tb O
liver O
( O
1 O
) O
, O
abdominal O
sepsis O
( O
1 O
) O
, O
mycotic B-ADR
aneurysm I-ADR
( O
1 O
) O
and O
gastroenteritis O
( O
1 O

although O
the O
literature O
on O
the O
use O
of O
risperidone B-DRUG
in O
elderly O
patients O
with O
dementia O
consists O
largely O
of O
uncontrolled O
trials O
, O
case O
reports O
, O
and O
chart O
reviews O
, O
it O
appears O
that O
this O
agent O
is O
effective O
for O
managing O
agitation O
in O
this O
population O
and O
does O
so O
with O
a O
low O
frequency O
of O
extrapyramidal B-ADR
symptoms I-ADR
( O
eps O

it O
was O
hypothesized O
that O
valproic O
acid O
may O
interfere O
with O
glucuronidation O
of O
lamotrigine B-DRUG
, O
leading O
to O
increased B-ADR
serum I-ADR
lamotrigine I-ADR
levels I-ADR
, O
or O
perhaps O
alter O
the O
drug O
's O
metabolism O
, O
resulting O
in O
accumulation O
of O
a O
toxic O
intermediate O
metabolite O

we O
concluded O
that O
the O
colonic O
ulcer O
and O
the O
sigmoidovesical B-ADR
fistula I-ADR
had O
been O
caused O
by O
the O
administration O
of O
calcium B-DRUG
polystyrene I-DRUG
sulfonate I-DRUG
and O
sorbitol O

central O
nervous O
system O
effects O
secondary O
to O
ciprofloxacin B-DRUG
treatment O
are O
uncommon O
and O
usually O
consist O
only O
of O
minor B-ADR
dizziness I-ADR
or O
mild O
headache O
, O
although O
rare O
occurrences O
of O
seizures O
and O
hallucinations O
have O
been O
reported O

although O
transient O
increases O
in O
ectopy O
after O
bretylium B-DRUG
therapy O
have O
been O
described O
, O
presumably O
due O
to O
catecholamine O
release O
, O
the O
occurrence O
of O
life-threatening O
ventricular O
arrhythmia O
leading O
to O
cardiac B-ADR
arrest I-ADR
has O
not O
previously O
been O
emphasized O

this O
patient O
, O
who O
had O
a O
history O
of O
osteoarthritis O
, O
had O
severe O
hepatitis B-ADR
5 O
weeks O
after O
being O
started O
on O
diclofenac B-DRUG
for O
increasing O
pain O
in O
the O
joints O

jaundice B-ADR
induced O
by O
streptokinase B-DRUG

it O
was O
postulated O
that O
the O
allergic B-ADR
reaction I-ADR
was O
most O
likely O
caused O
by O
capecitabine B-DRUG
or O
the O
intermediate O
metabolites O
based O
on O
the O
immediate O
reappearance O
of O
symptoms O
from O
the O
rechallenge O
, O
pharmacokinetic O
data O
, O
and O
well-tolerance O
of O
fluorouracil O

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash B-ADR
, O
fever O
, O
leukopenia O
and O
positive O
anti-nuclear O
antibody O
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine B-DRUG
( O
cbz O
; O
tegretol O
) O
used O
against O
benign O
rolandic O
epilepsy O

six O
of O
13 O
outpatients O
with O
schizophrenia O
who O
participated O
in O
a O
ten-week O
open O
trial O
of O
risperidone B-DRUG
had O
an O
initial O
good O
response O
to O
the O
medication O
followed O
by O
development O
of O
intolerable O
affect O
, O
including O
feelings B-ADR
of I-ADR
agitation I-ADR
and O
depression O
and O
periods O
of O
crying O
and O
insomnia O

in O
this O
article O
lithium B-DRUG
is O
not O
discussed O
, O
although O
there O
are O
a O
number O
of O
concerns O
about O
lithium B-DRUG
's O
potential O
teratogenicity B-ADR
, O
and O
it O
has O
been O
implicated O
in O
epstein O
's O
anomaly O
, O
a O
congenital O
heart O
defect O
among O
infants O
born O
to O
women O
taking O
lithium B-DRUG
; O
as O
with O
other O
medications O
, O
however O
, O
the O
data O
have O
specific O
limitations O

this O
is O
the O
first O
reported O
case O
of O
boop B-ADR
associated O
with O
single-agent O
rituximab B-DRUG
, O
and O
along O
with O
two O
other O
patients O
we O
describe O
, O
as O
well O
as O
two O
prior O
reports O
of O
boop B-ADR
in O
nhl O
patients O
receiving O
rituximab-based O
combinations O
, O
strengthens O
the O
possibility O
of O
a O
causal O
relationship O

fever O
, O
lymphadenopathy O
, O
eosinophilia O
, O
lymphocytosis B-ADR
, O
hepatitis O
, O
and O
dermatitis O
: O
a O
severe O
adverse O
reaction O
to O
minocycline B-DRUG

the O
clinical O
picture O
was O
identical O
to O
that O
of O
chloroquine B-DRUG
and O
hydroxychloroquine O
maculopathy B-ADR

two O
patients O
with O
extrapyramidal B-ADR
side I-ADR
effects I-ADR
after O
the O
use O
of O
fluphenazine B-DRUG
decanoate I-DRUG
were O
evaluated O
by O
means O
of O
ibzm-spect O

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion O
, O
agitation O
, O
tachycardia O
, O
tremors B-ADR
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

development O
of O
persistent B-ADR
late I-ADR
onset I-ADR
asthma I-ADR
following O
treatment O
with O
captopril B-DRUG

probable O
early O
acute B-ADR
hepatitis I-ADR
with O
parenteral O
amiodarone B-DRUG

these O
cases O
indicate O
that O
sulpiride B-DRUG
can O
cause O
tardive B-ADR
dyskinesia I-ADR
and O
that O
this O
drug O
should O
be O
administered O
with O
caution O

fatal B-ADR
radiation I-ADR
myelopathy I-ADR
after O
high-dose O
busulfan O
and O
melphalan B-DRUG
chemotherapy O
and O
radiotherapy O
for O
ewing O
's O
sarcoma O
: O
a O
review O
of O
the O
literature O
and O
implications O
for O
practice O

conclusion O
: O
while O
thrombosis B-ADR
has O
been O
reported O
with O
gnrh-a B-DRUG
therapy O
in O
men O
with O
prostate O
cancer O
, O
its O
association O
with O
treatment O
in O
this O
benign O
case O
may O
have O
been O
a O
consequence O
of O
the O
massive O
tumor O
size O

priapism B-ADR
associated O
with O
olanzapine B-DRUG

myasthenic O
patients O
receiving O
ampicillin B-DRUG
should O
be O
closely O
monitored O
for O
possible O
acute B-ADR
exacerbations I-ADR

a O
patient O
with O
intracranial O
osteosarcoma O
that O
arose O
16 O
years O
after O
radiation O
therapy O
for O
hereditary O
retinoblastoma O
developed O
fatal O
cerebral O
edema O
and O
brainstem B-ADR
herniation I-ADR
after O
she O
received O
a O
single O
dose O
of O
intravenous O
methotrexate B-DRUG

we O
have O
successfully O
overcome O
severe B-ADR
neutropenia I-ADR
in O
an O
ra O
patient O
treated O
with O
gold B-DRUG
salts O
, O
using O
granulocyte O
colony-stimulating O
factor O
( O
g-csf O
) O
, O
reducing O
the O
duration O
of O
neutropenia O
and O
risk O
of O
infection O

background O
: O
ovarian B-ADR
cancer I-ADR
arising O
from O
an O
endometriotic O
cyst O
in O
a O
postmenopausal O
woman O
under O
tamoxifen B-DRUG
therapy O
is O
rare O

background O
: O
reproductive O
endocrine O
disorders O
characterized O
by O
menstrual O
disorders O
, O
polycystic B-ADR
ovaries I-ADR
, O
and O
hyperandrogenism O
seem O
to O
be O
common O
among O
women O
treated O
with O
sodium B-DRUG
valproate I-DRUG
for O
epilepsy O

we O
report O
an O
82-year-old O
man O
who O
developed O
ventricular O
tachycardia O
and O
torsades O
de O
pointes O
( O
tdp B-ADR
) O
after O
oral O
administration O
of O
garenoxacin B-DRUG
, O
a O
novel O
quinolone O
antibiotic O
agent O
that O
differs O
from O
the O
third-generation O
quinolones O
, O
for O
pneumonia O

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram B-DRUG
developed O
confusion O
, O
agitation O
, O
tachycardia O
, O
tremors O
, O
myoclonic B-ADR
jerks I-ADR
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl O
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl O

vancomycin B-DRUG
is O
the O
most O
frequently O
implicated O
drug O
, O
but O
other O
agents O
have O
been O
reported O
to O
cause O
labd B-ADR

we O
report O
a O
case O
with O
chronic O
hepatitis O
c O
( O
chc O
) O
who O
developed O
sarcoidosis B-ADR
after O
the O
treatment O
by O
interferon O
alpha O
and O
ribavirin B-DRUG

a O
58-yr-old O
male O
patient O
with O
essential O
thrombocythaemia O
( O
et O
) O
developed O
chronic O
myeloid O
leukaemia O
( O
cml B-ADR
) O
after O
continuous O
uneventful O
treatment O
with O
hydroxyurea B-DRUG
for O
18 O
yr O

fluoxetine-related O
death B-ADR
in O
a O
child O
with O
cytochrome O
p-450 O
2d6 O
genetic O
deficiency O

carbamazepine-induced O
systemic B-ADR
lupus I-ADR
erythematosus-like I-ADR
disease I-ADR

the O
authors O
present O
an O
elderly O
patient O
with O
mixed O
dementia O
who O
developed O
td O
at O
multiple O
sites O
, O
( O
including O
respiratory O
dyskinesia O
[ O
rd B-ADR
] O
, O
limb O
dyskinesia O
, O
and O
orofacial O
dyskinesia O
) O
following O
abrupt O
withdrawal O
of O
risperidone B-DRUG
therapy O

antibiotic-associated O
colitis B-ADR
( O
pseudomembranous O
colitis B-ADR
) O
developed O
in O
four O
patients O
with O
spinal O
cord O
injury O
and O
taking O
oral O
trimethoprim-sulfamethoxazole O

he O
was O
started O
on O
oral O
lansoprazole B-DRUG
60 O
mg O
twice O
daily O
and O
, O
on O
hospital O
day O
2 O
, O
his O
platelet B-ADR
count I-ADR
decreased I-ADR
to O
102 O
x O
10 O
( O
3 O
)/ O
mm O
( O
3 O
) O
; O
on O
hospital O
day O
3 O
, O
the O
platelet O
count O
was O
36 O
x O
10 O
( O
3 O
)/ O
mm O
( O
3 O

seizures B-ADR
and O
extrapyramidal O
symptoms O
in O
a O
patient O
with O
tourette O
's O
syndrome O
, O
asperger O
's O
syndrome O
, O
and O
multiple O
sclerosis O
treated O
with O
interferon O
beta-1a O
and O
clomipramine B-DRUG

this O
case O
demonstrates O
the O
value O
of O
dwi O
in O
evaluation O
and O
diagnosis O
of O
sub-acute B-ADR
toxic I-ADR
leukoencephalopathy I-ADR
in O
patients O
being O
treated O
with O
methotrexate B-DRUG

the O
aim O
of O
this O
report O
is O
to O
describe O
the O
clinical O
and O
electroencephalographic O
findings O
seen O
in O
an O
elderly O
woman O
without O
previous O
history O
of O
seizures O
who O
developed O
a O
nonconvulsive B-ADR
generalized I-ADR
status I-ADR
epilepticus I-ADR
following O
acute O
withdrawal O
of O
lorazepam B-DRUG

we O
describe O
the O
first O
case O
of O
de O
novo O
asthma B-ADR
following O
treatment O
with O
the O
angiotensin O
converting O
enzyme O
( O
ace O
) O
inhibitor O
captopril B-DRUG

a O
36-year-old O
man O
being O
treated O
with O
cisplatinum O
, O
vinblastine O
, O
and O
bleomycin B-DRUG
for O
testicular O
carcinoma O
developed O
a O
dense O
left B-ADR
homonymous I-ADR
hemianopsia I-ADR
, O
encephalopathy O
, O
and O
a O
partial O
nondominant O
parietal O
lobe O
syndrome O

a O
case O
of O
heatstroke B-ADR
is O
reported O
in O
a O
32-year-old O
man O
diagnosed O
with O
schizophrenia O
and O
on O
clozapine B-DRUG
monotherapy O

conclusion O
: O
in O
some O
abstainers O
who O
take O
cyanamide B-DRUG
for O
several O
years O
, O
thin O
septum-like B-ADR
liver I-ADR
fibrosis I-ADR
progresses O
along O
with O
the O
emergence O
of O
ground-glass O
hepatocytes O

nineteen O
cases O
of O
unusual O
enhanced O
vincristine O
neurotoxicity B-ADR
related O
to O
itraconazole B-DRUG
have O
been O
reported O
in O
children O

clofazimine B-DRUG
enteropathy B-ADR
caused O
by O
crystal O
deposition O
can O
be O
life-threatening O

we O
report O
a O
16-year-old O
male O
who O
developed O
nephrotic O
syndrome O
related O
to O
membranous O
glomerulopathy O
with O
clinical O
and O
serological O
evidence O
of O
systemic B-ADR
lupus I-ADR
erythematosus I-ADR
after O
treatment O
with O
griseofulvin B-DRUG

even O
after O
a O
strict O
warning O
, O
he O
took O
another O
quinine B-DRUG
tablet O
that O
evening O
, O
which O
triggered O
his O
fifth O
episode O
of O
severe O
thrombocytopenia B-ADR
, O
and O
confirmed O
the O
etiology O
of O
quinine-induced O
thrombocytopenia B-ADR

the O
toxicity B-ADR
and O
plasma O
concentrations O
of O
ifosfamide B-DRUG
, O
chloroacetaldehyde O
, O
and O
4-hydroxyifosfamide O
were O
then O
determined O
over O
24 O
h O
after O
a O
single O
1.6 O
g O
/ O
m2 O
dose O
of O
ifosfamide B-DRUG

we O
report O
the O
case O
of O
a O
lung O
cancer O
patient O
with O
bronquiloalveolar O
carcinoma O
( O
bac O
) O
presenting O
with O
boop O
after O
chemotherapy O
with O
docetaxel O
and O
gemcitabine B-DRUG
producing O
severe B-ADR
respiratory I-ADR
insufficiency I-ADR
, O
and O
simulating O
a O
progression O
of O
the O
tumor O

less O
common O
adverse O
events O
to O
dapsone B-DRUG
include O
the O
idiosyncratic O
reactions O
of O
leukopenia O
and O
agranulocytosis O
, O
cutaneous O
eruptions O
, O
peripheral O
neuropathy O
, O
psychosis O
, O
toxic O
hepatitis O
, O
cholestatic O
jaundice O
, O
nephrotic O
syndrome O
, O
renal O
papillary O
necrosis O
, O
severe O
hypoalbuminemia O
without O
proteinuria O
, O
an B-ADR
infectious I-ADR
mononucleosis-like I-ADR
syndrome I-ADR
, O
and O
minor O
neurological O
and O
gastrointestinal O
complaints O

we O
report O
a O
case O
of O
a O
60-year-old O
woman O
affected O
by O
squamous O
lung O
carcinoma O
, O
who O
developed O
paroxysmal B-ADR
supraventricular I-ADR
tachycardia I-ADR
during O
cisplatin B-DRUG
and O
etoposide O
combination O
chemotherapy O

elderly O
patients O
for O
whom O
nitrate B-DRUG
has O
been O
prescribed O
should O
be O
warned O
of O
the O
occurrence O
of O
hypotension O
, O
leading O
to O
unconsciousness B-ADR

conclusions O
: O
this O
study O
confirmed O
that O
in O
most O
patients O
mtx-induced O
liver B-ADR
cirrhosis I-ADR
is O
not O
aggressive O

fluorouracil O
for O
allergic B-ADR
reactions I-ADR
to O
capecitabine B-DRUG

the O
use O
of O
methotrexate O
( O
mtx B-DRUG
) O
has O
been O
contraindicated O
for O
treatment O
of O
severe O
psoriasis O
in O
hiv O
infection O
on O
the O
basis O
of O
six O
previously O
reported O
cases O
in O
which O
mtx B-DRUG
appeared O
to O
potentiate O
opportunistic O
infections O
and O
accelerate B-ADR
hiv I-ADR
disease I-ADR

primary O
cns B-ADR
lymphoma I-ADR
regressed O
on O
withdrawal O
of O
mm B-DRUG

the O
second O
patient O
developed O
both O
autoimmune O
thyroid O
disease O
and O
a O
refractory B-ADR
pre-patellar I-ADR
bursitis I-ADR
after O
50 O
months O
of O
ifn-beta B-DRUG
therapy O

however O
, O
follow-up O
revealed O
that O
gestational O
diabetes O
when O
associated O
with O
norethisterone B-DRUG
had O
a O
lesser O
risk O
of O
emerging O
diabetes O
mellitus O
and O
impaired B-ADR
glucose I-ADR
tolerance I-ADR

recurrent B-ADR
hyponatremia I-ADR
associated O
with O
citalopram B-DRUG
and O
mirtazapine O

even O
after O
a O
strict O
warning O
, O
he O
took O
another O
quinine B-DRUG
tablet O
that O
evening O
, O
which O
triggered O
his O
fifth O
episode O
of O
severe O
thrombocytopenia B-ADR
, O
and O
confirmed O
the O
etiology O
of O
quinine-induced O
thrombocytopenia B-ADR

purpose O
: O
to O
report O
two O
cases O
of O
acute B-ADR
endophthalmitis I-ADR
following O
intravitreal O
bevacizumab B-DRUG
injection O

thoracoscopic O
biopsy O
to O
confirm O
metastasis O
revealed O
instead O
fibrotic B-ADR
lesions I-ADR
apparently O
attributable O
to O
bleomycin B-DRUG
or O
cyclophosphamide O

increased B-ADR
ocular I-ADR
pressure I-ADR
in O
two O
patients O
with O
narrow O
angle O
glaucoma O
treated O
with O
venlafaxine B-DRUG

however O
, O
one O
patient O
exhibited O
severe O
hypersensitivity O
reactions O
including O
cardiac B-ADR
arrest I-ADR
and O
apnea O
, O
and O
another O
four O
patients O
developed O
eruptions O
, O
hypotension O
, O
and O
tachycardia O
soon O
after O
administration O
of O
cbdca B-DRUG

objective O
: O
to O
report O
the O
occurrence O
of O
acute O
cytolytic O
hepatitis B-ADR
in O
a O
patient O
exposed O
to O
pulse O
itraconazole B-DRUG
therapy O
for O
24 O
weeks O
and O
provide O
a O
concise O
review O
of O
the O
literature O
on O
cases O
of O
itraconazole-induced O
hepatitis B-ADR

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash O
, O
fever O
, O
leukopenia O
and O
positive O
anti-nuclear O
antibody O
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine O
( O
cbz O
; O
tegretol B-DRUG
) O
used O
against O
benign O
rolandic O
epilepsy O

we O
report O
the O
case O
of O
a O
lung O
cancer O
patient O
with O
bronquiloalveolar O
carcinoma O
( O
bac O
) O
presenting O
with O
boop B-ADR
after O
chemotherapy O
with O
docetaxel B-DRUG
and O
gemcitabine O
producing O
severe O
respiratory O
insufficiency O
, O
and O
simulating O
a O
progression O
of O
the O
tumor O

exacerbation O
of O
5-fu B-DRUG
dermatologic B-ADR
toxicities I-ADR
in O
patients O
with O
preexisting O
conditions O
suggests O
the O
importance O
of O
aggressive O
ocular O
prophylaxis O
, O
using O
frequent O
ocular O
lubrication O
and O
topical O
steroid O
preparations O
with O
concurrent O
medical O
management O
of O
pre-existing O
dermatologic O
conditions O

a O
case O
of O
anaphylactoid B-ADR
reaction I-ADR
due O
solely O
to O
the O
use O
of O
gelofusine B-DRUG
in O
a O
patient O
with O
non-haemorrhagic O
hypovolaemia O
is O
presented O
, O
with O
a O
discussion O
on O
the O
management O
and O
the O
use O
of O
allergy O
identification O
jewellery O

reversible B-ADR
posterior I-ADR
leukoencephalopathy I-ADR
syndrome I-ADR
in O
systemic O
lupus O
erythematosus O
with O
thrombocytopenia O
treated O
with O
cyclosporine B-DRUG

this O
case O
suggests O
that O
bh-ac B-DRUG
, O
a O
derivative O
of O
cytosine O
arabinoside O
( O
1-beta-d-arabinofuranosylcytosine O
) O
could O
be O
a O
cause O
of O
reversible O
encephalopathy B-ADR
syndrome I-ADR

we O
describe O
a O
patient O
who O
experienced O
a O
lichenoid B-ADR
eruption I-ADR
after O
the O
initiation O
of O
salsalate B-DRUG
for O
relief O
of O
arthritic O
pain O

acute B-ADR
myeloid I-ADR
leukemia I-ADR
evolving O
from O
essential O
thrombocythemia O
in O
two O
patients O
treated O
with O
hydroxyurea B-DRUG

dipyrone-induced O
granulocytopenia B-ADR
: O
a O
case O
for O
awareness O

minocycline B-DRUG
as O
a O
cause O
of O
drug-induced O
autoimmune B-ADR
hepatitis I-ADR

because O
of O
serious O
side O
effects O
of O
an O
increase O
in O
the O
qt O
interval O
causing O
torsades B-ADR
de I-ADR
pointes I-ADR
, O
dofetilide B-DRUG
must O
be O
initiated O
with O
close O
monitoring O
of O
the O
qt O
interval O
in O
an O
inpatient O
setting O

we O
report O
the O
case O
of O
a O
21-year-old O
female O
patient O
with O
dapsone B-DRUG
hypersensitivity B-ADR
syndrome I-ADR

iatrogenic O
hypercalcemia B-ADR
due O
to O
vitamin O
d3 O
ointment O
( O
1,24 O
( O
oh O
) O
2d3 O
) O
combined O
with O
thiazide O
diuretics O
in O
a O
case O
of O
psoriasis O

this O
case O
report O
describes O
an O
adolescent O
with O
severe B-ADR
lupus I-ADR
erythematosus I-ADR
who O
received O
cyclophosphamide B-DRUG
( O
cy O
) O
paired O
with O
taste O
( O
cod O
liver O
oil O
) O
and O
smell O
( O
rose O
perfume O
) O
as O
conditioned O
stimuli O

visceral B-ADR
herpesvirus I-ADR
infections I-ADR
in O
leukemic O
patients O
receiving O
cytarabine B-DRUG

focal O
glomerulonephritis O
and O
interstitial B-ADR
nephritis I-ADR
in O
methicillin-treated O
, O
heroin-related O
infective O
endocarditis O

the O
case O
reported O
here O
is O
of O
a O
child O
given O
a O
large O
dose O
of O
intravenous O
iron B-DRUG
sucrose I-DRUG
( O
16 O
mg O
/ O
kg O
) O
over O
3 O
hours O
, O
who O
subsequently O
developed O
features O
of O
systemic B-ADR
iron I-ADR
toxicity I-ADR

interferon-alpha O
( O
ifn-alpha B-DRUG
) O
may O
precipitate O
or O
exacerbate O
the O
occurrence O
of O
mpgn B-ADR

to O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
patient O
with O
captopril-induced O
pemphigus B-ADR
in O
whom O
no O
new O
lesions O
developed O
after O
subsequent O
treatment O
with O
enalapril O

our O
experience O
supports O
hemodialysis O
for O
esrf O
patients O
with O
atenolol B-ADR
toxicity I-ADR

lower O
extremity O
arterial B-ADR
insufficiency I-ADR
after O
long-term O
methysergide B-DRUG
maleate I-DRUG
therapy O

ciprofloxacin-induced O
hemorrhagic B-ADR
vasculitis I-ADR
is O
a O
rare O
side O
effect O

we O
describe O
the O
side O
effects O
of O
5-fu B-DRUG
in O
a O
colon O
cancer O
patient O
who O
suffered O
severe B-ADR
mucositis I-ADR
, O
desquamating O
dermatitis O
, O
prolonged O
myelosuppression O
, O
and O
neurologic O
toxicity O
that O
required O
admission O
to O
the O
intensive O
care O
unit O

the O
possibility O
of O
phenytoin B-DRUG
hypersensitivity O
reactions O
should O
be O
considered O
when O
patients O
receiving O
phenytoin B-DRUG
have O
unusual O
symptoms O
, O
particularly O
fever O
, O
rash O
, O
and O
lymphadenopathy B-ADR

tetany B-ADR
in O
a O
child O
with O
aids O
receiving O
intravenous O
tobramycin B-DRUG

carboplatin B-DRUG
hypersensitivity B-ADR
induced O
by O
low-dose O
paclitaxel O
/ O
carboplatin O
in O
multiple O
platinum-treated O
patients O
with O
recurrent O
ovarian O
cancer O

a O
16-year-old O
boy O
developed O
fever B-ADR
, O
generalized O
rigidity O
, O
leukocytosis O
, O
and O
increased O
serum O
transaminase O
and O
creatine O
kinase O
levels O
while O
receiving O
treatment O
with O
olanzapine O
and O
lithium B-DRUG

during O
dose-finding O
studies O
for O
intravenous O
proton O
pump O
inhibitors O
omeprazole O
and O
pantoprazole B-DRUG
, O
three O
of O
six O
young O
female O
volunteers O
receiving O
omeprazole O
and O
two O
young O
female O
volunteers O
receiving O
pantoprazole B-DRUG
developed O
peripheral B-ADR
edema I-ADR
within O
8 O
hr O
when O
high O
doses O
of O
the O
proton O
pump O
inhibitors O
were O
applied O
by O
continuous O
infusion O
together O
with O
large O
volumes O
of O
fluid O

atrial O
fibrillation O
was O
induced O
by O
diltiazem O
in O
two O
patients O
and O
verapamil B-DRUG
induced O
syncope B-ADR
in O
one O
patient O

increased O
awareness O
is O
needed O
on O
the O
possible O
occurrence O
of O
lpd B-ADR
resembling O
gastric O
cancer O
in O
rheumatoid O
arthritis O
patients O
treated O
with O
mtx B-DRUG

the O
association O
with O
prolonged O
unopposed O
estrogen-like O
stimulation O
with O
tamoxifen B-DRUG
as O
a O
possible O
factor O
in O
the O
development O
of O
ovarian B-ADR
endometrioid I-ADR
carcinoma I-ADR
is O
discussed O

we O
believe O
this O
is O
the O
first O
report O
of O
myocardial B-ADR
infarction I-ADR
due O
to O
coronary O
spasm O
, O
demonstrated O
by O
angiography O
associated O
with O
l-thyroxine B-DRUG
therapy O

two O
cases O
of O
lepromatous O
leprosy O
with O
erythema O
nodosum O
leprosum O
who O
were O
on O
high O
doses O
of O
clofazimine B-DRUG
, O
showed O
discoloration O
of O
nail O
plate O
, O
subungual B-ADR
hyperkeratosis I-ADR
and O
onycholysis O

sulindac B-DRUG
( O
clinoril O
) O
, O
a O
nonsteroidal O
anti-inflammatory O
agent O
, O
has O
few O
reported O
neurologic B-ADR
toxic I-ADR
effects I-ADR
, O
all O
of O
which O
have O
been O
associated O
with O
systemic O
disease O

stupor B-ADR
from O
lamotrigine B-DRUG
toxicity O

hypoglycemia B-ADR
induced O
by O
long-acting O
somatostatin B-DRUG
analogues O
in O
a O
patient O
with O
nonfunctional O
neuroendocrine O
tumor O

after O
a O
second O
dose O
of O
metoclopramide B-DRUG
, O
these O
symptoms O
recurred O
and O
were O
associated O
with O
confusion O
, O
agitation O
, O
fever O
, O
diaphoresis O
, O
tachypnea O
, O
tachycardia B-ADR
, O
and O
hypertension O

the O
authors O
describe O
a O
case O
of O
combined O
lithium B-DRUG
and O
haloperidol O
toxicity O
characterized O
by O
hyperpyrexia O
, O
severe O
rigidity O
, O
mutism B-ADR
, O
and O
development O
of O
irreversible O
tardive O
dyskinesia O

carbamazepine B-ADR
toxicity I-ADR
following O
oxybutynin B-DRUG
and O
dantrolene O
administration O
: O
a O
case O
report O

life-threatening O
interstitial B-ADR
lung I-ADR
disease I-ADR
associated O
with O
trastuzumab B-DRUG
: O
case O
report O

alprazolam-induced O
mania B-ADR
: O
two O
clinical O
cases O

hepatotoxicity B-ADR
induced O
by O
cyproterone B-DRUG
acetate I-DRUG
: O
a O
report O
of O
three O
cases O

finally O
, O
reserpine B-ADR
toxicity I-ADR
, O
in O
particular O
central O
nervous O
system O
( O
cns O
) O
disturbances O
, O
was O
reported O
more O
frequently O
in O
patients O
also O
receiving O
barbiturates O
, O
suggesting O
additive O
cns O
effects O

a O
7-year-old O
boy O
developed O
a O
severe B-ADR
unilateral I-ADR
grand I-ADR
mal I-ADR
seizure I-ADR
at O
the O
age O
of O
5 O
years O
( O
phenobarbitone O
therapy O
) O
; O
1.5 O
years O
later O
valproate O
( O
2-propylpentanoic O
acid O
, O
vpa B-DRUG
) O
was O
added O
to O
the O
therapy O

a O
child O
in O
whom O
a O
phenobarbital B-DRUG
hypersensitivity O
drug O
reaction O
developed O
which O
consisted O
of O
fever O
, O
a O
pruritic O
desquamating O
erythrodermic O
rash O
, O
alopecia O
, O
icterus O
, O
protein-losing O
enteropathy O
, O
myositis B-ADR
, O
and O
nephritis O
, O
is O
described O

we O
describe O
a O
patient O
who O
became O
hypothyroid B-ADR
while O
taking O
ferrous B-DRUG
sulfate I-DRUG

methods O
: O
a O
case O
is O
presented O
of O
a O
45-year-old O
woman O
on O
prolonged O
gemcitabine B-DRUG
treatment O
for O
ovarian O
cancer O
who O
developed O
hus B-ADR
and O
recovered O
after O
drug O
discontinuation O

we O
observed O
transient O
panhypogammaglobulinaemia B-ADR
in O
a O
patient O
with O
neuropsychiatric O
sle O
after O
treatment O
with O
prednisolone O
and O
cyclophosphamide B-DRUG

physicians O
should O
be O
aware O
of O
the O
risk O
of O
severe O
aiha O
in O
cll O
patients O
with O
a O
history O
of O
aiha O
or O
positivation B-ADR
of I-ADR
the I-ADR
dat I-ADR
during O
previous O
fludarabine B-DRUG
administration O
, O
or O
in O
case O
of O
secondary O
fixation O
of O
complement O
to O
the O
red O
cell O
membrane O
occurring O
during O
fludarabine B-DRUG
treatment O

these O
are O
the O
first O
reported O
patients O
to O
show O
mferg B-ADR
abnormalities I-ADR
that O
correspond O
to O
bitemporal O
visual O
field O
defects O
and O
add O
to O
the O
growing O
evidence O
that O
ethambutol B-DRUG
damages O
the O
retina O

pulmonary O
hemorrhage O
is O
an O
uncommon O
feature O
in O
the O
hus B-ADR
, O
and O
seems O
to O
appear O
especially O
in O
the O
hus B-ADR
associated O
with O
mmc B-DRUG
therapy O

during O
the O
first O
days O
of O
arsenic B-DRUG
trioxide I-DRUG
treatment O
a O
rapid O
decrease O
in O
the O
d-dimers O
was O
seen O
( O
normal O
values O
reached O
until O
day O
7 O
) O
, O
together O
with O
a O
slight B-ADR
decrease I-ADR
in I-ADR
peripheral I-ADR
blood I-ADR
leukocytes I-ADR

lichen B-ADR
planus I-ADR
induced O
by O
hepatitis B-DRUG
b I-DRUG
vaccination I-DRUG
: O
a O
new O
case O
and O
review O
of O
the O
literature O

hypogammaglobulinemia B-ADR
associated O
with O
gold B-DRUG
therapy O
: O
evidence O
for O
a O
partial O
maturation O
blockade O
of O
b O
cells O

detection O
of O
activated O
eosinophils O
in O
nasal O
polyps O
of O
an O
aspirin-induced O
asthma B-ADR
patient O

gold-induced O
aplastic B-ADR
anemia I-ADR

the O
use O
of O
methotrexate O
( O
mtx B-DRUG
) O
has O
been O
contraindicated O
for O
treatment O
of O
severe O
psoriasis O
in O
hiv O
infection O
on O
the O
basis O
of O
six O
previously O
reported O
cases O
in O
which O
mtx B-DRUG
appeared O
to O
potentiate O
opportunistic O
infections O
and O
accelerate B-ADR
hiv I-ADR
disease I-ADR

nine O
eyes O
from O
6 O
patients O
, O
74 O
years O
to O
90 O
years O
of O
age O
, O
referred O
by O
ophthalmologists O
for O
repair O
of O
cicatricial B-ADR
entropion I-ADR
after O
at O
least O
2 O
years O
of O
twice-a-day O
application O
of O
dipivefrin B-DRUG

lichen B-ADR
planus I-ADR
and O
acne O
provoked O
by O
gold B-DRUG

transient O
leucopenia O
and O
thrombocytopenia B-ADR
associated O
with O
sodium B-DRUG
nitroprusside I-DRUG
infusion O

the O
occurrence O
of O
bmtn B-ADR
in O
two O
children O
treated O
with O
ra B-DRUG
in O
our O
unit O
is O
unlikely O
to O
be O
coincidental O

extrapyramidal B-ADR
side I-ADR
effects I-ADR
induced O
by O
some O
selective O
serotonin O
reuptake O
inhibitors O
( O
ssris O
) O
, O
i.e. O
fluoxetine O
and O
sertraline B-DRUG
, O
have O
been O
previously O
reported O
in O
patients O
with O
depression O
and O
obsessive-compulsive O
disorder O
( O
ocd O

in O
case O
1 O
, O
a O
total O
daily O
dose O
of O
25 O
mg O
sertraline B-DRUG
, O
with O
nondetectable O
sertraline B-DRUG
and O
desmethylsertraline O
blood O
levels O
, O
resulted O
in O
a O
doubling O
of O
the O
lamotrigine O
blood O
level O
with O
symptoms B-ADR
of I-ADR
toxicity I-ADR

because O
of O
serious O
side O
effects O
of O
an O
increase B-ADR
in I-ADR
the I-ADR
qt I-ADR
interval I-ADR
causing O
torsades O
de O
pointes O
, O
dofetilide B-DRUG
must O
be O
initiated O
with O
close O
monitoring O
of O
the O
qt O
interval O
in O
an O
inpatient O
setting O

the O
patient O
experienced O
hallucinations O
, O
agitation O
, O
vomiting B-ADR
, O
tachycardia O
and O
seizures O
after O
ingestion O
of O
1050 O
( O
48 O
mg O
/ O
kg O
) O
of O
extended-release O
bupropion B-DRUG

a O
patient O
developed O
typical O
ecm B-ADR
after O
subcutaneous O
selfinjection O
of O
glatiramer B-DRUG
acetate I-DRUG
for O
multiple O
sclerosis O

prominent O
eye O
movements O
during O
nrem O
sleep O
and O
rem B-ADR
sleep I-ADR
behavior I-ADR
disorder I-ADR
associated O
with O
fluoxetine B-DRUG
treatment O
of O
depression O
and O
obsessive-compulsive O
disorder O

mitomycin-c B-DRUG
is O
used O
widely O
in O
the O
treatment O
of O
malignancies O
and O
is O
associated O
with O
serious O
dose O
related O
adverse O
effects O
including O
the O
occurrence O
of O
hemolytic B-ADR
uremic I-ADR
syndrome I-ADR

a O
possible O
mechanism O
for O
focal B-ADR
neurological I-ADR
deficit I-ADR
in O
brain-damaged O
patients O
on O
phenytoin B-DRUG
therapy O
is O
discussed O

thus O
, O
we O
confirm O
that O
desensitization O
may O
be O
a O
safe O
procedure O
in O
patients O
with O
cancer O
who O
experience O
methotrexate-induced O
anaphylaxis B-ADR

conversely O
, O
diffuse B-ADR
interstitial I-ADR
pulmonary I-ADR
fibrosis I-ADR
should O
be O
considered O
in O
the O
differential O
diagnosis O
of O
patients O
receiving O
methotrexate B-DRUG
who O
develop O
bilateral O
pulmonary O
infiltrates O
seen O
on O
chest O
roentgenograms O

this O
supports O
the O
well-reported O
potential O
of O
bleomycin B-DRUG
to O
trigger O
acral B-ADR
vascular I-ADR
toxicity I-ADR

46-year-old O
woman O
developed O
painful O
ulcers O
over O
her O
lower O
abdomen O
in O
the O
form O
of O
reticulate B-ADR
erythema I-ADR
after O
injecting O
interferon B-DRUG
beta-1b I-DRUG
subcutaneously O
for O
multiple O
sclerosis O

conclusion O
: O
the O
present O
findings O
suggest O
that O
fluvoxamine B-DRUG
can O
cause O
increased B-ADR
libido I-ADR
in O
some O
patients O

the O
second O
patient O
exhibited O
sudden O
plms B-ADR
following O
olanzapine B-DRUG
injection O

methotrexate B-DRUG
is O
an O
effective O
but O
potentially B-ADR
toxic I-ADR
treatment O
for O
psoriasis O

we O
present O
findings O
from O
three O
patients O
who O
experienced O
a O
psoriasiform B-ADR
eruption I-ADR
apparently O
due O
to O
the O
antiepileptic O
agents O
sodium B-DRUG
valproate I-DRUG
and O
carbamazepine O

phenytoin O
was O
discontinued O
after O
admission O
; O
however O
, O
phenytoin B-DRUG
1 O
g O
i.v. O
was O
given O
for O
a O
tonic-clonic O
seizure O
two O
days O
after O
admission O
, O
after O
which O
swelling O
of O
the O
face O
and O
legs O
and O
pruritus B-ADR
developed O

acute B-ADR
dystonic I-ADR
reaction I-ADR
with O
low-dose O
pimozide B-DRUG

dilated B-ADR
cardiomyopathy I-ADR
associated O
with O
chronic O
overuse O
of O
an O
adrenaline B-DRUG
inhaler O

hypercalcemia B-ADR
in O
an O
aids O
patient O
treated O
with O
growth B-DRUG
hormone I-DRUG

syndrome B-ADR
of I-ADR
inappropriate I-ADR
secretion I-ADR
of I-ADR
adh I-ADR
( O
siadh O
) O
following O
cisplatin B-DRUG
administration O
in O
a O
pulmonary O
adenocarcinoma O
patient O
with O
a O
malignant O
pleural O
effusion O

a O
case O
of O
mania B-ADR
associated O
with O
fluoxetine B-DRUG

we O
report O
two O
cases O
of O
neutropenia B-ADR
following O
captopril B-DRUG
use O
in O
cardiac O
patients O
with O
trisomy O
21 O

the O
treatment O
for O
acidosis O
and O
hyperkalaemia O
should O
be O
started O
as O
soon O
as O
rta B-ADR
is O
diagnosed O
, O
and O
the O
dosage O
of O
fk506 B-DRUG
should O
also O
be O
reduced O
if O
possible O

this O
case O
report O
illustrates O
the O
use O
of O
continuous O
high-dose O
intracoronary O
nitroglycerin O
infusion O
through O
a O
6 O
french O
coronary O
guiding O
catheter O
in O
the O
treatment O
of O
a O
patient O
with O
cocaine-induced O
refractory B-ADR
coronary I-ADR
vasospasm I-ADR

conclusions O
: O
we O
present O
a O
case O
of O
a O
patient O
with O
cml O
who O
developed O
ks B-ADR
12 O
months O
after O
starting O
treatment O
with O
imatinib B-DRUG
400 O
mg O
/ O
d O

ritonavir B-DRUG
acted O
as O
a O
cyp3a4 O
inhibitor O
, O
diminishing O
carbamazepine O
metabolism O
and O
provoking O
an O
increase B-ADR
in I-ADR
serum I-ADR
levels I-ADR
and O
clinical O
toxicity O

we O
report O
a O
case O
of O
neh B-ADR
masquerading O
as O
cutaneous O
vasculitis O
in O
a O
woman O
receiving O
cyclophosphamide B-DRUG
for O
lupus O
nephritis O

fatal B-ADR
venous I-ADR
thrombembolism I-ADR
complicating O
imatinib B-DRUG
therapy O
in O
a O
patient O
with O
metastatic O
gastrointestinal O
stromal O
tumor O

the O
authors O
describe O
a O
case O
of O
the O
catatonia B-ADR
syndrome I-ADR
associated O
with O
disulfiram B-DRUG
therapy O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever B-ADR
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp O
)- O
sulfamethoxazole B-DRUG
( O
smx O
) O
treatment O

animals O
treated O
with O
hal B-DRUG
showed O
a O
highly O
significant O
32 O
%- O
46 O
% O
loss O
of O
tyrosine O
hydroxylase O
( O
th O
) O
immunoreactive O
neurons O
in O
the O
substantia O
nigra O
, O
and O
20 O
% O
contraction O
of O
the O
th O
stained O
dendritic O
arbour O

to O
our O
knowledge O
, O
these O
cases O
are O
the O
first O
published O
reports O
of O
lovastatin-induced O
rhabdomyolysis B-ADR
associated O
with O
azithromycin O
and O
clarithromycin O

despite O
a O
response O
of O
the O
meningeal O
tumor O
the O
patient O
developed O
in O
the O
third O
week O
of O
mtx B-DRUG
treatment O
a O
progressive O
visual O
loss O
and O
loss B-ADR
of I-ADR
consciousness I-ADR
which O
worsened O
during O
subsequent O
ara-c O
treatment O
and O
led O
to O
death O
within O
3 O
weeks O

a O
64 O
year O
old O
woman O
with O
previous O
history O
of O
coronary O
stenting O
five O
days O
before O
was O
admitted O
in O
our O
institution O
for O
intracranial B-ADR
bleeding I-ADR
while O
receiving O
aspirin B-DRUG
and O
clopidogrel O

bulbar O
and O
pseudobulbar B-ADR
palsy I-ADR
complicating O
therapy O
with O
high-dose O
cytosine B-DRUG
arabinoside I-DRUG
in O
children O
with O
leukemia O

cyclophosphamide B-DRUG
can O
rarely O
cause O
interstitial O
pneumonitis O
and O
fibrosis B-ADR

treatment O
of O
chronic O
hepatitis O
c O
with O
interferon O
alpha O
( O
ifn-alpha B-DRUG
) O
is O
relatively O
contraindicated O
in O
patients O
with O
psychiatric O
disorders O
because O
of O
possible O
severe O
psychiatric B-ADR
side I-ADR
effects I-ADR

a O
selective O
association O
between O
fluoxetine B-DRUG
and O
extensive O
, O
prominent O
eye O
movements O
in O
nonrapid O
eye O
movement O
( O
nrem O
) O
sleep O
was O
detected O
, O
utilizing O
fisher O
's O
exact O
one-tailed O
statistic O
( O
p O
less O
than O
0.00001 O
for O
each O
comparison O

methods O
: O
a O
68-year-old O
man O
developed O
intense O
conjunctival O
hyperemia O
and O
cystoid B-ADR
macula I-ADR
edema I-ADR
after O
switching O
from O
latanoprost O
to O
bimatoprost B-DRUG
9 O
months O
after O
cataract O
surgery O
in O
an O
eye O
at O
low-risk O
for O
this O
cystoid O
macular O
edema O

we O
present O
the O
first O
case O
of O
a O
patient O
with O
priapism B-ADR
after O
oral O
intake O
of O
the O
phenothiazine O
prothipendylhydrochloride B-DRUG

conclusions O
: O
ltg B-DRUG
overdose O
may O
result O
in O
a O
severe O
but O
reversible O
encephalopathy B-ADR
, O
a O
previously O
undescribed O
phenomenon O

we O
report O
a O
case O
of O
baclofen B-DRUG
withdrawal B-ADR
syndrome I-ADR
resulting O
from O
oral O
baclofen B-DRUG
underdosing O

during O
clarithromycin O
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate-to-severe O
toxic O
symptoms O
of O
carbamazepine B-DRUG
, O
such O
as O
drowsiness B-ADR
, O
dizziness O
, O
and O
ataxia O
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin O
discontinuation O

because O
there O
were O
no O
other O
obvious O
causes O
of O
renal O
failure O
in O
either O
patient O
, O
we O
propose O
that O
skeletal B-ADR
muscle I-ADR
ischemia I-ADR
developed O
during O
vasopressin B-DRUG
infusion O
, O
followed O
by O
release O
of O
myoglobin O
and O
renal O
damage O

in O
one O
patient O
the O
vasculitis O
resolved O
after O
termination O
of O
the O
ciprofloxacin B-DRUG
therapy O
; O
in O
the O
other O
patient O
the O
ciprofloxacin-induced O
hemorrhagic O
vasculitis O
was O
superimposed O
on O
a O
severe B-ADR
forefoot I-ADR
infection I-ADR
, O
leading O
to O
progressive O
gangrene O
and O
a O
below-knee O
amputation O

gold-salt B-DRUG
therapy O
may O
result O
in O
damage B-ADR
to I-ADR
proximal I-ADR
tubules I-ADR
that O
leak O
renal O
tubular O
antigens O
, O
which O
in O
turn O
complex O
with O
autoantibody O
and O
produce O
an O
autoimmune O
membranous O
nephropathy O

we O
report O
three O
patients O
, O
all O
of O
whom O
had O
preexisting O
diabetic O
dyslipidemia O
, O
who O
showed O
a O
profound O
reduction B-ADR
in I-ADR
plasma I-ADR
hdl I-ADR
cholesterol I-ADR
and I-ADR
apolipoprotein I-ADR
ai I-ADR
levels I-ADR
soon O
after O
the O
initiation O
of O
rosiglitazone B-DRUG
therapy O

we O
report O
five O
cases O
of O
carboplatin O
( O
cbdca B-DRUG
) O
hypersensitivity B-ADR
after O
weekly O
low-dose O
paclitaxel O
( O
60 O
mg O
/ O
m2 O
)/ O
cbdca B-DRUG
( O
area O
under O
the O
concentration O
curve O
= O
2 O
) O
therapy O
in O
patients O
with O
recurrent O
ovarian O
cancer O
receiving O
multiple O
platinum-based O
chemotherapy O

drug-induced O
agranulocytosis B-ADR
during O
treatment O
with O
infliximab B-DRUG
in O
enteropathic O
spondyloarthropathy O

method O
: O
we O
describe O
two O
patients O
who O
presented O
with O
diabetic B-ADR
ketoacidosis I-ADR
after O
treatment O
with O
quetiapine B-DRUG
and O
risperidone O
, O
respectively O

autopsy O
evidence O
of O
herpesvirus B-ADR
infection I-ADR
was O
found O
in O
visceral O
organs O
of O
four O
leukemic O
patients O
who O
had O
received O
large O
doses O
of O
cytarabine O
( O
cytosine B-DRUG
arabinoside I-DRUG
; O
ara-c O
) O
shortly O
before O
their O
death O

a O
65-year-old O
female O
patient O
presented O
with O
jaundice O
followed O
2 O
days O
later O
by O
severe O
dyspnea O
and O
tachypnea B-ADR
which O
worsened O
when O
patient O
was O
lying O
flat O
, O
1 O
week O
after O
the O
fourth O
dose O
of O
adalimumab B-DRUG

objective O
: O
to O
describe O
a O
case O
of O
sertraline-induced O
rhabdomyolysis B-ADR
in O
an O
elderly O
patient O
with O
dementia O
and O
comorbidities O

pathogenesis O
of O
methotrexate-induced O
papular O
eruption O
in O
psoriasis O
may O
involve O
immune O
mechanisms O
other O
than O
those O
of O
methotrexate-induced O
cutaneous B-ADR
vasculitis I-ADR
in O
collagen O
vascular O
disease O

she O
was O
treated O
with O
pancrease B-DRUG
mt I-DRUG
16 I-DRUG
, O
but O
had O
consistent O
vomiting B-ADR
1 O
to O
2 O
hours O
after O
administration O
of O
enzymes O

one O
of O
the O
subjects O
who O
was O
using O
extemporaneous O
topical O
minoxidil B-DRUG
had O
hypertension B-ADR
and O
arteriosclerotic O
disease O
and O
the O
other O
died O
of O
a O
myocardial O
infarction O

oral O
25-hydroxyvitain B-DRUG
d3 I-DRUG
in O
treatment O
of O
osteomalacia O
associated O
with O
ileal B-ADR
resection I-ADR
and O
cholestyramine O
therapy O

it O
was O
hypothesized O
that O
valproic B-DRUG
acid I-DRUG
may O
interfere O
with O
glucuronidation O
of O
lamotrigine O
, O
leading O
to O
increased O
serum O
lamotrigine O
levels O
, O
or O
perhaps O
alter O
the O
drug O
's O
metabolism O
, O
resulting O
in O
accumulation B-ADR
of I-ADR
a I-ADR
toxic I-ADR
intermediate I-ADR
metabolite I-ADR

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash O
, O
fever O
, O
leukopenia O
and O
positive B-ADR
anti-nuclear I-ADR
antibody I-ADR
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine O
( O
cbz B-DRUG
; O
tegretol O
) O
used O
against O
benign O
rolandic O
epilepsy O

phenolphthalein-induced O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR

cholestatic B-ADR
liver I-ADR
disease I-ADR
with O
ductopenia O
( O
vanishing O
bile O
duct O
syndrome O
) O
after O
administration O
of O
clindamycin O
and O
trimethoprim-sulfamethoxazole B-DRUG

conclusion O
: O
a O
37-year-old O
african O
- O
american O
man O
with O
g6pd O
deficiency O
developed O
hemolytic B-ADR
anemia I-ADR
, O
hepatitis O
, O
orthostatic O
hypotension O
, O
and O
aseptic O
meningitis O
simultaneously O
after O
using O
trimethoprim-sulfamethoxazole O

the O
visual O
loss O
in O
this O
patient O
seems O
to O
result O
from O
phenol B-DRUG
neurotoxicity B-ADR
rather O
than O
mechanical O
compression O
of O
the O
intraorbital O
optic O
nerve O

based O
on O
our O
findings O
, O
it O
is O
thus O
concluded O
that O
cisplatin B-DRUG
may O
cause O
c. B-ADR
difficile I-ADR
colitis I-ADR

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash O
, O
fever O
, O
leukopenia O
and O
positive B-ADR
anti-nuclear I-ADR
antibody I-ADR
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine O
( O
cbz O
; O
tegretol B-DRUG
) O
used O
against O
benign O
rolandic O
epilepsy O

a O
7-year-old O
with O
congenital O
toxoplasmosis O
who O
took O
pyrimethamine B-DRUG
and O
sulfadiazine O
for O
reactivated O
chorioretinitis O
developed O
fever O
, O
severe O
cutaneous O
involvement O
, O
swelling O
, O
abdominal B-ADR
pain I-ADR
and O
transaminitis O
, O
persisting O
weeks O
after O
withholding O
medicines O

a O
case O
of O
metoclopramide-induced O
oculogyric B-ADR
crisis I-ADR
in O
a O
16-year-old O
girl O
with O
cystic O
fibrosis O

pneumonitis O
with O
pleural O
and O
pericardial O
effusion O
and O
neuropathy B-ADR
during O
amiodarone B-DRUG
therapy O

sudden B-ADR
cardiac I-ADR
death I-ADR
due O
to O
hypersensitivity O
myocarditis O
during O
clozapine B-DRUG
treatment O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin B-ADR
eruptions I-ADR
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp B-DRUG
)- O
sulfamethoxazole O
( O
smx O
) O
treatment O

we O
observed O
5 O
reactions O
in O
3 O
patients O
that O
appear O
to O
be O
related O
to O
a O
high O
dose-infusion O
time O
ratio O
, O
indicating O
that O
dose O
and O
rate O
of O
infusion O
may O
be O
important O
factors O
in O
precipitating O
anaphylactoid B-ADR
reactions I-ADR
with O
cisplatin B-DRUG

quetiapine-induced O
leucopenia O
and O
thrombocytopenia B-ADR

torsades B-ADR
de I-ADR
pointes I-ADR
induced O
by O
a O
combination O
of O
garenoxacin O
and O
disopyramide B-DRUG
and O
other O
cytochrome O
p450 O
, O
family O
3 O
, O
subfamily O
a O
polypeptide-4-influencing O
drugs O
during O
hypokalemia O
due O
to O
licorice O

severe O
bleomycin B-DRUG
lung B-ADR
toxicity I-ADR
: O
reversal O
with O
high O
dose O
corticosteroids O

these O
multiple O
overlapping O
factors O
probably O
lead O
to O
rhabdomyolysis B-ADR
in O
a O
minority O
of O
patients O
receiving O
vasopressin B-DRUG
infusion O

sixteen O
of O
33 O
patients O
developed O
significant O
hyponatremia B-ADR
and O
hypoosmolality O
during O
oral O
treatment O
with O
lorcainide B-DRUG

this O
case O
report O
describes O
a O
patient O
who O
was O
previously O
prescribed O
alendronate O
( O
fosamax B-DRUG
) O
and O
presented O
with O
postoperative O
hypophosphatemia B-ADR
and O
hypocalcemic O
tetany O
after O
bowel O
preparation O
with O
fleet O
phospho-soda O

the O
day O
after O
methotrexate B-DRUG
administration O
, O
the O
patient O
complained O
of O
severe O
back O
pain O
and O
urinary B-ADR
retention I-ADR

a O
case O
is O
reported O
of O
theophylline B-ADR
intoxication I-ADR
due O
to O
a O
dramatic O
decrease O
in O
theophylline B-DRUG
clearance O
following O
concomitant O
administration O
of O
viloxazine O

diagnosis O
: O
interferon B-DRUG
alpha-2b-induced O
cardiomyopathy B-ADR

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin O
, O
grepafloxacin O
, O
trovafloxacin O
, O
gatifloxacin B-DRUG
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache B-ADR
, O
dizziness O
and O
insomnia O

methods O
: O
we O
report O
two O
cases O
of O
pseudoporphyria B-ADR
caused O
by O
naproxen O
and O
oxaprozin B-DRUG

we O
report O
a O
case O
of O
aild O
in O
an O
80-year-old O
male O
who O
presented O
with O
a O
generalized B-ADR
pruritic I-ADR
maculopapular I-ADR
eruption I-ADR
and O
fever O
following O
doxycycline B-DRUG
administration O

although O
gabapentin B-DRUG
withdrawal O
has O
been O
previously O
reported O
and O
usually O
consists O
of O
anxiety O
, O
diaphoresis B-ADR
, O
and O
palpitations O
, O
this O
is O
the O
first O
reported O
patient O
with O
generalized O
seizures O
and O
status O
epilepticus O
secondary O
to O
gabapentin B-DRUG
withdrawal O

serotonin B-ADR
syndrome I-ADR
induced O
by O
transitioning O
from O
phenelzine B-DRUG
to O
venlafaxine O
: O
four O
patient O
reports O

we O
report O
a O
case O
of O
generalized B-ADR
cutaneous I-ADR
sclerosis I-ADR
associated O
with O
muscle O
and O
oesophageal O
involvement O
in O
a O
patient O
exposed O
to O
herbicides O
containing O
bromocil O
, O
diuron B-DRUG
and O
aminotriazole O

inhaled O
tobramycin B-DRUG
solution-associated O
recurrent O
eosinophilia O
and O
severe B-ADR
persistent I-ADR
bronchospasm I-ADR
in O
a O
patient O
with O
cystic O
fibrosis O
: O
a O
case O
report O

amphotericin B-DRUG
b I-DRUG
( O
amb O
) O
is O
effective O
, O
but O
its O
use O
is O
limited O
by O
toxicity O
: O
renal O
impairment O
, O
anaemia O
, O
fever O
, O
malaise O
, O
and O
hypokalaemia B-ADR
are O
common O

atypical O
neuroleptic B-ADR
malignant I-ADR
syndrome I-ADR
associated O
with O
olanzapine B-DRUG

gynecomastia B-ADR
associated O
with O
theophylline B-DRUG

we O
present O
a O
fatal O
case O
of O
subacute O
methanol B-DRUG
toxicity O
with O
associated O
diffuse O
brain O
involvement O
, O
including O
bilateral O
putaminal O
necrosis O
and O
cerebral B-ADR
edema I-ADR
with O
ventricular O
compression O

an O
8-year-old O
girl O
, O
who O
had O
been O
vaccinated O
with O
bcg B-DRUG
without O
subsequent O
regional O
reactions O
, O
developed O
osteomyelitis B-ADR
in I-ADR
the I-ADR
left I-ADR
calcaneus I-ADR
7 O
months O
later O

methotrexate O
( O
mtx B-DRUG
) O
is O
a O
commonly O
used O
second O
line O
agent O
for O
ra O
, O
and O
there O
have O
been O
several O
recent O
reports O
of O
epstein-barr O
virus O
( O
ebv O
)- O
associated O
polyclonal O
b O
cell O
lymphoproliferative O
disorder O
in O
mtx-treated O
ra O
patients O

the O
present O
report O
suggests O
that O
clarithromycin B-DRUG
coadministration O
induces O
increased O
plasma O
carbamazepine O
concentrations O
, O
which O
may O
result O
in O
carbamazepine B-ADR
toxicity I-ADR

to O
our O
knowledge O
, O
the O
syndrome O
of O
fever B-ADR
, O
pulmonary O
infiltrates O
, O
and O
pleural O
effusion O
following O
use O
of O
acyclovir B-DRUG
has O
not O
been O
previously O
reported O

we O
describe O
a O
case O
of O
advanced O
ovarian O
carcinoma O
who O
developed O
difficulty B-ADR
walking I-ADR
because O
of O
marked O
pain O
in O
the O
lower O
extremities O
and O
loss O
of O
proprioception O
25 O
days O
after O
treatment O
with O
weekly O
taxol B-DRUG
( O
80 O
mg O
/ O
m O
( O
2 O
) O
x3 O

amphotericin O
b O
( O
amb B-DRUG
) O
is O
effective O
, O
but O
its O
use O
is O
limited O
by O
toxicity O
: O
renal O
impairment O
, O
anaemia O
, O
fever B-ADR
, O
malaise O
, O
and O
hypokalaemia O
are O
common O

possible O
interaction O
between O
lopinavir O
/ O
ritonavir O
and O
valproic B-DRUG
acid I-DRUG
exacerbates O
bipolar B-ADR
disorder I-ADR

we O
report O
an O
allogeneic O
bone O
marrow O
transplant O
recipient O
who O
developed O
cmv B-ADR
infection I-ADR
refractory O
to O
sequential O
therapy O
with O
ganciclovir O
, O
foscarnet B-DRUG
, O
and O
cidofovir O

in O
this O
report O
, O
one O
patient O
who O
developed O
gangrene O
after O
bleomycin O
and O
vincristine O
/ O
vinblastine B-DRUG
chemotherapy O
for O
aids-related O
kaposi O
's O
sarcoma O
and O
another O
hiv-infected O
patient O
who O
exhibited O
symptoms O
of O
severe B-ADR
raynaud I-ADR
's I-ADR
phenomenon I-ADR
related O
to O
the O
same O
regimen O
are O
presented O

in O
addition O
, O
loading O
with O
one O
low O
oral O
dose O
of O
serine B-DRUG
produced O
psychotic B-ADR
symptoms I-ADR
5 O
h O
later O
which O
lasted O
3-6 O
h O

previous O
studies O
have O
demonstrated O
the O
interaction O
of O
mtx B-DRUG
and O
a O
variety O
of O
non-steroidal O
, O
anti-inflammatory O
drugs O
( O
nsaids O
) O
with O
various O
clinical O
manifestations O
including O
acute O
renal O
failure O
, O
pancytopenia O
, O
vomiting O
, O
diarrhea O
, O
elevated B-ADR
liver I-ADR
transaminases I-ADR
, O
jaundice O
, O
mucosal O
ulcerations O
, O
and O
pyrexia O

objective O
: O
to O
report O
2 O
cases O
of O
serotonin B-ADR
syndrome I-ADR
with O
serious O
extrapyramidal O
movement O
disorders O
occurring O
when O
metoclopramide B-DRUG
was O
coadministered O
with O
sertraline O
or O
venlafaxine O

a O
child O
in O
whom O
a O
phenobarbital B-DRUG
hypersensitivity O
drug O
reaction O
developed O
which O
consisted O
of O
fever O
, O
a O
pruritic O
desquamating O
erythrodermic O
rash O
, O
alopecia O
, O
icterus O
, O
protein-losing B-ADR
enteropathy I-ADR
, O
myositis O
, O
and O
nephritis O
, O
is O
described O

conclusion O
: O
a O
37-year-old O
african O
- O
american O
man O
with O
g6pd O
deficiency O
developed O
hemolytic O
anemia O
, O
hepatitis O
, O
orthostatic O
hypotension O
, O
and O
aseptic B-ADR
meningitis I-ADR
simultaneously O
after O
using O
trimethoprim-sulfamethoxazole O

high-grade B-ADR
atrioventricular I-ADR
block I-ADR
during O
dipyridamole B-DRUG
stress O
testing O

recombinant O
viia O
concentrate O
in O
the O
management O
of O
bleeding O
following O
prothrombin B-DRUG
complex I-DRUG
concentrate-related O
myocardial B-ADR
infarction I-ADR
in O
patients O
with O
haemophilia O
and O
inhibitors O

conclusion O
: O
gemcitabine-induced O
recall B-ADR
pneumonitis I-ADR
is O
a O
rarely O
reported O
phenomenon O
and O
should O
be O
taken O
into O
account O
even O
after O
extended O
time O
interval O
to O
the O
previous O
radiotherapy O

high-grade B-ADR
endometrial I-ADR
stromal I-ADR
sarcoma I-ADR
after O
tamoxifen B-DRUG
therapy O
for O
breast O
cancer O

however O
, O
given O
the O
clinically O
significant O
result O
to O
the O
interaction O
between O
tolazoline B-DRUG
and O
cimetidine O
we O
report O
, O
the O
use O
of O
cimetidine O
in O
tolazoline B-DRUG
induced O
upper B-ADR
gastrointestinal I-ADR
hemorrhage I-ADR
should O
deserve O
more O
attention O

case O
report O
: O
life-threatening B-ADR
hypoglycaemia I-ADR
associated O
with O
sulfadoxine-pyrimethamine B-DRUG
, O
a O
commonly O
used O
antimalarial O
drug O

the O
third O
patient O
had O
been O
suffering O
from O
serious O
akathisia O
while O
on O
risperidone O
, O
and O
was O
cured O
after O
switching O
to O
olanzapine B-DRUG
, O
but O
thereafter O
the O
patient O
suffered O
from O
rls B-ADR
at O
nighttime O

conclusions O
: O
this O
observation O
of O
" O
on-off O
" O
risperidone B-DRUG
treatment O
suggests O
that O
risperidone B-DRUG
may O
have O
worsened O
both O
psychiatric B-ADR
and I-ADR
physical I-ADR
manifestations I-ADR
of O
the O
mitochondrial O
disorder O
in O
this O
adolescent O

introduction O
: O
although O
gefitinib B-DRUG
used O
for O
the O
treatment O
of O
non-small-cell O
lung O
cancer O
is O
a O
well-known O
cause O
of O
interstitial O
lung O
disease O
( O
ild B-ADR
) O
, O
few O
case O
reports O
on O
erlotinib-induced O
ild B-ADR
have O
been O
issued O

we O
describe O
two O
women O
who O
developed O
hus O
after O
mmc B-DRUG
therapy O
and O
presented O
massive B-ADR
pulmonary I-ADR
bleeding I-ADR

a O
44-year-old O
woman O
is O
described O
in O
whom O
amiodarone B-DRUG
, O
disopyramide O
, O
and O
quinidine O
, O
administered O
alone O
separately O
, O
induced O
atypical B-ADR
ventricular I-ADR
tachycardia I-ADR
( O
avt O
, O
torsade O
de O
pointes O

the O
goal O
of O
this O
study O
is O
to O
describe O
three O
patients O
diagnosed O
with O
migraine O
and O
epilepsy O
( O
both O
under O
control O
) O
who O
evolved O
into O
status B-ADR
migrainosus I-ADR
after O
the O
introduction O
of O
oxcarbazepine O
( O
oxc O
) O
, O
as O
part O
of O
a O
switch O
off O
from O
carbamazepine B-DRUG
( O
cbz O

severe B-ADR
aphthous I-ADR
stomatitis I-ADR
associated O
with O
oral O
calcineurin B-DRUG
and O
mtor O
inhibitors O

risperidone-induced O
tardive B-ADR
dyskinesia I-ADR

electro-oculography O
, O
electroretinography O
, O
visual O
evoked O
potentials O
, O
and O
multifocal O
electroretinography O
in O
patients O
with O
vigabatrin-attributed O
visual B-ADR
field I-ADR
constriction I-ADR

ten O
days O
after O
itraconazole B-DRUG
was O
started O
, O
he O
developed O
paralytic O
ileus O
, O
neurogenic B-ADR
bladder I-ADR
, O
mild O
left O
ptosis O
, O
and O
absence O
of O
deep O
reflexes O
, O
with O
severe O
paralysis O
of O
the O
lower O
extremities O
and O
mild O
weakness O
of O
the O
upper O
extremities O

to O
our O
knowledge O
this O
is O
the O
first O
report O
of O
pancytopenia B-ADR
due O
to O
mmi B-DRUG
, O
where O
the O
usual O
hypoplasia O
found O
is O
replaced O
by O
massive O
plasmocytosis O

choanal O
atresia O
and O
athelia B-ADR
: O
methimazole B-DRUG
teratogenicity O
or O
a O
new O
syndrome O

it O
is O
well-recognized O
that O
flucloxacillin B-DRUG
may O
occasionally O
result O
in O
fatal B-ADR
hepatic I-ADR
injury I-ADR

clinicians O
should O
be O
aware O
of O
fasting B-ADR
hypoglycemia I-ADR
as O
an O
unusual O
but O
potentially O
serious O
complication O
of O
disopyramide B-DRUG
therapy O

we O
present O
a O
46-year-old O
african-american O
man O
with O
aids O
who O
was O
admitted O
on O
two O
different O
occasions O
within O
three O
weeks O
for O
signs O
and O
symptoms O
of O
meningitis B-ADR
after O
using O
trimethoprim O
/ O
sulfamethoxazole B-DRUG
( O
tmp O
/ O
smx O

cardiomyopathy B-ADR
after O
widely O
separated O
courses O
of O
adriamycin B-DRUG
exacerbated O
by O
actinomycin-d O
and O
mithramycin O

pheripheral B-ADR
edema I-ADR
was O
observed O
in O
five O
female O
patients O
after O
taking O
proton O
pump O
inhibitors O
omeprazole B-DRUG
, O
lansoprazole O
, O
or O
pantoprazole O
for O
7-15 O
days O
for O
peptic O
acid O
diseases O
in O
recommended O
standard O
doses O

vancomycin B-DRUG
is O
widely O
used O
against O
methicillin-resistant O
staphylococcus O
aureus O
infections O
, O
but O
it O
is O
associated O
with O
many O
adverse O
effects O
such O
as O
nephrotoxicity O
, O
ototoxicity O
, O
gastrointestinal O
disturbances O
, O
blood O
disorders O
, O
and O
two O
types O
of O
hypersensitivity B-ADR
reactions I-ADR
- O
an O
anaphylactoid O
reaction O
known O
as O
" O
red O
man O
syndrome O
" O
and O
anaphylaxis O

a O
case O
of O
phenytoin-induced O
hepatitis B-ADR
with O
mononucleosis O
is O
reported O
, O
and O
syndromes O
associated O
with O
phenytoin B-DRUG
hypersensitivity O
reactions O
are O
discussed O

rebound B-ADR
hyperglycemia I-ADR
was O
observed O
with O
both O
intermediate O
( O
neutral O
protamine O
hagedorn O
) O
and O
long-acting O
( O
protamine B-DRUG
zinc I-DRUG
iletin I-DRUG
) O
insulins O
, O
and O
the O
range O
of O
insulin O
doses O
at O
which O
the O
disorder O
developed O
overlapped O
previously O
determined O
therapeutic O
doses O
for O
these O
insulins O
in O
the O
cat O

a O
retrospective O
epidemiological O
study O
of O
deaths O
from O
hepatic B-ADR
angiosarcoma I-ADR
( O
has O
) O
in O
the O
u.s. O
showed O
that O
during O
1964 O
-- O
74 O
there O
were O
168 O
such O
cases O
, O
of O
which O
37 O
( O
22 O
%) O
were O
associated O
with O
previously O
known O
causes O
( O
vinyl O
chloride O
, O
' O
thorotrast B-DRUG
' O
, O
and O
inorganic O
arsenic O
) O
and O
4 O
( O
3.1 O
%) O
of O
the O
remaining O
131 O
cases O
with O
the O
use O
of O
androgenic-anabolic O
steroids O

captopril-induced O
lichen B-ADR
planus I-ADR
pemphigoides I-ADR
with O
pemphigus-like O
features O

we O
report O
a O
patient O
in O
whom O
the O
anti-depressant O
trazodone B-DRUG
hydrochloride I-DRUG
( O
molipaxin O
, O
roussel O
) O
, O
a O
serotonin O
antagonist O
, O
provoked O
generalized B-ADR
pustular I-ADR
psoriasis I-ADR
( O
gpp O

method O
: O
case O
analysis O
of O
a O
poly-drug O
overdose O
( O
venlafaxine O
, O
topiramate B-DRUG
, O
divalproex O
sodium O
, O
risperidone O
, O
and O
carbamazepine O
) O
presenting O
with O
mixed O
ss O
/ O
nms B-ADR
features O
and O
whose O
clinical O
management O
suggests O
a O
practical O
algorithm O
for O
treatment O
of O
undifferentiated O
ss O
/ O
nms B-ADR
in O
critical O
care O
settings O

gigantomastia B-ADR
induced O
by O
bucillamine B-DRUG

the O
diagnosis O
was O
based O
on O
the O
rapid O
onset O
of O
renal O
failure O
, O
presence O
of O
eosinophilia O
, O
skin B-ADR
rash I-ADR
, O
and O
characteristic O
renal O
biopsy O
finding O
, O
following O
the O
administration O
of O
ampicillin B-DRUG

clozapine-induced O
tardive B-ADR
dyskinesia I-ADR
in O
schizophrenic O
patients O
taking O
clozapine O
as O
a O
first-line O
antipsychotic O
drug O

agranulocytosis B-ADR
is O
a O
rare O
adverse O
effect O
associated O
with O
prolonged O
vancomycin B-DRUG
therapy O
, O
and O
is O
potentially O
serious O
, O
especially O
in O
end O
stage O
renal O
disease O
( O
esrd O
) O
patients O

a O
patient O
is O
described O
with O
the O
characteristic O
features O
of O
phenytoin B-DRUG
hypersensitivity O
syndrome O
( O
phs O
) O
including O
fever O
, O
erythroderma O
, O
tibial O
and O
facial O
oedema O
, O
pinhead-sized B-ADR
facial I-ADR
pustules I-ADR
and O
abnormal O
liver O
function O
tests O

myocardial B-ADR
ischemia I-ADR
associated O
with O
high-dose O
carmustine B-DRUG
infusion O

the O
authors O
report O
on O
two O
patients O
with O
corneal B-ADR
ulcers I-ADR
refractory I-ADR
to I-ADR
conventional I-ADR
treatment I-ADR
while O
the O
patients O
were O
undergoing O
oral O
colchicine B-DRUG
therapy O

however O
here O
we O
reported O
two O
patients O
, O
presenting O
with O
pd B-ADR
during O
high O
dose O
colchicine B-DRUG
treatment O
for O
familiar O
mediterranean O
fever O
( O
fmf O

we O
conjectured O
that O
the O
side O
effects O
of O
insulin B-DRUG
, O
such O
as O
anti-natriuresis O
and O
increased O
vascular O
permeability O
, O
might O
be O
pronounced O
in O
the O
presence O
of O
the O
hepatic O
dysfunction O
that O
accompanies O
insulin B-DRUG
insensitivity O
, O
hyperinsulinaemia O
and O
hypoalbuminaemia B-ADR

purpose O
: O
a O
case O
of O
carbamazepine-induced O
hyperammonemia B-ADR
is O
presented O

when O
dscg B-DRUG
was O
withdrawn O
, O
urticaria B-ADR
vanished O
and O
the O
child O
remained O
symptom-free O

the O
exacerbation B-ADR
of I-ADR
psoriasis I-ADR
was O
accompanied O
by O
a O
massive O
induction O
of O
lesional O
type O
i O
interferon O
activity O
, O
detected O
by O
mxa O
expression O
after O
imiquimod B-DRUG
therapy O

amphotericin B-DRUG
b-induced O
cutaneous B-ADR
leucocytoclastic I-ADR
vasculitis I-ADR
: O
case O
report O

the O
authors O
describe O
valproate-induced O
hyperammonemia B-ADR
and O
mental O
status O
changes O
in O
an O
88-year-old O
man O
, O
the O
first O
known O
reported O
case O
in O
an O
elderly O
patient O

rifampin B-DRUG
can O
be O
associated O
with O
severe O
adverse O
effects O
such O
as O
hepatitis B-ADR
, O
acute O
renal O
failure O
, O
hemolytic O
anemia O
, O
and O
thrombocytopenia O

case O
report O
: O
lack O
of O
control O
of O
diabetes B-ADR
and O
weight O
gain O
in O
a O
patient O
on O
initiation O
and O
rechallenge O
of O
therapy O
with O
olanzapine B-DRUG

potential O
causes O
of O
methamphetamine-related O
keratitis O
can O
be O
divided O
into O
four O
categories O
resulting O
from O
( O
a O
) O
direct O
pharmacologic O
and O
physical O
effects O
of O
methamphetamine O
; O
( O
b O
) O
the O
toxic B-ADR
effects I-ADR
of O
diluting O
or O
" O
cutting O
" O
agents O
such O
as O
lidocaine B-DRUG
and O
quinine O
; O
( O
c O
) O
effects O
related O
to O
the O
route O
of O
drug O
administration O
( O
intravenous O
, O
inhalation O
, O
smoking O
) O
; O
and O
( O
d O
) O
manufacture-related O
effects O
of O
exposure O
to O
unintentional O
caustic O
contaminants O
in O
the O
final O
product O

cutaneous O
rashes O
and O
eruptions B-ADR
can O
be O
caused O
by O
many O
medications O
, O
including O
carbamazepine B-DRUG

herein O
, O
we O
describe O
a O
patient O
with O
aids O
who O
presented O
to O
medical O
attention O
with O
pancytopenia B-ADR
48 O
months O
postchemotherapy O
with O
etoposide O
, O
prednisone O
, O
vincristine O
, O
cyclophosphamide O
, O
doxorubicin B-DRUG
, O
and O
rituximab O
( O
r-epoch O
) O
for O
diffuse O
large O
b-cell O
lymphoma O

an O
11-year-old O
boy O
who O
was O
treated O
with O
a O
relatively O
high O
dose O
of O
methotrimeprazine O
meleate O
( O
levemepromazine B-DRUG
) O
a O
phenothiazine O
antipsychotic O
drug O
, O
was O
admitted O
to O
the O
pediatric O
intensive O
care O
unit O
suffering O
from O
respiratory B-ADR
distress I-ADR
syndrome I-ADR

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin O
, O
grepafloxacin O
, O
trovafloxacin B-DRUG
, O
gatifloxacin O
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache O
, O
dizziness B-ADR
and O
insomnia O

there O
are O
major O
side O
effects O
of O
anastrozole B-DRUG
including O
decrease B-ADR
in I-ADR
both I-ADR
lumbar I-ADR
spine I-ADR
and O
total O
hip O
bone O
mineral O
density O
, O
increase O
in O
the O
incidence O
of O
all O
bone O
fractures O
( O
especially O
fractures O
of O
spine O
, O
hip O
and O
wrist O
) O
, O
joint O
disorders O
and O
increase O
in O
the O
cholesterol O
level O

subsequent O
in O
vivo O
/ O
vitro O
studies O
clearly O
demonstrated O
that O
the O
neurological B-ADR
effects I-ADR
were O
due O
to O
a O
synergistic O
action O
of O
desferrioxamine B-DRUG
and O
prochlorperazine O
, O
probably O
resulting O
in O
exceptional O
fluxes O
of O
intra O
/ O
extra O
cellular O
iron O
/ O
copper O
disturbing O
noradrenergic O
and O
serotonergic O
systems O

fulminant B-ADR
hepatitis I-ADR
associated O
with O
disulfiram B-DRUG

this O
is O
a O
rare O
case O
of O
ards B-ADR
associated O
with O
lithium B-DRUG
intoxication O

there O
are O
major O
side O
effects O
of O
anastrozole B-DRUG
including O
decrease O
in O
both O
lumbar O
spine O
and O
total O
hip O
bone O
mineral O
density O
, O
increase O
in O
the O
incidence O
of O
all O
bone O
fractures O
( O
especially O
fractures O
of O
spine O
, O
hip O
and O
wrist O
) O
, O
joint O
disorders O
and O
increase B-ADR
in I-ADR
the I-ADR
cholesterol I-ADR
level I-ADR

a O
44-year-old O
woman O
is O
described O
in O
whom O
amiodarone O
, O
disopyramide B-DRUG
, O
and O
quinidine O
, O
administered O
alone O
separately O
, O
induced O
atypical O
ventricular O
tachycardia O
( O
avt O
, O
torsade B-ADR
de I-ADR
pointes I-ADR

the O
toxic O
effects O
of O
methotrexate B-DRUG
included O
elevated B-ADR
liver I-ADR
transaminases I-ADR
( O
3 O
/ O
4 O
) O
, O
nausea O
( O
2 O
/ O
4 O
) O
, O
abdominal O
pain O
( O
2 O
/ O
4 O
) O
, O
bone O
pain O
( O
2 O
/ O
4 O
) O
, O
mild O
neutropenia O
( O
1 O
/ O
4 O
) O
, O
and O
mild O
pruritus O
( O
1 O
/ O
4 O

acute B-ADR
coronary I-ADR
events I-ADR
following O
cisplatin-based O
chemotherapy O

although O
visual O
hallucinations O
have O
not O
been O
reported O
as O
an O
adverse O
effect O
of O
this O
agent O
, O
we O
describe O
three O
patients O
who O
experienced O
complex O
visual O
hallucinations O
and O
altered B-ADR
mental I-ADR
status I-ADR
after O
zonisamide B-DRUG
treatment O
was O
begun O
or O
its O
dosage O
increased O

phantom B-ADR
limb I-ADR
pain I-ADR
as O
a O
manifestation O
of O
paclitaxel B-DRUG
neurotoxicity O

there O
have O
been O
many O
reports O
of O
probable O
lithium-induced O
organic B-ADR
brain I-ADR
syndromes I-ADR
occurring O
when O
serum O
lithium B-DRUG
levels O
are O
within O
or O
close O
to O
the O
therapeutic O
range O

ischaemia B-ADR
following O
selfadministered O
intra-arterial O
injection O
of O
methylphenidate O
and O
diamorphine B-DRUG

in O
some O
cases O
this O
seems O
to O
happen O
because O
spironolactone B-DRUG
causes O
diarrhoea B-ADR

the O
possible O
development O
of O
a O
drug-induced O
vasculitis O
or O
lupus-like B-ADR
syndrome I-ADR
should O
be O
added O
to O
the O
list O
of O
rare O
toxic O
effects O
of O
vancomycin B-DRUG

fenclofenac-induced O
selective O
iga B-ADR
deficiency I-ADR
in O
rheumatoid O
arthritis O

we O
report O
a O
case O
of O
drug-induced O
kaposi B-ADR
's I-ADR
sarcoma I-ADR
( O
ks O
) O
on O
the O
sole O
of O
the O
right O
foot O
in O
a O
71-year-old O
man O
, O
treated O
for O
6 O
months O
with O
corticosteroid O
therapy O
( O
prednisolone B-DRUG
25 O
mg O
/ O
day O
) O
for O
pericardial O
effusion O

conclusions O
: O
metoclopramide B-DRUG
may O
cause O
reversible O
nonthrombocytopenic B-ADR
vascular-type I-ADR
palpable I-ADR
purpura I-ADR

after O
other O
potential O
causes O
of O
liver B-ADR
toxicity I-ADR
were O
excluded O
, O
tmp-smx B-DRUG
was O
determined O
to O
be O
the O
cause O
of O
his O
acute O
liver B-ADR
toxicity I-ADR

we O
report O
a O
case O
of O
torsade B-ADR
de I-ADR
pointes I-ADR
following O
a O
single O
oral O
dose O
of O
amiodarone B-DRUG
( O
1400 O
mg O
or O
30 O
mg O
kg-1 O
) O
administered O
after O
short O
intravenous O
loading O
for O
prevention O
of O
paroxysmal O
atrial O
flutter O

two O
reports O
of O
spindle B-ADR
coma I-ADR
are O
noted O
with O
alcohol O
and O
imipramine B-DRUG

juvenile B-ADR
absence I-ADR
epilepsy I-ADR
exacerbated O
by O
valproic B-DRUG
acid I-DRUG

disulfiram-induced O
hepatitis B-ADR

cerebrovascular O
complications O
of O
l-asparaginase B-DRUG
therapy O
in O
children O
with O
leukemia O
: O
aphasia B-ADR
and O
other O
neuropsychological O
deficits O

interferon-alpha B-DRUG
( O
ifn-alpha O
) O
may O
precipitate O
or O
exacerbate O
the O
occurrence O
of O
mpgn B-ADR

he O
was O
started O
on O
digoxin B-DRUG
, O
0.25 O
mg O
daily O
, O
because O
of O
echocardiographically O
demonstrated O
left O
ventricular O
dilatation O
and O
functional O
impairment O
; O
he O
died O
of O
ventricular B-ADR
fibrillation I-ADR
15 O
days O
later O

discontinuation O
of O
simvastatin O
and O
cyclosporine B-DRUG
resulted O
in O
resolution O
of O
rhabdomyolysis B-ADR
and O
normalization O
of O
renal O
function O

fever B-ADR
and O
maculopapular O
rashes O
appeared O
at O
10 O
days O
after O
phenytoin B-DRUG
initiation O
, O
and O
then O
the O
drug O
was O
discontinued O

however O
, O
acute O
cardiomyopathy O
and O
pericarditis B-ADR
secondary O
to O
methylphenidate B-DRUG
use O
has O
been O
rarely O
reported O

we O
present O
here O
a O
female O
patient O
who O
developed O
acute B-ADR
bilateral I-ADR
parotitis I-ADR
within O
minutes O
of O
i.v. O
enalaprilat B-DRUG
injection O
and O
recovered O
within O
24 O
hours O
of O
stopping O
the O
drug O
and O
with O
symptomatic O
treatment O

two O
of O
the O
five O
patients O
who O
worsened O
motorically O
also O
developed O
encephalopathy B-ADR
during O
risperidone B-DRUG
treatment O
; O
the O
encephalopathy B-ADR
resolved O
when O
the O
patients O
were O
switched O
to O
clozapine O
treatment O

these O
findings O
suggest O
that O
the O
corneal B-ADR
and I-ADR
retinal I-ADR
changes I-ADR
are O
the O
result O
of O
a O
toxic O
effect O
of O
tamoxifen B-DRUG
when O
used O
in O
the O
doses O
and O
duration O
described O

we O
believe O
that O
this O
represents O
an O
unusual O
case O
of O
moderate-dose O
mtx-induced O
neurotoxicity B-ADR
in O
a O
patient O
with O
gastric O
cancer O
, O
which O
has O
not O
previously O
been O
reported O

hus B-ADR
has O
been O
reported O
after O
several O
anticancer O
chemotherapies O
and O
most O
often O
after O
mitomycin B-DRUG
c-based O
chemotherapy O
regimens O

trimethoprim-sulfamethoxazole-induced O
hepatotoxicity B-ADR
in O
a O
pediatric O
patient O

chronic O
fentanyl B-DRUG
application O
induces O
adrenocortical B-ADR
insufficiency I-ADR

acceleration B-ADR
of I-ADR
ventricular I-ADR
response I-ADR
to O
atrial O
flutter O
after O
intravenous O
adenosine B-DRUG

atypical B-ADR
ventricular I-ADR
tachycardia I-ADR
( O
torsade O
de O
pointes O
) O
induced O
by O
amiodarone B-DRUG
: O
arrhythmia O
previously O
induced O
by O
quinidine O
and O
disopyramide O

case O
report O
: O
lack O
of O
control O
of O
diabetes O
and O
weight B-ADR
gain I-ADR
in O
a O
patient O
on O
initiation O
and O
rechallenge O
of O
therapy O
with O
olanzapine B-DRUG

fatal B-ADR
radiation I-ADR
myelopathy I-ADR
after O
high-dose O
busulfan B-DRUG
and O
melphalan O
chemotherapy O
and O
radiotherapy O
for O
ewing O
's O
sarcoma O
: O
a O
review O
of O
the O
literature O
and O
implications O
for O
practice O

a O
case O
of O
timolol-associated O
heart B-ADR
failure I-ADR
in O
a O
73-year O
old O
white O
man O
is O
reported O

the O
case O
histories O
are O
presented O
of O
two O
patients O
who O
developed O
lung B-ADR
disease I-ADR
associated O
with O
the O
use O
of O
nitrofurantoin B-DRUG
with O
histological O
features O
of O
bronchiolitis O
obliterans O
organising O
pneumonia O
( O
boop O
) O
, O
a O
rare O
but O
recognised O
form O
of O
drug O
induced O
injury O

agranulocytosis O
and O
granulocytopenia B-ADR
associated O
with O
quetiapine B-DRUG

a O
78-year-old O
man O
with O
a O
transvenous O
cardioverter O
defibrillator O
system O
developed O
frequent O
shocks B-ADR
during O
oral O
procainamide B-DRUG
therapy O

amphotericin B-DRUG
b I-DRUG
( O
amb O
) O
is O
effective O
, O
but O
its O
use O
is O
limited O
by O
toxicity O
: O
renal O
impairment O
, O
anaemia B-ADR
, O
fever O
, O
malaise O
, O
and O
hypokalaemia O
are O
common O

the O
first O
patient O
is O
undergoing O
hemodialysis O
and O
, O
though O
responding O
to O
sunitinib B-DRUG
, O
is O
having O
significant O
fatigue O
and O
hypertension B-ADR

in O
case O
no O
. O
2 O
, O
the O
pathogenic O
mechanism O
seemed O
to O
be O
persistent O
light O
reaction O
preceded O
by O
systemic O
photoallergy O
, O
as O
he O
had O
taken O
mequitazine O
for O
6 O
months O
, O
and O
there O
were O
strong O
positive O
photopatch O
test O
results O
with O
immediate O
erythema O
reaction O
, O
cross-reaction O
to O
promethazine B-DRUG
, O
decreased O
med O
to O
both O
uva O
and O
uvb O
, O
and O
persistence B-ADR
of I-ADR
the I-ADR
photosensitivity I-ADR
over O
a O
3-year O
follow-up O
period O
after O
discontinuation O
of O
the O
mequitazine O

aim O
: O
to O
report O
a O
patient O
with O
diabetic O
rubeosis O
who O
suffered O
from O
acute B-ADR
retinal I-ADR
ischemic I-ADR
change I-ADR
and O
stroke O
after O
intravitreal O
injection O
of O
bevacizumab B-DRUG

the O
administration O
of O
" O
sweet O
spirits O
of O
nitre O
" O
( O
4 B-DRUG
% I-DRUG
ethyl I-DRUG
nitrite I-DRUG
ch3ch2ono I-DRUG
in I-DRUG
70 I-DRUG
% I-DRUG
ethyl I-DRUG
alcohol I-DRUG
) O
was O
followed O
by O
acute O
methemoglobinemia O
and O
severe O
anoxic O
metabolic O
acidosis O
in O
infant O
twins O
, O
methylene O
blue O
administration O
reversed O
methemoglobinemia O
in O
both O
, O
but O
one O
twin O
died O
from O
the O
consequences O
of O
hypoxemia B-ADR

we O
report O
the O
case O
of O
an O
adult O
patient O
with O
acute O
lymphoblastic O
leukemia O
who O
presented O
with O
repeated O
transient B-ADR
ischemic I-ADR
attacks I-ADR
followed O
by O
a O
seizure O
during O
consolidation O
treatment O
with O
l-asparaginase B-DRUG

capecitabine-induced O
headache B-ADR
responding O
to O
diltiazem O

here O
we O
describe O
a O
patient O
with O
crohn O
's O
disease O
who O
developed O
a O
severe B-ADR
infliximab I-ADR
infusion I-ADR
reaction I-ADR
( O
iir O
) O
, O
complicated O
1 O
day O
later O
by O
severe O
swelling O
of O
the O
forearm O
and O
hand O
ipsilateral O
to O
the O
site O
of O
infliximab B-DRUG
infusion O

results O
: O
after O
4 O
- O
to O
14-month O
period O
of O
therapy O
with O
the O
combination O
of O
indapamide B-DRUG
( O
2.5 O
mg O
/ O
day O
) O
and O
fosinopril O
( O
10 O
mg O
/ O
day O
) O
in O
three O
patients O
and O
6-month O
period O
of O
monotherapy O
with O
indapamide B-DRUG
( O
2.5 O
mg O
/ O
day O
) O
in O
one O
patient O
, O
glucose O
levels O
of O
all O
patients O
increased O
and O
achieve O
criteria O
of O
diabetes B-ADR
diagnoses O

aim O
: O
report O
of O
a O
case O
of O
a O
woman O
patient O
who O
developed O
celiac B-ADR
disease I-ADR
after O
pegylated O
interferon O
alpha-2a O
and O
ribavirin B-DRUG
use O
for O
chronic O
hepatitis O
c O

we O
present O
the O
case O
of O
an O
adult O
crohn O
's O
disease O
patient O
with O
a O
parvovirus O
b19 O
infection O
and O
leukopenia B-ADR
during O
long-term O
aza B-DRUG
therapy O

although O
they O
had O
complex O
medical O
problems O
, O
the O
high O
serum O
concentrations O
of O
ampicillin B-DRUG
at O
the O
time O
of O
seizures B-ADR
without O
their O
recurrence O
after O
discontinuing O
the O
antibiotic O
suggest O
that O
the O
seizures B-ADR
were O
related O
to O
the O
ampicillin B-DRUG
therapy O

results O
: O
similar O
to O
previous O
findings O
of O
drug-induced O
vortex B-ADR
keratopathy I-ADR
, O
atovaquone B-DRUG
vortex B-ADR
keratopathy I-ADR
is O
presumably O
caused O
by O
its O
lipophilic O
properties O

pulmonary B-ADR
hypertension I-ADR
during O
lithium B-DRUG
therapy O
: O
clinical O
case O
study O

this O
is O
the O
first O
report O
of O
uft-induced B-ADR
scleroderma-like I-ADR
reaction I-ADR

we O
describe O
a O
case O
of O
an O
nhl O
patient O
who O
received O
rituximab B-DRUG
and O
developed O
symptomatic O
, O
biopsy-proven O
multinodular O
bronchiolitis B-ADR
obliterans I-ADR
with I-ADR
organizing I-ADR
pneumonia I-ADR
( O
boop O

objective O
: O
to O
describe O
what O
is O
believed O
, O
as O
of O
november O
4 O
, O
2003 O
, O
to O
be O
the O
first O
case O
published O
in O
the O
literature O
of O
acute B-ADR
interstitial I-ADR
nephritis I-ADR
( O
ain O
) O
due O
to O
pantoprazole B-DRUG

she O
continued O
taking O
verapamil B-DRUG
for O
6 O
months O
, O
then O
, O
on O
her O
own O
, O
stopped O
all O
medications O
including O
the O
sustained-release O
verapamil B-DRUG
, O
and O
her O
asthma B-ADR
symptoms O
disappeared O

conclusions O
: O
this O
is O
the O
first O
report O
of O
a O
possible O
interaction O
between O
propafenone O
and O
citalopram B-DRUG
, O
which O
caused O
propafenone O
adverse O
effects O
( O
eg O
, O
dizziness B-ADR
, O
falls O
) O
and O
mimicked O
coronary O
artery O
disease O

this O
is O
a O
case O
of O
pseudoephedrine-induced O
intracerebral B-ADR
hemorrhage I-ADR
in O
a O
patient O
with O
an O
underlying O
vascular O
malformation O

in O
this O
case O
, O
unlike O
those O
previously O
reported O
, O
hyponatremia B-ADR
recurred O
5 O
months O
after O
switching O
from O
citalopram O
to O
mirtazapine B-DRUG
, O
which O
is O
believed O
to O
be O
a O
safe O
antidepressant O

a O
40-year-old O
man O
with O
a O
long O
standing O
history O
of O
rheumatoid O
arthritis O
was O
treated O
with O
mtx B-DRUG
over O
a O
6 O
month O
period O
and O
developed O
an O
overwhelming B-ADR
hepatic I-ADR
necrosis I-ADR

to O
our O
knowledge O
, O
we O
describe O
the O
first O
reported O
case O
of O
isolated O
paresthesia O
and O
peripheral B-ADR
neuropathy I-ADR
, O
without O
systemic O
involvement O
, O
secondary O
to O
sulindac B-DRUG
administration O

adverse O
effects O
of O
amiodarone B-DRUG
including O
pulmonary O
toxicity O
, O
hepatotoxicity O
, O
aggravation O
of O
arrhythmia O
, O
and O
thyroid B-ADR
diseases I-ADR
are O
well O
understood O

we O
present O
the O
case O
of O
a O
postictal O
patient O
with O
lethargy O
, O
hyperammonemia B-ADR
, O
otherwise O
normal O
liver O
function O
tests O
, O
and O
a O
therapeutic O
valproic B-DRUG
acid I-DRUG
level O

deepening B-ADR
of I-ADR
lid I-ADR
sulcus I-ADR
from O
topical O
bimatoprost B-DRUG
therapy O

localized O
dyskeratotic O
plaque O
with O
milia B-ADR
associated O
with O
sorafenib B-DRUG

administration O
of O
intravenous O
nitroglycerin B-DRUG
in O
a O
patient O
with O
idiopathic O
pulmonary O
hypertension O
resulted O
in O
an O
increase O
in O
pulmonary O
artery O
pressure O
associated O
with O
a O
decrease B-ADR
in I-ADR
blood I-ADR
flow I-ADR
that O
is O
best O
explained O
by O
an O
increase O
in O
pulmonary O
vascular O
resistance O

to O
date O
, O
this O
is O
the O
first O
reported O
case O
of O
what O
appears O
to O
be O
isolated O
thrombocytopenia B-ADR
associated O
with O
lansoprazole B-DRUG

objective O
: O
to O
report O
the O
late O
development O
of O
immune-mediated B-ADR
diabetes I-ADR
mellitus I-ADR
after O
completion O
of O
alfa-interferon B-DRUG
therapy O
for O
hepatitis O
c O
in O
an O
asian O
patient O

the O
renal O
consequences O
of O
indinavir-associated O
nephrotoxicity B-ADR
are O
uncertain O

2-chloro-deoxyadenosine B-DRUG
induces O
durable O
complete O
remission O
in O
castleman O
's O
disease O
but O
may O
accelerate O
its O
transformation O
to O
non-hodgkin B-ADR
's I-ADR
lymphoma I-ADR

observations O
in O
our O
patient O
suggest O
that O
the O
leukoencephalopathy B-ADR
that O
developed O
in O
previously O
reported O
patients O
who O
received O
5-fluorouracil B-DRUG
and O
levamisole O
may O
have O
been O
caused O
at O
least O
partly O
by O
levamisole O

eighty-two O
patients O
with O
various O
malignancies O
who O
received O
imipenem O
/ O
cilastatin B-DRUG
143 O
times O
for O
neutropenic B-ADR
fever I-ADR
between O
march O
1994 O
and O
october O
1999 O
in O
department O
of O
pediatric O
oncology O
, O
gazi O
university O
, O
were O
identified O

we O
hypothesize O
that O
capecitabine-induced O
headache B-ADR
is O
vascular O
in O
nature O

we O
report O
the O
case O
of O
intoxication B-ADR
of O
a O
41-year-old O
female O
patient O
suffering O
from O
major O
depression O
with O
mirtazapine B-DRUG
complicated O
by O
severe O
hypothermia O

conclusion O
: O
the O
results O
suggest O
that O
olanzapine O
may O
be O
useful O
in O
treating O
patients O
with O
clozapine-induced O
granulocytopenia B-ADR
without O
the O
risk O
of O
recurrence O
of O
hematologic O
side O
effects O

on O
the O
fifth O
day O
of O
tocolysis O
with O
magnesium O
sulfate O
, O
nifedipine O
, O
terbutaline B-DRUG
and O
betamethasone O
, O
edema B-ADR
developed O
in O
both O
labia O

rhabdomyolysis B-ADR
caused O
by O
tocolysis O
with O
oral O
ritodrine B-DRUG
hydrochloride I-DRUG
in O
a O
pregnant O
patient O
with O
myotonic O
dystrophy O

sweet B-ADR
's I-ADR
syndrome I-ADR
associated O
with O
sargramostim B-DRUG
( O
granulocyte-macrophage O
colony O
stimulating O
factor O
) O
treatment O

foscarnet-induced O
severe B-ADR
hypomagnesemia I-ADR
and O
other O
electrolyte O
disorders O

ritonavir B-DRUG
acted O
as O
a O
cyp3a4 O
inhibitor O
, O
diminishing B-ADR
carbamazepine I-ADR
metabolism I-ADR
and O
provoking O
an O
increase O
in O
serum O
levels O
and O
clinical O
toxicity O

case O
presentation O
: O
three O
cases O
of O
leishmania B-ADR
infantum I-ADR
leishmaniasis I-ADR
in O
corticosteroid O
( O
cs B-DRUG
)- O
treated O
patients O
are O
reported O
: O
an O
isolated O
lingual O
leishmaniasis O
in O
a O
farmer O
treated O
with O
cs B-DRUG
for O
asthma O
, O
a O
severe O
visceral O
leishmaniasis O
associated O
with O
cutaneous O
lesions O
in O
a O
woman O
with O
myasthenia O
gravis O
, O
and O
a O
visceral O
involvement O
after O
cutaneous O
leishmaniasis O
in O
a O
man O
receiving O
cs B-DRUG

methanol B-ADR
toxicity I-ADR
can O
cause O
severe O
central O
nervous O
system O
insult O
in O
which O
a O
characteristic O
pattern O
of O
bilateral O
putaminal O
injury O
is O
noted O
on O
brain O
imaging O
studies O

a O
second O
possibility O
is O
an O
interaction O
between O
clarithromycin O
and O
isradipine B-DRUG
, O
potentially O
increasing B-ADR
the I-ADR
hepatic I-ADR
toxicity I-ADR
of O
isradipine B-DRUG

pellagra O
should O
be O
suspected O
whenever O
tuberculous O
patients O
under O
treatment O
with O
isoniazid B-DRUG
develop O
mental B-ADR
, I-ADR
neurological I-ADR
or I-ADR
gastrointestinal I-ADR
symptoms I-ADR
, O
even O
in O
the O
absence O
of O
typical O
pellagra O
dermatitis O

we O
report O
3 O
cases O
of O
children O
with O
acute O
lymphoblastic O
leukemia O
who O
developed O
seizures O
and O
altered B-ADR
sensorium I-ADR
after O
l-asparaginase B-DRUG
therapy O

conclusions O
: O
optic O
neuritis O
in O
combination O
with O
other O
neurological B-ADR
signs I-ADR
, O
simulating O
multiple O
sclerosis O
, O
should O
be O
included O
in O
the O
list O
of O
adverse O
effects O
of O
recombinant O
and O
natural O
interferon B-DRUG
alpha I-DRUG
administration O

in O
our O
patient O
, O
an O
objective O
causality O
scale O
showed O
that O
therapeutic O
doses O
of O
colchicine B-DRUG
for O
fmf O
were O
the O
definite O
cause O
of O
myopathy B-ADR
, O
even O
though O
his O
renal O
and O
hepatic O
function O
were O
normal O

clofazimine B-DRUG
induced O
nail B-ADR
changes I-ADR

l-carnitine O
supplementation O
has O
been O
recommended O
to O
prevent O
the O
fatal B-ADR
hepatotoxic I-ADR
effects I-ADR
associated O
with O
valproic B-DRUG
acid I-DRUG

we O
further O
used O
immunohistochemistry O
( O
ihc O
) O
to O
examine O
the O
relative O
role O
of O
platelet-derived O
growth O
factor-b O
( O
pdgf-b O
) O
, O
insulin-like O
growth O
factor O
i O
( O
igf-i O
) O
, O
transforming O
growth O
factor-beta1 O
( O
tgf-beta1 O
) O
and O
cyclooxygenase-2 O
( O
cox-2 O
) O
in O
the O
pathogenesis O
of O
bcnu-related O
pulmonary B-ADR
fibrosis I-ADR

secretory B-ADR
endometrial I-ADR
adenocarcinoma I-ADR
in O
a O
patient O
on O
tamoxifen B-DRUG
for O
breast O
cancer O
: O
a O
report O
of O
a O
case O

this O
report O
suggests O
that O
bleomycin B-DRUG
lung B-ADR
toxicity I-ADR
may O
be O
reversible O
if O
treated O
aggressively O

delayed O
bowel B-ADR
injury I-ADR
is O
an O
infrequently O
observed O
complication O
of O
chromic B-DRUG
phosphate I-DRUG
administration O

in O
a O
postoperative O
patient O
with O
pre-existent O
myasthenia O
gravis O
, O
oral O
verapamil B-DRUG
caused O
a O
marked O
exacerbation B-ADR
in I-ADR
myasthenic I-ADR
weakness I-ADR

we O
report O
2 O
cases O
of O
maculopapular O
eruption O
and O
fever B-ADR
in O
patients O
infected O
with O
human O
immunodeficiency O
virus O
( O
hiv O
) O
on O
the O
2nd O
day O
of O
first O
administration O
of O
ritonavir B-DRUG
, O
a O
protease O
inhibitor O

administration O
of O
sumatriptan B-DRUG
in O
subarachnoid O
haemorrhage O
( O
sah O
) O
patients O
, O
misdiagnosed O
as O
migraine O
patients O
, O
may O
induce O
symptomatic B-ADR
cerebral I-ADR
vasospasm I-ADR
with O
potentially O
dangerous O
consequences O

the O
mechanism O
by O
which O
sunitinib B-DRUG
induces O
gynaecomastia B-ADR
is O
thought O
to O
be O
associated O
with O
an O
unknown O
direct O
action O
on O
breast O
hormonal O
receptors O

a O
35-year-old O
nephrotic O
man O
developed O
acute B-ADR
renal I-ADR
failure I-ADR
with O
serum O
creatinine O
to O
1543 O
micromol O
/ O
l O
after O
a O
month O
of O
therapy O
with O
enalapril B-DRUG

we O
report O
on O
7 O
patients O
( O
2 O
women O
, O
5 O
men O
) O
with O
chronic O
renal O
failure O
, O
who O
developed O
under O
a O
high O
dosage O
of O
the O
new O
diuretic O
muzolimine B-DRUG
( O
range O
240 O
to O
1440 O
mg O
per O
day O
) O
fatal B-ADR
neuromyeloencephalopathy I-ADR

adult B-ADR
respiratory I-ADR
distress I-ADR
syndrome I-ADR
after O
treatment O
with O
pegylated O
interferon O
alpha-2a O
and O
ribavirin B-DRUG

the O
development O
of O
cutaneous O
ecchymosis O
associated O
with O
a O
sudden O
fall O
in O
hemoglobin O
after O
the O
administration O
of O
alteplase B-DRUG
should O
strongly O
suggest O
the O
possibility O
of O
diffuse B-ADR
subfascial I-ADR
hematoma I-ADR

despite O
a O
response O
of O
the O
meningeal O
tumor O
the O
patient O
developed O
in O
the O
third O
week O
of O
mtx O
treatment O
a O
progressive O
visual O
loss O
and O
loss B-ADR
of I-ADR
consciousness I-ADR
which O
worsened O
during O
subsequent O
ara-c B-DRUG
treatment O
and O
led O
to O
death O
within O
3 O
weeks O

the O
patient O
described O
feeling O
cold O
with O
worsening O
headache O
and O
chills B-ADR
approximately O
one O
hour O
after O
infusion O
of O
the O
first O
dose O
of O
penicillin B-DRUG

with O
the O
use O
of O
optical O
coherence O
tomography O
( O
oct O
) O
, O
two O
patients O
with O
ifn-associated O
retinopathy O
who O
had O
developed O
macular O
edema O
and O
reduced B-ADR
visual I-ADR
acuity I-ADR
during O
the O
clinical O
course O
of O
ifn B-DRUG
therapy O
were O
observed O

colitis O
as O
a O
manifestation O
of O
infliximab-associated O
disseminated B-ADR
cryptococcosis I-ADR

objective O
: O
to O
report O
a O
case O
of O
neuroleptic B-ADR
malignant I-ADR
syndrome I-ADR
( O
nms O
) O
associated O
with O
fluphenazine B-DRUG
in O
a O
schizophrenic O
patient O
and O
review O
the O
literature O
related O
to O
this O
condition O

twenty-four O
hours O
after O
the O
administration O
of O
gemcitabine B-DRUG
, O
a O
symmetric B-ADR
, I-ADR
bullous I-ADR
, I-ADR
herpetiform I-ADR
eruption I-ADR
appeared O
on O
his O
trunk O
and O
upper O
limbs O

a O
56-year-old O
male O
parkinsonian O
patient O
developed O
a O
unique O
behavioral B-ADR
change I-ADR
following O
the O
oral O
administration O
of O
cinepazide B-DRUG
, O
a O
cerebral O
vasodilator O

the O
patient O
received O
only O
the O
ophthalmic O
sulfonamide B-DRUG
, O
and O
it O
was O
used O
for O
one O
day O
, O
but O
he O
developed O
stevens-johnson B-ADR
syndrome I-ADR

acute B-ADR
myocardial I-ADR
necrosis I-ADR
during O
administration O
of O
amsacrine B-DRUG

alternating O
sinus O
rhythm O
and O
intermittent B-ADR
sinoatrial I-ADR
block I-ADR
induced O
by O
propranolol B-DRUG

we O
report O
the O
case O
of O
an O
87-year-old O
white O
woman O
with O
myasthenia O
gravis O
who O
presented O
with O
nausea O
, O
shortness B-ADR
of I-ADR
breath I-ADR
, O
azotemia O
, O
and O
hyperkalemia O
shortly O
after O
completing O
a O
course O
of O
intravenous O
immunoglobulin B-DRUG
( O
ivig O

a O
case O
of O
contact B-ADR
dermatitis I-ADR
due O
to O
sodium B-DRUG
bisulfite I-DRUG
in O
an O
ophthalmic O
solution O

this O
patient O
developed O
sequential O
symptoms O
including O
alternative O
hemiparesis B-ADR
, O
dysarthria O
and O
altered O
consciousness O
5 O
days O
after O
the O
second O
course O
of O
hd-mtx B-DRUG
( O
8 O
gm O
/ O
m2 O
by O
6 O
h O
continuous O
infusion O
) O
with O
leucovorin O
rescue O

we O
report O
a O
case O
of O
stevens-johnson O
syndrome O
/ O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
( O
sjs O
/ O
ten O
) O
secondary O
to O
trimethoprim-sulfamethoxazole O
( O
tmp-sx B-DRUG
) O
therapy O
for O
presumed O
community-associated O
methicillin-resistant O
staphylococcus O
aureus O
( O
ca-mrsa O
) O
infection O

we O
present O
a O
patient O
with O
human O
immunodeficiency O
virus O
infection O
under O
treatment O
with O
foscarnet B-DRUG
for O
cmv O
retinitis O
who O
complained O
of O
thirst O
and O
polyuria B-ADR

epstein-barr B-ADR
virus-associated I-ADR
lymphoproliferative I-ADR
disorder I-ADR
in O
a O
patient O
with O
rheumatoid O
arthritis O
on O
methotrexate O
and O
rofecoxib B-DRUG
: O
idiosyncratic O
reaction O
or O
pharmacogenetics O

case O
3 O
: O
a O
29-year-old O
female O
alcoholic O
complained O
of O
general O
fatigue O
and O
a O
slight O
fever B-ADR
after O
1.5 O
years O
of O
abstinence O
with O
cyanamide B-DRUG
treatment O

drug-induced O
fever B-ADR
due O
to O
diltiazem B-DRUG

contact B-ADR
dermatitis I-ADR
due O
to O
budesonide B-DRUG
: O
report O
of O
five O
cases O
and O
review O
of O
the O
japanese O
literature O

this O
case O
represents O
the O
third O
example O
of O
erythroid B-ADR
aplasia I-ADR
associated O
with O
an O
anti-inflammatory O
agent O
and O
the O
first O
instance O
due O
to O
fenoprofen B-DRUG

a O
71-year-old O
man O
, O
who O
had O
a O
history O
of O
a O
previous O
bullous B-ADR
drug I-ADR
reaction I-ADR
to O
a O
sulfonamide B-DRUG
, O
began O
receiving O
an O
ophthalmic O
preparation O
that O
contained O
sulfacetamide O
sodium O

a O
59-year-old O
woman O
with O
myasthenia O
gravis O
who O
received O
a O
large O
dose O
of O
pyridostigmine B-DRUG
bromide I-DRUG
developed O
postoperative O
psychosis O
and O
was O
diagnosed O
as O
having O
bromide B-ADR
intoxication I-ADR

a O
patient O
is O
described O
with O
the O
characteristic O
features O
of O
phenytoin B-DRUG
hypersensitivity O
syndrome O
( O
phs O
) O
including O
fever B-ADR
, O
erythroderma O
, O
tibial O
and O
facial O
oedema O
, O
pinhead-sized O
facial O
pustules O
and O
abnormal O
liver O
function O
tests O

conclusions O
: O
although O
budesonide B-DRUG
may O
be O
beneficial O
because O
of O
its O
anti-inflammatory O
effects O
, O
clinicians O
should O
be O
alert O
to O
its O
potential O
for O
causing O
contact B-ADR
dermatitis I-ADR

fde B-ADR
from O
cephalosporins B-DRUG
has O
been O
rarely O
reported O
, O
and O
to O
the O
best O
of O
our O
knowledge O
there O
is O
no O
published O
report O
of O
ceftriaxone-induced O
fde B-ADR
in O
the O
literature O

we O
report O
a O
case O
of O
hyperpigmentation B-ADR
due O
to O
bleomycin B-DRUG
treatment O
in O
a O
patient O
with O
acquired O
immune O
deficiency O
syndrome O
( O
aids O

two O
patients O
are O
described O
in O
whom O
subtle O
cognitive B-ADR
impairments I-ADR
are O
associated O
with O
therapeutic O
doses O
of O
amoxapine B-DRUG

results O
: O
in O
a O
22-year-old O
thai O
woman O
with O
graves' O
disease O
, O
tinnitus B-ADR
, O
hearing O
impairment O
in O
the O
left O
ear O
( O
with O
progression O
to O
the O
right O
ear O
) O
, O
and O
vertigo O
developed O
after O
3 O
years O
of O
therapy O
with O
ptu B-DRUG

bromide B-ADR
intoxication I-ADR
secondary O
to O
pyridostigmine B-DRUG
bromide I-DRUG
therapy O

conclusions O
: O
intrathecal O
baclofen B-DRUG
can O
impair B-ADR
sexual I-ADR
function I-ADR
and O
ejaculation O
in O
some O
patients O

postoperatively O
, O
the O
first O
two O
patients O
treated O
with O
1 O
to O
2 O
cc O
of O
thrombin B-DRUG
were O
slow O
to O
awaken O
; O
one O
had O
evidence O
of O
vasospasm O
by O
transcranial O
doppler O
ultrasound O
studies O
and O
multiple B-ADR
infarcts I-ADR
on O
cranial O
computerized O
tomography O
, O
while O
the O
other O
had O
a O
moderate-sized O
frontal O
hematoma O
with O
intracranial O
hypertension O

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin O
, O
grepafloxacin O
, O
trovafloxacin O
, O
gatifloxacin O
and O
moxifloxacin B-DRUG
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache O
, O
dizziness O
and O
insomnia B-ADR

case O
: O
we O
report O
a O
case O
of O
a O
woman O
with O
severe O
human O
insulin-induced O
lipoatrophy B-ADR
who O
has O
been O
treated O
exclusively O
with O
recombinant B-DRUG
dna I-DRUG
human I-DRUG
insulin I-DRUG
since O
the O
onset O
of O
iddm O

we O
report O
five O
cases O
of O
restless B-ADR
legs I-ADR
syndrome I-ADR
( O
rls O
) O
and O
periodic O
limb O
movements O
during O
sleep O
( O
plms O
) O
that O
were O
probably O
associated O
with O
olanzapine B-DRUG

two O
patients O
who O
developed O
decreased B-ADR
visual I-ADR
acuity I-ADR
after O
several O
months O
of O
ethambutol B-DRUG
treatment O
for O
mycobacterium O
avium-intracellulare O
infection O
had O
bitemporal O
visual O
field O
defects O
that O
suggested O
optic O
chiasm O
damage O

previous O
studies O
have O
demonstrated O
the O
interaction O
of O
mtx B-DRUG
and O
a O
variety O
of O
non-steroidal O
, O
anti-inflammatory O
drugs O
( O
nsaids O
) O
with O
various O
clinical O
manifestations O
including O
acute O
renal O
failure O
, O
pancytopenia O
, O
vomiting O
, O
diarrhea O
, O
elevated O
liver O
transaminases O
, O
jaundice O
, O
mucosal O
ulcerations O
, O
and O
pyrexia B-ADR

complications O
associated O
with O
primary B-ADR
and I-ADR
secondary I-ADR
perforation I-ADR
of I-ADR
the I-ADR
bladder I-ADR
following O
immediate O
instillations O
of O
epirubicin B-DRUG
after O
transurethral O
resection O
of O
superficial O
urothelial O
tumours O

various O
case O
reports O
concerning O
dapsone-induced O
agranulocytosis B-ADR
are O
reviewed O

this O
case O
report O
describes O
a O
patient O
who O
was O
previously O
prescribed O
alendronate O
( O
fosamax O
) O
and O
presented O
with O
postoperative O
hypophosphatemia B-ADR
and O
hypocalcemic O
tetany O
after O
bowel O
preparation O
with O
fleet B-DRUG
phospho-soda I-DRUG

in O
a O
single O
practice O
during O
the O
21 O
years O
1971-1991 O
, O
the O
incidence O
of O
gestational B-ADR
diabetes I-ADR
in O
pregnancies O
in O
which O
norethisterone B-DRUG
was O
prescribed O
was O
32.4 O
% O
( O
22 O
of O
69 O
) O
in O
comparison O
with O
7.1 O
% O
in O
pregnancies O
in O
which O
the O
women O
did O
not O
take O
norethisterone B-DRUG
( O
137 O
of O
1,684 O
) O
( O
p O
< O
0.001 O

oxcarbazepine-induced O
drug B-ADR
reaction I-ADR
with I-ADR
eosinophilia I-ADR
and I-ADR
systemic I-ADR
symptoms I-ADR
( O
dress O

k O
bipolar O
manic-depressive O
patient O
, O
developed O
while O
on O
lithium B-DRUG
prophylaxis O
, O
akathisia B-ADR
at O
therapeutic O
serum O
lithium B-DRUG
levels O
and O
subsequently O
bucco-linguo-masticatory O
dyskinesia O

how O
low O
can O
you O
go O
? O
use O
of O
very O
low O
dosage O
of O
gold B-DRUG
in O
patients O
with O
mucocutaneous B-ADR
reactions I-ADR

the O
diagnosis O
was O
supported O
by O
the O
temporal O
course O
of O
renal B-ADR
deterioration I-ADR
during O
exposure O
to O
cefuroxime B-DRUG
and O
improvement O
on O
its O
discontinuation O
; O
the O
pattern O
repeated O
with O
rechallenge O

a O
case O
report O
of O
fatal O
dapsone-induced O
agranulocytosis B-ADR
in O
an O
indian O
mid-borderline O
leprosy O
patient O

six O
patients O
developed O
peripheral B-ADR
neuropathy I-ADR
and O
five O
patients O
bone O
marrow O
depression O
, O
blood O
transfusions O
were O
given O
to O
three O
patients O
and O
in O
all O
five O
patients O
bone O
marrow O
function O
normalized O
after O
cessation O
of O
linezolid B-DRUG

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin B-DRUG
, O
sparfloxacin O
, O
grepafloxacin O
, O
trovafloxacin O
, O
gatifloxacin O
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache B-ADR
, O
dizziness O
and O
insomnia O

in O
a O
patient O
with O
severe O
renovascular O
hypertension O
, O
nonoliguric B-ADR
acute I-ADR
renal I-ADR
failure I-ADR
developed O
after O
she O
received O
captopril B-DRUG
treatment O

fatal B-ADR
interstitial I-ADR
pneumonitis I-ADR
following O
high-dose O
intermittent O
chlorambucil B-DRUG
therapy O
for O
chronic O
lymphocyte O
leukemia O

we O
report O
a O
case O
of O
a O
women O
in O
whom O
a O
malignant B-ADR
mixed I-ADR
mesodermal I-ADR
tumor I-ADR
was O
diagnosed O
while O
she O
was O
taking O
raloxifene B-DRUG
, O
which O
is O
also O
a O
selective O
estrogen O
receptor O
modulator O

we O
report O
the O
use O
of O
pamidronate O
for O
acute O
, O
severe O
hypercalcemia O
secondary O
to O
iatrogenic O
vitamin B-ADR
d I-ADR
poisoning I-ADR

the O
side O
effects O
of O
mmf B-DRUG
, O
such O
as O
bone B-ADR
marrow I-ADR
toxicity I-ADR
, O
have O
been O
reported O

theophylline B-ADR
intoxication I-ADR
mimicking O
diabetic O
ketoacidosis O
in O
a O
child O

by O
means O
of O
the O
in O
vitro O
heparin-induced O
platelet B-ADR
activation I-ADR
( O
hipa O
) O
assay O
it O
was O
shown O
that O
standard O
heparin O
and O
the O
lmw O
heparins O
fragmin O
and O
fraxiparin O
( O
sanofi O
labaz O
, O
munich O
, O
frg O
) O
, O
as O
well O
as O
the O
enoxaparine O
clexane B-DRUG
( O
nattermann O
, O
cologne O
, O
frg O
) O
, O
all O
induced O
platelet B-ADR
activation I-ADR
with O
the O
patient O
's O
serum O

valproate B-ADR
embryopathy I-ADR
in O
three O
sets O
of O
siblings O
: O
further O
proof O
of O
hereditary O
susceptibility O

in O
the O
present O
paper O
the O
authors O
describe O
2 O
female O
patients O
who O
developed O
incontinence B-ADR
secondary O
to O
the O
selective O
serotonin O
reuptake O
inhibitors O
paroxetine B-DRUG
and O
sertraline O
, O
as O
well O
as O
a O
third O
who O
developed O
this O
side O
effect O
on O
venlafaxine O

lithium B-ADR
neurotoxicity I-ADR
should O
be O
considered O
in O
creutzfeldt-jakob O
disease O
differential O
diagnosis O
, O
serial O
electroencephalograms O
being O
the O
most O
valuable O

infant O
twins O
sustained O
severe O
circumoral B-ADR
and I-ADR
pharyngeal I-ADR
burns I-ADR
from O
a O
concentrated O
solution O
of O
benzalkonium O
( O
zephiran B-DRUG
) O
chloride O
prescribed O
for O
treatment O
of O
candidiasis O

common O
adverse O
events O
( O
frequency O
10 O
%) O
of O
lacosamide B-DRUG
doses O
up O
to O
600 O
mg O
/ O
day O
include O
nonspecific O
central O
nervous O
system O
effects O
( O
e.g. O
, O
dizziness O
, O
ataxia B-ADR
, O
diplopia O
, O
and O
somnolence O

after O
four O
months O
, O
while O
receiving O
rh B-DRUG
, O
he O
developed O
painful O
bilateral B-ADR
gynaecomastia I-ADR

the O
possible O
role O
of O
interferon B-DRUG
beta I-DRUG
in O
the O
pathogenesis O
of O
sarcoidosis B-ADR
in O
this O
patient O
is O
discussed O

case O
summary O
: O
an O
80-year-old O
white O
female O
, O
followed O
up O
at O
the O
memory O
clinic O
for O
mild B-ADR
cognitive I-ADR
impairment I-ADR
, O
had O
been O
taking O
propafenone B-DRUG
900 O
mg O
/ O
d O
for O
> O
10 O
years O
for O
paroxysmal O
atrial O
fibrillation O
without O
adverse O
effects O

conclusions O
: O
this O
is O
the O
first O
report O
of O
a O
possible O
interaction O
between O
propafenone B-DRUG
and O
citalopram O
, O
which O
caused O
propafenone B-DRUG
adverse O
effects O
( O
eg O
, O
dizziness B-ADR
, O
falls O
) O
and O
mimicked O
coronary O
artery O
disease O

although O
major O
hazards O
of O
treatment O
of O
hypophosphatemic O
osteomalacia O
with O
phosphate B-DRUG
and O
calcitriol O
are O
secondary B-ADR
hyperparathyroidism I-ADR
and O
vitamin O
d O
intoxication O
, O
potassium O
loss O
also O
should O
be O
kept O
in O
mind O

polyarthritis B-ADR
, O
hepatitis O
and O
anti-native O
dna O
antibodies O
after O
treatment O
with O
ethambutol O
and O
rifampicin B-DRUG

acute O
isoniazid B-DRUG
neurotoxicity B-ADR
in O
an O
urban O
hospital O

this O
represents O
the O
first O
report O
of O
nonconvulsive B-ADR
status I-ADR
epilepticus I-ADR
induced O
by O
ifosfamide B-DRUG

a O
79-year-old O
man O
with O
ischemic O
heart O
disease O
, O
chronic O
atrial O
fibrillation O
, O
chronic O
renal O
failure O
, O
hypothyroidism O
, O
and O
gout O
arthritis O
was O
hospitalized O
because O
of O
fatigue O
, O
myalgia O
, O
and O
leg B-ADR
weakness I-ADR
, O
shortly O
after O
starting O
treatment O
with O
colchicine B-DRUG

a O
sixty-year-old O
woman O
with O
advanced O
breast O
cancer O
, O
previously O
treated O
with O
cisplatin O
, O
developed O
an O
irreversible B-ADR
lethal I-ADR
renal I-ADR
failure I-ADR
with O
anuria O
, O
the O
day O
after O
5 O
g O
/ O
m2 O
bolus O
ifosfamide B-DRUG

observations O
in O
our O
patient O
suggest O
that O
the O
leukoencephalopathy B-ADR
that O
developed O
in O
previously O
reported O
patients O
who O
received O
5-fluorouracil O
and O
levamisole B-DRUG
may O
have O
been O
caused O
at O
least O
partly O
by O
levamisole B-DRUG

relapse B-ADR
in I-ADR
the I-ADR
external I-ADR
auditory I-ADR
canal I-ADR
of I-ADR
acute I-ADR
promyelocytic I-ADR
leukemia I-ADR
after O
treatment O
with O
all-trans B-DRUG
retinoic I-DRUG
acid I-DRUG

hyponatraemia B-ADR
during O
low-dose O
carbamazepine B-DRUG
therapy O

objective O
: O
to O
report O
a O
case O
of O
significant O
hepatic O
and O
renal O
failure O
with O
the O
use O
of O
argatroban O
in O
a O
patient O
with O
heparin-induced O
thrombocytopenia B-ADR
( O
hit O
) O
requiring O
continuous O
veno-veno O
hemodialysis O
( O
cvvhd O

fk506 B-DRUG
, O
which O
began O
to O
be O
administered O
12 O
days O
earlier O
, O
rose O
to O
a O
level O
of O
44 O
ng O
/ O
ml O
( O
normal O
range O
, O
10-20 O
ng O
/ O
ml O
) O
1 O
day O
before O
neurologic B-ADR
abnormalities I-ADR
began O

a O
toxic O
encephalopathy O
characterized O
by O
depressed O
level O
of O
consciousness O
, O
marked O
irritability O
, O
and O
ataxia B-ADR
developed O
in O
seven O
children O
, O
5 O
years O
of O
age O
and O
younger O
, O
following O
administration O
of O
an O
antiemetic O
combination O
of O
pentobarbital B-DRUG
and O
pyrilamine O
maleate O

mycophenolate B-DRUG
mofetil-induced O
neutropenia B-ADR
in O
liver O
transplantation O

an O
adult O
male O
presented O
with O
central B-ADR
blindness I-ADR
after O
ingesting O
methanol B-DRUG

the O
literature O
on O
thiabendazole-induced O
cholestasis O
and O
its O
association O
with O
sicca B-ADR
complex I-ADR
is O
reviewed O

though O
they O
are O
generally O
considered O
safe O
, O
there O
have O
been O
a O
few O
reports O
of O
myocardial B-ADR
infarction I-ADR
and O
stroke O
associated O
with O
triptan B-DRUG
use O

a O
52-year-old O
, O
white O
female O
developed O
low-grade B-ADR
fever I-ADR
, O
cough O
, O
and O
dyspnea O
after O
8 O
weeks O
treatment O
with O
sodium B-DRUG
aurothiomalate I-DRUG
for O
rheumatoid O
arthritis O

tumor-volume B-ADR
increase I-ADR
at O
beginning O
of O
primary O
treatment O
with O
topical O
interferon B-DRUG
alpha I-DRUG
2-beta I-DRUG
in O
a O
case O
of O
conjunctiva-cornea O
intraepithelial O
neoplasia O

the O
gynecomastia B-ADR
regressed O
when O
the O
theophylline B-DRUG
was O
discontinued O

although O
a O
lot O
of O
amiodarone-induced O
torsades B-ADR
de I-ADR
pointe I-ADR
have O
been O
published O
, O
a O
review O
of O
all O
these O
cases O
and O
the O
underlying O
risk-factors O
has O
never O
been O
made O

we O
report O
an O
unusually O
short O
lived O
and O
asymptomatic O
episode O
of O
severe O
cisplatin-induced O
renal B-ADR
tubular I-ADR
salt I-ADR
wasting I-ADR
in O
a O
fit O
41-year-old O
patient O
with O
malignant O
teratoma O

the O
first O
patient O
developed O
mild O
nitritoid O
symptoms O
and O
pain O
in O
a O
band-like O
distribution O
, O
corresponding O
to O
t10-t12 B-ADR
dermatomes I-ADR
, O
shortly O
after O
gold B-DRUG
sodium I-DRUG
thiomalate I-DRUG
( O
gstm O
) O
injection O

conclusions O
: O
we O
report O
a O
typical O
symptoms O
of O
charles-bonnet B-ADR
syndrome I-ADR
( O
cbs O
) O
in O
patients O
with O
severe O
amd O
after O
intravitreal O
avastin-injections O

gynecomastia B-ADR
developed O
in O
two O
epileptic O
patients O
some O
months O
after O
the O
addition O
of O
oral O
fluoresone O
750 O
mg O
daily O
to O
the O
phenobarbital O
and O
phenytoin B-DRUG
already O
being O
administered O

a O
65-year-old O
woman O
with O
bipolar O
disorder O
and O
complicated O
cardiovascular O
disease O
who O
was O
on O
maintenance O
lithium B-DRUG
therapy O
developed O
a O
movement B-ADR
disorder I-ADR
following O
high O
doses O
of O
trazodone O
for O
treatment O
of O
an O
acute O
depression O

this O
compound O
, O
used O
by O
adults O
in O
the O
child O
's O
home O
, O
had O
caused O
accidental O
theophylline B-ADR
poisoning I-ADR
, O
mimicking O
diabetic O
ketoacidosis O

an O
11-day-old O
infant O
became O
lethargic O
and O
apneic B-ADR
after O
a O
single O
drop O
of O
brimonidine B-DRUG

we O
report O
the O
occurrence O
of O
renal B-ADR
failure I-ADR
due O
to O
cholesterol O
crystal O
embolization O
following O
thrombolytic O
therapy O
with O
intravenous O
recombinant O
tissue-type O
plasminogen O
activator O
( O
t-pa B-DRUG

a O
retrospective O
epidemiological O
study O
of O
deaths O
from O
hepatic B-ADR
angiosarcoma I-ADR
( O
has O
) O
in O
the O
u.s. O
showed O
that O
during O
1964 O
-- O
74 O
there O
were O
168 O
such O
cases O
, O
of O
which O
37 O
( O
22 O
%) O
were O
associated O
with O
previously O
known O
causes O
( O
vinyl O
chloride O
, O
' O
thorotrast O
' O
, O
and O
inorganic B-DRUG
arsenic I-DRUG
) O
and O
4 O
( O
3.1 O
%) O
of O
the O
remaining O
131 O
cases O
with O
the O
use O
of O
androgenic-anabolic O
steroids O

conclusion O
: O
patients O
with O
insulin B-DRUG
allergy O
may O
not O
have O
complete O
resolution O
of O
their O
symptoms O
after O
standard O
desensitization O
, O
particularly O
those O
patients O
with O
concomitant O
protamine B-ADR
allergy I-ADR

spontaneous B-ADR
splenic I-ADR
infarction I-ADR
associated O
with O
sumatriptan B-DRUG
use O

sle B-ADR
receded O
after O
withdrawal O
of O
carbamazepine B-DRUG
and O
treatment O
with O
anti-inflammatory O
drugs O

only O
one O
report O
links O
phenylpropanolamine B-DRUG
consumption O
to O
an O
intracerebral B-ADR
hemorrhage I-ADR
in O
a O
patient O
with O
an O
avm O

the O
main O
side-effects O
of O
lp-tae B-DRUG
combined O
with O
ht O
were O
low-grade O
fever O
, O
localized O
pain O
, O
myelo-suppression O
and O
liver B-ADR
dysfunction I-ADR
, O
but O
these O
were O
transient O
and O
eventually O
disappeared O

infliximab B-DRUG
therapy O
may O
cause O
a O
lupus-like B-ADR
syndrome I-ADR
that O
is O
reversible O
upon O
discontinuing O
this O
agent O

the O
cause O
of O
death O
was O
determined O
to O
be O
acute B-ADR
intoxication I-ADR
by O
olanzapine B-DRUG
, O
and O
the O
manner O
of O
death O
was O
accidental O

we O
describe O
a O
patient O
with O
idiopathic O
rls O
who O
developed O
augmentation B-ADR
after O
8 O
months O
of O
levodopa B-DRUG
treatment O

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin B-DRUG
, O
sparfloxacin O
, O
grepafloxacin O
, O
trovafloxacin O
, O
gatifloxacin O
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache O
, O
dizziness B-ADR
and O
insomnia O

the O
present O
report O
suggests O
that O
clarithromycin O
coadministration O
induces O
increased O
plasma O
carbamazepine B-DRUG
concentrations O
, O
which O
may O
result O
in O
carbamazepine B-ADR
toxicity I-ADR

here O
we O
report O
a O
patient O
with O
newly O
diagnosed O
acute O
promyelocytic O
leukemia O
who O
developed O
acute B-ADR
focal I-ADR
myositis I-ADR
, O
synovitis O
, O
and O
possible O
vasculitis O
, O
after O
receiving O
all-trans B-DRUG
retinoic I-DRUG
acid I-DRUG
therapy O

four O
patients O
receiving O
high-dose O
tamoxifen B-DRUG
for O
greater O
than O
1 O
year O
have O
demonstrated O
similar O
retinal B-ADR
changes I-ADR

in O
each O
of O
the O
three O
reported O
patients O
, O
alteration O
of O
eyelid O
appearance O
with O
deepening B-ADR
of I-ADR
the I-ADR
lid I-ADR
sulcus I-ADR
was O
evident O
as O
the O
result O
of O
topical O
bimatoprost B-DRUG
therapy O

the O
main O
side-effects O
of O
lp-tae B-DRUG
combined O
with O
ht O
were O
low-grade O
fever O
, O
localized B-ADR
pain I-ADR
, O
myelo-suppression O
and O
liver O
dysfunction O
, O
but O
these O
were O
transient O
and O
eventually O
disappeared O

one O
patient O
was O
an O
80-year-old O
woman O
who O
was O
admitted O
for O
staphylococcus B-ADR
aureus I-ADR
knee I-ADR
arthritis I-ADR
after O
several O
intraarticular O
injections O
of O
sodium B-DRUG
hyaluronate I-DRUG
and O
corticosteroids O

ampicillin B-DRUG
may O
aggravate O
clinical O
and O
experimental O
myasthenia B-ADR
gravis I-ADR

a O
patient O
with O
chronic O
myeloid O
leukaemia O
treated O
with O
busulphan B-DRUG
for O
4-5 O
years O
, O
developed O
signs O
of O
busulphan B-DRUG
toxicity O
and O
portal O
hypertension O
with O
ascites O
, O
oesophageal B-ADR
varices I-ADR
and O
jaundice O

from O
1996 O
to O
2002 O
several O
medications O
were O
changed O
due O
to O
their O
adverse O
effects O
: O
indinavir O
( O
renal O
colic O
and O
fever O
) O
, O
nelfinavir O
( O
cutaneous O
rash O
) O
, O
and O
efavirenz B-DRUG
( O
nausea O
and O
temporary B-ADR
memory I-ADR
loss I-ADR

objective O
: O
to O
describe O
a O
case O
of O
exacerbated O
mania B-ADR
potentially O
related O
to O
an O
interaction O
between O
lopinavir O
/ O
ritonavir O
and O
valproic O
acid O
( O
vpa B-DRUG
) O
and O
propose O
a O
mechanism O
of O
action O
for O
this O
interaction O

we O
discuss O
our O
observations O
in O
the O
cases O
of O
two O
patients O
with O
acyclovir B-DRUG
neurotoxicity B-ADR
and O
review O
the O
findings O
of O
all O
previous O
reports O
in O
the O
english O
language O
literature O

however O
, O
there O
remain O
questions O
concerning O
whether O
these O
drugs O
, O
especially O
methimazole O
( O
mmi B-DRUG
) O
, O
may O
be O
associated O
with O
aplasia B-ADR
cutis I-ADR
congenita I-ADR
( O
acc O
) O
and O
how O
best O
to O
avoid O
impairment O
of O
fetal O
thyroid O
function O
during O
their O
use O

we O
present O
the O
case O
of O
a O
patient O
who O
had O
undergone O
cholecystectomy O
previously O
, O
but O
in O
whom O
morphine B-DRUG
given O
in O
the O
emergency O
department O
precipitated O
pain O
consistent O
with O
biliary B-ADR
colic I-ADR
; O
the O
pain O
resolved O
promptly O
after O
administration O
of O
naloxone O

we O
describe O
a O
57-year-old O
man O
with O
acral O
erythrocyanosis O
progressing O
to O
acute B-ADR
digital I-ADR
ischemia I-ADR
and O
gangrene O
that O
developed O
after O
combined O
chemotherapy O
( O
bleomycin B-DRUG
and O
methotrexate O
) O
used O
to O
treat O
a O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
hypopharynx O

while O
doxorubicin B-DRUG
was O
administered O
, O
the O
patient O
presented O
thoracic B-ADR
pain I-ADR
and O
breathing O
distress O
due O
to O
superior O
vena O
cava O
perforation O
by O
the O
central O
catheter O
and O
subsequent O
extravasation O
of O
the O
drug O
into O
the O
mediastinum O

allergic O
side O
effects O
of O
aza B-DRUG
are O
rare O
, O
and O
reported O
allergic B-ADR
skin I-ADR
eruptions I-ADR
from O
aza B-DRUG
are O
very O
limited O
in O
japan O

this O
article O
reports O
the O
occurrence O
of O
rifampin-associated O
thrombocytopenia B-ADR
in O
an O
indigent O
patient O
after O
a O
four-month O
lapse O
in O
therapy O
for O
pulmonary O
tuberculosis O

severe O
steroid-induced O
glaucoma B-ADR
following O
intravitreal O
injection O
of O
triamcinolone B-DRUG
acetonide I-DRUG

successful O
treatment O
with O
carbimazole O
of O
a O
hyperthyroid O
pregnancy O
with O
hepatic B-ADR
impairment I-ADR
after O
propylthiouracil B-DRUG
administration O
: O
a O
case O
report O

we O
review O
the O
literature O
on O
previously O
reported O
cases O
of O
cutaneous B-ADR
necrosis I-ADR
after O
injection O
of O
standard O
interferon B-DRUG
alfa I-DRUG
or O
pegylated O
interferon B-DRUG
alfa-2b O
and O
discuss O
the O
different O
pathophysiologic O
mechanisms O
that O
might O
be O
involved O

carboplatin O
hypersensitivity B-ADR
induced O
by O
low-dose O
paclitaxel B-DRUG
/ O
carboplatin O
in O
multiple O
platinum-treated O
patients O
with O
recurrent O
ovarian O
cancer O

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram B-DRUG
developed O
confusion O
, O
agitation O
, O
tachycardia B-ADR
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl O
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl O

results O
: O
including O
our O
own O
patient O
, O
a O
total O
of O
26 O
cases O
of O
gemcitabine-associated O
hus B-ADR
were O
identified O

although O
high-dose O
methotrexate B-DRUG
has O
been O
shown O
to O
be O
useful O
in O
the O
treatment O
of O
primary O
osteogenic O
sarcoma O
, O
the O
tumoricidal O
effects O
of O
therapy O
appear O
to O
have O
caused O
a O
fatal B-ADR
rise I-ADR
in I-ADR
intracranial I-ADR
pressure I-ADR

herein O
, O
we O
describe O
a O
patient O
with O
aids O
who O
presented O
to O
medical O
attention O
with O
pancytopenia B-ADR
48 O
months O
postchemotherapy O
with O
etoposide O
, O
prednisone O
, O
vincristine O
, O
cyclophosphamide O
, O
doxorubicin O
, O
and O
rituximab B-DRUG
( O
r-epoch O
) O
for O
diffuse O
large O
b-cell O
lymphoma O

a O
case O
is O
presented O
which O
illustrates O
a O
probably O
fatal B-ADR
interaction I-ADR
between O
minoxidil B-DRUG
and O
a O
coagulation O
disorder O

with O
the O
negative O
viral O
serologies O
, O
the O
clinical O
picture O
was O
most O
consistent O
with O
an O
infectious O
mononucleosis-like B-ADR
syndrome I-ADR
produced O
by O
the O
minocycline O
ingestion O

the O
multiple B-ADR
comedones I-ADR
and O
ruptured O
epidermoid O
cysts O
are O
newly O
reported O
adverse O
effects O
of O
imiquimod B-DRUG
therapy O

actinomycin B-DRUG
d I-DRUG
associated O
hepatic B-ADR
veno-occlusive I-ADR
disease I-ADR
-- O
a O
report O
of O
2 O
cases O

first O
, O
a O
review O
of O
the O
literature O
produced O
41 O
anecdotic O
cases O
of O
neutropenia O
or O
agranulocytosis B-ADR
during O
treatment O
with O
olanzapine B-DRUG
( O
zyprexa O
) O
reported O
in O
a O
total O
of O
24 O
publications O

videopolysomnographic O
and O
pharmacokinetic O
studies O
with O
monitoring O
of O
plasma O
levodopa B-DRUG
levels O
demonstrated O
marked O
motor O
hyperactivity O
during O
augmentation O
, O
with O
anarchic O
discharges O
of O
motor O
unit O
potentials O
, O
tonic O
grouped O
discharges O
and O
flexor B-ADR
spasms I-ADR
, O
associated O
with O
painful O
dysesthesia O

a O
second O
possibility O
is O
an O
interaction O
between O
clarithromycin O
and O
isradipine B-DRUG
, O
potentially O
increasing B-ADR
the I-ADR
hepatic I-ADR
toxicity I-ADR
of O
isradipine B-DRUG

normalization O
of O
generalized O
retinal O
function O
and O
progression O
of O
maculopathy O
after O
cessation O
of O
therapy O
in O
a O
case O
of O
severe O
hydroxychloroquine B-DRUG
retinopathy B-ADR
with O
19 O
years O
follow-up O

a O
well-recognized O
complication O
of O
ethambutol B-DRUG
use O
is O
optic B-ADR
neuropathy I-ADR
, O
but O
the O
potential O
ocular O
toxicity O
of O
isoniazid O
is O
often O
overlooked O

these O
findings O
suggest O
that O
bicytopenia B-ADR
in O
this O
patient O
was O
caused O
by O
d-pen B-DRUG
and O
may O
be O
due O
to O
different O
sensitivities O
in O
the O
hematopoietic O
lineage O

autopsy O
evidence O
of O
herpesvirus B-ADR
infection I-ADR
was O
found O
in O
visceral O
organs O
of O
four O
leukemic O
patients O
who O
had O
received O
large O
doses O
of O
cytarabine O
( O
cytosine O
arabinoside O
; O
ara-c B-DRUG
) O
shortly O
before O
their O
death O

at O
the O
end O
of O
his O
fifth O
cycle O
of O
sunitinib B-DRUG
therapy O
, O
the O
patient O
complained O
of O
the O
development O
of O
abnormally O
large O
mammary O
glands O
associated O
with O
pain B-ADR
and O
peri-areolar O
erythema O

dural B-ADR
sinus I-ADR
thrombosis I-ADR
developed O
in O
two O
children O
with O
acute O
lymphoblastic O
leukemia O
during O
induction O
treatment O
with O
vincristine O
sulfate O
, O
prednisone O
, O
and O
asparaginase B-DRUG

we O
report O
5 O
patients O
( O
3 O
patients O
with O
chronic O
hepatitis O
c O
treated O
with O
pegylated B-DRUG
interferon I-DRUG
alfa-2b I-DRUG
in O
association O
with O
oral O
ribavirin O
and O
two O
patients O
with O
chronic O
myelocytic O
leukemia O
) O
who O
developed O
local B-ADR
cutaneous I-ADR
reactions I-ADR
at O
sites O
of O
injection O
after O
the O
administration O
of O
weekly O
subcutaneous O
injections O
of O
pegylated B-DRUG
interferon I-DRUG
alfa-2b I-DRUG
at O
different O
doses O

here O
we O
present O
the O
case O
of O
a O
generalized B-ADR
lichen I-ADR
nitidus I-ADR
with O
involvement O
of O
the O
palms O
in O
a O
patient O
with O
hepatitis O
c O
after O
systemic O
treatment O
with O
interferon O
alpha O
and O
ribavirin B-DRUG

acute B-ADR
interstitial I-ADR
nephritis I-ADR
due O
to O
pantoprazole B-DRUG

since O
this O
amount O
of O
fab O
was O
insufficient O
to O
bind O
all O
dgtx B-DRUG
present O
in O
the O
serum O
, O
cardiac O
dgtx B-DRUG
toxicity O
( O
total B-ADR
av-block I-ADR
) O
persisted O

chronic O
myelogenous O
leukemia O
( O
cml O
) O
, O
hepatitis O
c O
, O
and O
interferon O
alpha O
( O
ifnalpha B-DRUG
) O
have O
all O
been O
associated O
with O
renal B-ADR
dysfunction I-ADR

abrupt O
, O
accidental O
withdrawal O
of O
trihexyphenidyl B-DRUG
triggered O
severe O
exacerbation O
of O
the O
cranial O
dystonia O
associated O
with O
inspiratory O
stridor O
and O
acute B-ADR
respiratory I-ADR
difficulties I-ADR
, O
prompting O
emergency O
admission O

conclusions O
: O
the O
risk O
of O
drug-induced O
rhabdomyolysis B-ADR
due O
to O
the O
potential O
interaction O
between O
lovastatin O
and O
azithromycin B-DRUG
or O
clarithromycin O
should O
be O
considered O
before O
the O
concomitant O
use O
of O
these O
agents O

results O
: O
two O
patients O
with O
ocular O
inflammation O
of O
unknown O
origin O
developed O
severe B-ADR
chorioretinitis I-ADR
after O
ivta B-DRUG
injection O

upper B-ADR
tract I-ADR
urothelial I-ADR
malignancy I-ADR
after O
cyclophosphamide B-DRUG
therapy O
: O
a O
case O
report O
and O
literature O
review O

there O
are O
major O
side O
effects O
of O
anastrozole B-DRUG
including O
decrease O
in O
both O
lumbar O
spine O
and O
total O
hip O
bone O
mineral O
density O
, O
increase O
in O
the O
incidence O
of O
all O
bone O
fractures O
( O
especially O
fractures O
of O
spine O
, O
hip O
and O
wrist O
) O
, O
joint B-ADR
disorders I-ADR
and O
increase O
in O
the O
cholesterol O
level O

transient B-ADR
global I-ADR
amnesia I-ADR
after O
clioquinol B-DRUG
: O
five O
personal O
observations O
from O
outside O
japan O

voriconazole O
( O
vrc B-DRUG
) O
has O
not O
previously O
been O
reported O
to O
cause O
angio-oedema B-ADR

less O
common O
adverse O
events O
to O
dapsone B-DRUG
include O
the O
idiosyncratic O
reactions O
of O
leukopenia O
and O
agranulocytosis O
, O
cutaneous O
eruptions O
, O
peripheral O
neuropathy O
, O
psychosis O
, O
toxic O
hepatitis O
, O
cholestatic O
jaundice O
, O
nephrotic O
syndrome O
, O
renal B-ADR
papillary I-ADR
necrosis I-ADR
, O
severe O
hypoalbuminemia O
without O
proteinuria O
, O
an O
infectious O
mononucleosis-like O
syndrome O
, O
and O
minor O
neurological O
and O
gastrointestinal O
complaints O

a O
patient O
suffering O
from O
heparin-associated O
thrombocytopenia O
( O
hat O
) O
, O
recurrent B-ADR
arteriothromboses I-ADR
, O
and O
acute O
renal O
failure O
after O
treatment O
with O
standard O
heparin B-DRUG
is O
described O

drug B-ADR
rash I-ADR
with I-ADR
eosinophilia I-ADR
and I-ADR
systemic I-ADR
symptoms I-ADR
after O
chlorambucil B-DRUG
treatment O
in O
chronic O
lymphocytic O
leukaemia O

four O
patients O
who O
manifested O
symptoms O
of O
the O
antiepileptic O
drug O
( O
aed O
) O
hypersensitivity B-ADR
syndrome I-ADR
during O
therapy O
with O
carbamazepine B-DRUG
are O
reported O

lithium O
treatment O
was O
terminated O
in O
1975 O
because O
of O
lithium B-ADR
intoxication I-ADR
with O
a O
diabetes O
insipidus-like O
syndrome O

we O
conclude O
that O
while O
thrombocytopenia O
and O
schistocytosis B-ADR
can O
be O
seen O
in O
quinine-associated O
ttp O
/ O
hus O
, O
the O
pathophysiology O
seems O
to O
be O
distinct O
from O
that O
seen O
in O
most O
cases O
of O
idiopathic O
ttp O
( O
i.e. O
, O
severely O
decreased O
adamts13 O
with O
an O
inhibitor O

objective O
: O
to O
report O
the O
case O
of O
a O
young O
woman O
with O
graves' O
disease O
in O
whom O
ototoxicity B-ADR
developed O
because O
of O
propylthiouracil O
( O
ptu B-DRUG
)- O
induced O
antineutrophil O
cytoplasmic O
antibody O
( O
anca O
)- O
associated O
vasculitis O

when O
the O
trazodone B-DRUG
was O
reduced O
, O
the O
involuntary B-ADR
movements I-ADR
promptly O
ceased O

a O
10-year-old O
boy O
with O
osteosarcoma O
and O
normal O
renal O
function O
manifested O
laboratory O
evidence O
of O
impending O
renal O
toxicity O
and O
extreme O
elevation B-ADR
of I-ADR
aspartate I-ADR
aminotrasferase I-ADR
and O
alanine O
aminotransferase O
within O
2 O
hours O
after O
the O
completion O
of O
a O
4-hour O
infusion O
of O
high-dose O
methotrexate B-DRUG
( O
mtx O
) O
( O
12 O
g O
/ O
m2 O
) O
, O
and O
went O
on O
to O
develop O
acute O
renal O
failure O
with O
life-threatening O
hyperkalemia O
29 O
hours O
later O

methylphenidate B-DRUG
( O
ritalin O
)- O
associated O
cataract B-ADR
and O
glaucoma O

based O
upon O
the O
observed O
fall O
of O
the O
filtration O
fraction O
, O
the O
rise B-ADR
in I-ADR
the I-ADR
relative I-ADR
clearance I-ADR
of I-ADR
99tc-dimercaptosuccinic I-ADR
acid I-ADR
and O
the O
increase O
in O
proteinuria O
, O
we O
suggest O
that O
in O
this O
case O
the O
tubules O
and O
/ O
or O
interstitium O
are O
the O
main O
targets O
for O
cyclosporine B-DRUG
a I-DRUG
nephrotoxicity O

moreover O
, O
these O
findings O
suggest O
that O
the O
incidence O
of O
boop B-ADR
following O
rituximab B-DRUG
therapy O
may O
be O
higher O
than O
has O
been O
previously O
appreciated O

objective O
: O
to O
describe O
onset O
of O
syndrome B-ADR
of I-ADR
inappropriate I-ADR
antidiuretic I-ADR
hormone I-ADR
( O
siadh O
) O
associated O
with O
vinorelbine B-DRUG
therapy O
for O
advanced O
breast O
cancer O

the O
rash B-ADR
seen O
in O
this O
patient O
, O
who O
was O
treated O
with O
cephalexin O
, O
may O
be O
similar O
to O
the O
rash B-ADR
seen O
with O
ampicillin B-DRUG
treatment O
of O
patients O
with O
infectious O
mononucleosis O

we O
report O
marked O
qt B-ADR
prolongation I-ADR
and O
torsades O
de O
pointes O
in O
a O
setting O
of O
flash O
pulmonary O
edema O
resulting O
from O
acute O
myocardial O
ischemia O
in O
a O
patient O
who O
was O
being O
treated O
with O
dofetilide B-DRUG
for O
atrial O
fibrillation O

total O
blindness O
with O
a O
transient O
tonic O
pupillary O
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal B-ADR
visual-evoked I-ADR
potentials I-ADR
developed O
in O
a O
54-year-old O
man O
after O
the O
use O
of O
quinine B-DRUG
sulfate I-DRUG
for O
leg O
cramps O

we O
report O
the O
case O
of O
an O
11-month-old O
female O
infant O
with O
a O
depressed B-ADR
level I-ADR
of I-ADR
consciousness I-ADR
after O
ingestion O
of O
ibuprofen B-DRUG
whose O
mental O
status O
markedly O
improved O
with O
administration O
of O
naloxone O

after O
5-asa B-DRUG
was O
discontinued O
, O
the O
polyneuropathy B-ADR
symptoms O
recovered O
gradually O

case O
presentation O
: O
three O
cases O
of O
leishmania O
infantum O
leishmaniasis O
in O
corticosteroid O
( O
cs B-DRUG
)- O
treated O
patients O
are O
reported O
: O
an O
isolated O
lingual B-ADR
leishmaniasis I-ADR
in O
a O
farmer O
treated O
with O
cs B-DRUG
for O
asthma O
, O
a O
severe O
visceral O
leishmaniasis O
associated O
with O
cutaneous O
lesions O
in O
a O
woman O
with O
myasthenia O
gravis O
, O
and O
a O
visceral O
involvement O
after O
cutaneous O
leishmaniasis O
in O
a O
man O
receiving O
cs B-DRUG

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate O
with O
folinic B-DRUG
acid I-DRUG
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia O
, O
hyperkalaemia O
and O
hyperphosphataemia O
with O
hypocalcaemia O
and O
tetany O
, O
with O
metabolic O
acidosis O
and O
acute B-ADR
renal I-ADR
impairment I-ADR
) O
are O
described O

attenuation O
of O
asparaginase-induced O
hyperglycemia B-ADR
after O
substitution O
of O
the O
erwinia O
carotovora O
for O
the O
escherichia O
coli O
enzyme O
preparation O

post O
marketing O
studies O
of O
interferon-beta O
( O
ifn B-DRUG
beta I-DRUG
) O
therapy O
in O
multiple O
sclerosis O
( O
ms O
) O
have O
demonstrated O
surprisingly O
high O
rates O
of O
hepatotoxicity B-ADR

thalidomide B-DRUG
neuropathy B-ADR
is O
often O
associated O
with O
proximal O
weakness O
and O
may O
progress O
even O
after O
discontinuation O
of O
treatment O
, O
in O
the O
phenomenon O
of O
' O
coasting O

clozapine B-DRUG
is O
speculated O
to O
cause O
rhabdomyolysis B-ADR
in O
patients O
with O
defective O
calcium-activated O
k O
+ O
channels O

we O
describe O
a O
63 O
year O
old O
woman O
with O
a O
suppurative O
mediastinitis O
, O
treated O
with O
continuous O
pi B-DRUG
irrigation O
who O
developed O
an O
acute B-ADR
oliguric I-ADR
renal I-ADR
failure I-ADR

after O
gastric-outlet B-ADR
obstruction I-ADR
was O
recognized O
in O
several O
infants O
who O
received O
prostaglandin B-DRUG
e1 I-DRUG
, O
we O
studied O
the O
association O
between O
the O
drug O
and O
this O
complication O

objective O
: O
to O
report O
2 O
cases O
of O
serotonin B-ADR
syndrome I-ADR
with O
serious O
extrapyramidal O
movement O
disorders O
occurring O
when O
metoclopramide O
was O
coadministered O
with O
sertraline B-DRUG
or O
venlafaxine O

in O
both O
cases O
, O
high O
fever O
, O
skin B-ADR
rash I-ADR
, O
liver O
dysfunction O
and O
atypical O
lymphocytosis O
developed O
3 O
weeks O
after O
initiating O
treatment O
with O
sasp B-DRUG

we O
describe O
2 O
patients O
with O
severe O
erosive O
rheumatoid O
arthritis O
and O
rheumatoid O
vasculitis O
, O
respectively O
, O
in O
whom O
infliximab B-DRUG
therapy O
was O
associated O
with O
peripheral O
neuropathy O
due O
to O
necrotizing O
vasculitis O
in O
one O
patient O
and O
to O
progression B-ADR
of I-ADR
preexisting I-ADR
mononeuritis I-ADR
multiplex I-ADR
in O
the O
other O

isonicotinic B-DRUG
acid I-DRUG
hydrazide I-DRUG
induced O
anagen B-ADR
effluvium I-ADR
and O
associated O
lichenoid O
eruption O

linezolid-induced O
dyserythropoiesis B-ADR
: O
chloramphenicol O
toxicity O
revisited O

we O
describe O
two O
cases O
of O
acute B-ADR
pancreatitis I-ADR
that O
occurred O
after O
long O
term O
mesalamine B-DRUG
therapy O
for O
ulcerative O
colitis O

we O
report O
a O
case O
of O
generalized B-ADR
cutaneous I-ADR
sclerosis I-ADR
associated O
with O
muscle O
and O
oesophageal O
involvement O
in O
a O
patient O
exposed O
to O
herbicides O
containing O
bromocil O
, O
diuron O
and O
aminotriazole B-DRUG

sulfasalazine-induced O
lung O
disorder O
is O
an O
extremely O
rare O
entity O
which O
must O
be O
considered O
in O
all O
ulcerative B-ADR
colitis I-ADR
patients O
while O
on O
sulfasalazine B-DRUG
therapy O
, O
despite O
the O
absence O
of O
pulmonary O
symptomatology O

objective O
: O
to O
report O
a O
case O
of O
calcineurin-induced O
pain B-ADR
syndrome I-ADR
( O
cips O
) O
in O
a O
child O
undergoing O
his O
second O
hematopoietic O
stem O
cell O
transplant O
( O
hsct O

we O
attribute O
the O
clinical O
and O
radiographic O
findings O
to O
cytotoxic B-ADR
edema I-ADR
secondary O
to O
intrathecal O
methotrexate B-DRUG

a O
56-year-old O
white O
woman O
with O
a O
diagnosis O
of O
reactive O
depression O
developed O
severe O
ui B-ADR
after O
a O
30 O
days' O
treatment O
with O
venlafaxine B-DRUG
75 O
mg O
/ O
day O

after O
initiation O
of O
topical O
vitamin B-DRUG
d3 I-DRUG
ointment O
( O
20 O
micro O
g O
/ O
g O
of O
tacalcitol O
) O
10 O
g O
/ O
day O
for O
the O
skin O
lesions O
, O
both O
the O
serum B-ADR
level I-ADR
of I-ADR
calcium I-ADR
and I-ADR
urinary I-ADR
excretion I-ADR
of I-ADR
calcium I-ADR
increased I-ADR
gradually O

a O
case O
report O
of O
the O
hypersensitivity B-ADR
syndrome I-ADR
occurring O
in O
a O
patient O
being O
treated O
with O
dapsone B-DRUG
for O
a O
brown O
recluse O
spider O
bite O
is O
presented O

multiple B-ADR
seizures I-ADR
after O
bupropion B-DRUG
overdose O
in O
a O
small O
child O

we O
hypothesize O
that O
decreased O
renal O
elimination O
of O
mtx B-DRUG
induced O
by O
the O
cox-2 O
inhibitor O
resulted O
in O
enhanced O
hematopoietic O
toxicity O
and O
immunosuppression O
causing O
the O
ebv-associated B-ADR
lymphoproliferative I-ADR
disease I-ADR

a O
toxic O
encephalopathy O
characterized O
by O
depressed O
level O
of O
consciousness O
, O
marked B-ADR
irritability I-ADR
, O
and O
ataxia O
developed O
in O
seven O
children O
, O
5 O
years O
of O
age O
and O
younger O
, O
following O
administration O
of O
an O
antiemetic O
combination O
of O
pentobarbital B-DRUG
and O
pyrilamine O
maleate O

focal B-ADR
renal I-ADR
cortical I-ADR
necrosis I-ADR
associated O
with O
zomepirac B-DRUG

discussion O
: O
no O
published O
clinical O
studies O
in O
patients O
receiving O
clindamycin B-DRUG
vaginal O
cream O
for O
bacterial O
vaginosis O
have O
documented O
c. B-ADR
difficile I-ADR
toxin I-ADR
in I-ADR
stool I-ADR
samples O
of O
patients O
with O
diarrhea O

in O
this O
article O
lithium B-DRUG
is O
not O
discussed O
, O
although O
there O
are O
a O
number O
of O
concerns O
about O
lithium B-DRUG
's O
potential O
teratogenicity O
, O
and O
it O
has O
been O
implicated O
in O
epstein B-ADR
's I-ADR
anomaly I-ADR
, O
a O
congenital O
heart O
defect O
among O
infants O
born O
to O
women O
taking O
lithium B-DRUG
; O
as O
with O
other O
medications O
, O
however O
, O
the O
data O
have O
specific O
limitations O

eleven O
patients O
developed O
infection O
requiring O
hospitalization O
while O
taking O
leflunomide B-DRUG
including O
: O
lower O
respiratory O
tract O
infections O
( O
3 O
) O
, O
cellulitis O
( O
2 O
) O
, O
disseminated O
herpes O
zoster O
( O
2 O
) O
, O
probable O
tb O
liver O
( O
1 O
) O
, O
abdominal O
sepsis O
( O
1 O
) O
, O
mycotic O
aneurysm O
( O
1 O
) O
and O
gastroenteritis B-ADR
( O
1 O

thalidomide B-DRUG
neuropathy O
is O
often O
associated O
with O
proximal B-ADR
weakness I-ADR
and O
may O
progress O
even O
after O
discontinuation O
of O
treatment O
, O
in O
the O
phenomenon O
of O
' O
coasting O

diagnosis O
: O
severe O
temozolomide-induced O
immunosuppression O
, O
exacerbated O
by O
corticosteroids O
, O
with O
profound O
t-cell O
lymphocytopenia O
and O
simultaneous O
opportunistic O
infections B-ADR
with I-ADR
pneumocystis I-ADR
jiroveci I-ADR
pneumonia I-ADR
, O
brain O
abscess O
with O
listeria O
monocytogenes O
, O
and O
cutaneous O
kaposi O
's O
sarcoma O

protease O
inhibitors O
( O
ritonavir B-DRUG
and O
saquinavir O
) O
were O
added O
to O
the O
treatment O
and O
the O
patient O
developed O
progressive O
ataxia O
related O
to O
carbamazepine B-ADR
toxicity I-ADR

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity O
reactions O
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general O
erythema O
, O
dyspnea O
, O
and O
hypotension B-ADR
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal O
pain O
, O
general O
erythema O
, O
and O
fever O

after O
the O
chlorambucil B-DRUG
was O
discontinued O
, O
the O
wbc O
count O
began O
to O
slowly O
rise O
and O
the O
patient O
developed O
clinical O
aml B-ADR

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate B-DRUG
with O
folinic O
acid O
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia O
, O
hyperkalaemia O
and O
hyperphosphataemia B-ADR
with O
hypocalcaemia O
and O
tetany O
, O
with O
metabolic O
acidosis O
and O
acute O
renal O
impairment O
) O
are O
described O

a O
7-year-old O
with O
congenital O
toxoplasmosis O
who O
took O
pyrimethamine O
and O
sulfadiazine B-DRUG
for O
reactivated O
chorioretinitis O
developed O
fever O
, O
severe O
cutaneous O
involvement O
, O
swelling B-ADR
, O
abdominal O
pain O
and O
transaminitis O
, O
persisting O
weeks O
after O
withholding O
medicines O

torsades B-ADR
de I-ADR
pointes I-ADR
induced O
by O
a O
combination O
of O
garenoxacin B-DRUG
and O
disopyramide O
and O
other O
cytochrome O
p450 O
, O
family O
3 O
, O
subfamily O
a O
polypeptide-4-influencing O
drugs O
during O
hypokalemia O
due O
to O
licorice O

this O
case O
suggests O
the O
importance O
of O
careful O
observation O
for O
extramedullary B-ADR
relapse I-ADR
in O
patients O
who O
are O
treated O
with O
atra B-DRUG

methanol B-DRUG
toxicity O
can O
cause O
severe B-ADR
central I-ADR
nervous I-ADR
system I-ADR
insult I-ADR
in O
which O
a O
characteristic O
pattern O
of O
bilateral O
putaminal O
injury O
is O
noted O
on O
brain O
imaging O
studies O

early O
recognition O
of O
renal B-ADR
toxicity I-ADR
of O
high-dose O
methotrexate B-DRUG
therapy O
: O
a O
case O
report O

results O
: O
extensive O
squamous B-ADR
metaplasia I-ADR
was O
found O
in O
endometrial O
glands O
following O
progestin B-DRUG
therapy O

severe B-ADR
hyperkalemia I-ADR
as O
a O
complication O
of O
timolol B-DRUG
, O
a O
topically O
applied O
beta-adrenergic O
antagonist O

he O
had O
priapism B-ADR
following O
the O
use O
of O
olanzapine B-DRUG

valproate-induced O
hyperammonemia B-ADR
as O
a O
cause O
of O
altered O
mental O
status O

pulmonary B-ADR
leukostasis I-ADR
secondary O
to O
all-trans B-DRUG
retinoic I-DRUG
acid I-DRUG
in O
the O
treatment O
of O
acute O
promyelocytic O
leukemia O
in O
first O
relapse O

thrombocytopenia O
with O
or O
without O
microangiopathy O
following O
quinine B-DRUG
is O
often O
referred O
to O
as O
quinine B-DRUG
" O
hypersensitivity. O
" O
when O
schistocytes O
are O
present O
it O
is O
frequently O
termed O
" O
quinine-associated O
ttp B-ADR
/ I-ADR
hus. O
" O
a O
severe O
deficiency O
of O
the O
vwf-cleaving O
protease O
, O
adamts13 O
, O
is O
associated O
with O
idiopathic O
ttp O

propylthiouracil-induced O
cutaneous B-ADR
vasculitis I-ADR

when O
sasp O
was O
changed O
to O
5-aminosalicylic B-DRUG
acid I-DRUG
( O
5-asa O
) O
, O
his O
skin O
eruptions O
were O
resolved O
, O
however O
, O
he O
developed O
weakness O
and O
atrophy O
in O
his O
right O
arm O
as O
well O
as O
progressive O
worsening B-ADR
of I-ADR
the I-ADR
dysesthesia I-ADR
in O
his O
legs O
and O
gait O
disturbance O

albeit O
rare O
among O
western O
patients O
, O
such O
lithium-associated O
thyroid B-ADR
dysfunctions I-ADR
appeared O
to O
be O
more O
likely O
to O
occur O
in O
hong O
kong O
chinese O

we O
introduce O
a O
case O
of O
a O
sixty O
years O
old O
woman O
with O
several O
previous O
episodes O
of O
rhinitis O
, O
conjunctivitis O
and O
perspiration B-ADR
immediately O
after O
the O
administration O
of O
salmon O
calcitonin B-DRUG
with O
nasal O
spray O
or O
intramuscular O
administration O
( O
calsynar O

both O
had O
impaired B-ADR
lung I-ADR
function I-ADR
and O
abnormal O
computed O
tomographic O
scans O
, O
and O
their O
condition O
improved O
when O
nitrofurantoin B-DRUG
was O
withdrawn O
and O
corticosteroid O
treatment O
commenced O

method O
: O
case O
analysis O
of O
a O
poly-drug O
overdose O
( O
venlafaxine O
, O
topiramate O
, O
divalproex O
sodium O
, O
risperidone O
, O
and O
carbamazepine B-DRUG
) O
presenting O
with O
mixed O
ss O
/ O
nms B-ADR
features O
and O
whose O
clinical O
management O
suggests O
a O
practical O
algorithm O
for O
treatment O
of O
undifferentiated O
ss O
/ O
nms B-ADR
in O
critical O
care O
settings O

theophylline O
intoxication O
following O
viloxazine B-DRUG
induced O
decrease B-ADR
in I-ADR
clearance I-ADR

we O
conjectured O
that O
the O
side O
effects O
of O
insulin B-DRUG
, O
such O
as O
anti-natriuresis O
and O
increased O
vascular O
permeability O
, O
might O
be O
pronounced O
in O
the O
presence O
of O
the O
hepatic O
dysfunction O
that O
accompanies O
insulin B-DRUG
insensitivity O
, O
hyperinsulinaemia B-ADR
and O
hypoalbuminaemia O

we O
report O
the O
case O
of O
an O
87-year-old O
white O
woman O
with O
myasthenia O
gravis O
who O
presented O
with O
nausea O
, O
shortness O
of O
breath O
, O
azotemia O
, O
and O
hyperkalemia B-ADR
shortly O
after O
completing O
a O
course O
of O
intravenous O
immunoglobulin O
( O
ivig B-DRUG

apparent O
cyclophosphamide B-DRUG
( O
cytoxan O
) O
embryopathy B-ADR
: O
a O
distinct O
phenotype O

an O
infant O
girl O
with O
choanal O
atresia O
, O
athelia B-ADR
, O
minor O
anomalies O
, O
and O
mild O
to O
moderate O
mental O
retardation O
was O
born O
to O
a O
woman O
treated O
for O
hyperthyroidism O
throughout O
pregnancy O
with O
methimazole O
and O
propranolol B-DRUG

this O
is O
the O
first O
report O
of O
a O
possible O
association O
between O
an O
acute B-ADR
cardiovascular I-ADR
event I-ADR
and O
venlafaxine B-DRUG

we O
report O
the O
cases O
of O
two O
patients O
who O
developed O
acute O
hepatitis B-ADR
after O
taking O
riluzole B-DRUG
at O
the O
recommended O
dose O
( O
100 O
mg O
daily O
) O
for O
7 O
and O
4 O
weeks O
, O
respectively O

propranolol B-DRUG
: O
an O
unrecognized O
cause O
of O
central B-ADR
nervous I-ADR
system I-ADR
dysfunction I-ADR
in O
patients O
undergoing O
cardiopulmonary O
bypass O

purpose O
: O
the O
case O
of O
a O
patient O
who O
developed O
aseptic O
meningitis O
, O
hemolytic B-ADR
anemia I-ADR
, O
hepatitis O
, O
and O
orthostatic O
hypotension O
simultaneously O
during O
treatment O
with O
trimethoprim-sulfamethoxazole O
is O
described O

we O
suspect O
that O
nefazodone O
inhibits B-ADR
metabolism I-ADR
of I-ADR
tacrolimus I-ADR

two O
days O
after O
administration O
of O
kalimate B-DRUG
enema O
, O
he O
had O
profuse O
hematochezia O
, O
and O
a O
sigmoidoscopy O
showed O
diffuse O
colonic B-ADR
mucosal I-ADR
necrosis I-ADR
in I-ADR
the I-ADR
rectum I-ADR
and O
sigmoid O
colon O

extensive O
immunological O
investigations O
were O
performed O
in O
a O
patient O
with O
definite O
seronegative O
rheumatoid O
arthritis O
who O
developed O
hypogammaglobulinemia B-ADR
in O
the O
course O
of O
gold B-DRUG
therapy O

peripheral B-ADR
neuropathy I-ADR
and O
cerebellar O
syndrome O
associated O
with O
amiodarone B-DRUG
therapy O

we O
report O
five O
cases O
of O
carboplatin B-DRUG
( O
cbdca O
) O
hypersensitivity B-ADR
after O
weekly O
low-dose O
paclitaxel O
( O
60 O
mg O
/ O
m2 O
)/ O
cbdca O
( O
area O
under O
the O
concentration O
curve O
= O
2 O
) O
therapy O
in O
patients O
with O
recurrent O
ovarian O
cancer O
receiving O
multiple O
platinum-based O
chemotherapy O

however O
, O
prolongation O
of O
5-fu B-DRUG
half-life O
and O
an O
increase B-ADR
in I-ADR
inr I-ADR
have O
been O
reported O
with O
the O
concurrent O
use O
of O
5-fu B-DRUG
and O
warfarin O

we O
report O
a O
patient O
with O
chronic O
renal O
failure O
and O
ischemic O
heart O
disease O
who O
developed O
clinically O
significant O
methemoglobinemia B-ADR
after O
an O
axillary O
block O
with O
bupivacaine B-DRUG
and O
additional O
injection O
of O
lidocaine O
in O
the O
operative O
field O

neuroleptic B-ADR
malignant I-ADR
syndrome I-ADR
in O
an O
adolescent O
receiving O
olanzapine-lithium O
combination O
therapy O

conclusions O
: O
the O
piloerection B-ADR
observed O
after O
the O
replacement O
of O
fluvoxamine O
with O
milnacipran B-DRUG
in O
this O
patient O
appears O
to O
have O
been O
due O
to O
an O
increase O
in O
the O
alpha O
( O
1 O
)- O
adrenoceptor O
occupancy O
by O
endogenous O
norepinephrine O
induced O
by O
milnacipran B-DRUG

peculiar O
nail-changes B-ADR
in O
a O
70-year-old O
woman O
with O
rheumatoid O
arthritis O
occurring O
after O
approximately O
1 O
year O
of O
penicillamine B-DRUG
treatment O
are O
described O

a O
case O
is O
reported O
of O
an O
elderly O
woman O
who O
developed O
febrile B-ADR
agranulocytosis I-ADR
several O
weeks O
after O
commencing O
ticlopidine B-DRUG
but O
who O
had O
a O
favorable O
outcome O
after O
cessation O
of O
that O
drug O
and O
treatment O
with O
filgastrim O

angioedema B-ADR
and O
dysphagia O
caused O
by O
contact O
allergy O
to O
inhaled O
budesonide B-DRUG

histopathology O
of O
the O
thyroid O
in O
amiodarone-induced O
hypothyroidism B-ADR

conclusions O
: O
this O
is O
the O
second O
case O
report O
that O
describes O
gemcitabine-induced O
radiation B-ADR
recall I-ADR
in O
rectus O
abdominus O
muscles O
after O
gemcitabine-based O
radiation O
therapy O

however O
, O
he O
developed O
acute B-ADR
renal I-ADR
failure I-ADR
, O
hyperkalemia O
, O
and O
hyperuricemia O
30 O
d O
after O
receiving O
the O
sorafenib B-DRUG
treatment O

two O
cases O
are O
reported O
of O
patients O
who O
developed O
a O
hematologic B-ADR
malignancy I-ADR
several O
years O
after O
intravesical O
chemotherapy O
of O
superficial O
bladder O
cancer O
with O
etoglucid B-DRUG
, O
doxorubicin O
, O
and O
mitomycin O
c O

premature B-ADR
closure I-ADR
of I-ADR
the I-ADR
ductus I-ADR
arteriosus I-ADR
: O
variable O
response O
among O
monozygotic O
twins O
after O
in O
utero O
exposure O
to O
indomethacin B-DRUG

the O
authors O
report O
two O
cases O
of O
delayed O
elimination O
of O
methotrexate O
in O
patients O
receiving O
ciprofloxacin B-DRUG
, O
with O
severe O
toxicity B-ADR

she O
was O
placed O
on O
adjuvant O
adriamycin B-DRUG
( O
doxorubicin O
) O
chemotherapy O
, O
but O
6 O
months O
later O
died B-ADR
of O
adriamycin B-DRUG
toxicity O

pulmonary B-ADR
toxicity I-ADR
secondary O
to O
procarbazine B-DRUG

foscarnet-induced O
severe O
hypomagnesemia O
and O
other O
electrolyte B-ADR
disorders I-ADR

an O
unusual O
cause O
of O
burn B-DRUG
injury I-DRUG
: O
unsupervised O
use O
of O
drugs O
that O
contain O
psoralens B-ADR

the O
interval O
between O
initiating O
treatment O
with O
interferon B-DRUG
alfa O
and O
onset O
of O
anterior O
ischemic O
optic O
neuropathy O
was O
similar O
to O
that O
of O
interferon-associated O
vascular B-ADR
retinopathy I-ADR

our O
patient O
developed O
both O
nephrogenic B-ADR
diabetes I-ADR
insipidus I-ADR
and O
renal O
tubular O
acidosis O
with O
a O
temporal O
pattern O
that O
demonstrated O
a O
link O
between O
foscarnet B-DRUG
therapy O
and O
these O
abnormalities O

bradycardia B-ADR
and O
congestive O
heart O
failure O
associated O
with O
ocular O
timolol B-DRUG
maleate I-DRUG

similar O
to O
reports O
in O
patients O
receiving O
gefitinib O
, O
those O
with O
pathologic O
findings O
of O
uip O
on O
resected O
lung O
specimens O
or O
known O
pulmonary O
fibrosis O
may O
be O
at O
particular O
risk O
for O
erlotinib B-DRUG
pulmonary B-ADR
toxicity I-ADR

deposits B-ADR
of I-ADR
plasma I-ADR
proteins I-ADR
in I-ADR
the I-ADR
skin I-ADR
during O
treatment O
with O
carbamazepine B-DRUG
and O
diphenylhydantoin O

conclusion O
: O
a O
37-year-old O
african O
- O
american O
man O
with O
g6pd O
deficiency O
developed O
hemolytic O
anemia O
, O
hepatitis O
, O
orthostatic B-ADR
hypotension I-ADR
, O
and O
aseptic O
meningitis O
simultaneously O
after O
using O
trimethoprim-sulfamethoxazole O

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity O
reactions O
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general O
erythema O
, O
dyspnea O
, O
and O
hypotension O
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal B-ADR
pain I-ADR
, O
general O
erythema O
, O
and O
fever O

after O
having O
received O
gemcitabine B-DRUG
on O
day O
1 O
of O
the O
second O
course O
, O
the O
patient O
developed O
dry O
cough O
, O
subfebrile B-ADR
temperatures I-ADR
and O
dyspnea O
within O
48 O
h O

she O
received O
an O
accidental O
450-mg O
bolus O
injection O
of O
morphine B-DRUG
intrathecally O
and O
developed O
hypertension O
, O
status O
epilepticus O
, O
intracerebral O
hemorrhage O
, O
and O
respiratory B-ADR
failure I-ADR

we O
presented O
a O
patient O
with O
status O
asthmaticus O
treated O
with O
a O
combination O
of O
theophylline B-DRUG
and O
prednisone O
who O
developed O
a O
perforated B-ADR
gastric I-ADR
ulcer I-ADR

therapy O
with O
ifn-alpha B-DRUG
may O
be O
associated O
with O
a O
number O
of O
neuropsychiatric B-ADR
symptoms I-ADR
, O
such O
as O
parkinsonism O
, O
akathisia O
, O
seizure O
, O
and O
depressive O
disorders O

a O
patient O
with O
chronic O
myeloid O
leukaemia O
treated O
with O
busulphan B-DRUG
for O
4-5 O
years O
, O
developed O
signs O
of O
busulphan B-DRUG
toxicity O
and O
portal B-ADR
hypertension I-ADR
with O
ascites O
, O
oesophageal O
varices O
and O
jaundice O

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin O
, O
grepafloxacin O
, O
trovafloxacin O
, O
gatifloxacin O
and O
moxifloxacin B-DRUG
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache O
, O
dizziness B-ADR
and O
insomnia O

atrioventricular B-ADR
block I-ADR
complicating O
amiodarone-induced O
hypothyroidism O
in O
a O
patient O
with O
pre-excitation O
and O
rate-dependent O
bilateral O
bundle O
branch O
block O

conclusions O
: O
clinicians O
should O
be O
aware O
of O
a O
risk O
of O
serotonin O
syndrome O
with O
serious O
extrapyramidal B-ADR
reactions I-ADR
in O
patients O
receiving O
sertraline O
or O
venlafaxine O
when O
metoclopramide B-DRUG
is O
coadministered O
even O
in O
a O
single O
, O
conventional O
dose O

we O
report O
the O
case O
of O
a O
young O
man O
, O
affected O
by O
rheumatoid O
arthritis O
who O
developed O
a O
rapid-onset O
short-of-breath B-ADR
, O
hemoptysis O
, O
and O
severe O
weakness O
, O
about O
2 O
weeks O
after O
the O
administration O
of O
leflunomide B-DRUG

ectropion B-ADR
secondary O
to O
bolus O
injection O
of O
5-fluorouracil B-DRUG

methotrexate B-DRUG
induced O
sprue-like B-ADR
syndrome I-ADR

calcipotriol B-DRUG
( O
daivonex O
r O
; O
leo O
pharmaceuticals O
, O
zurich O
, O
switzerland O
) O
may O
cause O
irritation O
of O
the O
skin O
, O
whereas O
allergic B-ADR
reactions I-ADR
are O
less O
common O

we O
believe O
that O
this O
is O
the O
first O
report O
of O
secretory B-ADR
carcinoma I-ADR
of I-ADR
the I-ADR
endometrium I-ADR
associated O
with O
tamoxifen B-DRUG
use O

data O
synthesis O
: O
genetic O
deficiencies O
in O
dpd O
, O
the O
rate-limiting O
enzyme O
responsible O
for O
5-fu B-DRUG
catabolism O
, O
may O
occur O
in O
3 O
% O
or O
more O
of O
patients O
with O
cancer O
putting O
them O
at O
increased O
risk O
for O
unusually O
severe O
adverse O
reactions O
( O
e.g. O
, O
diarrhea O
, O
stomatitis O
, O
mucositis O
, O
myelosuppression O
, O
neurotoxicity B-ADR
) O
to O
standard O
doses O
of O
5-fu B-DRUG

suspected O
ciprofloxacin-induced O
interstitial B-ADR
nephritis I-ADR

an O
insulin-dependent O
diabetic O
patient O
with O
nephropathy O
developed O
severe B-ADR
acidosis I-ADR
after O
treatment O
with O
acetazolamide B-DRUG
for O
glaucoma O

the O
authors O
caution O
that O
treatment O
with O
alprazolam B-DRUG
may O
be O
complicated O
by O
the O
induction O
of O
mania B-ADR

torsade B-ADR
de I-ADR
pointes I-ADR
during O
loading O
with O
amiodarone B-DRUG

purpose O
: O
to O
investigate O
the O
concentration-side O
effect O
relationship O
in O
a O
patient O
with O
severe O
acyclovir-induced O
neurotoxicity B-ADR
and O
to O
summarize O
the O
information O
available O
in O
the O
literature O
about O
central O
nervous O
system O
side O
effects O
due O
to O
acyclovir B-DRUG

this O
case O
presentation O
is O
of O
a O
patient O
who O
had O
the O
clinical O
appearance O
of O
epiglottitis B-ADR
, O
but O
actually O
had O
an O
oro-pharyngeal O
dystonic O
reaction O
to O
prochlorperazine B-DRUG

conclusions O
: O
clarithromycin B-DRUG
may O
be O
a O
cause O
of O
fulminant B-ADR
liver I-ADR
failure I-ADR
either O
alone O
or O
by O
inhibiting O
the O
metabolism O
of O
other O
drugs O

purpose O
: O
the O
occurrence O
of O
myoclonus B-ADR
associated O
with O
continuous O
i.v. O
infusion O
of O
dobutamine B-DRUG
in O
a O
patient O
with O
end-stage O
renal O
disease O
( O
esrd O
) O
is O
described O

the O
patient O
described O
feeling O
cold O
with O
worsening B-ADR
headache I-ADR
and O
chills O
approximately O
one O
hour O
after O
infusion O
of O
the O
first O
dose O
of O
penicillin B-DRUG

here O
, O
we O
report O
a O
case O
of O
rfp-induced O
hypothyroidism B-ADR
without O
underlying O
thyroid O
disease O

we O
report O
the O
case O
of O
a O
patient O
who O
developed O
polyserositis O
( O
pericardial B-ADR
effusion I-ADR
, O
pleural O
effusion O
, O
and O
pericarditis O
) O
after O
being O
started O
on O
clozapine B-DRUG
, O
and O
whose O
symptoms O
remitted O
upon O
discontinuation O
of O
clozapine B-DRUG

life-threatening O
anaphylactoid B-ADR
reaction I-ADR
to O
amifostine B-DRUG
used O
with O
concurrent O
chemoradiotherapy O
for O
nasopharyngeal O
cancer O
in O
a O
patient O
with O
dermatomyositis O
: O
a O
case O
report O
with O
literature O
review O

to O
our O
knowledge O
, O
we O
describe O
the O
first O
reported O
case O
of O
isolated B-ADR
paresthesia I-ADR
and O
peripheral O
neuropathy O
, O
without O
systemic O
involvement O
, O
secondary O
to O
sulindac B-DRUG
administration O

we O
reviewed O
the O
literature O
in O
an O
attempt O
to O
characterize O
the O
pattern O
and O
predictors O
of O
tmp B-DRUG
/ O
smx-induced O
aseptic B-ADR
meningitis I-ADR

two O
patients O
with O
osteomyelitis O
who O
developed O
reversible B-ADR
cholestatic I-ADR
jaundice I-ADR
during O
treatment O
with O
oxacillin B-DRUG
derivatives O
are O
described O

monoclonal O
gammopathy O
and O
subsequent O
multiple B-ADR
myeloma I-ADR
in O
a O
patient O
on O
chronic O
diphenylhydantoin B-DRUG
therapy O

we O
describe O
3 O
as O
patients O
treated O
with O
etanercept B-DRUG
for O
active O
as O
who O
developed O
new O
onset O
of O
cd B-ADR
while O
as O
related O
symptoms O
responded O
well O
to O
etanercept B-DRUG

an O
association O
of O
granulocytopenia B-ADR
, O
eosinophilia O
, O
skin O
reaction O
and O
hepatitis O
during O
propylthiouracil O
( O
ptu B-DRUG
) O
therapy O
for O
thyrotoxicosis O
in O
a O
47 O
year O
old O
black O
female O
is O
reported O

we O
report O
5 O
patients O
( O
3 O
patients O
with O
chronic O
hepatitis O
c O
treated O
with O
pegylated B-DRUG
interferon I-DRUG
alfa-2b I-DRUG
in O
association O
with O
oral O
ribavirin O
and O
two O
patients O
with O
chronic O
myelocytic O
leukemia O
) O
who O
developed O
local B-ADR
cutaneous I-ADR
reactions I-ADR
at O
sites O
of O
injection O
after O
the O
administration O
of O
weekly O
subcutaneous O
injections O
of O
pegylated B-DRUG
interferon I-DRUG
alfa-2b I-DRUG
at O
different O
doses O

we O
describe O
a O
relatively O
healthy O
, O
9-year-old O
boy O
who O
developed O
a O
ca-mrsa O
skin O
and O
soft B-ADR
tissue I-ADR
infection I-ADR
and O
was O
treated O
with O
tmp-smx B-DRUG

methods O
: O
double-blind O
, O
placebo-controlled O
titrated O
oral O
challenges O
with O
pancreatic O
enzymes O
resulted O
in O
definite O
vomiting B-ADR
within O
1 O
to O
1.5 O
hours O
after O
challenges O
with O
viokase B-DRUG
and O
pancrease O
mt O
16 O
, O
but O
not O
with O
placebo O

several O
cases O
of O
lithium-induced O
creutzfeldt-jakob B-ADR
syndrome I-ADR
have O
been O
reported O
to O
date O
; O
all O
of O
them O
were O
elderly O
patients O
and O
a O
half O
had O
" O
therapeutic O
" O
lithium B-DRUG
serum O
levels O

stevens-johnson B-ADR
syndrome I-ADR
in O
a O
boy O
with O
nephrotic O
syndrome O
during O
prednisolone B-DRUG
therapy O

after O
only O
the O
third O
dose O
of O
pentamidine B-DRUG
, O
it O
was O
noted O
that O
the O
patient O
's O
heart B-ADR
rate I-ADR
had I-ADR
decreased I-ADR
to O
48 O
beats O
/ O
minute O

methimazole-associated O
cholestatic B-ADR
liver I-ADR
injury I-ADR
: O
case O
report O
and O
brief O
literature O
review O

this O
report O
describes O
the O
first O
case O
of O
insulin-induced O
cardiac B-ADR
failure I-ADR
in O
a O
patient O
without O
underlying O
heart O
disease O

multiple O
mechanisms O
for O
ciprofloxacin-induced O
nephrotoxicity B-ADR
have O
been O
proposed O

iatrogenic O
hypercalcemia B-ADR
due O
to O
vitamin O
d3 O
ointment O
( O
1,24 O
( O
oh O
) O
2d3 O
) O
combined O
with O
thiazide B-DRUG
diuretics O
in O
a O
case O
of O
psoriasis O

we O
report O
a O
case O
of O
successful O
surgical O
management O
of O
arterial B-ADR
thrombosis I-ADR
after O
percutaneous O
thrombin B-DRUG
injection O
of O
a O
femoral O
artery O
pseudoaneurysm O
in O
a O
69-year-old O
woman O

vanishing B-ADR
bile I-ADR
duct I-ADR
and O
stevens-johnson O
syndrome O
associated O
with O
ciprofloxacin B-DRUG
treated O
with O
tacrolimus O

the O
day O
after O
clozapine B-DRUG
was O
stopped O
, O
while O
he O
was O
still O
receiving O
clomipramine O
150 O
mg O
/ O
d O
, O
he O
began O
behaving O
oddly O
, O
started O
sweating B-ADR
profusely I-ADR
, O
shivering O
, O
and O
became O
tremulous O
, O
agitated O
, O
and O
confused O

we O
describe O
a O
case O
of O
severe O
aplastic O
anemia O
( O
aa B-ADR
) O
that O
was O
probably O
induced O
by O
lenalidomide B-DRUG

we O
present O
a O
unique O
case O
of O
gtbm B-ADR
in O
a O
patient O
with O
myeloma O
following O
treatment O
with O
melphalan B-DRUG

although O
risk O
factors O
for O
mtx-induced O
pulmonary O
toxicity O
are O
poorly O
understood O
, O
the O
presence O
in O
3 O
out O
of O
5 O
of O
our O
patients O
of O
pre-existing O
lung O
disease O
, O
represented O
by O
diffuse O
interstitial O
changes O
on O
chest O
x-ray O
, O
and O
mild O
bronchial O
asthma O
in O
two O
ra O
patients O
and O
by O
pulmonary O
silicosis O
in O
the O
patient O
with O
psa O
may O
account O
for O
a O
predisposition O
to O
the O
development O
of O
mtx B-DRUG
pneumonitis B-ADR

therapy O
with O
ifn-alpha B-DRUG
may O
be O
associated O
with O
a O
number O
of O
neuropsychiatric O
symptoms O
, O
such O
as O
parkinsonism O
, O
akathisia O
, O
seizure B-ADR
, O
and O
depressive O
disorders O

over O
the O
past O
3 O
years O
there O
have O
been O
several O
reports O
of O
uveitis B-ADR
associated O
with O
rifabutin B-DRUG
therapy O

pulmonary O
infiltrates O
and O
skin B-ADR
pigmentation I-ADR
associated O
with O
sulfasalazine B-DRUG

hypoglycemia O
can O
be O
a O
serious O
side O
effect O
of O
etanercept O
in O
patients O
already O
on O
antidiabetic O
medications O
known O
to O
cause O
hypoglycemia B-ADR
, O
such O
as O
sulfonylureas O
, O
meglitinides B-DRUG
, O
and O
insulin O

a O
16-year-old O
boy O
developed O
fever O
, O
generalized O
rigidity O
, O
leukocytosis O
, O
and O
increased B-ADR
serum I-ADR
transaminase I-ADR
and I-ADR
creatine I-ADR
kinase I-ADR
levels O
while O
receiving O
treatment O
with O
olanzapine B-DRUG
and O
lithium O

concurrent B-ADR
acute I-ADR
megaloblastic I-ADR
anaemia I-ADR
and O
pneumonitis O
: O
a O
severe O
side-effect O
of O
low-dose O
methotrexate B-DRUG
therapy O
during O
rheumatoid O
arthritis O

thus O
, O
clinical O
recognition O
of O
sleep B-ADR
disordered I-ADR
breathing I-ADR
should O
be O
taken O
into O
account O
when O
rheumatoid O
arthritis O
patients O
are O
to O
be O
treated O
with O
infliximab B-DRUG

fulminant B-ADR
hepatic I-ADR
failure I-ADR
developed O
in O
a O
24-year-old O
black O
woman O
who O
had O
been O
treated O
with O
propylthiouracil O
and O
propranolol B-DRUG
for O
hyperthyroidism O

case O
report O
: O
soon O
after O
initiation O
of O
amiodarone B-DRUG
hcl I-DRUG
( O
200 O
mg O
/ O
day O
) O
, O
a O
76-year-old O
man O
came O
to O
us O
with O
symptoms O
of O
visual O
" O
shining O
," O
glare O
, O
color B-ADR
vision I-ADR
anomalies I-ADR
, O
and O
gradually O
decreased O
vision O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical B-ADR
lymphocytosis I-ADR
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim B-DRUG
( O
tmp O
)- O
sulfamethoxazole O
( O
smx O
) O
treatment O

therefore O
, O
it O
is O
reasonable O
to O
conclude O
that O
: O
1 O
) O
2-cda B-DRUG
can O
induce O
durable O
complete O
remission O
in O
mcd O
patients O
but O
unfortunately O
it O
cannot O
cure O
the O
disease O
; O
2 O
) O
the O
possibility O
that O
2-cda B-DRUG
may O
accelerate O
the O
transformation B-ADR
of I-ADR
mcd I-ADR
to I-ADR
nhl I-ADR
cannot O
be O
ruled O
out O

aggressive O
management O
of O
doxorubicin-induced O
cardiomyopathy B-ADR
associated O
with O
' O
low O
' O
doses O
of O
doxorubicin B-DRUG

improved O
awareness O
of O
and O
further O
investigation O
into O
the O
neurotoxic B-ADR
effects I-ADR
of O
ofloxacin B-DRUG
may O
enhance O
its O
safe O
use O

she O
developed O
a O
severe B-ADR
urticarial I-ADR
rash I-ADR
3 O
weeks O
following O
initiation O
of O
therapy O
with O
enoxaparin B-DRUG

a O
case O
report O
is O
presented O
concerning O
the O
administration O
of O
ketanserin O
in O
the O
treatment O
of O
pulmonary O
vasoconstriction O
and O
right B-ADR
ventricular I-ADR
failure I-ADR
following O
the O
infusion O
of O
protamine B-DRUG
in O
a O
patient O
undergoing O
coronary O
artery O
bypass O
surgery O
and O
mitral O
valve O
replacement O

during O
intravenous O
treatment O
with O
terlipressin B-DRUG
for O
recurrent O
gastrointestinal O
( O
gi O
) O
bleeding O
, O
a O
50-year-old O
male O
with O
no O
history O
of O
heart O
disease O
developed O
a O
newly O
prolonged O
qt O
interval O
and O
torsade B-ADR
de I-ADR
pointes I-ADR

the O
authors O
report O
five O
cases O
of O
tremor B-ADR
related O
to O
itraconazole B-DRUG
therapy O
, O
which O
occurred O
within O
1-12 O
months O
of O
initiating O
treatment O
and O
resolved O
gradually O
following O
itraconazole B-DRUG
withdrawal O

although O
the O
existence O
of O
an O
acute O
pericarditis O
or O
an O
acute O
myocarditis O
as O
possible O
causes O
of O
the O
st O
elevation O
cannot O
be O
fully O
ruled O
out O
, O
the O
sudden O
onset O
, O
prominent O
magnitude O
, O
and O
brief O
duration O
of O
the O
st O
elevation O
are O
perhaps O
more O
indicative O
of O
an O
acute O
ischemic O
event O
, O
possibly O
related O
to O
a O
transient O
coronary B-ADR
vasoconstriction I-ADR
induced O
by O
the O
dopamine B-DRUG
infusion O

this O
report O
describes O
a O
case O
of O
acute O
compromise O
of O
renal O
function O
associated O
with O
hypotension B-ADR
in O
a O
7-year-old O
boy O
treated O
with O
the O
ace O
inhibitor O
lisinopril B-DRUG
and O
the O
arb O
losartan O

chlorambucil B-DRUG
central B-ADR
nervous I-ADR
toxicity I-ADR
: O
a O
significant O
side O
effect O
of O
chlorambucil O
therapy O
in O
childhood O
nephrotic O
syndrome O

anhedonic B-ADR
ejaculation I-ADR
with O
desipramine B-DRUG

hemolytic B-ADR
uremic I-ADR
syndrome I-ADR
in O
a O
patient O
on O
cis-platinum O
, O
vinblastine B-DRUG
and O
bleomycin O

this O
report O
describes O
two O
patients O
who O
developed O
acute B-ADR
myelocytic I-ADR
leukemia I-ADR
only O
after O
exposure O
to O
cyclophosphamide B-DRUG
, O
methotrexate O
, O
and O
5-fluorouracil O
adjuvant O
therapy O

clearance O
rates O
of O
cerivastatin B-DRUG
metabolites O
in O
a O
patient O
with O
cerivastatin-induced O
rhabdomyolysis B-ADR

development O
of O
nephrotic B-ADR
syndrome I-ADR
in O
a O
patient O
with O
acute O
myeloblastic O
leukemia O
after O
treatment O
with O
macrophage-colony-stimulating B-DRUG
factor I-DRUG

cd4 O
t-lymphocyte O
depletion O
, O
myelosuppression O
, O
and O
subsequent O
severe B-ADR
infections I-ADR
are O
the O
major O
side O
effects O
of O
fludarabine B-DRUG
phosphate I-DRUG
therapy O

in O
this O
study O
, O
we O
report O
on O
three O
individual O
patients O
who O
received O
btx-b B-DRUG
and O
who O
subsequently O
developed O
parasympathetic B-ADR
dysfunction I-ADR
of I-ADR
the I-ADR
visual I-ADR
system I-ADR
after O
injections O
of O
btx-b B-DRUG
at O
remote O
sites O

fatal B-ADR
toxic I-ADR
epidermal I-ADR
necrolysis I-ADR
related O
to O
lamotrigine B-DRUG
administration O

renal B-ADR
hypophosphatemia I-ADR
in O
this O
patient O
was O
caused O
by O
the O
erroneous O
intake O
of O
1 O
g O
doxycycline B-DRUG

the O
authors O
report O
2 O
cases O
of O
renal B-ADR
damage I-ADR
associated O
with O
lithium B-DRUG
carbonate I-DRUG
treatment O

a O
rechallenge O
, O
performed O
in O
both O
patients O
, O
confirmed O
the O
diagnosis O
of O
mesalamine-induced O
pancreatitis B-ADR

therapy O
with O
ifn-alpha B-DRUG
may O
be O
associated O
with O
a O
number O
of O
neuropsychiatric O
symptoms O
, O
such O
as O
parkinsonism B-ADR
, O
akathisia O
, O
seizure O
, O
and O
depressive O
disorders O

physicians O
should O
therefore O
be O
aware O
of O
its O
occurrence O
and O
carefully O
monitor O
serum O
levels O
of O
cpk O
, O
got O
and O
gpt O
during O
the O
treatment O
of O
diabetes O
insipidus O
with O
clofibrate B-DRUG
, O
especially O
in O
patients O
with O
associated O
hypothyroidism O
, O
latent O
or O
overt O
, O
which O
possibly O
favors O
the O
development O
of O
myopathy B-ADR

the O
authors O
describe O
three O
families O
in O
whom O
the O
occurrence O
of O
fvs B-ADR
in O
all O
the O
siblings O
strongly O
suggests O
hereditary O
susceptibility O
to O
valproic B-DRUG
acid-induced O
adverse O
outcome O

reversible B-ADR
cardiomyopathy I-ADR
caused O
by O
administration O
of O
interferon B-DRUG
alpha I-DRUG

long-term O
follow-up O
after O
neoplastic B-ADR
seeding I-ADR
complicating O
percutaneous O
ethanol B-DRUG
injection O
for O
treatment O
of O
hepatocellular O
carcinoma O

less O
common O
adverse O
events O
to O
dapsone B-DRUG
include O
the O
idiosyncratic O
reactions O
of O
leukopenia O
and O
agranulocytosis O
, O
cutaneous O
eruptions O
, O
peripheral O
neuropathy O
, O
psychosis B-ADR
, O
toxic O
hepatitis O
, O
cholestatic O
jaundice O
, O
nephrotic O
syndrome O
, O
renal O
papillary O
necrosis O
, O
severe O
hypoalbuminemia O
without O
proteinuria O
, O
an O
infectious O
mononucleosis-like O
syndrome O
, O
and O
minor O
neurological O
and O
gastrointestinal O
complaints O

tamoxifen B-DRUG
is O
suggested O
to O
be O
carcinogenic B-ADR
both O
through O
direct O
genotoxic O
and O
epigenetic O
mechanisms O

disseminated B-ADR
eruptive I-ADR
giant I-ADR
mollusca I-ADR
contagiosa I-ADR
in O
an O
adult O
psoriasis O
patient O
during O
efalizumab B-DRUG
therapy O

the O
aim O
of O
our O
paper O
was O
to O
describe O
hepatotoxicity B-ADR
of O
sirolimus B-DRUG
( O
srl O
) O
in O
a O
kidney O
graft O
recipient O

ramipril-induced O
cutaneous B-ADR
vasculitis I-ADR
is O
particularly O
rare O
and O
our O
case O
was O
atypical O
because O
the O
patient O
had O
tolerated O
lisinopril O
before O

this O
is O
, O
to O
the O
best O
of O
our O
knowledge O
, O
the O
first O
report O
of O
a O
case O
in O
which O
agranulocytosis B-ADR
followed O
treatment O
with O
both O
propylthiouracil B-DRUG
and O
methimazole O
in O
the O
same O
patient O

in O
this O
paper O
we O
report O
a O
case O
of O
nimodipine B-DRUG
overdosage O
resulting O
in O
prolonged O
hypotension O
and O
hypoxemia B-ADR
, O
which O
was O
successfully O
treated O
with O
calcium O
gluconate O

the O
oligohidrosis B-ADR
caused O
by O
zonisamide B-DRUG
was O
reversible O
in O
that O
the O
patient O
regained O
the O
ability O
to O
sweat O
within O
2 O
weeks O
of O
the O
cessation O
of O
drug O
administration O

we O
herein O
report O
this O
rare O
case O
of O
acute O
onset O
of O
nephrotic B-ADR
syndrome I-ADR
during O
interferon-alpha B-DRUG
retreatment O

corneal B-ADR
endothelial I-ADR
deposits I-ADR
associated O
with O
rifabutin B-DRUG
use O

on O
day O
7 O
of O
linezolid B-DRUG
treatment O
, O
the O
patient O
developed O
severe O
pruritus O
, O
macular B-ADR
rash I-ADR
, O
facial O
edema O
, O
eosinophilia O
, O
marked O
increase O
in O
serum O
creatinine O
level O
, O
and O
mild O
hepatitis O

we O
conclude O
that O
low-dose O
hu B-DRUG
therapy O
in O
patients O
with O
thalassemia O
intermedia O
may O
increase B-ADR
total I-ADR
hb I-ADR
levels O
sufficiently O
to O
eliminate O
the O
need O
for O
transfusions O

he O
developed O
recurrent O
skin O
rash O
, O
fever O
, O
hypereosinophilia O
, O
and O
acute B-ADR
renal I-ADR
failure I-ADR
after O
rechallenge O
with O
chlorambucil B-DRUG

cholestatic B-ADR
liver I-ADR
disease I-ADR
with O
ductopenia O
( O
vanishing O
bile O
duct O
syndrome O
) O
after O
administration O
of O
clindamycin B-DRUG
and O
trimethoprim-sulfamethoxazole O

we O
describe O
a O
74-year-old O
man O
with O
rheumatoid O
arthritis O
( O
ra O
) O
who O
developed O
syndrome B-ADR
of I-ADR
inappropriate I-ADR
secretion I-ADR
of I-ADR
antidiuretic I-ADR
hormone I-ADR
( O
siadh O
) O
1.5 O
months O
after O
commencement O
of O
mizoribin B-DRUG
prescription O
when O
his O
arthritis O
was O
improved O

nephrogenic O
diabetes O
insipidus O
and O
renal B-ADR
tubular I-ADR
acidosis I-ADR
secondary O
to O
foscarnet B-DRUG
therapy O

flaccid B-ADR
quadriparesis I-ADR
was O
noted O
after O
discontinuation O
of O
vecuronium B-DRUG

we O
observed O
transient O
panhypogammaglobulinaemia B-ADR
in O
a O
patient O
with O
neuropsychiatric O
sle O
after O
treatment O
with O
prednisolone B-DRUG
and O
cyclophosphamide O

a O
60-year-old O
white O
man O
with O
chronic O
bronchitis O
was O
noted O
to O
develop O
acute O
respiratory O
failure O
and O
metabolic B-ADR
acidosis I-ADR
four O
days O
after O
being O
started O
on O
methazolamide O
( O
neptazane B-DRUG
) O
for O
an O
ophthalmologic O
problem O

the O
authors O
report O
a O
case O
of O
a O
patient O
who O
received O
alteplase B-DRUG
for O
acute O
myocardial O
infarction O
and O
developed O
spontaneous O
subfascial B-ADR
hematoma I-ADR
without O
any O
evidence O
of O
direct O
trauma O

we O
report O
a O
premature O
infant O
who O
developed O
seizures B-ADR
associated O
with O
intraventricular O
administration O
of O
nafcillin B-DRUG
and O
discuss O
the O
need O
for O
electroencephalographic O
monitoring O
of O
patients O
receiving O
intraventricular O
antibiotics O

chronic O
myelogenous O
leukemia O
( O
cml O
) O
, O
hepatitis O
c O
, O
and O
interferon B-DRUG
alpha I-DRUG
( O
ifnalpha O
) O
have O
all O
been O
associated O
with O
renal B-ADR
dysfunction I-ADR

the O
ocular O
toxicity O
of O
dcf B-DRUG
, O
previously O
described O
as O
conjunctivitis O
, O
appears O
to O
be O
a O
keratitis B-ADR
of O
moderate O
severity O
which O
requires O
further O
study O

restless B-ADR
legs I-ADR
syndrome I-ADR
may O
thus O
be O
an O
adverse O
effect O
of O
ifn B-DRUG
alpha I-DRUG
treatment O

rta O
is O
one O
type O
of O
nephrotoxicity B-ADR
induced O
by O
fk506 B-DRUG
, O
and O
it O
is O
reversible O
in O
mild O
cases O
when O
appropriately O
treated O

we O
report O
a O
case O
of O
pediatric O
bupropion B-DRUG
ingestion O
resulting O
in O
multiple B-ADR
seizures I-ADR

results O
: O
a O
clinical O
diagnosis O
of O
fixed B-ADR
drug I-ADR
eruption I-ADR
owing O
to O
use O
of O
the O
pde5 O
inhibitor O
tadalafil B-DRUG
( O
cialis O
) O
was O
made O

in O
one O
case O
, O
disulfiram B-DRUG
was O
the O
only O
potential O
teratogen B-ADR
exposed O
to O
the O
fetus O

typical O
symptoms O
of O
active O
cd B-ADR
occurred O
11 O
, O
12 O
, O
and O
26 O
months O
after O
start O
of O
etanercept B-DRUG
therapy O
, O
respectively O

an O
acute B-ADR
ischaemic I-ADR
event I-ADR
associated O
with O
the O
use O
of O
venlafaxine B-DRUG
: O
a O
case O
report O
and O
proposed O
pathophysiological O
mechanisms O

the O
chemotherapeutics O
, O
including O
vincristine O
, O
actinomycin B-DRUG
d I-DRUG
, O
and O
epirubicin O
in O
case O
1 O
and O
vincristine O
and O
actinomycin B-DRUG
d I-DRUG
in O
case O
2 O
, O
were O
given O
before O
the O
hepatotoxicity B-ADR
developed O

polyarthritis O
, O
hepatitis B-ADR
and O
anti-native O
dna O
antibodies O
after O
treatment O
with O
ethambutol B-DRUG
and O
rifampicin O

metipranolol B-DRUG
associated O
granulomatous B-ADR
anterior I-ADR
uveitis I-ADR
: O
not O
so O
uncommon O
as O
thought O

when O
sasp O
was O
changed O
to O
5-aminosalicylic O
acid O
( O
5-asa B-DRUG
) O
, O
his O
skin O
eruptions O
were O
resolved O
, O
however O
, O
he O
developed O
weakness O
and O
atrophy B-ADR
in O
his O
right O
arm O
as O
well O
as O
progressive O
worsening O
of O
the O
dysesthesia O
in O
his O
legs O
and O
gait O
disturbance O

oral O
intake O
and O
acarbose B-DRUG
were O
withheld O
and O
the O
ileus B-ADR
spontaneously O
resolved O
after O
2 O
days O

neurologic B-ADR
symptoms I-ADR
resolved O
after O
stopping O
cap B-DRUG
for O
4 O
weeks O
in O
patient O
a O
, O
with O
no O
recurrence O
after O
reinitiating O
cap B-DRUG
alone O
at O
2000 O
mg O
/ O
m2 O

design O
: O
we O
reviewed O
the O
medical O
records O
of O
four O
patients O
, O
who O
were O
seen O
by O
us O
between O
july O
2000 O
and O
february O
2004 O
for O
sudden O
onset O
of O
a O
central B-ADR
neurological I-ADR
syndrome I-ADR
within O
days O
of O
intrathecal O
mtx B-DRUG

we O
describe O
a O
57-year-old O
man O
with O
acral O
erythrocyanosis O
progressing O
to O
acute B-ADR
digital I-ADR
ischemia I-ADR
and O
gangrene O
that O
developed O
after O
combined O
chemotherapy O
( O
bleomycin O
and O
methotrexate B-DRUG
) O
used O
to O
treat O
a O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
hypopharynx O

as O
these O
cases O
revealed O
, O
close O
monitoring O
of O
blood O
chemistry O
is O
mandatory O
after O
starting O
spironolactone B-DRUG
, O
and O
patients O
should O
be O
advised O
to O
stop O
spironolactone B-DRUG
immediately O
if O
diarrhoea B-ADR
develops O

kaposi B-ADR
's I-ADR
sarcoma I-ADR
in O
a O
patient O
treated O
with O
imatinib B-DRUG
mesylate I-DRUG
for O
chronic O
myeloid O
leukemia O

neurological O
improvement O
and O
rehabilitation O
potential O
following O
toxic B-ADR
myelopathy I-ADR
due O
to O
intrathecal O
injection O
of O
doxorubicin B-DRUG

we O
describe O
two O
dark-skinned O
patients O
who O
developed O
hyperpigmented O
skin O
and O
tongue B-ADR
lesions I-ADR
during O
combination O
therapy O
with O
ifn O
and O
ribavirin B-DRUG

to O
our O
knowledge O
this O
is O
the O
first O
report O
of O
pancytopenia O
due O
to O
mmi B-DRUG
, O
where O
the O
usual O
hypoplasia O
found O
is O
replaced O
by O
massive B-ADR
plasmocytosis I-ADR

imatinib B-DRUG
mesylate-related O
fatal B-ADR
acute I-ADR
hepatic I-ADR
failure I-ADR
in O
a O
patient O
with O
chronic O
myeloid O
leukaemia O
and O
chronic O
hepatitis O
b O
infection O

thirty-six O
patients O
with O
al O
received O
, O
in O
a O
three-month O
period O
, O
51 O
cycles O
of O
combined O
chemotherapy O
which O
included O
, O
in O
all O
of O
them O
, O
cytosine O
arabinoside O
( O
ara-c B-DRUG
) O
; O
among O
them O
, O
along O
with O
myelosuppression O
, O
five O
experienced O
fever O
, O
infectious O
complications O
, O
gastrointestinal B-ADR
tract I-ADR
symptoms I-ADR
and O
severe O
myalgias O

we O
describe O
a O
41 O
yr O
old O
leprosy O
patient O
treated O
for O
10 O
yrs O
with O
clofazimine B-DRUG
who O
underwent O
laparotomy O
for O
severe O
abdominal B-ADR
pain I-ADR

corneal B-ADR
endothelial I-ADR
dysfunction I-ADR
associated O
with O
amantadine B-DRUG
toxicity O

three O
patients O
with O
niacin-induced O
visual B-ADR
symptoms I-ADR
had O
cystoid O
maculopathy O
without O
leakage O
on O
fluorescein O
angiography O
, O
and O
a O
fourth O
patient O
with O
no O
fundus O
abnormality O
experienced O
cessation O
of O
visual B-ADR
symptoms I-ADR
upon O
discontinuation O
of O
niacin B-DRUG

erythema B-ADR
multiforme I-ADR
bullosum I-ADR
due O
to O
rifampicin B-DRUG

cerebrovascular B-ADR
complications I-ADR
of O
l-asparaginase B-DRUG
therapy O
in O
children O
with O
leukemia O
: O
aphasia O
and O
other O
neuropsychological O
deficits O

we O
report O
a O
rare O
case O
of O
recurrent O
( O
stuttering O
) O
priapism B-ADR
in O
a O
patient O
with O
protein O
c O
deficiency O
while O
maintained O
on O
warfarin B-DRUG
therapy O

in O
the O
presented O
case O
fluvoxamine-induced O
akathisia B-ADR
in O
an O
ocd O
patient O
was O
partially O
resistant O
to O
the O
anticholinergic O
agent O
biperiden O
, O
and O
was O
successfully O
treated O
with O
the O
5-ht2a O
/ O
5-ht2c O
antagonist O
mianserin O

in O
case O
no O
. O
2 O
, O
the O
pathogenic O
mechanism O
seemed O
to O
be O
persistent O
light O
reaction O
preceded O
by O
systemic O
photoallergy O
, O
as O
he O
had O
taken O
mequitazine B-DRUG
for O
6 O
months O
, O
and O
there O
were O
strong O
positive O
photopatch O
test O
results O
with O
immediate O
erythema O
reaction O
, O
cross-reaction B-ADR
to I-ADR
promethazine I-ADR
, O
decreased O
med O
to O
both O
uva O
and O
uvb O
, O
and O
persistence O
of O
the O
photosensitivity O
over O
a O
3-year O
follow-up O
period O
after O
discontinuation O
of O
the O
mequitazine B-DRUG

albendazole-induced O
pseudomembranous B-ADR
colitis I-ADR

conclusions O
: O
the O
observation O
that O
neurotoxicity B-ADR
developed O
with O
a O
delay O
of O
24 O
to O
48 O
hours O
after O
acyclovir B-DRUG
peak O
serum O
concentrations O
could O
explain O
the O
wide O
range O
of O
acyclovir B-DRUG
levels O
reported O
in O
similar O
cases O

currently O
the O
use O
of O
zidovudine B-DRUG
is O
one O
of O
the O
few O
specific O
measures O
available O
, O
and O
as O
a O
potentially O
teratogenic O
and O
fetotoxic B-ADR
agent O
, O
any O
decision O
for O
its O
use O
requires O
evaluation O
of O
the O
potential O
for O
fetal O
damage O

we O
report O
a O
case O
of O
severe B-ADR
avp I-ADR
three O
weeks O
following O
the O
administration O
of O
infliximab B-DRUG
for O
the O
treatment O
of O
crohn O
's O
disease O
( O
cd O

this O
case O
of O
linezolid-associated O
acute O
interstitial O
nephritis O
within O
the O
context O
of O
a O
drug B-ADR
rash I-ADR
with I-ADR
eosinophilia I-ADR
and I-ADR
systemic I-ADR
symptoms I-ADR
( O
dress O
) O
syndrome O
in O
a O
patient O
treated O
with O
linezolid B-DRUG
raises O
concerns O
about O
the O
presumed O
renal O
safety O
of O
this O
drug O

conclusions O
: O
this O
is O
the O
first O
report O
of O
a O
possible O
interaction O
between O
propafenone B-DRUG
and O
citalopram O
, O
which O
caused O
propafenone B-DRUG
adverse O
effects O
( O
eg O
, O
dizziness O
, O
falls B-ADR
) O
and O
mimicked O
coronary O
artery O
disease O

four O
weeks O
earlier O
she O
had O
developed O
hepatopathy B-ADR
during O
a O
regimen O
of O
carbamazepine B-DRUG
, O
lynestrenol O
and O
sodium O
valproate O

five O
and O
one-half O
years O
after O
the O
diagnosis O
of O
myeloma O
, O
while O
in O
remission O
on O
cyclophosphamide B-DRUG
therapy O
, O
the O
patient O
experienced O
severe O
abdominal B-ADR
right I-ADR
lower I-ADR
quadrant I-ADR
pain I-ADR
due O
to O
a O
large O
cecal O
lymphoma O

pemphigus B-ADR
foliaceus I-ADR
was O
seen O
in O
a O
patient O
with O
pulmonary O
tuberculosis O
during O
rifampicin B-DRUG
therapy O

neutropenia B-ADR
is O
an O
infrequent O
complication O
following O
administration O
of O
the O
angiotensin-converting O
enzyme O
( O
ace O
) O
inhibitor O
, O
captopril B-DRUG

posthypoglycemic B-ADR
hyperglycemia I-ADR
( O
rebound O
hyperglycemia O
) O
after O
overdosing O
of O
insulin B-DRUG
was O
diagnosed O
in O
6 O
cats O
with O
diabetes O
mellitus O

background O
: O
hydroxyurea B-DRUG
is O
a O
cytostatic O
agent O
used O
to O
treat O
myeloproliferative O
disorders O
and O
long-term O
treatment O
is O
associated O
with O
mucocutaneous B-ADR
adverse I-ADR
events I-ADR
and O
nail O
hyperpigmentation O

in O
the O
present O
paper O
the O
authors O
describe O
2 O
female O
patients O
who O
developed O
incontinence B-ADR
secondary O
to O
the O
selective O
serotonin O
reuptake O
inhibitors O
paroxetine O
and O
sertraline O
, O
as O
well O
as O
a O
third O
who O
developed O
this O
side O
effect O
on O
venlafaxine B-DRUG

this O
report O
suggests O
that O
anemia B-ADR
can O
occur O
due O
to O
mmf B-DRUG
, O
in O
particular O
when O
it O
is O
given O
with O
prednisone O
, O
a O
side O
effect O
well O
documented O
in O
the O
transplantation O
literature O
when O
the O
triple O
combination O
of O
mmf B-DRUG
, O
cyclosporine O
and O
prednisone O
is O
used O

one O
patient O
had O
a O
lower B-ADR
average I-ADR
heart I-ADR
rate I-ADR
and O
two O
patients O
had O
lower O
average O
mean O
blood O
pressure O
values O
during O
propranolol B-DRUG
treatment O
, O
none O
of O
which O
was O
clinically O
significant O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin B-ADR
eruptions I-ADR
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim B-DRUG
( O
tmp O
)- O
sulfamethoxazole O
( O
smx O
) O
treatment O

conclusion O
: O
significant O
ocular O
complications O
such O
as O
an O
irreversible B-ADR
decrease I-ADR
of I-ADR
visual I-ADR
acuity I-ADR
may O
develop O
in O
patients O
treated O
with O
pegylated B-DRUG
interferon I-DRUG

rapamycin O
/ O
sirolimus B-DRUG
( O
sr O
) O
, O
trade O
named O
rapammune O
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression O
, O
hypertension B-ADR
, O
hyperlipidemia O
, O
and O
infection O

the O
authors O
suggest O
that O
risperidone B-DRUG
may O
increase B-ADR
affect I-ADR
in O
patients O
with O
schizophrenia O
and O
that O
some O
patients O
, O
especially O
those O
with O
anxiety O
, O
may O
have O
difficulty O
managing O
the O
increase O

skin B-ADR
rash I-ADR
and O
splinter O
hemorrhages O
from O
ganciclovir B-DRUG

the O
dermatology O
literature O
heretofore O
has O
not O
noted O
that O
anemia B-ADR
is O
a O
side O
effect O
of O
patients O
taking O
mmf B-DRUG
to O
treat O
pemphigus O

we O
report O
an O
hiv-infected O
woman O
who O
developed O
mild O
leukopenia B-ADR
as O
the O
first O
sign O
of O
a O
nevirapine-related O
adverse O
event O
, O
which O
was O
followed O
by O
skin O
and O
hepatic O
toxicity O
associated O
with O
a O
more O
severe O
leukopenia B-ADR

on O
the O
fifth O
day O
after O
administration O
of O
a O
high O
dose O
of O
ara-c B-DRUG
( O
2 O
g O
/ O
m2 O
intravenously O
every O
12 O
hours O
) O
, O
she O
developed O
bullous B-ADR
lesions I-ADR
on I-ADR
the I-ADR
hands I-ADR
and I-ADR
soles I-ADR
that I-ADR
disseminated I-ADR
, I-ADR
evolving I-ADR
to I-ADR
necrosis I-ADR
, O
sepsis O
, O
and O
death O
on O
the O
22nd O
day O

the O
polycystic O
changes O
disappeared O
from O
the O
ovaries O
in O
2 O
of O
the O
women O
after O
valproate B-DRUG
therapy O
was O
discontinued O
, O
and O
the O
2 O
women O
who O
had O
gained B-ADR
weight I-ADR
and O
developed O
amenorrhea O
while O
being O
treated O
with O
valproate B-DRUG
lost O
weight O
and O
resumed O
menstruating O
after O
the O
change O
in O
medication O

nitrendipine-induced O
gingival B-ADR
hyperplasia I-ADR

this O
is O
a O
report O
of O
a O
renal O
transplant O
patient O
with O
pneumocystis O
pneumonia O
who O
developed O
chemical B-ADR
cellulitis I-ADR
and O
ulceration O
following O
the O
extravasation O
of O
intravenous O
pentamidine B-DRUG
into O
the O
soft O
tissues O
of O
the O
left O
hand O
and O
forearm O

we O
report O
a O
child O
with O
yolk O
sac O
tumor O
who O
developed O
localized B-ADR
pigmentation I-ADR
after O
the O
first O
course O
of O
chemotherapy O
regimen O
that O
included O
cisplatin B-DRUG
, O
etoposide O
and O
bleomycin O

our O
findings O
suggest O
that O
significant O
progression B-ADR
of I-ADR
marrow I-ADR
reticulin I-ADR
fibrosis I-ADR
during O
imatinib B-DRUG
therapy O
can O
be O
an O
indicator O
for O
a O
return O
or O
progression O
of O
cml O
and O
, O
in O
some O
patients O
with O
cml O
, O
imatinib B-DRUG
may O
promote O
cytogenetic O
clonal O
evolution O
, O
resulting O
in O
a O
poor O
response O
to O
treatment O

we O
describe O
a O
case O
of O
pres B-ADR
in O
a O
patient O
with O
collapsing O
focal O
glomeruloesclerosis O
( O
collapsing O
fgs O
) O
with O
complete O
recovery O
after O
withdrawal O
of O
cyclosporine O
( O
csa B-DRUG

we O
report O
the O
case O
of O
a O
60-year-old O
woman O
who O
developed O
erythema O
and O
erosions B-ADR
in I-ADR
the I-ADR
axilla I-ADR
and I-ADR
groin I-ADR
while O
on O
pld B-DRUG
for O
breast O
cancer O

objective O
: O
to O
report O
a O
case O
of O
linear O
immunoglobulin O
( O
ig O
) O
a O
bullous O
dermatosis O
( O
labd O
) O
induced O
by O
gemcitabine B-DRUG

a O
49-year-old O
man O
with O
crohn O
's O
disease O
treated O
with O
prednisone O
and O
mesalamine O
( O
5-asa B-DRUG
) O
developed O
worsening O
respiratory O
distress O
and O
fever B-ADR

two O
patients O
developed O
diabetic B-ADR
coma I-ADR
when O
taking O
a O
combination O
of O
a O
thiazide O
diuretic O
and O
propranolol B-DRUG

a O
56-year-old O
caucasian O
man O
who O
received O
concomitant O
chemotherapy O
and O
radiation O
for O
head O
and O
neck O
cancer O
developed O
fever B-ADR
concurrent O
with O
the O
administration O
of O
amifostine B-DRUG

mammary B-ADR
gigantism I-ADR
is O
a O
rare O
complication O
of O
d-penicillamine B-DRUG
treatment O

conclusions O
: O
prolonged O
exposure O
to O
itraconazole B-DRUG
, O
administered O
either O
continuously O
or O
intermittently O
, O
may O
precipitate O
severe B-ADR
and I-ADR
irreversible I-ADR
hepatotoxic I-ADR
events I-ADR

fatal B-ADR
hepatitis I-ADR
after O
long-term O
pulse O
itraconazole B-DRUG
treatment O
for O
onychomycosis O

successful O
treatment O
of O
hyperthyroidism O
with O
amiodarone O
in O
a O
patient O
with O
propylthiouracil-induced O
acute B-ADR
hepatic I-ADR
failure I-ADR

allopurinol B-DRUG
hypersensitivity B-ADR

in O
patients O
with O
swallowing O
dysfunction O
and O
pneumonia B-ADR
, O
a O
history O
of O
mineral B-DRUG
oil I-DRUG
use O
should O
be O
obtained O
and O
a O
diagnosis O
of O
elp O
should O
be O
considered O
in O
the O
differential O
diagnoses O
if O
mineral B-DRUG
oil I-DRUG
use O
has O
occurred O

esophageal B-ADR
candidiasis I-ADR
following O
omeprazole B-DRUG
therapy O
: O
a O
report O
of O
two O
cases O

we O
report O
two O
patients O
with O
infectious B-ADR
mononucleosis-like I-ADR
syndrome I-ADR
induced O
by O
salazosulfapyridine O
( O
sasp B-DRUG

this O
finding O
suggests O
that O
fluvoxamine B-DRUG
can O
precipitate O
schneiderian B-ADR
first-rank I-ADR
symptoms I-ADR
in O
some O
susceptible O
patients O

widespread O
cutaneous B-ADR
vasculitis I-ADR
associated O
with O
diltiazem B-DRUG

cardiac B-ADR
decompensation I-ADR
following O
verapamil B-DRUG
therapy O
in O
infants O
with O
supraventricular O
tachycardia O

this O
paper O
reports O
a O
case O
of O
fatal B-ADR
perhexiline I-ADR
maleate I-ADR
liver I-ADR
injury I-ADR

thirty-six O
patients O
with O
al O
received O
, O
in O
a O
three-month O
period O
, O
51 O
cycles O
of O
combined O
chemotherapy O
which O
included O
, O
in O
all O
of O
them O
, O
cytosine B-DRUG
arabinoside I-DRUG
( O
ara-c O
) O
; O
among O
them O
, O
along O
with O
myelosuppression O
, O
five O
experienced O
fever B-ADR
, O
infectious O
complications O
, O
gastrointestinal O
tract O
symptoms O
and O
severe O
myalgias O

ciprofloxacin-induced O
psychosis B-ADR

gemcitabine-induced O
pericardial B-ADR
effusion I-ADR
and O
tamponade O
after O
unblocked O
cardiac O
irradiation O

background O
: O
to O
assess O
the O
nature O
, O
incidence O
, O
and O
risk O
factors O
of O
retinopathy B-ADR
associated O
with O
pegylated O
interferon O
and O
ribavirin B-DRUG
combination O
therapy O
in O
chronic O
hepatitis O
c O
patients O

with O
the O
first O
cyclosporine B-DRUG
dose O
, O
the O
patient O
complained O
of O
leg B-ADR
pain I-ADR
that O
was O
most O
severe O
during O
the O
cyclosporine B-DRUG
infusion O

we O
describe O
3 O
cases O
of O
diphenhydramine-induced O
cardiac B-ADR
toxicity I-ADR
that O
were O
responsive O
to O
bicarbonate O

the O
observation O
of O
cutaneous B-ADR
vasculitis I-ADR
during O
administration O
of O
propylthiouracil B-DRUG
suggested O
that O
clinical O
awareness O
of O
this O
complication O
should O
be O
of O
considerable O
importance O

this O
is O
the O
first O
case O
of O
hbv B-ADR
reactivation I-ADR
occurring O
during O
the O
year O
following O
rituximab B-DRUG
monotherapy O
in O
the O
absence O
of O
any O
other O
immunosuppressive O
factor O

despite O
the O
known O
pulmonary B-ADR
side I-ADR
effects I-ADR
of O
nitrofurantoin B-DRUG
, O
there O
is O
no O
report O
of O
this O
toxicity O
occurring O
in O
pregnant O
patients O

ziprasidone B-DRUG
is O
an O
atypical O
antipsychotic O
drug O
that O
is O
believed O
to O
have O
a O
low O
propensity O
for O
inducing O
extrapyramidal O
symptoms O
, O
including O
tardive B-ADR
dyskinesia I-ADR
( O
td O

we O
report O
two O
adults O
who O
received O
gabapentin B-DRUG
( O
gbp O
) O
and O
subsequently O
developed O
behavioural B-ADR
side I-ADR
effects I-ADR

three O
years O
later O
, O
treatment O
with O
ampicillin B-DRUG
caused O
another O
episode O
of O
cholestatic B-ADR
hepatitis I-ADR
with O
cholestasis O
and O
duct O
paucity O
on O
rebiopsy O

catatonia B-ADR
associated O
with O
disulfiram B-DRUG
therapy O

renal B-ADR
failure I-ADR
after O
high-dose O
methotrexate B-DRUG
in O
a O
child O
homozygous O
for O
mthfr O
c677t O
polymorphism O

adverse O
effects O
of O
amiodarone B-DRUG
including O
pulmonary B-ADR
toxicity I-ADR
, O
hepatotoxicity O
, O
aggravation O
of O
arrhythmia O
, O
and O
thyroid O
diseases O
are O
well O
understood O

administration O
of O
pyridoxine B-DRUG
to O
an O
infant O
after O
a O
long O
period O
of O
convulsions O
was O
followed O
by O
acute B-ADR
hypotonia I-ADR

conclusion O
: O
under O
certain O
circumstances O
topical O
brimonidine B-DRUG
can O
cause O
paradoxical B-ADR
raised I-ADR
iop I-ADR
necessitating O
vigilance O
in O
follow-up O
of O
patients O
on O
topical O
brimonidine B-DRUG

a O
syndrome B-ADR
of I-ADR
increased I-ADR
affect I-ADR
in O
response O
to O
risperidone B-DRUG
among O
patients O
with O
schizophrenia O

our O
report O
suggested O
that O
cbdca B-DRUG
hypersensitivity B-ADR
was O
correlated O
with O
the O
total O
dose O
of O
previously O
administered O
platinum O
agents O
and O
that O
cbdca B-DRUG
should O
be O
excluded O
in O
patients O
who O
have O
received O
multiple O
platinum-based O
chemotherapy O
, O
even O
in O
platinum-sensitive O
cases O
, O
because O
cbdca B-DRUG
hypersensitivity B-ADR
can O
occur O
even O
with O
low-dose O
cbdca B-DRUG
administration O

massive O
plasmocytosis O
due O
to O
methimazole-induced O
bone B-ADR
marrow I-ADR
toxicity I-ADR

in O
this O
report O
, O
one O
patient O
who O
developed O
gangrene O
after O
bleomycin B-DRUG
and O
vincristine O
/ O
vinblastine O
chemotherapy O
for O
aids-related O
kaposi O
's O
sarcoma O
and O
another O
hiv-infected O
patient O
who O
exhibited O
symptoms O
of O
severe B-ADR
raynaud I-ADR
's I-ADR
phenomenon I-ADR
related O
to O
the O
same O
regimen O
are O
presented O

acute O
myopathy O
with O
selective O
degeneration B-ADR
of I-ADR
myosin I-ADR
filaments I-ADR
following O
status O
asthmaticus O
treated O
with O
methylprednisolone B-DRUG
and O
vecuronium O

case O
summaries O
: O
two O
patients O
with O
stable O
hypothyroidism O
experienced O
symptoms O
of O
hypothyroidism O
with O
increased B-ADR
serum I-ADR
thyroid-stimulating I-ADR
hormone I-ADR
( O
tsh O
) O
concentrations O
after O
switching O
from O
1 O
levothyroxine B-DRUG
product O
to O
another O

background O
: O
interferon B-DRUG
( O
ifn O
)- O
associated O
retinopathy O
is O
typically O
characterized O
by O
retinal O
hemorrhages O
and O
cotton B-ADR
wool I-ADR
spots I-ADR
at O
the O
posterior O
fundus O
, O
but O
visual O
function O
is O
usually O
maintained O

syndrome O
of O
inappropriate O
secretion O
of O
adh O
( O
siadh B-ADR
) O
following O
cisplatin B-DRUG
administration O
in O
a O
pulmonary O
adenocarcinoma O
patient O
with O
a O
malignant O
pleural O
effusion O

reversible O
methotrexate-associated O
lymphoproliferative B-ADR
disorder I-ADR
resembling O
advanced O
gastric O
cancer O
in O
a O
patient O
with O
rheumatoid O
arthritis O

a O
drug O
addict O
with O
staphylococcal O
endocarditis O
treated O
with O
methicillin B-DRUG
, O
who O
developed O
massive B-ADR
proteinuria I-ADR
and O
acute O
nephritic O
syndrome O
is O
described O

this O
is O
the O
third O
report O
of O
reversible O
hepatic B-ADR
decompensation I-ADR
associated O
with O
prolonged O
mtx B-DRUG
therapy O
in O
patients O
with O
rheumatoid O
arthritis O

she O
developed O
neurotoxicity B-ADR
with O
an O
adjustment O
dosage O
of O
valacyclovir B-DRUG
for O
a O
cutaneous O
zoster O
infection O

one O
explanation O
for O
the O
noted O
increase B-ADR
in I-ADR
the I-ADR
theophylline I-ADR
level I-ADR
is O
that O
metabolism O
occurs O
mainly O
by O
cytochrome O
p450 O
( O
cyp O
1a2 O
) O
, O
an O
enzyme O
that O
is O
known O
to O
be O
inhibited O
with O
high O
concentrations O
of O
zafirlukast B-DRUG

a O
case O
of O
a O
53-year-old O
man O
who O
developed O
acute B-ADR
pneumonitis I-ADR
after O
bleomycin O
and O
moderate O
oxygen B-DRUG
administration O
is O
presented O

overdose O
of O
magnesium B-DRUG
sulfate O
in O
combination O
with O
renal O
insufficiency O
, O
hypocalcemia O
, O
or O
compromise O
of O
intestinal O
integrity O
may O
predispose O
horses O
to O
magnesium B-ADR
toxicosis I-ADR

a O
reversible B-ADR
toxic I-ADR
liver I-ADR
damage I-ADR
was O
observed O
in O
a O
non-alcoholic O
woman O
treated O
with O
disulfiram B-DRUG

the O
purpose O
of O
this O
article O
is O
to O
present O
the O
first O
case-series O
of O
posterior B-ADR
reversible I-ADR
encephalopathy I-ADR
syndrome I-ADR
( O
pres O
) O
associated O
with O
l-asparaginase B-DRUG
treatment O

severe B-ADR
akathisia I-ADR
during O
olanzapine B-DRUG
treatment O
of O
acute O
schizophrenia O

the O
patient O
developed O
occipital B-ADR
infarcts I-ADR
and O
was O
found O
to O
have O
extremely O
elevated O
levels O
of O
ppa B-DRUG
in O
his O
blood O
and O
dialysis O
fluid O

a O
62-year-old O
woman O
treated O
with O
pranlukast B-DRUG
for O
2 O
months O
developed O
interstitial B-ADR
pneumonitis I-ADR
with O
a O
high O
fever O

cerebrovascular O
complications O
of O
l-asparaginase B-DRUG
therapy O
in O
children O
with O
leukemia O
: O
aphasia O
and O
other O
neuropsychological B-ADR
deficits I-ADR

to O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
insulin-induced O
lipohypertrophy B-ADR
with O
detailed O
histological O
examinations O

we O
report O
the O
case O
of O
a O
patient O
who O
developed O
polyserositis B-ADR
( O
pericardial O
effusion O
, O
pleural O
effusion O
, O
and O
pericarditis O
) O
after O
being O
started O
on O
clozapine B-DRUG
, O
and O
whose O
symptoms O
remitted O
upon O
discontinuation O
of O
clozapine B-DRUG

thyroid B-ADR
dysfunction I-ADR
has O
been O
reported O
in O
patients O
with O
malignant O
disease O
treated O
with O
recombinant B-DRUG
alpha I-DRUG
interferon I-DRUG

this O
report O
describes O
a O
case O
of O
flucytosine-associated O
ulcerating O
enteritis O
in O
which O
the O
small O
bowel O
x-ray O
demonstrated O
severe O
luminal O
narrowing O
, O
ulceration B-ADR
, O
and O
marked O
separation O
of O
loops O
of O
bowel O

failure O
of O
plasmapheresis O
, O
corticosteroids O
and O
thionamides O
to O
ameliorate O
a O
case O
of O
protracted O
amiodarone-induced O
thyroiditis B-ADR

a O
65-year-old O
man O
on O
warfarin B-DRUG
therapy O
with O
a O
sudden O
spontaneous O
onset O
of O
sub-conjunctival B-ADR
haematoma I-ADR
associated O
with O
bloody O
tears O
was O
assessed O
in O
the O
clinic O
following O
a O
referral O
from O
an O
optometrist O

does O
the O
use O
of O
insulin B-DRUG
in O
a O
patient O
with O
liver O
dysfunction O
increase O
water O
retention O
in O
the O
body O
, O
i.e. O
cause O
insulin B-DRUG
oedema B-ADR

without O
other O
causes O
for O
the O
hyponatremia B-ADR
, O
she O
was O
diagnosed O
with O
the O
syndrome O
of O
inappropriate O
antidiuretic O
hormone O
, O
presumably O
caused O
by O
desmopressin B-DRUG

conclusion O
: O
acetic B-DRUG
acid I-DRUG
is O
corrosive O
and O
may O
cause O
vagina B-ADR
bleeding I-ADR

the O
second O
patient O
developed O
both O
autoimmune B-ADR
thyroid I-ADR
disease I-ADR
and O
a O
refractory O
pre-patellar O
bursitis O
after O
50 O
months O
of O
ifn-beta B-DRUG
therapy O

conclusion O
: O
a O
26-year-old O
man O
with O
bipolar O
disorder O
developed O
hyperammonemia B-ADR
three O
weeks O
after O
initiating O
carbamazepine B-DRUG
therapy O

following O
discontinuation O
of O
clozapine B-DRUG
, O
she O
was O
rechallenged O
and O
again O
was O
observed O
to O
have O
seizures B-ADR

results O
: O
similar O
to O
previous O
findings O
of O
drug-induced O
vortex B-ADR
keratopathy I-ADR
, O
atovaquone B-DRUG
vortex B-ADR
keratopathy I-ADR
is O
presumably O
caused O
by O
its O
lipophilic O
properties O

possible O
mechanisms O
for O
damage B-ADR
to I-ADR
the I-ADR
urothelium I-ADR
by O
ketamine B-DRUG
are O
suggested O

in O
this O
report O
, O
we O
present O
a O
case O
of O
hypoglycaemic B-ADR
coma I-ADR
associated O
with O
sp B-DRUG
, O
an O
adverse O
reaction O
that O
is O
likely O
to O
be O
underreported O
and O
expected O
to O
occur O
with O
greater O
frequency O
as O
the O
use O
of O
sp B-DRUG
increases O

methotrexate-induced O
papular B-ADR
eruption I-ADR
following O
treatment O
of O
psoriasis O
has O
not O
been O
previously O
reported O

docetaxel-induced O
meibomian O
duct O
inflammation O
and O
blockage O
leading O
to O
chalazion B-ADR
formation O

special O
care O
should O
be O
taken O
when O
pulmonary B-ADR
symptoms I-ADR
appear O
in O
association O
with O
ticlopidine B-DRUG
treatment O

although O
the O
t-aml B-ADR
developed O
following O
oral O
etoposide B-DRUG
therapy O
, O
the O
child O
had O
previously O
received O
high-dose O
, O
multiagent O
chemotherapy O
, O
and O
rearrangement O
of O
the O
mll O
gene O
was O
not O
demonstrated O

soon O
after O
introduction O
of O
insulin B-DRUG
therapy O
, O
she O
developed O
severe B-ADR
anasarca I-ADR
, O
including O
marked O
peripheral O
oedema O
, O
ascites O
and O
pleural O
effusion O

objective O
: O
to O
report O
a O
case O
of O
significant O
hepatic B-ADR
and I-ADR
renal I-ADR
failure I-ADR
with O
the O
use O
of O
argatroban B-DRUG
in O
a O
patient O
with O
heparin-induced O
thrombocytopenia O
( O
hit O
) O
requiring O
continuous O
veno-veno O
hemodialysis O
( O
cvvhd O

the O
second O
was O
an O
82-year-old O
man O
receiving O
ticlopidine B-DRUG
for O
2 O
years O
when O
, O
during O
a O
febrile O
episode O
, O
he O
was O
found O
neutropenic B-ADR
with O
marrow O
aplasia O

peripheral B-ADR
nervous I-ADR
system I-ADR
disturbances I-ADR
caused O
by O
cytosine B-DRUG
arabinoside I-DRUG
have O
rarely O
been O
reported O

conclusion O
: O
this O
rare O
case O
of O
ptu-induced O
anca-associated B-ADR
vasculitis I-ADR
manifested O
with O
ototoxicity O
in O
combination O
with O
systemic O
involvement O

adrenal B-ADR
suppression I-ADR
in I-ADR
a I-ADR
fetus I-ADR
due O
to O
administration O
of O
methylprednisolone B-DRUG
has O
hitherto O
been O
rarely O
published O

destructive O
thyrotoxicosis O
appeared O
4-6 O
months O
after O
starting O
ifn-alpha B-DRUG
, O
followed O
by O
graves' B-ADR
hyperthyroidism I-ADR
within O
8 O
to O
11 O
months O

l-asparaginase-induced O
severe B-ADR
necrotizing I-ADR
pancreatitis I-ADR
successfully O
treated O
with O
percutaneous O
drainage O

ten O
days O
after O
itraconazole B-DRUG
was O
started O
, O
he O
developed O
paralytic O
ileus O
, O
neurogenic O
bladder O
, O
mild B-ADR
left I-ADR
ptosis I-ADR
, O
and O
absence O
of O
deep O
reflexes O
, O
with O
severe O
paralysis O
of O
the O
lower O
extremities O
and O
mild O
weakness O
of O
the O
upper O
extremities O

in O
one O
patient O
the O
vasculitis O
resolved O
after O
termination O
of O
the O
ciprofloxacin B-DRUG
therapy O
; O
in O
the O
other O
patient O
the O
ciprofloxacin-induced O
hemorrhagic O
vasculitis O
was O
superimposed O
on O
a O
severe O
forefoot O
infection O
, O
leading O
to O
progressive O
gangrene O
and O
a O
below-knee B-ADR
amputation I-ADR

we O
report O
a O
case O
of O
a O
young O
woman O
with O
sle O
and O
thrombocytopenia O
, O
who O
developed O
severe O
perspiration O
, O
headache B-ADR
, O
and O
seizure O
after O
receiving O
cyclosporine B-DRUG

this O
was O
accepted O
as O
evidence O
for O
propranolol B-DRUG
being O
the O
cause O
of O
this O
conduction B-ADR
disorder I-ADR

severe B-ADR
loss I-ADR
of I-ADR
vision I-ADR
after O
removal O
of O
cataract O
caused O
by O
intravitreal O
triamcinolone B-DRUG
in O
combination O
with O
photodynamic O
therapy O
for O
exudative O
age-related O
macular O
degeneration O

case O
summary O
: O
two O
children O
with O
attention O
deficit O
disorder O
treated O
with O
methylphenidate B-DRUG
as O
a O
simple O
drug O
developed O
fixed B-ADR
drug I-ADR
eruption I-ADR
of I-ADR
the I-ADR
scrotum I-ADR

soon O
after O
introduction O
of O
insulin B-DRUG
therapy O
, O
she O
developed O
severe O
anasarca O
, O
including O
marked O
peripheral O
oedema O
, O
ascites O
and O
pleural B-ADR
effusion I-ADR

sunburn B-ADR
may O
sometimes O
be O
a O
major O
injury O
in O
psoralen B-DRUG
users O
because O
high O
doses O
or O
inappropriate O
use O
of O
the O
drug O
may O
render O
the O
skin O
extremely O
sensitive O

the O
authors O
report O
one O
case O
of O
incomplete B-ADR
posterior I-ADR
hyaloid I-ADR
detachment I-ADR
( O
phd O
) O
following O
intravitreal O
pegaptanib B-DRUG
to O
treat O
dme O

inh B-DRUG
, O
which O
is O
a O
leading O
cause O
of O
drug B-ADR
eruptions I-ADR
in O
the O
above O
group O
of O
drugs O
was O
withdrawn O

a O
10-year-old O
girl O
with O
lennox-gastaut O
syndrome O
who O
received O
intravenous O
lorazepam B-DRUG
for O
atypical O
absence O
status O
seizures B-ADR
is O
reported O

mesalamine-induced O
hypersensitivity B-ADR
pneumonitis I-ADR

the O
wide O
use O
of O
phenytoin B-DRUG
during O
the O
recent O
tuberculosis O
epidemic O
makes O
it O
imperative O
to O
suspect O
this O
drug O
interaction O
in O
patients O
exhibiting O
clinical O
features O
that O
might O
be O
related O
to O
phenytoin B-ADR
toxicity I-ADR

methods O
: O
a O
68-year-old O
man O
developed O
intense O
conjunctival O
hyperemia O
and O
cystoid B-ADR
macula I-ADR
edema I-ADR
after O
switching O
from O
latanoprost B-DRUG
to O
bimatoprost O
9 O
months O
after O
cataract O
surgery O
in O
an O
eye O
at O
low-risk O
for O
this O
cystoid O
macular O
edema O

however O
, O
we O
recently O
saw O
two O
patients O
with O
renal O
tuberculosis O
treated O
with O
ethambutol B-DRUG
in O
whom O
visual B-ADR
loss I-ADR
from O
toxic O
optic O
neuropathies O
was O
severe O
and O
irreversible O
despite O
careful O
ophthalmological O
monitoring O
and O
prompt O
discontinuation O
of O
the O
agent O
at O
the O
first O
sign O
of O
impaired O
visual O
function O

we O
report O
a O
rare O
case O
of O
recurrent O
( O
stuttering B-ADR
) O
priapism O
in O
a O
patient O
with O
protein O
c O
deficiency O
while O
maintained O
on O
warfarin B-DRUG
therapy O

two O
patients O
treated O
with O
5-fluorouracil O
( O
5-fu B-DRUG
) O
for O
disseminated O
adenocarcinoma O
of O
the O
colon O
developed O
cerebellar O
dysfunction O
typical O
of O
5-fu B-DRUG
neurotoxicity B-ADR

a O
case O
of O
halothane B-DRUG
induced O
hepatitis B-ADR
is O
reported O
in O
a O
middle O
aged O
woman O
who O
underwent O
gastric O
surgery O
for O
morbid O
obesity O

there O
remains O
a O
paucity O
of O
information O
pertaining O
to O
alternative O
anticoagulation O
strategies O
for O
use O
during O
cardiopulmonary O
bypass O
concomitant O
with O
heparin-induced O
thrombocytopenia B-ADR
, O
especially O
in O
children O

a O
young O
patient O
experienced O
marked O
sinus B-ADR
tachycardia I-ADR
while O
smoking O
marijuana O
and O
receiving O
therapeutic O
doses O
of O
nortriptyline B-DRUG

fatal B-ADR
lung I-ADR
fibrosis I-ADR
caused O
by O
paclitaxel O
toxicity O
has O
not O
been O
reported O
in O
this O
report O
, O
we O
describe O
the O
case O
of O
a O
62-year-old O
woman O
who O
received O
six O
cycles O
of O
paclitaxel O
and O
carboplatin B-DRUG
as O
combination O
chemotherapy O
for O
advanced O
ovarian O
cancer O

delayed B-ADR
pseudocyst I-ADR
of I-ADR
the I-ADR
pancreas I-ADR
can O
be O
a O
complication O
of O
intramuscular O
l-asparaginase B-DRUG

lethargy B-ADR
in O
a O
newborn O
: O
lithium B-DRUG
toxicity O
or O
lab O
error O

after O
the O
second O
infliximab B-DRUG
infusion O
, O
he O
was O
found O
to O
have O
a O
severe B-ADR
transient I-ADR
neutropenia I-ADR
( O
0.5 O
x O
10 O
( O
9 O
)/ O
l O

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash B-ADR
, O
fever O
, O
leukopenia O
and O
positive O
anti-nuclear O
antibody O
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine O
( O
cbz B-DRUG
; O
tegretol O
) O
used O
against O
benign O
rolandic O
epilepsy O

we O
report O
a O
4-year-old O
girl O
who O
presented O
with O
acute B-ADR
bilateral I-ADR
blindness I-ADR
, O
a O
focal O
seizure O
and O
hypertension O
10 O
days O
after O
commencing O
oxybutynin B-DRUG
to O
treat O
enuresis O

because O
sumatriptan B-DRUG
can O
cause O
coronary B-ADR
artery I-ADR
vasospasm I-ADR
, O
patients O
with O
significant O
risk O
factors O
for O
coronary O
artery O
disease O
should O
be O
carefully O
evaluated O
for O
cardiovascular O
disease O
prior O
to O
the O
use O
of O
sumatriptan B-DRUG

pneumonitis B-ADR
, O
bilateral O
pleural O
effusions O
, O
echocardiographic O
evidence O
of O
cardiac O
tamponade O
, O
and O
positive O
autoantibodies O
developed O
in O
a O
43-year-old O
man O
, O
who O
was O
receiving O
long-term O
sulfasalazine B-DRUG
therapy O
for O
chronic O
ulcerative O
colitis O

results O
: O
a O
44-year-old O
man O
taking O
naproxen B-DRUG
for O
chronic O
low O
back O
pain O
and O
a O
20-year-old O
woman O
on O
oxaprozin O
for O
rheumatoid O
arthritis O
presented O
with O
tense B-ADR
bullae I-ADR
and O
cutaneous O
fragility O
on O
the O
face O
and O
the O
back O
of O
the O
hands O

caution O
is O
, O
therefore O
, O
needed O
to O
prevent O
undesired O
accumulation O
of O
tca B-DRUG
that O
may O
lead O
to O
protracted O
cushing B-ADR
's I-ADR
syndrome I-ADR

a O
woman O
38-year-old O
, O
suffering O
for O
about O
ten O
years O
from O
multiple O
sclerosis O
and O
treated O
with O
repeated O
therapy O
cycles O
of O
intrathecal O
depo-medrol B-DRUG
, O
developed O
a O
spastic B-ADR
paraparesis I-ADR
at I-ADR
the I-ADR
lower I-ADR
limbs I-ADR

when O
co-trimoxazole B-DRUG
was O
stopped O
the O
red B-ADR
cell I-ADR
aplasia I-ADR
resolved O

however O
, O
given O
the O
clinically O
significant O
result O
to O
the O
interaction O
between O
tolazoline O
and O
cimetidine B-DRUG
we O
report O
, O
the O
use O
of O
cimetidine B-DRUG
in O
tolazoline O
induced O
upper B-ADR
gastrointestinal I-ADR
hemorrhage I-ADR
should O
deserve O
more O
attention O

extensive B-ADR
forearm I-ADR
deep I-ADR
venous I-ADR
thrombosis I-ADR
following O
a O
severe O
infliximab B-DRUG
infusion O
reaction O

myoglobinuria O
and O
acute B-ADR
renal I-ADR
failure I-ADR
were O
observed O
in O
two O
patients O
with O
vasopressin-treated O
gastrointestinal O
hemorrhage O

this O
is O
the O
second O
report O
of O
acute B-ADR
lung I-ADR
injury I-ADR
and O
diffuse O
alveolar O
damage O
caused O
by O
mefloquine B-DRUG

carbamazepine B-ADR
toxicity I-ADR
induced O
by O
clarithromycin O
coadministration O
in O
psychiatric O
patients O

conclusion O
: O
we O
have O
introduced O
a O
case O
of O
anaphylaxis B-ADR
by O
calcitonin B-DRUG
that O
suggest O
an O
ige O
mediated O
hypersensitivity O
reaction O

results O
: O
we O
recently O
experienced O
a O
case O
of O
fatal O
erlotinib-induced O
ild B-ADR
, O
diagnosed O
based O
on O
clinical O
and O
radiologic O
findings O
, O
which O
occurred O
in O
a O
patient O
with O
radiation O
fibrosis O

a O
noninvasive O
method O
in O
the O
differential O
diagnosis O
of O
vecuronium-induced O
and O
magnesium-induced O
protracted B-ADR
neuromuscular I-ADR
block I-ADR
in O
a O
severely O
preeclamptic O
patient O

dipyrone O
, O
also O
known O
as O
metamizole B-DRUG
, O
is O
an O
analgesic O
and O
antipyretic O
drug O
that O
was O
banned O
by O
the O
united O
states O
food O
and O
drug O
administration O
because O
of O
its O
association O
with O
agranulocytosis B-ADR

methods O
: O
a O
patient O
who O
developed O
dramatic O
, O
permanent O
vision B-ADR
loss I-ADR
after O
a O
9-month O
course O
of O
treatment O
with O
ethambutol B-DRUG
and O
isoniazid O
for O
pulmonary O
tuberculosis O
is O
presented O

cutaneous B-ADR
vasculitis I-ADR
secondary O
to O
ramipril B-DRUG

the O
clinical O
course O
suggests O
that O
caffeine B-DRUG
, O
which O
is O
present O
in O
oolong O
tea O
, O
was O
mainly O
responsible O
for O
the O
rhabdomyolysis O
as O
well O
as O
the O
delirium O
, O
although O
severe O
hyponatremia B-ADR
has O
been O
reported O
to O
cause O
rhabdomyolysis O
on O
rare O
occasions O

in O
this O
report O
, O
two O
newborns O
with O
congenital O
heart O
anomalies O
demonstrated O
the O
harlequin B-ADR
color I-ADR
change I-ADR
, O
one O
whose O
skin O
findings O
showed O
a O
course O
related O
to O
the O
dose O
of O
systemic O
prostaglandin B-DRUG
e1 I-DRUG
, O
suggesting O
a O
possible O
association O

conclusion O
: O
alendronate B-DRUG
led O
to O
nodular O
scleritis B-ADR
and O
rechallenge O
caused O
recurrence O
of O
scleritis B-ADR

in O
this O
study O
, O
we O
report O
on O
three O
individual O
patients O
who O
received O
btx-b B-DRUG
and O
who O
subsequently O
developed O
parasympathetic B-ADR
dysfunction I-ADR
of I-ADR
the I-ADR
visual I-ADR
system I-ADR
after O
injections O
of O
btx-b B-DRUG
at O
remote O
sites O

conclusions O
: O
clinicians O
should O
be O
aware O
of O
a O
risk O
of O
serotonin O
syndrome O
with O
serious O
extrapyramidal B-ADR
reactions I-ADR
in O
patients O
receiving O
sertraline B-DRUG
or O
venlafaxine O
when O
metoclopramide O
is O
coadministered O
even O
in O
a O
single O
, O
conventional O
dose O

in O
rare O
cases O
mitomycin B-DRUG
c I-DRUG
( O
mmc O
) O
may O
induce O
cancer-associated O
hemolytic O
uremic O
syndrome O
, O
which O
is O
characterized O
by O
hemolytic B-ADR
anemia I-ADR
, O
thrombocytopenia O
and O
progressive O
renal O
failure O

we O
report O
a O
patient O
who O
developed O
heparin B-DRUG
associated O
thrombocytopenia B-ADR
during O
continuous O
arteriovenous O
haemofiltration O
and O
discuss O
its O
implications O
and O
alternative O
anticoagulant O
treatment O

the O
epivodes O
of O
nms B-ADR
occured O
under O
treatment O
with O
clozapine O
, O
risperidone B-DRUG
, O
and O
amisulpride O

a O
small O
initial O
dose O
of O
prazosin B-DRUG
ranging O
from O
0.5 O
to O
1 O
mg O
has O
been O
recommended O
to O
avoid O
the O
first-dose O
phenomenon O
characterized O
by O
a O
sudden O
and O
severe B-ADR
drop I-ADR
in I-ADR
blood I-ADR
pressure I-ADR
after O
the O
administration O
of O
the O
first O
dose O
of O
prazosin B-DRUG

proton O
mrs O
examination O
demonstrated O
a O
persistent O
lactate B-ADR
elevation I-ADR
during O
metronidazole B-DRUG
treatment O

we O
report O
the O
case O
of O
a O
patient O
who O
developed O
polyserositis O
( O
pericardial O
effusion O
, O
pleural O
effusion O
, O
and O
pericarditis B-ADR
) O
after O
being O
started O
on O
clozapine B-DRUG
, O
and O
whose O
symptoms O
remitted O
upon O
discontinuation O
of O
clozapine B-DRUG

in O
keeping O
with O
findings O
in O
the O
literature O
, O
the O
aortic B-ADR
wall I-ADR
in I-ADR
this I-ADR
case I-ADR
was I-ADR
damaged I-ADR
by O
secondary O
changes O
following O
irradiation O
and O
bleomycin B-DRUG
treatment O

this O
case O
supports O
the O
assessment O
that O
mh B-ADR
and O
diabetes O
are O
associated O
diseases O
and O
that O
cresol B-DRUG
could O
possibly O
trigger O
mh B-ADR

case O
report O
: O
we O
report O
the O
case O
of O
a O
58 O
year O
old O
patient O
who O
, O
after O
2 O
days O
of O
treatment O
with O
roxithromycin B-DRUG
and O
betamethasone O
, O
manifested O
acute B-ADR
pancreatitis I-ADR

dural B-ADR
sinus I-ADR
thrombosis I-ADR
developed O
in O
two O
children O
with O
acute O
lymphoblastic O
leukemia O
during O
induction O
treatment O
with O
vincristine O
sulfate O
, O
prednisone B-DRUG
, O
and O
asparaginase O

we O
report O
4 O
patients O
, O
2 O
on O
methylphenidate O
and O
2 O
on O
dextroamphetamine B-DRUG
who O
presented O
with O
acral O
cyanosis O
, O
livedo B-ADR
reticularis I-ADR
, O
or O
raynaud O
phenomenon O

this O
prompted O
us O
to O
suspect O
that O
ddi B-DRUG
might O
be O
responsible O
for O
fulminant B-ADR
hepatitis I-ADR
in O
all O
three O
aids O
patients O

we O
conjectured O
that O
the O
side O
effects O
of O
insulin B-DRUG
, O
such O
as O
anti-natriuresis B-ADR
and O
increased O
vascular O
permeability O
, O
might O
be O
pronounced O
in O
the O
presence O
of O
the O
hepatic O
dysfunction O
that O
accompanies O
insulin B-DRUG
insensitivity O
, O
hyperinsulinaemia O
and O
hypoalbuminaemia O

potential O
causes O
of O
methamphetamine-related O
keratitis O
can O
be O
divided O
into O
four O
categories O
resulting O
from O
( O
a O
) O
direct O
pharmacologic O
and O
physical O
effects O
of O
methamphetamine B-DRUG
; O
( O
b O
) O
the O
toxic B-ADR
effects I-ADR
of O
diluting O
or O
" O
cutting O
" O
agents O
such O
as O
lidocaine O
and O
quinine O
; O
( O
c O
) O
effects O
related O
to O
the O
route O
of O
drug O
administration O
( O
intravenous O
, O
inhalation O
, O
smoking O
) O
; O
and O
( O
d O
) O
manufacture-related O
effects O
of O
exposure O
to O
unintentional O
caustic O
contaminants O
in O
the O
final O
product O

however O
, O
there O
are O
few O
reports O
in O
the O
literature O
of O
ampicillin B-DRUG
as O
a O
cause O
of O
acute B-ADR
interstitial I-ADR
nephritis I-ADR

toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
resulted O
after O
19 O
days O
of O
treatment O
with O
5-fluorocytosine O
and O
amphotericin B-DRUG
b I-DRUG

a O
patient O
with O
generalized O
mg O
was O
effectively O
managed O
with O
mm B-DRUG
but O
developed O
cns B-ADR
lymphoma I-ADR
after O
3 O
years O
of O
treatment O

in O
the O
other O
patient O
, O
a O
78-year-old O
woman O
, O
neisseria B-ADR
mucosa I-ADR
knee I-ADR
arthritis I-ADR
occurred O
after O
a O
single O
sodium B-DRUG
hyaluronate I-DRUG
injection O

six O
of O
13 O
outpatients O
with O
schizophrenia O
who O
participated O
in O
a O
ten-week O
open O
trial O
of O
risperidone B-DRUG
had O
an O
initial O
good O
response O
to O
the O
medication O
followed O
by O
development O
of O
intolerable O
affect O
, O
including O
feelings O
of O
agitation O
and O
depression B-ADR
and O
periods O
of O
crying O
and O
insomnia O

however O
, O
there O
remain O
questions O
concerning O
whether O
these O
drugs O
, O
especially O
methimazole B-DRUG
( O
mmi O
) O
, O
may O
be O
associated O
with O
aplasia O
cutis O
congenita O
( O
acc B-ADR
) O
and O
how O
best O
to O
avoid O
impairment O
of O
fetal O
thyroid O
function O
during O
their O
use O

an O
elderly O
man O
with O
procainamide B-DRUG
hydrochloride-induced O
lupus B-ADR
syndrome I-ADR
had O
a O
circulating O
anticoagulant O
against O
factor O
xi O
and O
a O
biologic O
false-positive O
( O
bfp O
) O
test O
result O
for O
syphilis O

hypotension B-ADR
and O
sinus O
arrest O
with O
nifedipine B-DRUG
in O
pulmonary O
hypertension O

generalised B-ADR
cutaneous I-ADR
rash I-ADR
associated O
with O
ganciclovir B-DRUG
therapy O
has O
rarely O
been O
reported O
in O
literature O

retinal B-ADR
dysfunction I-ADR
and O
anterior O
segment O
deposits O
in O
a O
patient O
treated O
with O
rifabutin B-DRUG

high-dose O
intravenous O
mannitol B-DRUG
infusion O
in O
various O
clinical O
settings O
may O
result O
in O
acute O
renal O
failure O
( O
arf B-ADR

we O
report O
three O
cases O
of O
severe B-ADR
hepatotoxicity I-ADR
related O
to O
benzarone B-DRUG
, O
a O
benzofuran O
derivative O

although O
the O
movement B-ADR
disorder I-ADR
could O
not O
with O
certainty O
be O
attributed O
to O
trazodone B-DRUG
alone O
, O
the O
drug O
at O
least O
acted O
as O
an O
eliciting O
agent O

cutaneous B-ADR
sarcoidosis I-ADR
during O
interferon O
alfa O
and O
ribavirin B-DRUG
treatment O
of O
hepatitis O
c O
virus O
infection O
: O
two O
cases O

it O
is O
concluded O
that O
simultaneous O
administration O
of O
ciprofloxacin B-DRUG
and O
tazobactam O
/ O
piperacillin O
may O
cause O
marked O
thrombocytosis B-ADR

objective O
: O
to O
report O
a O
case O
of O
phenolphthalein-induced O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
( O
ten O
) O
in O
a O
patient O
maintained O
on O
several O
other O
medications O
more O
commonly O
known O
to O
be O
associated O
with O
ten O

intravenous O
cytarabine O
and O
methotrexate B-DRUG
appear O
to O
act O
synergistically O
to O
enhance O
the O
potential O
for O
central B-ADR
nervous I-ADR
system I-ADR
toxicity I-ADR

visual B-ADR
system I-ADR
side I-ADR
effects I-ADR
caused O
by O
parasympathetic O
dysfunction O
after O
botulinum B-DRUG
toxin I-DRUG
type I-DRUG
b I-DRUG
injections O

a O
58-year-old O
woman O
developed O
unilateral B-ADR
acute I-ADR
angle-closure I-ADR
glaucoma I-ADR
four O
days O
after O
the O
application O
of O
a O
patch O
of O
transdermal O
scopolamine B-DRUG
delivery O
system O
( O
transderm-v O

cerebral B-ADR
edema I-ADR
associated O
with O
gliadel B-DRUG
wafers O
: O
two O
case O
studies O

delayed O
neurotoxicity B-ADR
of O
intraventricular O
interleukin-2 B-DRUG
: O
a O
case O
report O

pulmonary B-ADR
edema I-ADR
occurred O
24 O
hours O
after O
intravenous O
ritodrine B-DRUG
therapy O
and O
10 O
hours O
after O
subcutaneous O
terbutaline O
therapy O

subsequent O
in O
vivo O
/ O
vitro O
studies O
clearly O
demonstrated O
that O
the O
neurological B-ADR
effects I-ADR
were O
due O
to O
a O
synergistic O
action O
of O
desferrioxamine O
and O
prochlorperazine B-DRUG
, O
probably O
resulting O
in O
exceptional O
fluxes O
of O
intra O
/ O
extra O
cellular O
iron O
/ O
copper O
disturbing O
noradrenergic O
and O
serotonergic O
systems O

severe B-ADR
cardiomyopathy I-ADR
following O
treatment O
with O
the O
tumour O
necrosis O
factor-alpha O
inhibitor O
adalimumab B-DRUG
for O
crohn O
's O
disease O

a O
52-year-old O
, O
white O
female O
developed O
low-grade O
fever O
, O
cough B-ADR
, O
and O
dyspnea O
after O
8 O
weeks O
treatment O
with O
sodium B-DRUG
aurothiomalate I-DRUG
for O
rheumatoid O
arthritis O

dexamethasone O
treatment O
of O
amiodarone-induced O
thyrotoxicosis B-ADR
( O
ait O
) O
with O
or O
without O
persistent O
administration O
of O
the O
drug O

objective O
: O
to O
report O
a O
case O
of O
colchicine-induced O
myopathy B-ADR
in O
a O
teenager O
with O
familial O
mediterranean O
fever O
( O
fmf O

because O
psoralens B-DRUG
sensitize O
skin O
to O
ultraviolet O
a O
light O
, O
phototoxic B-ADR
reactions I-ADR
are O
the O
most O
frequent O
adverse O
effect O
of O
this O
treatment O

we O
believe O
the O
temporal O
association O
of O
the O
abnormal B-ADR
liver I-ADR
enzymes I-ADR
in O
this O
patient O
, O
in O
the O
absence O
of O
other O
offending O
agents O
, O
argues O
strongly O
in O
favor O
of O
6-tg B-DRUG
as O
a O
cause O
of O
liver O
enzyme O
abnormalities O

allergic B-ADR
contact I-ADR
dermatitis I-ADR
to O
compound O
tincture O
of O
benzoin B-DRUG

we O
postulate O
that O
gastritis O
caused O
by O
dexamethasone O
, O
mucositis B-ADR
caused O
by O
doxorubicin B-DRUG
, O
and O
the O
unique O
anatomic O
nature O
of O
a O
meckel O
diverticulum O
may O
have O
contributed O
to O
this O
extremely O
unlikely O
and O
previously O
unreported O
event O

high-resolution O
computed O
tomography O
scan O
findings O
were O
consistent O
with O
ild B-ADR
, O
which O
was O
sufficient O
to O
diagnose O
as O
erlotinib-induced O
ild B-ADR

uveitis B-ADR
during O
treatment O
of O
disseminated O
mycobacterium O
avium-intracellulare O
complex O
infection O
with O
the O
combination O
of O
rifabutin O
, O
clarithromycin O
and O
ethambutol B-DRUG

previous O
studies O
have O
demonstrated O
the O
interaction O
of O
mtx B-DRUG
and O
a O
variety O
of O
non-steroidal O
, O
anti-inflammatory O
drugs O
( O
nsaids O
) O
with O
various O
clinical O
manifestations O
including O
acute O
renal O
failure O
, O
pancytopenia O
, O
vomiting O
, O
diarrhea O
, O
elevated O
liver O
transaminases O
, O
jaundice B-ADR
, O
mucosal O
ulcerations O
, O
and O
pyrexia O

we O
suggest O
that O
itraconazole B-DRUG
should O
be O
added O
to O
the O
list O
of O
drugs O
that O
may O
be O
responsible O
for O
a O
drug-induced O
vanishing B-ADR
bile I-ADR
duct I-ADR
syndrome I-ADR

an O
11-day-old O
infant O
became O
lethargic B-ADR
and O
apneic O
after O
a O
single O
drop O
of O
brimonidine B-DRUG

a O
52-year-old O
woman O
developed O
symmetric O
sensorimotor O
polyneuropathy O
and O
cerebellar B-ADR
syndrome I-ADR
after O
24 O
months O
of O
amiodarone B-DRUG
treatment O

we O
describe O
two O
patients O
with O
aspergillus B-ADR
arthritis I-ADR
of I-ADR
the I-ADR
knee I-ADR
joint I-ADR
following O
fludarabine-based O
non-myeloablative O
stem O
cell O
transplantation O

tacrolimus B-DRUG
( O
fk506 O
)- O
induced O
mutism B-ADR
after O
liver O
transplant O

two O
infants O
developed O
hyperkalemia B-ADR
shortly O
after O
cessation O
of O
prolonged O
acth B-DRUG
therapy O
for O
infantile O
spasms O

conclusions O
: O
the O
piloerection B-ADR
observed O
after O
the O
replacement O
of O
fluvoxamine B-DRUG
with O
milnacipran O
in O
this O
patient O
appears O
to O
have O
been O
due O
to O
an O
increase O
in O
the O
alpha O
( O
1 O
)- O
adrenoceptor O
occupancy O
by O
endogenous O
norepinephrine O
induced O
by O
milnacipran O

the O
typical O
fluoxetine-induced O
symptoms O
of O
restlessness B-ADR
, O
constant O
pacing O
, O
purposeless O
movements O
of O
the O
feet O
and O
legs O
, O
and O
marked O
anxiety O
were O
indistinguishable O
from O
those O
of O
neuroleptic-induced O
akathisia O

the O
case O
history O
and O
toxicological O
findings O
of O
an O
infant O
fatality B-ADR
involving O
pseudoephedrine B-DRUG
, O
brompheniramine O
, O
and O
dextromethorphan O
are O
presented O

we O
describe O
two O
cases O
of O
sulfadiazine-induced O
crystalluria O
and O
renal B-ADR
failure I-ADR
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
, O
review O
the O
pertinent O
literature O
, O
and O
discuss O
the O
pathogenesis O

since O
early O
symptoms O
of O
the O
toxic O
effects O
of O
theophylline B-DRUG
can O
mimic O
peptic B-ADR
ulcer I-ADR
disease I-ADR
, O
cimetidine O
might O
be O
prescribed O
for O
the O
gastrointestinal O
symptoms O
with O
subsequent O
worsening O
of O
theophylline B-DRUG
poisoning O

can O
ketamine B-DRUG
prescribed O
for O
pain O
cause O
damage B-ADR
to I-ADR
the I-ADR
urinary I-ADR
tract I-ADR

a O
toxic O
encephalopathy O
characterized O
by O
depressed B-ADR
level I-ADR
of I-ADR
consciousness I-ADR
, O
marked O
irritability O
, O
and O
ataxia O
developed O
in O
seven O
children O
, O
5 O
years O
of O
age O
and O
younger O
, O
following O
administration O
of O
an O
antiemetic O
combination O
of O
pentobarbital B-DRUG
and O
pyrilamine O
maleate O

the O
dose-limiting O
toxicity O
of O
kw-2149 B-DRUG
is O
pulmonary B-ADR
toxicity I-ADR

a O
study O
following O
large O
patient O
groups O
on O
theophylline B-DRUG
and O
a O
combination O
of O
theophylline B-DRUG
and O
steroids O
might O
clarify O
the O
risk O
of O
ulcer B-ADR
formation O
in O
patients O
being O
treated O
with O
these O
medications O
for O
asthma O

anterior B-ADR
spinal I-ADR
artery I-ADR
syndrome I-ADR
-- O
a O
complication O
of O
cervical O
intrathecal O
phenol B-DRUG
injection O

hepatitis B-ADR
with O
bridging O
fibrosis O
and O
reversible O
hepatic O
insufficiency O
in O
a O
woman O
with O
rheumatoid O
arthritis O
taking O
methotrexate B-DRUG

valvular B-ADR
heart I-ADR
disease I-ADR
in O
a O
patient O
taking O
benfluorex B-DRUG

discussion O
: O
amphotericin B-DRUG
b I-DRUG
deoxycholate I-DRUG
has O
been O
reported O
to O
produce O
significant O
cardiac O
toxicity O
, O
with O
ventricular B-ADR
arrhythmias I-ADR
and O
bradycardia O
reported O
in O
overdoses O
in O
children O
and O
in O
adults O
with O
preexisting O
cardiac O
disease O
, O
even O
when O
administered O
in O
conventional O
dosages O
and O
infusion O
rates O

it O
is O
likely O
that O
ra B-DRUG
contributed O
to O
the O
deterioration B-ADR
in I-ADR
renal I-ADR
function I-ADR
in O
these O
patients O

objective O
: O
to O
report O
the O
safe O
use O
of O
fluorouracil O
in O
a O
patient O
with O
breast O
cancer O
who O
had O
allergic B-ADR
reactions I-ADR
to O
capecitabine B-DRUG

we O
describe O
a O
patient O
with O
rheumatoid O
arthritis O
treated O
with O
gold B-DRUG
salts O
, O
who O
developed O
bilateral B-ADR
interstitial I-ADR
pulmonary I-ADR
abnormalities I-ADR
and O
showed O
a O
dramatic O
response O
on O
corticosteroid O
therapy O

although O
there O
is O
one O
case O
report O
of O
cholesterol O
crystal O
embolization O
following O
t-pa B-DRUG
therapy O
with O
only O
extrarenal B-ADR
manifestations I-ADR
( O
n O
engl O
j O
med O
321:1270 O
, O
1989 O
) O
, O
this O
is O
the O
first O
reported O
case O
of O
atheroembolic O
acute O
renal O
failure O
following O
t-pa B-DRUG
therapy O

during O
clarithromycin B-DRUG
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate-to-severe O
toxic O
symptoms O
of O
carbamazepine O
, O
such O
as O
drowsiness B-ADR
, O
dizziness O
, O
and O
ataxia O
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin B-DRUG
discontinuation O

a O
case O
of O
skeletal B-ADR
fluorosis I-ADR
induced O
by O
prolonged O
treatment O
with O
niflumic B-DRUG
acid I-DRUG
, O
a O
fast-acting O
non-steroid O
antiinflammatory O
agent O
, O
is O
reported O
in O
a O
35-year-old O
woman O
suffering O
from O
rheumatoid O
arthritis O
and O
treated O
, O
in O
addition O
, O
with O
corticosteroids O

rapamycin O
/ O
sirolimus O
( O
sr O
) O
, O
trade O
named O
rapammune B-DRUG
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression O
, O
hypertension B-ADR
, O
hyperlipidemia O
, O
and O
infection O

oncologists O
supervising O
future O
clinical O
trials O
for O
lung O
cancer O
should O
be O
alert O
to O
the O
fact O
that O
sorafenib B-DRUG
can O
potentially O
induce O
serious O
interstitial B-ADR
lung I-ADR
disease I-ADR
, O
although O
this O
might O
depend O
on O
racial O
differences O

conclusion O
: O
the O
administration O
of O
tissue B-DRUG
plasminogen I-DRUG
activator I-DRUG
was O
responsible O
for O
the O
large O
extent O
of O
hemorrhage O
and O
should O
be O
considered O
in O
the O
differential O
diagnosis O
of O
hemorrhagic B-ADR
choroidal I-ADR
detachment I-ADR

losartan-induced O
angioedema B-ADR

ovarian B-ADR
endometrioid I-ADR
carcinoma I-ADR
and O
endometriosis O
developing O
in O
a O
postmenopausal O
breast O
cancer O
patient O
during O
tamoxifen B-DRUG
therapy O
: O
a O
case O
report O
and O
review O
of O
the O
literature O

intensive O
high-flux O
hemodiafiltration O
is O
often O
used O
in O
the O
management O
of O
vancomycin B-ADR
toxicity I-ADR

we O
report O
the O
first O
case O
of O
acute B-ADR
renal I-ADR
failure I-ADR
with O
hyperkalemia O
associated O
with O
the O
recently O
marketed O
direct O
renin O
inhibitor O
aliskiren B-DRUG

results O
: O
all O
cases O
developed O
corneal B-ADR
endothelial I-ADR
deposits I-ADR
after O
previous O
use O
of O
rifabutin B-DRUG

ampicillin-induced O
interstitial O
nephritis O
with O
generalised B-ADR
exfoliative I-ADR
dermatitis I-ADR

withdrawal O
of O
depakote B-DRUG
resulted O
in O
resolution O
of O
the O
effusion B-ADR

one O
patient O
had O
a O
lower O
average O
heart O
rate O
and O
two O
patients O
had O
lower B-ADR
average I-ADR
mean I-ADR
blood I-ADR
pressure I-ADR
values O
during O
propranolol B-DRUG
treatment O
, O
none O
of O
which O
was O
clinically O
significant O

the O
case O
of O
a O
4-year-old O
girl O
with O
valproate-induced O
stupor B-ADR
and O
electroencephalographic O
pattern O
of O
increased O
fast O
activity O
is O
reported O

this O
is O
the O
first O
report O
of O
pulmonary B-ADR
hypertension I-ADR
in O
an O
adult O
patient O
during O
lithium B-DRUG
therapy O

we O
hypothesize O
that O
caffeine B-DRUG
toxicity O
injured O
the O
muscle O
cells O
, O
which O
were O
fragile O
due O
to O
the O
potassium B-ADR
depletion I-ADR
induced O
by O
the O
coexisting O
hyponatremia O
, O
to O
result O
in O
unusually O
severe O
rhabdomyolysis O

fatal B-ADR
acute I-ADR
encephalomyelitis I-ADR
after O
a O
single O
dose O
of O
intrathecal O
methotrexate B-DRUG

after O
5 O
days O
of O
treatment O
with O
il-2 B-DRUG
, O
the O
patient O
developed O
a O
hemorrhagic B-ADR
lesion I-ADR
that O
progressed O
to O
toxic O
epidermal O
necrolysis O
, O
as O
well O
as O
grade O
4 O
pancytopenia O

rifampin-associated O
thrombocytopenia B-ADR
secondary O
to O
poor O
compliance O

the O
reversal O
of O
heparin O
by O
protamine B-DRUG
may O
cause O
severe O
hemodynamic O
deterioration O
, O
characterized O
by O
systemic B-ADR
hypotension I-ADR
, O
pulmonary O
hypertension O
, O
and O
bronchoconstriction O

soon O
after O
its O
introduction O
in O
1952 O
, O
chlorpromazine B-DRUG
was O
noted O
to O
induce O
symptoms B-ADR
resembling I-ADR
parkinson I-ADR
's I-ADR
disease I-ADR

acute B-ADR
generalized I-ADR
exanthematous I-ADR
pustulosis I-ADR
induced O
by O
nimesulide B-DRUG

here O
we O
describe O
another O
case O
of O
vod B-ADR
occurring O
after O
lt O
, O
but O
in O
which O
the O
causative O
role O
was O
played O
by O
azathioprine B-DRUG

acute O
renal O
failure O
with O
severe B-ADR
tubulointerstitial I-ADR
changes I-ADR
in O
a O
patient O
with O
minimal O
change O
nephrotic O
syndrome O
treated O
with O
enalapril B-DRUG

though O
hypotension O
, O
dry O
mouth O
, O
and O
constipation O
are O
well-documented O
possible O
adverse O
effects O
, O
the O
possibility O
of O
clonidine-induced O
bradycardia B-ADR
is O
less O
well O
recognized O
and O
is O
rare O

it O
is O
thought O
that O
the O
clinico-pathological O
features O
and O
chronology O
of O
this O
case O
bore O
the O
hallmarks O
of O
the O
so-called O
" O
3-week O
sulphasalazine B-ADR
syndrome I-ADR
" O
, O
a O
rare O
, O
but O
often O
fatal O
, O
immunoallergic O
reaction O
to O
sulphasalazine B-DRUG

the O
naranjo O
probability O
scale O
suggests O
a O
highly O
probable O
relationship O
between O
ain B-ADR
and O
pantoprazole B-DRUG
therapy O
in O
this O
patient O

a O
potential O
role O
for O
renal O
and O
hepatic O
impairment O
in O
the O
observed O
protracted O
course O
of O
amiodarone-induced O
thyrotoxicosis B-ADR
is O
suggested O

the O
hiv O
protease O
inhibitor O
indinavir B-DRUG
may O
cause O
nephrolithiasis O
and O
interstitial B-ADR
nephritis I-ADR

anaphylactic B-ADR
reaction I-ADR
to O
bacitracin B-DRUG
ointment O

two O
patients O
treated O
with O
5-fluorouracil O
( O
5-fu B-DRUG
) O
for O
disseminated O
adenocarcinoma O
of O
the O
colon O
developed O
cerebellar O
dysfunction O
typical O
of O
5-fu B-DRUG
neurotoxicity B-ADR

systemic B-ADR
lupus I-ADR
erythematosus I-ADR
during O
penicillamine B-DRUG
therapy O
for O
rheumatoid O
arthritis O

antithyroid O
treatment O
with O
propylthiouracil B-DRUG
( O
ptu O
) O
resulted O
in O
elevated B-ADR
hepatic I-ADR
enzymes I-ADR
and O
after O
the O
12th O
week O
of O
pregnancy O
treatment O
was O
changed O
to O
carbimazole O
( O
cbz O

a O
patient O
with O
disseminated O
herpes O
zoster O
developed O
a O
syndrome O
of O
inappropriate O
antidiuretic O
hormone O
and O
profound O
hyponatremia B-ADR
secondary O
to O
the O
administration O
of O
adenine B-DRUG
arabinoside I-DRUG

purpose O
: O
the O
case O
of O
a O
patient O
who O
developed O
aseptic O
meningitis O
, O
hemolytic O
anemia O
, O
hepatitis B-ADR
, O
and O
orthostatic O
hypotension O
simultaneously O
during O
treatment O
with O
trimethoprim-sulfamethoxazole O
is O
described O

objective O
: O
to O
describe O
a O
patient O
with O
ifosfamide-induced O
nonconvulsive B-ADR
status I-ADR
epilepticus I-ADR

the O
development O
of O
systemic B-ADR
lupus I-ADR
erythematosus I-ADR
( O
sle O
) O
after O
38 O
months O
of O
therapy O
with O
recombinant B-DRUG
human I-DRUG
interferon I-DRUG
gamma I-DRUG
( O
rifn-gamma O
) O
was O
observed O
in O
a O
patient O
with O
rheumatoid O
arthritis O

a O
major O
limitation O
in O
the O
use O
of O
amphotericin B-DRUG
b I-DRUG
is O
its O
potential O
to O
cause O
nephrotoxicity B-ADR

trimethoprim-sulfamethoxazole-induced O
aseptic B-ADR
meningitis I-ADR

we O
report O
on O
a O
patient O
who O
developed O
acute B-ADR
rhabdomyolysis I-ADR
after O
taking O
cerivastatin B-DRUG

this O
patient O
developed O
sequential O
symptoms O
including O
alternative O
hemiparesis O
, O
dysarthria B-ADR
and O
altered O
consciousness O
5 O
days O
after O
the O
second O
course O
of O
hd-mtx B-DRUG
( O
8 O
gm O
/ O
m2 O
by O
6 O
h O
continuous O
infusion O
) O
with O
leucovorin O
rescue O

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin B-DRUG
, O
grepafloxacin O
, O
trovafloxacin O
, O
gatifloxacin O
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache O
, O
dizziness O
and O
insomnia B-ADR

study O
design O
: O
case O
reports O
are O
presented O
of O
three O
premature O
infants O
( O
mean O
gestational O
age O
27 O
weeks O
) O
cared O
for O
in O
the O
intensive O
care O
nursery O
in O
whom O
clinically O
significant O
septal B-ADR
hypertrophy I-ADR
and O
left O
ventricular O
outflow O
tract O
obstruction O
developed O
during O
dexamethasone B-DRUG
treatment O
for O
bronchopulmonary O
dysplasia O

scleromyxedema B-ADR
in O
a O
patient O
with O
multiple O
sclerosis O
and O
monoclonal O
gammopathy O
on O
interferon B-DRUG
beta-1a I-DRUG

acute O
pulmonary O
reactions O
to O
nitrofurantoin B-DRUG
are O
an O
uncommon O
side O
effect O
of O
therapy O
and O
can O
cause O
minor O
or O
life-threatening O
pulmonary B-ADR
dysfunction I-ADR

behavioral O
side O
effects O
associated O
with O
clonazepam B-DRUG
may O
include O
agitation O
, O
aggression O
, O
hyperactivity O
, O
irritability O
, O
property O
destruction O
, O
and O
temper B-ADR
tantrums I-ADR

we O
present O
a O
case O
of O
severe B-ADR
unilateral I-ADR
posterior I-ADR
scleritis I-ADR
associated O
with O
zoledronic B-DRUG
acid I-DRUG
administration O
that O
was O
recognized O
and O
treated O
in O
a O
timely O
manner O

conclusion O
: O
a O
37-year-old O
african O
- O
american O
man O
with O
g6pd O
deficiency O
developed O
hemolytic O
anemia O
, O
hepatitis B-ADR
, O
orthostatic O
hypotension O
, O
and O
aseptic O
meningitis O
simultaneously O
after O
using O
trimethoprim-sulfamethoxazole O

the O
current O
study O
investigated O
the O
visual O
fields O
and O
visual O
electrophysiology O
of O
eight O
patients O
with O
known O
vigabatrin-attributed O
visual B-ADR
field I-ADR
loss I-ADR
, O
three O
of O
whom O
were O
reported O
previously O

an O
objective O
causality O
assessment O
by O
use O
of O
the O
naranjo O
probability O
scale O
revealed O
that O
ncse B-ADR
due O
to O
ifosfamide B-DRUG
was O
probable O

this O
report O
rules O
out O
other O
causes O
of O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
and O
implicates O
ofloxacin B-DRUG
in O
what O
appears O
to O
be O
an O
atypical O
presentation O
of O
drug-induced O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR

objective O
: O
to O
present O
a O
single O
case O
of O
zuclopenthixol-induced O
priapism B-ADR
and O
a O
literature O
review O

it O
also O
highlights O
a O
current O
major O
etiologic O
question O
, O
that O
is O
, O
whether O
and O
to O
what O
degree O
lead B-DRUG
exposure O
contributes O
to O
the O
development O
of O
hypertension B-ADR
, O
and O
raises O
the O
issue O
of O
whether O
lead-induced O
hypertension B-ADR
constitutes O
a O
subset O
of O
hypertension B-ADR
that O
is O
especially O
amenable O
to O
therapy O
with O
dietary O
calcium O

an O
infant O
girl O
with O
choanal O
atresia O
, O
athelia O
, O
minor O
anomalies O
, O
and O
mild O
to O
moderate O
mental B-ADR
retardation I-ADR
was O
born O
to O
a O
woman O
treated O
for O
hyperthyroidism O
throughout O
pregnancy O
with O
methimazole B-DRUG
and O
propranolol O

case O
report O
: O
soon O
after O
initiation O
of O
amiodarone B-DRUG
hcl I-DRUG
( O
200 O
mg O
/ O
day O
) O
, O
a O
76-year-old O
man O
came O
to O
us O
with O
symptoms O
of O
visual B-ADR
" I-ADR
shining I-ADR
," O
glare O
, O
color O
vision O
anomalies O
, O
and O
gradually O
decreased O
vision O

the O
disease-modifying O
drugs O
he O
was O
taking O
, O
cyclosporin O
and O
methotrexate B-DRUG
, O
were O
stopped O
, O
and O
the O
lymphoma B-ADR
resolved O
spontaneously O
without O
the O
use O
of O
chemotherapy O

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion B-ADR
, O
agitation O
, O
tachycardia O
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

life-threatening O
hyponatremia B-ADR
caused O
by O
vinblastine B-DRUG

case O
presentation O
: O
we O
report O
a O
patient O
with O
cf O
who O
developed O
recurrent O
eosinophilia O
and O
severe B-ADR
persistent I-ADR
bronchospasm I-ADR
following O
repeated O
administration O
of O
preservative-free O
tobramycin B-DRUG
by O
inhalation O
, O
beginning O
at O
16 O
months O
of O
age O

we O
report O
a O
case O
of O
secondary O
glaucoma B-ADR
caused O
by O
epithelial O
downgrowth O
in O
which O
filtration O
surgery O
was O
performed O
with O
adjunctive O
use O
of O
subconjunctival O
5-fluorouracil B-DRUG

although O
neurotoxicity B-ADR
is O
a O
frequent O
complication O
of O
methotrexate B-DRUG
therapy O
, O
fatal O
acute O
neurotoxicity B-ADR
is O
extremely O
uncommon O
, O
especially O
in O
adults O

six O
patients O
with O
no O
previous O
signs O
or O
symptoms O
suggestive O
of O
coronary O
artery O
disease O
developed O
acute B-ADR
coronary I-ADR
ischemia I-ADR
/ O
infarction O
shortly O
after O
cis-diamine-dichloroplatinum O
ii O
( O
cisplatin B-DRUG
) O
- O
based O
chemotherapy O

a O
44-year-old O
woman O
is O
described O
in O
whom O
amiodarone O
, O
disopyramide O
, O
and O
quinidine B-DRUG
, O
administered O
alone O
separately O
, O
induced O
atypical O
ventricular O
tachycardia O
( O
avt O
, O
torsade B-ADR
de I-ADR
pointes I-ADR

pulmonary B-ADR
hemorrhage I-ADR
as O
a O
clinical O
manifestation O
of O
hemolytic-uremic O
syndrome O
associated O
with O
mitomycin B-DRUG
c I-DRUG
therapy O

zolpidem O
( O
ambien B-DRUG
) O
, O
a O
relatively O
new O
nonbenzodiazepine O
sedative-hypnotic O
, O
was O
involved O
in O
the O
death B-ADR
of O
a O
39-year-old O
obese O
male O
who O
was O
being O
treated O
for O
depression O
and O
insomnia O

a O
77-year-old O
man O
developed O
ankle B-ADR
, I-ADR
hand I-ADR
, I-ADR
and I-ADR
facial I-ADR
swelling I-ADR
2 O
weeks O
after O
starting O
rosiglitazone B-DRUG

although O
this O
combination O
agent O
has O
been O
associated O
with O
a O
hypersensitivity O
syndrome O
involving O
cutaneous B-ADR
skin I-ADR
eruptions I-ADR
, O
pediatric O
cases O
of O
tmp-smx-induced O
hepatotoxicity O
are O
rare O

spontaneous B-ADR
hemothorax I-ADR
following O
anticoagulation O
with O
low-molecular-weight O
heparin B-DRUG

here O
we O
describe O
a O
patient O
with O
crohn O
's O
disease O
who O
developed O
a O
severe O
infliximab B-DRUG
infusion O
reaction O
( O
iir B-ADR
) O
, O
complicated O
1 O
day O
later O
by O
severe O
swelling O
of O
the O
forearm O
and O
hand O
ipsilateral O
to O
the O
site O
of O
infliximab B-DRUG
infusion O

severe B-ADR
acidosis I-ADR
from O
acetazolamide B-DRUG
in O
a O
diabetic O
patient O

ibuprofen B-DRUG
overdose O
is O
usually O
characterized O
by O
gi O
upset O
, O
dizziness B-ADR
, O
and O
mild O
sedation O

a O
young O
diamond O
dealer O
developed O
visual O
impairment O
attributed O
to O
bilateral O
posterior O
subcapsular O
cataracts O
following O
only O
four O
courses O
of O
intermittent O
decadron O
used O
as O
part O
of O
a O
five-drug O
antiemetic O
regimen O
for O
cisplatin-associated O
nausea B-ADR

we O
report O
a O
case O
of O
aild O
in O
an O
80-year-old O
male O
who O
presented O
with O
a O
generalized O
pruritic O
maculopapular O
eruption O
and O
fever B-ADR
following O
doxycycline B-DRUG
administration O

in O
two O
patients O
clozapine B-DRUG
was O
reinstated O
after O
risperidone O
was O
discontinued O
; O
serum B-ADR
triglyceride I-ADR
levels I-ADR
increased I-ADR

fatal B-ADR
agranulocytosis I-ADR
in O
an O
indian O
male O
receiving O
100mg O
of O
dapsone B-DRUG
daily O
, O
hospitalized O
for O
mid-borderline O
leprosy O
in O
type O
i O
reaction O
with O
triple O
nerve O
paralysis O
is O
reported O

the O
chemotherapeutics O
, O
including O
vincristine B-DRUG
, O
actinomycin O
d O
, O
and O
epirubicin O
in O
case O
1 O
and O
vincristine B-DRUG
and O
actinomycin O
d O
in O
case O
2 O
, O
were O
given O
before O
the O
hepatotoxicity B-ADR
developed O

thus O
, O
tacrolimus-induced O
hus B-ADR
is O
a O
rare O
cause O
of O
arf O
in O
nephrotic O
syndrome O

one O
patient O
who O
received O
clindamycin B-DRUG
had O
liver O
biopsy O
findings O
of O
marked O
cholestasis O
, O
portal O
inflammation O
, O
bile O
duct O
injury O
and O
bile O
duct O
paucity O
( O
ductopenia B-ADR

nitrofurantoin-induced O
acute B-ADR
liver I-ADR
damage I-ADR
in O
pregnancy O

after O
therapy O
for O
diabetic O
coma O
with O
insulin O
( O
containing O
the O
preservative O
cresol B-DRUG
) O
and O
electrolyte O
solutions O
was O
started O
, O
the O
patient O
complained O
of O
increasing O
myalgia O
, O
developed O
a O
high B-ADR
fever I-ADR
and O
respiratory O
and O
metabolic O
acidosis O
and O
lost O
consciousness O

an O
adverse O
reaction O
to O
ifn B-DRUG
was O
strongly O
suspected O
as O
the O
cause O
of O
chf B-ADR

presentation O
of O
three O
palliative O
care O
patients O
who O
were O
given O
ketamine B-DRUG
as O
an O
analgesic O
and O
subsequently O
developed O
significant O
and O
debilitating O
urological B-ADR
symptoms I-ADR

objective O
: O
to O
report O
2 O
cases O
of O
nonconvulsive B-ADR
status I-ADR
epilepticus I-ADR
( O
ncse O
) O
following O
infusion O
of O
ifosfamide B-DRUG

painful O
neutrophilic B-ADR
skin I-ADR
lesions I-ADR
were O
observed O
in O
two O
children O
receiving O
granulocyte O
colony-stimulating O
factor O
( O
g-csf B-DRUG
) O
for O
treatment O
of O
idiopathic O
neutropenia O

case O
presentation O
: O
three O
cases O
of O
leishmania O
infantum O
leishmaniasis O
in O
corticosteroid B-DRUG
( O
cs O
)- O
treated O
patients O
are O
reported O
: O
an O
isolated O
lingual B-ADR
leishmaniasis I-ADR
in O
a O
farmer O
treated O
with O
cs O
for O
asthma O
, O
a O
severe O
visceral O
leishmaniasis O
associated O
with O
cutaneous O
lesions O
in O
a O
woman O
with O
myasthenia O
gravis O
, O
and O
a O
visceral O
involvement O
after O
cutaneous O
leishmaniasis O
in O
a O
man O
receiving O
cs O

the O
possibility O
of O
phenytoin B-DRUG
hypersensitivity O
reactions O
should O
be O
considered O
when O
patients O
receiving O
phenytoin B-DRUG
have O
unusual O
symptoms O
, O
particularly O
fever B-ADR
, O
rash O
, O
and O
lymphadenopathy O

objective O
: O
clozapine B-DRUG
causes O
few O
extrapyramidal B-ADR
symptoms I-ADR
and O
is O
recommended O
as O
a O
treatment O
drug O
for O
severe O
tardive O
dyskinesia O
( O
td O

review O
of O
this O
and O
previously O
reported O
cases O
indicates O
the O
need O
for O
early O
diagnosis O
of O
amiodarone B-DRUG
pneumonitis B-ADR
, O
immediate O
withdrawal O
of O
amiodarone B-DRUG
, O
and O
prompt O
but O
continued O
steroid O
therapy O
to O
ensure O
full O
recovery O

we O
present O
a O
case O
of O
a O
20-year-old O
woman O
who O
ingested O
900 O
mg O
of O
glyburide B-DRUG
causing O
refractory O
hypoglycemia B-ADR
resistant O
to O
treatment O
with O
intravenous O
dextrose O
, O
glucagon O
, O
and O
diazoxide O

the O
patient O
was O
positive O
for O
antibody O
against O
complexes O
of O
heparin B-DRUG
and O
platelet O
factor O
4 O
, O
and O
was O
diagnosed O
as O
heparin-induced O
thrombocytopenia B-ADR
with O
thrombosis O
syndrome O
( O
hitts O

while O
both O
amiodarone B-DRUG
and O
digoxin O
can O
cause O
permanent O
visual B-ADR
changes I-ADR
, O
the O
ocular O
effects O
are O
often O
reversible O

a O
7-year-old O
boy O
developed O
a O
severe B-ADR
unilateral I-ADR
grand I-ADR
mal I-ADR
seizure I-ADR
at O
the O
age O
of O
5 O
years O
( O
phenobarbitone O
therapy O
) O
; O
1.5 O
years O
later O
valproate O
( O
2-propylpentanoic B-DRUG
acid I-DRUG
, O
vpa O
) O
was O
added O
to O
the O
therapy O

we O
report O
a O
case O
of O
graves' B-ADR
hyperthyroidism I-ADR
induced O
by O
long-term O
interferon O
( O
ifn B-DRUG
) O
therapy O

this O
eruption B-ADR
appears O
to O
be O
a O
distinct O
cutaneous O
toxicity O
of O
pld B-DRUG

reversible B-ADR
leukopenia I-ADR
was O
documented O
in O
an O
81-year-old O
woman O
treated O
with O
adjunctive O
ibopamine B-DRUG
100 O
mg O
t.i.d. O
for O
chronic O
congestive O
heart O
failure O

interaction B-ADR
between O
tacrolimus B-DRUG
and O
nefazodone O
in O
a O
stable O
renal O
transplant O
recipient O

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate B-DRUG
with O
folinic O
acid O
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia O
, O
hyperkalaemia O
and O
hyperphosphataemia O
with O
hypocalcaemia O
and O
tetany B-ADR
, O
with O
metabolic O
acidosis O
and O
acute O
renal O
impairment O
) O
are O
described O

cutaneous B-ADR
seeding I-ADR
after O
ultrasound-guided O
percutaneous O
ethanol B-DRUG
injection I-DRUG
for O
treatment O
of O
hepatocellular O
carcinoma O

seizures O
and O
transient B-ADR
blindness I-ADR
following O
intravenous O
pulse O
methylprednisolone B-DRUG
in O
children O
with O
primary O
glomerulonephritis O

musculoskeletal B-ADR
complaints I-ADR
were O
the O
presenting O
symptoms O
in O
four O
of O
44 O
children O
( O
9 O
%) O
treated O
for O
relapsed O
wilms' O
tumors O
with O
ifosfamide B-DRUG
, O
a O
derivative O
of O
cyclophosphamide O

adenosine-induced O
ventricular B-ADR
fibrillation I-ADR

we O
present O
two O
cases O
of O
nitrofurantoin-induced O
pulmonary O
toxicity O
in O
which O
the O
initial O
hrct O
showed O
a O
widespread B-ADR
reticular I-ADR
pattern I-ADR
and O
associated O
distortion O
of O
the O
lung O
parenchyma O
, O
thought O
to O
represent O
established O
fibrosis O

most O
cardiac O
surgical O
patients O
have O
had O
previous O
exposure O
to O
heparin B-DRUG
for O
diagnostic O
or O
therapeutic O
interventions O
and O
hence O
have O
an O
increased O
susceptibility O
to O
developing O
heparin-induced O
thrombocytopenia B-ADR
( O
hit O
) O
postoperatively O

insulin-dependent B-ADR
diabetes I-ADR
mellitus I-ADR
developed O
in O
a O
young O
woman O
8 O
weeks O
after O
the O
initiation O
of O
danazol B-DRUG
for O
treatment O
of O
pelvic O
endometriosis O

ibopamine-induced O
reversible O
leukopenia B-ADR
during O
treatment O
for O
congestive O
heart O
failure O

potential O
causes O
of O
methamphetamine-related O
keratitis O
can O
be O
divided O
into O
four O
categories O
resulting O
from O
( O
a O
) O
direct O
pharmacologic O
and O
physical O
effects O
of O
methamphetamine O
; O
( O
b O
) O
the O
toxic B-ADR
effects I-ADR
of O
diluting O
or O
" O
cutting O
" O
agents O
such O
as O
lidocaine O
and O
quinine B-DRUG
; O
( O
c O
) O
effects O
related O
to O
the O
route O
of O
drug O
administration O
( O
intravenous O
, O
inhalation O
, O
smoking O
) O
; O
and O
( O
d O
) O
manufacture-related O
effects O
of O
exposure O
to O
unintentional O
caustic O
contaminants O
in O
the O
final O
product O

he O
had O
also O
developed O
elevated B-ADR
serum I-ADR
ammonia I-ADR
levels I-ADR
while O
on O
valproic B-DRUG
acid I-DRUG

primary O
cutaneous O
coccidioidomycosis O
and O
subsequent O
drug B-ADR
eruption I-ADR
to O
itraconazole B-DRUG
in O
a O
dog O

observations O
: O
a O
48-year-old O
woman O
presented O
with O
disfiguring B-ADR
facial I-ADR
edema I-ADR
10 O
weeks O
after O
she O
began O
antiviral O
therapy O
with O
peginterferon B-DRUG
alfa-2a I-DRUG
and O
ribavirin O
for O
chronic O
hepatitis O
c O
infection O

following O
7 O
days O
of O
tigecycline B-DRUG
she O
developed O
severe O
abdominal O
pain O
and O
elevated O
pancreatic O
enzymes O
suggesting O
acute B-ADR
pancreatitis I-ADR

additive B-ADR
pulmonary I-ADR
toxicity I-ADR
with O
melphalan O
and O
busulfan B-DRUG
therapy O

the O
cases O
are O
important O
in O
documenting O
that O
drug-induced O
dystonias O
do O
occur O
in O
patients O
with O
dementia O
, O
that O
risperidone B-DRUG
appears O
to O
have O
contributed O
to O
dystonia B-ADR
among O
elderly O
patients O
, O
and O
that O
the O
categorization O
of O
dystonic O
reactions O
needs O
further O
clarification O

discussion O
: O
to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
report O
illustrating O
neuralgic B-ADR
amyotrophy I-ADR
triggered O
by O
exposure O
to O
the O
antibiotics O
vancomycin O
, O
tobramycin B-DRUG
, O
and O
piperacillin O
/ O
tazobactam O

the O
administration O
of O
" O
sweet O
spirits O
of O
nitre O
" O
( O
4 B-DRUG
% I-DRUG
ethyl I-DRUG
nitrite I-DRUG
ch3ch2ono I-DRUG
in I-DRUG
70 I-DRUG
% I-DRUG
ethyl I-DRUG
alcohol I-DRUG
) O
was O
followed O
by O
acute O
methemoglobinemia O
and O
severe B-ADR
anoxic I-ADR
metabolic I-ADR
acidosis I-ADR
in O
infant O
twins O
, O
methylene O
blue O
administration O
reversed O
methemoglobinemia O
in O
both O
, O
but O
one O
twin O
died O
from O
the O
consequences O
of O
hypoxemia O

linezolid-associated O
acute O
interstitial O
nephritis O
and O
drug O
rash O
with O
eosinophilia O
and O
systemic O
symptoms O
( O
dress B-ADR
) O
syndrome O

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin B-DRUG
, O
grepafloxacin O
, O
trovafloxacin O
, O
gatifloxacin O
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache B-ADR
, O
dizziness O
and O
insomnia O

in O
this O
report O
, O
one O
patient O
who O
developed O
gangrene B-ADR
after O
bleomycin O
and O
vincristine O
/ O
vinblastine B-DRUG
chemotherapy O
for O
aids-related O
kaposi O
's O
sarcoma O
and O
another O
hiv-infected O
patient O
who O
exhibited O
symptoms O
of O
severe O
raynaud O
's O
phenomenon O
related O
to O
the O
same O
regimen O
are O
presented O

the O
reported O
cases O
of O
in O
utero O
exposure O
to O
cyclosposphamide B-DRUG
shared O
the O
following O
manifestations O
with O
our O
patient O
: O
growth O
deficiency O
, O
developmental O
delay O
, O
craniosynostosis O
, O
blepharophimosis O
, O
flat O
nasal O
bridge O
, O
abnormal O
ears O
, O
and O
distal O
limb O
defects O
including O
hypoplastic O
thumbs O
and O
oligodactyly B-ADR

pure B-ADR
red I-ADR
cell I-ADR
aplasia I-ADR
associated O
with O
fenoprofen B-DRUG

this O
report O
describes O
a O
case O
of O
bilateral B-ADR
ptosis I-ADR
induced O
by O
chloroquine B-DRUG

we O
describe O
a O
patient O
who O
developed O
hus B-ADR
after O
treatment O
with O
mitomycin B-DRUG
c I-DRUG
( O
total O
dose O
144 O
mg O
/ O
m2 O
) O
due O
to O
a O
carcinoma O
of O
the O
ascending O
colon O

data O
synthesis O
: O
genetic O
deficiencies O
in O
dpd O
, O
the O
rate-limiting O
enzyme O
responsible O
for O
5-fu B-DRUG
catabolism O
, O
may O
occur O
in O
3 O
% O
or O
more O
of O
patients O
with O
cancer O
putting O
them O
at O
increased O
risk O
for O
unusually O
severe O
adverse O
reactions O
( O
e.g. O
, O
diarrhea O
, O
stomatitis O
, O
mucositis O
, O
myelosuppression O
, O
neurotoxicity B-ADR
) O
to O
standard O
doses O
of O
5-fu B-DRUG

we O
concluded O
that O
the O
colonic O
ulcer O
and O
the O
sigmoidovesical B-ADR
fistula I-ADR
had O
been O
caused O
by O
the O
administration O
of O
calcium O
polystyrene O
sulfonate O
and O
sorbitol B-DRUG

patient O
and O
method O
: O
a O
34-year-old O
woman O
with O
chronic O
hepatitis O
c O
, O
genotype O
3 O
, O
receiving O
pegylated B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
and O
ribavirin O
for O
6 O
months O
, O
developed O
progressive B-ADR
malaise I-ADR
and O
anemia O
6 O
months O
after O
the O
end O
of O
treatment O

after O
therapy O
for O
diabetic O
coma O
with O
insulin B-DRUG
( O
containing O
the O
preservative O
cresol O
) O
and O
electrolyte O
solutions O
was O
started O
, O
the O
patient O
complained O
of O
increasing O
myalgia O
, O
developed O
a O
high O
fever O
and O
respiratory B-ADR
and I-ADR
metabolic I-ADR
acidosis I-ADR
and O
lost O
consciousness O

the O
association O
of O
venlafaxine B-DRUG
treatment O
with O
ischaemic B-ADR
events I-ADR
could O
be O
explained O
by O
its O
unique O
pharmacological O
and O
haemodynamic O
properties O

one O
patient O
required O
nursing O
home O
placement O
and O
a O
feeding B-ADR
gastrostomy I-ADR
as O
a O
result O
of O
the O
worsening O
parkinsonism O
during O
risperidone B-DRUG
treatment O
, O
but O
was O
able O
to O
return O
home O
and O
have O
the O
gastrostomy O
removed O
after O
switching O
from O
risperidone B-DRUG
to O
clozapine O

this O
article O
describes O
two O
cases O
of O
aplastic O
anemia O
, O
at O
least O
one O
of O
which O
was O
almost O
certainly O
induced O
by O
the O
use O
of O
methazolamide B-DRUG
, O
and O
one O
case O
of O
agranulocytosis B-ADR
related O
to O
the O
use O
of O
methazolamide B-DRUG

symptoms O
and O
endoscopic B-ADR
lesions I-ADR
quickly O
regressed O
within O
1 O
week O
of O
meloxicam B-DRUG
withdrawal O

although O
no O
coagulation O
study O
was O
done O
and O
the O
meckel O
's O
diverticulum O
is O
normally O
associated O
with O
bleeding O
, O
the O
particular O
intensity O
of O
the O
following O
hemorrhage B-ADR
may O
have O
been O
favored O
by O
metformin B-DRUG

acute B-ADR
renal I-ADR
failure I-ADR
in O
a O
patient O
treated O
by O
continuous O
povidone-iodine O
mediastinal O
irrigation O

selective O
estrogen O
receptor O
modulator O
raloxifene-associated O
aggravation B-ADR
of I-ADR
nonalcoholic I-ADR
steatohepatitis I-ADR

we O
describe O
a O
case O
of O
pneumonitis B-ADR
following O
local O
administration O
of O
methotrexate B-DRUG
for O
nonsurgical O
termination O
of O
an O
ectopic O
pregnancy O

a O
patient O
with O
severe B-ADR
cholestatic I-ADR
jaundice I-ADR
induced O
by O
captopril B-DRUG
is O
presented O

these O
in O
vitro O
findings O
and O
clinical O
course O
suggest O
that O
trab O
/ O
tbii O
without O
thyroid-stimulating O
activity O
may O
develop O
in O
patients O
with O
amiodarone-induced O
destructive B-ADR
thyroiditis I-ADR
, O
as O
reported O
in O
patients O
with O
destructive B-ADR
thyroiditis I-ADR
, O
such O
as O
subacute O
and O
silent O
thyroiditis O

the O
first O
patient O
developed O
mild O
nitritoid O
symptoms O
and O
pain B-ADR
in O
a O
band-like O
distribution O
, O
corresponding O
to O
t10-t12 O
dermatomes O
, O
shortly O
after O
gold B-DRUG
sodium I-DRUG
thiomalate I-DRUG
( O
gstm O
) O
injection O

propylthiouracil-induced O
sensorineural O
hearing O
loss O
associated O
with O
antineutrophil B-ADR
cytoplasmic I-ADR
antibodies I-ADR

treatment O
of O
amiodarone-induced O
thyrotoxicosis B-ADR
( O
ait O
) O
with O
thionamide O
, O
lithium O
or O
radioactive O
iodine O
is O
ineffective O

ulcer B-ADR
became I-ADR
worse I-ADR
after O
tobramycin O
and O
gentamycin B-DRUG
treatment O
for O
2 O
days O

introduction O
: O
although O
gefitinib O
used O
for O
the O
treatment O
of O
non-small-cell O
lung O
cancer O
is O
a O
well-known O
cause O
of O
interstitial O
lung O
disease O
( O
ild B-ADR
) O
, O
few O
case O
reports O
on O
erlotinib-induced O
ild B-ADR
have O
been O
issued O

case O
2 O
: O
a O
43-year-old O
male O
alcoholic O
remained O
completely O
abstinent O
with O
cyanamide B-DRUG
treatment O
for O
5 O
years O
and O
complained O
of O
general B-ADR
fatigue I-ADR

this O
increase O
when O
clozapine B-DRUG
was O
switched O
to O
risperidone O
and O
vice O
versa O
is O
consistent O
with O
our O
previous O
report O
of O
elevated B-ADR
serum I-ADR
triglyceride I-ADR
levels I-ADR
in O
clozapine-treated O
patients O

our O
findings O
reveal O
that O
even O
in O
patients O
without O
a O
history O
of O
seizures O
, O
pregabalin B-DRUG
can O
cause O
a O
cortical B-ADR
negative I-ADR
myoclonus I-ADR

retinopathy B-ADR
in O
hepatitis O
c O
patients O
due O
to O
combination O
therapy O
with O
pegylated O
interferon O
and O
ribavirin B-DRUG

this O
is O
the O
second O
report O
of O
lactic B-ADR
acidosis I-ADR
in O
a O
patient O
on O
stavudine B-DRUG
and O
lamivudine O

the O
authors O
describe O
a O
case O
of O
combined O
lithium O
and O
haloperidol B-DRUG
toxicity O
characterized O
by O
hyperpyrexia O
, O
severe O
rigidity O
, O
mutism B-ADR
, O
and O
development O
of O
irreversible O
tardive O
dyskinesia O

cardiac B-ADR
hypersensitivity I-ADR
and O
myopericarditis O
have O
been O
reported O
during O
long-term O
treatment O
with O
mesalazine B-DRUG

heparin-induced O
hyperkalemia B-ADR

protease O
inhibitor-induced O
carbamazepine B-ADR
toxicity I-ADR

unique O
behavioral B-ADR
change I-ADR
with O
cinepazide B-DRUG
in O
parkinsonism O

this O
case O
and O
a O
review O
of O
the O
literature O
show O
the O
severe O
and O
unpredictable O
nature O
of O
ethambutol B-ADR
toxicity I-ADR
and O
its O
potential O
for O
irreversible O
vision O
loss O
despite O
careful O
ophthalmologic O
monitoring O

two O
weeks O
following O
rechallenge O
with O
alendronate B-DRUG
sodium I-DRUG
resulted O
in O
recurrence O
of O
his O
scleritis B-ADR

amiodarone B-DRUG
hydrochloride I-DRUG
, O
a O
new O
antiarrhythmic O
agent O
, O
has O
been O
associated O
with O
pulmonary O
toxicity O
characterized O
by O
cough B-ADR
, O
dyspnea O
and O
diffuse O
pulmonary O
infiltrates O

we O
describe O
the O
clinical O
and O
liver O
biopsy O
morphologic O
features O
for O
4 O
patients O
with O
minocycline-induced O
autoimmune B-ADR
hepatitis I-ADR
( O
group O
1 O

after O
abstinence O
from O
oolong B-DRUG
tea I-DRUG
his O
delirium B-ADR
resolved O

post O
marketing O
studies O
of O
interferon-beta B-DRUG
( O
ifn O
beta O
) O
therapy O
in O
multiple O
sclerosis O
( O
ms O
) O
have O
demonstrated O
surprisingly O
high O
rates O
of O
hepatotoxicity B-ADR

method O
: O
case O
analysis O
of O
a O
poly-drug O
overdose O
( O
venlafaxine O
, O
topiramate O
, O
divalproex O
sodium O
, O
risperidone O
, O
and O
carbamazepine B-DRUG
) O
presenting O
with O
mixed O
ss B-ADR
/ O
nms O
features O
and O
whose O
clinical O
management O
suggests O
a O
practical O
algorithm O
for O
treatment O
of O
undifferentiated O
ss B-ADR
/ O
nms O
in O
critical O
care O
settings O

deposits B-ADR
of I-ADR
plasma I-ADR
proteins I-ADR
in I-ADR
the I-ADR
skin I-ADR
during O
treatment O
with O
carbamazepine O
and O
diphenylhydantoin B-DRUG

objective O
: O
to O
document O
a O
case O
of O
serotonin O
syndrome O
( O
ss B-ADR
) O
associated O
with O
mirtazapine B-DRUG
monotherapy O
, O
review O
the O
previously O
reported O
cases O
of O
ss B-ADR
associated O
with O
this O
tetracyclic O
antidepressant O
, O
and O
discuss O
the O
possible O
pathogenic O
mechanisms O
leading O
to O
this O
serious O
adverse O
drug O
reaction O

are O
nasal O
decongestants O
safer O
than O
rhinitis O
? O
a O
case O
of O
oxymetazoline-induced O
syncope B-ADR

the O
objective O
of O
this O
report O
is O
to O
describe O
a O
case O
of O
fixed O
drug O
eruption B-ADR
that O
occurred O
during O
omeprazole B-DRUG
treatment O

severe B-ADR
hepatitis I-ADR
caused O
by O
cyproterone B-DRUG
acetate I-DRUG

alternating B-ADR
sinus I-ADR
rhythm I-ADR
and O
intermittent O
sinoatrial O
block O
induced O
by O
propranolol B-DRUG

hydrocortisone O
may O
decrease O
the O
incidence O
of O
mortality B-ADR
associated O
with O
cardiac O
arrhythmias O
in O
children O
receiving O
amphotericin B-DRUG
b I-DRUG
overdoses O

the O
authors O
also O
determined O
that O
their O
case O
of O
myositis O
developing O
in O
the O
rectus O
abdominus O
muscle O
of O
a O
patient O
with O
pancreatic O
adenocarcinoma O
was O
the O
manifestation O
of O
radiation B-ADR
recall I-ADR
, O
thereby O
bringing O
the O
number O
of O
patients O
who O
developed O
radiation B-ADR
recall I-ADR
to O
gemcitabine B-DRUG
and O
were O
discussed O
in O
the O
current O
study O
to O
13 O

two O
cases O
of O
lepromatous O
leprosy O
with O
erythema O
nodosum O
leprosum O
who O
were O
on O
high O
doses O
of O
clofazimine B-DRUG
, O
showed O
discoloration O
of O
nail O
plate O
, O
subungual O
hyperkeratosis O
and O
onycholysis B-ADR

a O
36-year-old O
man O
being O
treated O
with O
cisplatinum O
, O
vinblastine B-DRUG
, O
and O
bleomycin O
for O
testicular O
carcinoma O
developed O
a O
dense O
left O
homonymous O
hemianopsia O
, O
encephalopathy O
, O
and O
a O
partial B-ADR
nondominant I-ADR
parietal I-ADR
lobe I-ADR
syndrome I-ADR

thrombocytosis B-ADR
induced O
by O
enoxaparin B-DRUG
has O
been O
reported O
as O
a O
rare O
adverse O
effect O
of O
this O
medication O
in O
adults O

slow O
acetylator O
genotypes O
as O
a O
possible O
risk O
factor O
for O
infectious B-ADR
mononucleosis-like I-ADR
syndrome I-ADR
induced O
by O
salazosulfapyridine B-DRUG

herein O
, O
we O
describe O
a O
patient O
with O
aids O
who O
presented O
to O
medical O
attention O
with O
pancytopenia B-ADR
48 O
months O
postchemotherapy O
with O
etoposide O
, O
prednisone B-DRUG
, O
vincristine O
, O
cyclophosphamide O
, O
doxorubicin O
, O
and O
rituximab O
( O
r-epoch O
) O
for O
diffuse O
large O
b-cell O
lymphoma O

pneumonitis O
, O
bilateral B-ADR
pleural I-ADR
effusions I-ADR
, O
echocardiographic O
evidence O
of O
cardiac O
tamponade O
, O
and O
positive O
autoantibodies O
developed O
in O
a O
43-year-old O
man O
, O
who O
was O
receiving O
long-term O
sulfasalazine B-DRUG
therapy O
for O
chronic O
ulcerative O
colitis O

according O
to O
the O
naranjo O
et O
al. O
adverse-reaction O
probability O
scale O
, O
enoxaparin B-DRUG
was O
the O
probable O
cause O
of O
hepatotoxicity B-ADR
in O
this O
patient O

our O
cases O
constitute O
the O
most O
severe O
cases O
of O
benzarone B-DRUG
hepatotoxicity B-ADR
reported O
so O
far O
, O
and O
comprise O
the O
first O
cases O
of O
( O
sub O
) O
fulminant O
hepatitis O
and O
cirrhosis O
related O
to O
benzarone B-DRUG

in O
this O
report O
, O
a O
patient O
who O
had O
undergone O
a O
renal O
transplantation O
as O
a O
result O
of O
malignant O
hypertension O
, O
and O
who O
was O
on O
immunosuppressive O
therapy O
consisting O
of O
cyclosporin B-DRUG
, O
prednisone O
and O
azathioprine O
, O
developed O
thrombosis B-ADR
of O
the O
central O
retinal O
vein O
5 O
years O
following O
the O
transplantation O

after O
induction O
of O
general O
anesthesia O
and O
administration O
of O
a O
standard O
dose O
of O
intravenous O
esmolol B-DRUG
hydrochloride I-DRUG
, O
her O
cardiac O
rhythm O
progressed O
to O
asystole B-ADR

for O
patients O
who O
suffer O
from O
osteogenic O
sarcoma O
and O
have O
anaphylactic B-ADR
reactions I-ADR
to O
mtx B-DRUG
, O
this O
desensitization O
protocol O
will O
allow O
these O
patients O
to O
continue O
with O
needed O
therapeutic O
or O
palliative O
chemotherapy O

the O
possibility O
of O
deep B-ADR
vein I-ADR
thrombosis I-ADR
caused O
by O
the O
compression O
of O
the O
veins O
by O
necrotic O
tumor O
should O
be O
considered O
in O
patients O
with O
abdominal O
or O
pelvic O
metastases O
of O
gist O
, O
including O
patients O
treated O
with O
imatinib B-DRUG

risperidone B-DRUG
withdrawal-related O
respiratory B-ADR
dyskinesia I-ADR
: O
a O
case O
diagnosed O
by O
spirography O
and O
fibroscopy O

in O
one O
case O
, O
the O
readministration O
of O
riluzole B-DRUG
was O
followed O
by O
the O
relapse O
of O
hepatitis B-ADR

bone B-ADR
marrow I-ADR
aplasia I-ADR
and O
severe O
skin O
rash O
after O
a O
single O
low O
dose O
of O
methotrexate B-DRUG

salicylate-induced O
hepatotoxicity B-ADR
is O
reviewed O

to O
our O
knowledge O
, O
these O
cases O
are O
the O
first O
published O
reports O
of O
lovastatin-induced O
rhabdomyolysis B-ADR
associated O
with O
azithromycin B-DRUG
and O
clarithromycin O

recently O
, O
cd20-negative B-ADR
tumors I-ADR
have O
been O
described O
after O
rituximab B-DRUG
therapy O

from O
1996 O
to O
2002 O
several O
medications O
were O
changed O
due O
to O
their O
adverse O
effects O
: O
indinavir B-DRUG
( O
renal O
colic O
and O
fever B-ADR
) O
, O
nelfinavir O
( O
cutaneous O
rash O
) O
, O
and O
efavirenz O
( O
nausea O
and O
temporary O
memory O
loss O

we O
have O
described O
three O
patients O
with O
hepatitis O
c O
for O
whom O
ifn-alpha O
and O
ribavirin B-DRUG
were O
prescribed O
and O
who O
developed O
two O
successive O
phases O
of O
silent O
thyroiditis O
followed O
by O
hyperthryroidism B-ADR
relapse O
due O
to O
graves' O
disease O

a O
clinically O
atypical O
, O
neuropathologically O
verified O
case O
of O
creutzfeldt-jakob B-ADR
disease I-ADR
is O
described O
in O
a O
32-year-old O
new O
zealand O
woman O
with O
idiopathic O
hypopituitarism O
who O
had O
been O
treated O
in O
late O
adolescence O
( O
1970 O
to O
1973 O
) O
with O
human B-DRUG
growth I-DRUG
hormone I-DRUG
processed O
from O
pooled O
cadaveric O
pituitary O
glands O

a O
54-year-old O
man O
, O
treated O
with O
amiodarone B-DRUG
, O
developed O
thyrotoxicosis B-ADR

primary O
cns B-ADR
lymphoma I-ADR
complicating O
treatment O
of O
myasthenia O
gravis O
with O
mycophenolate B-DRUG
mofetil I-DRUG

in O
the O
second O
case O
, O
five O
cardiac B-ADR
arrests I-ADR
due O
to O
ventricular O
tachycardia O
and O
fibrillation O
occurred O
during O
several O
hours O
after O
beginning O
a O
trial O
of O
bretylium B-DRUG
maintenance O
therapy O
for O
complex O
ventricular O
ectopy O

sodium O
phenylbutyrate O
was O
added O
to O
treatment O
with O
hu B-DRUG
in O
two O
patients O
, O
but O
failed O
to O
produce O
an O
increase O
in O
total O
hb O
despite O
increasing B-ADR
hb I-ADR
f I-ADR
levels O

he O
developed O
recurrent O
skin B-ADR
rash I-ADR
, O
fever O
, O
hypereosinophilia O
, O
and O
acute O
renal O
failure O
after O
rechallenge O
with O
chlorambucil B-DRUG

therapy O
with O
ifn-alpha B-DRUG
may O
be O
associated O
with O
a O
number O
of O
neuropsychiatric O
symptoms O
, O
such O
as O
parkinsonism O
, O
akathisia B-ADR
, O
seizure O
, O
and O
depressive O
disorders O

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate B-DRUG
with O
folinic O
acid O
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia O
, O
hyperkalaemia O
and O
hyperphosphataemia O
with O
hypocalcaemia O
and O
tetany O
, O
with O
metabolic B-ADR
acidosis I-ADR
and O
acute O
renal O
impairment O
) O
are O
described O

to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
reported O
in O
the O
english O
literature O
of O
a O
generalized B-ADR
exanthem I-ADR
due O
to O
subcutaneous O
injection O
of O
enoxaparin B-DRUG

heparin-dependent O
antibodies O
and O
thrombosis O
without O
heparin-induced O
thrombocytopenia B-ADR

after O
treatment O
with O
a O
beta-sympathomimetic O
drug O
( O
partusisten B-DRUG
) O
one O
fetus O
developed O
supraventricular B-ADR
tachycardia I-ADR

this O
is O
the O
first O
case O
, O
to O
our O
knowledge O
, O
of O
onset O
of O
prolonged O
infliximab-induced O
lupus B-ADR

in O
rare O
cases O
mitomycin O
c O
( O
mmc B-DRUG
) O
may O
induce O
cancer-associated O
hemolytic B-ADR
uremic I-ADR
syndrome I-ADR
, O
which O
is O
characterized O
by O
hemolytic O
anemia O
, O
thrombocytopenia O
and O
progressive O
renal O
failure O

a O
high O
dose O
of O
cotrimoxazole B-DRUG
induced O
hyperkalaemia O
with O
the O
elevation O
of O
serum O
creatinine O
and O
blood O
urea O
, O
and O
increased O
urinary O
n-acetyl O
glucosaminase O
after O
several O
days O
of O
the O
drug O
administration O
in O
these O
patients O
; O
one B-ADR
patient I-ADR
became I-ADR
unconscious I-ADR

therefore O
, O
amantadine B-DRUG
was O
permanently O
discontinued O
and O
the O
cornea B-ADR
cleared O
again O

fatal B-ADR
ventricular I-ADR
fibrillation I-ADR
after O
treatment O
with O
digoxin B-DRUG
in O
a O
27-year-old O
man O
with O
mitral O
leaflet O
prolapse O
syndrome O

the O
failure O
of O
therapy O
with O
disopyramide O
and O
mexiletine O
to O
reproduce O
this O
observation O
suggests O
either O
a O
previously O
unreported O
electrophysiologic B-ADR
effect I-ADR
of O
, O
or O
idiosyncratic O
response O
to O
, O
procainamide B-DRUG

hydroxyurea O
( O
hu O
) O
and O
sodium B-DRUG
phenylbutyrate I-DRUG
( O
spb O
) O
have O
been O
shown O
to O
increase B-ADR
fetal I-ADR
hemoglobin I-ADR
( O
hb O
f O
) O
levels O
in O
patients O
with O
thalassemia O
intermedia O

we O
conclude O
that O
vincristine B-DRUG
and O
actinomycin O
d O
were O
the O
cause O
of O
this O
rare O
from O
of O
hepatotoxicity B-ADR
and O
that O
chemotherapy O
for O
the O
underlying O
malignant O
disease O
could O
be O
given O
safely O
after O
clinical O
recovery O

severe O
rhabdomyolysis B-ADR
following O
massive O
ingestion O
of O
oolong B-DRUG
tea I-DRUG
: O
caffeine O
intoxication O
with O
coexisting O
hyponatremia O

conclusion O
: O
this O
case O
illustrates O
a O
potential O
link O
between O
dermatologic B-ADR
and I-ADR
ocular I-ADR
5-fu I-ADR
toxicities I-ADR

administration O
of O
excessive O
insulin B-DRUG
induced O
hypoglycemia O
within O
4 O
to O
8 O
hours O
, O
followed O
by O
rebound B-ADR
hyperglycemia I-ADR

method O
: O
the O
authors O
followed O
a O
patient O
with O
chronic O
hcv O
who O
received O
interferon O
and O
ribavirin B-DRUG
and O
who O
developed O
hallucinations B-ADR
ultimately O
requiring O
psychiatric O
hospitalization O

the O
diagnosis O
of O
hypothermia B-ADR
was O
delayed O
until O
it O
was O
apparent O
for O
several O
days O
but O
resolved O
with O
the O
discontinuation O
of O
risperidone B-DRUG
and O
continuation O
of O
clozapine O

the O
most O
common O
side O
effects O
associated O
with O
amifostine B-DRUG
are O
nausea O
, O
vomiting O
, O
hypotension O
, O
hypocalcemia O
and O
allergic B-ADR
reactions I-ADR

although O
this O
combination O
agent O
has O
been O
associated O
with O
a O
hypersensitivity B-ADR
syndrome I-ADR
involving O
cutaneous O
skin O
eruptions O
, O
pediatric O
cases O
of O
tmp-smx-induced O
hepatotoxicity O
are O
rare O

intraventricular O
vancomycin-induced O
cerebrospinal B-ADR
fluid I-ADR
eosinophilia I-ADR
: O
report O
of O
two O
patients O

we O
report O
on O
a O
child O
with O
fatal O
valproate-related O
hepatotoxic B-ADR
effects I-ADR
despite O
this O
supplementation O

we O
describe O
a O
case O
of O
prolonged O
terbinafine-induced O
cholestatic B-ADR
liver I-ADR
disease I-ADR

it O
should O
be O
recognized O
that O
ibuprofen O
may O
be O
associated O
with O
salt B-ADR
and I-ADR
water I-ADR
retention I-ADR
in O
the O
same O
fashion O
as O
previously O
described O
with O
phenylbutazone O
and O
indomethacin B-DRUG

myelodysplasia O
terminating O
in O
acute B-ADR
myeloid I-ADR
leukemia I-ADR
in O
a O
hairy O
cell O
leukemia O
patient O
treated O
with O
2-deoxycoformycin B-DRUG

fludarabine O
induced O
lung O
toxicity O
must O
be O
considered O
in O
all O
patients O
who O
develop O
unexplained O
lung B-ADR
disease I-ADR
while O
receiving O
fludarabine B-DRUG

management O
of O
hypophosphatemia O
induced O
by O
high-flux O
hemodiafiltration O
for O
the O
treatment O
of O
vancomycin B-ADR
toxicity I-ADR
: O
intravenous O
phosphorus O
therapy O
versus O
use O
of O
a O
phosphorus-enriched O
dialysate O

cushing B-ADR
's I-ADR
syndrome I-ADR
persisted O
more O
than O
6 O
months O
while O
tca B-DRUG
concentrations O
remained O
detectable O
for O
at O
least O
80 O
days O

neurologic B-ADR
symptoms I-ADR
resolved O
after O
stopping O
cap B-DRUG
for O
4 O
weeks O
in O
patient O
a O
, O
with O
no O
recurrence O
after O
reinitiating O
cap B-DRUG
alone O
at O
2000 O
mg O
/ O
m2 O

we O
present O
the O
case O
of O
a O
58-year-old O
woman O
who O
ingested O
more O
than O
35 O
g O
of O
caffeine B-DRUG
in O
a O
suicide B-ADR
attempt I-ADR

pulmonary B-ADR
oedema I-ADR
after O
hexoprenaline B-DRUG
administration O
in O
preterm O
labour O

halothane B-DRUG
hepatitis B-ADR
and O
prompt O
resolution O
with O
methionine O
therapy O
: O
case O
report O

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity O
reactions O
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general B-ADR
erythema I-ADR
, O
dyspnea O
, O
and O
hypotension O
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal O
pain O
, O
general B-ADR
erythema I-ADR
, O
and O
fever O

behavioral O
side O
effects O
associated O
with O
clonazepam B-DRUG
may O
include O
agitation B-ADR
, O
aggression O
, O
hyperactivity O
, O
irritability O
, O
property O
destruction O
, O
and O
temper O
tantrums O

eleven O
days O
after O
initiation O
of O
therapy O
with O
amiodarone B-DRUG
, O
the O
patient O
experienced O
syncope O
and O
was O
noted O
to O
have O
recurrent O
episodes O
of O
polymorphous B-ADR
ventricular I-ADR
tachycardia I-ADR

retinoic B-DRUG
acid I-DRUG
may O
increase O
the O
risk O
of O
bone B-ADR
marrow I-ADR
transplant I-ADR
nephropathy I-ADR

continuous O
eeg O
monitoring O
is O
helpful O
in O
managing O
seizures B-ADR
that O
occur O
as O
a O
complication O
of O
cbz B-DRUG
od O
, O
after O
the O
course O
of O
recovery O
or O
worsening O
, O
and O
in O
providing O
assistance O
with O
prognosis O

patient O
and O
method O
: O
a O
34-year-old O
woman O
with O
chronic O
hepatitis O
c O
, O
genotype O
3 O
, O
receiving O
pegylated O
interferon O
alpha-2a O
and O
ribavirin B-DRUG
for O
6 O
months O
, O
developed O
progressive O
malaise O
and O
anemia B-ADR
6 O
months O
after O
the O
end O
of O
treatment O

the O
case O
demonstrates O
that O
hypersensitivity B-ADR
reaction I-ADR
to O
pranlukast B-DRUG
and O
resultant O
atin O
is O
possible O
, O
and O
that O
periodic O
urine O
testing O
in O
patients O
receiving O
pranlukast B-DRUG
should O
be O
considered O

in O
conclusion O
, O
this O
case O
strongly O
suggests O
that O
gliclazide B-DRUG
can O
induce O
acute B-ADR
icteric I-ADR
liver I-ADR
necro-inflammation I-ADR
which O
may O
be O
misdiagnosed O
clinically O
as O
acute O
viral O
hepatitis O

in O
case O
1 O
, O
a O
total O
daily O
dose O
of O
25 O
mg O
sertraline B-DRUG
, O
with O
nondetectable O
sertraline B-DRUG
and O
desmethylsertraline O
blood O
levels O
, O
resulted O
in O
a O
doubling O
of O
the O
lamotrigine O
blood O
level O
with O
symptoms B-ADR
of I-ADR
toxicity I-ADR

this O
case O
report O
describes O
a O
patient O
who O
was O
previously O
prescribed O
alendronate O
( O
fosamax B-DRUG
) O
and O
presented O
with O
postoperative O
hypophosphatemia O
and O
hypocalcemic B-ADR
tetany I-ADR
after O
bowel O
preparation O
with O
fleet O
phospho-soda O

rapidly O
developing O
hyperglycemia B-ADR
during O
treatment O
with O
olanzapine B-DRUG

acute B-ADR
vision I-ADR
loss I-ADR
after O
intravitreal O
injection O
of O
bevacizumab B-DRUG
( O
avastin O
) O
associated O
with O
ocular O
ischemic O
syndrome O

the O
cause O
of O
his O
bleeding O
was O
a O
severe B-ADR
thrombocytopoaenia I-ADR
, O
induced O
by O
chronic O
ingestion O
of O
quinine B-DRUG

diarrhoea B-ADR
, O
t-cd4 O
+ O
lymphopenia O
and O
bilateral O
patchy O
pulmonary O
infiltrates O
developed O
in O
a O
male O
60 O
yrs O
of O
age O
, O
who O
was O
treated O
with O
oxaliplatinum O
and O
5-fluorouracil B-DRUG
for O
unresectable O
rectum O
carcinoma O

she O
was O
placed O
on O
adjuvant O
adriamycin O
( O
doxorubicin B-DRUG
) O
chemotherapy O
, O
but O
6 O
months O
later O
died O
of O
adriamycin B-ADR
toxicity I-ADR

he O
had O
been O
taking O
trimethoprim-sulfamethoxazole O
for O
approximately O
eight O
days O
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches B-ADR
, O
dizziness O
, O
difficulty O
with O
speech O
, O
weakness O
, O
and O
itching O
on O
the O
trunk O
of O
his O
body O
and O
legs O
, O
where O
a O
maculopapular O
rash O
was O
noted O

interstitial B-ADR
lung I-ADR
disease I-ADR
( O
ild O
) O
related O
to O
therapy O
with O
the O
drug O
gefitinib B-DRUG
has O
been O
well O
reported O

controversy O
concerning O
the O
nephrotoxicity O
of O
lithium B-DRUG
is O
discussed O
, O
and O
recommendations O
for O
the O
evaluation O
of O
renal B-ADR
failure I-ADR
during O
lithium B-DRUG
therapy O
are O
provided O

two O
65-year-old O
white O
men O
with O
coronary O
heart O
disease O
, O
given O
niacin B-DRUG
therapy O
for O
dyslipidemia O
for O
5 O
months O
, O
developed O
intense B-ADR
dental I-ADR
and I-ADR
gingival I-ADR
pain I-ADR
that O
was O
associated O
with O
increases O
in O
dose O
and O
that O
was O
relieved O
with O
discontinuance O
of O
niacin B-DRUG
treatment O

conclusions O
: O
cicatrization O
in O
the O
substantia O
propria O
of O
the O
conjunctiva O
by O
excessive O
lymphocytic O
infiltration O
after O
topically O
administered O
antiglaucoma O
drugs O
including O
dipivefrin B-DRUG
is O
a O
possible O
mechanism O
of O
action O
for O
entropion B-ADR

caution O
in O
longterm O
usage O
and O
early O
recognition O
of O
pentazocine B-DRUG
toxicity O
as O
a O
neuromuscular O
complication O
are O
important O
in O
order O
to O
prevent O
irreversible O
drug-induced O
fibrous O
myopathy O
and O
localized O
neuropathy B-ADR

the O
authors O
report O
a O
case O
of O
balint B-ADR
syndrome I-ADR
with O
irreversible O
posterior O
leukoencephalopathy O
on O
mri O
following O
intrathecal O
methotrexate O
and O
cytarabine B-DRUG

acute O
nitrite B-ADR
toxicity I-ADR
results O
from O
industrial O
exposure O
, O
accidental O
ingestion O
( O
e.g. O
, O
abuse O
of O
organic O
nitrites O
as O
an O
aphrodisiac O
, O
especially O
in O
the O
male O
homosexual O
population O
) O
, O
and O
suicidal O
ingestion O

nail-changes B-ADR
induced O
by O
penicillamine B-DRUG

purpose O
: O
the O
aim O
of O
this O
study O
was O
to O
report O
on O
the O
possible O
development O
of O
corneal B-ADR
endothelial I-ADR
deposits I-ADR
resulting O
from O
the O
use O
of O
rifabutin B-DRUG

danazol B-DRUG
induced O
thrombocytopenia B-ADR

in O
case O
no O
. O
2 O
, O
the O
pathogenic O
mechanism O
seemed O
to O
be O
persistent O
light O
reaction O
preceded O
by O
systemic O
photoallergy O
, O
as O
he O
had O
taken O
mequitazine B-DRUG
for O
6 O
months O
, O
and O
there O
were O
strong O
positive O
photopatch O
test O
results O
with O
immediate O
erythema O
reaction O
, O
cross-reaction B-ADR
to I-ADR
promethazine I-ADR
, O
decreased O
med O
to O
both O
uva O
and O
uvb O
, O
and O
persistence O
of O
the O
photosensitivity O
over O
a O
3-year O
follow-up O
period O
after O
discontinuation O
of O
the O
mequitazine B-DRUG

decreased B-ADR
plasma I-ADR
cortisol I-ADR
level I-ADR
during O
alprazolam B-DRUG
treatment O
of O
panic O
disorder O
: O
a O
case O
report O

the O
fourth O
patient O
showed O
rls B-ADR
symptoms I-ADR
that O
were O
initially O
caused O
by O
a O
20-mg O
daily O
olanzapine B-DRUG
dosage O
and O
were O
later O
mitigated O
when O
olanzapine B-DRUG
was O
reduced O
and O
ropinirole O
was O
administered O

in O
this O
report O
, O
we O
describe O
a O
patient O
receiving O
lenalidomide B-DRUG
in O
whom O
dyspnea O
, O
fever O
, O
hypoxia O
, O
and O
diffuse B-ADR
pulmonary I-ADR
infiltrates I-ADR
developed O

a O
53-year-old O
man O
developed O
nms B-ADR
without O
rigidity O
while O
taking O
olanzapine B-DRUG

so O
far O
, O
few O
cases O
of O
pulmonary B-ADR
side I-ADR
effects I-ADR
caused O
by O
ticlopidine B-DRUG
have O
been O
reported O

cephalosporin-induced O
leukopenia B-ADR
following O
rechallenge O
with O
cefoxitin O

we O
present O
a O
fatal O
case O
of O
subacute O
methanol B-DRUG
toxicity O
with O
associated O
diffuse O
brain O
involvement O
, O
including O
bilateral O
putaminal O
necrosis O
and O
cerebral O
edema O
with O
ventricular B-ADR
compression I-ADR

we O
report O
a O
patient O
who O
developed O
acute B-ADR
pancreatitis I-ADR
during O
amiodarone B-DRUG
therapy O

anastrozole-associated O
sclerosing B-ADR
glomerulonephritis I-ADR
in O
a O
patient O
with O
breast O
cancer O

data O
synthesis O
: O
genetic O
deficiencies O
in O
dpd O
, O
the O
rate-limiting O
enzyme O
responsible O
for O
5-fu B-DRUG
catabolism O
, O
may O
occur O
in O
3 O
% O
or O
more O
of O
patients O
with O
cancer O
putting O
them O
at O
increased O
risk O
for O
unusually O
severe O
adverse O
reactions O
( O
e.g. O
, O
diarrhea O
, O
stomatitis O
, O
mucositis B-ADR
, O
myelosuppression O
, O
neurotoxicity O
) O
to O
standard O
doses O
of O
5-fu B-DRUG

like O
other O
atypical O
neuroleptics O
olanzapine B-DRUG
is O
considered O
to O
show O
a O
reduced O
prevalence O
of O
extrapyramidal B-ADR
side I-ADR
effects I-ADR
when O
compared O
to O
classical O
neuroleptic O
drugs O

dorzolamide-induced O
choroidal B-ADR
detachment I-ADR
in O
a O
surgically O
untreated O
eye O

gold O
nephropathy O
due O
to O
auranofin O
obscured O
by O
tolmetin B-DRUG
pseudoproteinuria B-ADR

a O
74-year-old O
man O
received O
oral O
administration O
of O
pilsicainide B-DRUG
, O
a O
pure O
sodium O
channel O
blocker O
with O
slow O
recovery O
kinetics O
, O
to O
convert O
paroxysmal O
atrial O
fibrillation O
to O
sinus O
rhythm O
and O
developed O
loss B-ADR
of I-ADR
consciousness I-ADR
two O
days O
later O

in O
this O
report O
, O
two O
cases O
of O
et O
which O
evolved O
into O
al B-ADR
without O
prior O
exposure O
to O
radiation O
or O
alkylating O
agents O
, O
and O
which O
were O
treated O
with O
long-term O
hydroxyurea B-DRUG
therapy O
, O
are O
described O

metabolic B-ADR
acidosis I-ADR
induced O
by O
acetazolamide B-DRUG

two O
patients O
treated O
for O
chronic O
myeloid O
leukemia O
with O
high O
doses O
of O
ccnu B-DRUG
( O
1100 O
mg O
/ O
m2 O
and O
1240 O
mg O
/ O
m2 O
, O
respectively O
) O
developed O
a O
fatal B-ADR
pulmonary I-ADR
fibrosis I-ADR

purpose O
: O
to O
report O
a O
case O
of O
angiographically O
documented O
cystoid B-ADR
macula I-ADR
edema I-ADR
occurring O
after O
switching O
a O
pseudophakic O
patient O
from O
latanoprost B-DRUG
to O
bimatoprost O

in O
this O
case O
, O
it O
was O
suspected O
that O
a O
combination O
of O
cigarette O
smoking O
, O
pulmonary O
fibrosis O
, O
and O
low-dose O
methotrexate B-DRUG
therapy O
might O
have O
promoted O
the O
development O
of O
lung B-ADR
cancer I-ADR

we O
describe O
a O
patient O
with O
a O
liver O
abscess O
due O
to O
entamoeba O
histolytica O
, O
in O
whom O
metronidazole B-DRUG
therapy O
( O
total O
dose O
, O
21 O
g O
over O
14 O
days O
) O
was O
complicated O
by O
reversible B-ADR
deafness I-ADR
, O
tinnitus O
, O
and O
ataxia O
and O
who O
relapsed O
5 O
months O
later O
with O
a O
splenic O
abscess O

pulmonary O
eosinophilia O
or O
granulomas O
, O
classically O
seen O
in O
previously O
reported O
cases O
of O
methotrexate B-DRUG
pneumonitis B-ADR
, O
were O
not O
observed O

four O
chinese O
female O
patients O
who O
suffered O
from O
manic-depressive O
disorder O
and O
underlying O
autoimmune O
thyroiditis O
developed O
transient O
episodes O
of O
thyrotoxicosis B-ADR
during O
maintenance O
lithium B-DRUG
therapy O

a O
young O
woman O
developed O
galactorrhea B-ADR
during O
treatment O
with O
a O
new O
dibenzoxazepine O
antidepressant O
, O
amoxapine B-DRUG

case O
presentation O
: O
we O
report O
a O
patient O
with O
cf O
who O
developed O
recurrent B-ADR
eosinophilia I-ADR
and O
severe O
persistent O
bronchospasm O
following O
repeated O
administration O
of O
preservative-free O
tobramycin B-DRUG
by O
inhalation O
, O
beginning O
at O
16 O
months O
of O
age O

we O
describe O
a O
15-year-old O
female O
patient O
diagnosed O
with O
acute B-ADR
lymphoblastic I-ADR
leukemia I-ADR
presenting O
with O
status O
epilepticus O
after O
receiving O
intrathecal O
methotrexate B-DRUG

objectives O
: O
to O
describe O
the O
presentation O
and O
treatment O
of O
acute O
isoniazid O
( O
inh B-DRUG
) O
neurotoxicity B-ADR
appearing O
at O
an O
inner-city O
municipal O
hospital O

we O
describe O
the O
development O
of O
ischemic O
colitis O
in O
a O
woman O
who O
was O
treated O
with O
tegaserod B-DRUG
and O
review O
the O
relationship O
among O
ischemic O
colitis O
, O
tegaserod B-DRUG
use O
, O
and O
irritable B-ADR
bowel I-ADR
syndrome I-ADR

reversal O
of O
severe O
methanol-induced O
visual B-ADR
impairment I-ADR
: O
no O
evidence O
of O
retinal O
toxicity O
due O
to O
fomepizole O

administration O
of O
lamotrigine B-DRUG
, O
especially O
in O
combination O
with O
valproic O
acid O
, O
may O
lead O
to O
the O
development O
of O
ten B-ADR

while O
both O
amiodarone O
and O
digoxin B-DRUG
can O
cause O
permanent O
visual O
changes O
, O
the O
ocular B-ADR
effects I-ADR
are O
often O
reversible O

three O
cases O
of O
gold-related O
neuropathy B-ADR
are O
reported O

the O
authors O
think O
that O
although O
lamivudine B-DRUG
is O
widely O
used O
and O
well O
tolerated O
, O
it O
can O
cause O
adrs B-ADR
, O
which O
are O
reversible O
after O
drug O
withdrawal O

the O
main O
side-effects O
of O
lp-tae B-DRUG
combined O
with O
ht O
were O
low-grade O
fever O
, O
localized O
pain O
, O
myelo-suppression B-ADR
and O
liver O
dysfunction O
, O
but O
these O
were O
transient O
and O
eventually O
disappeared O

physicians O
should O
be O
aware O
of O
the O
risk O
of O
severe O
aiha O
in O
cll O
patients O
with O
a O
history O
of O
aiha O
or O
positivation B-ADR
of I-ADR
the I-ADR
dat I-ADR
during O
previous O
fludarabine B-DRUG
administration O
, O
or O
in O
case O
of O
secondary O
fixation O
of O
complement O
to O
the O
red O
cell O
membrane O
occurring O
during O
fludarabine B-DRUG
treatment O

we O
report O
the O
case O
of O
a O
young O
healthy O
woman O
who O
presented O
an O
early O
overanticoagulation B-ADR
when O
receiving O
acenocoumarol B-DRUG
for O
a O
first O
thromboembolic O
episode O

the O
reported O
cases O
of O
in O
utero O
exposure O
to O
cyclosposphamide B-DRUG
shared O
the O
following O
manifestations O
with O
our O
patient O
: O
growth O
deficiency O
, O
developmental B-ADR
delay I-ADR
, O
craniosynostosis O
, O
blepharophimosis O
, O
flat O
nasal O
bridge O
, O
abnormal O
ears O
, O
and O
distal O
limb O
defects O
including O
hypoplastic O
thumbs O
and O
oligodactyly O

hydroxyurea B-DRUG
( O
hu O
) O
and O
sodium O
phenylbutyrate O
( O
spb O
) O
have O
been O
shown O
to O
increase B-ADR
fetal I-ADR
hemoglobin I-ADR
( O
hb O
f O
) O
levels O
in O
patients O
with O
thalassemia O
intermedia O

due O
to O
the O
increasing O
use O
of O
tmp-smx B-DRUG
in O
children O
, O
clinicians O
should O
be O
aware O
of O
this O
potentially O
life-threatening O
, O
immunemediated B-ADR
hypersensitivity I-ADR
reaction I-ADR

we O
report O
on O
a O
patient O
with O
subarachnoid O
haemorrhage O
who O
developed O
an O
acute O
life-threatening O
pseudo-obstruction O
of O
the O
colon O
, O
a O
variant O
of O
adynamic B-ADR
ileus I-ADR
, O
while O
being O
treated O
with O
intravenous O
nimodipine B-DRUG

elevated B-ADR
serum I-ADR
triglycerides I-ADR
with O
clozapine B-DRUG
resolved O
with O
risperidone O
in O
four O
patients O

ten O
days O
after O
itraconazole B-DRUG
was O
started O
, O
he O
developed O
paralytic B-ADR
ileus I-ADR
, O
neurogenic O
bladder O
, O
mild O
left O
ptosis O
, O
and O
absence O
of O
deep O
reflexes O
, O
with O
severe O
paralysis O
of O
the O
lower O
extremities O
and O
mild O
weakness O
of O
the O
upper O
extremities O

portal B-ADR
vein I-ADR
thrombosis I-ADR
in O
a O
patient O
with O
severe O
haemophilia O
a O
and O
f O
v O
g1691a O
mutation O
during O
continuous O
infusion O
of O
f B-DRUG
viii I-DRUG
after O
intramural O
jejunal O
bleeding O
-- O
successful O
thrombolysis O
under O
heparin O
therapy O

it O
is O
concluded O
that O
the O
aforementioned O
pathological O
manifestations O
were O
due O
to O
chemotherapy O
and O
included O
a O
pulmonary B-ADR
adverse I-ADR
reaction I-ADR
, O
a O
feature O
never O
previously O
associated O
with O
oxaliplatinum B-DRUG
and O
5-fluorouracil O
regimens O

we O
describe O
longitudinal O
diffusion-weighted O
mri O
findings O
of O
sub-acute B-ADR
leukoencephalopathy I-ADR
following O
methotrexate B-DRUG
therapy O
in O
a O
24-year-old O
man O
diagnosed O
with O
pre-b-cell O
acute O
lymphoblastic O
leukemia O
( O
all O
) O
, O
presenting O
with O
right-sided O
paralysis O
and O
aphasia O
after O
second O
consolidation O
with O
intrathecal O
triple-drug O
therapy O
given O
intrathecally O

seizures B-ADR
associated O
with O
fluoxetine B-DRUG
therapy O

in O
addition O
, O
a O
31-year-old O
man O
with O
obsessive-compulsive O
disorder O
developed O
rbd B-ADR
soon O
after O
starting O
fluoxetine B-DRUG
therapy O
, O
which O
persisted O
at O
psg O
study O
19 O
months O
after O
fluoxetine B-DRUG
discontinuation O

conclusions O
: O
we O
report O
this O
case O
of O
the O
concomitant O
appearance O
of O
multiple B-ADR
skin I-ADR
cancers I-ADR
and O
nail O
changes O
associated O
with O
hydroxyurea B-DRUG
use O

flecainide B-DRUG
overdose O
can O
rapidly O
result O
in O
profound O
cardiovascular B-ADR
collapse I-ADR
, O
and O
is O
associated O
with O
a O
relatively O
high O
mortality O

we O
describe O
a O
patient O
who O
experienced O
chronic B-ADR
nausea I-ADR
and O
an O
episode O
of O
confusion O
while O
treated O
with O
a O
small O
, O
stable O
dose O
of O
oral O
morphine B-DRUG
in O
the O
setting O
of O
mild O
renal O
insufficiency O

ticlopidine B-DRUG
is O
an O
oral O
antiplatelet O
agent O
frequently O
utilized O
in O
the O
treatment O
of O
cerebrovascular O
disease O
and O
is O
rarely O
associated O
with O
severe B-ADR
bone I-ADR
marrow I-ADR
suppression I-ADR
, O
typically O
aplastic O
anemia O

conclusion O
: O
marked O
visual B-ADR
field I-ADR
constriction I-ADR
appears O
to O
be O
associated O
with O
vigabatrin B-DRUG
therapy O

we O
report O
a O
case O
of O
biopsy-proven O
acute B-ADR
tubulointerstitial I-ADR
nephritis I-ADR
associated O
with O
a O
second O
course O
of O
flurbiprofen B-DRUG
, O
a O
nonsteroidal O
anti-inflammatory O
drug O
of O
the O
propionic O
acid O
class O

acute B-ADR
neutrophilic I-ADR
dermatosis I-ADR
induced O
by O
all-trans-retinoic B-DRUG
acid I-DRUG
treatment O
for O
acute O
promyelocytic O
leukemia O

fever O
, O
lymphadenopathy O
, O
eosinophilia O
, O
lymphocytosis O
, O
hepatitis O
, O
and O
dermatitis B-ADR
: O
a O
severe O
adverse O
reaction O
to O
minocycline B-DRUG

results O
: O
after O
4 O
- O
to O
14-month O
period O
of O
therapy O
with O
the O
combination O
of O
indapamide B-DRUG
( O
2.5 O
mg O
/ O
day O
) O
and O
fosinopril O
( O
10 O
mg O
/ O
day O
) O
in O
three O
patients O
and O
6-month O
period O
of O
monotherapy O
with O
indapamide B-DRUG
( O
2.5 O
mg O
/ O
day O
) O
in O
one O
patient O
, O
glucose O
levels O
of O
all O
patients O
increased O
and O
achieve O
criteria O
of O
diabetes B-ADR
diagnoses O

we O
propose O
that O
cyclophosphamide B-DRUG
be O
added O
to O
the O
list O
of O
exposures O
potentially O
associated O
with O
hepatic B-ADR
angiosarcoma I-ADR

successful O
recovery O
from O
interstitial B-ADR
pneumonitis I-ADR
, O
induced O
by O
bicalutamide B-DRUG
and O
leuprorelin O
acetate O
given O
as O
treatment O
for O
prostate O
cancer O

patient O
and O
method O
: O
a O
34-year-old O
woman O
with O
chronic O
hepatitis O
c O
, O
genotype O
3 O
, O
receiving O
pegylated B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
and O
ribavirin O
for O
6 O
months O
, O
developed O
progressive O
malaise O
and O
anemia B-ADR
6 O
months O
after O
the O
end O
of O
treatment O

the O
polycystic B-ADR
changes I-ADR
disappeared O
from O
the O
ovaries O
in O
2 O
of O
the O
women O
after O
valproate B-DRUG
therapy O
was O
discontinued O
, O
and O
the O
2 O
women O
who O
had O
gained O
weight O
and O
developed O
amenorrhea O
while O
being O
treated O
with O
valproate B-DRUG
lost O
weight O
and O
resumed O
menstruating O
after O
the O
change O
in O
medication O

a O
45-year-old O
woman O
with O
steroid-dependent O
crohn O
's O
colitis O
, O
successfully O
managed O
with O
maintenance O
infliximab B-DRUG
infusions O
and O
methotrexate O
, O
developed O
a O
lupus-like B-ADR
syndrome I-ADR
eight O
months O
after O
her O
initial O
infusion O

cryptococcus B-ADR
neoformans I-ADR
fatal I-ADR
sepsis I-ADR
in O
a O
chronic O
lymphocytic O
leukemia O
patient O
treated O
with O
alemtuzumab B-DRUG
: O
case O
report O
and O
review O
of O
the O
literature O

complete O
remission O
of O
the O
nephrosis B-ADR
occurred O
after O
discontinuation O
of O
hydroxychloroquine B-DRUG
therapy O

sexual B-ADR
dysfunction I-ADR
associated O
with O
intrathecal O
baclofen B-DRUG
use O
: O
a O
report O
of O
two O
cases O

regardless O
of O
a O
negative O
history O
of O
asthma O
, O
therefore O
, O
life-threatening O
bronchospasm B-ADR
must O
be O
considered O
a O
possible O
complication O
of O
propranolol B-DRUG
therapy O

the O
hypercalcemia B-ADR
responded O
to O
discontinuation O
of O
rhgh B-DRUG
and O
a O
single O
dose O
of O
intravenous O
pamidronate O
disodium O
and O
has O
not O
recurred O
in O
8 O
months O
of O
follow-up O

the O
authors O
present O
a O
case O
study O
of O
a O
mentally O
healthy O
man O
who O
repeatedly O
experienced O
short-lived O
, O
obsessional-like B-ADR
suicidal I-ADR
ideas I-ADR
and I-ADR
images I-ADR
after O
ingestion O
of O
the O
anti-fungal O
drug O
ketoconazole B-DRUG

a O
58-year-old O
woman O
with O
rheumatoid O
arthritis O
( O
ra O
) O
developed O
fever O
, O
skin O
eruptions O
, O
leukocytopenia O
, O
and O
thrombocytopenia B-ADR
, O
3 O
weeks O
after O
treatment O
with O
sulfasalazine B-DRUG

despite O
a O
response O
of O
the O
meningeal O
tumor O
the O
patient O
developed O
in O
the O
third O
week O
of O
mtx B-DRUG
treatment O
a O
progressive O
visual O
loss O
and O
loss O
of O
consciousness O
which O
worsened O
during O
subsequent O
ara-c O
treatment O
and O
led O
to O
death B-ADR
within O
3 O
weeks O

detection O
of O
antineutrophil O
cytoplasmic O
antibody O
in O
a O
patient O
with O
l-tryptophan B-DRUG
induced O
eosinophilia-myalgia B-ADR
syndrome I-ADR

we O
describe O
a O
case O
of O
life-threatening O
hyponatremia B-ADR
associated O
with O
sibutramine B-DRUG
use O
in O
an O
obese O
woman O

we O
report O
on O
three O
patients O
with O
acute O
schizophrenia O
, O
who O
developed O
severe B-ADR
akathisia I-ADR
during O
treatment O
with O
olanzapine B-DRUG
( O
20-25 O
mg O
/ O
d O

these O
case O
reports O
provide O
evidence O
that O
5-aminosalicylic B-DRUG
acid I-DRUG
may O
induce O
acute B-ADR
pancreatitis I-ADR
after O
long O
term O
treatment O

a O
71-year-old O
man O
with O
paroxysmal O
atrial O
fibrillation O
who O
had O
a O
previous O
anterior O
myocardial O
infarction O
exhibited O
granulocytopenia B-ADR
8 O
days O
following O
the O
administration O
of O
oral O
sustained-release O
procainamide B-DRUG
( O
750 O
mg O
/ O
day O

the O
ocular O
motor O
disturbances O
are O
probably O
an O
expression O
of O
regional O
5-fu B-DRUG
neurotoxicity B-ADR
primarily O
affecting O
the O
brain O
stem O

retrospectively O
, O
bucillamine B-DRUG
was O
believed O
to O
be O
the O
cause O
of O
the O
giant B-ADR
hypertrophy I-ADR
because O
of O
its O
structural O
similarity O
to O
d-penicillamine O
, O
which O
was O
the O
subject O
of O
an O
abundance O
of O
reports O
of O
mammary O
hyperplasia O

hepatoxicity B-ADR
is O
a O
rare O
complication O
of O
srl B-DRUG
therapy O
and O
may O
be O
connected O
with O
some O
diagnostic O
and O
/ O
or O
therapeutic O
problems O

during O
the O
first O
days O
of O
arsenic B-DRUG
trioxide I-DRUG
treatment O
a O
rapid O
decrease B-ADR
in I-ADR
the I-ADR
d-dimers I-ADR
was O
seen O
( O
normal O
values O
reached O
until O
day O
7 O
) O
, O
together O
with O
a O
slight O
decrease O
in O
peripheral O
blood O
leukocytes O

conclusion O
: O
significant O
ocular B-ADR
complications I-ADR
such O
as O
an O
irreversible O
decrease O
of O
visual O
acuity O
may O
develop O
in O
patients O
treated O
with O
pegylated B-DRUG
interferon I-DRUG

transient O
phenytoin B-DRUG
induced O
iga B-ADR
deficiency I-ADR
and O
permanent O
ige O
increase O

we O
report O
on O
a O
child O
with O
fatal B-ADR
valproate-related O
hepatotoxic O
effects O
despite O
this O
supplementation O

physicians O
using O
this O
" O
new O
" O
drug O
must O
be O
aware O
of O
the O
potential O
danger O
of O
sulfonamide-induced O
injury B-ADR
to I-ADR
the I-ADR
urinary I-ADR
tract I-ADR

conclusion O
: O
anterior B-ADR
ischemic I-ADR
optic I-ADR
neuropathy I-ADR
may O
complicate O
treatment O
with O
interferon B-DRUG
alfa I-DRUG

myoglobinuria B-ADR
and O
acute O
renal O
failure O
associated O
with O
intravenous O
vasopressin B-DRUG
infusion O

in O
addition O
, O
the O
tachycardia B-ADR
persisted O
and O
was O
repeatedly O
spontaneously O
reinitiated O
for O
prolonged O
periods O
after O
procainamide B-DRUG

the O
hearing O
impairment O
and O
tinnitus B-ADR
were O
gradually O
reduced O
after O
ptu B-DRUG
withdrawal O
and O
corticosteroid O
and O
azathioprine O
treatment O

acute B-ADR
leukaemia I-ADR
during O
tamoxifen B-DRUG
therapy O

this O
report O
describes O
an O
unexpected O
drug-induced O
hepatitis B-ADR
in O
a O
previously O
healthy O
young O
woman O
exposed O
to O
2 O
doses O
of O
amodiaquine B-DRUG
and O
artesunate O

anaphylactic B-ADR
reaction I-ADR
to O
recombinant B-DRUG
insulin-like I-DRUG
growth I-DRUG
factor-i I-DRUG

carbamazepine B-ADR
toxicity I-ADR
following O
oxybutynin O
and O
dantrolene O
administration O
: O
a O
case O
report O

no O
other O
endogenous O
or O
exogenous O
cause O
for O
the O
gynecomastia B-ADR
could O
be O
found O
except O
for O
the O
theophylline B-DRUG

diazepam B-DRUG
use O
by O
pregnant O
women O
can O
be O
associated O
with O
a O
later O
presentation O
of O
withdrawal B-ADR
symptoms I-ADR
in O
the O
neonate O
than O
that O
induced O
by O
the O
use O
of O
other O
drugs O

we O
report O
an O
hiv-infected O
woman O
who O
developed O
mild O
leukopenia B-ADR
as O
the O
first O
sign O
of O
a O
nevirapine-related O
adverse O
event O
, O
which O
was O
followed O
by O
skin O
and O
hepatic O
toxicity O
associated O
with O
a O
more O
severe O
leukopenia B-ADR

a O
patient O
presented O
with O
dilated B-ADR
cardiomyopathy I-ADR
after O
many O
years O
of O
overusing O
an O
adrenaline B-DRUG
inhaler O

anaphylactoid B-ADR
reaction I-ADR
to O
50 O
% O
solution O
of O
dextrose B-DRUG

in O
this O
paper O
, O
we O
report O
a O
case O
of O
3 O
years-old O
boy O
who O
developed O
acute B-ADR
onset I-ADR
tetraparesia I-ADR
following O
a O
viral O
respiratory O
infecction O
and O
hepatitis B-DRUG
b I-DRUG
vaccination I-DRUG

three O
of O
50 O
patients O
treated O
with O
isotretinoin B-DRUG
( O
1 O
mg O
/ O
kg O
/ O
day O
) O
for O
cystic O
acne O
complained O
of O
poor O
night O
vision O
and O
/ O
or O
excessive B-ADR
glare I-ADR
sensitivity I-ADR

rapamycin O
/ O
sirolimus B-DRUG
( O
sr O
) O
, O
trade O
named O
rapammune O
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression O
, O
hypertension O
, O
hyperlipidemia B-ADR
, O
and O
infection O

objective O
: O
to O
report O
the O
clinical O
course O
of O
a O
woman O
with O
cryptococcal O
meningitis O
and O
no O
previous O
cardiac O
disease O
who O
developed O
a O
fatal B-ADR
cardiac I-ADR
arrhythmia I-ADR
after O
an O
acute O
overdose O
of O
amphotericin B-DRUG
b I-DRUG
and O
to O
review O
its O
toxicity O

new O
onset O
of O
cd O
may O
be O
considered O
as O
an O
immune-mediated B-ADR
injury I-ADR
induced O
by O
etanercept B-DRUG

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion O
, O
agitation O
, O
tachycardia B-ADR
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

to O
our O
knowledge O
, O
this O
case O
is O
the O
first O
published O
report O
of O
levofloxacin-induced O
ten B-ADR

a O
66-year-old O
japanese O
woman O
with O
severe O
scleroderma O
developed O
anemia B-ADR
and O
thrombocytopenia O
due O
to O
d-penicillamine B-DRUG
( O
d-pen O
) O
treatment O
, O
although O
the O
leukopenia O
was O
not O
markedly O
severe O

polyarthritis O
, O
hepatitis O
and O
anti-native B-ADR
dna I-ADR
antibodies I-ADR
after O
treatment O
with O
ethambutol O
and O
rifampicin B-DRUG

severe B-ADR
hepatocellular I-ADR
dysfunction I-ADR
following O
cyproterone B-DRUG
acetate I-DRUG
therapy O

in O
case O
no O
. O
2 O
, O
the O
pathogenic O
mechanism O
seemed O
to O
be O
persistent O
light O
reaction O
preceded O
by O
systemic O
photoallergy O
, O
as O
he O
had O
taken O
mequitazine O
for O
6 O
months O
, O
and O
there O
were O
strong O
positive O
photopatch O
test O
results O
with O
immediate O
erythema B-ADR
reaction O
, O
cross-reaction O
to O
promethazine B-DRUG
, O
decreased O
med O
to O
both O
uva O
and O
uvb O
, O
and O
persistence O
of O
the O
photosensitivity O
over O
a O
3-year O
follow-up O
period O
after O
discontinuation O
of O
the O
mequitazine O

valproic B-DRUG
acid I-DRUG
induced O
coma B-ADR
is O
presented O
in O
an O
adult O
patient O
without O
a O
history O
of O
metabolic O
disease O

five O
days O
after O
the O
fourth O
dose O
of O
vincristine B-DRUG
, O
she O
presented O
with O
bilateral B-ADR
ptosis I-ADR

ifnalpha-induced O
recurrence O
of O
graves' B-ADR
disease I-ADR
ten O
years O
after O
thyroidectomy O
in O
chronic O
viral O
hepatitis O
c O

the O
administration O
of O
" O
sweet B-DRUG
spirits I-DRUG
of I-DRUG
nitre I-DRUG
" O
( O
4 O
% O
ethyl O
nitrite O
ch3ch2ono O
in O
70 O
% O
ethyl O
alcohol O
) O
was O
followed O
by O
acute O
methemoglobinemia O
and O
severe B-ADR
anoxic I-ADR
metabolic I-ADR
acidosis I-ADR
in O
infant O
twins O
, O
methylene O
blue O
administration O
reversed O
methemoglobinemia O
in O
both O
, O
but O
one O
twin O
died O
from O
the O
consequences O
of O
hypoxemia O

discussion O
: O
olanzapine B-DRUG
, O
like O
other O
atypical O
antipsychotic O
drugs O
, O
may O
cause O
muscle B-ADR
injury I-ADR
with I-ADR
concomitant I-ADR
elevations I-ADR
of I-ADR
serum I-ADR
ck I-ADR
of O
muscle O
origin O

clostridium B-ADR
difficile I-ADR
colitis I-ADR
associated O
with O
cisplatin-based O
chemotherapy O
in O
ovarian O
cancer O
patients O

we O
suggest O
that O
nicotinic B-DRUG
acid I-DRUG
was O
the O
cause O
of O
his O
liver B-ADR
disease I-ADR
, O
that O
this O
case O
is O
of O
particular O
note O
because O
of O
the O
rather O
short O
period O
of O
therapy O
before O
the O
onset O
of O
liver O
injury O
and O
the O
severity O
of O
the O
hepatic O
failure O
, O
and O
that O
the O
probable O
increased O
use O
of O
nicotinic B-DRUG
acid I-DRUG
for O
serum O
cholesterol O
control O
makes O
it O
especially O
important O
for O
physicians O
and O
their O
patients O
to O
be O
alert O
to O
the O
signs O
of O
hepatotoxicity O

pancreatitis B-ADR
has O
been O
noted O
to O
be O
a O
complication O
in O
2-16 O
% O
of O
patients O
undergoing O
treatment O
with O
l-asparaginase B-DRUG
for O
a O
variety O
of O
pediatric O
neoplasms O

symptomatic O
hypocalcaemia O
and O
renal B-ADR
impairment I-ADR
associated O
with O
bisphosphonate B-DRUG
treatment O
in O
patients O
with O
multiple O
myeloma O

it O
should O
be O
recognized O
that O
ibuprofen O
may O
be O
associated O
with O
salt B-ADR
and I-ADR
water I-ADR
retention I-ADR
in O
the O
same O
fashion O
as O
previously O
described O
with O
phenylbutazone B-DRUG
and O
indomethacin O

flecainide-associated O
pneumonitis O
with O
acute B-ADR
respiratory I-ADR
failure I-ADR
in O
a O
patient O
with O
the O
leopard O
syndrome O

restless B-ADR
legs I-ADR
syndrome I-ADR
due O
to O
interferon-alpha B-DRUG

our O
report O
suggested O
that O
cbdca B-DRUG
hypersensitivity B-ADR
was O
correlated O
with O
the O
total O
dose O
of O
previously O
administered O
platinum O
agents O
and O
that O
cbdca B-DRUG
should O
be O
excluded O
in O
patients O
who O
have O
received O
multiple O
platinum-based O
chemotherapy O
, O
even O
in O
platinum-sensitive O
cases O
, O
because O
cbdca B-DRUG
hypersensitivity B-ADR
can O
occur O
even O
with O
low-dose O
cbdca B-DRUG
administration O

quetiapine-induced O
myoclonus B-ADR

previous O
studies O
have O
demonstrated O
the O
interaction O
of O
mtx B-DRUG
and O
a O
variety O
of O
non-steroidal O
, O
anti-inflammatory O
drugs O
( O
nsaids O
) O
with O
various O
clinical O
manifestations O
including O
acute O
renal O
failure O
, O
pancytopenia B-ADR
, O
vomiting O
, O
diarrhea O
, O
elevated O
liver O
transaminases O
, O
jaundice O
, O
mucosal O
ulcerations O
, O
and O
pyrexia O

we O
present O
a O
case O
of O
hypereosinophilia B-ADR
related O
to O
zafirlukast B-DRUG
therapy O

acute B-ADR
renal I-ADR
failure I-ADR
with O
severe O
tubulointerstitial O
changes O
in O
a O
patient O
with O
minimal O
change O
nephrotic O
syndrome O
treated O
with O
enalapril B-DRUG

acute B-ADR
pancreatitis I-ADR
after O
long-term O
5-aminosalicylic B-DRUG
acid I-DRUG
therapy O

on O
the O
other O
hand O
, O
mtx-induced O
pneumonitis B-ADR
seems O
to O
be O
very O
rare O
in O
psoriatic O
arthritis O
( O
psa O

a O
30-year-old O
pharmacist O
suffered O
from O
acute B-ADR
allergic I-ADR
contact I-ADR
dermatitis I-ADR
due O
to O
4-chloro-7-nitrobenzofurazan O
( O
nbd-cl B-DRUG

data O
synthesis O
: O
genetic O
deficiencies O
in O
dpd O
, O
the O
rate-limiting O
enzyme O
responsible O
for O
5-fu B-DRUG
catabolism O
, O
may O
occur O
in O
3 O
% O
or O
more O
of O
patients O
with O
cancer O
putting O
them O
at O
increased O
risk O
for O
unusually O
severe O
adverse O
reactions O
( O
e.g. O
, O
diarrhea O
, O
stomatitis O
, O
mucositis O
, O
myelosuppression B-ADR
, O
neurotoxicity O
) O
to O
standard O
doses O
of O
5-fu B-DRUG

ulcerative B-ADR
proctitis I-ADR
in O
juvenile O
systemic O
lupus O
erythematosus O
after O
ibuprofen B-DRUG
treatment O

we O
describe O
two O
patients O
in O
whom O
painful B-ADR
erosions I-ADR
of I-ADR
their I-ADR
psoriasis I-ADR
developed O
as O
the O
presenting O
sign O
of O
methotrexate B-DRUG
toxicity O
and O
review O
the O
literature O
, O
emphasizing O
the O
risk O
factors O
associated O
with O
this O
manifestation O

we O
describe O
a O
patient O
with O
wilson O
's O
disease O
who O
presented O
with O
neurologic O
disease O
, O
was O
treated O
with O
d-penicillamine B-DRUG
, O
and O
suffered O
sudden O
neurologic B-ADR
deterioration I-ADR
coincident O
with O
therapy O

she O
was O
receiving O
phenytoin O
sodium O
300 O
mg O
/ O
day O
; O
carbamazepine B-DRUG
200 O
mg O
four O
times O
daily O
had O
been O
discontinued O
four O
days O
before O
admission O
because O
of O
leukopenia B-ADR

we O
report O
a O
fatal B-ADR
case I-ADR
of I-ADR
acute I-ADR
interstitial I-ADR
pneumonitis I-ADR
in O
a O
patient O
treated O
with O
carmustine B-DRUG
( O
bcnu O
) O
for O
a O
brain O
tumor O

cutaneous B-ADR
ulceration I-ADR
: O
an O
unusual O
complication O
of O
intravenous O
pentamidine B-DRUG
therapy O

background O
: O
colchicine B-DRUG
has O
a O
known O
adverse B-ADR
effect I-ADR
on I-ADR
wound I-ADR
healing I-ADR
through O
its O
inhibitory O
effect O
on O
tubulin-dependent O
cell O
functions O
and O
through O
collagenase O
activation O

diarrhoea B-ADR
, O
t-cd4 O
+ O
lymphopenia O
and O
bilateral O
patchy O
pulmonary O
infiltrates O
developed O
in O
a O
male O
60 O
yrs O
of O
age O
, O
who O
was O
treated O
with O
oxaliplatinum B-DRUG
and O
5-fluorouracil O
for O
unresectable O
rectum O
carcinoma O

a O
51-yr-old O
nonsmoking O
male O
patient O
without O
any O
history O
of O
previous O
allergies O
, O
asthma O
, O
hay O
fever O
, O
or O
urticaria O
developed O
attacks B-ADR
of I-ADR
asthma I-ADR
when O
captopril O
was O
added O
to O
the O
nadolol B-DRUG
and O
dyazide O
treatment O
for O
his O
high O
blood O
pressure O

we O
report O
the O
successful O
treatment O
of O
heparin-induced O
thrombocytopenia O
and O
subsequent O
hemorrhagic B-ADR
complications I-ADR
postoperatively O
in O
a O
2-year-old O
child O
with O
danaparoid O
( O
orgaran O

four O
months O
after O
receiving O
an O
orthotopic O
liver O
transplant O
, O
a O
51-year-old O
man O
was O
admitted O
for O
progressive O
liver O
failure O
and O
severe B-ADR
hepatocellular I-ADR
necrosis I-ADR
thought O
to O
be O
due O
to O
tacrolimus B-DRUG

the O
present O
report O
suggests O
that O
clarithromycin O
coadministration O
induces O
increased B-ADR
plasma I-ADR
carbamazepine I-ADR
concentrations O
, O
which O
may O
result O
in O
carbamazepine B-DRUG
toxicity O

the O
patient O
presented O
with O
fulminant O
microangiopathic O
hemolytic O
anemia O
and O
thrombocytopenia B-ADR
within O
48 O
hr O
of O
initiating O
therapy O
with O
trimethoprim-sulfamethoxazole O

less O
common O
adverse O
events O
to O
dapsone B-DRUG
include O
the O
idiosyncratic O
reactions O
of O
leukopenia O
and O
agranulocytosis O
, O
cutaneous O
eruptions O
, O
peripheral B-ADR
neuropathy I-ADR
, O
psychosis O
, O
toxic O
hepatitis O
, O
cholestatic O
jaundice O
, O
nephrotic O
syndrome O
, O
renal O
papillary O
necrosis O
, O
severe O
hypoalbuminemia O
without O
proteinuria O
, O
an O
infectious O
mononucleosis-like O
syndrome O
, O
and O
minor O
neurological O
and O
gastrointestinal O
complaints O

we O
describe O
a O
patient O
who O
developed O
granulocytopenia B-ADR
and O
fever O
after O
taking O
dipyrone B-DRUG
and O
discuss O
the O
available O
literature O

morphea B-ADR
after O
bromocriptine B-DRUG
therapy O

we O
report O
a O
71-year O
male O
with O
castration-resistant O
metastatic O
prostate O
cancer O
who O
was O
treated O
with O
weekly O
docetaxel B-DRUG
for O
12 O
weeks O
and O
developed O
significant O
eye B-ADR
irritation I-ADR
and I-ADR
dryness I-ADR
during O
treatment O

seizures B-ADR
associated O
with O
fluoxetine B-DRUG
therapy O
are O
uncommon O

we O
wish O
to O
call O
for O
cautious O
approach O
at O
time O
of O
cessation O
of O
prolonged O
acth B-DRUG
therapy O
because O
of O
possible O
unexpected O
and O
only O
partially O
understood O
hazardous O
side O
effects O
such O
as O
hyperkalemia B-ADR

the O
occurrence O
of O
severe O
aiha B-ADR
in O
cll O
patients O
treated O
with O
fludarabine B-DRUG
has O
been O
reported O
by O
several O
authors O

herein O
is O
reported O
an O
unusual O
case O
of O
coexistent O
warfarin-induced O
skin B-ADR
necrosis I-ADR
and O
heparin-induced O
thrombocytopenia O
following O
mitral O
valve O
replacement O
for O
thromboembolic O
phenomena O
associated O
with O
marantic O
endocarditis O
and O
bronchial O
adenocarcinoma O

we O
report O
a O
case O
of O
sustained B-ADR
hypotension I-ADR
after O
administration O
of O
parenteral O
verapamil B-DRUG

we O
present O
a O
case O
of O
hemolytic-uremic B-ADR
syndrome I-ADR
that O
developed O
during O
the O
4th O
cycle O
of O
combination O
chemotherapy O
with O
oxaliplatin O
, O
5-fluorouracil B-DRUG
and O
leucovorin O

prothipendylhydrochloride-induced O
priapism B-ADR
: O
case O
report O

she O
developed O
a O
generalized O
rash O
and O
itching B-ADR
, O
sore O
throat O
, O
and O
dizziness O
approximately O
4 O
hours O
after O
the O
first O
dose O
of O
capecitabine B-DRUG

fulminant O
hepatitis O
with O
severe B-ADR
lactate I-ADR
acidosis I-ADR
in O
hiv-infected O
patients O
on O
didanosine B-DRUG
therapy O

the O
most O
common O
complication O
of O
warfarin B-DRUG
use O
is O
adverse O
bleeding B-ADR

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity B-ADR
reactions I-ADR
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general O
erythema O
, O
dyspnea O
, O
and O
hypotension O
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal O
pain O
, O
general O
erythema O
, O
and O
fever O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical B-ADR
lymphocytosis I-ADR
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp B-DRUG
)- O
sulfamethoxazole O
( O
smx O
) O
treatment O

we O
present O
a O
case O
of O
hus B-ADR
in O
an O
advanced O
ovarian O
cancer O
patient O
treated O
with O
carboplatin O
and O
gemcitabine B-DRUG
, O
and O
described O
its O
favorable O
outcome O
after O
chemotherapy O
interruption O
and O
supportive O
care O
with O
a O
1 O
year O
follow-up O

progressive B-ADR
hypokalemia I-ADR
developed O
during O
phosphate B-DRUG
treatment O

arthritis O
and O
bursitis B-ADR
in O
multiple O
sclerosis O
patients O
treated O
with O
interferon-beta B-DRUG

among O
12 O
thyrotoxic O
patients O
, O
a O
patient O
with O
arrhythmogenic O
right O
ventricular O
dysplasia O
, O
who O
had O
been O
taking O
amiodarone B-DRUG
for O
4 O
years O
, O
developed O
thyrotoxicosis B-ADR
with O
subacute O
onset O
, O
accompanied O
by O
transiently O
positive O
thyrotropin O
( O
tsh O
) O
receptor O
antibody O
( O
trab O
) O
, O
or O
thyrotropin-binding O
inhibiting O
immunoglobulin O
( O
tbii O

clinicians O
should O
be O
aware O
of O
the O
possibility O
that O
vinorelbine B-DRUG
may O
cause O
siadh O
and O
possibly O
hypokalemia B-ADR

we O
report O
a O
13 O
year-old O
male O
who O
developed O
life-threatening O
anaphylaxis B-ADR
early O
in O
the O
course O
of O
increlex B-DRUG
therapy O

iatrogenic O
hypercalcemia B-ADR
due O
to O
vitamin B-DRUG
d3 I-DRUG
ointment O
( O
1,24 O
( O
oh O
) O
2d3 O
) O
combined O
with O
thiazide O
diuretics O
in O
a O
case O
of O
psoriasis O

we O
report O
a O
case O
of O
zidovudine B-DRUG
induced O
anaemia O
and O
bone B-ADR
marrow I-ADR
aplasia I-ADR
in O
a O
patient O
infected O
with O
hiv O

polysomnographic O
and O
pharmacokinetic O
findings O
in O
levodopa-induced O
augmentation O
of O
restless B-ADR
legs I-ADR
syndrome I-ADR

however O
, O
one O
patient O
exhibited O
severe O
hypersensitivity O
reactions O
including O
cardiac O
arrest O
and O
apnea O
, O
and O
another O
four O
patients O
developed O
eruptions O
, O
hypotension B-ADR
, O
and O
tachycardia O
soon O
after O
administration O
of O
cbdca B-DRUG

type B-ADR
1 I-ADR
diabetes I-ADR
mellitus I-ADR
provoked O
by O
peginterferon B-DRUG
alpha-2b I-DRUG
plus O
ribavirin O
treatment O
for O
chronic O
hepatitis O
c O

cholelithiasis B-ADR
and O
thrombosis O
of O
the O
central O
retinal O
vein O
in O
a O
renal O
transplant O
recipient O
treated O
with O
cyclosporin B-DRUG

case O
studies O
in O
heparin-induced O
thrombocytopenia B-ADR

background O
: O
we O
describe O
the O
ophthalmic O
features O
and O
clinical O
course O
of O
two O
cases O
of O
acute B-ADR
syphilitic I-ADR
posterior I-ADR
placoid I-ADR
chorioretinitis I-ADR
( O
asppc O
) O
that O
developed O
after O
intravitreal O
triamcinolone O
acetonide O
( O
ivta B-DRUG
) O
injection O

fulminant B-ADR
hepatic I-ADR
failure I-ADR
associated O
with O
bicalutamide B-DRUG

renal B-ADR
injury I-ADR
due O
to O
anastrozole B-DRUG
has O
not O
been O
published O
in O
the O
english O
literature O

pulmonary B-ADR
fibrosis I-ADR
is O
a O
severe O
complication O
associated O
with O
bis-chloronitrosourea O
( O
bcnu B-DRUG
) O
therapy O

rifampin B-DRUG
can O
be O
associated O
with O
severe O
adverse O
effects O
such O
as O
hepatitis O
, O
acute B-ADR
renal I-ADR
failure I-ADR
, O
hemolytic O
anemia O
, O
and O
thrombocytopenia O

electrocardiographic O
findings O
and O
laboratory O
data O
indicated O
a O
diagnosis O
of O
acute B-ADR
myocardial I-ADR
infarction I-ADR
due O
to O
the O
l-thyroxine B-DRUG
therapy O

diarrhea-associated B-ADR
over-anticoagulation I-ADR
in O
a O
patient O
taking O
warfarin B-DRUG
: O
therapeutic O
role O
of O
cholestyramine O

conclusion O
: O
a O
37-year-old O
african O
- O
american O
man O
with O
g6pd O
deficiency O
developed O
hemolytic O
anemia O
, O
hepatitis O
, O
orthostatic B-ADR
hypotension I-ADR
, O
and O
aseptic O
meningitis O
simultaneously O
after O
using O
trimethoprim-sulfamethoxazole O

although O
gabapentin B-DRUG
withdrawal O
has O
been O
previously O
reported O
and O
usually O
consists O
of O
anxiety O
, O
diaphoresis O
, O
and O
palpitations O
, O
this O
is O
the O
first O
reported O
patient O
with O
generalized O
seizures O
and O
status B-ADR
epilepticus I-ADR
secondary O
to O
gabapentin B-DRUG
withdrawal O

a O
diagnosis O
of O
trastuzumab-induced O
pneumonitis B-ADR
was O
made O

anaphylactic B-ADR
reaction I-ADR
to O
oral O
prednisone B-DRUG
: O
a O
case O
report O
and O
review O
of O
the O
literature O

a O
49-year-old O
man O
with O
crohn O
's O
disease O
treated O
with O
prednisone B-DRUG
and O
mesalamine O
( O
5-asa O
) O
developed O
worsening O
respiratory O
distress O
and O
fever B-ADR

aim O
: O
to O
report O
three O
cases O
of O
extensive O
skin B-ADR
necrosis I-ADR
in O
cirrhotic O
patients O
treated O
with O
the O
vasoconstrictor O
agent O
terlipressin O
( O
glypressin B-DRUG

niacin B-DRUG
causes O
a O
reversible B-ADR
toxic I-ADR
cystoid I-ADR
maculopathy I-ADR
that O
occurs O
in O
approximately O
0.67 O
% O
of O
patients O
taking O
high O
doses O
of O
the O
drug O

pellagra B-ADR
encephalopathy I-ADR
among O
tuberculous O
patients O
: O
its O
relation O
to O
isoniazid B-DRUG
therapy O

although O
praziquantel B-DRUG
administration O
may O
have O
been O
effective O
in O
killing O
the O
parasite O
in O
both O
patients O
, O
we O
are O
concerned O
about O
the O
production O
of O
marked O
inflammation B-ADR
as O
a O
result O
of O
treatment O

the O
successful O
development O
and O
implementation O
of O
this O
protocol O
will O
have O
impact O
on O
patients O
who O
have O
anaphylactic B-ADR
reactions I-ADR
to O
mtx B-DRUG
but O
require O
this O
medication O
for O
specific O
diseases O

although O
myelosuppression O
is O
mild O
, O
immunosuppression B-ADR
and O
superinfection O
are O
potential O
hazards O
of O
treatment O
with O
dcf B-DRUG

to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
griseofulvin-exacerbated O
lupus B-ADR
in O
which O
nephrotic O
syndrome O
has O
been O
observed O

the O
course O
of O
delirium B-ADR
due O
to O
lithium B-DRUG
intoxication O

the O
authors O
report O
a O
case O
of O
acute O
pancreatitis B-ADR
( O
ap O
) O
occurring O
in O
a O
patient O
under O
treatment O
with O
carbamazepine O
( O
cbz B-DRUG
) O
for O
post-traumatic O
petit O
mal O
epilepsy O
, O
and O
review O
the O
current O
literature O
of O
drug-induced O
ap O

although O
combinations O
of O
belladonna B-DRUG
, O
ergotamine O
, O
and O
phenobarbital O
have O
been O
used O
for O
medical O
treatment O
of O
menopausal O
symptoms O
since O
the O
1960s O
, O
this O
is O
the O
first O
known O
case O
report O
of O
its O
association O
with O
anticonvulsant B-ADR
hypersensitivity I-ADR
syndrome I-ADR

common O
adverse O
events O
( O
frequency O
10 O
%) O
of O
lacosamide B-DRUG
doses O
up O
to O
600 O
mg O
/ O
day O
include O
nonspecific O
central O
nervous O
system O
effects O
( O
e.g. O
, O
dizziness B-ADR
, O
ataxia O
, O
diplopia O
, O
and O
somnolence O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin B-ADR
eruptions I-ADR
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp O
)- O
sulfamethoxazole O
( O
smx B-DRUG
) O
treatment O

a O
patient O
with O
an O
allergy O
to O
a O
macrolide O
antibiotic O
was O
given O
tacrolimus B-DRUG
and O
developed O
a O
sudden B-ADR
cutaneous I-ADR
reaction I-ADR

we O
present O
a O
case O
of O
a O
sustained B-ADR
monomorphic I-ADR
ventricular I-ADR
tachycardia I-ADR
following O
adenosine B-DRUG
infusion O

a O
61 O
year-old O
male O
patient O
developed O
gynecomastia B-ADR
after O
starting O
theophylline B-DRUG

abdominal B-ADR
wall I-ADR
ulceration I-ADR
and O
mucinosis O
secondary O
to O
recombinant B-DRUG
human I-DRUG
interferon-beta-1b I-DRUG

the O
known O
side O
effects O
of O
sibutramine B-DRUG
, O
ie O
, O
hypertension O
and O
tachycardia B-ADR
, O
depend O
on O
its O
adrenergic O
and O
serotoninergic O
effects O

a O
variety O
of O
movement B-ADR
disorders I-ADR
are O
known O
to O
occur O
in O
association O
with O
carbamazepine B-DRUG
( O
cbz O
) O
therapy O
in O
adults O
and O
children O
, O
but O
development O
of O
tics O
has O
been O
described O
infrequently O
and O
only O
in O
patients O
with O
underlying O
tourette O
's O
syndrome O
or O
other O
movement B-ADR
disorders I-ADR

we O
discuss O
the O
association O
between O
carbamazepine B-DRUG
and O
hyponatremia B-ADR
and O
the O
causes O
of O
hyponatremia B-ADR
after O
cardiopulmonary O
bypass O

patients O
receiving O
amifostine B-DRUG
who O
develop O
only O
fever B-ADR
should O
be O
evaluated O
for O
an O
adverse O
drug O
reaction O
, O
as O
well O
as O
for O
sepsis O
and O
fevers O
of O
neutropenia O
, O
and O
it O
may O
be O
necessary O
to O
discontinue O
the O
drug O

drug-induced O
hepatitis B-ADR
in O
an O
acromegalic O
patient O
during O
combined O
treatment O
with O
pegvisomant B-DRUG
and O
octreotide O
long-acting O
repeatable O
attributed O
to O
the O
use O
of O
pegvisomant B-DRUG

we O
report O
a O
76-year-old O
man O
who O
developed O
an O
acute B-ADR
blistering I-ADR
eruption I-ADR
following O
high-dose O
penicillin B-DRUG
treatment O
for O
pneumococcal O
septicaemia O

panic B-ADR
anxiety I-ADR
after O
abrupt O
discontinuation O
of O
mianserin B-DRUG

disseminated B-ADR
tuberculous I-ADR
lesions I-ADR
post O
intravesical O
bcg B-DRUG
therapy O
are O
rare O
but O
need O
to O
be O
identified O
and O
treated O
quickly O

the O
cause O
of O
these O
previously O
unreported O
side O
effects O
of O
niacin B-DRUG
therapy O
is O
uncertain O
but O
may O
be O
related O
to O
prostaglandin-mediated B-ADR
vasodilatation I-ADR
, O
hyperalgesia O
of O
sensory O
nerve O
receptors O
, O
and O
potentiation O
of O
inflammation O
in O
the O
gingiva O
with O
referral O
of O
pain O
to O
the O
teeth O

two O
years O
later O
, O
24 O
hours O
following O
an O
increase O
in O
the O
dose O
of O
disopyramide B-DRUG
from O
300 O
to O
600 O
mg O
/ O
day O
, O
avt B-ADR
with O
syncope O
occurred O
; O
isoproterenol O
abolished O
the O
arrhythmia O
instantly O

investigation O
confirmed O
the O
diagnosis O
of O
rhabdomyolysis O
, O
and O
discontinuation O
of O
colchicine B-DRUG
resulted O
in O
resolution O
of O
clinical O
and O
biochemical O
features O
of O
rhabdomylysis B-ADR

avascular B-ADR
necrosis I-ADR
of I-ADR
the I-ADR
femoral I-ADR
head I-ADR
in O
patients O
with O
prostate O
cancer O
treated O
with O
cyproterone B-DRUG
acetate I-DRUG
and O
radiotherapy O

a O
sixty-year-old O
woman O
with O
advanced O
breast O
cancer O
, O
previously O
treated O
with O
cisplatin O
, O
developed O
an O
irreversible O
lethal O
renal O
failure O
with O
anuria B-ADR
, O
the O
day O
after O
5 O
g O
/ O
m2 O
bolus O
ifosfamide B-DRUG

the O
presented O
patient O
was O
treated O
with O
200 O
mg O
tca B-DRUG
and O
developed O
cushing B-ADR
's I-ADR
syndrome I-ADR
6 O
weeks O
later O
( O
cortisol O
and O
acth O
concentrations O
were O
below O
limits O
of O
detection O
, O
tca B-DRUG
concentrations O
were O
> O
3 O
micrograms O
/ O
l O

thymic B-ADR
enlargement I-ADR
in O
a O
patient O
with O
juvenile O
idiopathic O
arthritis O
during O
etanercept B-DRUG
therapy O

discussion O
: O
no O
published O
clinical O
studies O
in O
patients O
receiving O
clindamycin B-DRUG
vaginal O
cream O
for O
bacterial O
vaginosis O
have O
documented O
c. O
difficile O
toxin O
in O
stool O
samples O
of O
patients O
with O
diarrhea B-ADR

high-dose O
methylprednisolone B-DRUG
in O
a O
pregnant O
woman O
with O
crohn O
's O
disease O
and O
adrenal B-ADR
suppression I-ADR
in O
her O
newborn O

doxorubicin B-DRUG
cardiotoxicity B-ADR
: O
possible O
role O
of O
digoxin O
in O
its O
prevention O

therefore O
, O
parenteral O
amiodarone B-DRUG
was O
implicated O
as O
the O
cause O
of O
acute B-ADR
hepatitis I-ADR
in O
this O
patient O

one O
patient O
was O
an O
80-year-old O
woman O
who O
was O
admitted O
for O
staphylococcus B-ADR
aureus I-ADR
knee I-ADR
arthritis I-ADR
after O
several O
intraarticular O
injections O
of O
sodium O
hyaluronate O
and O
corticosteroids B-DRUG

five O
patients O
are O
described O
in O
whom O
only O
gentamicin B-DRUG
sulfate I-DRUG
appeared O
responsible O
for O
acute B-ADR
renal I-ADR
failure I-ADR

a O
64 O
year O
old O
man O
with O
recurrent O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
developed O
severe O
skin O
rash O
and O
bone B-ADR
marrow I-ADR
aplasia I-ADR
4 O
and O
7 O
days O
, O
respectively O
, O
following O
a O
single O
dose O
of O
40 O
mg O
/ O
m2 O
methotrexate B-DRUG
( O
mtx O

dasatinib-induced O
pleural B-ADR
effusions I-ADR
: O
a O
lymphatic O
network O
disorder O

cases O
: O
" O
a O
" O
was O
an O
8-year-old O
boy O
with O
attention O
deficit O
and O
chronic O
tic O
disorder O
who O
developed O
obsessive-compulsive B-ADR
symptoms I-ADR
within O
2 O
weeks O
of O
starting O
risperidone B-DRUG

a O
73-year-old O
woman O
presented O
with O
fever O
and O
cough B-ADR
2 O
weeks O
after O
completing O
the O
third O
cycle O
of O
fludarabine B-DRUG
for O
chronic O
lymphocytic O
leukemia O
( O
cll O

we O
suggest O
that O
the O
previous O
classification O
of O
nitrofurantoin B-ADR
induced I-ADR
lung I-ADR
injury I-ADR
into O
" O
acute O
" O
and O
" O
chronic O
" O
injury O
is O
an O
oversimplification O
in O
view O
of O
the O
wide O
variety O
of O
pathological O
entities O
that O
have O
subsequently O
emerged O

optic B-ADR
neuropathy I-ADR
associated O
with O
penicillamine B-DRUG
therapy O
in O
a O
patient O
with O
rheumatoid O
arthritis O

cyclosporine B-DRUG
is O
a O
potent O
inhibitor O
of O
simvastatin O
metabolism O
, O
and O
may O
therefore O
facilitate O
simvastatin-induced O
rhabdomyolysis B-ADR

neurologic B-ADR
toxicity I-ADR
associated O
with O
hepatic O
artery O
infusion O
hai O
of O
fudr B-DRUG

we O
report O
the O
first O
case O
, O
to O
our O
knowledge O
, O
of O
rituximab-related O
autoimmune B-ADR
hemolytic I-ADR
anemia I-ADR

the O
hospital O
course O
of O
the O
acute B-ADR
renal I-ADR
failure I-ADR
is O
presented O
with O
a O
review O
of O
the O
literature O
on O
cases O
of O
acute B-ADR
renal I-ADR
failure I-ADR
after O
ivig B-DRUG

our O
cases O
constitute O
the O
most O
severe O
cases O
of O
benzarone B-DRUG
hepatotoxicity O
reported O
so O
far O
, O
and O
comprise O
the O
first O
cases O
of O
( O
sub O
) O
fulminant O
hepatitis O
and O
cirrhosis B-ADR
related O
to O
benzarone B-DRUG

ards B-ADR
has O
been O
associated O
with O
the O
administration O
of O
other O
monoclonal O
antibodies O
, O
such O
as O
infliximab B-DRUG
, O
gemtuzumab O
ozogamicin O
, O
and O
okt3 O
and O
is O
believed O
to O
be O
directly O
mediated O
by O
release O
of O
proinflammatory O
cytokines O

a O
case O
of O
acute B-ADR
cardiomyopathy I-ADR
and O
pericarditis O
associated O
with O
methylphenidate B-DRUG

a O
patient O
with O
coccidioidal O
meningitis O
was O
treated O
with O
intrathecally O
administered O
amphotericin B-DRUG
b I-DRUG
, O
and O
an O
acute O
toxic O
delirium O
with O
eeg B-ADR
abnormalities I-ADR
developed O

intrahepatic B-ADR
cholestasis I-ADR
and O
sicca O
complex O
after O
thiabendazole B-DRUG

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity O
reactions O
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general B-ADR
erythema I-ADR
, O
dyspnea O
, O
and O
hypotension O
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal O
pain O
, O
general B-ADR
erythema I-ADR
, O
and O
fever O

granulocytopenia B-ADR
and O
agranulocytosis O
are O
considered O
among O
the O
most O
dangerous O
adverse O
effects O
of O
clozapine B-DRUG

cyclosporin B-DRUG
side O
effects O
included O
hirsutism O
, O
hypertension O
, O
increased B-ADR
blood I-ADR
levels I-ADR
of I-ADR
urea I-ADR
and I-ADR
creatinine I-ADR
, O
and O
abnormalities O
in O
liver O
function O
tests O

the O
use O
of O
methotrexate B-DRUG
( O
mtx O
) O
has O
been O
contraindicated O
for O
treatment O
of O
severe O
psoriasis O
in O
hiv O
infection O
on O
the O
basis O
of O
six O
previously O
reported O
cases O
in O
which O
mtx O
appeared O
to O
potentiate O
opportunistic O
infections O
and O
accelerate B-ADR
hiv I-ADR
disease I-ADR

a O
57-year-old O
woman O
presented O
with O
a O
3-week O
history O
of O
dysphagia B-ADR
for I-ADR
solids I-ADR
, O
6 O
months O
after O
starting O
treatment O
with O
nifedipine B-DRUG

erosion B-ADR
of I-ADR
psoriatic I-ADR
plaques I-ADR
after O
chronic O
methotrexate B-DRUG
administration O

a O
short O
review O
on O
imatinib-related O
hepatotoxicity B-ADR
is O
also O
presented O

a O
case O
is O
described O
of O
severe B-ADR
splenic I-ADR
hemorrhage I-ADR
and I-ADR
rupture I-ADR
which O
developed O
3 O
h O
after O
completion O
of O
tpa B-DRUG
infusion O
for O
suspected O
acute O
myocardial O
infarction O

reflex B-ADR
sympathetic I-ADR
dystrophy I-ADR
syndrome I-ADR
in O
renal O
transplanted O
patients O
under O
immunosuppression O
with O
tacrolimus B-DRUG

eleven O
patients O
developed O
infection O
requiring O
hospitalization O
while O
taking O
leflunomide B-DRUG
including O
: O
lower O
respiratory O
tract O
infections O
( O
3 O
) O
, O
cellulitis B-ADR
( O
2 O
) O
, O
disseminated O
herpes O
zoster O
( O
2 O
) O
, O
probable O
tb O
liver O
( O
1 O
) O
, O
abdominal O
sepsis O
( O
1 O
) O
, O
mycotic O
aneurysm O
( O
1 O
) O
and O
gastroenteritis O
( O
1 O

objective O
: O
to O
describe O
a O
probable O
case O
of O
transient B-ADR
global I-ADR
amnesia I-ADR
caused O
by O
propafenone B-DRUG

herpes B-ADR
simplex I-ADR
esophagitis I-ADR
in O
a O
renal O
transplant O
patient O
treated O
with O
cyclosporine B-DRUG
a I-DRUG
: O
a O
case O
report O

she O
died O
within O
six O
weeks O
of O
developing O
congestive O
heart O
failure O
coupled O
with O
liver O
failure O
due O
to O
haemosiderosis B-ADR
despite O
regular O
use O
of O
desferrioxamine B-DRUG

the O
latter O
form O
( O
macrodantin B-DRUG
) O
is O
reported O
to O
engender O
less O
gastrointestinal O
intolerance O
but O
it O
can O
produce O
the O
same O
adverse O
effects O
as O
the O
conventional O
form O
-- O
liver O
damage O
, O
acute O
and O
chronic O
pulmonary O
reactions O
, O
peripheral O
neuropathy O
, O
blood O
dyscrasias O
and O
allergic B-ADR
reactions I-ADR
-- O
and O
does O
so O
just O
as O
rapidly O
and O
floridly O
; O
one O
such O
case O
is O
reported O
here O

a O
patient O
is O
described O
with O
the O
characteristic O
features O
of O
phenytoin B-ADR
hypersensitivity I-ADR
syndrome I-ADR
( O
phs O
) O
including O
fever O
, O
erythroderma O
, O
tibial O
and O
facial O
oedema O
, O
pinhead-sized O
facial O
pustules O
and O
abnormal O
liver O
function O
tests O

hypersensitivity B-ADR
reaction I-ADR
following O
chloramphenicol B-DRUG
administration O
in O
a O
patient O
with O
typhoid O
fever O

vigabatrin-induced O
visual B-ADR
field I-ADR
defects I-ADR
are O
at O
present O
the O
most O
important O
safety O
issue O
in O
the O
use O
of O
the O
drug O

this O
is O
a O
case O
report O
of O
fatal O
cryptococcal B-ADR
meningitis I-ADR
in O
a O
child O
with O
systemic O
lupus O
erythematosus O
being O
treated O
with O
prednisolone O
and O
azathioprine B-DRUG

cholesterol B-ADR
crystal I-ADR
embolization-associated O
renal O
failure O
after O
therapy O
with O
recombinant O
tissue-type B-DRUG
plasminogen I-DRUG
activator I-DRUG

development O
of O
essential O
thrombocythemia B-ADR
in O
a O
patient O
treated O
with O
interferon B-DRUG
alfa I-DRUG
and O
pentostatin O
for O
hairy O
cell O
leukemia O

acute O
inh B-DRUG
neurotoxicity B-ADR
was O
not O
suspected O
on O
the O
first O
admission O
; O
however O
, O
when O
readmitted O
4 O
weeks O
later O
with O
another O
seizure O
, O
the O
diagnosis O
of O
acute O
inh B-DRUG
neurotoxicity B-ADR
was O
made O

one O
patient O
who O
received O
clindamycin B-DRUG
had O
liver O
biopsy O
findings O
of O
marked B-ADR
cholestasis I-ADR
, O
portal O
inflammation O
, O
bile O
duct O
injury O
and O
bile O
duct O
paucity O
( O
ductopenia O

she O
developed O
a O
generalized O
rash O
and O
itching O
, O
sore B-ADR
throat I-ADR
, O
and O
dizziness O
approximately O
4 O
hours O
after O
the O
first O
dose O
of O
capecitabine B-DRUG

a O
patient O
receiving O
vancomycin B-DRUG
for O
a O
serious O
staphylococcal O
infection O
had O
a O
lupus-like O
syndrome O
characterized O
by O
a O
malar O
rash O
, O
pain O
and O
erythema B-ADR
of I-ADR
the I-ADR
cartilage I-ADR
of I-ADR
both I-ADR
ears I-ADR
, O
and O
tender O
erythematous O
and O
hemorrhagic O
lesions O
of O
the O
finger O
tips O

administration O
of O
cisplatin O
in O
three O
patients O
with O
carboplatin B-DRUG
hypersensitivity B-ADR
: O
is O
skin O
testing O
useful O

gabapentin-induced O
mood O
changes O
with O
hypomanic B-ADR
features O
in O
adults O

we O
describe O
the O
case O
of O
a O
50-year-old O
woman O
with O
advanced O
non-small O
cell O
lung O
cancer O
who O
developed O
status B-ADR
epilepticus I-ADR
shortly O
after O
receiving O
cisplatin O
and O
gemcitabine B-DRUG
chemotherapy O

mitomycin O
c O
( O
mmc B-DRUG
) O
is O
an O
alkylating O
agent O
that O
has O
been O
recently O
associated O
with O
the O
hemolytic-uremic B-ADR
syndrome I-ADR
( O
hus O

one O
of O
the O
subjects O
who O
was O
using O
extemporaneous O
topical O
minoxidil B-DRUG
had O
hypertension O
and O
arteriosclerotic B-ADR
disease I-ADR
and O
the O
other O
died O
of O
a O
myocardial O
infarction O

a O
7-year-old O
girl O
developed O
diabetes B-ADR
mellitus I-ADR
and O
exocrine O
pancreatic O
insufficiency O
after O
3.5 O
years O
of O
almost O
continuous O
treatment O
with O
azathioprine O
and O
/ O
or O
prednisone B-DRUG
for O
idiopathic O
auto-immune O
haemolytic O
anaemia O

neurologic B-ADR
degeneration I-ADR
associated O
with O
nitrous B-DRUG
oxide I-DRUG
anesthesia O
in O
patients O
with O
vitamin O
b12 O
deficiency O

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate O
with O
folinic B-DRUG
acid I-DRUG
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia O
, O
hyperkalaemia O
and O
hyperphosphataemia O
with O
hypocalcaemia O
and O
tetany B-ADR
, O
with O
metabolic O
acidosis O
and O
acute O
renal O
impairment O
) O
are O
described O

ataxia B-ADR
caused O
by O
propafenone B-DRUG
has O
been O
reported O
to O
the O
pharmaceutical O
companies O
and O
drug O
monitoring O
agencies O
, O
but O
has O
not O
been O
well O
described O
or O
emphasized O
in O
the O
medical O
literature O

these O
in O
vitro O
findings O
and O
clinical O
course O
suggest O
that O
trab O
/ O
tbii O
without O
thyroid-stimulating O
activity O
may O
develop O
in O
patients O
with O
amiodarone-induced O
destructive B-ADR
thyroiditis I-ADR
, O
as O
reported O
in O
patients O
with O
destructive B-ADR
thyroiditis I-ADR
, O
such O
as O
subacute O
and O
silent O
thyroiditis O

we O
report O
the O
case O
of O
a O
lung O
cancer O
patient O
with O
bronquiloalveolar O
carcinoma O
( O
bac O
) O
presenting O
with O
boop B-ADR
after O
chemotherapy O
with O
docetaxel O
and O
gemcitabine B-DRUG
producing O
severe O
respiratory O
insufficiency O
, O
and O
simulating O
a O
progression O
of O
the O
tumor O

in O
a O
series O
of O
104 O
cases O
of O
intentional O
or O
inadvertent O
use O
of O
zidovudine B-DRUG
at O
differing O
gestations O
in O
pregnancy O
, O
there O
were O
eight O
spontaneous O
first B-ADR
trimester I-ADR
abortions I-ADR
, O
eight O
therapeutic O
terminations O
, O
and O
eight O
cases O
of O
fetal O
abnormality O
occurring O
among O
a O
total O
of O
88 O
cases O
where O
the O
pregnancy O
progressed O

an O
83-year-old O
man O
receiving O
glipizide O
10 O
mg O
bid O
developed O
symptomatic B-ADR
hypoglycemia I-ADR
within O
three O
days O
of O
adding O
trimethoprim O
/ O
sulfamethoxazole B-DRUG
( O
tmp O
/ O
smx O
) O
to O
his O
regimen O

this O
is O
the O
first O
report O
of O
acute O
kidney O
injury O
due O
to O
zonisamide-induced O
dress O
/ O
dihs B-ADR

upon O
discontinuation O
of O
mtx B-DRUG
, O
her O
ascites B-ADR
resolved O
, O
and O
her O
arthritis O
became O
more O
active O

iatrogenic B-ADR
cushing I-ADR
syndrome I-ADR
after O
epidural O
triamcinolone B-DRUG
injections O
in O
an O
hiv O
type O
1-infected O
patient O
receiving O
therapy O
with O
ritonavir-lopinavir O

the O
typical O
fluoxetine-induced O
symptoms O
of O
restlessness O
, O
constant O
pacing O
, O
purposeless O
movements O
of O
the O
feet O
and O
legs O
, O
and O
marked B-ADR
anxiety I-ADR
were O
indistinguishable O
from O
those O
of O
neuroleptic-induced O
akathisia O

we O
report O
a O
third O
case O
of O
a O
6-week-old O
infant O
with O
escherichia O
coli O
sepsis O
who O
received O
ampicillin B-DRUG
and O
other O
antibiotics O
and O
subsequently O
developed O
ten B-ADR

the O
authors O
describe O
a O
case O
of O
neuroleptic B-ADR
malignant I-ADR
syndrome I-ADR
that O
occurred O
in O
a O
patient O
on O
amitriptyline O
and O
lithium B-DRUG
carbonate I-DRUG

she O
developed O
a O
generalized B-ADR
rash I-ADR
and O
itching O
, O
sore O
throat O
, O
and O
dizziness O
approximately O
4 O
hours O
after O
the O
first O
dose O
of O
capecitabine B-DRUG

intrahepatic B-ADR
cholestasis I-ADR
and O
cutaneous O
bullae O
associated O
with O
glibenclamide B-DRUG
therapy O

a O
7-year-old O
with O
congenital O
toxoplasmosis O
who O
took O
pyrimethamine O
and O
sulfadiazine B-DRUG
for O
reactivated O
chorioretinitis O
developed O
fever B-ADR
, O
severe O
cutaneous O
involvement O
, O
swelling O
, O
abdominal O
pain O
and O
transaminitis O
, O
persisting O
weeks O
after O
withholding O
medicines O

the O
international O
literature O
regarding O
opportunistic O
infections O
after O
immunosuppressive O
therapy O
with O
alemtuzumab B-DRUG
with O
particular O
attention O
on O
fungal B-ADR
infections I-ADR
has O
also O
been O
reviewed O

a O
patient O
receiving O
vancomycin B-DRUG
for O
a O
serious O
staphylococcal O
infection O
had O
a O
lupus-like O
syndrome O
characterized O
by O
a O
malar B-ADR
rash I-ADR
, O
pain O
and O
erythema O
of O
the O
cartilage O
of O
both O
ears O
, O
and O
tender O
erythematous O
and O
hemorrhagic O
lesions O
of O
the O
finger O
tips O

alternating O
sinus O
rhythm O
and O
intermittent O
sinoatrial O
( O
s-a O
) O
block O
was O
observed O
in O
a O
57-year-old O
woman O
, O
under O
treatment O
for O
angina O
with O
80 O
mg O
propranolol B-DRUG
daily O

we O
postulate O
that O
cyclosporin B-DRUG
, O
possibly O
together O
with O
ganciclovir O
, O
can O
produce O
transient O
brain O
stem O
or O
neuromuscular O
dysfunction O
with O
eye B-ADR
movement I-ADR
abnormality I-ADR
in O
occasional O
patients O

conclusions O
: O
peripheral O
administration O
of O
low-dose O
vasopressin B-DRUG
for O
septic O
shock O
should O
be O
discouraged O
because O
of O
the O
risk O
of O
ischemic B-ADR
skin I-ADR
complications I-ADR

can O
propofol B-DRUG
precipitate O
pancreatitis B-ADR
in O
patients O
with O
cushing O
's O
syndrome O

hyperglycemia O
and O
diabetic B-ADR
coma I-ADR
: O
possible O
relationship O
to O
diuretic-propranolol O
therapy O

monoclonal B-ADR
gammopathy I-ADR
and O
subsequent O
multiple O
myeloma O
in O
a O
patient O
on O
chronic O
diphenylhydantoin B-DRUG
therapy O

conclusions O
: O
this O
report O
indicates O
clindamycin B-DRUG
phosphate O
vaginal O
cream O
as O
the O
most O
probable O
cause O
of O
cdic O
due O
to O
the O
temporal O
relationship O
between O
the O
occurrence O
of O
diarrhea B-ADR
and O
clindamycin B-DRUG
administration O
, O
lack O
of O
concomitant O
medications O
, O
and O
documentation O
of O
c. O
difficile O
toxin O

acute O
hyperphosphatemia B-ADR
caused O
by O
sodium B-DRUG
phosphate I-DRUG
enema O
in O
a O
patient O
with O
liver O
dysfunction O
and O
chronic O
renal O
failure O

a O
previous O
review O
described O
data O
on O
15 O
patients O
who O
experienced O
acute O
hemoglobinemia O
or O
hemoglobinuria B-ADR
following O
anti-d B-DRUG
igiv I-DRUG
administration O
for O
itp O
or O
secondary O
thrombocytopenia O

on O
the O
next O
day O
, O
after O
a O
total O
dose O
of O
only O
600 O
mg O
of O
danazol B-DRUG
, O
gingival O
bleeding O
and O
purpura B-ADR
occurred O

the O
introduction O
of O
para-aminosalicylic B-DRUG
acid I-DRUG
( O
pas O
) O
led O
to O
hypoglycaemic B-ADR
coma I-ADR

based O
on O
the O
naranjo O
algorithm O
, O
the O
adverse O
reaction O
observed O
was O
probably O
related O
to O
the O
hydroxyurea B-DRUG
treatment O
( O
score O
= O
6 O
) O
; O
however O
, O
the O
hydroxyurea B-DRUG
chemotherapy O
could O
not O
be O
discontinued O
because O
of O
the O
myeloproliferative B-ADR
disorder I-ADR

it O
remains O
to O
be O
seen O
whether O
the O
hepatotoxicity B-ADR
associated O
with O
troglitazone B-DRUG
is O
a O
drug-class O
effect O
or O
specific O
to O
troglitazone B-DRUG

a O
drug O
addict O
with O
staphylococcal O
endocarditis O
treated O
with O
methicillin B-DRUG
, O
who O
developed O
massive O
proteinuria O
and O
acute B-ADR
nephritic I-ADR
syndrome I-ADR
is O
described O

toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
after O
the O
use O
of O
high-dose O
cytosine B-DRUG
arabinoside I-DRUG

we O
report O
a O
case O
of O
glaucoma B-ADR
induced O
by O
doxetaxel B-DRUG
therapy O
for O
metastatic O
breast O
cancer O

however O
, O
one O
patient O
exhibited O
severe O
hypersensitivity O
reactions O
including O
cardiac O
arrest O
and O
apnea O
, O
and O
another O
four O
patients O
developed O
eruptions O
, O
hypotension O
, O
and O
tachycardia B-ADR
soon O
after O
administration O
of O
cbdca B-DRUG

potential O
mechanisms O
regarding O
the O
pathophysiology O
of O
lithium-associated O
cdi B-ADR
are O
discussed O

cardiac O
glycosides O
are O
thought O
to O
prevent O
doxorubicin B-DRUG
cardiomyopathy B-ADR
by O
competitively O
inhibiting O
doxorubicin B-DRUG
at O
its O
receptor O
sites O
, O
but O
ouabain O
has O
a O
much O
shorter O
half O
life O
than O
doxorubicin B-DRUG
and O
its O
metabolites O
and O
so O
is O
less O
effective O
than O
digoxin O

we O
present O
two O
cases O
of O
nitrofurantoin-induced O
pulmonary O
toxicity O
in O
which O
the O
initial O
hrct O
showed O
a O
widespread O
reticular O
pattern O
and O
associated O
distortion O
of O
the O
lung O
parenchyma O
, O
thought O
to O
represent O
established O
fibrosis B-ADR

we O
report O
a O
case O
of O
stevens-johnson B-ADR
syndrome I-ADR
/ O
toxic O
epidermal O
necrolysis O
( O
sjs O
/ O
ten O
) O
secondary O
to O
trimethoprim-sulfamethoxazole B-DRUG
( O
tmp-sx O
) O
therapy O
for O
presumed O
community-associated O
methicillin-resistant O
staphylococcus O
aureus O
( O
ca-mrsa O
) O
infection O

we O
describe O
the O
first O
documented O
case O
of O
azathioprine-induced O
severe O
myelosuppression B-ADR
due O
to O
thiopurine O
methyltransferase O
deficiency O
in O
autoimmune O
liver O
disease O

possible O
mechanisms O
by O
which O
clonidine B-DRUG
decreases O
spasticity O
are O
described O
, O
probable O
mechanisms O
of O
induced O
bradycardia B-ADR
are O
reviewed O
, O
and O
specific O
treatment O
recommendations O
for O
the O
use O
of O
clonidine B-DRUG
in O
spinal O
cord O
injured O
patients O
are O
presented O

in O
one O
patient O
, O
treatment O
with O
dca B-DRUG
was O
associated O
with O
a O
decrease B-ADR
in I-ADR
blood I-ADR
lactate I-ADR
levels I-ADR
from O
11.2 O
mm O
before O
treatment O
to O
0.8 O
mm O
16 O
h O
later O

the O
reported O
cases O
of O
in O
utero O
exposure O
to O
cyclosposphamide B-DRUG
shared O
the O
following O
manifestations O
with O
our O
patient O
: O
growth O
deficiency O
, O
developmental O
delay O
, O
craniosynostosis O
, O
blepharophimosis O
, O
flat B-ADR
nasal I-ADR
bridge I-ADR
, O
abnormal O
ears O
, O
and O
distal O
limb O
defects O
including O
hypoplastic O
thumbs O
and O
oligodactyly O

behavioral O
side O
effects O
associated O
with O
clonazepam B-DRUG
may O
include O
agitation O
, O
aggression B-ADR
, O
hyperactivity O
, O
irritability O
, O
property O
destruction O
, O
and O
temper O
tantrums O

two O
renal O
transplant O
patients O
developed O
anemia B-ADR
during O
treatment O
of O
hypertension O
with O
enalapril B-DRUG
medication O

lamotrigine B-ADR
toxicity I-ADR
secondary O
to O
sertraline O

when O
sasp O
was O
changed O
to O
5-aminosalicylic B-DRUG
acid I-DRUG
( O
5-asa O
) O
, O
his O
skin O
eruptions O
were O
resolved O
, O
however O
, O
he O
developed O
weakness O
and O
atrophy B-ADR
in O
his O
right O
arm O
as O
well O
as O
progressive O
worsening O
of O
the O
dysesthesia O
in O
his O
legs O
and O
gait O
disturbance O

a O
case O
of O
basilar B-ADR
invagination I-ADR
which O
is O
thought O
to O
have O
arisen O
from O
the O
patient O
's O
intrauterine O
exposure O
to O
phenytoin B-DRUG
is O
presented O

neutropenia O
and O
agranulocytosis B-ADR
are O
risks O
known O
to O
occur O
with O
phenothiazines B-DRUG
and O
clozapine O

our O
patient O
had O
headache O
, O
mild O
fever O
, O
nausea O
, O
vomiting O
, O
rash O
, O
and O
eosinophilia B-ADR
after O
3 O
weeks O
of O
disulfiram B-DRUG
therapy O

this O
is O
a O
case O
report O
of O
fatal O
cryptococcal B-ADR
meningitis I-ADR
in O
a O
child O
with O
systemic O
lupus O
erythematosus O
being O
treated O
with O
prednisolone B-DRUG
and O
azathioprine O

biopsy-proven O
acute B-ADR
interstitial I-ADR
nephritis I-ADR
associated O
with O
the O
tyrosine O
kinase O
inhibitor O
sunitinib B-DRUG
: O
a O
class O
effect O

conclusions O
: O
optic B-ADR
neuritis I-ADR
in O
combination O
with O
other O
neurological O
signs O
, O
simulating O
multiple O
sclerosis O
, O
should O
be O
included O
in O
the O
list O
of O
adverse O
effects O
of O
recombinant O
and O
natural O
interferon B-DRUG
alpha I-DRUG
administration O

intrahepatic B-ADR
cholestasis I-ADR
and O
cutaneous O
bullae O
associated O
with O
glibenclamide B-DRUG
therapy O
are O
described O
in O
a O
61-year-old O
diabetic O
patient O
who O
presented O
wit O
hypoglycaemic O
coma O

during O
the O
anti-tuberculous O
therapy O
, O
visual B-ADR
loss I-ADR
can O
be O
related O
to O
ethambutol B-DRUG
toxicity O
or O
the O
tuberculosis O
infection O
itself O

thrombotic B-ADR
microangiopathy I-ADR
with O
renal O
failure O
in O
two O
patients O
undergoing O
gemcitabine B-DRUG
chemotherapy O

thirty-six O
patients O
with O
al O
received O
, O
in O
a O
three-month O
period O
, O
51 O
cycles O
of O
combined O
chemotherapy O
which O
included O
, O
in O
all O
of O
them O
, O
cytosine O
arabinoside O
( O
ara-c B-DRUG
) O
; O
among O
them O
, O
along O
with O
myelosuppression O
, O
five O
experienced O
fever B-ADR
, O
infectious O
complications O
, O
gastrointestinal O
tract O
symptoms O
and O
severe O
myalgias O

interaction B-ADR
between O
tacrolimus O
and O
nefazodone B-DRUG
in O
a O
stable O
renal O
transplant O
recipient O

emphasis O
is O
given O
to O
the O
differentiation O
of O
diphenylhydantoin B-DRUG
induced O
gingival B-ADR
hyperplasia I-ADR
from O
the O
angiomatous O
enlargement O
of O
the O
gingiva O
before O
any O
treatment O
is O
planned O

we O
report O
a O
patient O
in O
whom O
the O
anti-depressant O
trazodone O
hydrochloride O
( O
molipaxin B-DRUG
, O
roussel O
) O
, O
a O
serotonin O
antagonist O
, O
provoked O
generalized B-ADR
pustular I-ADR
psoriasis I-ADR
( O
gpp O

acute B-ADR
kidney I-ADR
injury I-ADR
caused O
by O
zonisamide-induced O
hypersensitivity O
syndrome O

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin O
, O
grepafloxacin O
, O
trovafloxacin B-DRUG
, O
gatifloxacin O
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache B-ADR
, O
dizziness O
and O
insomnia O

during O
clarithromycin B-DRUG
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate-to-severe O
toxic O
symptoms O
of O
carbamazepine O
, O
such O
as O
drowsiness O
, O
dizziness B-ADR
, O
and O
ataxia O
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin B-DRUG
discontinuation O

horner O
's O
syndrome O
and O
demyelinating B-ADR
peripheral I-ADR
neuropathy I-ADR
caused O
by O
high-dose O
cytosine B-DRUG
arabinoside I-DRUG

mean O
time O
between O
initiation O
of O
gemcitabine B-DRUG
therapy O
and O
onset O
of O
hus B-ADR
was O
7.4 O
+/- O
3.5 O
months O
, O
or O
21.9 O
+/- O
10.9 O
doses O
of O
gemcitabine B-DRUG

a O
patient O
suffering O
from O
heparin-associated O
thrombocytopenia O
( O
hat B-ADR
) O
, O
recurrent O
arteriothromboses O
, O
and O
acute O
renal O
failure O
after O
treatment O
with O
standard O
heparin B-DRUG
is O
described O

severe B-ADR
adenovirus I-ADR
pneumonia I-ADR
( O
avp O
) O
following O
infliximab B-DRUG
infusion O
for O
the O
treatment O
of O
crohn O
's O
disease O

a O
44-year-old O
woman O
is O
described O
in O
whom O
amiodarone B-DRUG
, O
disopyramide O
, O
and O
quinidine O
, O
administered O
alone O
separately O
, O
induced O
atypical O
ventricular O
tachycardia O
( O
avt O
, O
torsade B-ADR
de I-ADR
pointes I-ADR

in O
all O
the O
patients O
, O
pellagra B-ADR
symptoms O
appeared O
during O
isoniazid B-DRUG
therapy O

however O
, O
a O
large O
case-control O
study O
included O
three O
cases O
of O
either O
stevens-johnson O
syndrome O
or O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
associated O
with O
ofloxacin B-DRUG
use O
, O
but O
no O
details O
of O
the O
cases O
were O
given O

we O
conjectured O
that O
the O
side O
effects O
of O
insulin B-DRUG
, O
such O
as O
anti-natriuresis O
and O
increased O
vascular O
permeability O
, O
might O
be O
pronounced O
in O
the O
presence O
of O
the O
hepatic O
dysfunction O
that O
accompanies O
insulin B-ADR
insensitivity I-ADR
, O
hyperinsulinaemia O
and O
hypoalbuminaemia O

enoxaparin-induced O
generalized B-ADR
exanthem I-ADR

idiosyncratic O
factors O
involving O
vasopressin B-DRUG
receptor O
affinity O
and O
distribution O
, O
vasopressin-associated O
vasodilation B-ADR
in O
some O
vascular O
beds O
, O
and O
the O
effect O
of O
vasopressin B-DRUG
on O
the O
renin-angiotensin O
system O
may O
further O
contribute O
to O
impaired O
tissue O
perfusion O

these O
cases O
suggest O
the O
possibility O
that O
, O
in O
some O
patients O
, O
leukopenia O
or O
agranulocytosis B-ADR
during O
olanzapine B-DRUG
treatment O
might O
be O
dose-related O

digestive B-ADR
hemorrhage I-ADR
caused O
by O
a O
meckel O
's O
diverticulum O
in O
a O
metformin-treated O
patient O
: O
is O
there O
any O
connection O

we O
cared O
for O
a O
patient O
with O
progressive O
renal O
impairment O
who O
presented O
with O
blurred B-ADR
vision I-ADR
, O
qrs O
broadening O
and O
cardiac O
failure O
due O
to O
chronic O
cibenzoline B-DRUG
intoxication O

acute O
vision O
loss O
after O
intravitreal O
injection O
of O
bevacizumab B-DRUG
( O
avastin O
) O
associated O
with O
ocular B-ADR
ischemic I-ADR
syndrome I-ADR

neurointensive O
care O
management O
of O
raised B-ADR
intracranial I-ADR
pressure I-ADR
caused O
by O
severe O
valproic B-DRUG
acid I-DRUG
intoxication O

methods O
: O
a O
55-year-old O
woman O
became O
stuporous B-ADR
after O
overdose O
with O
lamotrigine O
( O
ltg B-DRUG
) O
and O
valproic O
acid O
( O
vpa O
) O
tablets O

intravenous O
sodium O
bicarbonate O
appears O
to O
be O
indicated O
prophylactically O
in O
combating O
the O
associated O
metabolic B-ADR
acidosis I-ADR
due O
to O
absorbed O
formic B-DRUG
acid I-DRUG

thrombotic O
microangiopathy O
with O
renal B-ADR
failure I-ADR
in O
two O
patients O
undergoing O
gemcitabine B-DRUG
chemotherapy O

early-onset O
pentamidine-associated O
second-degree B-ADR
heart I-ADR
block I-ADR
and O
sinus O
bradycardia O
: O
case O
report O
and O
review O
of O
the O
literature O

the O
authors O
describe O
a O
woman O
with O
chronic O
schizophrenia O
who O
experienced O
delirium O
, O
grand O
mal O
seizure O
, O
and O
photosensitivity B-ADR
after O
the O
addition O
of O
propranolol B-DRUG
to O
her O
neuroleptic O
regimen O

method O
: O
we O
describe O
three O
case-reports O
concerning O
haematological B-ADR
adverse I-ADR
effects I-ADR
of O
quetiapine B-DRUG

adr B-ADR
induced O
by O
drug O
treatment O
can O
be O
a O
side O
effect O
of O
treatment O
with O
antipsychotic O
drugs O
and O
other O
drugs O
; O
however O
, O
there O
have O
been O
no O
reports O
of O
lamivudine-induced O
adr B-ADR
in O
the O
english O
literature O

however O
, O
we O
recently O
saw O
two O
patients O
with O
renal O
tuberculosis O
treated O
with O
ethambutol B-DRUG
in O
whom O
visual O
loss O
from O
toxic B-ADR
optic I-ADR
neuropathies I-ADR
was O
severe O
and O
irreversible O
despite O
careful O
ophthalmological O
monitoring O
and O
prompt O
discontinuation O
of O
the O
agent O
at O
the O
first O
sign O
of O
impaired O
visual O
function O

the O
authors O
report O
a O
further O
case O
of O
methimazole-associated O
liver B-ADR
damage I-ADR
and O
present O
a O
brief O
review O
of O
eleven O
previous O
cases O
found O
in O
the O
literature O

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity O
reactions O
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general B-ADR
erythema I-ADR
, O
dyspnea O
, O
and O
hypotension O
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal O
pain O
, O
general B-ADR
erythema I-ADR
, O
and O
fever O

the O
ampicillin B-ADR
rash I-ADR
occurring O
in O
cases O
of O
infectious O
mononucleosis O
is O
well O
documented O

response O
of O
a O
promethazine-induced O
coma B-ADR
to O
flumazenil O

excluding O
other O
causes O
, O
pentasa-associated O
pancytopenia B-ADR
was O
considered O

fatal B-ADR
pulmonary I-ADR
fibrosis I-ADR
following O
1,3-bis O
( O
2-chloroethyl O
)- O
1-nitrosourea O
( O
bcnu B-DRUG
) O
therapy O

leiomyosarcoma B-ADR
in O
urinary O
bladder O
after O
cyclophosphamide B-DRUG
therapy O
for O
retinoblastoma O
and O
review O
of O
bladder O
sarcomas O

however O
, O
cyclosporine B-DRUG
dependency O
is O
associated O
with O
the O
risk O
of O
nephrotoxicity B-ADR

methysergide-induced O
retroperitoneal B-ADR
fibrosis I-ADR
: O
successful O
outcome O
and O
two O
new O
laboratory O
features O

alopecia B-ADR
, O
nausea O
, O
and O
vomiting O
were O
attributed O
to O
the O
cyclophosphamide B-DRUG
component O
of O
the O
therapy O

interstitial B-ADR
fibrosis I-ADR
of I-ADR
the I-ADR
lung I-ADR
is O
a O
potential O
complication O
of O
methotrexate B-DRUG
therapy O
for O
psoriasis O

caution O
in O
longterm O
usage O
and O
early O
recognition O
of O
pentazocine B-DRUG
toxicity O
as O
a O
neuromuscular O
complication O
are O
important O
in O
order O
to O
prevent O
irreversible O
drug-induced O
fibrous B-ADR
myopathy I-ADR
and O
localized O
neuropathy O

phenylpropanolamine O
( O
ppa B-DRUG
) O
recently O
has O
been O
publicly O
implicated O
as O
a O
cause O
of O
stroke B-ADR
and O
other O
neurologic O
events O

neurotoxicity B-ADR
of O
intrathecal O
administration O
of O
amphotericin B-DRUG
b I-DRUG

during O
dose-finding O
studies O
for O
intravenous O
proton O
pump O
inhibitors O
omeprazole B-DRUG
and O
pantoprazole O
, O
three O
of O
six O
young O
female O
volunteers O
receiving O
omeprazole B-DRUG
and O
two O
young O
female O
volunteers O
receiving O
pantoprazole O
developed O
peripheral B-ADR
edema I-ADR
within O
8 O
hr O
when O
high O
doses O
of O
the O
proton O
pump O
inhibitors O
were O
applied O
by O
continuous O
infusion O
together O
with O
large O
volumes O
of O
fluid O

we O
report O
an O
82-year-old O
man O
who O
developed O
ventricular O
tachycardia O
and O
torsades B-ADR
de I-ADR
pointes I-ADR
( O
tdp O
) O
after O
oral O
administration O
of O
garenoxacin B-DRUG
, O
a O
novel O
quinolone O
antibiotic O
agent O
that O
differs O
from O
the O
third-generation O
quinolones O
, O
for O
pneumonia O

conclusions O
: O
acute B-ADR
severe I-ADR
hepatitis I-ADR
though O
rare O
is O
occasionally O
observed O
with O
egfr O
inhibitors O
gefitinib O
or O
erlotinib B-DRUG

anisocoria B-ADR
from O
transdermal O
scopolamine B-DRUG

we O
report O
an O
unusual O
case O
of O
massive O
fluoxetine B-DRUG
ingestion O
resulting O
in O
neurological B-ADR
and I-ADR
cardiovascular I-ADR
toxicity I-ADR
resulting O
in O
death O

hypersensitivity B-ADR
reactions I-ADR
to O
cisplatin B-DRUG
following O
multiple O
uncomplicated O
courses O
: O
a O
report O
on O
two O
cases O

the O
vomiting B-ADR
occurred O
on O
switching O
to O
different O
pancreatic O
enzymes O
preparations O
, O
ie O
, O
creon O
10 O
, O
viokase B-DRUG
, O
and O
pancrease O
mt O
16 O

naproxen B-DRUG
is O
a O
commonly O
used O
nonsteroidal O
anti-inflammatory O
drug O
( O
nsaid O
) O
whose O
side O
effects O
include O
tinnitus O
and O
transient B-ADR
hearing I-ADR
loss I-ADR

she O
died O
within O
six O
weeks O
of O
developing O
congestive B-ADR
heart I-ADR
failure I-ADR
coupled O
with O
liver O
failure O
due O
to O
haemosiderosis O
despite O
regular O
use O
of O
desferrioxamine B-DRUG

upper B-ADR
gastrointestinal I-ADR
haemorrhage I-ADR
is O
a O
serious O
complication O
of O
aspirin B-DRUG
and O
clopidogrel O
( O
dual O
) O
anti-platelet O
therapy O
with O
a O
high O
morbidity O
and O
mortality O

used O
injudiciously O
, O
naloxone B-DRUG
can O
lead O
to O
withdrawal B-ADR
syndrome I-ADR
, O
return O
of O
severe O
pain O
, O
and O
other O
adverse O
effects O

acute O
asymptomatic B-ADR
hepatitis I-ADR
in O
a O
healthy O
normal O
volunteer O
exposed O
to O
2 O
oral O
doses O
of O
amodiaquine B-DRUG
and O
artesunate O

carbamazepine B-ADR
toxicity I-ADR
following O
oxybutynin O
and O
dantrolene B-DRUG
administration O
: O
a O
case O
report O

we O
report O
a O
male O
patient O
with O
advanced O
aids O
who O
developed O
hypercalcemia B-ADR
2 O
weeks O
after O
institution O
of O
rhgh B-DRUG
therapy O

two O
elderly O
women O
suffered O
an O
acute B-ADR
deterioration I-ADR
of I-ADR
renal I-ADR
function I-ADR
after O
treatment O
with O
cefoxitin B-DRUG
sodium I-DRUG

background O
: O
hydroxyurea B-DRUG
is O
a O
cytostatic O
agent O
used O
to O
treat O
myeloproliferative O
disorders O
and O
long-term O
treatment O
is O
associated O
with O
mucocutaneous O
adverse O
events O
and O
nail B-ADR
hyperpigmentation I-ADR

a O
patient O
with O
intracranial O
osteosarcoma O
that O
arose O
16 O
years O
after O
radiation O
therapy O
for O
hereditary O
retinoblastoma O
developed O
fatal B-ADR
cerebral I-ADR
edema I-ADR
and O
brainstem O
herniation O
after O
she O
received O
a O
single O
dose O
of O
intravenous O
methotrexate B-DRUG

however O
, O
continued O
low-dose O
mtx B-DRUG
led O
, O
in O
spite O
of O
normal O
liver O
tests O
, O
8 O
years O
after O
the O
last O
biopsy O
to O
liver B-ADR
failure I-ADR
and O
death O
in O
1 O
of O
our O
patients O

painful O
erosion O
of O
psoriatic O
plaques O
is O
a O
less O
common O
sign O
of O
methotrexate B-ADR
toxicity I-ADR
that O
may O
precede O
evidence O
of O
bone O
marrow O
suppression O

acute B-ADR
renal I-ADR
failure I-ADR
most O
likely O
was O
secondary O
to O
the O
nephrotoxic O
effect O
of O
captopril B-DRUG
on O
chronically O
hypoperfused O
kidneys O

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion O
, O
agitation O
, O
tachycardia O
, O
tremors O
, O
myoclonic B-ADR
jerks I-ADR
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

the O
authors O
report O
a O
case O
of O
balint O
syndrome O
with O
irreversible O
posterior B-ADR
leukoencephalopathy I-ADR
on O
mri O
following O
intrathecal O
methotrexate B-DRUG
and O
cytarabine O

aseptic O
meningitis O
, O
hemolytic O
anemia O
, O
hepatitis O
, O
and O
orthostatic B-ADR
hypotension I-ADR
in O
a O
patient O
treated O
with O
trimethoprim-sulfamethoxazole O

disseminated B-ADR
intravascular I-ADR
coagulation I-ADR
associated O
with O
acute O
hemoglobinemia O
or O
hemoglobinuria O
following O
rh O
( O
0 O
)( O
d O
) O
immune O
globulin O
intravenous O
administration O
for O
immune O
thrombocytopenic O
purpura O

cephalexin B-ADR
rash I-ADR
in O
infectious O
mononucleosis O

a O
47 O
year-old O
woman O
who O
had O
a O
4-year O
history O
of O
intramuscular O
pentazocine B-DRUG
injections O
in O
the O
lower O
extremities O
, O
developed O
gradual B-ADR
stiffness I-ADR
and O
weakness O
of O
the O
lower O
extremities O

early O
overanticoagulation B-ADR
with O
acenocoumarol B-DRUG
due O
to O
a O
genetic O
polymorphism O
of O
cytochrome O
p450 O
cyp2c9 O

chlorambucil-induced O
chromosome B-ADR
damage I-ADR
to O
human O
lymphocytes O
is O
dose-dependent O
and O
cumulative O

spontaneous O
bacterial B-ADR
peritonitis I-ADR
induced O
by O
intraarterial O
vasopressin B-DRUG
therapy O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical B-ADR
lymphadenopathy I-ADR
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp O
)- O
sulfamethoxazole O
( O
smx B-DRUG
) O
treatment O

previous O
studies O
have O
demonstrated O
the O
interaction O
of O
mtx B-DRUG
and O
a O
variety O
of O
non-steroidal O
, O
anti-inflammatory O
drugs O
( O
nsaids O
) O
with O
various O
clinical O
manifestations O
including O
acute O
renal O
failure O
, O
pancytopenia O
, O
vomiting O
, O
diarrhea O
, O
elevated O
liver O
transaminases O
, O
jaundice O
, O
mucosal B-ADR
ulcerations I-ADR
, O
and O
pyrexia O

valproate-induced O
hyperammonemia O
as O
a O
cause O
of O
altered B-ADR
mental I-ADR
status I-ADR

we O
report O
two O
patients O
with O
acne O
vulgaris O
with O
a O
fourth O
type O
of O
minocycline-induced O
cutaneous B-ADR
pigmentation I-ADR

we O
report O
the O
case O
of O
a O
17-year-old O
male O
who O
developed O
chest O
pain O
, O
elevated O
cardiac O
biomarkers O
, O
and O
acute B-ADR
left I-ADR
ventricular I-ADR
dysfunction I-ADR
following O
a O
single O
dose O
of O
methylphenidate B-DRUG

following O
the O
institution O
of O
intravenous O
therapy O
with O
acyclovir B-DRUG
, O
the O
patient O
developed O
fever O
, O
hemoptysis B-ADR
, O
and O
a O
pleural O
friction O
rub O

conclusion O
: O
a O
37-year-old O
african O
- O
american O
man O
with O
g6pd O
deficiency O
developed O
hemolytic O
anemia O
, O
hepatitis O
, O
orthostatic O
hypotension O
, O
and O
aseptic B-ADR
meningitis I-ADR
simultaneously O
after O
using O
trimethoprim-sulfamethoxazole O

the O
main O
clinical O
features O
of O
this O
58-year-old O
female O
patient O
were O
laboratory O
evidence O
of O
leucopenia O
and O
cholestasis O
, O
and O
biopsy O
features O
of O
fatty B-ADR
liver I-ADR
parenchyma I-ADR
degeneration I-ADR
with O
granulocytic O
portal O
infiltration O
and O
bile O
stasis O
, O
demonstrated O
20 O
days O
after O
the O
initiation O
of O
antithyroid O
therapy O
with O
20 O
mg O
methimazole B-DRUG
daily O

data O
synthesis O
: O
genetic O
deficiencies O
in O
dpd O
, O
the O
rate-limiting O
enzyme O
responsible O
for O
5-fu B-DRUG
catabolism O
, O
may O
occur O
in O
3 O
% O
or O
more O
of O
patients O
with O
cancer O
putting O
them O
at O
increased O
risk O
for O
unusually O
severe O
adverse O
reactions O
( O
e.g. O
, O
diarrhea O
, O
stomatitis B-ADR
, O
mucositis O
, O
myelosuppression O
, O
neurotoxicity O
) O
to O
standard O
doses O
of O
5-fu B-DRUG

colitis B-ADR
as O
a O
manifestation O
of O
infliximab-associated O
disseminated O
cryptococcosis O

objective O
: O
to O
report O
a O
case O
of O
a O
diffuse B-ADR
papular I-ADR
eruption I-ADR
following O
treatment O
of O
psoriasis O
with O
methotrexate B-DRUG
injections O

combining O
methylephedrine B-DRUG
and O
chinese O
herbal O
drugs O
might O
carry O
a O
risk O
of O
stroke B-ADR

we O
report O
three O
cases O
of O
severe B-ADR
hypocalcaemia I-ADR
associated O
with O
i.v. O
bisphosphonate B-DRUG
treatment O
in O
patients O
with O
multiple O
myeloma O

the O
concomitant O
use O
, O
however O
, O
of O
colchicine O
and O
statin B-DRUG
has O
been O
associated O
with O
the O
rapid O
onset O
of O
muscle B-ADR
weakness I-ADR

a O
new O
case O
of O
creutzfeldt-jakob B-ADR
disease I-ADR
associated O
with O
human B-DRUG
growth I-DRUG
hormone I-DRUG
therapy O
in O
new O
zealand O

priapism B-ADR
associated O
with O
trazodone B-DRUG
therapy O
: O
case O
report O

we O
believe O
that O
these O
skin O
eruptions O
belong O
to O
a O
spectrum O
of O
neutrophilic B-ADR
dermatoses I-ADR
that O
can O
be O
induced O
or O
aggravated O
by O
g-csf B-DRUG
therapy O

when O
vague O
symptoms O
develop O
during O
desmopressin B-DRUG
therapy O
, O
hyponatremia B-ADR
must O
be O
considered O
as O
part O
of O
the O
differential O
diagnosis O

phenylpropanolamine-induced O
psychosis B-ADR

in O
the O
following O
case O
report O
, O
a O
patient O
developed O
acute O
interstitial O
nephritis O
with O
renal B-ADR
failure I-ADR
and O
exfoliative O
dermatitis O
following O
ampicillin B-DRUG
therapy O

fatal B-ADR
lung I-ADR
fibrosis I-ADR
caused O
by O
paclitaxel B-DRUG
toxicity O
has O
not O
been O
reported O
in O
this O
report O
, O
we O
describe O
the O
case O
of O
a O
62-year-old O
woman O
who O
received O
six O
cycles O
of O
paclitaxel B-DRUG
and O
carboplatin O
as O
combination O
chemotherapy O
for O
advanced O
ovarian O
cancer O

nine O
azotemic O
patients O
who O
developed O
a O
coagulopathy B-ADR
associated O
with O
the O
use O
of O
either O
cephalosporin O
or O
moxalactam B-DRUG
antibiotics O
are O
reported O

all-trans B-DRUG
retinoic I-DRUG
acid-induced O
focal B-ADR
myositis I-ADR
, O
synovitis O
, O
and O
mononeuritis O

pulmonary B-ADR
gold I-ADR
toxicity I-ADR

a O
case O
of O
the O
rett O
syndrome O
with O
acute B-ADR
encephalopathy I-ADR
induced O
during O
calcium B-DRUG
hopantenate I-DRUG
treatment O

the O
patient O
was O
diagnosed O
with O
carbamazepine B-ADR
toxicity I-ADR
related O
to O
the O
introduction O
of O
ritonavir B-DRUG

a O
35-year-old O
man O
with O
seropositive O
rheumatoid O
arthritis O
developed O
selective O
iga B-ADR
deficiency I-ADR
during O
treatment O
with O
fenclofenac B-DRUG

rapid O
onset O
of O
muscle B-ADR
weakness I-ADR
( O
rhabdomyolysis O
) O
associated O
with O
the O
combined O
use O
of O
simvastatin B-DRUG
and O
colchicine O

as O
linezolid B-DRUG
has O
been O
shown O
to O
have O
hematologic B-ADR
side I-ADR
effects I-ADR
, O
blood O
count O
monitoring O
is O
recommended O
in O
patients O
receiving O
this O
drug O
for O
long-term O
therapy O

drug O
induced O
liver B-ADR
injury I-ADR
secondary O
to O
interferon-beta O
( O
ifn-beta B-DRUG
) O
in O
multiple O
sclerosis O

in O
summary O
, O
we O
report O
herein O
the O
first O
case O
of O
siadh B-ADR
believed O
to O
be O
an O
adverse O
effect O
of O
mizoribin B-DRUG
, O
which O
may O
therefore O
needed O
to O
be O
added O
to O
the O
list O
of O
drugs O
which O
can O
induce O
siadh B-ADR

she O
was O
placed O
on O
adjuvant O
adriamycin O
( O
doxorubicin B-DRUG
) O
chemotherapy O
, O
but O
6 O
months O
later O
died B-ADR
of O
adriamycin O
toxicity O

we O
present O
findings O
from O
three O
patients O
who O
experienced O
a O
psoriasiform B-ADR
eruption I-ADR
apparently O
due O
to O
the O
antiepileptic O
agents O
sodium O
valproate O
and O
carbamazepine B-DRUG

the O
patient O
's O
previous O
rash B-ADR
and O
the O
temporal O
relation O
of O
this O
event O
and O
the O
ingestion O
of O
phenolphthalein B-DRUG
, O
as O
well O
as O
the O
similarity O
of O
this O
case O
to O
other O
reports O
, O
point O
to O
phenolphthalein B-DRUG
as O
the O
cause O
of O
ten O
in O
this O
patient O

the O
present O
study O
describes O
a O
patient O
who O
had O
unusual B-ADR
weight I-ADR
fluctuation I-ADR
under O
corticosteroid O
and O
psychotropic O
treatment O
such O
as O
mianserin B-DRUG
and O
aripiprazole O

we O
describe O
four O
patients O
who O
had O
seizures B-ADR
while O
receiving O
ofloxacin B-DRUG
; O
no O
other O
causes O
were O
evident O

onset O
of O
male O
gynaecomastia B-ADR
in O
a O
patient O
treated O
with O
sunitinib B-DRUG
for O
metastatic O
renal O
cell O
carcinoma O

patient O
a O
reported O
right B-ADR
leg I-ADR
weakness I-ADR
( O
foot O
drop O
) O
during O
week O
4 O
of O
cap-xrt B-DRUG
( O
1600 O
mg O
/ O
m2 O

because O
the O
combination O
of O
bleomycin B-DRUG
and O
vinca O
alkaloids O
is O
commonly O
used O
for O
the O
treatment O
of O
aids-related O
kaposi O
's O
sarcoma O
, O
clinicians O
should O
be O
aware O
of O
the O
risk O
of O
provoking O
acral O
necrosis O
in O
patients O
who O
develop O
raynaud B-ADR
's I-ADR
phenomenon I-ADR
under O
chemotherapy O

methylphenidate O
and O
dextroamphetamine-induced O
peripheral B-ADR
vasculopathy I-ADR

we O
report O
a O
case O
of O
a O
previously O
healthy O
, O
postmenopausal O
woman O
who O
developed O
anticonvulsant B-ADR
hypersensitivity I-ADR
syndrome I-ADR
while O
taking O
bellamine O
s O
( O
belladonna O
alkaloids O
; O
ergotamine B-DRUG
; O
phenobarbital O
) O
for O
hot O
flashes O

localized O
panniculitis O
and O
subsequent O
lipoatrophy B-ADR
with O
subcutaneous O
glatiramer B-DRUG
acetate I-DRUG
( O
copaxone O
) O
injection O
for O
the O
treatment O
of O
multiple O
sclerosis O

discussion O
: O
a O
review O
of O
the O
cases O
of O
ss B-ADR
with O
implication O
of O
mirtazapine B-DRUG
as O
the O
cause O
was O
performed O

amphotericin B-DRUG
b I-DRUG
overdose O
in O
pediatric O
patients O
with O
associated O
cardiac B-ADR
arrest I-ADR

infant O
twins O
sustained O
severe O
circumoral B-ADR
and I-ADR
pharyngeal I-ADR
burns I-ADR
from O
a O
concentrated O
solution O
of O
benzalkonium B-DRUG
( O
zephiran O
) O
chloride O
prescribed O
for O
treatment O
of O
candidiasis O

conclusion O
: O
alendronate B-DRUG
led O
to O
nodular B-ADR
scleritis I-ADR
and O
rechallenge O
caused O
recurrence O
of O
scleritis O

this O
fourth O
type O
of O
cutaneous O
minocycline B-DRUG
hyperpigmentation B-ADR
may O
be O
a O
variant O
of O
type O
i O
, O
but O
based O
on O
clinical O
, O
pathological O
and O
microanalytical O
differences O
, O
appears O
to O
be O
a O
new O
entity O

massive O
cbz B-DRUG
od O
may O
produce O
a O
reversible O
encephalopathy O
that O
includes O
cortical O
hyperexcitability O
, O
a O
profound B-ADR
burst-suppression I-ADR
eeg I-ADR
pattern I-ADR
, O
and O
cranial O
nerve O
areflexia O

a O
case O
of O
toxic B-ADR
hepatitis I-ADR
caused O
by O
combination O
therapy O
with O
methotrexate O
and O
etretinate B-DRUG
in O
the O
treatment O
of O
severe O
psoriasis O
is O
presented O
in O
a O
47-year-old O
woman O

hypoglycemia O
can O
be O
a O
serious O
side O
effect O
of O
etanercept O
in O
patients O
already O
on O
antidiabetic O
medications O
known O
to O
cause O
hypoglycemia B-ADR
, O
such O
as O
sulfonylureas O
, O
meglitinides O
, O
and O
insulin B-DRUG

a O
woman O
with O
a O
20-year O
history O
of O
acral O
pustular O
psoriasis O
of O
hallopeau O
and O
recurrent O
pustular O
lesions O
of O
the O
forearms O
and O
lower O
legs O
, O
developed O
a O
b-cell B-ADR
lymphoma I-ADR
of O
the O
lip O
following O
4 O
1 O
/ O
2 O
years O
of O
treatment O
with O
razoxane B-DRUG

a O
case O
of O
tuberculosis B-ADR
in O
a O
patient O
on O
efalizumab O
and O
etanercept B-DRUG
for O
treatment O
of O
refractory O
palmopustular O
psoriasis O
and O
psoriatic O
arthritis O

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash O
, O
fever O
, O
leukopenia O
and O
positive O
anti-nuclear O
antibody O
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine B-DRUG
( O
cbz O
; O
tegretol O
) O
used O
against O
benign O
rolandic O
epilepsy O

acute O
aluminum B-ADR
toxicity I-ADR
after O
continuous O
intravesical O
alum B-DRUG
irrigation O
for O
hemorrhagic O
cystitis O

sodium B-DRUG
phenylbutyrate I-DRUG
was O
added O
to O
treatment O
with O
hu O
in O
two O
patients O
, O
but O
failed O
to O
produce O
an O
increase O
in O
total O
hb O
despite O
increasing B-ADR
hb I-ADR
f I-ADR
levels O

four O
months O
after O
receiving O
an O
orthotopic O
liver O
transplant O
, O
a O
51-year-old O
man O
was O
admitted O
for O
progressive B-ADR
liver I-ADR
failure I-ADR
and O
severe O
hepatocellular O
necrosis O
thought O
to O
be O
due O
to O
tacrolimus B-DRUG

as O
this O
relapse O
coincided O
with O
development O
of O
a O
strong O
delayed-type O
hypersensitivity B-ADR
response I-ADR
to O
tuberculin B-DRUG
and O
improved O
after O
treatment O
with O
the O
anti-inflammatory O
agent O
oxpentifylline O
, O
it O
was O
probably O
caused O
by O
restoration O
of O
pathogen-specific O
cellular O
immunity O

isoniazid B-DRUG
associated O
, O
painful O
, O
bilateral B-ADR
gynaecomastia I-ADR

conclusions O
: O
clinicians O
should O
be O
aware O
of O
this O
adverse O
reaction O
when O
facing O
similar O
complex O
neurologic B-ADR
symptoms I-ADR
in O
patients O
who O
are O
receiving O
the O
antibiotic O
treatment O
described O
here O
, O
especially O
vancomycin B-DRUG

case O
summary O
: O
a O
39-year-old O
white O
jewish O
schizophrenic O
man O
treated O
with O
olanzapine B-DRUG
developed O
an O
elevated B-ADR
serum I-ADR
ck I-ADR
concentration I-ADR
with O
a O
peak O
concentration O
of O
4000 O
iu O
/ O
l O
( O
normal O
< O
230 O

the O
main O
clinical O
features O
of O
this O
58-year-old O
female O
patient O
were O
laboratory O
evidence O
of O
leucopenia O
and O
cholestasis O
, O
and O
biopsy O
features O
of O
fatty O
liver O
parenchyma O
degeneration O
with O
granulocytic O
portal O
infiltration O
and O
bile B-ADR
stasis I-ADR
, O
demonstrated O
20 O
days O
after O
the O
initiation O
of O
antithyroid O
therapy O
with O
20 O
mg O
methimazole B-DRUG
daily O

antacid O
and O
sucralfate-induced O
hypophosphatemic B-ADR
osteomalacia I-ADR
: O
a O
case O
report O
and O
review O
of O
the O
literature O

in O
both O
cases O
, O
high O
fever O
, O
skin O
rash O
, O
liver O
dysfunction O
and O
atypical B-ADR
lymphocytosis I-ADR
developed O
3 O
weeks O
after O
initiating O
treatment O
with O
sasp B-DRUG

oculomotor B-ADR
disturbances I-ADR
associated O
with O
5-fluorouracil B-DRUG
chemotherapy O

skin B-ADR
necrosis I-ADR
secondary O
to O
low-molecular B-DRUG
weight I-DRUG
heparin I-DRUG
in O
a O
patient O
with O
antiphospholipid O
antibody O
syndrome O

mitomycin B-DRUG
c I-DRUG
( O
mmc O
) O
is O
an O
alkylating O
agent O
that O
has O
been O
recently O
associated O
with O
the O
hemolytic-uremic O
syndrome O
( O
hus B-ADR

we O
describe O
a O
detailed O
case O
of O
fulminant B-ADR
hepatitis I-ADR
induced O
by O
nevirapine O
( O
viramune B-DRUG
) O
and O
treated O
by O
liver O
transplantation O

spinal B-ADR
cord I-ADR
infarction I-ADR
during O
use O
of O
zolmitriptan B-DRUG
: O
a O
case O
report O

a O
case O
of O
severe B-ADR
aplastic I-ADR
anemia I-ADR
secondary O
to O
treatment O
with O
lenalidomide B-DRUG
for O
multiple O
myeloma O

beginning O
ductopenia B-ADR
was O
present O
in O
two O
, O
suggesting O
that O
itraconazole B-DRUG
might O
be O
responsible O
for O
the O
occurrence O
of O
prolonged O
drug-induced O
cholangiopathy O

thiopurine O
methyltransferase O
deficiency O
occurs O
at O
a O
frequency O
of O
one O
in O
300 O
and O
is O
associated O
with O
profound O
myelosuppression B-ADR
after O
a O
short O
course O
of O
azathioprine B-DRUG

since O
recent O
studies O
have O
reported O
no O
negative O
interactions O
with O
concurrent O
use O
, O
we O
here O
report O
three O
cases O
( O
one O
case O
of O
a O
prolonged O
seizure O
, O
a O
serotonin O
syndrome O
and O
a O
focal B-ADR
seizure I-ADR
) O
of O
severe O
lithium-induced O
side O
effects O
while O
patients O
underwent O
ect O
without O
complications O
and O
lithium B-DRUG
serum O
levels O
were O
still O
subtherapeutic O

ciprofloxacin O
is O
among O
the O
standard O
treatments O
for O
infected O
ischemic O
ulcers O
; O
in O
the O
rare O
case O
of O
ciprofloxacin-induced O
hemorrhagic B-ADR
vasculitis I-ADR
, O
it O
might O
be O
interpreted O
as O
progression O
of O
infection O
, O
instead O
of O
a O
complication O
of O
the O
treatment O
, O
thus O
leading O
to O
faulty O
diagnosis O
and O
treatment O

our O
patient O
developed O
both O
nephrogenic O
diabetes O
insipidus O
and O
renal B-ADR
tubular I-ADR
acidosis I-ADR
with O
a O
temporal O
pattern O
that O
demonstrated O
a O
link O
between O
foscarnet B-DRUG
therapy O
and O
these O
abnormalities O

this O
is O
the O
first O
report O
of O
a O
fluoxetine-related O
death B-ADR
in O
a O
child O
with O
a O
confirmed O
genetic O
polymorphism O
of O
the O
cyp2d6 O
gene O
that O
results O
in O
impaired O
drug O
metabolism O

possible O
serotonin B-ADR
syndrome I-ADR
associated O
with O
clomipramine O
after O
withdrawal O
of O
clozapine B-DRUG

flumazenil O
reversal O
of O
benzodiazepine-induced O
sedation B-ADR
for O
a O
patient O
with O
severe O
pre-ect O
anxiety O

hepatitis O
with O
bridging B-ADR
fibrosis I-ADR
and O
reversible O
hepatic O
insufficiency O
in O
a O
woman O
with O
rheumatoid O
arthritis O
taking O
methotrexate B-DRUG

quetiapine B-DRUG
and O
obsessive-compulsive O
symptoms O
( O
ocs B-ADR
) O
: O
case O
report O
and O
review O
of O
atypical O
antipsychotic-induced O
ocs B-ADR

unusual O
hypersensitivity B-ADR
to O
warfarin B-DRUG
in O
a O
critically O
ill O
patient O

late O
development O
of O
diabetes B-ADR
mellitus I-ADR
after O
interferon-alfa O
and O
ribavirin B-DRUG
therapy O
for O
chronic O
hepatitis O
c O
: O
a O
case O
report O

the O
biochemistry O
of O
paracetamol B-DRUG
hepatotoxicity B-ADR
is O
outlined O
and O
the O
increased O
susceptibility O
of O
alcoholic O
patients O
to O
the O
hepatotoxic O
effects O
of O
paracetamol B-DRUG
is O
remarked O
upon O

three O
senile O
patients O
developed O
fatal B-ADR
acute I-ADR
encephalopathy I-ADR
while O
receiving O
calcium B-DRUG
hopantenate I-DRUG

nms B-ADR
is O
a O
drug-related O
response O
to O
various O
medications O
, O
such O
as O
haloperidol B-DRUG
, O
which O
the O
patient O
was O
receiving O

the O
authors O
present O
a O
case O
report O
of O
a O
granulomatous O
reaction O
leading O
to O
urethral B-ADR
prolapse I-ADR
, O
3 O
months O
after O
the O
transurethral O
injection O
of O
calcium B-DRUG
hydroxylapatite I-DRUG

pheripheral B-ADR
edema I-ADR
was O
observed O
in O
five O
female O
patients O
after O
taking O
proton O
pump O
inhibitors O
omeprazole O
, O
lansoprazole B-DRUG
, O
or O
pantoprazole O
for O
7-15 O
days O
for O
peptic O
acid O
diseases O
in O
recommended O
standard O
doses O

after O
other O
potential O
causes O
of O
liver O
toxicity O
were O
excluded O
, O
tmp-smx B-DRUG
was O
determined O
to O
be O
the O
cause O
of O
his O
acute B-ADR
liver I-ADR
toxicity I-ADR

neutrophilic B-ADR
eccrine I-ADR
hidradenitis I-ADR
mimicking O
cutaneous O
vasculitis O
in O
a O
lupus O
patient O
: O
a O
complication O
of O
cyclophosphamide B-DRUG

amiodarone B-DRUG
induced O
torsades B-ADR
de I-ADR
pointe I-ADR

the O
hepatic B-ADR
enzyme I-ADR
disturbances I-ADR
normalized O
after O
discontinuation O
of O
pegvisomant B-DRUG

a O
35-year-old O
woman O
presented O
with O
neurotoxicity O
correlated O
to O
an O
i.v. O
regimen O
of O
5-fluorouracil B-DRUG
as O
episodes O
of O
acute B-ADR
confusional I-ADR
state I-ADR
and O
abnormalities O
of O
symmetrically O
restricted O
diffusion O
in O
the O
periventricular O
white O
matter O
and O
corpus O
callosum O

the O
present O
report O
illustrates O
a O
rare O
case O
of O
refractory O
akathisia O
after O
interferon-alpha B-DRUG
treatment O
and O
also O
that O
levodopa O
treatment O
would O
be O
theoretically O
and O
practically O
useful O
in O
reducing O
the O
neurotoxicity B-ADR
associated O
with O
interferon-alpha B-DRUG

we O
report O
a O
59-year-old O
patient O
with O
chronic O
myeloid O
leukemia O
, O
who O
developed O
severe B-ADR
interstitial I-ADR
lung I-ADR
fibrosis I-ADR
after O
short O
term O
and O
sequential O
treatment O
with O
melphalan B-DRUG
and O
busulfan O

due O
to O
discomfort O
, O
diplopia O
and O
lagophthalmos B-ADR
, O
the O
haematoma O
necessitated O
suspension O
of O
warfarin B-DRUG
therapy O
and O
a O
surgical O
evacuation O

objective O
: O
to O
report O
2 O
cases O
of O
nonconvulsive O
status O
epilepticus O
( O
ncse B-ADR
) O
following O
infusion O
of O
ifosfamide B-DRUG

method O
: O
case O
analysis O
of O
a O
poly-drug O
overdose O
( O
venlafaxine O
, O
topiramate B-DRUG
, O
divalproex O
sodium O
, O
risperidone O
, O
and O
carbamazepine O
) O
presenting O
with O
mixed O
ss B-ADR
/ O
nms O
features O
and O
whose O
clinical O
management O
suggests O
a O
practical O
algorithm O
for O
treatment O
of O
undifferentiated O
ss B-ADR
/ O
nms O
in O
critical O
care O
settings O

the O
authors O
present O
an O
elderly O
patient O
with O
mixed O
dementia O
who O
developed O
td O
at O
multiple O
sites O
, O
( O
including O
respiratory O
dyskinesia O
[ O
rd O
] O
, O
limb O
dyskinesia O
, O
and O
orofacial B-ADR
dyskinesia I-ADR
) O
following O
abrupt O
withdrawal O
of O
risperidone B-DRUG
therapy O

the O
development O
of O
an O
igg B-ADR
lambda-type I-ADR
monoclonal I-ADR
gammopathy I-ADR
and O
subsequent O
multiple O
myeloma O
in O
an O
epilepsy O
patient O
on O
diphenylhydantoin O
( O
dilantin B-DRUG
) O
therapy O
for O
20 O
years O
is O
reported O

a O
patient O
developed O
transient O
, O
acute B-ADR
myopia I-ADR
while O
on O
isotretinoin O
( O
accutane B-DRUG
) O
therapy O
for O
acne O

tigecycline-induced O
acute B-ADR
pancreatitis I-ADR
: O
case O
report O
and O
literature O
review O

tardive B-ADR
oculogyric I-ADR
crisis I-ADR
during O
treatment O
with O
clozapine B-DRUG
: O
report O
of O
three O
cases O

seizures B-ADR
associated O
with O
ofloxacin B-DRUG
therapy O

however O
, O
because O
diphenhydramine B-DRUG
also O
exhibits O
type O
ia O
sodium O
channel O
blockade O
, O
cardiac B-ADR
toxicity I-ADR
is O
also O
possible O

this O
eruption B-ADR
emerged O
after O
1 O
month O
of O
therapy O
with O
salsalate B-DRUG
, O
persisted O
for O
as O
long O
as O
salsalate B-DRUG
was O
administered O
, O
and O
cleared O
within O
3 O
weeks O
of O
discontinuing O
the O
medication O

severe B-ADR
acidosis I-ADR
in O
patients O
taking O
metformin B-DRUG
-- O
rapid O
reversal O
and O
survival O
despite O
high O
apache O
score O

development O
of O
essential O
thrombocythemia B-ADR
in O
a O
patient O
treated O
with O
interferon O
alfa O
and O
pentostatin B-DRUG
for O
hairy O
cell O
leukemia O

we O
report O
a O
fatal O
case O
of O
toxic O
epidermal O
necrolysis O
( O
ten B-ADR
) O
resulting O
from O
a O
high O
dose O
of O
cytosine O
arabinoside O
( O
ara-c B-DRUG

rapamycin O
/ O
sirolimus-induced O
pneumonitis O
has O
been O
described O
previously O
in O
renal O
transplant O
recipients O
, O
and O
this O
report O
describes O
a O
stable O
heart-lung O
transplant O
recipient O
who O
developed O
a O
pulmonary B-ADR
infiltrate I-ADR
that O
reversed O
after O
ceasing O
sr B-DRUG
therapy O

bronchiolitis B-ADR
obliterans I-ADR
with I-ADR
organizing I-ADR
pneumonia I-ADR
after O
rituximab B-DRUG
therapy O
for O
non-hodgkin O
's O
lymphoma O

a O
case O
of O
sideroblastic B-ADR
anemia I-ADR
is O
presented O
in O
a O
patient O
with O
a O
left O
ventricular O
assist O
device O
drive-line O
infection O
who O
was O
receiving O
linezolid B-DRUG
, O
an O
antibiotic O
used O
for O
serious O
infections O
with O
gram-positive O
organisms O

massive O
cbz B-DRUG
od O
may O
produce O
a O
reversible B-ADR
encephalopathy I-ADR
that O
includes O
cortical O
hyperexcitability O
, O
a O
profound O
burst-suppression O
eeg O
pattern O
, O
and O
cranial O
nerve O
areflexia O

rifampicin-induced O
adrenal B-ADR
insufficiency I-ADR
in O
the O
acquired O
immunodeficiency O
syndrome O
: O
difficulties O
in O
diagnosis O
and O
treatment O

after O
administration O
of O
oxybutynin O
concomitantly O
with O
an O
increase O
in O
the O
dose O
of O
dantrolene O
, O
she O
presented O
the O
clinical O
symptoms O
and O
laboratory O
finding O
of O
carbamazepine B-ADR
intoxication I-ADR

five O
months O
after O
initiating O
mirtazapine B-DRUG
therapy O
, O
she O
developed O
symptomatic B-ADR
hyponatremia I-ADR

it O
was O
restarted O
6 O
weeks O
later O
, O
and O
10 O
weeks O
after O
that O
, O
the O
patient O
presented O
with O
fulminant B-ADR
hepatic I-ADR
failure I-ADR
, O
which O
resolved O
rapidly O
after O
cessation O
of O
nicotinic B-DRUG
acid I-DRUG
therapy O

a O
case O
report O
is O
presented O
concerning O
the O
administration O
of O
ketanserin O
in O
the O
treatment O
of O
pulmonary B-ADR
vasoconstriction I-ADR
and O
right O
ventricular O
failure O
following O
the O
infusion O
of O
protamine B-DRUG
in O
a O
patient O
undergoing O
coronary O
artery O
bypass O
surgery O
and O
mitral O
valve O
replacement O

the O
patient O
was O
positive O
for O
antibody O
against O
complexes O
of O
heparin B-DRUG
and O
platelet O
factor O
4 O
, O
and O
was O
diagnosed O
as O
heparin-induced O
thrombocytopenia O
with O
thrombosis B-ADR
syndrome I-ADR
( O
hitts O

cardiomyopathy B-ADR
after O
widely O
separated O
courses O
of O
adriamycin O
exacerbated O
by O
actinomycin-d B-DRUG
and O
mithramycin O

since O
the O
thrombocyte B-ADR
count I-ADR
started I-ADR
to I-ADR
increase I-ADR
immediately O
after O
initiation O
and O
dropped O
immediately O
after O
discontinuation O
of O
ciprofloxacin O
and O
tazobactam O
/ O
piperacillin B-DRUG
and O
all O
other O
drugs O
were O
discontinued O
already O
before O
or O
were O
started O
after O
the O
nadir O
of O
the O
thrombocyte O
count O
, O
these O
two O
antibiotics O
were O
regarded O
causative O

in O
rare O
cases O
mitomycin O
c O
( O
mmc B-DRUG
) O
may O
induce O
cancer-associated O
hemolytic O
uremic O
syndrome O
, O
which O
is O
characterized O
by O
hemolytic B-ADR
anemia I-ADR
, O
thrombocytopenia O
and O
progressive O
renal O
failure O

in O
deciding O
if O
tamoxifen B-DRUG
therapy O
is O
warranted O
, O
all O
potentially O
life-threatening O
adverse O
events O
associated O
with O
tamoxifen B-DRUG
should O
be O
considered O
, O
including O
endometrial O
adenocarcinoma O
or O
uterine B-ADR
sarcoma I-ADR

pemphigus B-ADR
vulgaris I-ADR
precipitated O
by O
glibenclamide B-DRUG
therapy O

amebic B-ADR
abscess I-ADR
of I-ADR
the I-ADR
spleen I-ADR
complicated O
by O
metronidazole-induced O
neurotoxicity O
: O
case O
report O

this O
report O
describes O
a O
case O
of O
paradoxical B-DRUG
, O
intravenous O
valproic O
acid-induced O
seizure B-ADR
exacerbation I-ADR
in O
a O
child O
with O
juvenile O
absence O
epilepsy O
, O
documented O
by O
video-electroencephalography O

the O
present O
study O
describes O
a O
patient O
who O
had O
unusual B-ADR
weight I-ADR
fluctuation I-ADR
under O
corticosteroid O
and O
psychotropic O
treatment O
such O
as O
mianserin O
and O
aripiprazole B-DRUG

case O
report O
: O
soon O
after O
initiation O
of O
amiodarone B-DRUG
hcl I-DRUG
( O
200 O
mg O
/ O
day O
) O
, O
a O
76-year-old O
man O
came O
to O
us O
with O
symptoms O
of O
visual O
" O
shining O
," O
glare B-ADR
, O
color O
vision O
anomalies O
, O
and O
gradually O
decreased O
vision O

systemic B-ADR
capillary I-ADR
leak I-ADR
syndrome I-ADR
after O
granulocyte O
colony-stimulating O
factor O
( O
g-csf B-DRUG

data O
synthesis O
: O
genetic O
deficiencies O
in O
dpd O
, O
the O
rate-limiting O
enzyme O
responsible O
for O
5-fu B-DRUG
catabolism O
, O
may O
occur O
in O
3 O
% O
or O
more O
of O
patients O
with O
cancer O
putting O
them O
at O
increased O
risk O
for O
unusually O
severe O
adverse O
reactions O
( O
e.g. O
, O
diarrhea O
, O
stomatitis O
, O
mucositis B-ADR
, O
myelosuppression O
, O
neurotoxicity O
) O
to O
standard O
doses O
of O
5-fu B-DRUG

when O
measured O
, O
the O
serum B-ADR
lithium I-ADR
level I-ADR
had I-ADR
increased I-ADR
4-fold O
during O
acyclovir O
therapy O

the O
patient O
, O
a O
28-year-old O
man O
suffering O
from O
panic O
disorder O
, O
developed O
several O
first-rank B-ADR
symptoms I-ADR
during O
fluvoxamine B-DRUG
administration O

a O
43-year-old O
woman O
with O
multiple O
sclerosis O
( O
ms O
) O
had O
nephrotic B-ADR
syndrome I-ADR
21 O
months O
after O
starting O
treatment O
with O
interferon O
( O
ifn O
)- O
beta-1b O
( O
subcutaneous O
administration O

central O
nervous O
system O
effects O
secondary O
to O
ciprofloxacin B-DRUG
treatment O
are O
uncommon O
and O
usually O
consist O
only O
of O
minor O
dizziness O
or O
mild O
headache O
, O
although O
rare O
occurrences O
of O
seizures B-ADR
and O
hallucinations O
have O
been O
reported O

meperidine-associated O
central O
nervous O
system O
( O
cns O
) O
excitatory O
toxicities O
are O
believed O
to O
be O
caused O
by O
accumulation O
of O
the O
active O
metabolite O
normeperidine O

severe O
c. B-ADR
difficile I-ADR
colitis I-ADR
occurred O
in O
2 O
patients O
( O
6.1 O
%) O
after O
receiving O
cisplatin-based O
combination O
chemotherapy O
for O
ovarian O
malignancies O

infectious B-ADR
toxicity I-ADR
of O
dexamethasone B-DRUG
during O
all O
remission-induction O
chemotherapy O
: O
report O
of O
two O
cases O
and O
literature O
review O

exacerbations B-ADR
of I-ADR
the I-ADR
heart I-ADR
failure I-ADR
were O
temporally O
related O
to O
the O
administration O
of O
the O
antitumor O
antibiotics O
actinomycin-d O
( O
nsc-3053 O
) O
and O
mithramycin B-DRUG
( O
nsc-24559 O

toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
resulted O
after O
19 O
days O
of O
treatment O
with O
5-fluorocytosine B-DRUG
and O
amphotericin O
b O

life-threatening O
alterations B-ADR
in I-ADR
heart I-ADR
rate I-ADR
after O
the O
use O
of O
adenosine B-DRUG
in O
atrial O
flutter O

the O
intramuscular O
challenge O
test O
with O
25 O
ui O
of O
miacalcic B-DRUG
was O
positive O
with O
an O
immediate O
anaphylactic B-ADR
reaction I-ADR

thrombotic B-ADR
thrombocytopenic I-ADR
purpura I-ADR
during O
penicillamine B-DRUG
therapy O
in O
rheumatoid O
arthritis O

we O
present O
the O
first O
case O
of O
ovarian B-ADR
endometrioid I-ADR
carcinoma I-ADR
and O
endometriosis O
in O
a O
postmenopausal O
patient O
who O
was O
treated O
with O
tamoxifen B-DRUG
for O
breast O
cancer O

cutaneous B-ADR
rashes I-ADR
and O
eruptions O
can O
be O
caused O
by O
many O
medications O
, O
including O
carbamazepine B-DRUG

all-trans B-DRUG
retinoic I-DRUG
acid-induced O
focal O
myositis O
, O
synovitis B-ADR
, O
and O
mononeuritis O

in O
a O
patient O
suffering O
from O
rheumatoid O
arthritis O
, O
we O
report O
the O
first O
simultaneous O
occurrence O
of O
two O
side O
effects O
of O
low-dose O
methotrexate B-DRUG
: O
an O
acute B-ADR
megaloblastic I-ADR
anaemia I-ADR
and O
a O
pneumonitis O

high-dose O
methotrexate-associated O
acute B-ADR
renal I-ADR
failure I-ADR
may O
be O
an O
avoidable O
complication O

objective O
: O
to O
report O
a O
case O
of O
marked O
elevation B-ADR
of I-ADR
serum I-ADR
creatine I-ADR
kinase I-ADR
( O
ck O
) O
associated O
with O
olanzapine B-DRUG
therapy O

cd4 O
t-lymphocyte O
depletion O
, O
myelosuppression B-ADR
, O
and O
subsequent O
severe O
infections O
are O
the O
major O
side O
effects O
of O
fludarabine B-DRUG
phosphate I-DRUG
therapy O

possible O
linkage O
of O
amprenavir B-DRUG
with O
intracranial B-ADR
bleeding I-ADR
in O
an O
hiv-infected O
hemophiliac O

the O
ocular B-ADR
motor I-ADR
disturbances I-ADR
are O
probably O
an O
expression O
of O
regional O
5-fu B-DRUG
neurotoxicity O
primarily O
affecting O
the O
brain O
stem O

in O
one O
instance O
a O
systemic O
hypoglycemic O
reaction O
resulting O
in O
head O
trauma O
and O
confusion B-ADR
ended O
in O
an O
emegency O
hospital O
admission O
following O
the O
substitution O
of O
acetohexamide B-DRUG
for O
acetazolamide O

a O
73-year-old O
woman O
presented O
with O
fever B-ADR
and O
cough O
2 O
weeks O
after O
completing O
the O
third O
cycle O
of O
fludarabine B-DRUG
for O
chronic O
lymphocytic O
leukemia O
( O
cll O

pneumonitis O
, O
bilateral O
pleural O
effusions O
, O
echocardiographic O
evidence O
of O
cardiac B-ADR
tamponade I-ADR
, O
and O
positive O
autoantibodies O
developed O
in O
a O
43-year-old O
man O
, O
who O
was O
receiving O
long-term O
sulfasalazine B-DRUG
therapy O
for O
chronic O
ulcerative O
colitis O

children O
receiving O
zonisamide B-DRUG
should O
be O
monitored O
for O
oligohidrosis O
and O
the O
development O
of O
neurological B-ADR
symptoms I-ADR
associated O
with O
an O
elevation O
of O
body O
temperature O

tubulointerstitial B-ADR
nephritis I-ADR
induced O
by O
the O
leukotriene O
receptor O
antagonist O
pranlukast B-DRUG

although O
myelosuppression O
is O
mild O
, O
immunosuppression O
and O
superinfection B-ADR
are O
potential O
hazards O
of O
treatment O
with O
dcf B-DRUG

we O
report O
the O
first O
case O
of O
a O
human O
immunodeficiency O
virus O
type O
1 O
( O
hiv-1 O
)- O
infected O
individual O
receiving O
combination O
antiretroviral O
therapy O
, O
which O
included O
ritonavir O
, O
who O
developed O
cushing B-ADR
syndrome I-ADR
with O
profound O
complications O
after O
epidural O
triamcinolone B-DRUG
injections O

papilloedema B-ADR
and O
hepatic O
dysfunction O
apparently O
induced O
by O
perhexiline B-DRUG
maleate I-DRUG
( O
pexid O

the O
first O
known O
report O
of O
quetiapine B-DRUG
exacerbating B-ADR
ocs I-ADR
in O
a O
43-year-old O
man O
with O
obsessive-compulsive O
disorder O
( O
ocd O
) O
, O
trichotillomania O
, O
delusional O
disorder O
and O
bipolar O
ii O
disorder O
is O
presented O

shortly O
after O
chemotherapy O
and O
an O
injection O
of O
pegfilgrastim B-DRUG
, O
the O
patient O
developed O
poorly O
defined O
, O
rapidly O
progressive O
erythema O
, O
edema B-ADR
, O
and O
pain O
in O
his O
right O
forearm O

these O
features O
have O
not O
previously O
been O
reported O
as O
side O
effects O
of O
glibenclamide O
therapy O
, O
but O
intrahepatic B-ADR
cholestasis I-ADR
may O
occur O
with O
chlorpropamide B-DRUG
, O
a O
similar O
sulphonylurea O
agent O

stevens-johnson B-ADR
syndrome I-ADR
caused O
by O
the O
antiretroviral O
drug O
nevirapine B-DRUG

aplastic B-ADR
anemia I-ADR
and O
agranulocytosis O
in O
patients O
using O
methazolamide B-DRUG
for O
glaucoma O

life-threatening O
cranial B-ADR
dystonia I-ADR
following O
trihexyphenidyl B-DRUG
withdrawal O

we O
introduce O
a O
case O
of O
a O
sixty O
years O
old O
woman O
with O
several O
previous O
episodes O
of O
rhinitis B-ADR
, O
conjunctivitis O
and O
perspiration O
immediately O
after O
the O
administration O
of O
salmon O
calcitonin O
with O
nasal O
spray O
or O
intramuscular O
administration O
( O
calsynar B-DRUG

discussion O
: O
patients O
with O
5-fu-induced O
ectropion B-ADR
experience O
tender O
, O
red O
, O
scaled O
lids O
, O
making O
contact O
lens O
wear O
difficult O

a O
51-year O
old O
physically O
fit O
woman O
experienced O
angio-oedema O
and O
hypotensive B-ADR
shock I-ADR
after O
irbesartan B-DRUG
ingestion O
requiring O
noradrenaline O
infusion O

a O
child O
in O
whom O
a O
phenobarbital B-DRUG
hypersensitivity O
drug O
reaction O
developed O
which O
consisted O
of O
fever B-ADR
, O
a O
pruritic O
desquamating O
erythrodermic O
rash O
, O
alopecia O
, O
icterus O
, O
protein-losing O
enteropathy O
, O
myositis O
, O
and O
nephritis O
, O
is O
described O

herein O
, O
we O
describe O
2 O
patients O
who O
developed O
unusual O
cd8 O
+ O
cutaneous O
lymphoproliferative O
disorders O
after O
treatment O
with O
efalizumab B-DRUG
and O
infliximab O

she O
had O
just O
finished O
a O
3-week O
course O
of O
intravenous O
tobramycin B-DRUG
for O
bronchiectasis O
and O
had O
an O
elevated O
serum O
tobramycin B-DRUG
trough O
level O
1 O
week O
before O
the O
onset O
of O
tetany B-ADR

trazodone-induced O
transient B-ADR
hypomanic I-ADR
symptoms I-ADR
and O
their O
management O

to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
spontaneous O
remission O
of O
mtx-associated O
gastric B-ADR
lpd I-ADR
after O
discontinuation O
of O
mtx B-DRUG
therapy O

eleven O
patients O
developed O
infection O
requiring O
hospitalization O
while O
taking O
leflunomide B-DRUG
including O
: O
lower O
respiratory O
tract O
infections O
( O
3 O
) O
, O
cellulitis O
( O
2 O
) O
, O
disseminated B-ADR
herpes I-ADR
zoster I-ADR
( O
2 O
) O
, O
probable O
tb O
liver O
( O
1 O
) O
, O
abdominal O
sepsis O
( O
1 O
) O
, O
mycotic O
aneurysm O
( O
1 O
) O
and O
gastroenteritis O
( O
1 O

this O
case O
of O
linezolid-associated O
acute O
interstitial O
nephritis O
within O
the O
context O
of O
a O
drug O
rash O
with O
eosinophilia O
and O
systemic O
symptoms O
( O
dress B-ADR
) O
syndrome O
in O
a O
patient O
treated O
with O
linezolid B-DRUG
raises O
concerns O
about O
the O
presumed O
renal O
safety O
of O
this O
drug O

one O
patient O
developed O
large B-ADR
intramural I-ADR
esophageal I-ADR
hematoma I-ADR
as O
a O
complication O
of O
heparin B-DRUG
therapy O

the O
reversal O
of O
heparin O
by O
protamine B-DRUG
may O
cause O
severe O
hemodynamic O
deterioration O
, O
characterized O
by O
systemic O
hypotension O
, O
pulmonary B-ADR
hypertension I-ADR
, O
and O
bronchoconstriction O

induction O
of O
rapid B-ADR
mood I-ADR
cycling I-ADR
during O
l-dopa B-DRUG
treatment O
in O
a O
bipolar O
patient O

although O
major O
hazards O
of O
treatment O
of O
hypophosphatemic O
osteomalacia O
with O
phosphate O
and O
calcitriol B-DRUG
are O
secondary O
hyperparathyroidism O
and O
vitamin B-ADR
d I-ADR
intoxication I-ADR
, O
potassium O
loss O
also O
should O
be O
kept O
in O
mind O

we O
described O
the O
occurrence O
of O
l-dopa-induced O
myoclonus B-ADR
and O
seizures O
in O
a O
case O
of O
parkinsonism O
with O
its O
seps O
findings O

videopolysomnographic O
and O
pharmacokinetic O
studies O
with O
monitoring O
of O
plasma O
levodopa B-DRUG
levels O
demonstrated O
marked B-ADR
motor I-ADR
hyperactivity I-ADR
during O
augmentation O
, O
with O
anarchic O
discharges O
of O
motor O
unit O
potentials O
, O
tonic O
grouped O
discharges O
and O
flexor O
spasms O
, O
associated O
with O
painful O
dysesthesia O

easily O
reversible O
hypoxemia O
and O
hypotension B-ADR
induced O
by O
nimodipine B-DRUG

we O
report O
the O
case O
of O
a O
patient O
with O
the O
acquired O
immunodeficiency O
syndrome O
treated O
with O
rifampicin B-DRUG
who O
had O
a O
' O
normal O
' O
screening O
test O
for O
adrenal O
insufficiency O
, O
yet O
had O
clinical O
evidence O
of O
adrenal B-ADR
failure I-ADR

in O
our O
patient O
, O
dian B-ADR
possibly O
was O
related O
to O
cefuroxime B-DRUG
, O
but O
the O
patient O
did O
not O
experience O
associated O
allergic O
symptoms O

amiodarone B-DRUG
was O
the O
third O
drug O
to O
induce O
avt B-ADR
in O
this O
patient O
; O
she O
received O
200 O
mg O
/ O
day O
six O
days O
per O
week O
for O
six O
months O

a O
patient O
is O
presented O
with O
typical O
hyperthyroidism O
, O
who O
developed O
a O
severe B-ADR
proximal I-ADR
muscle I-ADR
weakness I-ADR
and O
a O
raised O
creatine O
phosphokinase O
after O
treatment O
for O
hyperthyroidism O
with O
propylthiouracil B-DRUG
( O
100 O
mg O
orally O
, O
three O
times O
a O
day O

red B-ADR
blood I-ADR
cell I-ADR
anemia I-ADR
in O
a O
patient O
with O
pemphigus O
vulgaris O
induced O
by O
the O
use O
of O
mycophenolate O
mofetil O
and O
prednisone B-DRUG

our O
literature O
review O
revealed O
an O
additional O
six O
cases O
of O
onset O
of O
inflammatory B-ADR
arthritis I-ADR
in O
ms O
patients O
receiving O
ifn-beta B-DRUG

renal B-ADR
failure I-ADR
associated O
with O
the O
use O
of O
dextran-40 B-DRUG

two O
patients O
are O
described O
who O
developed O
testicular B-ADR
swelling I-ADR
and O
pain O
during O
treatment O
with O
desipramine B-DRUG

sulfasalazine-induced O
lupus B-ADR
erythematosus I-ADR

intravenous O
haloperidol B-DRUG
is O
generally O
well O
tolerated O
, O
but O
multiform B-ADR
ventricular I-ADR
tachycardia I-ADR
has O
been O
reported O

case O
2 O
demonstrated O
after O
40 O
months O
on O
chlorambucil B-DRUG
the O
presence O
of O
a O
balanced B-ADR
translocation I-ADR
, O
t O
( O
1 O
; O
5 O
) O
( O
p36 O
; O
q31 O
) O
in O
90 O
% O
of O
the O
cells O

a O
66-year-old O
japanese O
woman O
with O
severe O
scleroderma O
developed O
anemia O
and O
thrombocytopenia B-ADR
due O
to O
d-penicillamine O
( O
d-pen B-DRUG
) O
treatment O
, O
although O
the O
leukopenia O
was O
not O
markedly O
severe O

while O
undergoing O
treatment O
with O
albendazole B-DRUG
, O
he O
developed O
worsening B-ADR
diarrhea I-ADR
with O
abdominal O
pain O
and O
fever O

this O
report O
describes O
a O
case O
of O
flucytosine-associated O
ulcerating O
enteritis O
in O
which O
the O
small O
bowel O
x-ray O
demonstrated O
severe O
luminal O
narrowing O
, O
ulceration O
, O
and O
marked B-ADR
separation I-ADR
of I-ADR
loops I-ADR
of I-ADR
bowel I-ADR

epstein-barr B-ADR
virus-associated I-ADR
lymphoproliferative I-ADR
disorder I-ADR
in O
a O
patient O
with O
rheumatoid O
arthritis O
on O
methotrexate B-DRUG
and O
rofecoxib O
: O
idiosyncratic O
reaction O
or O
pharmacogenetics O

the O
present O
case O
is O
the O
first O
report O
of O
hypercalcemia B-ADR
induced O
by O
vitamin B-DRUG
d3 I-DRUG
ointment O
and O
thiazide O
simultaneously O

aim O
: O
to O
report O
three O
cases O
of O
extensive O
skin B-ADR
necrosis I-ADR
in O
cirrhotic O
patients O
treated O
with O
the O
vasoconstrictor O
agent O
terlipressin B-DRUG
( O
glypressin O

acute B-ADR
non-lymphocytic I-ADR
leukemia I-ADR
in O
patients O
with O
ovarian O
carcinoma O
following O
long-term O
treatment O
with O
treosulfan B-DRUG
(= O
dihydroxybusulfan O

here O
we O
report O
a O
patient O
with O
newly O
diagnosed O
acute O
promyelocytic O
leukemia O
who O
developed O
acute O
focal O
myositis O
, O
synovitis B-ADR
, O
and O
possible O
vasculitis O
, O
after O
receiving O
all-trans B-DRUG
retinoic I-DRUG
acid I-DRUG
therapy O

case O
summary O
: O
a O
58-year-old O
white O
woman O
developed O
fulminant B-ADR
liver I-ADR
failure I-ADR
while O
being O
treated O
with O
the O
macrolide O
antibiotic O
clarithromycin B-DRUG
for O
pneumonia O

after O
receiving O
3 O
doses O
of O
ifosfamide B-DRUG
/ O
mesna O
, O
she O
was O
found O
to O
be O
unresponsive B-ADR

both O
patients O
suddenly O
became O
hypotensive B-ADR
after O
injection O
of O
chymopapain B-DRUG
into O
a O
disk O

multifocal B-ADR
inflammatory I-ADR
leukoencephalopathy I-ADR
associated O
with O
levamisole B-DRUG
therapy O

however O
, O
1 O
eye O
had O
vitreous B-ADR
hemorrhage I-ADR
after O
repeated O
injections O
of O
tpa B-DRUG

in O
this O
article O
lithium B-DRUG
is O
not O
discussed O
, O
although O
there O
are O
a O
number O
of O
concerns O
about O
lithium B-DRUG
's O
potential O
teratogenicity B-ADR
, O
and O
it O
has O
been O
implicated O
in O
epstein O
's O
anomaly O
, O
a O
congenital O
heart O
defect O
among O
infants O
born O
to O
women O
taking O
lithium B-DRUG
; O
as O
with O
other O
medications O
, O
however O
, O
the O
data O
have O
specific O
limitations O

a O
review O
of O
the O
literature O
found O
11 O
children O
and O
2 O
adults O
in O
whom O
intranasal O
desmopressin B-DRUG
was O
associated O
with O
hyponatremia O
, O
all O
of O
whom O
experienced O
seizures O
or O
altered B-ADR
mental I-ADR
status I-ADR

one O
other O
patient O
on O
digoxin B-DRUG
stopped O
taking O
it O
and O
developed O
cardiomyopathy B-ADR

late O
lethal O
hepatitis B-ADR
b I-ADR
virus I-ADR
reactivation I-ADR
after O
rituximab B-DRUG
treatment O
of O
low-grade O
cutaneous O
b-cell O
lymphoma O

this O
report O
describes O
a O
case O
of O
flucytosine-associated O
ulcerating O
enteritis O
in O
which O
the O
small O
bowel O
x-ray O
demonstrated O
severe B-ADR
luminal I-ADR
narrowing I-ADR
, O
ulceration O
, O
and O
marked O
separation O
of O
loops O
of O
bowel O

hemorrhagic B-ADR
cystitis I-ADR
is O
a O
significant O
toxic O
effect O
of O
cyclophosphamide B-DRUG
therapy O

the O
temporal O
sequence O
of O
the O
respiratory B-ADR
insufficiency I-ADR
and O
the O
histopathology O
, O
when O
compared O
to O
the O
previous O
examples O
in O
the O
literature O
, O
suggest O
that O
cyclophosphamide B-DRUG
was O
aetiologically O
responsible O
for O
the O
lung O
disease O

several O
hypersensitivity B-ADR
reactions O
to O
cloxacillin B-DRUG
have O
been O
reported O
, O
although O
ige-mediated O
allergic O
reactions O
to O
the O
drug O
are O
rare O
and O
there O
is O
little O
information O
about O
possible O
tolerance O
to O
other O
semisynthetic O
penicillins O
or O
cephalosporins O
in O
patients O
with O
cloxacillin B-DRUG
allergy O

a O
young O
woman O
with O
epilepsy O
had O
tonic-clonic B-ADR
seizures I-ADR
during O
antineoplastic O
therapy O
with O
adriamycin O
and O
cisplatin B-DRUG

benzocaine-induced O
methemoglobinemia B-ADR
has O
been O
reported O
in O
man O
, O
dogs O
, O
and O
cats O

pancreatitis O
has O
been O
associated O
with O
the O
tetracycline O
class O
of O
antibiotics O
and O
concerns O
about O
tigecycline-induced O
acute B-ADR
pancreatitis I-ADR
have O
recently O
been O
raised O

it O
is O
concluded O
that O
simultaneous O
administration O
of O
ciprofloxacin O
and O
tazobactam B-DRUG
/ O
piperacillin O
may O
cause O
marked O
thrombocytosis B-ADR

there O
are O
, O
however O
, O
case O
studies O
describing O
patients O
experiencing O
recurrences O
of O
tics B-ADR
following O
treatment O
with O
atomoxetine B-DRUG

background O
: O
interferon O
( O
ifn B-DRUG
)- O
associated O
retinopathy B-ADR
is O
typically O
characterized O
by O
retinal O
hemorrhages O
and O
cotton O
wool O
spots O
at O
the O
posterior O
fundus O
, O
but O
visual O
function O
is O
usually O
maintained O

localized B-ADR
panniculitis I-ADR
and O
subsequent O
lipoatrophy O
with O
subcutaneous O
glatiramer O
acetate O
( O
copaxone B-DRUG
) O
injection O
for O
the O
treatment O
of O
multiple O
sclerosis O

this O
is O
the O
first O
report O
of O
acute B-ADR
kidney I-ADR
injury I-ADR
due O
to O
zonisamide-induced O
dress O
/ O
dihs O

these O
findings O
are O
consistent O
with O
an O
immune-complex O
form O
of O
glomerulopathy O
in O
which O
gold B-DRUG
is O
neither O
the O
antigen O
nor O
a O
hapten O
in O
the O
glomerular O
deposits O
, O
and O
they O
suggest O
the O
hypothesis O
that O
antibodies O
to O
tubular O
epithelial O
antigens O
induced O
by O
gold B-DRUG
therapy O
may O
be O
a O
causative O
factor O
in O
the O
renal B-ADR
disease I-ADR
associated O
with O
gold B-DRUG
therapy O
in O
rheumatoid O
arthritis O

after O
rechallenge O
with O
monotherapy O
pegvisomant B-DRUG
, O
however O
, O
the O
hepatic B-ADR
enzyme I-ADR
disturbances I-ADR
reappeared O
within O
a O
few O
weeks O
, O
indicating O
that O
most O
likely O
pegvisomant B-DRUG
alone O
and O
not O
the O
long-acting O
somatostatin O
analog O
or O
the O
combination O
of O
these O
two O
drugs O
was O
responsible O
for O
this O
case O
of O
drug-induced O
hepatitis O

we O
report O
a O
case O
of O
hyponatremia O
associated O
with O
a O
grand B-ADR
mal I-ADR
seizure I-ADR
in O
a O
28 O
month-old O
child O
after O
intra-nasal O
desmopressin B-DRUG
administration O
for O
high O
fluid O
intake O
with O
nocturnal O
enuresis O

multifocal O
electroretinographic O
abnormalities O
in O
ethambutol-induced O
visual B-ADR
loss I-ADR

we O
report O
one O
case O
of O
non-hodgkin B-ADR
lymphoma I-ADR
in O
a O
patient O
, O
with O
a O
30-year O
history O
of O
rheumatoid O
arthritis O
, O
taking O
low O
dose O
methotrexate B-DRUG
weekly O
over O
a O
10-month O
period O

scleroderma-like B-ADR
reaction I-ADR
induced O
by O
uracil-tegafur O
( O
uft B-DRUG
) O
, O
a O
second-generation O
anticancer O
agent O

acute B-ADR
renal I-ADR
failure I-ADR
in O
a O
child O
associated O
with O
acyclovir B-DRUG

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion O
, O
agitation B-ADR
, O
tachycardia O
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

the O
probable O
proarrhythmic B-ADR
action O
of O
amiodarone B-DRUG
, O
although O
rare O
, O
is O
reviewed O
along O
with O
a O
discussion O
of O
the O
novel O
use O
of O
intravenous O
magnesium O
sulfate O
therapy O

sunburn O
may O
sometimes O
be O
a O
major O
injury O
in O
psoralen B-DRUG
users O
because O
high O
doses O
or O
inappropriate O
use O
of O
the O
drug O
may O
render O
the O
skin B-ADR
extremely I-ADR
sensitive I-ADR

a O
56-year-old O
woman O
with O
scleroderma O
developed O
rapidly O
progressive O
glomerulonephritis O
with O
epithelial B-ADR
crescents I-ADR
associated O
with O
hemoptysis O
after O
27 O
months O
of O
d-penicillamine B-DRUG
therapy O
and O
a O
cumulative O
dose O
of O
1,200 O
g O

physicians O
should O
be O
cognizant O
of O
this O
potential O
complication O
in O
patients O
receiving O
thalidomide B-DRUG
or O
thalidomide-like O
drugs O
who O
present O
with O
fever O
and O
pulmonary B-ADR
infiltrates I-ADR
and O
fail O
to O
improve O
despite O
treatment O
with O
broad-spectrum O
antibiotics O

it O
is O
thought O
that O
the O
clinico-pathological O
features O
and O
chronology O
of O
this O
case O
bore O
the O
hallmarks O
of O
the O
so-called O
" O
3-week O
sulphasalazine B-DRUG
syndrome O
" O
, O
a O
rare O
, O
but O
often O
fatal O
, O
immunoallergic B-ADR
reaction I-ADR
to O
sulphasalazine B-DRUG

lithium B-DRUG
is O
known O
to O
cause O
acute O
renal O
failure O
and O
tubulo-interstitial B-ADR
disease I-ADR
, O
but O
the O
recently O
described O
association O
with O
proteinuria O
or O
nephrotic O
syndrome O
is O
little O
recognized O

in O
case O
no O
. O
2 O
, O
the O
pathogenic O
mechanism O
seemed O
to O
be O
persistent O
light O
reaction O
preceded O
by O
systemic O
photoallergy O
, O
as O
he O
had O
taken O
mequitazine B-DRUG
for O
6 O
months O
, O
and O
there O
were O
strong O
positive O
photopatch O
test O
results O
with O
immediate O
erythema O
reaction O
, O
cross-reaction O
to O
promethazine O
, O
decreased B-ADR
med I-ADR
to I-ADR
both I-ADR
uva I-ADR
and I-ADR
uvb I-ADR
, O
and O
persistence O
of O
the O
photosensitivity O
over O
a O
3-year O
follow-up O
period O
after O
discontinuation O
of O
the O
mequitazine B-DRUG

we O
describe O
a O
patient O
with O
acute O
leukemia O
who O
developed O
horner B-ADR
's I-ADR
syndrome I-ADR
and O
a O
severe O
demyelinating O
peripheral O
neuropathy O
leading O
to O
death O
after O
receiving O
high-dose O
cytosine B-DRUG
arabinoside I-DRUG

amiodarone-induced O
dysthyroidism B-ADR

when O
the O
data O
of O
the O
57 O
patients O
are O
evaluated O
, O
a O
reversible O
direct O
cytotoxic B-ADR
effect I-ADR
of O
ticlopidine B-DRUG
on O
the O
pluripotent O
/ O
bipotent O
hematopoietic O
progenitor O
stem O
cell O
is O
proposed O

in O
this O
report O
, O
we O
describe O
a O
fatal O
gemcitabine-induced O
pulmonary B-ADR
toxicity I-ADR
in O
a O
patient O
with O
gallbladder O
metastatic O
adenocarcinoma O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia B-ADR
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp B-DRUG
)- O
sulfamethoxazole O
( O
smx O
) O
treatment O

interferon-alpha-induced O
hyperthyroidism B-ADR
: O
a O
three-stage O
evolution O
from O
silent O
thyroiditis O
towards O
graves' O
disease O

conclusions O
: O
topiramate B-DRUG
may O
be O
associated O
with O
ciliochoroidal O
effusion O
with O
forward O
displacement O
of O
the O
lens-iris O
diaphragm O
and O
anterior B-ADR
chamber I-ADR
shallowing I-ADR
, O
resulting O
in O
acute O
myopia O
and O
angle-closure O
glaucoma O

prior O
neurologic O
illness O
and O
the O
syndrome O
of O
irreversible O
lithium-effectuated O
neurotoxicity B-ADR
( O
silent O

it O
has O
been O
reported O
that O
fluoroquinolone B-DRUG
antimicrobials O
prolong O
the O
corrected O
qt O
interval O
but O
rarely O
cause O
torsade B-ADR
de I-ADR
pointes I-ADR

sustained-release O
procainamide-induced O
reversible B-ADR
granulocytopenia I-ADR
after O
myocardial O
infarction O

the O
patient O
experienced O
hallucinations O
, O
agitation B-ADR
, O
vomiting O
, O
tachycardia O
and O
seizures O
after O
ingestion O
of O
1050 O
( O
48 O
mg O
/ O
kg O
) O
of O
extended-release O
bupropion B-DRUG

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion O
, O
agitation O
, O
tachycardia O
, O
tremors B-ADR
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

adh O
hypersecretion O
in O
relation O
to O
plasma O
osmolality O
was O
reversed O
by O
mizoribin O
withdrawal O
, O
suggesting O
that O
bredinin B-DRUG
might O
adversely O
induce O
siadh B-ADR

the O
reported O
cases O
of O
in O
utero O
exposure O
to O
cyclosposphamide B-DRUG
shared O
the O
following O
manifestations O
with O
our O
patient O
: O
growth O
deficiency O
, O
developmental O
delay O
, O
craniosynostosis O
, O
blepharophimosis O
, O
flat O
nasal O
bridge O
, O
abnormal O
ears O
, O
and O
distal O
limb O
defects O
including O
hypoplastic B-ADR
thumbs I-ADR
and O
oligodactyly O

thirty-six O
patients O
with O
al O
received O
, O
in O
a O
three-month O
period O
, O
51 O
cycles O
of O
combined O
chemotherapy O
which O
included O
, O
in O
all O
of O
them O
, O
cytosine O
arabinoside O
( O
ara-c B-DRUG
) O
; O
among O
them O
, O
along O
with O
myelosuppression O
, O
five O
experienced O
fever O
, O
infectious O
complications O
, O
gastrointestinal O
tract O
symptoms O
and O
severe B-ADR
myalgias I-ADR

objective O
: O
to O
report O
a O
case O
of O
severe B-ADR
apnea I-ADR
in O
an O
infant O
exposed O
to O
lamotrigine B-DRUG
through O
breast-feeding O

controversy O
concerning O
the O
nephrotoxicity B-ADR
of O
lithium B-DRUG
is O
discussed O
, O
and O
recommendations O
for O
the O
evaluation O
of O
renal O
failure O
during O
lithium B-DRUG
therapy O
are O
provided O

pneumocystis O
pneumonia O
should O
be O
considered O
in O
asthmatic O
patients O
taking O
methotrexate B-DRUG
who O
present O
with O
fever B-ADR
, O
pulmonary O
infiltrates O
, O
and O
hypoxia O

a O
66-year-old O
japanese O
woman O
with O
severe O
scleroderma O
developed O
anemia O
and O
thrombocytopenia B-ADR
due O
to O
d-penicillamine B-DRUG
( O
d-pen O
) O
treatment O
, O
although O
the O
leukopenia O
was O
not O
markedly O
severe O

gemcitabine B-DRUG
is O
a O
known O
risk O
factor O
for O
hemolytic O
uremic O
syndrome O
( O
hus B-ADR
) O
, O
which O
can O
often O
have O
a O
rapidly O
fatal O
clinical O
course O
despite O
intervention O
with O
steroids O
, O
plasmapheresis O
and O
hemodialysis O

we O
present O
a O
case O
of O
hemolytic-uremic B-ADR
syndrome I-ADR
that O
developed O
during O
the O
4th O
cycle O
of O
combination O
chemotherapy O
with O
oxaliplatin B-DRUG
, O
5-fluorouracil O
and O
leucovorin O

interpretation O
: O
when O
high O
doses O
of O
fluticasone B-DRUG
propionate I-DRUG
are O
used O
, O
growth B-ADR
may I-ADR
be I-ADR
retarded I-ADR
and O
adrenal O
suppression O
may O
occur O

prolonged O
severe B-ADR
cholestasis I-ADR
induced O
by O
oxacillin B-DRUG
derivatives O

our O
patient O
had O
headache O
, O
mild O
fever O
, O
nausea O
, O
vomiting B-ADR
, O
rash O
, O
and O
eosinophilia O
after O
3 O
weeks O
of O
disulfiram B-DRUG
therapy O

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash B-ADR
, O
fever O
, O
leukopenia O
and O
positive O
anti-nuclear O
antibody O
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine O
( O
cbz O
; O
tegretol B-DRUG
) O
used O
against O
benign O
rolandic O
epilepsy O

colchicine-induced O
myopathy B-ADR
in O
renal O
failure O

conclusions O
: O
in O
our O
reported O
case O
, O
a O
local O
hyperproduction O
of O
tnf-alpha O
from O
macrophages O
that O
was O
induced O
by O
the O
injected O
insulin B-DRUG
could O
explain O
the O
dedifferentiation B-ADR
of I-ADR
the I-ADR
adipocytes I-ADR
of O
the O
subcutaneous O
tissue O
and O
the O
reversion O
that O
was O
induced O
by O
the O
local O
injection O
of O
dexamethasone O

in O
rare O
cases O
mitomycin O
c O
( O
mmc B-DRUG
) O
may O
induce O
cancer-associated O
hemolytic O
uremic O
syndrome O
, O
which O
is O
characterized O
by O
hemolytic O
anemia O
, O
thrombocytopenia B-ADR
and O
progressive O
renal O
failure O

after O
3 O
- O
to O
13-month O
period O
of O
therapy O
without O
indapamide B-DRUG
, O
glucose O
levels O
of O
all O
patients O
decreased O
and O
diabetes B-ADR
disappeared O

thirty-six O
patients O
with O
al O
received O
, O
in O
a O
three-month O
period O
, O
51 O
cycles O
of O
combined O
chemotherapy O
which O
included O
, O
in O
all O
of O
them O
, O
cytosine B-DRUG
arabinoside I-DRUG
( O
ara-c O
) O
; O
among O
them O
, O
along O
with O
myelosuppression O
, O
five O
experienced O
fever O
, O
infectious O
complications O
, O
gastrointestinal O
tract O
symptoms O
and O
severe B-ADR
myalgias I-ADR

replicate O
brain O
magnetic O
resonance O
imaging O
examinations O
after O
six O
weeks O
and O
11 O
months O
of O
penicillamine B-DRUG
therapy O
documented O
the O
development O
of O
new O
brain B-ADR
lesions I-ADR
during O
this O
period O
, O
while O
liver O
biopsy O
specimen O
data O
disclosed O
that O
excellent O
hepatic O
decoppering O
had O
occurred O

pamidronate O
therapy O
should O
be O
considered O
in O
patients O
with O
hypercalcemia B-ADR
secondary O
to O
acute O
vitamin B-DRUG
d I-DRUG
poisoning O

ophthalmologists O
should O
be O
aware O
of O
the O
ocular O
side O
effects O
of O
ifn B-DRUG
therapy O
and O
carefully O
monitor O
patients O
for O
the O
possible O
occurrence O
of O
hypoalbuminemia B-ADR
and O
thrombocytopenia O

this O
article O
presents O
a O
case O
of O
an O
atypical B-ADR
localized I-ADR
cutaneous I-ADR
eruption I-ADR
with O
an O
unusual O
course O
and O
protracted O
resolution O
time O
associated O
with O
sorafenib B-DRUG
therapy O

atrial B-ADR
fibrillation I-ADR
occurring O
in O
a O
patient O
taking O
etanercept B-DRUG
plus O
methotrexate O
for O
rheumatoid O
arthritis O

both O
6-mp B-DRUG
and O
aza O
are O
widely O
used O
and O
are O
known O
to O
cause O
hepatotoxicity B-ADR
in O
a O
proportion O
of O
patients O

pentazocine-induced O
fibrous O
myopathy O
and O
localized O
neuropathy B-ADR

a O
28 O
year O
old O
white O
schizophrenic O
male O
has O
been O
under O
risperidone B-DRUG
monotherapy O
for O
about O
one O
year O
when O
he O
developed O
dyskinetic B-ADR
movements I-ADR

amphotericin B-DRUG
b I-DRUG
( O
amb O
) O
is O
effective O
, O
but O
its O
use O
is O
limited O
by O
toxicity O
: O
renal O
impairment O
, O
anaemia O
, O
fever B-ADR
, O
malaise O
, O
and O
hypokalaemia O
are O
common O

benzocaine B-DRUG
, O
an O
ester-type O
local O
anesthetic O
, O
was O
believed O
responsible O
for O
apparent O
methemoglobinemia B-ADR
in O
a O
cat O

toxicity B-ADR
related O
to O
chloroquine B-DRUG
treatment O
of O
resistant O
vivax O
malaria O

the O
occurrence O
of O
neuromuscular O
blockade O
and O
the O
resulting O
potentiation B-ADR
of I-ADR
muscle I-ADR
relaxants I-ADR
during O
magnesium O
sulfate O
( O
mgso4 B-DRUG
) O
administration O
is O
well O
known O

since O
the O
bronchospasm B-ADR
was O
relieved O
with O
discontinuation O
of O
propranolol B-DRUG
and O
supportive O
bronchodilator O
therapy O
, O
the O
bronchospasm B-ADR
was O
believed O
to O
be O
caused O
by O
propranolol B-DRUG

while O
most O
physicians O
are O
aware O
of O
heparin-induced O
thrombocytopenia O
and O
skin O
necrosis O
, O
the O
association O
of O
heparin B-DRUG
and O
hyperkalemia B-ADR
is O
less O
well O
recognized O

we O
report O
a O
16-year-old O
male O
who O
developed O
nephrotic B-ADR
syndrome I-ADR
related O
to O
membranous O
glomerulopathy O
with O
clinical O
and O
serological O
evidence O
of O
systemic O
lupus O
erythematosus O
after O
treatment O
with O
griseofulvin B-DRUG

although O
various O
manifestations O
of O
pentamidine-induced O
cardiotoxicity B-ADR
have O
been O
reported O
, O
to O
our O
knowledge O
, O
second-degree O
heart O
block O
associated O
with O
this O
agent O
has O
not O
been O
described O

objective O
: O
to O
report O
a O
case O
of O
serotonin B-ADR
syndrome I-ADR
associated O
with O
interaction O
between O
fentanyl B-DRUG
and O
citalopram O
, O
as O
evidenced O
by O
medication O
history O
, O
clinical O
features O
and O
reversal O
following O
discontinuation O
of O
fentanyl B-DRUG

objectives O
: O
the O
authors O
described O
a O
case O
of O
hashimoto B-ADR
's I-ADR
disease I-ADR
during O
interferon-alpha B-DRUG
( O
ifn-alpha O
) O
treatment O
for O
chronic O
viral O
c O
hepatitis O
in O
a O
patient O
with O
the O
specific O
genetic O
susceptibility O
associated O
with O
the O
thyroid O
disease O

we O
describe O
a O
patient O
with O
acute O
leukemia O
who O
developed O
horner O
's O
syndrome O
and O
a O
severe O
demyelinating O
peripheral O
neuropathy O
leading O
to O
death B-ADR
after O
receiving O
high-dose O
cytosine B-DRUG
arabinoside I-DRUG

cerebral B-ADR
and I-ADR
ocular I-ADR
toxicity I-ADR
induced O
by O
desferrioxamine B-DRUG

grade B-ADR
3 I-ADR
hepatotoxicity I-ADR
( O
ast O
and O
alt O
> O
5 O
to O
20 O
upper O
limit O
normal O
) O
or O
higher O
has O
been O
observed O
in O
as O
many O
as O
1.4 O
% O
of O
ms O
patients O
on O
ifn B-DRUG
beta I-DRUG

during O
her O
third O
cycle O
, O
she O
again O
received O
cisplatin B-DRUG
100 O
mg O
/ O
m2 O
over O
30 O
minutes O
and O
developed O
palmar O
pruritus O
, O
urticaria O
, O
and O
edema B-ADR

acute B-ADR
intravascular I-ADR
hemolysis I-ADR
developed O
when O
a O
diabetic O
patient O
, O
previously O
treated O
with O
glyburide B-DRUG
, O
was O
started O
on O
another O
oral O
sulfonylurea O
drug O
, O
chlorpropamide O

we O
thus O
concluded O
that O
an O
excessive O
dose O
of O
az B-DRUG
had O
probably O
destroyed O
the O
gastric O
mucosal O
barrier O
or O
thrombocytopenia B-ADR
due I-ADR
to I-ADR
bone I-ADR
marrow I-ADR
disorder I-ADR
and O
thus O
eventually O
led O
to O
the O
development O
of O
hemorrhagic O
gastritis O

case O
report O
: O
acute B-ADR
renal I-ADR
failure I-ADR
after O
administering O
intravenous O
immunoglobulin B-DRUG

acute B-ADR
non-lymphocytic I-ADR
leukemia I-ADR
occurred O
in O
eight O
women O
following O
long-term O
treatment O
with O
treosulfan O
(= O
dihydroxybusulfan B-DRUG
) O
for O
ovarian O
carcinoma O

the O
aim O
of O
this O
study O
was O
to O
describe O
the O
occurrence O
of O
acute B-ADR
coronary I-ADR
syndromes I-ADR
in O
3 O
cases O
of O
rituximab B-DRUG
infusions O

acute B-ADR
myeloid I-ADR
leukemia I-ADR
and O
lung O
cancer O
occurring O
in O
a O
chronic O
lymphocytic O
leukemia O
patient O
treated O
with O
fludarabine B-DRUG
and O
autologous O
peripheral O
blood O
stem-cell O
transplantation O

we O
suggest O
that O
meloxicam B-DRUG
might O
have O
intestinal B-ADR
toxic I-ADR
effects I-ADR
when O
taken O
in O
high O
doses O
, O
because O
of O
reduced O
cox-2 O
selectivity O

antithyroid O
treatment O
with O
propylthiouracil O
( O
ptu B-DRUG
) O
resulted O
in O
elevated B-ADR
hepatic I-ADR
enzymes I-ADR
and O
after O
the O
12th O
week O
of O
pregnancy O
treatment O
was O
changed O
to O
carbimazole O
( O
cbz O

secondary O
acute B-ADR
myeloid I-ADR
leukemia I-ADR
after O
etoposide B-DRUG
therapy O
for O
haemophagocytic O
lymphohistiocytosis O

we O
describe O
a O
patient O
with O
m4 O
aml O
treated O
with O
standard O
chemotherapy O
followed O
by O
g-csf B-DRUG
who O
developed O
marked O
monocytosis B-ADR
on O
day O
8 O
of O
g-csf B-DRUG
therapy O

however O
, O
prolongation O
of O
5-fu O
half-life O
and O
an O
increase B-ADR
in I-ADR
inr I-ADR
have O
been O
reported O
with O
the O
concurrent O
use O
of O
5-fu O
and O
warfarin B-DRUG

near B-ADR
fatal I-ADR
acute O
colchicine B-DRUG
intoxication O
in O
a O
child O

a O
complex O
pattern O
of O
melanonychia O
and O
onycholysis B-ADR
after O
treatment O
with O
pemetrexed B-DRUG
for O
lung O
cancer O

polymyositis B-ADR
after O
propylthiouracil B-DRUG
treatment O
for O
hyperthyroidism O

this O
case O
underscores O
problems O
in O
clinical O
management O
with O
sulfadiazine B-DRUG
hypersensitivity B-ADR
, O
potential O
immunosuppression O
from O
corticosteroids O
and O
selection O
of O
medications O
for O
recurrences O
of O
toxoplasmic O
chorioretinitis O

three O
of O
these O
patients O
had O
convulsions B-ADR
attributed O
to O
imipenem O
/ O
cilastatin B-DRUG
; O
3.6 O
% O
of O
the O
patients O
had O
seizure O
, O
or O
2 O
% O
of O
imipenem O
/ O
cilastatin B-DRUG
administrations O
was O
followed O
by O
a O
seizure O
attack O

conclusions O
: O
the O
risk O
of O
drug-induced O
rhabdomyolysis B-ADR
due O
to O
the O
potential O
interaction O
between O
lovastatin O
and O
azithromycin O
or O
clarithromycin B-DRUG
should O
be O
considered O
before O
the O
concomitant O
use O
of O
these O
agents O

a O
50-year-old O
woman O
with O
a O
history O
of O
migraine O
without O
aura O
, O
predominantly O
occurring O
around O
her O
menstrual O
periods O
, O
developed O
a O
spinal B-ADR
cord I-ADR
lesion I-ADR
following O
the O
use O
of O
zolmitriptan B-DRUG

because O
the O
cerebellar B-ADR
toxicity I-ADR
may O
be O
worsened O
by O
continuation O
of O
therapy O
after O
initial O
onset O
of O
symptoms O
, O
prompt O
termination O
of O
hdarac B-DRUG
is O
recommended O

two O
patients O
developed O
diabetic B-ADR
coma I-ADR
when O
taking O
a O
combination O
of O
a O
thiazide B-DRUG
diuretic O
and O
propranolol O

this O
report O
details O
a O
case O
of O
bilateral B-ADR
avascular I-ADR
necrosis I-ADR
of I-ADR
the I-ADR
femoral I-ADR
heads I-ADR
in O
a O
patient O
receiving O
' O
standard O
' O
doses O
of O
dexamethasone B-DRUG
as O
part O
of O
the O
antiemetic O
regimen O
used O
in O
cisplatin-based O
combination O
chemotherapy O

circulating O
anticoagulant O
in O
the O
procainamide-induced O
lupus B-ADR
syndrome I-ADR

three O
patients O
are O
reported O
without O
a O
history O
of O
angina O
pectoris O
who O
had O
clinical O
and O
electrocardiographic O
evidence O
of O
myocardial B-ADR
ischemia I-ADR
during O
and O
immediately O
after O
bcnu B-DRUG
infusion O

controversy O
concerning O
the O
nephrotoxicity O
of O
lithium B-DRUG
is O
discussed O
, O
and O
recommendations O
for O
the O
evaluation O
of O
renal B-ADR
failure I-ADR
during O
lithium B-DRUG
therapy O
are O
provided O

quetiapine B-DRUG
and O
obsessive-compulsive B-ADR
symptoms I-ADR
( O
ocs O
) O
: O
case O
report O
and O
review O
of O
atypical O
antipsychotic-induced O
ocs O

the O
first O
patient O
developed O
a O
monoarthritis B-ADR
2 O
weeks O
after O
initiation O
of O
ifn-beta B-DRUG
, O
which O
persisted O
during O
the O
14 O
months O
of O
therapy O
and O
resolved O
with O
discontinuation O
of O
the O
medication O

results O
: O
a O
male O
and O
a O
female O
patient O
with O
spasticity O
treated O
with O
intrathecal O
baclofen B-DRUG
were O
recognized O
to O
have O
sexual B-ADR
dysfunction I-ADR
side O
effects O
from O
treatment O

well-differentiated O
endometrial B-ADR
adenocarcinoma I-ADR
of I-ADR
the I-ADR
secretory I-ADR
type I-ADR
( O
figo O
grade O
1 O
) O
with O
minimal O
myometrial O
invasion O
occurred O
in O
a O
postmenopausal O
patient O
on O
tamoxifen B-DRUG
therapy O
5 O
years O
after O
mastectomy O
for O
breast O
carcinoma O

although O
other O
nitrites O
induce O
methemoglobinemia B-ADR
, O
exposure O
to O
methyl B-DRUG
nitrite I-DRUG
during O
phenylpropanolamine O
production O
appears O
to O
be O
a O
new O
cause O
of O
occupational O
methemoglobinemia B-ADR

four O
years O
after O
the O
beginning O
of O
ifn B-DRUG
therapy O
, O
he O
acutely O
developed O
moderate O
hyperglycemia O
and O
severe B-ADR
ketonuria I-ADR
with O
positive O
islet O
cell O
antibody O
, O
and O
then O
28 O
units O
/ O
day O
of O
insulin O
injection O
was O
started O

this O
is O
the O
first O
reported O
case O
of O
boop B-ADR
associated O
with O
single-agent O
rituximab B-DRUG
, O
and O
along O
with O
two O
other O
patients O
we O
describe O
, O
as O
well O
as O
two O
prior O
reports O
of O
boop B-ADR
in O
nhl O
patients O
receiving O
rituximab-based O
combinations O
, O
strengthens O
the O
possibility O
of O
a O
causal O
relationship O

torsemide B-DRUG
appears O
to O
also O
be O
a O
part O
of O
a O
long O
list O
of O
agents O
that O
can O
cause O
pancreatitis B-ADR

in O
four O
patients O
, O
thrombosis O
occurred O
2-45 O
days O
after O
severe O
hepatic B-ADR
veno-occlusive I-ADR
disease I-ADR
( O
hvod O
) O
secondary O
to O
intensive O
chemotherapy O
containing O
busulfan B-DRUG

intrahepatic O
cholestasis O
and O
sicca B-ADR
complex I-ADR
after O
thiabendazole B-DRUG

in O
patients O
with O
cirrhosis O
, O
the O
metabolism O
of O
meperidine B-DRUG
is O
decreased O
, O
leading O
to O
accumulation B-ADR
of I-ADR
the I-ADR
parent I-ADR
drug I-ADR
and O
possible O
cns O
depressive O
effects O
similar O
to O
hepatic O
encephalopathy O

a O
second O
possibility O
is O
an O
interaction O
between O
clarithromycin B-DRUG
and O
isradipine O
, O
potentially O
increasing B-ADR
the I-ADR
hepatic I-ADR
toxicity I-ADR
of O
isradipine O

after O
therapy O
for O
diabetic O
coma O
with O
insulin B-DRUG
( O
containing O
the O
preservative O
cresol O
) O
and O
electrolyte O
solutions O
was O
started O
, O
the O
patient O
complained O
of O
increasing O
myalgia O
, O
developed O
a O
high O
fever O
and O
respiratory O
and O
metabolic O
acidosis O
and O
lost B-ADR
consciousness I-ADR

lithium B-DRUG
neurotoxicity O
should O
be O
considered O
in O
creutzfeldt-jakob B-ADR
disease I-ADR
differential O
diagnosis O
, O
serial O
electroencephalograms O
being O
the O
most O
valuable O

fsgs B-ADR
induced O
by O
adriamycin B-DRUG
( O
pharmacia O
& O
upjohn O
, O
columbus O
, O
oh O
) O
has O
been O
observed O
experimentally O
in O
rats O

a O
58-year-old O
woman O
with O
rheumatoid O
arthritis O
( O
ra O
) O
developed O
fever B-ADR
, O
skin O
eruptions O
, O
leukocytopenia O
, O
and O
thrombocytopenia O
, O
3 O
weeks O
after O
treatment O
with O
sulfasalazine B-DRUG

she O
was O
placed O
on O
adjuvant O
adriamycin B-DRUG
( O
doxorubicin O
) O
chemotherapy O
, O
but O
6 O
months O
later O
died O
of O
adriamycin B-ADR
toxicity I-ADR

the O
authors O
suggest O
that O
fluoxetine-induced O
akathisia B-ADR
may O
be O
caused O
by O
serotonergically O
mediated O
inhibition O
of O
dopaminergic O
neurotransmission O
and O
that O
the O
pathophysiology O
of O
fluoxetine-induced O
akathisia B-ADR
and O
tricyclic O
antidepressant-induced O
" O
jitteriness O
" O
may O
be O
identical O

a O
dapsone B-DRUG
hypersensitivity B-ADR
syndrome I-ADR
, O
consisting O
of O
fever O
, O
headache O
, O
nausea O
, O
vomiting O
, O
lymphadenopathy O
, O
hepatitis O
, O
hemolysis O
, O
leukopenia O
, O
and O
mononucleosis O
, O
has O
been O
described O
in O
patients O
treated O
with O
the O
drug O
for O
leprosy O

despite O
these O
antithrombotic O
effects O
, O
the O
patient O
developed O
repeated O
venous B-ADR
thromboembolism I-ADR
during O
treatment O
with O
low-molecular-weight O
heparin B-DRUG

case O
report O
: O
a O
woman O
of O
80 O
years O
, O
on O
long-term O
warfarin B-DRUG
therapy O
presented O
with O
an O
acute B-ADR
dissecting I-ADR
thoracic I-ADR
aortic I-ADR
aneurysm I-ADR
; O
on O
investigation O
the O
only O
precipitating O
factor O
found O
was O
an O
international O
normalised O
ratio O
of O
4.8 O

background O
: O
gemcitabine B-DRUG
has O
mild O
renal O
toxicity O
, O
but O
cases O
of O
gemcitabine-associated O
hemolytic-uremic O
syndrome O
( O
hus B-ADR
) O
have O
been O
reported O

a O
case O
report O
of O
a O
patient O
with O
probable O
cisplatin O
and O
bleomycin-induced O
tma B-ADR
is O
presented O

clinicians O
have O
been O
aware O
of O
lithium B-DRUG
toxicity O
for O
many O
years O
and O
traditionally O
have O
administered O
thiazide O
diuretics O
for O
lithium-induced O
polyuria O
and O
nephrogenic B-ADR
diabetes I-ADR
insipidus I-ADR

methylphenidate-associated O
enuresis B-ADR
in O
attention O
deficit O
hyperactivity O
disorder O

results O
: O
evidence O
of O
neurological O
improvement O
and O
rehabilitation O
potential O
after O
severe B-ADR
myelopathy I-ADR
due O
to O
intrathecal O
injection O
of O
doxorubicin B-DRUG

the O
capacity O
of O
zuclopenthixol B-DRUG
to O
induce O
priapism B-ADR
is O
thought O
to O
be O
due O
to O
its O
antagonist O
activity O
on O
alpha-adrenergic O
receptors O

progressive B-ADR
interstitial I-ADR
fibrosis I-ADR
with O
roentgenographic O
honeycombing O
developed O
in O
the O
case O
of O
a O
psoriatic O
patient O
who O
had O
been O
on O
a O
regimen O
of O
methotrexate B-DRUG
for O
18 O
years O

sodium O
valproate O
and O
carbamazepine B-DRUG
, O
antiepileptic O
drugs O
that O
are O
associated O
with O
a O
relatively O
low O
rate O
of O
adverse O
cutaneous O
reactions O
, O
should O
be O
added O
to O
the O
growing O
list O
of O
drugs O
that O
produce O
psoriasiform B-ADR
eruptions I-ADR

we O
report O
a O
case O
of O
ritalin-associated O
cataract O
and O
glaucoma B-ADR

diagnosis O
: O
severe O
temozolomide-induced O
immunosuppression O
, O
exacerbated O
by O
corticosteroids O
, O
with O
profound O
t-cell O
lymphocytopenia O
and O
simultaneous O
opportunistic O
infections O
with O
pneumocystis O
jiroveci O
pneumonia O
, O
brain O
abscess O
with O
listeria O
monocytogenes O
, O
and O
cutaneous B-ADR
kaposi I-ADR
's I-ADR
sarcoma I-ADR

acute B-ADR
reversible I-ADR
ataxo-myoclonic I-ADR
encephalopathy I-ADR
with O
flecainide B-DRUG
therapy O

we O
also O
describe O
a O
case O
of O
timolol-induced O
ocular B-ADR
pemphigoid I-ADR

hepatotoxic B-ADR
effects I-ADR
in O
a O
child O
receiving O
valproate B-DRUG
and O
carnitine O

we O
report O
a O
rare O
case O
of O
colonic B-ADR
mucosal I-ADR
necrosis I-ADR
following O
kalimate O
( O
calcium O
polystryrene O
sulfonate O
) O
, O
an O
analogue O
of O
kayexalate B-DRUG
without O
sorbitol O
in O
a O
34-yr-old O
man O

purpose O
: O
to O
describe O
spectral-domain O
optical O
coherence O
tomography O
( O
sd-oct O
) O
and O
adaptive O
optics O
( O
ao O
) O
imaging O
in O
hydroxychloroquine B-DRUG
retinal B-ADR
toxicity I-ADR

we O
report O
two O
cases O
that O
developed O
acute B-ADR
myeloid I-ADR
leukaemia I-ADR
( O
aml O
) O
during O
tamoxifen B-DRUG
therapy O
for O
breast O
cancer O

the O
authors O
describe O
a O
patient O
with O
hemiparesis O
who O
developed O
the O
syndrome O
of O
irreversible O
lithium-effectuated O
neurotoxicity B-ADR
( O
silent O
) O
while O
being O
treated O
with O
lithium B-DRUG
for O
a O
manic O
episode O

a O
31-year-old O
female O
developed O
multiple O
episodes O
of O
grand B-ADR
mal I-ADR
seizures I-ADR
after O
combination O
chemotherapy O
with O
cisplatin B-DRUG
, O
vinblastine O
and O
bleomycin O
for O
germ O
cell O
ovarian O
cancer O
stage O
ic O

protease O
inhibitors O
( O
ritonavir O
and O
saquinavir B-DRUG
) O
were O
added O
to O
the O
treatment O
and O
the O
patient O
developed O
progressive O
ataxia O
related O
to O
carbamazepine B-ADR
toxicity I-ADR

verapamil B-DRUG
is O
widely O
used O
for O
the O
termination O
of O
paroxysmal O
supraventricular O
tachycardia O
( O
psvt O
) O
with O
little O
proarrhythmic B-ADR
effect I-ADR

she O
died O
within O
six O
weeks O
of O
developing O
congestive O
heart O
failure O
coupled O
with O
liver B-ADR
failure I-ADR
due O
to O
haemosiderosis O
despite O
regular O
use O
of O
desferrioxamine B-DRUG

case O
report O
: O
we O
report O
the O
case O
of O
a O
58 O
year O
old O
patient O
who O
, O
after O
2 O
days O
of O
treatment O
with O
roxithromycin O
and O
betamethasone B-DRUG
, O
manifested O
acute B-ADR
pancreatitis I-ADR

conclusions O
: O
this O
is O
the O
first O
report O
of O
a O
possible O
interaction O
between O
propafenone O
and O
citalopram B-DRUG
, O
which O
caused O
propafenone O
adverse O
effects O
( O
eg O
, O
dizziness O
, O
falls B-ADR
) O
and O
mimicked O
coronary O
artery O
disease O

sulfasalazine-induced O
lung B-ADR
disorder I-ADR
is O
an O
extremely O
rare O
entity O
which O
must O
be O
considered O
in O
all O
ulcerative O
colitis O
patients O
while O
on O
sulfasalazine O
therapy O
, O
despite O
the O
absence O
of O
pulmonary O
symptomatology O

a O
65-year-old O
female O
patient O
presented O
with O
jaundice B-ADR
followed O
2 O
days O
later O
by O
severe O
dyspnea O
and O
tachypnea O
which O
worsened O
when O
patient O
was O
lying O
flat O
, O
1 O
week O
after O
the O
fourth O
dose O
of O
adalimumab B-DRUG

we O
present O
a O
case O
of O
a O
diabetic O
patient O
taking O
glyburide B-DRUG
who O
was O
prescribed O
ciprofloxacin O
and O
developed O
prolonged B-ADR
hypoglycemia I-ADR
, O
which O
persisted O
for O
over O
24 O
hours O

purpose O
/ O
objectives O
: O
to O
describe O
the O
pharmacogenetic O
syndrome O
of O
dihydropyrimidine O
dehydrogenase O
( O
dpd O
) O
deficiency O
, O
which O
predisposes O
patients O
with O
cancer O
to O
potentially O
lethal B-ADR
adverse I-ADR
reactions I-ADR
following O
5-fluorouracil B-DRUG
( O
5-fu O
)- O
based O
chemotherapy O

the O
site O
of O
thrombosis O
and O
the O
chronological O
relationship O
with O
the O
iir O
implicates O
a O
hypersensitivity O
to O
infliximab B-DRUG
in O
the O
causation O
of O
the O
venous B-ADR
thrombosis I-ADR
in O
this O
case O

lansoprazole-associated O
collagenous B-ADR
colitis I-ADR
: O
a O
case O
report O

herein O
, O
we O
describe O
a O
patient O
with O
aids O
who O
presented O
to O
medical O
attention O
with O
pancytopenia B-ADR
48 O
months O
postchemotherapy O
with O
etoposide O
, O
prednisone O
, O
vincristine B-DRUG
, O
cyclophosphamide O
, O
doxorubicin O
, O
and O
rituximab O
( O
r-epoch O
) O
for O
diffuse O
large O
b-cell O
lymphoma O

concurrent O
acute O
megaloblastic O
anaemia O
and O
pneumonitis B-ADR
: O
a O
severe O
side-effect O
of O
low-dose O
methotrexate B-DRUG
therapy O
during O
rheumatoid O
arthritis O

two O
case O
reports O
of O
bilateral B-ADR
granulomatous I-ADR
anterior I-ADR
uveitis I-ADR
are O
described O
in O
patients O
with O
open O
angle O
glaucoma O
treated O
with O
metripranolol B-DRUG
0.6 O
% O
eye O
drops O

coagulopathy B-ADR
associated O
with O
the O
use O
of O
cephalosporin B-DRUG
or O
moxalactam O
antibiotics O
in O
acute O
and O
chronic O
renal O
failure O

visual B-ADR
hallucinations I-ADR
associated O
with O
zonisamide B-DRUG

epoprostenol B-DRUG
may O
be O
associated O
rarely O
with O
severe O
erythroderma B-ADR

statin-associated O
myasthenia B-ADR
gravis I-ADR
: O
report O
of O
4 O
cases O
and O
review O
of O
the O
literature O

cardiorespiratory B-ADR
toxicity I-ADR
due O
to O
miconazole B-DRUG

in O
a O
phase O
ii O
study O
of O
hycanthone B-DRUG
in O
patients O
with O
breast O
cancer O
we O
have O
recently O
observed O
severe B-ADR
hepatotoxicity I-ADR
, O
even O
at O
lower O
doses O
, O
which O
resulted O
in O
two O
drug-related O
deaths O

flucytosine-associated O
diarrhea B-ADR
has O
been O
previously O
described O
in O
6 O
%- O
10 O
% O
of O
patients O
receiving O
the O
drug O

we O
report O
the O
case O
of O
a O
40-year-old O
woman O
who O
developed O
fulminant B-ADR
hepatic I-ADR
failure I-ADR
and O
aplastic O
anaemia O
following O
a O
course O
of O
oral O
flucloxacillin B-DRUG

we O
suspect O
that O
nefazodone B-DRUG
inhibits B-ADR
metabolism I-ADR
of I-ADR
tacrolimus I-ADR

transient B-ADR
cardiac I-ADR
arrhythmias I-ADR
related O
to O
lopinavir O
/ O
ritonavir B-DRUG
in O
two O
patients O
with O
hiv O
infection O

pneumonitis B-ADR
with O
pleural O
and O
pericardial O
effusion O
and O
neuropathy O
during O
amiodarone B-DRUG
therapy O

we O
report O
a O
patient O
who O
experienced O
labd B-ADR
shortly O
after O
starting O
carbamazepine B-DRUG
therapy O

horner B-ADR
's I-ADR
syndrome I-ADR
and O
demyelinating O
peripheral O
neuropathy O
caused O
by O
high-dose O
cytosine B-DRUG
arabinoside I-DRUG

cholestatic O
liver O
disease O
with O
ductopenia O
( O
vanishing B-ADR
bile I-ADR
duct I-ADR
syndrome I-ADR
) O
after O
administration O
of O
clindamycin B-DRUG
and O
trimethoprim-sulfamethoxazole O

the O
administration O
of O
" O
sweet B-DRUG
spirits I-DRUG
of I-DRUG
nitre I-DRUG
" O
( O
4 O
% O
ethyl O
nitrite O
ch3ch2ono O
in O
70 O
% O
ethyl O
alcohol O
) O
was O
followed O
by O
acute B-ADR
methemoglobinemia I-ADR
and O
severe O
anoxic O
metabolic O
acidosis O
in O
infant O
twins O
, O
methylene O
blue O
administration O
reversed O
methemoglobinemia O
in O
both O
, O
but O
one O
twin O
died O
from O
the O
consequences O
of O
hypoxemia O

we O
present O
a O
case O
of O
significant O
over-anticoagulation O
temporally O
associated O
with O
a O
bout O
of O
protracted O
diarrhea B-ADR
in O
a O
patient O
on O
warfarin B-DRUG
therapy O

in O
contrast O
to O
chronic O
or O
subacute B-ADR
thyroiditis I-ADR
, O
graves' O
disease O
rarely O
complicates O
ifn-alpha B-DRUG
therapy O
for O
chronic O
viral O
c O
hepatitis O

severe B-ADR
hyperkalemia I-ADR
occurred O
in O
a O
patient O
with O
radiation O
pneumonitis O
and O
glaucoma O
shortly O
after O
beginning O
prednisone B-DRUG
therapy O

didanosine B-DRUG
also O
has O
a O
potential O
for O
inducing O
seizures B-ADR

phenytoin B-DRUG
toxicity O
: O
an O
easily O
missed O
cause O
of O
cerebellar B-ADR
syndrome I-ADR

severe O
vancomycin-induced O
anaphylactic B-ADR
reaction I-ADR

acute O
myeloid O
leukemia O
and O
lung B-ADR
cancer I-ADR
occurring O
in O
a O
chronic O
lymphocytic O
leukemia O
patient O
treated O
with O
fludarabine B-DRUG
and O
autologous O
peripheral O
blood O
stem-cell O
transplantation O

a O
55-year-old O
woman O
developed O
symptoms O
suggestive O
of O
hepatitis B-ADR
12 O
weeks O
after O
first O
receiving O
methyldopa B-DRUG
for O
hypertension O

in O
association O
with O
this O
tocolysis O
, O
urinary B-ADR
calculus I-ADR
of O
magnesium B-DRUG
ammonium I-DRUG
phosphate I-DRUG
occurred O
at O
34 O
weeks O
gestation O

we O
describe O
a O
case O
of O
severe B-ADR
aplastic I-ADR
anemia I-ADR
( O
aa O
) O
that O
was O
probably O
induced O
by O
lenalidomide B-DRUG

pleuropulmonary B-ADR
fibrosis I-ADR
after O
long-term O
treatment O
with O
the O
dopamine O
agonist O
pergolide B-DRUG
for O
parkinson O
disease O

that O
review O
suggested O
that O
patients O
receiving O
anti-d B-DRUG
igiv I-DRUG
be O
monitored O
for O
those O
and O
other O
potential O
complications O
of O
hemoglobinemia O
, O
particularly O
disseminated O
intravascular O
coagulation O
( O
dic B-ADR

a O
15-year O
follow-up O
of O
phenytoin-induced O
unilateral B-ADR
gingival I-ADR
hyperplasia I-ADR
: O
a O
case O
report O

listeria O
brain O
abscess O
, O
pneumocystis O
pneumonia O
and O
kaposi B-ADR
's I-ADR
sarcoma I-ADR
after O
temozolomide B-DRUG

primary B-ADR
central I-ADR
nervous I-ADR
system I-ADR
lymphoma I-ADR
in O
a O
patient O
treated O
with O
natalizumab B-DRUG

a O
16-year-old O
boy O
developed O
fever O
, O
generalized O
rigidity O
, O
leukocytosis B-ADR
, O
and O
increased O
serum O
transaminase O
and O
creatine O
kinase O
levels O
while O
receiving O
treatment O
with O
olanzapine O
and O
lithium B-DRUG

there O
was O
a O
clear O
relationship O
between O
restarting O
the O
accutane B-DRUG
and O
recurrence O
of O
the O
transient B-ADR
myopia I-ADR

a O
search O
of O
the O
united O
states O
food O
and O
drug O
administration O
's O
adverse O
event O
reporting O
system O
identified O
nine O
cases O
of O
oxcarbazepine-associated O
angioedema B-ADR
in O
pediatric O
patients O
aged O
16 O
years O
and O
younger O

three O
patients O
with O
niacin-induced O
visual O
symptoms O
had O
cystoid B-ADR
maculopathy I-ADR
without O
leakage O
on O
fluorescein O
angiography O
, O
and O
a O
fourth O
patient O
with O
no O
fundus O
abnormality O
experienced O
cessation O
of O
visual O
symptoms O
upon O
discontinuation O
of O
niacin B-DRUG

abnormalities O
of O
the O
pupil O
and O
visual-evoked O
potential O
in O
quinine B-DRUG
amblyopia B-ADR

isoniazid B-DRUG
induced O
gynaecomastia B-ADR
: O
a O
case O
report O

norethisterone B-DRUG
in O
these O
69 O
pregnancies O
accounted O
for O
33.3 O
% O
( O
5 O
of O
15 O
) O
cases O
of O
clitoral B-ADR
hypertrophy I-ADR
diagnosed O
in O
100,756 O
consecutive O
births O

arrhythmias O
and O
cardiac B-ADR
arrest I-ADR
have O
been O
reported O
during O
amphotericin B-DRUG
b I-DRUG
administration O
but O
no O
effective O
technique O
has O
been O
described O
to O
prevent O
them O

destructive O
thyrotoxicosis B-ADR
appeared O
4-6 O
months O
after O
starting O
ifn-alpha B-DRUG
, O
followed O
by O
graves' O
hyperthyroidism O
within O
8 O
to O
11 O
months O

the O
authors O
suggest O
that O
in O
the O
absence O
of O
any O
proven O
benefit O
of O
itraconazole B-DRUG
prophylaxis O
, O
and O
given O
the O
interaction O
of O
this O
drug O
with O
vincristine O
leading O
to O
severe O
and O
even O
potentially O
fatal B-ADR
toxicities I-ADR
, O
the O
combination O
use O
of O
these O
drugs O
should O
be O
avoided O

the O
pathophysiological O
mechanisms O
remain O
unknown O
, O
although O
the O
drug O
could O
act O
through O
massive B-ADR
cytokines I-ADR
liberation I-ADR
after O
destruction O
of O
cd20 O
positive O
cells O
by O
rituximab B-DRUG

a O
16-year-old O
boy O
developed O
fever O
, O
generalized B-ADR
rigidity I-ADR
, O
leukocytosis O
, O
and O
increased O
serum O
transaminase O
and O
creatine O
kinase O
levels O
while O
receiving O
treatment O
with O
olanzapine B-DRUG
and O
lithium O

cutaneous B-ADR
necrosis I-ADR
after O
injection O
of O
polyethylene O
glycol-modified O
interferon B-DRUG
alfa I-DRUG

metformin-associated O
lactic B-ADR
acidosis I-ADR
( O
mala O
) O
is O
a O
serious O
metabolic O
complication O
that O
occurs O
because O
of O
metformin B-DRUG
accumulation O
in O
patients O
who O
become O
dehydrated O
or O
developed O
acute O
renal O
failure O

this O
case O
supports O
the O
view O
that O
in O
gold-induced O
pneumonitis B-ADR
a O
prolonged O
treatment O
with O
corticosteroids O
may O
be O
necessary O
, O
as O
lung O
function O
continued O
to O
improve O

however O
, O
there O
remain O
questions O
concerning O
whether O
these O
drugs O
, O
especially O
methimazole B-DRUG
( O
mmi O
) O
, O
may O
be O
associated O
with O
aplasia B-ADR
cutis I-ADR
congenita I-ADR
( O
acc O
) O
and O
how O
best O
to O
avoid O
impairment O
of O
fetal O
thyroid O
function O
during O
their O
use O

in O
case O
no O
. O
2 O
, O
the O
pathogenic O
mechanism O
seemed O
to O
be O
persistent O
light O
reaction O
preceded O
by O
systemic O
photoallergy O
, O
as O
he O
had O
taken O
mequitazine B-DRUG
for O
6 O
months O
, O
and O
there O
were O
strong O
positive O
photopatch O
test O
results O
with O
immediate O
erythema B-ADR
reaction O
, O
cross-reaction O
to O
promethazine O
, O
decreased O
med O
to O
both O
uva O
and O
uvb O
, O
and O
persistence O
of O
the O
photosensitivity O
over O
a O
3-year O
follow-up O
period O
after O
discontinuation O
of O
the O
mequitazine B-DRUG

two O
heroin B-DRUG
addicts O
, O
aged O
34 O
and O
19 O
years O
, O
developed O
ballistic B-ADR
movements I-ADR
after O
intravenous O
heroin B-DRUG
overdose O

rapamycin O
/ O
sirolimus B-DRUG
( O
sr O
) O
, O
trade O
named O
rapammune O
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression B-ADR
, O
hypertension O
, O
hyperlipidemia O
, O
and O
infection O

we O
report O
a O
case O
of O
st O
elevation O
in O
right O
precordial O
leads O
compatible O
with O
type B-ADR
1 I-ADR
brugada I-ADR
syndrome I-ADR
following O
administration O
of O
propafenone B-DRUG
in O
a O
patient O
with O
wolff-parkinson-white O
syndrome O
who O
was O
receiving O
lithium O
at O
concentrations O
within O
therapeutic O
levels O

according O
to O
the O
naranjo O
adverse O
drug O
reaction O
probability O
scale O
, O
the O
likelihood O
that O
temozolomide B-DRUG
was O
responsible O
for O
the O
adverse O
drug O
reaction O
of O
fever B-ADR
was O
probable O
( O
score O
of O
6 O

we O
report O
a O
case O
of O
a O
patient O
with O
mild O
chronic O
renal O
insufficiency O
who O
had O
been O
taking O
simvastatin B-DRUG
for O
over O
a O
year O
and O
developed O
acute B-ADR
weakness I-ADR
within O
3 O
weeks O
after O
the O
start O
of O
treatment O
with O
colchicine O
for O
acute O
gouty O
bursitis O

severe O
heparin B-DRUG
associated O
thrombocytopenia B-ADR
is O
a O
rare O
complication O
of O
heparin B-DRUG
therapy O

caution O
in O
longterm O
usage O
and O
early O
recognition O
of O
pentazocine B-DRUG
toxicity O
as O
a O
neuromuscular B-ADR
complication I-ADR
are O
important O
in O
order O
to O
prevent O
irreversible O
drug-induced O
fibrous O
myopathy O
and O
localized O
neuropathy O

when O
the O
acute O
manic O
state O
is O
characterized O
by O
marked O
psychotic B-ADR
symptoms I-ADR
and O
intense O
anxiety O
, O
it O
may O
be O
associated O
with O
increased O
vulnerability O
to O
the O
development O
of O
severe O
lithium B-DRUG
neurotoxicity O

we O
report O
the O
case O
of O
a O
14-year-old O
female O
with O
acute O
promyelocytic O
leukemia O
who O
developed O
symptomatic B-ADR
cardiomyopathy I-ADR
only O
4 O
months O
into O
treatment O
with O
a O
combination O
of O
daunomycin O
and O
all-trans B-DRUG
retinoic I-DRUG
acid I-DRUG
( O
atra O

a O
case O
of O
siadh B-ADR
induced O
by O
mizoribin B-DRUG
administration O

method O
: O
case O
analysis O
of O
a O
poly-drug O
overdose O
( O
venlafaxine B-DRUG
, O
topiramate O
, O
divalproex O
sodium O
, O
risperidone O
, O
and O
carbamazepine O
) O
presenting O
with O
mixed O
ss O
/ O
nms B-ADR
features O
and O
whose O
clinical O
management O
suggests O
a O
practical O
algorithm O
for O
treatment O
of O
undifferentiated O
ss O
/ O
nms B-ADR
in O
critical O
care O
settings O

livedo B-ADR
reticularis I-ADR
associated O
with O
interferon B-DRUG
alpha I-DRUG
therapy O
in O
two O
melanoma O
patients O

one O
patient O
had O
severe B-ADR
temporary I-ADR
weakness I-ADR
after O
an O
ampicillin B-DRUG
sodium I-DRUG
challenge O

stuttering B-ADR
priapism I-ADR
complicating O
warfarin B-DRUG
therapy O
in O
a O
patient O
with O
protein O
c O
deficiency O

hence O
, O
hyperthyroidism B-ADR
induced O
by O
ifn-alpha B-DRUG
could O
correspond O
to O
the O
first O
phase O
of O
silent O
thyroiditis O
, O
to O
graves' O
disease O
or O
to O
the O
succession O
of O
both O

polyarthritis B-ADR
, O
hepatitis O
and O
anti-native O
dna O
antibodies O
after O
treatment O
with O
ethambutol B-DRUG
and O
rifampicin O

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity O
reactions O
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general O
erythema O
, O
dyspnea B-ADR
, O
and O
hypotension O
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal O
pain O
, O
general O
erythema O
, O
and O
fever O

despite O
a O
postulated O
dopaminergic O
mechanism O
, O
there O
seems O
to O
have O
been O
only O
one O
previous O
report O
of O
amantadine B-DRUG
's O
precipitating B-ADR
psychosis I-ADR
in O
a O
schizophrenic O
patient O

successful O
desensitization O
to O
high-dose O
methotrexate B-DRUG
after O
systemic B-ADR
anaphylaxis I-ADR

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin O
, O
grepafloxacin O
, O
trovafloxacin O
, O
gatifloxacin B-DRUG
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache O
, O
dizziness O
and O
insomnia B-ADR

we O
report O
two O
cases O
of O
cerebrospinal B-ADR
fluid I-ADR
eosinophilia I-ADR
( O
csfe O
) O
secondary O
to O
the O
intraventricular O
administration O
of O
vancomycin B-DRUG

sorafenib B-DRUG
induced O
tumor B-ADR
lysis I-ADR
syndrome I-ADR
in O
an O
advanced O
hepatocellular O
carcinoma O
patient O

l-asparaginase-provoked O
seizures B-ADR
as O
singular O
expression O
of O
central O
nervous O
toxicity O

subcutaneous O
il-2 B-DRUG
is O
safe O
and O
well O
tolerated O
, O
with O
a O
mortality B-ADR
rate I-ADR
< I-ADR
3 I-ADR

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever B-ADR
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp B-DRUG
)- O
sulfamethoxazole O
( O
smx O
) O
treatment O

we O
present O
a O
fatal O
case O
of O
subacute O
methanol B-ADR
toxicity I-ADR
with O
associated O
diffuse O
brain O
involvement O
, O
including O
bilateral O
putaminal O
necrosis O
and O
cerebral O
edema O
with O
ventricular O
compression O

methotrexate-induced O
papular B-ADR
eruption I-ADR
following O
treatment O
of O
psoriasis O

this O
review O
presents O
the O
first O
case O
series O
of O
dic B-ADR
associated O
with O
acute O
hemoglobinemia O
or O
hemoglobinuria O
following O
anti-d B-DRUG
igiv I-DRUG
administration O
for O
itp O

case O
2 O
, O
a O
29-year-old O
woman O
, O
developed O
bilateral B-ADR
optic I-ADR
neuritis I-ADR
combined O
with O
numbness O
of O
the O
lower O
extremities O
as O
well O
as O
bowel O
and O
bladder O
dysfunction O
after O
a O
22-month O
use O
of O
recombinant B-DRUG
interferon I-DRUG
alpha-2b I-DRUG
for O
chronic O
myelogenous O
leukemia O

elderly O
patients O
for O
whom O
nitrate B-DRUG
has O
been O
prescribed O
should O
be O
warned O
of O
the O
occurrence O
of O
hypotension B-ADR
, O
leading O
to O
unconsciousness O

acute B-ADR
unilateral I-ADR
total I-ADR
visual I-ADR
loss I-ADR
after O
retrogasserian O
phenol B-DRUG
injection O
for O
the O
treatment O
of O
trigeminal O
neuralgia O
: O
a O
case O
report O

however O
, O
follow-up O
revealed O
that O
gestational B-ADR
diabetes I-ADR
when O
associated O
with O
norethisterone B-DRUG
had O
a O
lesser O
risk O
of O
emerging O
diabetes O
mellitus O
and O
impaired O
glucose O
tolerance O

thus O
cabergoline O
may O
cause O
similar O
pleuropulmonary B-ADR
abnormalities I-ADR
to O
bromocriptine B-DRUG

the O
development O
of O
an O
igg O
lambda-type O
monoclonal O
gammopathy O
and O
subsequent O
multiple B-ADR
myeloma I-ADR
in O
an O
epilepsy O
patient O
on O
diphenylhydantoin O
( O
dilantin B-DRUG
) O
therapy O
for O
20 O
years O
is O
reported O

propranolol-related O
bronchospasm B-ADR
in O
patients O
without O
history O
of O
asthma O

the O
most O
common O
side O
effects O
associated O
with O
amifostine B-DRUG
are O
nausea O
, O
vomiting O
, O
hypotension O
, O
hypocalcemia B-ADR
and O
allergic O
reactions O

after O
a O
second O
dose O
of O
metoclopramide B-DRUG
, O
these O
symptoms O
recurred O
and O
were O
associated O
with O
confusion O
, O
agitation B-ADR
, O
fever O
, O
diaphoresis O
, O
tachypnea O
, O
tachycardia O
, O
and O
hypertension O

we O
describe O
a O
patient O
with O
acute O
leukemia O
who O
developed O
horner O
's O
syndrome O
and O
a O
severe B-ADR
demyelinating I-ADR
peripheral I-ADR
neuropathy I-ADR
leading O
to O
death O
after O
receiving O
high-dose O
cytosine B-DRUG
arabinoside I-DRUG

a O
68-year-old O
female O
patient O
with O
advanced O
ovarian O
carcinoma O
collapsed B-ADR
whilst O
receiving O
a O
carboplatin O
and O
cyclophosphamide B-DRUG
infusion O

the O
authors O
report O
a O
case O
of O
balint B-ADR
syndrome I-ADR
with O
irreversible O
posterior O
leukoencephalopathy O
on O
mri O
following O
intrathecal O
methotrexate B-DRUG
and O
cytarabine O

it O
is O
suggested O
that O
the O
fatal O
stroke O
may O
have O
resulted O
from O
arterial B-ADR
spasm I-ADR
caused O
by O
ergotamine B-DRUG
overdosage O
and O
possibly O
complicated O
by O
thrombosis O

we O
report O
a O
fatal O
case O
of O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
( O
ten O
) O
resulting O
from O
a O
high O
dose O
of O
cytosine O
arabinoside O
( O
ara-c B-DRUG

alternating B-ADR
sinus I-ADR
rhythm I-ADR
and O
intermittent O
sinoatrial O
( O
s-a O
) O
block O
was O
observed O
in O
a O
57-year-old O
woman O
, O
under O
treatment O
for O
angina O
with O
80 O
mg O
propranolol B-DRUG
daily O

unexpected O
severe O
reversible O
cyclosporine B-DRUG
a-induced O
nephrotoxicity B-ADR
in O
a O
patient O
with O
systemic O
lupus O
erythematosus O
and O
tubulointerstitial O
renal O
disease O

nonspecific O
but O
significant B-ADR
abnormalities I-ADR
have O
been O
described O
in O
the O
infants O
of O
women O
treated O
with O
disulfiram B-DRUG
in O
the O
first O
trimester O
of O
their O
pregnancies O

aseptic B-ADR
meningitis I-ADR
, O
hemolytic O
anemia O
, O
hepatitis O
, O
and O
orthostatic O
hypotension O
in O
a O
patient O
treated O
with O
trimethoprim-sulfamethoxazole O

with O
the O
increasing O
use O
of O
cyclosporine B-DRUG
a I-DRUG
in O
transplant O
patients O
, O
the O
incidence O
of O
herpes B-ADR
esophagitis I-ADR
may O
increase O

during O
clarithromycin O
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate-to-severe O
toxic B-ADR
symptoms I-ADR
of O
carbamazepine B-DRUG
, O
such O
as O
drowsiness O
, O
dizziness O
, O
and O
ataxia O
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin O
discontinuation O

a O
10-year-old O
boy O
with O
osteosarcoma O
and O
normal O
renal O
function O
manifested O
laboratory O
evidence O
of O
impending O
renal O
toxicity O
and O
extreme O
elevation B-ADR
of I-ADR
aspartate I-ADR
aminotrasferase I-ADR
and O
alanine O
aminotransferase O
within O
2 O
hours O
after O
the O
completion O
of O
a O
4-hour O
infusion O
of O
high-dose O
methotrexate O
( O
mtx B-DRUG
) O
( O
12 O
g O
/ O
m2 O
) O
, O
and O
went O
on O
to O
develop O
acute O
renal O
failure O
with O
life-threatening O
hyperkalemia O
29 O
hours O
later O

cutaneous B-ADR
necrosis I-ADR
as O
a O
result O
of O
interferon B-DRUG
alfa I-DRUG
is O
an O
infrequent O
complication O
with O
unknown O
pathogenesis O
, O
in O
which O
a O
cutaneous O
local O
immune-mediated O
inflammatory O
process O
might O
be O
involved O

four O
days O
after O
the O
initial O
injection O
of O
3.6 O
mg O
of O
goserelin B-DRUG
acetate I-DRUG
, O
severe O
dyspnea O
developed O
due O
to O
worsening O
pleuritis O
carcinomatosa O
, O
which O
was O
considered O
as O
a O
flare-up B-ADR

during O
clarithromycin B-DRUG
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate-to-severe O
toxic O
symptoms O
of O
carbamazepine O
, O
such O
as O
drowsiness O
, O
dizziness O
, O
and O
ataxia B-ADR
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin B-DRUG
discontinuation O

methylene O
blue O
in O
the O
treatment O
and O
prevention O
of O
ifosfamide-induced B-ADR
encephalopathy I-ADR
: O
report O
of O
12 O
cases O
and O
a O
review O
of O
the O
literature O

metformin-associated O
lactic B-ADR
acidosis I-ADR
precipitated O
by O
diarrhea O

after O
seven O
months' O
continuous O
treatment O
for O
suspected O
tuberculosis O
with O
rifampicin O
and O
ethambutol B-DRUG
a O
nine-year-old O
boy O
developed O
polyarthritis O
, O
rash O
and O
hepatitis B-ADR
in O
association O
with O
anti-native O
dna O
antibodies O
and O
positive O
antinuclear O
factor O

aseptic O
meningitis O
, O
hemolytic O
anemia O
, O
hepatitis O
, O
and O
orthostatic B-ADR
hypotension I-ADR
in O
a O
patient O
treated O
with O
trimethoprim-sulfamethoxazole O

akathisia B-ADR
is O
a O
relatively O
rare O
side O
effect O
with O
the O
newer O
atypical O
antipsychotic O
agents O
, O
particularly O
clozapine B-DRUG
, O
and O
is O
easily O
misdiagnosed O
in O
children O

these O
novel O
findings O
may O
offer O
specific O
therapeutic O
targets O
in O
the O
treatment O
of O
bcnu-associated O
pulmonary B-ADR
fibrosis I-ADR

to O
our O
knowledge O
, O
this O
recurrence O
of O
amiodarone B-DRUG
pulmonary B-ADR
toxicity I-ADR
has O
not O
been O
reported O
previously O

he O
developed O
a O
late O
secondary B-ADR
infection I-ADR
in O
some O
sites O
treated O
with O
imiquimod B-DRUG

cefoxitin-associated O
renal B-ADR
failure I-ADR

the O
allopurinol B-DRUG
hypersensitivity B-ADR
syndrome I-ADR
is O
a O
rare O
adverse O
drug O
reaction O

rofecoxib B-DRUG
, O
used O
for O
dysmenorrhea O
, O
caused O
a O
herpetiform O
fixed O
drug O
eruption O
predominantly O
involving O
the O
lips O
with O
classic O
clinical O
and O
histological O
findings O
in O
a O
red-brown B-ADR
lesion I-ADR
on O
the O
dorsal O
hand O

the O
possibility O
can O
be O
raised O
that O
m-csf B-DRUG
accelerated O
the O
underlying O
renal B-ADR
disease I-ADR
in O
this O
case O
through O
enhancing O
macrophage O
accumulation O
into O
the O
glomerulus O
, O
leading O
to O
the O
development O
of O
nephrotic O
syndrome O

we O
report O
3 O
children O
with O
epilepsy O
who O
developed O
facial B-ADR
motor I-ADR
tics I-ADR
after O
initiation O
of O
cbz B-DRUG
for O
complex O
partial O
seizures O

we O
report O
an O
allogeneic O
bone O
marrow O
transplant O
recipient O
who O
developed O
cmv B-ADR
infection I-ADR
refractory O
to O
sequential O
therapy O
with O
ganciclovir B-DRUG
, O
foscarnet O
, O
and O
cidofovir O

among O
12 O
thyrotoxic O
patients O
, O
a O
patient O
with O
arrhythmogenic O
right O
ventricular O
dysplasia O
, O
who O
had O
been O
taking O
amiodarone B-DRUG
for O
4 O
years O
, O
developed O
thyrotoxicosis O
with O
subacute O
onset O
, O
accompanied O
by O
transiently O
positive O
thyrotropin O
( O
tsh O
) O
receptor O
antibody O
( O
trab O
) O
, O
or O
thyrotropin-binding B-ADR
inhibiting I-ADR
immunoglobulin I-ADR
( O
tbii O

one O
type O
of O
smon B-ADR
is O
associated O
with O
acrodermatitis O
enteropathica O
which O
has O
a O
very O
high O
frequency O
of O
occurrence O
in O
association O
with O
administration O
of O
clioquinol B-DRUG

acute O
hemorrhagic O
gastritis O
associated O
with O
acetazolamide B-ADR
intoxication I-ADR
in O
a O
patient O
with O
chronic O
renal O
failure O

transient B-ADR
left I-ADR
homonymous I-ADR
hemianopsia I-ADR
and O
encephalopathy O
following O
treatment O
of O
testicular O
carcinoma O
with O
cisplatinum B-DRUG
, O
vinblastine O
, O
and O
bleomycin O

a O
16-year-old O
boy O
developed O
fever O
, O
generalized O
rigidity O
, O
leukocytosis O
, O
and O
increased B-ADR
serum I-ADR
transaminase I-ADR
and I-ADR
creatine I-ADR
kinase I-ADR
levels O
while O
receiving O
treatment O
with O
olanzapine O
and O
lithium B-DRUG

brugada B-ADR
type I-ADR
electrocardiographic I-ADR
changes I-ADR
induced O
by O
concomitant O
use O
of O
lithium O
and O
propafenone B-DRUG
in O
patient O
with O
wolff-parkinson-white O
syndrome O

the O
authors O
postulate O
that O
two O
types O
of O
combined O
lithium-neuroleptic O
toxicity O
occur O
: O
a O
neuroleptic O
malignant O
extrapyramidal O
syndrome O
and O
a O
lithium B-ADR
toxicity I-ADR
that O
occurs O
in O
combination O
with O
phenothiazines O
, O
primarily O
thioridazine O

severe O
dapsone B-DRUG
hypersensitivity B-ADR
syndrome I-ADR

it O
occasionally O
accompanies O
the O
heparin-associated O
thrombocytopenia B-ADR
and O
thrombosis O
syndrome O

the O
azathioprine B-DRUG
dose O
was O
low O
( O
1 O
mg O
/ O
kg O
) O
and O
pancytopenia B-ADR
occurred O
after O
56 O
days O
therapy O

methods O
: O
a O
55-year-old O
woman O
became O
stuporous B-ADR
after O
overdose O
with O
lamotrigine B-DRUG
( O
ltg O
) O
and O
valproic O
acid O
( O
vpa O
) O
tablets O

proconvulsive B-ADR
tendency O
of O
imipenem B-DRUG
/ O
cilastatin O
is O
one O
of O
its O
well-known O
side O
effects O

2-cda B-DRUG
typically O
causes O
a O
long-lasting O
state O
of O
immunodeficiency O
and O
the O
profound O
influence O
of O
this O
drug O
on O
the O
immune O
system O
has O
raised O
questions O
concerning O
the O
emergence O
of O
secondary B-ADR
neoplasms I-ADR
after O
its O
use O

argatroban O
for O
heparin-induced O
thrombocytopenia B-ADR
in O
hepato-renal O
failure O
and O
cvvhd O

reports O
of O
colonic B-ADR
perforation I-ADR
as O
a O
result O
of O
the O
administration O
of O
calcium B-DRUG
polystyrene I-DRUG
sulfonate I-DRUG
and O
sorbitol O
are O
rare O

a O
51-yr-old O
nonsmoking O
male O
patient O
without O
any O
history O
of O
previous O
allergies O
, O
asthma O
, O
hay O
fever O
, O
or O
urticaria O
developed O
attacks B-ADR
of I-ADR
asthma I-ADR
when O
captopril B-DRUG
was O
added O
to O
the O
nadolol O
and O
dyazide O
treatment O
for O
his O
high O
blood O
pressure O

an O
83-year-old O
man O
receiving O
glipizide B-DRUG
10 O
mg O
bid O
developed O
symptomatic B-ADR
hypoglycemia I-ADR
within O
three O
days O
of O
adding O
trimethoprim O
/ O
sulfamethoxazole O
( O
tmp O
/ O
smx O
) O
to O
his O
regimen O

large O
dose O
of O
methylphenidate B-DRUG
may O
cause O
cataract B-ADR
and O
glaucoma O

minor B-ADR
electrocardiographical I-ADR
changes I-ADR
were O
noted O
in O
five O
out O
of O
six O
patients O
who O
were O
not O
receiving O
a O
cardiac O
glycoside O
and O
four O
out O
of O
six O
who O
were O
receiving O
ouabain B-DRUG
, O
and O
none O
of O
the O
16 O
who O
were O
receiving O
digoxin O

acute B-ADR
hepatic I-ADR
failure I-ADR
is O
a O
rare O
and O
potentially O
lethal O
complication O
of O
propylthiouracil B-DRUG
( O
ptu O
) O
use O
for O
hyperthyroidism O

the O
events O
of O
non-convulsive B-ADR
status I-ADR
epilepticus I-ADR
subsided O
following O
reduction O
in O
tiagabine B-DRUG
dosages O

unusual O
pigmentary B-ADR
changes I-ADR
associated O
with O
5-fluorouracil B-DRUG
therapy O

we O
report O
four O
patients O
, O
three O
of O
whom O
first O
developed O
psoriasis B-ADR
and O
one O
who O
had O
an O
aggravation O
of O
the O
condition O
during O
treatment O
with O
interferon-alpha B-DRUG

a O
57-year-old O
woman O
with O
right O
bundle O
branch O
block O
+ O
lph O
and O
ventricular O
premature O
contractions O
developed O
complete O
heart O
block O
( O
chb B-ADR
) O
following O
administration O
of O
disopyramide B-DRUG
phosphate I-DRUG
( O
norpace O

we O
report O
a O
case O
of O
radiotherapy-enhanced O
aminoglutethimide B-DRUG
skin B-ADR
toxicity I-ADR
in O
a O
patient O
with O
metastatic O
breast O
cancer O

objective O
: O
to O
determine O
the O
frequency O
of O
weight B-ADR
loss I-ADR
in O
patients O
treated O
with O
leflunomide B-DRUG
for O
rheumatoid O
arthritis O
at O
an O
arthritis O
referral O
center O

acyclovir-induced O
neurotoxicity B-ADR
: O
concentration-side O
effect O
relationship O
in O
acyclovir O
overdose O

second O
, O
we O
report O
a O
case O
of O
neutropenia B-ADR
, O
which O
proved O
to O
be O
fatal O
in O
a O
schizophrenia O
patient O
receiving O
olanzapine B-DRUG
and O
thiazide O

the O
currently O
available O
clinical O
and O
neuropharmacologic O
data O
suggest O
that O
carbamazepine B-DRUG
may O
be O
an O
antagonist O
of O
dopamine O
and O
that O
this O
property O
is O
responsible O
for O
the O
production O
of O
dystonia B-ADR

we O
report O
the O
case O
of O
a O
patient O
with O
chronic O
lymphocytic O
leukemia O
( O
cll O
) O
who O
developed O
fatal O
intravascular O
autoimmune O
hemolytic O
anemia O
( O
aiha B-ADR
) O
after O
fludarabine B-DRUG
treatment O

a O
woman O
developed O
delusional B-ADR
parasitosis I-ADR
when O
taking O
phenelzine B-DRUG

a O
dapsone B-DRUG
hypersensitivity O
syndrome O
, O
consisting O
of O
fever O
, O
headache O
, O
nausea B-ADR
, O
vomiting O
, O
lymphadenopathy O
, O
hepatitis O
, O
hemolysis O
, O
leukopenia O
, O
and O
mononucleosis O
, O
has O
been O
described O
in O
patients O
treated O
with O
the O
drug O
for O
leprosy O

generalized B-ADR
pustular I-ADR
psoriasis I-ADR
precipitated O
by O
trazodone B-DRUG
in O
the O
treatment O
of O
depression O

a O
case O
is O
reported O
of O
theophylline O
intoxication O
due O
to O
a O
dramatic O
decrease B-ADR
in I-ADR
theophylline I-ADR
clearance I-ADR
following O
concomitant O
administration O
of O
viloxazine B-DRUG

we O
report O
a O
case O
of O
severe B-ADR
anemia I-ADR
, O
which O
responded O
well O
to O
steroid O
therapy O
, O
in O
a O
patient O
receiving O
il-2 O
plus O
ifn-alpha B-DRUG
for O
metastatic O
renal O
cell O
carcinoma O

fortunately O
, O
a O
hypersensitivity B-ADR
reaction I-ADR
to O
one O
formulation O
of O
cyclosporine B-DRUG
does O
not O
preclude O
use O
of O
a O
different O
formulation O

intravenous O
valproate B-DRUG
associated O
with O
significant O
hypotension B-ADR
in O
the O
treatment O
of O
status O
epilepticus O

nephrotic O
syndrome O
related O
to O
systemic B-ADR
lupus I-ADR
erythematosus I-ADR
after O
griseofulvin B-DRUG
therapy O

after O
identification O
of O
the O
index O
patient O
, O
additional O
inquiry O
revealed O
that O
the O
patient O
's O
mother O
was O
hospitalized O
previously O
for O
overwhelming O
sepsis B-ADR
associated O
with O
metamizole B-DRUG
use O

massive O
cbz B-DRUG
od O
may O
produce O
a O
reversible O
encephalopathy O
that O
includes O
cortical O
hyperexcitability O
, O
a O
profound O
burst-suppression O
eeg O
pattern O
, O
and O
cranial B-ADR
nerve I-ADR
areflexia I-ADR

she O
was O
admitted O
following O
a O
fall O
and O
, O
after O
being O
given O
metoclopramide B-DRUG
, O
developed O
movement B-ADR
disorder I-ADR
and O
a O
period O
of O
unresponsiveness O

here O
we O
describe O
a O
patient O
with O
crohn O
's O
disease O
who O
developed O
a O
severe O
infliximab B-DRUG
infusion O
reaction O
( O
iir B-ADR
) O
, O
complicated O
1 O
day O
later O
by O
severe O
swelling O
of O
the O
forearm O
and O
hand O
ipsilateral O
to O
the O
site O
of O
infliximab B-DRUG
infusion O

chlormadinone B-DRUG
acetate I-DRUG
withdrawal B-ADR
syndrome I-ADR
under O
combined O
androgen O
blockade O
for O
advanced O
prostate O
cancer O

objective O
: O
to O
report O
a O
patient O
developing O
fulminant B-ADR
liver I-ADR
failure I-ADR
while O
being O
treated O
with O
clarithromycin B-DRUG
for O
pneumonia O

disulfiram-like B-ADR
reactions I-ADR
with O
newer O
cephalosporins O
: O
cefmenoxime B-DRUG

ritonavir B-DRUG
acted O
as O
a O
cyp3a4 O
inhibitor O
, O
diminishing O
carbamazepine O
metabolism O
and O
provoking O
an O
increase O
in O
serum O
levels O
and O
clinical B-ADR
toxicity I-ADR

after O
five O
and O
six O
weeks O
of O
continuous O
oral O
administration O
of O
methylprednisolone B-DRUG
, O
the O
boys O
developed O
steroid B-ADR
diabetes I-ADR

these O
cases O
highlight O
the O
occurrence O
of O
livedo B-ADR
reticularis I-ADR
as O
an O
uncommon O
side-effect O
of O
interferon B-DRUG
alpha I-DRUG
treatment O

two O
fatal B-ADR
cases O
of O
poisoning O
by O
paracetamol B-DRUG
are O
described O

here O
, O
we O
describe O
levofloxacin-induced O
delirium B-ADR
with I-ADR
psychotic I-ADR
features I-ADR
in O
a O
relatively O
young O
, O
otherwise O
healthy O
female O

patients O
receiving O
amifostine B-DRUG
who O
develop O
only O
fever O
should O
be O
evaluated O
for O
an O
adverse O
drug O
reaction O
, O
as O
well O
as O
for O
sepsis O
and O
fevers B-ADR
of I-ADR
neutropenia I-ADR
, O
and O
it O
may O
be O
necessary O
to O
discontinue O
the O
drug O

insulin-induced O
lipoatrophy B-ADR
in O
type O
i O
diabetes O

we O
describe O
a O
patient O
with O
androgen-independent O
prostate O
cancer O
in O
whom O
psa B-ADR
continued I-ADR
to I-ADR
decrease I-ADR
for O
a O
period O
of O
15 O
months O
after O
flutamide B-DRUG
withdrawal O

dlst O
is O
a O
good O
diagnostic O
tool O
for O
aza B-DRUG
allergy B-ADR
, O
especially O
for O
severe O
drug O
allergy B-ADR
cases O

a O
patient O
with O
acute O
esophageal O
variceal O
bleeding O
developed O
fatal B-ADR
rhabdomyolysis I-ADR
during O
treatment O
with O
a O
continuous O
intravenous O
infusion O
of O
vasopressin B-DRUG

we O
report O
a O
case O
of O
a O
scleroderma-like B-ADR
reaction I-ADR
induced O
by O
long-term O
administration O
of O
uft B-DRUG

recently O
, O
some O
studies O
have O
also O
reported O
association O
between O
patients O
with O
juvenile O
rheumatoid O
arthritis O
( O
jra O
) O
treated O
with O
methotrexate B-DRUG
( O
mtx O
) O
and O
malignant B-ADR
lymphoma I-ADR
developing O

coadministration O
of O
antidepressant O
agents O
such O
as O
nefazodone O
, O
or O
any O
other O
drug O
that O
inhibits O
the O
cyp3a4 O
isoenzyme O
subfamily O
, O
should O
be O
anticipated O
to O
interfere B-ADR
with I-ADR
tacrolimus I-ADR
metabolism I-ADR

marked O
elevation B-ADR
of I-ADR
serum I-ADR
creatine I-ADR
kinase I-ADR
associated O
with O
olanzapine B-DRUG
therapy O

three O
patients O
with O
niacin-induced O
visual B-ADR
symptoms I-ADR
had O
cystoid O
maculopathy O
without O
leakage O
on O
fluorescein O
angiography O
, O
and O
a O
fourth O
patient O
with O
no O
fundus O
abnormality O
experienced O
cessation O
of O
visual B-ADR
symptoms I-ADR
upon O
discontinuation O
of O
niacin B-DRUG

the O
condition O
should O
be O
suspected O
in O
patients O
who O
develop O
unexplained O
abdominal O
pain O
or O
collapse B-ADR
following O
vasopressin B-DRUG
treatment O

we O
report O
a O
patient O
with O
pulmonary O
adenocarcinoma O
complicated O
by O
the O
syndrome O
of O
inappropriate O
secretion O
of O
antidiuretic O
hormone O
( O
siadh B-ADR
) O
following O
systemic O
chemotherapy O
with O
cisplatin O
( O
cddp O
) O
and O
vindesine B-DRUG
( O
vds O

the O
case O
of O
a O
bipolar O
patient O
who O
developed O
thyrotoxicosis B-ADR
with O
severe O
exophthalmos O
while O
on O
lithium B-DRUG
therapy O
is O
described O

due O
to O
discomfort O
, O
diplopia B-ADR
and O
lagophthalmos O
, O
the O
haematoma O
necessitated O
suspension O
of O
warfarin B-DRUG
therapy O
and O
a O
surgical O
evacuation O

systemic B-ADR
vasculitis I-ADR
complicating O
hairy O
cell O
leukaemia O
treatment O
with O
cladribine B-DRUG

pseudomembranous B-ADR
colitis I-ADR
readily O
occurs O
in O
at O
least O
certain O
population O
groups O
receiving O
trimethoprim-sulfamethoxazole O

infections B-ADR
are O
a O
major O
adverse O
effect O
during O
the O
treatment O
with O
anti-tnf-alpha B-DRUG

this O
is O
a O
case O
report O
of O
possible O
association O
of O
methylphenidate B-DRUG
and O
enuresis B-ADR
in O
an O
11-year-old O
boy O
with O
attention O
deficit O
hyperactivity O
disorder O

the O
day O
after O
clozapine O
was O
stopped O
, O
while O
he O
was O
still O
receiving O
clomipramine B-DRUG
150 O
mg O
/ O
d O
, O
he O
began O
behaving O
oddly O
, O
started O
sweating O
profusely O
, O
shivering O
, O
and O
became O
tremulous O
, O
agitated O
, O
and O
confused B-ADR

objective O
: O
this O
case O
report O
outlines O
a O
significant O
type O
of O
morbidity O
due O
to O
continued O
use O
of O
gabapentin B-DRUG
during O
an O
episode O
of O
acute B-ADR
renal I-ADR
failure I-ADR

we O
describe O
a O
case O
of O
interstitial B-ADR
hypoxaemiant I-ADR
pneumonitis I-ADR
probably O
related O
to O
flecainide B-DRUG
in O
a O
patient O
with O
the O
leopard O
syndrome O
, O
a O
rare O
congenital O
disorder O

gynaecomastia B-ADR
is O
a O
rarely O
reported O
adverse O
drug O
reaction O
due O
to O
isoniazid B-DRUG
therapy O

aggressive B-ADR
endometrial I-ADR
carcinoma I-ADR
in O
a O
breast O
cancer O
patient O
treated O
with O
tamoxifen B-DRUG
with O
normal O
transvaginal O
ultrasonography O

the O
chemotherapeutics O
, O
including O
vincristine B-DRUG
, O
actinomycin O
d O
, O
and O
epirubicin O
in O
case O
1 O
and O
vincristine B-DRUG
and O
actinomycin O
d O
in O
case O
2 O
, O
were O
given O
before O
the O
hepatotoxicity B-ADR
developed O

in O
addition O
, O
while O
cases O
of O
loop O
diuretic-induced O
pancreatitis B-ADR
, O
including O
furosemide B-DRUG
, O
have O
been O
published O
, O
the O
allergic O
manifestations O
with O
both O
sulfonamide O
antibiotics O
and O
non-antibiotics O
in O
our O
patient O
suggest O
possible O
cross-reactivity O
between O
these O
2 O
drug O
classes O

we O
report O
a O
case O
of O
penile B-ADR
fibrosis I-ADR
after O
intracavernous O
self-injection O
of O
a O
combination O
of O
phentolamine B-DRUG
and O
papaverine O

acute B-ADR
respiratory I-ADR
depression I-ADR
as O
a O
complication O
of O
nebulised O
morphine B-DRUG

this O
case O
of O
linezolid-associated O
acute B-ADR
interstitial I-ADR
nephritis I-ADR
within O
the O
context O
of O
a O
drug O
rash O
with O
eosinophilia O
and O
systemic O
symptoms O
( O
dress O
) O
syndrome O
in O
a O
patient O
treated O
with O
linezolid B-DRUG
raises O
concerns O
about O
the O
presumed O
renal O
safety O
of O
this O
drug O

the O
other O
woman O
had O
rheumatoid O
arthritis O
and O
developed O
acute B-ADR
tubular I-ADR
necrosis I-ADR
after O
treatment O
with O
gentamicin B-DRUG
and O
cefoxitin O

development O
of O
porphyria B-ADR
cutanea I-ADR
tarda I-ADR
after O
treatment O
with O
cyclophosphamide B-DRUG

although O
the O
data O
indicate O
an O
immune-complex O
cause O
for O
gold-salt B-DRUG
nephropathy B-ADR
, O
the O
incident O
antigen O
( O
or O
antigens O
) O
and O
mechanism O
of O
action O
remain O
unidentified O

in O
the O
following O
case O
report O
, O
a O
patient O
developed O
acute B-ADR
interstitial I-ADR
nephritis I-ADR
with O
renal O
failure O
and O
exfoliative O
dermatitis O
following O
ampicillin B-DRUG
therapy O

torsade B-ADR
de I-ADR
pointes I-ADR
associated O
with O
moxifloxacin B-DRUG
: O
a O
rare O
but O
potentially O
fatal O
adverse O
event O

drug-induced O
mammary B-ADR
hyperplasias I-ADR
have O
been O
reported O
as O
rare O
complications O
of O
d-penicillamine B-DRUG
and O
neothetazone O

we O
cared O
for O
a O
patient O
with O
progressive O
renal O
impairment O
who O
presented O
with O
blurred O
vision O
, O
qrs O
broadening O
and O
cardiac O
failure O
due O
to O
chronic O
cibenzoline B-ADR
intoxication I-ADR

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram B-DRUG
developed O
confusion O
, O
agitation O
, O
tachycardia O
, O
tremors B-ADR
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl O
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl O

a O
patient O
with O
wegener O
's O
granulomatosis O
rapidly O
developed O
a O
circumferential B-ADR
subglottic I-ADR
stenosis I-ADR
while O
on O
a O
cyclophosphamide B-DRUG
regimen O
that O
had O
caused O
resolution O
of O
systemic O
symptoms O
and O
pulmonary O
infiltrates O

one O
of O
the O
subjects O
who O
was O
using O
extemporaneous O
topical O
minoxidil B-DRUG
had O
hypertension O
and O
arteriosclerotic O
disease O
and O
the O
other O
died O
of O
a O
myocardial B-ADR
infarction I-ADR

results O
: O
budesonide B-DRUG
use O
can O
cause O
contact B-ADR
dermatitis I-ADR

the O
reported O
cases O
of O
in O
utero O
exposure O
to O
cyclosposphamide B-DRUG
shared O
the O
following O
manifestations O
with O
our O
patient O
: O
growth O
deficiency O
, O
developmental O
delay O
, O
craniosynostosis O
, O
blepharophimosis B-ADR
, O
flat O
nasal O
bridge O
, O
abnormal O
ears O
, O
and O
distal O
limb O
defects O
including O
hypoplastic O
thumbs O
and O
oligodactyly O

neutropenia O
and O
agranulocytosis B-ADR
are O
risks O
known O
to O
occur O
with O
phenothiazines O
and O
clozapine B-DRUG

in O
this O
report O
, O
we O
describe O
a O
patient O
receiving O
lenalidomide B-DRUG
in O
whom O
dyspnea O
, O
fever O
, O
hypoxia B-ADR
, O
and O
diffuse O
pulmonary O
infiltrates O
developed O

we O
report O
the O
development O
of O
squamous-cell B-ADR
carcinoma I-ADR
within O
a O
basal-cell O
epithelioma O
that O
was O
treated O
with O
intralesional O
injections O
of O
5-fu B-DRUG

rapamycin B-DRUG
/ O
sirolimus-induced O
pneumonitis O
has O
been O
described O
previously O
in O
renal O
transplant O
recipients O
, O
and O
this O
report O
describes O
a O
stable O
heart-lung O
transplant O
recipient O
who O
developed O
a O
pulmonary B-ADR
infiltrate I-ADR
that O
reversed O
after O
ceasing O
sr O
therapy O

the O
patient O
developed O
grade O
3 O
capecitabine-induced O
headache B-ADR

although O
differential O
diagnostic O
alternatives O
can O
be O
considered O
in O
all O
described O
cases O
it O
is O
very O
likely O
that O
vincristine B-DRUG
does O
cause O
severe B-ADR
visual I-ADR
loss I-ADR
in O
a O
small O
number O
of O
patients O

the O
three O
reported O
cases O
demonstrate O
that O
troglitazone B-DRUG
is O
an O
idiosyncratic O
hepatotoxin O
that O
can O
lead O
to O
irreversible B-ADR
liver I-ADR
injury I-ADR

mitomycin B-DRUG
c-related O
hemolytic B-ADR
uremic I-ADR
syndrome I-ADR
in O
cancer O
patients O

we O
report O
a O
case O
of O
a O
patient O
with O
rheumatoid O
arthritis O
treated O
with O
low-dose O
methotrexate B-DRUG
( O
15 O
mg O
/ O
week O
) O
who O
developed O
infection B-ADR
with I-ADR
both I-ADR
m. I-ADR
tuberculosis I-ADR
and I-ADR
m. I-ADR
chelonae I-ADR
after O
the O
revision O
of O
a O
prosthetic O
hip O

the O
site O
of O
thrombosis O
and O
the O
chronological O
relationship O
with O
the O
iir B-ADR
implicates O
a O
hypersensitivity O
to O
infliximab B-DRUG
in O
the O
causation O
of O
the O
venous O
thrombosis O
in O
this O
case O

metronidazole B-DRUG
neuropathy B-ADR

erosion B-ADR
of I-ADR
psoriatic I-ADR
plaques I-ADR
: O
an O
early O
sign O
of O
methotrexate B-DRUG
toxicity O

renal B-ADR
tubular I-ADR
acidosis I-ADR
secondary O
to O
fk506 B-DRUG
in O
living O
donor O
liver O
transplantation O
: O
a O
case O
report O

dapsone-induced O
erythroderma B-ADR
with O
beau O
's O
lines O

thrombotic B-ADR
thrombocytopenic I-ADR
purpura I-ADR
induced O
by O
trimethoprim-sulfamethoxazole O
in O
a O
jehovah O
's O
witness O

on O
day O
7 O
of O
linezolid B-DRUG
treatment O
, O
the O
patient O
developed O
severe O
pruritus O
, O
macular O
rash O
, O
facial O
edema O
, O
eosinophilia O
, O
marked O
increase O
in O
serum O
creatinine O
level O
, O
and O
mild B-ADR
hepatitis I-ADR

secondary O
hyperparathyroidism O
in O
certain O
patients O
with O
lithium B-DRUG
nephrotoxicity B-ADR
is O
also O
possible O

isoniazid O
and O
ethambutol B-DRUG
as O
a O
cause O
of O
optic B-ADR
neuropathy I-ADR

conclusions O
: O
the O
administration O
of O
prostaglandin B-DRUG
e1 I-DRUG
to O
neonates O
can O
cause O
gastric-outlet B-ADR
obstruction I-ADR
due O
to O
antral O
hyperplasia O

hepatotoxic B-ADR
effects I-ADR
in O
a O
child O
receiving O
valproate O
and O
carnitine B-DRUG

inadvertent O
subsequent O
rechallenge O
with O
celiprolol B-DRUG
led O
to O
recurrence O
of O
the O
pneumonitis B-ADR
, O
10 O
weeks O
after O
drug O
readministration O

objective O
: O
to O
report O
a O
case O
of O
phenolphthalein-induced O
toxic O
epidermal O
necrolysis O
( O
ten B-ADR
) O
in O
a O
patient O
maintained O
on O
several O
other O
medications O
more O
commonly O
known O
to O
be O
associated O
with O
ten B-ADR

clinical O
course O
of O
macular B-ADR
edema I-ADR
in O
two O
cases O
of O
interferon-associated O
retinopathy O
observed O
by O
optical O
coherence O
tomography O

chronic B-ADR
photosensitivity I-ADR
associated O
with O
hydrochlorothiazide B-DRUG
ingestion O
occurred O
in O
four O
patients O

captopril B-DRUG
is O
known O
to O
be O
associated O
with O
dermatologic B-ADR
, I-ADR
hematologic I-ADR
, I-ADR
and I-ADR
pulmonary I-ADR
adverse I-ADR
effects I-ADR

we O
describe O
the O
development O
of O
ischemic B-ADR
colitis I-ADR
in O
a O
woman O
who O
was O
treated O
with O
tegaserod B-DRUG
and O
review O
the O
relationship O
among O
ischemic B-ADR
colitis I-ADR
, O
tegaserod B-DRUG
use O
, O
and O
irritable O
bowel O
syndrome O

clinical O
profile O
of O
oxcarbazepine-related O
angioneurotic B-ADR
edema I-ADR
: O
case O
report O
and O
review O

a O
15-kg B-ADR
weight I-ADR
gain I-ADR
developed O
in O
a O
patient O
during O
the O
third O
week O
of O
ibuprofen B-DRUG
therapy O

stupor B-ADR
and O
fast O
activity O
on O
electroencephalography O
in O
a O
child O
treated O
with O
valproate B-DRUG

within O
24 O
hours O
of O
fluid O
restriction O
and O
cessation O
of O
desmopressin B-DRUG
, O
her O
symptoms O
and O
hyponatremia B-ADR
resolved O

this O
report O
highlights O
a O
case O
of O
drug-induced O
dysphagia B-ADR
in O
a O
patient O
receiving O
haloperidol B-DRUG
for O
obsessive O
nocturnal O
thoughts O
and O
auditory O
disturbances O

transient O
left O
homonymous O
hemianopsia O
and O
encephalopathy B-ADR
following O
treatment O
of O
testicular O
carcinoma O
with O
cisplatinum O
, O
vinblastine B-DRUG
, O
and O
bleomycin O

he O
was O
diagnosed O
with O
possible O
serotonin B-ADR
syndrome I-ADR
; O
his O
symptoms O
resolved O
after O
clomipramine B-DRUG
was O
stopped O
but O
before O
clozapine O
was O
restarted O
eight O
days O
later O

although O
combinations O
of O
belladonna O
, O
ergotamine O
, O
and O
phenobarbital B-DRUG
have O
been O
used O
for O
medical O
treatment O
of O
menopausal O
symptoms O
since O
the O
1960s O
, O
this O
is O
the O
first O
known O
case O
report O
of O
its O
association O
with O
anticonvulsant B-ADR
hypersensitivity I-ADR
syndrome I-ADR

conclusions O
: O
this O
report O
indicates O
clindamycin B-DRUG
phosphate I-DRUG
vaginal O
cream O
as O
the O
most O
probable O
cause O
of O
cdic O
due O
to O
the O
temporal O
relationship O
between O
the O
occurrence O
of O
diarrhea O
and O
clindamycin O
administration O
, O
lack O
of O
concomitant O
medications O
, O
and O
documentation O
of O
c. B-ADR
difficile I-ADR
toxin I-ADR

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin O
, O
grepafloxacin O
, O
trovafloxacin B-DRUG
, O
gatifloxacin O
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache O
, O
dizziness O
and O
insomnia B-ADR

we O
report O
a O
78-year-old O
man O
who O
had O
acute B-ADR
unilateral I-ADR
total I-ADR
visual I-ADR
loss I-ADR
after O
retrogasserian O
phenol B-DRUG
injection O
for O
the O
treatment O
of O
trigeminal O
neuralgia O

acute B-ADR
lung I-ADR
injury I-ADR
associated O
with O
5-fluorouracil B-DRUG
and O
oxaliplatinum O
combined O
chemotherapy O

conclusion O
: O
this O
is O
, O
to O
our O
knowledge O
, O
the O
first O
report O
of O
severe B-ADR
myelopathy I-ADR
following O
accidental O
intrathecal O
administration O
of O
doxorubicin B-DRUG

the O
patient O
had O
recurrence O
of O
urticaria B-ADR
and O
angioedema O
a O
year O
and O
a O
half O
later O
, O
at O
which O
point O
the O
nph O
was O
stopped O
and O
she O
was O
desensitized O
to O
regular O
insulin B-DRUG

severe B-ADR
rash I-ADR
, O
including O
the O
stevens-johnson O
syndrome O
( O
sjs O
) O
, O
is O
the O
major O
toxicity O
of O
nevirapine B-DRUG
and O
is O
described O
in O
the O
package O
labeling O
with O
a O
prominent O
, O
boxed O
warning O

electrical B-ADR
proarrhythmia I-ADR
with O
procainamide B-DRUG
: O
a O
new O
icd-drug O
interaction O

therefore O
, O
although O
garenoxacin B-DRUG
reportedly O
causes O
fewer O
adverse O
reactions O
for O
cardiac O
rhythms O
than O
third-generation O
quinolone O
antibiotics O
, O
one O
must O
be O
cautious O
of O
the O
interference O
of O
other O
drugs O
during O
hypokalemia B-ADR
in O
order O
to O
prevent O
tdp O

since O
imiquimod B-DRUG
induces O
large B-ADR
amounts I-ADR
of I-ADR
type I-ADR
i I-ADR
interferon I-ADR
production I-ADR
from O
tlr7-expressing O
plasmacytoid O
dendritic O
cell O
precursors O
( O
pdcs O
) O
, O
the O
natural O
interferon-producing O
cells O
of O
the O
peripheral O
blood O
, O
we O
asked O
whether O
pdcs O
are O
present O
in O
psoriatic O
skin O

acute B-ADR
lung I-ADR
injury I-ADR
associated O
with O
5-fluorouracil O
and O
oxaliplatinum B-DRUG
combined O
chemotherapy O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical B-ADR
lymphocytosis I-ADR
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp O
)- O
sulfamethoxazole B-DRUG
( O
smx O
) O
treatment O

conclusions O
: O
topiramate B-DRUG
may O
be O
associated O
with O
ciliochoroidal B-ADR
effusion I-ADR
with O
forward O
displacement O
of O
the O
lens-iris O
diaphragm O
and O
anterior O
chamber O
shallowing O
, O
resulting O
in O
acute O
myopia O
and O
angle-closure O
glaucoma O

acute B-ADR
myocardial I-ADR
infarction I-ADR
during O
high-dose O
methylprednisolone B-DRUG
therapy O
for O
graves' O
ophthalmopathy O

seizure O
with O
hyponatremia B-ADR
in O
a O
child O
prescribed O
desmopressin B-DRUG
for O
nocturnal O
enuresis O

discussion O
: O
after O
exclusion O
of O
other O
causes O
, O
the O
onset O
of O
thrombocytopenia B-ADR
after O
administration O
of O
lansoprazole B-DRUG
, O
the O
resolution O
of O
the O
adverse O
reaction O
after O
discontinuation O
of O
the O
drug O
, O
and O
the O
fact O
that O
no O
other O
medicines O
were O
introduced O
during O
this O
time O
frame O
lead O
us O
to O
believe O
that O
this O
was O
most O
likely O
an O
idiosyncratic O
thrombocytopenic O
response O
to O
lansoprazole B-DRUG

rebound O
hyperglycemia B-ADR
following O
overdosing O
of O
insulin B-DRUG
in O
cats O
with O
diabetes O
mellitus O

in O
the O
second O
case O
, O
five O
cardiac O
arrests O
due O
to O
ventricular B-ADR
tachycardia I-ADR
and O
fibrillation O
occurred O
during O
several O
hours O
after O
beginning O
a O
trial O
of O
bretylium B-DRUG
maintenance O
therapy O
for O
complex O
ventricular O
ectopy O

zidovudine B-DRUG
induced O
pure B-ADR
red I-ADR
cell I-ADR
aplasia I-ADR
: O
a O
case O
report O

a O
31-year-old O
female O
developed O
multiple O
episodes O
of O
grand B-ADR
mal I-ADR
seizures I-ADR
after O
combination O
chemotherapy O
with O
cisplatin O
, O
vinblastine O
and O
bleomycin B-DRUG
for O
germ O
cell O
ovarian O
cancer O
stage O
ic O

acute B-ADR
abdomen I-ADR
due O
to O
endometriosis O
in O
a O
premenopausal O
woman O
taking O
tamoxifen B-DRUG

the O
toxic O
effects O
of O
methotrexate B-DRUG
included O
elevated O
liver O
transaminases O
( O
3 O
/ O
4 O
) O
, O
nausea B-ADR
( O
2 O
/ O
4 O
) O
, O
abdominal O
pain O
( O
2 O
/ O
4 O
) O
, O
bone O
pain O
( O
2 O
/ O
4 O
) O
, O
mild O
neutropenia O
( O
1 O
/ O
4 O
) O
, O
and O
mild O
pruritus O
( O
1 O
/ O
4 O

we O
report O
3 O
patients O
with O
severe B-ADR
hepatocellular I-ADR
damage I-ADR
due O
to O
cpa B-DRUG
therapy O
, O
2 O
with O
fatal O
fulminant O
hepatitis O

anaphylactoid B-ADR
reaction I-ADR
to O
methylprednisolone B-DRUG
pulsed O
therapy O
for O
multiple O
sclerosis O

exposure O
of O
the O
fetus O
to O
indomethacin B-DRUG
by O
administration O
of O
the O
drug O
to O
the O
mother O
may O
cause O
many O
side O
effects O
, O
including O
premature B-ADR
closure I-ADR
of I-ADR
the I-ADR
ductus I-ADR
arteriosus I-ADR

this O
patient O
rapidly O
progressed O
from O
mild O
neurotoxicity O
to O
fatal B-ADR
encephalopathy I-ADR
after O
one O
dose O
of O
intrathecal O
methotrexate B-DRUG
during O
his O
third O
cycle O
of O
chemotherapy O

data O
synthesis O
: O
genetic O
deficiencies O
in O
dpd O
, O
the O
rate-limiting O
enzyme O
responsible O
for O
5-fu B-DRUG
catabolism O
, O
may O
occur O
in O
3 O
% O
or O
more O
of O
patients O
with O
cancer O
putting O
them O
at O
increased O
risk O
for O
unusually O
severe O
adverse O
reactions O
( O
e.g. O
, O
diarrhea O
, O
stomatitis B-ADR
, O
mucositis O
, O
myelosuppression O
, O
neurotoxicity O
) O
to O
standard O
doses O
of O
5-fu B-DRUG

two O
patients O
with O
rheumatoid O
arthritis O
developed O
evidence O
of O
hepatotoxicity B-ADR
while O
receiving O
d-penicillamine B-DRUG

aliskiren-associated O
acute B-ADR
renal I-ADR
failure I-ADR
with O
hyperkalemia O

localized O
panniculitis O
and O
subsequent O
lipoatrophy B-ADR
with O
subcutaneous O
glatiramer O
acetate O
( O
copaxone B-DRUG
) O
injection O
for O
the O
treatment O
of O
multiple O
sclerosis O

we O
present O
a O
surprising O
case O
of O
a O
woman O
schizophrenic O
patient O
treated O
with O
clozapine B-DRUG
suffering O
from O
eps B-ADR

conclusions O
: O
the O
pathogenesis O
of O
methotrexate-induced O
papular B-ADR
eruption I-ADR
in O
collagen O
vascular O
diseases O
may O
suggest O
cutaneous O
small-vessel O
vasculitis O

hyperkalaemia B-ADR
with O
renal O
tubular O
dysfunction O
by O
oral O
therapy O
of O
sulfamethoxazole-trimethoprim B-DRUG
( O
co-trimoxazole O
) O
is O
described O
in O
2 O
elderly O
japanese O
patients O
with O
lymphoid O
malignancy O
, O
who O
developed O
pneumocystis O
carinii O
pneumonia O
and O
improved O

we O
are O
concerned O
that O
the O
macular B-ADR
lesion I-ADR
was O
a O
retinal O
toxic O
effect O
of O
gentamicin B-DRUG
because O
of O
the O
recent O
description O
of O
similar O
lesions O
occurring O
after O
the O
inadvertent O
intraocular O
injection O
of O
massive O
doses O
of O
this O
drug O

arthritis B-ADR
and O
bursitis O
in O
multiple O
sclerosis O
patients O
treated O
with O
interferon-beta B-DRUG

hemodialysis O
should O
be O
performed O
for O
rapid O
reversal O
of O
mannitol-induced O
arf B-ADR

case O
: O
we O
present O
an O
11-year O
old O
male O
with O
budd-chiari O
syndrome O
who O
experienced O
profound O
worsening B-ADR
of I-ADR
chronic I-ADR
aphthous I-ADR
ulcers I-ADR
after O
immunosuppressive O
therapy O
was O
changed O
from O
tacrolimus O
to O
sirolimus B-DRUG

we O
report O
a O
case O
of O
exfoliative B-ADR
dermatitis I-ADR
clearly O
linked O
to O
intravenous O
and O
intraperitoneal O
administration O
of O
tobramycin B-DRUG

flutamide O
withdrawal O
syndrome O
is O
characterized O
by O
a O
decrease B-ADR
in I-ADR
prostate-specific I-ADR
antigen I-ADR
( O
psa O
) O
after O
flutamide B-DRUG
withdrawal O
in O
a O
subset O
of O
patients O
with O
progressing O
metastatic O
carcinoma O
of O
the O
prostate O

we O
discuss O
a O
variety O
of O
bronchopulmonary O
complications O
of O
ibd B-ADR
and O
their O
association O
with O
sulfasalazine B-DRUG

the O
authors O
describe O
a O
woman O
with O
chronic O
schizophrenia O
who O
experienced O
delirium O
, O
grand B-ADR
mal I-ADR
seizure I-ADR
, O
and O
photosensitivity O
after O
the O
addition O
of O
propranolol B-DRUG
to O
her O
neuroleptic O
regimen O

an O
association O
of O
granulocytopenia O
, O
eosinophilia O
, O
skin B-ADR
reaction I-ADR
and O
hepatitis O
during O
propylthiouracil O
( O
ptu B-DRUG
) O
therapy O
for O
thyrotoxicosis O
in O
a O
47 O
year O
old O
black O
female O
is O
reported O

near O
fatal O
acute O
colchicine B-ADR
intoxication I-ADR
in O
a O
child O

a O
58-year-old O
woman O
with O
rheumatoid O
arthritis O
( O
ra O
) O
developed O
fever O
, O
skin O
eruptions O
, O
leukocytopenia B-ADR
, O
and O
thrombocytopenia O
, O
3 O
weeks O
after O
treatment O
with O
sulfasalazine B-DRUG

hair B-ADR
loss I-ADR
associated O
with O
paroxetine B-DRUG
treatment O
: O
a O
case O
report O

because O
there O
were O
no O
other O
obvious O
causes O
of O
renal O
failure O
in O
either O
patient O
, O
we O
propose O
that O
skeletal O
muscle O
ischemia O
developed O
during O
vasopressin B-DRUG
infusion O
, O
followed O
by O
release O
of O
myoglobin O
and O
renal B-ADR
damage I-ADR

metamizole B-DRUG
, O
a O
nonsteroidal O
antiinflammatory O
agent O
, O
is O
prohibited O
in O
the O
united O
states O
because O
of O
the O
risk O
of O
agranulocytosis B-ADR
but O
is O
widely O
used O
in O
mexico O
and O
other O
countries O

an O
immediate O
hemolytic B-ADR
reaction I-ADR
induced O
by O
repeated O
administration O
of O
oxaliplatin B-DRUG

central O
nervous O
system O
effects O
secondary O
to O
ciprofloxacin B-DRUG
treatment O
are O
uncommon O
and O
usually O
consist O
only O
of O
minor O
dizziness O
or O
mild O
headache O
, O
although O
rare O
occurrences O
of O
seizures O
and O
hallucinations B-ADR
have O
been O
reported O

hyperammonemia O
has O
been O
described O
as O
a O
complication O
of O
valproic B-DRUG
acid I-DRUG
therapy O
but O
may O
often O
be O
overlooked O
as O
a O
cause O
of O
lethargy B-ADR
in O
the O
postictal O
patient O
who O
presents O
to O
the O
emergency O
department O

this O
experience O
supports O
the O
hypothesis O
that O
heparin B-DRUG
can O
be O
readministered O
early O
to O
patients O
with O
heparin-associated O
thrombocytopenia B-ADR
and O
thrombosis O
, O
provided O
antiplatelet O
therapy O
is O
given O

background O
: O
reproductive O
endocrine O
disorders O
characterized O
by O
menstrual B-ADR
disorders I-ADR
, O
polycystic O
ovaries O
, O
and O
hyperandrogenism O
seem O
to O
be O
common O
among O
women O
treated O
with O
sodium B-DRUG
valproate I-DRUG
for O
epilepsy O

method O
: O
case O
analysis O
of O
a O
poly-drug O
overdose O
( O
venlafaxine O
, O
topiramate O
, O
divalproex O
sodium O
, O
risperidone B-DRUG
, O
and O
carbamazepine O
) O
presenting O
with O
mixed O
ss B-ADR
/ O
nms O
features O
and O
whose O
clinical O
management O
suggests O
a O
practical O
algorithm O
for O
treatment O
of O
undifferentiated O
ss B-ADR
/ O
nms O
in O
critical O
care O
settings O

anaphylactoid B-ADR
reactions I-ADR
with O
intraperitoneal O
cisplatin B-DRUG

although O
major O
hazards O
of O
treatment O
of O
hypophosphatemic O
osteomalacia O
with O
phosphate O
and O
calcitriol B-DRUG
are O
secondary B-ADR
hyperparathyroidism I-ADR
and O
vitamin O
d O
intoxication O
, O
potassium O
loss O
also O
should O
be O
kept O
in O
mind O

subfulminant B-ADR
hepatitis I-ADR
b I-ADR
after O
infliximab B-DRUG
in O
crohn O
's O
disease O
: O
need O
for O
hbv-screening O

eleven O
days O
after O
initiation O
of O
therapy O
with O
amiodarone B-DRUG
, O
the O
patient O
experienced O
syncope B-ADR
and O
was O
noted O
to O
have O
recurrent O
episodes O
of O
polymorphous O
ventricular O
tachycardia O

during O
clarithromycin B-DRUG
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate-to-severe O
toxic O
symptoms O
of O
carbamazepine O
, O
such O
as O
drowsiness O
, O
dizziness B-ADR
, O
and O
ataxia O
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin B-DRUG
discontinuation O

the O
addition O
of O
intrathecal O
methotrexate B-DRUG
to O
treatment O
protocols O
has O
increased O
survival O
rates O
in O
children O
with O
acute O
lymphoblastic O
leukemia O
but O
is O
also O
associated O
with O
varying O
degrees O
of O
neurotoxicity B-ADR

in O
one O
child O
, O
a O
second O
course O
of O
carbamazepine B-DRUG
resulted O
in O
a O
return O
of O
the O
dystonia B-ADR

cd20-negative B-ADR
t-cell-rich I-ADR
b-cell I-ADR
lymphoma I-ADR
as O
a O
progression O
of O
a O
nodular O
lymphocyte-predominant O
hodgkin O
's O
lymphoma O
treated O
with O
rituximab B-DRUG
: O
a O
molecular O
analysis O
using O
laser O
capture O
microdissection O

after O
extensive O
neurological O
' O
work O
up O
' O
, O
we O
realized O
that O
the O
anisocoria B-ADR
was O
related O
to O
the O
transdermal O
scopolamine B-DRUG
patch O
that O
we O
had O
prescribed O
for O
weaning O
off O
the O
opioid O

in O
addition O
to O
the O
recognized O
arrhythmic O
complications O
, O
the O
authors O
emphasize O
myocardial B-ADR
necrosis I-ADR
as O
a O
possible O
further O
manifestation O
of O
amsacrine-related O
cardiotoxicity O

after O
a O
second O
dose O
of O
metoclopramide B-DRUG
, O
these O
symptoms O
recurred O
and O
were O
associated O
with O
confusion O
, O
agitation O
, O
fever O
, O
diaphoresis O
, O
tachypnea O
, O
tachycardia O
, O
and O
hypertension B-ADR

the O
changes O
were O
progressive O
regardless O
of O
discontinuation O
of O
cyclophosphamide B-DRUG
and O
led O
to O
severe B-ADR
restrictive I-ADR
ventilatory I-ADR
defect I-ADR

patients O
should O
be O
informed O
about O
the O
risk O
of O
osteonecrosis B-ADR
when O
taking O
dexamethasone B-DRUG
as O
an O
antiemetic O
drug O

generalised B-ADR
pustular I-ADR
psoriasis I-ADR
induced O
by O
cyclosporin B-DRUG
a I-DRUG
withdrawal O
responding O
to O
the O
tumour O
necrosis O
factor O
alpha O
inhibitor O
etanercept O

subsequent O
course O
: O
the O
nephrosis B-ADR
resolved O
almost O
completely O
once O
the O
interferon B-DRUG
was O
stopped O
and O
after O
immunosuppressive O
treatment O

although O
major O
hazards O
of O
treatment O
of O
hypophosphatemic O
osteomalacia O
with O
phosphate B-DRUG
and O
calcitriol O
are O
secondary O
hyperparathyroidism O
and O
vitamin B-ADR
d I-ADR
intoxication I-ADR
, O
potassium O
loss O
also O
should O
be O
kept O
in O
mind O

although O
major O
hazards O
of O
treatment O
of O
hypophosphatemic O
osteomalacia O
with O
phosphate O
and O
calcitriol B-DRUG
are O
secondary O
hyperparathyroidism O
and O
vitamin O
d O
intoxication O
, O
potassium B-ADR
loss I-ADR
also O
should O
be O
kept O
in O
mind O

only O
after O
three O
subsequent O
episodes O
of O
severe O
, O
symptomatic O
thrombocytopenia B-ADR
over O
the O
next O
four O
weeks O
did O
he O
say O
, O
upon O
repeat O
questioning O
, O
that O
he O
had O
continued O
to O
take O
quinine B-DRUG
for O
night O
leg O
cramps O

though O
physicians O
treating O
large O
populations O
of O
patients O
with O
hiv O
are O
well O
aware O
of O
this O
complication O
, O
only O
one O
other O
report O
of O
nevirapine-associated O
sjs B-ADR
has O
been O
documented O
in O
the O
dermatology O
literature O

prior O
reports O
have O
emphasized O
the O
tubular B-ADR
and I-ADR
interstitial I-ADR
lesions I-ADR
associated O
with O
intermittent O
or O
discontinuous O
rifampin B-DRUG
therapy O
for O
tuberculosis O

clinicians O
should O
be O
aware O
that O
an O
erythematous O
and O
exfoliative B-ADR
rash I-ADR
may O
be O
induced O
by O
temozolomide B-DRUG
, O
and O
be O
familiar O
with O
the O
pharmacologic O
and O
supportive O
measures O
necessary O
for O
its O
treatment O

purpose O
: O
we O
evaluated O
the O
in O
vitro O
hemodialysis O
ratio O
and O
subsequent O
toxicity B-DRUG
and O
pharmacokinetics O
of O
ifosfamide B-ADR
in O
an O
anephric O
patient O
with O
wilms' O
tumor O

two O
patients O
had O
ampicillin-associated O
seizures B-ADR

apparent O
central B-ADR
nervous I-ADR
system I-ADR
depression I-ADR
in O
infants O
after O
the O
use O
of O
topical O
brimonidine B-DRUG

a O
drug B-ADR
interaction I-ADR
between O
zafirlukast O
and O
theophylline B-DRUG

ocular B-ADR
hypertension I-ADR
occurred O
1 O
month O
after O
the O
second O
ranibizumab B-DRUG
injection O
in O
patients O
1 O
and O
3 O
, O
and O
1 O
month O
after O
the O
first O
ranibizumab B-DRUG
in O
patient O
2 O

this O
report O
describes O
a O
case O
of O
paradoxical O
, O
intravenous O
valproic B-DRUG
acid-induced O
seizure B-ADR
exacerbation I-ADR
in O
a O
child O
with O
juvenile O
absence O
epilepsy O
, O
documented O
by O
video-electroencephalography O

we O
conclude O
that O
while O
thrombocytopenia B-ADR
and O
schistocytosis O
can O
be O
seen O
in O
quinine-associated O
ttp O
/ O
hus O
, O
the O
pathophysiology O
seems O
to O
be O
distinct O
from O
that O
seen O
in O
most O
cases O
of O
idiopathic O
ttp O
( O
i.e. O
, O
severely O
decreased O
adamts13 O
with O
an O
inhibitor O

we O
hypothesize O
that O
caffeine B-DRUG
toxicity O
injured O
the O
muscle O
cells O
, O
which O
were O
fragile O
due O
to O
the O
potassium O
depletion O
induced O
by O
the O
coexisting O
hyponatremia O
, O
to O
result O
in O
unusually O
severe O
rhabdomyolysis B-ADR

protease O
inhibitors O
( O
ritonavir B-DRUG
and O
saquinavir O
) O
were O
added O
to O
the O
treatment O
and O
the O
patient O
developed O
progressive B-ADR
ataxia I-ADR
related O
to O
carbamazepine O
toxicity O

this O
case O
and O
other O
published O
evidence O
should O
alert O
physicians O
to O
the O
possibility O
of O
fatal O
erlotinib-induced O
ild B-ADR

these O
skin B-ADR
lesions I-ADR
may O
be O
induced O
or O
worsened O
during O
antiviral O
therapy O
with O
interferon-alpha O
( O
ifn B-DRUG

painful O
erosion O
of O
psoriatic O
plaques O
is O
a O
less O
common O
sign O
of O
methotrexate B-DRUG
toxicity O
that O
may O
precede O
evidence O
of O
bone B-ADR
marrow I-ADR
suppression I-ADR

we O
report O
a O
case O
of O
a O
previously O
healthy O
, O
postmenopausal O
woman O
who O
developed O
anticonvulsant B-ADR
hypersensitivity I-ADR
syndrome I-ADR
while O
taking O
bellamine O
s O
( O
belladonna B-DRUG
alkaloids I-DRUG
; O
ergotamine O
; O
phenobarbital O
) O
for O
hot O
flashes O

we O
present O
a O
46-year-old O
african-american O
man O
with O
aids O
who O
was O
admitted O
on O
two O
different O
occasions O
within O
three O
weeks O
for O
signs O
and O
symptoms O
of O
meningitis B-ADR
after O
using O
trimethoprim B-DRUG
/ O
sulfamethoxazole O
( O
tmp O
/ O
smx O

prick O
tests O
and O
intradermal O
tests O
with O
a O
series O
of O
dilutions O
of O
carboplatin B-DRUG
and O
cisplatin O
were O
performed O
on O
three O
patients O
who O
had O
exhibited O
medium O
and O
severe B-ADR
hypersensitivity I-ADR
reactions O
to O
carboplatin B-DRUG

we O
report O
marked O
qt O
prolongation O
and O
torsades B-ADR
de I-ADR
pointes I-ADR
in O
a O
setting O
of O
flash O
pulmonary O
edema O
resulting O
from O
acute O
myocardial O
ischemia O
in O
a O
patient O
who O
was O
being O
treated O
with O
dofetilide B-DRUG
for O
atrial O
fibrillation O

we O
report O
an O
additional O
case O
of O
isotretinoin B-DRUG
teratogenicity O
in O
which O
the O
patient O
had O
agenesis O
of O
the O
cerebellar O
vermis O
, O
multiple B-ADR
leptomeningeal I-ADR
neuroglial I-ADR
heterotopias I-ADR
, O
hydrocephalus O
, O
and O
abnormalities O
of O
the O
corticospinal O
tracts O

two O
patients O
with O
hlh O
developed O
etoposide-related O
secondary O
acute O
myeloid O
leukemia O
( O
saml B-ADR
) O
following O
therapy O
for O
hlh O

hepatopathy B-ADR
subsided O
after O
the O
cessation O
of O
carbamazepine B-DRUG
and O
lynestrenol O

a O
57-year-old O
woman O
with O
right O
bundle O
branch O
block O
+ O
lph O
and O
ventricular O
premature O
contractions O
developed O
complete O
heart O
block O
( O
chb B-ADR
) O
following O
administration O
of O
disopyramide O
phosphate O
( O
norpace B-DRUG

such O
a O
rapid O
and O
relentless O
progression O
of O
methyldopa-induced O
liver B-ADR
injury I-ADR
is O
undoubtedly O
rare O
, O
but O
it O
may O
be O
prevented O
by O
careful O
supervision O
of O
patients O
who O
exhibit O
liver O
function O
abnormalities O
early O
in O
the O
course O
of O
therapy O

a O
65-year-old O
female O
patient O
presented O
with O
jaundice O
followed O
2 O
days O
later O
by O
severe B-ADR
dyspnea I-ADR
and O
tachypnea O
which O
worsened O
when O
patient O
was O
lying O
flat O
, O
1 O
week O
after O
the O
fourth O
dose O
of O
adalimumab B-DRUG

insulin-induced O
lipohypertrophy B-ADR
: O
report O
of O
a O
case O
with O
histopathology O

conclusion O
: O
there O
may O
be O
an O
association O
between O
raloxifene B-DRUG
and O
the O
development O
of O
malignant B-ADR
mixed I-ADR
mesodermal I-ADR
tumor I-ADR

discussion O
: O
the O
main O
adverse O
effects O
of O
leflunomide B-DRUG
consist O
of O
diarrhea B-ADR
, O
nausea O
, O
liver O
enzyme O
elevation O
, O
hypertension O
, O
alopecia O
, O
and O
allergic O
skin O
reactions O

minimal B-ADR
change I-ADR
disease I-ADR
in O
a O
patient O
receiving O
ifn-alpha B-DRUG
therapy O
for O
chronic O
hepatitis O
c O
virus O
infection O

he O
developed O
fever O
, O
nausea O
, O
diarrhea B-ADR
, O
and O
malaise O
and O
stopped O
taking O
on O
the O
third O
day O
after O
commencing O
pentasa B-DRUG

triiodothyronine-induced O
thyrotoxicosis B-ADR
in O
ophthalmic O
graves O
disease O

goiter O
and O
hypothyroidism B-ADR
during O
re-treatment O
with O
amiodarone B-DRUG
in O
a O
patient O
who O
previously O
experienced O
amiodarone-induced O
thyrotoxicosis O

acute B-ADR
generalized I-ADR
exanthematous I-ADR
pustulosis I-ADR
caused O
by O
morphine B-DRUG
, O
confirmed O
by O
positive O
patch O
test O
and O
lymphocyte O
transformation O
test O

hemolytic B-ADR
uremic I-ADR
syndrome I-ADR
in O
a O
patient O
on O
cis-platinum B-DRUG
, O
vinblastine O
and O
bleomycin O

retinal O
abnormalities O
, O
including O
retinal O
hemorrhage O
and O
" B-ADR
cotton-wool I-ADR
" I-ADR
spots I-ADR
, O
often O
occur O
within O
the O
first O
8 O
weeks O
in O
the O
course O
of O
interferon B-DRUG
therapy O
in O
patients O
with O
chronic O
hepatitis O
c O

extra O
caution O
should O
be O
taken O
in O
using O
octreotide B-DRUG
or O
its O
long-acting O
analog O
in O
patients O
otherwise O
predisposed O
to O
intrahepatic B-ADR
bile I-ADR
stasis I-ADR

a O
35-year-old O
female O
with O
borderline O
lepromatous O
( O
bl O
) O
leprosy O
who O
suffered O
from O
dapsone-induced O
erythroderma B-ADR
is O
reported O

the O
principle O
treatment O
for O
dpd-deficient O
patients O
with O
severe O
acute O
5-fu B-DRUG
reactions O
is O
supportive O
care O
; O
however O
, O
the O
administration O
of O
thymidine O
potentially O
may O
reverse O
severe O
5-fu-induced O
neurologic O
symptoms O
such O
as O
encephalopathy B-ADR
and O
coma O

according O
to O
the O
literature O
, O
chlorambucil B-DRUG
central B-ADR
nervous I-ADR
toxicity I-ADR
is O
found O
almost O
exclusively O
in O
childhood O
nephrotic O
syndrome O

the O
favourable O
outcome O
in O
these O
two O
patients O
contrasts O
with O
the O
fatal B-ADR
outcome I-ADR
of O
the O
two O
other O
reported O
cases O
of O
nitrofurantoin B-DRUG
induced O
boop O

mechanism O
of O
topiramate-induced O
acute-onset B-ADR
myopia I-ADR
and O
angle O
closure O
glaucoma O

we O
report O
a O
patient O
who O
developed O
spontaneous B-ADR
splenic I-ADR
infarction I-ADR
after O
the O
use O
of O
sumatriptan B-DRUG
for O
the O
treatment O
of O
migraine O
headache O

a O
case O
of O
clozapine-induced O
tonic-clonic B-ADR
seizures I-ADR
managed O
with O
valproate O
: O
implications O
for O
clinical O
care O

objective O
: O
to O
report O
a O
case O
of O
chronic O
, O
nonproductive O
cough B-ADR
secondary O
to O
the O
angiotensin-converting O
enzyme O
( O
ace O
) O
inhibitor O
quinapril B-DRUG
, O
with O
complete O
resolution O
after O
switching O
to O
another O
ace O
inhibitor O
, O
fosinopril O

sirolimus-associated O
hepatotoxicity B-ADR
in O
the O
kidney O
graft O
recipient O

postoperatively O
, O
the O
first O
two O
patients O
treated O
with O
1 O
to O
2 O
cc O
of O
thrombin B-DRUG
were O
slow B-ADR
to I-ADR
awaken I-ADR
; O
one O
had O
evidence O
of O
vasospasm O
by O
transcranial O
doppler O
ultrasound O
studies O
and O
multiple O
infarcts O
on O
cranial O
computerized O
tomography O
, O
while O
the O
other O
had O
a O
moderate-sized O
frontal O
hematoma O
with O
intracranial O
hypertension O

purpose O
: O
to O
describe O
bilateral B-ADR
corneal I-ADR
endothelial I-ADR
dysfunction I-ADR
in O
a O
patient O
with O
parkinson O
disease O
who O
was O
treated O
with O
long-term O
amantadine B-DRUG

a O
study O
following O
large O
patient O
groups O
on O
theophylline B-DRUG
and O
a O
combination O
of O
theophylline B-DRUG
and O
steroids O
might O
clarify O
the O
risk O
of O
ulcer B-ADR
formation O
in O
patients O
being O
treated O
with O
these O
medications O
for O
asthma O

multiple O
complications O
of O
propylthiouracil B-DRUG
treatment O
: O
granulocytopenia O
, O
eosinophilia O
, O
skin O
reaction O
and O
hepatitis O
with O
lymphocyte B-ADR
sensitization I-ADR

on O
the O
fifth O
day O
after O
administration O
of O
a O
high O
dose O
of O
ara-c B-DRUG
( O
2 O
g O
/ O
m2 O
intravenously O
every O
12 O
hours O
) O
, O
she O
developed O
bullous O
lesions O
on O
the O
hands O
and O
soles O
that O
disseminated O
, O
evolving O
to O
necrosis O
, O
sepsis B-ADR
, O
and O
death O
on O
the O
22nd O
day O

nitrofurantoin-induced O
lung B-ADR
disease I-ADR
: O
two O
cases O
demonstrating O
resolution O
of O
apparently O
irreversible O
ct O
abnormalities O

reversible B-ADR
heart I-ADR
failure I-ADR
in O
a O
patient O
receiving O
etanercept B-DRUG
for O
ankylosing O
spondylitis O

gastric B-ADR
tumor I-ADR
, O
endometrial O
carcinoma O
and O
cervical O
adenocarcinoma O
in O
situ O
were O
detected O
after O
treatment O
with O
tamoxifen B-DRUG
for O
breast O
cancer O

amiodarone-induced O
thyrotoxicosis O
associated O
with O
thyrotropin B-ADR
receptor I-ADR
antibody I-ADR

lithium B-DRUG
is O
known O
to O
cause O
acute B-ADR
renal I-ADR
failure I-ADR
and O
tubulo-interstitial O
disease O
, O
but O
the O
recently O
described O
association O
with O
proteinuria O
or O
nephrotic O
syndrome O
is O
little O
recognized O

we O
hypothesize O
that O
caffeine B-DRUG
toxicity O
injured B-ADR
the I-ADR
muscle I-ADR
cells I-ADR
, O
which O
were O
fragile O
due O
to O
the O
potassium O
depletion O
induced O
by O
the O
coexisting O
hyponatremia O
, O
to O
result O
in O
unusually O
severe O
rhabdomyolysis O

a O
65-year-old O
man O
on O
warfarin B-DRUG
therapy O
with O
a O
sudden O
spontaneous O
onset O
of O
sub-conjunctival O
haematoma O
associated O
with O
bloody B-ADR
tears I-ADR
was O
assessed O
in O
the O
clinic O
following O
a O
referral O
from O
an O
optometrist O

reports O
of O
colonic B-ADR
perforation I-ADR
as O
a O
result O
of O
the O
administration O
of O
calcium O
polystyrene O
sulfonate O
and O
sorbitol B-DRUG
are O
rare O

we O
thus O
concluded O
that O
an O
excessive O
dose O
of O
az B-DRUG
had O
probably O
destroyed B-ADR
the I-ADR
gastric I-ADR
mucosal I-ADR
barrier I-ADR
or O
thrombocytopenia O
due O
to O
bone O
marrow O
disorder O
and O
thus O
eventually O
led O
to O
the O
development O
of O
hemorrhagic O
gastritis O

early-onset O
pentamidine-associated O
second-degree O
heart O
block O
and O
sinus B-ADR
bradycardia I-ADR
: O
case O
report O
and O
review O
of O
the O
literature O

two O
cases O
are O
reported O
of O
patients O
who O
developed O
a O
hematologic B-ADR
malignancy I-ADR
several O
years O
after O
intravesical O
chemotherapy O
of O
superficial O
bladder O
cancer O
with O
etoglucid O
, O
doxorubicin B-DRUG
, O
and O
mitomycin O
c O

as O
far O
as O
we O
know O
, O
this O
is O
the O
first O
case O
report O
of O
acute O
hemorrhagic O
gastritis O
associated O
with O
az B-ADR
intoxication I-ADR

fatal B-ADR
outcome I-ADR
of O
intravesical O
formalin B-DRUG
instillation O
, O
with O
changes O
mimicking O
renal O
tuberculosis O

conclusions O
: O
we O
have O
seen O
an O
increased O
incidence O
of O
acute O
inh B-DRUG
neurotoxicity B-ADR
because O
of O
the O
resurgence O
of O
tb O
in O
new O
york O
city O

patients O
treated O
with O
l-asparaginase B-DRUG
may O
present O
with O
hemorrhagic B-ADR
and O
thrombotic O
cerebrovascular O
events O

neurotoxicity B-ADR
of O
valacyclovir B-DRUG
in O
peritoneal O
dialysis O
: O
a O
pharmacokinetic O
study O

a O
patient O
with O
seropositive O
rheumatoid O
arthritis O
developed O
ascites B-ADR
while O
taking O
weekly O
doses O
of O
methotrexate B-DRUG
( O
mtx O

conclusions O
: O
patients O
receiving O
intravitreal O
injections O
of O
bevacizumab B-DRUG
should O
be O
evaluated O
for O
potential O
systemic O
risk O
factors O
such O
as O
carotid O
insufficiency O
, O
coagulopathy B-ADR
and O
poorly O
controlled O
diabetes O
mellitus O

acute B-ADR
renal I-ADR
failure I-ADR
in O
a O
patient O
treated O
by O
continuous O
povidone-iodine O
mediastinal O
irrigation O

we O
report O
the O
case O
histories O
of O
two O
patients O
with O
histologically O
confirmed O
adenocarcinoma O
of O
the O
prostate O
, O
both O
of O
whom O
had O
been O
treated O
with O
steroidal O
anti-androgen O
therapy O
in O
the O
form O
of O
cyproterone B-DRUG
acetate I-DRUG
prior O
to O
radical O
or O
palliative O
pelvic O
irradiation O
, O
and O
who O
subsequently O
developed O
femoral B-ADR
head I-ADR
avascular I-ADR
necrosis I-ADR

described O
here O
are O
2 O
patients O
who O
developed O
thrombotic B-ADR
microangiopathy I-ADR
of O
the O
kidneys O
after O
receiving O
high O
cumulative O
doses O
of O
the O
new O
anticancer O
drug O
gemcitabine B-DRUG

a O
patient O
presented O
with O
a O
painful B-ADR
, I-ADR
oedematous I-ADR
, I-ADR
cyanosed I-ADR
hand I-ADR
having O
injected O
a O
solution O
of O
diamorphine O
and O
methylphenidate B-DRUG
into O
his O
radial O
artery O

at O
the O
end O
of O
his O
fifth O
cycle O
of O
sunitinib B-DRUG
therapy O
, O
the O
patient O
complained O
of O
the O
development B-ADR
of I-ADR
abnormally I-ADR
large I-ADR
mammary I-ADR
glands I-ADR
associated O
with O
pain O
and O
peri-areolar O
erythema O

less O
common O
adverse O
events O
to O
dapsone B-DRUG
include O
the O
idiosyncratic O
reactions O
of O
leukopenia O
and O
agranulocytosis O
, O
cutaneous B-ADR
eruptions I-ADR
, O
peripheral O
neuropathy O
, O
psychosis O
, O
toxic O
hepatitis O
, O
cholestatic O
jaundice O
, O
nephrotic O
syndrome O
, O
renal O
papillary O
necrosis O
, O
severe O
hypoalbuminemia O
without O
proteinuria O
, O
an O
infectious O
mononucleosis-like O
syndrome O
, O
and O
minor O
neurological O
and O
gastrointestinal O
complaints O

they O
seemed O
to O
involve O
multiple O
aetiological O
factors O
, O
such O
as O
autoimmune O
thyroid O
disease O
, O
the O
toxic B-ADR
and I-ADR
immunomodulatory I-ADR
roles I-ADR
of O
lithium B-DRUG
and O
perhaps O
genetic O
and O
dietary O
factors O

this O
report O
presents O
a O
potential O
case O
of O
risperidone-induced O
tardive B-ADR
dyskinesia I-ADR

